HPLC Methods for Recently Approved Pharmaceuticals

George Lunn

Analysis of pharmaceutical and natural compounds and newer drugs is commonly used in all the stages of drug discovery and development process. HPTLC is an advanced type of planar chromatography used extensively in the recent years for fingerprinting of medicinal plants, products and for screening lichen substances. Major advantages include precise sample application, wide choice of stationary phases, simultaneous processing of standards, simultaneous scanning in different light sources and excellent documentation facility. It is more sensitive and possible to run more samples in a short period of time, by using small amount of solvent. It is one of the sophisticated instrumental techniques based on the full capabilities of thin layer chromatography. In the present review brief discussion is presented with regard to type of instrument used in HPTLC, its entire methodology and how this technique is better than TLC. This concise information consists of salient points showing immense use in the practical analysis of HPTLC. This article consists of compilation of 63 formulations in total, out of which 38 containing one active substances and 25 containing dual active substances are shown in separate Tables (Table 1 and 2). The names of products, solvent system, details of plates to be used and details of quantitation showing densitometric evaluation are shown against each formulation.

Regulatory Considerations for the Chromatographer, John A. Adamovics Sample Treatment, John A. Adamovics Planar Chromatography, John A. Adamovics and James C. Eschbach Gas Chromatography, John A. Adamovics and James C. Eschbach High-Performance Liquid Chromatography, John A. Adamovics and Daivd Farb Capillary Electrophoresis, Shelley R. Rabel and John F. Stobaugh Supercritical Fluid Chromatography of Bulk and Formulated Pharmaceuticals, James T. Stewart and Nirdosh K. Jagota Applications, John A. Adamovics

Chirality plays a major role in biological processes, and the enantiomers of a bioactive molecule often possess different biological effects. For example, all pharmacological activity may reside in one enantiomer of a molecule, or enantiomers may have identical qualitative and quantitative pharmacological activity. In some cases, enantiomers may have qualitatively similar pharmacological activity, but different quantitative potencies. Since drugs that are produced by chemical synthesis are usually a mixture of enantiomers, there is a need to quantify the level of the isomeric impurity in the active pharmaceutical ingredient. Accurate assessment of the enantiomeric purity of substances is critical because isomeric impurities may have unwanted toxicological, pharmacological, or other effects. Such impurities may be carried through a synthesis and preferentially react at one or more steps and yield an undesirable level of another impurity. The determination of a trace enantiomeric impu...

HPLC METHODS FOR RECENTLY APPROVED PHARMACEUTICALS HPLC METHODS FOR RECENTLY APPROVED PHARMACEUTICALS George Lunn A JOHN WILEY & SONS, INC., PUBLICATION Copyright  2005 by John Wiley & Sons, Inc. All rights reserved. Published by John Wiley & Sons, Inc., Hoboken, New Jersey. Published simultaneously in Canada. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400, fax 978-646-8600, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008. Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages. For general information on our other products and services please contact our Customer Care Department within the U.S. at 877-762-2974, outside the U.S. at 317-572-3993 or fax 317-572-4002. Wiley also publishes its books in a variety of electronic formats. Some content that appears in print, however, may not be available in electronic format. Library of Congress Cataloging-in-Publication Data: Lunn, George. HPLC methods for recently approved pharmaceuticals / George Lunn. p. cm. Includes index. ISBN 0-471-66941-5 (cloth) 1. High performance liquid chromatography. 2. Drugs–Analysis. I. Title. RS189.5.H54L773 2005 615′ .1–dc22 2004016046 Printed in the United States of America. 10 9 8 7 6 5 4 3 2 1 CONTENTS Preface / xi Acknowledgements / xiii About This Book / xv Abacavir / 1 Acarbose / 5 Acetyl sulfisoxazole / 6 Acrivastine / 7 Adapalene / 10 Adefovir dipivoxil / 11 Adrenocorticotropic hormone / 13 Afloqualone / 15 Alacepril / 16 Alclometasone 17,21-dipropionate / 18 Alitretinoin / 21 Allethrin / 24 Almotriptan / 27 Alosetron / 29 Amcinonide / 30 Aminolevulinic acid / 33 Amprenavir / 36 Anagrelide / 42 Anakinra / 43 Apraclonidine / 45 Aprepitant / 46 Aranidipine / 48 Arotinolol / 49 Arteether / 52 Articaine / 54 Asparaginase / 57 Atazanavir sulfate / 58 Atipamezole / 60 Atomoxetine hydrochloride / 62 Atorvastatin / 64 Atosiban / 66 Balofloxacin / 67 Bambermycins / 69 Befunolol / 70 Benzalkonium chloride / 71 Betaine / 72 Bethanechol chloride / 74 Bexarotene / 75 Biapenem / 77 Bimatoprost / 79 Bioresmethrin / 80 Bivalirudin / 81 Boldenone / 82 Bosentan / 83 β-Boswellic acid / 86 Brimonidine / 88 Bromfenac / 90 Brovincamine / 92 Bucillamine / 93 Budipine / 94 Bulaquine / 95 Butacaine / 97 Butamben / 99 Butoconazole / 100 Butyl flufenamate / 101 Cambendazole / 102 Candesartan cilexetil / 104 Capecitabine / 106 Casanthranol / 108 Caspofungin / 109 v vi Contents Castor oil / 112 Cefbuperazone / 113 Cefditoren / 114 Cefoselis / 116 Cefozopran / 117 Cefuzonam / 118 Celecoxib / 119 Cerivastatin / 123 Cetrorelix / 125 Cetyl alcohol / 128 Cevimeline hydrochloride / 130 Chlorobutanol / 132 Chloroprocaine / 133 Chorionic gonadotropin / 134 Cilnidipine / 135 Cimetropium bromide / 136 Cisatracurium besylate / 137 Citric acid / 139 Clioquinol / 142 Clobetasol 17-propionate / 143 Clopidogrel / 147 Clopidol / 149 Cloricromen / 151 Clorsulon / 152 Colistin / 153 Cypermethrin / 155 Dalfopristin / 156 Dalteparin / 158 Daptomycin / 159 Deferiprone / 161 Deflazacort / 162 Desloratadine / 164 Desogestrel / 166 Desoximetasone / 167 Desoxycorticosterone / 169 Dexrazoxane / 172 Dextran / 174 Diacerein / 176 Dichloroacetic acid / 177 Dichlorophen / 178 Diclazuril / 179 Dihydrotachysterol / 181 Dimethyl sulfoxide / 183 Dinitolmide / 185 Dipivefrin / 186 Dithiazanine iodide / 187 Docarpamine / 188 Dofetilide / 189 Dolasetron / 191 Donepezil / 193 Doxefazepam / 195 Doxercalciferol / 196 Dropropizine / 198 Drospirenone / 199 Droxicam / 200 Droxidopa / 201 Ebrotidine / 202 Edaravone / 204 EDTA / 206 Efavirenz / 208 Efrotomycin / 212 Egualen / 213 Eletriptan / 214 Emtricitabine / 215 Enoxaparin sodium / 217 Entacapone / 218 Eperisone / 220 Eplerenone / 222 Epoprostenol / 224 Eprosartan / 225 Eptazocine / 227 Eptifibatide / 228 Erdosteine / 229 Ergotamine / 230 Ertapenem / 234 Ethopabate / 236 Ethyl icosapentate / 237 Etonogestrel / 238 Etoricoxib / 240 Etorphine / 242 Exemestane / 243 Ezetimibe / 245 Fadrozole / 247 Falecalcitriol / 248 Fenoxycarb / 250 Fenticonazole / 251 Fexofenadine / 253 Flomoxef / 257 Florfenicol / 258 Fludrocortisone / 260 Fluprostenol / 262 Flurandrenolide / 264 Flurithromycin / 267 Flurogestone acetate / 268 Fluticasone propionate / 270 Flutrimazole / 273 Fomepizole / 274 Fomivirsen / 276 Fondaparinux / 277 Formestane / 278 Contents Formoterol / 279 Fosamprenavir calcium / 281 Fosinopril / 283 Fosphenytoin / 284 Frovatriptan / 286 Fumagillin / 288 Galantamine / 290 Ganirelix / 292 Gatifloxacin / 293 Gefitinib / 295 Gemcitabine / 296 Gemifloxacin / 298 Gestodene / 300 Gestrinone / 301 Glycerin / 302 Guanabenz / 304 Guanadrel / 305 Halobetasol propionate / 306 Halofuginone / 308 Hetastarch / 310 Hydroquinone / 311 Hygromycin B / 312 Iloprost / 313 Imatinib / 314 Imidocarb / 316 Iobenguane / 318 Iodixanol / 320 Iopanoic acid / 322 Iopromide / 324 Ioversol / 326 Ipratropium bromide / 327 Ipriflavone / 328 Isoflupredone / 329 Isopropamide iodide / 330 Itopride / 332 Kinetin / 333 Lafutidine / 334 Lamivudine / 335 Latanoprost / 339 Leflunomide / 341 Lercanidipine / 343 Letrozole / 345 Levetiracetam / 346 Levonordefrin / 348 Levosimendan / 349 Lidamidine / 351 Lincomycin / 352 Lindane / 354 Linezolid / 355 Liothyronine / 357 Lomerizine / 358 Lopinavir / 359 Loteprednol etabonate / 362 Marbofloxacin / 364 Masoprocol / 367 Maxacalcitol / 368 Medetomidine / 369 Meglutol / 371 Melatonin / 372 Melengestrol acetate / 375 Memantine / 378 Menthol / 380 Mepenzolate bromide / 381 Mepixanox / 383 Mequinol / 384 Methenamine / 385 Methoprene / 386 Methoxychlor / 387 Methyltestosterone / 392 Metrizamide / 393 Metyrosine / 394 Micafungin / 396 Milnacipran / 398 Mirtazapine / 400 Misoprostol / 405 Mizolastine / 406 Moexipril / 411 Mofezolac / 412 Mometasone furoate / 413 Monensin / 415 Morantel / 416 Mosapride / 417 Moxifloxacin / 420 Moxonidine / 423 Nadifloxacin / 424 Naftopidil / 425 Nandrolone / 427 Narasin / 429 Nartograstim / 430 Nateglinide / 431 Nebivolol / 433 Nelfinavir / 435 Nequinate / 440 Neridronic acid / 441 Nevirapine / 443 Nicarbazin / 447 Nilutamide / 448 Nipradilol / 449 Nitazoxanide / 450 Nitenpyram / 452 vii viii Contents Nomegestrol / 453 Nonoxynol-9 / 454 Nystatin / 455 Octocrylene / 456 Oleic acid / 457 Olmesartan / 469 Olopatadine / 470 Orbifloxacin / 472 Orlistat / 475 Oseltamivir / 477 Oxaliplatin / 479 Oxiconazole / 481 Panipenem / 483 Parecoxib / 484 Paricalcitol / 485 Pazufloxacin / 487 Penciclovir / 488 Pentaerythritol tetranitrate / 490 Pentosan polysulfate / 491 Perflubron / 492 Perospirone / 493 Phenazopyridine hydrochloride / 494 Phentermine / 497 Phosphatidylcholine / 501 Phosphatidylglycerol / 504 Piketoprofen / 508 Pilsicainide / 509 Pioglitazone / 511 Pipercuronium bromide / 514 Pirlimycin / 515 Poloxalene / 518 Pramipexole / 519 Pranlukast / 521 Prednicarbate / 523 Propionylpromazine / 524 Propoxycaine hydrochloride / 527 Propylene glycol / 528 Propylhexedrine / 529 Protirelin / 530 Prulifloxacin / 532 Pyrethrins / 533 Quetiapine / 536 Quinfamide / 539 Quinupristin / 540 Rabeprazole / 542 Ractopamine / 544 Raloxifene / 547 Ramosetron / 549 Rapacuronium bromide / 551 Remifentanil / 553 Repaglinide / 555 Ricinoleic acid / 557 Rifaximin / 558 Rilmazafone / 559 Risedronate sodium / 560 Rizatriptan / 561 Rofecoxib / 562 Ropinirole / 565 Rosiglitazone / 566 Rosuvastatin calcium / 568 Sarafloxacin / 569 Selamectin / 571 Sermorelin / 572 Sibutramine / 574 Sildenafil / 576 Simethicone / 579 Sivelestat / 580 Sodium oxybate / 582 Somatropin / 583 Squalane / 584 Squalene / 585 Stanozolol / 587 Succimer / 588 Succinylcholine chloride / 589 Sulfabromomethazine / 591 Sulfachlorpyridazine / 592 Sulfaethoxypyridazine / 596 Sulfamerazine / 598 Sulfanitran / 600 Sultamicillin / 602 Tacalcitol / 604 Talipexole / 605 Taltirelin / 607 Technetium Tc 99m bicisate / 608 Tegaserod / 609 Telithromycin / 610 Telmesteine / 611 Telmisartan / 612 Temocapril / 614 Temozolomide / 615 Tenofovir disoproxil fumarate / 617 Teprenone / 620 Teriparatide / 621 Tetrachlorvinphos / 622 Tetrahydrozoline / 623 Thalidomide / 626 Thialbarbital / 628 Thyrotropin / 629 Tiagabine / 630 Tiletamine hydrochloride / 631 Contents Tilmicosin / 633 Tiludronic acid / 634 Tirilazad / 635 Tirofiban / 637 Tiropramide / 639 Tizanidine / 641 Tolcapone / 643 Topiramate / 645 Topotecan / 647 Tosufloxacin / 649 Travoprost / 651 Trenbolone / 652 Treprostinil / 653 Trichlorfon / 655 Triethanolamine / 656 Trifluridine / 657 Cumulative Index / 685 Cross-Index to Other Substances / 703 Triptorelin / 658 Troleandomycin / 660 Troxipide / 661 Ubenimex / 662 Unoprostone isopropyl ester / 663 Valacyclovir / 664 Valdecoxib / 666 Valganciclovir / 668 Valrubicin / 670 Valsartan / 671 Zaleplon / 673 Zaltoprofen / 676 Zanamivir / 678 Zinostatin / 680 Zofenopril calcium / 681 Zolazepam hydrochloride / 683 ix PREFACE This book is a collection of procedures for the analysis of more than 390 pharmaceuticals using high-performance liquid chromatography (HPLC) and covers the literature up to the end of 2003. The current volume is a continuation of HPLC Methods for Pharmaceutical Analysis, published in four volumes from 1997 to 2000. The previous volumes described methods published in the literature through the middle of 1998. The current work lists procedures for the analysis of drugs in three broad categories: Drugs that have been approved since the previous volumes were published. Drugs that were approved when the previous volumes were published but for which analytical methods were not then available in the literature. ž Drugs for which procedures allowing determination in a blood matrix have only become available since the previous volumes were published. ž ž Please note that mention of a drug does not necessarily mean that it is currently approved for use in the United States or indeed in any country. Despite the ready availability of computer-aided literature, searching this resource is not exploited as much as it might be. One reason for this reluctance is, of course, that a computer search merely produces a listing of possibly relevant references. Tedious and time-consuming searches in the library are necessary to find the most relevant reference that can be turned into a practical analytical procedure in the searcher’s own laboratory. The reference finally chosen will, naturally, depend on the individual circumstances, such as the matrix in which the drug is present, availability of equipment, and so on. This book circumvents this lengthy process by providing a number of abstracted and evaluated procedures for the analysis of each drug. The analyst can rapidly identify a relevant procedure and put it into practice. In addition to the analytical matrix, other factors may be important when choosing an analytical procedure. Accordingly, we have noted such features of the analytical procedures as sensitivity, mode of detection, other compounds that interfere with the analysis, other drugs that may be determined at the same time, and so on. Readers familiar with our previous publications, HPLC Methods for Pharmaceutical Analysis, Volumes 1–4 (George Lunn and Norman R. Schmuff, John Wiley, New York, 1997–2000) and Handbook of Derivatization Reactions for HPLC (George Lunn and Louise C. Hellwig, John Wiley, New York, 1998), will notice many similarities. The abstract structure is very similar, and the philosophy that the procedures xi xii Preface should be reproducible without reference to the original literature is unchanged. A new feature is that the retention times (in minutes) of other drugs that may be determined using the same system have been added in parentheses after the drug name. Other data, such as the limit of detection (LOD), may also be added. The retention time is the number without units. Unlike the previous volumes, this book is not available on a CD in an electronic form. At the end of the book a Cumulative Index and a Cross-Index to Other Substances are provided. The Cumulative Index provides a comprehensive listing of the drugs covered in this book and the previous volumes. The Cross-Index lists the other compounds that may also be chromatographed under the conditions described in the monographs in this book. Using the information in the monographs it may be possible to develop chromatographic procedures for these compounds. GEORGE LUNN ACKNOWLEDGEMENTS I am grateful for the use of the National Institutes of Health Library, the FDA Medical Library, and the National Library of Medicine and I would like to express my appreciation for the hard work of the staff of these libraries, particularly those diligent workers who reshelve the journal volumes after one of my forays. Although many people have helped with the preparation of this work the mistakes are my own. I would appreciate hearing from anyone who has corrections, comments, or suggestions. I can be reached at lunng@cder.fda.gov. The content of this volume does not necessarily reflect the views or policies of the Food and Drug Administration, nor does the mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Also, mention of a drug does not necessarily mean that it is currently approved for use in the United States or indeed in any country. G.L. xiii ABOUT THIS BOOK SCOPE Newly approved drugs were identified from a variety of sources including the FDA’s annual lists of drug approvals (available at www.fda.gov/cder) and Annual Reports in Medicinal Chemistry published by Elsevier/Academic Press. The journals routinely surveyed for relevant articles are: American Journal of Health-System Pharmacy Analyst Analytica Chimica Acta Analytical Chemistry Analytical Letters Analytical Sciences Antimicrobial Agents and Chemotherapy Arzneimittelforschung Biological and Pharmaceutical Bulletin Biomedical Chromatography Biopharmaceutics and Drug Disposition Chemical and Pharmaceutical Bulletin Chromatographia Clinical Chemistry Clinical Pharmacology and Therapeutics Drug Metabolism and Disposition Farmaco Food Additives and Contaminants Journal of Analytical Toxicology Journal of AOAC International Journal of Chromatographic Science Journal of Chromatography, Part A and Part B Journal of Clinical Pharmacology Journal of Forensic Sciences xv xvi About This Book Journal of Liquid Chromatography & Related Technology Journal of Pharmaceutical and Biomedical Analysis Journal of Pharmaceutical Sciences Journal of Pharmacology and Experimental Therapeutics Pharmaceutical Research Pharmazie Therapeutic Drug Monitoring Xenobiotica Other journals were consulted when relevant articles were identified by computer searches. The literature was surveyed from 1998 through the end of 2003, although methods from some older articles (and a few from 2004) are included. NOMENCLATURE Each chapter is headed by the name and structure of the target compound as well as other useful data such as the CAS Registry Number, molecular formula, molecular weight, and Merck Index number (from the 13th edition).1 More useful information such as melting point, solubility, optical rotation, references to reviews, and so on can be found in the Merck Index. In general, the United States Adopted Name (USAN)2 is used throughout to identify each drug. Names of derivatives, such as esters, which would have different chromatographic properties, are identified by placing the derivative name in parentheses after the retention time. Increasingly, drugs previously marketed as racemates are being marketed as a single enantiomer with the name changed to reflect the enantiomer. For example, levofloxacin is the levorotatory form of ofloxacin. For an achiral HPLC method, the chromatography of a single enantiomer is no different from that of the racemate. In general, in this work and the preceding works, we have listed HPLC procedures under the name of the racemate rather than the single enantiomer. The interested reader is referred to the USP Dictionary2 (page 1208) for the naming conventions used. Generally: Levo rotatory Levo rotatory Dextro rotatory Dextro rotatory S isomer R isomer R isomer S isomer Prefix lev/levoPrefix arPrefix dex/dextroPrefix es- For racemates, the rac- prefix is used. In some cases, the chiral prefix is used. Thus, the following list shows the prefixes that are used in the different volumes: Dexrazoxane in this volume Dextromethorphan in Volume 2 Dextromoramide in Volume 2 Dextrothyroxine in Volume 2 About This Book Levallorphan in Volume 3 Levamisole in Volume 3 Levobunolol in Volume 3 Levodopa in Volume 3 Levonordefrin in Volume 3 and this volume Levorphanol in Volume 3 Levosimendan in this volume Levothyroxine in Volumes 1 and 3. More generally, the name of the racemic compound is used. Thus, For Consult Volume Arformoterol Formoterol 3, this volume Dexamisole Dexamphetamine Dexbrompheniramine Dexbudesonide Dexchlorpheniramine Dexfenfluramine Dexibuprofen Dexketoprofen Dexmedetomidine Dexmethylphenidate Dexpropranolol Dexsotalol Dextroamphetamine Dextropropoxyphene Dexverapamil Levamisole Amphetamine Brompheniramine Budesonide Chlorpheniramine Fenfluramine Ibuprofen Ketoprofen Medetomidine Methylphenidate Propranolol Sotalol Amphetamine Propoxyphene Verapamil 3 2 2 2 2 3 1, 4 1, 4 This volume 1 4 4 2 1, 4 1, 4 Esatenolol Escitalopram Esflurbiprofen Esketamine Esomeprazole Esoxybutynin chloride Eszopiclone Atenolol Citalopram Flurbiprofen Ketamine Omeprazole Oxybutynin chloride Zopiclone 1, 2 2 3 3 1, 3 3 4 Levalbuterol Levamfetamine Levamphetamine Levcycloserine Levdobutamine Levmetamfetamine Levobetaxolol Levobupivacaine Levocarnitine Levocetirizine Levodropropizine Albuterol Amphetamine Amphetamine Cycloserine Dobutamine Methamphetamine Betaxolol Bupivacaine Carnitine Cetirizine Dropropizine 1, 2 2 2 2 2 3 2 2 2 2 2, this volume xvii xviii About This Book Levofenfluramine Levofloxacin Levofuraltadone Levoleucovorin Levomenthol Levomethadone Levomoprolol Levonorgestrel Levopropoxyphene Levopropylhexedrine Levosalbutamol Levosulpiride Fenfluramine Ofloxacin Furaltadone Leucovorin Menthol Methadone Moprolol Norgestrel Propoxyphene Propylhexedrine Albuterol Sulpiride 3 1, 3 3 3 3, this volume 3 3 1 1, 4 4, this volume 1, 2 4 Racementhol Racemethorphan Racemetirosine Racemorphan Racephedrine Racepinephrine Menthol Dextromethorphan Metyrosine Levorphanol Ephedrine Epinephrine 3, this volume 2 This volume 3 3 3 BIBLIOGRAPHIES For reasons of space, it is not possible to abstract every relevant paper, and so at the end of some chapters an Annotated Bibliography lists other relevant papers. After the citation, a few features of the method that are not obvious from the title of the paper may be briefly mentioned to help the reader decide if this paper may be of use. For example, the limit of quantitation of the method may be cited. Unless otherwise mentioned, it may be assumed that a method involves liquid–liquid extraction of a biological fluid from a human and uses reversed-phase HPLC with UV detection. Thus, if a method uses solid-phase extraction (SPE) or fluorescence detection, this will be mentioned. ABSTRACT STRUCTURE The detailed procedures given normally contain the following sections. Of course, not all papers give full details, so some sections may be missing. Matrix Sample preparation Guard column Column Mobile phase Flow rate Injection volume Retention time Detector About This Book xix Internal standard Column temperature Extracted Simultaneous Also Noninterfering Interfering Limit of detection Limit of quantitation Key words Reference ABSTRACT CONVENTIONS Also Column Column temperature Derivatization Detector Extracted Flow rates Guard column Injection volume Interfering Matrix Mobile phase Compounds that can be analyzed at the same time. It is not specified whether they interfere, but they can be extracted. See also Extracted, Simultaneous. Dimensions are length (mm) × internal diameter (mm), and the material is stainless steel unless otherwise indicated. If other than ambient (all temperatures are in degrees C). Pre-column unless otherwise mentioned (in Key Words). Wavelengths in nanometers Compounds that can be extracted from the matrix in question and analyzed at the same time and do not interfere. See also Also, Simultaneous. In milliliters per minute. Dimensions are length (mm) × internal diameter (mm). In microliters (µL). Injection volume may be either the volume actually injected or the volume of the injection loop. If it is the volume actually injected, this value is also given in the Sample preparation section. If the actual injection volume is not given in the Sample preparation section, the Injection volume given is that of the injection loop. Compounds that interfere with the analysis of the target compound. Compounds that interfere with the chromatography of the internal standard (IS) are listed under simultaneous (another IS can always be selected or an external standard procedure can be used). A controlled vocabulary is used (see below) Ratios are v/v and gradients are linear, unless otherwise noted. Times given when describing gradient elution and other procedures such as column switching are the times for each step, e.g., ‘‘MeOH:water 15:85 for 4 min, to 50:50 over 2 min, maintain at 50:50 for 4 min.’’ If we were to include the cumulative times (t) in the example above it would read: ‘‘MeOH:water 15:85 for 4 min (t = 4), to 50:50 over 2 min (t = 6), maintain at 50:50 for 4 min (t = 10).’’ xx About This Book Noninterfering Retention time Simultaneous SPE Species Compounds that do not interfere with the analysis for various reasons, e.g., they are not extracted, they are not detected. In minutes. This is frequently estimated from a reproduced chromatogram, and so the accuracy may not be great. When available, retention times are given for the analyte, the internal standard, and other compounds that may be chromatographed under the same conditions. For the internal standard and other compounds that may be chromatographed under the same conditions, the retention times are given in parentheses after the compound name. Compounds that can be analyzed at the same time and do not interfere. Note that the compound cannot necessarily be extracted from the matrix in question (although it may be). See also Also, Extracted. For the sake of consistency, conditioning procedures for solid-phase extraction (SPE) cartridges are always described at the beginning of the sample preparation sections. Bear in mind, however, that the conditioning procedure should be carried out just prior to use. Thus, if sample preparation is a lengthy procedure, it may be necessary to delay SPE cartridge conditioning until the step requiring the cartridge. If other than human, noun is used instead of adjective, e.g., cow not bovine. In some cases, human may be specified. For example, if both human blood and rat blood are analyzed, both human and rat will be indicated (in Key Words). MATRIX To help with searching, a controlled vocabulary is used to limit the number of terms in the matrix section. For example, the terms raw material, drug substance, or API (active pharmaceutical ingredient) are not used; the term bulk is used instead. In a number of cases, the matrix is associated with various key words, which can be used to narrow the search. For example, the matrix term blood has the key words plasma, serum, and whole blood associated with it. Thus, if you are interested in the determination of the drug in blood in general, you should look in the matrix field for blood. If, however, you are specifically interested in finding the drug in plasma, you should look in the key words field for plasma. Matrix Bile Blood Bulk CSF Formulations Microsomal incubations Associated Key Words Plasma, serum, whole blood Capsules, creams, injections, ointment, tablets, etc. About This Book Milk Perfusate Reaction mixtures Saliva Tissue Urine xxi Brain, heart, kidney, liver, muscle, spleen, etc. ABBREVIATIONS BHT DMSO E em EtOH ex F GPC h HPLC ID IS L LOD LOQ M MeCN MeOH min mL mM MS MSPD MTBE nM psi s SEC SFC SFE SPE Temp U UV vol 2,6-Di-tert-butyl-4-methylphenol, butylated hydroxytoluene Dimethyl sulfoxide Electrochemical detection Emission wavelength Ethanol Excitation wavelength Fluorescence detection Gel permeation chromatography Hour High-performance liquid chromatography Internal diameter Internal standard Liter Limit of detection or some other description indicating that this is the smallest concentration or quantity that can be detected or analyzed for Lower limit of quantitation, either given as such in the paper or taken as the lower limit of the linear quantitation range Molar (i.e., moles/L) Acetonitrile Methanol Minutes Milliliter Millimolar (i.e., millimoles/L) Mass spectrometric detection Matrix solid phase dispersion Methyl tert-butyl ether Nanomolar (i.e., nanomoles/L) Pounds/sq. in. (1 psi = 6.89476 kPa) Seconds Size Exclusion Chromatography Supercritical fluid chromatography Supercritical fluid extraction Solid phase extraction Temperature Units Ultraviolet detection Volume xxii About This Book PIC REAGENTS These reagents are offered by Waters as buffered solutions containing the following compounds: PIC A is tetrabutylammonium sulfate PIC B5 is pentanesulfonic acid PIC B7 is heptanesulfonic acid. WORKING PRACTICES In general, good working practice, for example, using high-grade materials is assumed. Solutions should be protected from light, and silanized glassware should be used unless you have good reason to believe that these precautions are not necessary. Details of solution preparation are generally not given. It should be remembered that the preparation of a dilute aqueous solution of a relatively waterinsoluble compound can frequently be made by dissolving the compound in a small volume of a water-miscible organic solvent and diluting this solution with water. A number of excellent texts3 – 9 discuss good working practices and procedures in HPLC. Please note that all the temperatures are in degrees C. It is also assumed that safe working practices are observed. Organic solvents should only be evaporated in a properly functioning chemical fume hood, correct protective equipment should be worn when dealing with potentially hazardous biological materials, and waste solutions should be disposed of in accordance with all applicable regulations. A number of solvents are particularly hazardous. For example, benzene is a human carcinogen;10 chloroform,11 dichloromethane,12 dioxane,13 and carbon tetrachloride 14 are carcinogenic in experimental animals; and DMF 15 and MTBE 16,17 may be carcinogenic. Organic solvents are, in general, flammable and toxic by inhalation, ingestion, and skin absorption. Sodium azide is carcinogenic and toxic and liberates explosive, volatile, toxic hydrazoic acid when mixed with acid. Sodium azide can form explosive heavy metal azides, for example, with plumbing fixtures, and so should not be discharged down the drain.18 Disposal procedures have been described for a number of hazardous drugs and reagents,18 and a procedure for the hydrolysis of acetonitrile in waste solvent to the much less toxic acetic acid and ammonia19,20 has been described. n-Hexane is surprisingly toxic.21 REFERENCES 1. O’Neil, M.J., Ed., The Merck Index, 13th edition, Merck & Co. Inc, Whitehouse Station, NJ, 2001. 2. United States Pharmacopeial Convention. USP Dictionary of USAN and International Drug Names, United States Pharmacopeial Convention, Rockville, MD, 2004. 3. Snyder, L.R.; Kirkland, J.J. Introduction to Modern Liquid Chromatography, 2nd edition, John Wiley & Sons, New York, 1979. 4. Lawrence, J.F. Organic Trace Analysis by Liquid Chromatography, Academic Press, New York, 1981. 5. Sadek, P.C. The HPLC Solvent Guide, John Wiley & Sons, New York, 1996. About This Book xxiii 6. Snyder, L.R.; Kirkland, J.J.; Glajch, J.L. Practical HPLC Method Development, 2nd edition, John Wiley & Sons, New York, 1997. 7. Meyer, V.R. Pitfalls and Errors of HPLC in Pictures, Hüthig, Heidelberg, Germany, 1997. 8. Meyer, V.R. Practical High-Performance Liquid Chromatography, 3rd edition, John Wiley & Sons, Chichester, UK, 2000. 9. Sadek, P.C. Troubleshooting HPLC Systems. A Bench Manual, John Wiley & Sons, New York, 2000. 10. Lewis, R.J. Sr. Sax’s Dangerous Properties of Industrial Materials, 8th edition, Van Nostrand Reinhold, New York, 1992, pp. 356–358. 11. Lewis, R.J. Sr. Sax’s Dangerous Properties of Industrial Materials, 8th edition, Van Nostrand Reinhold, New York, 1992, pp. 815–816. 12. Lewis, R.J. Sr. Sax’s Dangerous Properties of Industrial Materials, 8th edition, Van Nostrand Reinhold, New York, 1992, pp. 2311–2312. 13. Lewis, R.J. Sr. Sax’s Dangerous Properties of Industrial Materials, 8th edition, Van Nostrand Reinhold, New York, 1992, pp. 1449–1450. 14. Lewis, R.J. Sr. Sax’s Dangerous Properties of Industrial Materials, 8th edition, Van Nostrand Reinhold, New York, 1992, pp. 701–702. 15. Lewis, R.J. Sr. Sax’s Dangerous Properties of Industrial Materials, 8th edition, Van Nostrand Reinhold, New York, 1992, p. 1378. 16. Belpoggi, F.; Soffritti, M.; Maltoni, C. Methyl-tertiary-butyl ether (MTBE) – a gasoline additive – causes testicular and lympho-haematopoietic cancers in rats, Toxicol.Ind.Health., 1995, 11, 119–149. 17. Mehlman, M.A. Dangerous and cancer-causing properties of products and chemicals in the oil refining and petrochemical industry: Part XV. Health hazards and health risks from oxygenated automobile fuels (MTBE): lessons not heeded, Int.J.Occup.Med.Toxicol., 1995, 4, 219–236. 18. Lunn, G.; Sansone, E.B. Destruction of Hazardous Chemicals in the Laboratory, 2nd edition, John Wiley & Sons, New York, 1994. 19. Gilomen, K.; Stauffer, H.P.; Meyer, V.R. Detoxification of acetonitrile – water wastes from liquid chromatography, Chromatographia, 1995, 41, 488–491. 20. Gilomen, K.; Stauffer, H.P.; Meyer, V.R. Management and detoxification of acetonitrile wastes from liquid chromatography, LC.GC, 1996, 14, 56–58. 21. Meyer, V. A safer solvent, Anal.Chem., 1997, 69, 18A. Abacavir H N N Molecular formula: C14 H18 N6 O Molecular weight: 286.33 CAS Registry No: 136470-78-5 (base), 188062-50-2 (sulfate) Merck Index: 13,1 HO N N N NH2 SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg Bond Elut-C SPE cartridge with 1 mL MeOH and 1 mL 100 mM pH 7.0 ammonium acetate buffer. Heat plasma at 58◦ for 1 h to inactivate HIV. Vortex 800 µL plasma with 300 µL 2 µg/mL hexobarbital in 25 mM pH 7.0 ammonium acetate buffer for 30 s and centrifuge at 18 000 g for 5 min. Add 1 mL of the supernatant to the SPE cartridge, wash with 1 mL 100 mM pH 7.0 ammonium acetate buffer, suck dry for 1 min, elute with 800 µL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 40◦ and reconstitute the residue with 100 µL mobile phase. Vortex for 30 s, centrifuge at 18 000 g for 3 min, and inject an 80 µL aliquot. HPLC VARIABLES Guard column: 20 × 3.9 5 µm Polarity dC18 (Waters) Column: 150 × 3.9 5 µm Polarity dC18 (Waters) Column temperature: 40 Mobile phase: Gradient. A was 10 mM pH 6.5 ammonium acetate buffer. B was 10 mM pH 6.5 ammonium acetate buffer:MeCN:MeOH 20:50:30. A:B 96:4 for 15 min, to 36:64 over 15 min, maintain at 36:64 for 3 min, re-equilibrate at initial conditions for 7 min. Flow rate: 1.1 Injection volume: 80 Detector: UV 269 for 11 min, UV 250 for 3 min, UV 271 for 10 min, UV 230 for 9 min CHROMATOGRAM Retention time: 25.1 Internal standard: hexobarbital (30.6) Limit of quantitation: 10.0 ng/mL OTHER SUBSTANCES Extracted: didanosine (13.6), lamivudine (8.6), nevirapine (27.3), stavudine (15.7), zalcitabine (5.9), zidovudine (23.8) Noninterfering: tenofovir KEY WORDS plasma; SPE REFERENCE Rezk, N.L.; Tidwell, R.R.; Kashuba, A.D.M. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection, J.Chromatogr.B, 2003, 791, 137–147. SAMPLE Matrix: blood Sample preparation: Condition a 100 mg Dual Zone C18 SPE cartridge (Diazem) with 2 mL MeOH and 2 mL water. Dilute 500 µL serum with 1 mL water, add to the SPE cartridge, wash with 500 µL water, elute with 1 mL MeOH. Evaporate the eluate to HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 1 2 Abacavir dryness with vortexing under reduced pressure at 40◦ and reconstitute the residue with 300 µL MeOH, inject a 10 µL aliquot. HPLC VARIABLES Column: two 150 × 4.6 3 µm Luna C18 columns in series Column temperature: 60 Mobile phase: Gradient. MeCN:water from 5:95 to 45:55 over 20 min. Flow rate: 0.85 Injection volume: 10 Detector: UV 250 CHROMATOGRAM Retention time: 17 Limit of detection: 75 ng/mL OTHER SUBSTANCES Extracted: didanosine (10.5, LOD 120 ng/mL), lamivudine (9.5, LOD 260 ng/mL), stavudine (11.5, LOD 40 ng/mL), zalcitabine (7.5, LOD 440 ng/mL), zidovudine (16, LOD 30 ng/mL) KEY WORDS SPE; serum REFERENCE Simon, V.A.; Thiam, M.D.; Lipford, L.C. Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography, J.Chromatogr.A, 2001, 913, 447–453. SAMPLE Matrix: blood Sample preparation: Mix 300 µL plasma with 75 µL 20% perchloric acid for 30 s, centrifuge at 1300 g for 15 min, inject a 100 µL aliquot. HPLC VARIABLES Guard column: 20 × 3.8 Symmetry C18 (Waters) Column: 100 × 4.6 3.5 µm Symmetry C18 (Waters) Column temperature: 41 ± 2 Mobile phase: MeCN:25 mM pH 7.0 phosphate buffer 15:85 Flow rate: 1 Injection volume: 100 Detector: UV 285 CHROMATOGRAM Retention time: 4.8 Limit of quantitation: 20 ng/mL OTHER SUBSTANCES Simultaneous: didanosine, folic acid, ganciclovir, lamivudine, nevirapine, pyrazinamide, ranitidine, rifampin, stavudine, sulfamethoxazole, trimethoprim, zidovudine Noninterfering: adefovir, amprenavir, delavirdine, efavirenz, fluconazole, indinavir, itraconazole, methadone, nelfinavir, oxazepam, pyrimethamine, rifampin, ritonavir, saquinavir, zalcitabine KEY WORDS plasma Abacavir 3 REFERENCE Veldkamp, A.I.; Sparidans, R.W.; Hoetelmans, R.M.W.; Beijnen, J.H. Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 1999, 736, 123–128. SAMPLE Matrix: blood Sample preparation: Centrifuge plasma at 4000 g for 20 min using a Centrifree micropartition device (Amicon), inject a 100 µL aliquot of the ultrafiltrate. HPLC VARIABLES Column: 250 × 4.6 Adsorbsphere C18 Mobile phase: Gradient. A was MeCN:water 80:20. B was 50 mM ammonium acetate containing 0.1% triethylamine adjusted to pH 5.5. A:B from 0:100 to 50:50 over 30 min, re-equilibrate at initial conditions for 10 min. Flow rate: 1 Injection volume: 100 Detector: UV 260, UV 285 CHROMATOGRAM Retention time: 23 OTHER SUBSTANCES Extracted: carbovir (20) KEY WORDS rat; pharmacokinetics; plasma REFERENCE Daluge, S.M.; Good, S.S.; Faletto, M.B.; Miller, W.H.; St.Clair, M.H.; Boone, L.R.; Tisdale, M.; Parry, N.R.; Reardon, J.E.; Dornsife, R.E.; Averett, D.R.; Krenitsky, T.A. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity, Antimicrob.Agents Chemother., 1997, 41, 1082–1093. SAMPLE Matrix: CSF, urine Sample preparation: Centrifuge CSF or urine at 12 000 g for 5 min, dilute a 75 µL aliquot to 750 µL with mobile phase, inject an aliquot. HPLC VARIABLES Column: 150 × 3.2 5 µm Kromasil C18 (Phenomenex) Mobile phase: Gradient. MeOH:25 mM pH 4.0 ammonium acetate buffer from 5:95 to 50:50 over 30 min, re-equilibrate at initial conditions for 10 min. Flow rate: 0.7 Detector: UV 295 CHROMATOGRAM Retention time: 25.5 Limit of quantitation: 62 ng/mL (CSF), 629 ng/mL (urine) OTHER SUBSTANCES Extracted: metabolites, abacavir 5′ -glucuronide, abacavir 5′ -carboxylate 4 Abacavir REFERENCE Ravitch, J.R.; Moseley, C.G. High-performance liquid chromatographic assay for abacavir and its two major metabolites in human urine and cerebrospinal fluid, J.Chromatogr., 2001, 762, 165–173. ANNOTATED BIBLIOGRAPHY Fung, E.N.; Cai, Z.; Burnette, T.C.; Sinhababu, A.K. Simultaneous determination of Ziagen and its phosphorylated metabolites by ion-pairing high-performance liquid chromatography-tandem mass spectrometry, J.Chromatogr.B, 2001, 754, 285–295. [LC-MS] Sparidans, R.W.; Hoetelmans, R.M.W.; Beijnen, J.H. Liquid chromatographic assay for simultaneous determination of abacavir and mycophenolic acid in human plasma using dual spectrophotometric detection, J.Chromatogr.B, 2001, 750, 155–161. Thomas, S.A.; Bye, E.; Segal, M.B. Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid, J.Pharmacol.Exp.Ther., 2001, 298, 947–953. Yuen, G.J.; Lou, Y.; Thompson, N.F.; Otto, V.R.; Allsup, T.L.; Mahony, W.B.; Hutman, H.W. Abacavir/lamivudine/zidovudine as a combined formulation tablet: Bioequivalence compared with each component administered concurrently and the effect of food on absorption, J.Clin.Pharmacol., 2001, 41, 277–288. Aymard, G.; Legrand, M.; Trichereau, N.; Diquet, B. Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography, J.Chromatogr.B, 2000, 744, 227–240. [for amprenavir; efavirenz; indinavir; nelfinavir; ritonavir; saquinavir; abacavir; didanosine; lamivudine; stavudine; nevirapine; zidovudine] McDowell, J.A.; Lou, Y.; Symonds, W.S.; Stein, D.S. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virusinfected adults, Antimicrob.Agents Chemother., 2000, 44, 2061–2067. Kumar, P.N.; Sweet, D.E.; McDowell, J.A.; Symonds, W.; Lou, Y.; Hetherington, S.; LaFon, S. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults, Antimicrob.Agents Chemother., 1999, 43, 603–608. McDowell, J.A.; Chittick, G.E.; Ravitch, J.R.; Polk, R.E.; Kerkering, T.M.; Stein, D.S. Pharmacokinetics of [14 C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study, Antimicrob.Agents Chemother., 1999, 43, 2855–2861. Wang, L.H.; Chittick, G.E.; McDowell, J.A. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection, Antimicrob.Agents Chemother., 1999, 43, 1708–1715. Acarbose Acarbose Molecular formula: C25 H43 NO18 5 OH HO HO Molecular weight: 645.60 CAS Registry No: 56180-94-0 Merck Index: 13, 18 OH H H3C N HO O OH O HO OH O OH O HO OH O OH OH SAMPLE Matrix: formulations Sample preparation: Powder tablet, extract 3 times with 5 mL aliquots of water with sonication for 15 min with vortexing at 5 min intervals each time, centrifuge at 2750 g for 5 min, combine supernatants, make up to 20 mL with water. Dilute a 50 µL aliquot to 1 mL with MeOH, filter (0.2 µM), inject a 20 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Nucleosil-NH2 Mobile phase: MeOH:dichloromethane 65:35 Flow rate: 1 Injection volume: 20 Detector: ELSD, nebulizing gas air at 2.5 bar and 4 L/min, solvent evaporated at 40◦ CHROMATOGRAM Retention time: 4.1 Limit of detection: 5 µg/mL Limit of quantitation: 15 µg/mL OTHER SUBSTANCES Simultaneous: sucrose (3.5) KEY WORDS comparison with capillary electrophoresis; tablets REFERENCE Cherkaoui, S.; Daali, Y.; Christen, P.; Veuthey, J.-L. Development and validation of liquid chromatography and capillary electrophoresis methods for acarbose determination in pharmaceutical tablets, J.Pharm.Biomed.Anal., 1998, 18, 729–735. 6 Acetyl sulfisoxazole Acetyl sulfisoxazole Molecular formula: C13 H15 N3 O4 S Molecular weight: 309.35 CAS Registry No: 80-74-0 Merck Index: 13, 9041 O O S H2N O O N CH3 N CH3 CH3 SAMPLE Matrix: formulations Sample preparation: Extract 1 mL suspension with three 15 mL aliquots of chloroform (Caution! Chloroform is a carcinogen!), combine the organic layers and make up to 50 mL with chloroform, filter (0.45 µm silver membrane, Selas Corp.). Evaporate a 2 mL aliquot of the filtrate to dryness under a stream of nitrogen, reconstitute with 5 mL 330 µg/mL benzanilide in MeCN, inject a 5 µL aliquot. HPLC VARIABLES Column: 300 × 4 10 µm µBondapak C18 Mobile phase: MeCN:water 40:60 Flow rate: 1.5 Injection volume: 5 Detector: UV 254 CHROMATOGRAM Retention time: 7 Internal standard: benzanilide (11) OTHER SUBSTANCES Simultaneous: sulfanilamide (2.5), sulfisoxazole (3) Noninterfering: erythromycin ethylsuccinate KEY WORDS oral suspensions REFERENCE Elrod, L. Jr.; Cox, R.D.; Plasz, A.C. Analysis of oral suspensions containing sulfonamides in combination with erythromycin ethylsuccinate, J.Pharm.Sci., 1982, 71, 161–166. ANNOTATED BIBLIOGRAPHY Suber, R.L.; Edds, G.T. High performance liquid chromatographic determinations of sulfonamides by ionic suppression, J.Liq.Chromatogr., 1980, 3, 257–268. [for sulfanilamide; sulfaguanidine; sulfamerazine; sulfamethazine; sulfapyridine; sulfisoxazole; N-acetylsulfisoxazole; sulfathiazole; in plasma] Acrivastine Acrivastine N N Molecular formula: C22 H24 N2 O2 Molecular weight: 348.44 CAS Registry No: 87848-99-5 Merck Index: 13, 129 7 COOH H3C SAMPLE Matrix: blood Sample preparation: Mix 1 mL whole blood with 20 µL 1 µg/mL dibenzepin in MeOH:water 50:50, add 300 µL pH 11 tris buffer, mix, add 500 µL butyl acetate, vortex for 2 min, centrifuge. Preserve the aqueous layer (A). Remove the organic layer and add it to 75 µL 10 mM ammonium acetate buffer containing 0.1% formic acid (pH 3.2), evaporate (?). Add 75 µL MeCN, sonicate for 5 min, centrifuge at 5000 rpm for 5 min, keep the extract as B. Add 20 µL 1 µg/mL enalapril in MeOH:water 50:50 and 120 mg NaCl to the aqueous layer (A), mix, add 500 µL pH 3 phosphate buffer, add 600 µL 8.5% phosphoric acid, add 5 mL dichloromethane:isopropanol 95:5, shake at 250 cycles/min in a bench-top shaker for 30 min, centrifuge at 5000 rpm for 5 min. Remove the lower organic layer and evaporate it to dryness under a stream of air at 45◦ . Reconstitute the residue with 150 µL initial mobile phase, sonicate, centrifuge, combine with extract B, inject a 30 µL aliquot. (Sample preparation from Gergov,M.; Robson,J.N.; Ojanperä,I.; Heinonen,O.P.; Vuori,E. Simultaneous screening and quantitation of 18 antihistamine drugs in blood by liquid chromatography ionspray tandem mass spectrometry. Forensic Sci.Inter. 2001, 121, 108–115.) HPLC VARIABLES Guard column: 40 mm long 4 µm Purospher RP-18 LiChro Cart 4-4 Column: 100 × 2.1 4 µm Genesis C18 (Jones Chromatography) Column temperature: 35 Mobile phase: Gradient. MeCN:buffer from 20:80 to 100:0 over 10 min, maintain at 0:100 for 3 min, re-equilibrate at initial conditions for 5 min. (Buffer was 10 mM ammonium acetate containing 0.1% formic acid (pH 3.2). Flow rate: 0.2 Injection volume: 30 Detector: MS, PE Sciex API 365 triple stage quadrupole LC-MS-MS, PE Sciex Turbo Ion Spray interface, positive ion mode, needle voltage 5.2 kV, nebulizer gas air at 60 psi, curtain gas nitrogen at 40 psi, collision cell gas nitrogen at 40 psi, turbo ionspray heater 375◦ , heater gas flow 7 L/min CHROMATOGRAM Retention time: 5.7 Internal standard: dibenzepin, enalapril Limit of detection: <20 ng/mL OTHER SUBSTANCES Extracted: acebutolol (3.8, LOD 0.1 µg/mL), acetaminophen (2.5, LOD <5 µg/mL), alprazolam (6.1, LOD <0.02 µg/mL), alprenolol (5.4, LOD 0.01 µg/mL), amantadine (3.4, LOD 0.1 µg/mL), amiloride (2.0, LOD 0.1 µg/mL), aminophenazone (2.8, LOD <5 µg/mL), amiodarone (10.2, LOD 0.05 µg/mL), amitriptyline (6.6, LOD <0.02 µg/mL), astemizole (5.8, LOD <0.02 µg/mL), atenolol (1.7, LOD 0.30 µg/mL), azacyclonol (5.1, LOD 0.02 µg/mL), benzhexol (6.6, LOD <0.02 µg/mL), benzoylecgonine (3.3, LOD 0.01 µg/mL), betaxolol (5.5, LOD 0.01 µg/mL), biperidine (6.2, LOD <0.02 µg/mL), bisoprolol (5.0, LOD <0.02 µg/mL), brompheniramine (5.3, LOD 0.002 µg/mL), bupivacaine (5.1, LOD <0.02 µg/mL), buprenorphine (5.9, LOD 0.01 µg/mL), buspirone (5.1, LOD 0.002 µg/mL), caffeine (2.8, LOD 1 µg/mL), carbamazepine 8 Acrivastine (6.1, LOD <0.02 µg/mL), carbinoxamine (5.1, LOD 0.002 µg/mL), carisoprodol (6.7, LOD <5 µg/mL), carvedilol (6.2, LOD <0.02 µg/mL), celiprolol (4.3, LOD 0.05 µg/mL), cetirizine (6.3, LOD 0.05 µg/mL), chlorcyclizine (6.6, LOD <0.02 µg/mL), chlordiazepoxide (5.7, LOD <0.02 µg/mL), chlormezanone (5.8, LOD <5 µg/mL), chloroquine (2.7, LOD 0.02 µg/mL), chlorpheniramine (5.1, LOD 0.002 µg/mL), chlorpromazine (7.0, LOD 0.02 µg/mL), chlorpropamide (6.7, LOD <5 µg/mL), chlorprothixene (7.0, LOD <0.02 µg/mL), cinnarizine (7.9, LOD <0.02 µg/mL), citalopram (5.7, LOD <0.02 µg/mL), clemastine (7.7, LOD 0.02 µg/mL), clobazam (7.3, LOD <0.02 µg/mL), clobutinol (5.3, LOD 0.02 µg/mL), clomethiazole (6.2, LOD 0.5 µg/mL), clomipramine (7.1, LOD <0.02 µg/mL), clonazepam (6.6, LOD <0.02 µg/mL), clonidine (2.8, LOD 0.1 µg/mL), clozapine (5.6, LOD <0.02 µg/mL), cocaine (4.6, LOD <0.02 µg/mL), codeine (2.5, LOD 0.1 µg/mL), coumatetralyl (8.4, LOD 0.05 µg/mL), cyclizine (5.8, LOD <0.02 µg/mL), dextropropoxyphene (6.6, LOD 0.05 µg/mL), demoxepam (5.8, LOD 0.02 µg/mL), dextromethorphan (5.5, LOD <0.02 µg/mL), diazepam (8.1, LOD 0.02 µg/mL), diltiazem (5.8, LOD <0.02 µg/mL), diphenhydramine (5.7, LOD <0.02 µg/mL), dipyridamole (5.4, LOD 0.005 µg/mL), disopyramine (4.4, LOD <0.02 µg/mL), dixyrazine (6.8, LOD 0.005 µg/mL), doxapram (4.8, LOD <0.02 µg/mL), doxepin (5.9, LOD <0.02 µg/mL), dronabinol (12.3, LOD 0.05 µg/mL), ebastine (9.6, LOD 0.005 µg/mL), embutramide (6.7, LOD 0.005 µg/mL), ergotamine (5.5, LOD 0.005 µg/mL), ethenzamide (5.0, LOD 0.05 µg/mL), ethylmorphine (3.2, LOD 0.05 µg/mL), ethylparathion (9.7, LOD <5 µg/mL), etodroxizine (6.4, LOD <0.02 µg/mL), felodipine (9.6, LOD 0.02 µg/mL), fenazepam (7.5, LOD <0.02 µg/mL), fenfluramine (5.3, LOD <0.02 µg/mL), fenkamfamine (5.1, LOD <0.02 µg/mL), fentanyl (5.5, LOD <0.02 µg/mL), fexofenadine (6.3, LOD <0.02 µg/mL), flecainide (5.9, LOD <0.02 µg/mL), fluconazole (4.0, LOD 0.1 µg/mL), flumazenil (5.2, LOD <0.02 µg/mL), flunitrazepam (7.1, LOD 0.002 µg/mL), fluoxetine (6.8, LOD 0.1 µg/mL), flupentixol (7.5, LOD 0.18 µg/mL), fluvoxamine (6.3, LOD 0.02 µg/mL), glibenclamide (8.5, LOD <0.02 µg/mL), glipizide (6.8, LOD <0.05 µg/mL), haloperidol (6.1, LOD <0.02 µg/mL), histapyrrodine (6.3, LOD 0.02 µg/mL), hydrocodone (3.0, LOD 0.05 µg/mL), hydroxychloroquine (2.4, LOD <0.3 µg/mL), hydroxyzine (6.3, LOD <0.02 µg/mL), imipramine (6.4, LOD 0.05 µg/mL), indomethacin (8.6, LOD 0.05 µg/mL), isoniazid (2.2, LOD 3 µg/mL), isradipine (8.6, LOD 0.05 µg/mL), ketamine (3.6, LOD <0.05 µg/mL), ketobemidone (3.3, LOD <0.05 µg/mL), ketoprofen (7.3, LOD 0.1 µg/mL), ketorolac (6.2, LOD 0.05 µg/mL), labetalol (4.9, LOD 0.05 µg/mL), lamotrigine (4.0, LOD 0.1 µg/mL), levocabastine (5.8, LOD 0.01 µg/mL), levomepromazine (6.5, LOD 0.02 µg/mL), lidocaine (3.7, LOD <0.05 µg/mL), loratadine (9.3, LOD 0.002 µg/mL), lorazepam (6.6, LOD 0.02 µg/mL), lormetazepam (7.4, LOD <0.02 µg/mL), LSD (4.7, LOD <0.02 µg/mL), malathion (8.9, LOD 10 µg/mL), maprotiline (6.4, LOD <0.02 µg/mL), MDMA (3.3, LOD 0.02 µg/mL), meclozine (8.5, LOD <0.02 µg/mL), medazepam (6.3, LOD <0.02 µg/mL), meloxicam (7.1, LOD 0.01 µg/mL), melperone (5.0, LOD <0.02 µg/mL), meperidine (4.7, LOD <0.02 µg/mL), mepivacaine (3.7, LOD <0.02 µg/mL), meprobamate (4.9, LOD 0.1 µg/mL), mesoridazine (5.4, LOD <0.02 µg/mL), methamphetamine (3.3, LOD 0.05 µg/mL), methadone (6.7, LOD <0.02 µg/mL), methylparathion (8.6, LOD 10 µg/mL), methylphenidate (4.2, LOD <0.02 µg/mL), metoclopramide (3.8, LOD <0.02 µg/mL), metoprolol (4.1, LOD 0.02 µg/mL), metronidazole (2.6, LOD 1 µg/mL), mexiletine (4.4, LOD 0.05 µg/mL), mianserin (5.7, LOD <0.02 µg/mL), midazolam (5.9, LOD <0.02 µg/mL), mirtazapine (4.4, LOD <0.02 µg/mL), mizolastine (5.5, LOD 0.01 µg/mL), moclobemide (3.7, LOD 0.05 µg/mL), molindone (4.0, LOD <0.02 µg/mL), monoacetylmorphine (2.7, LOD 0.1 µg/mL), morphine (2.0, LOD 0.1 µg/mL), nicotine (2.2, LOD 0.05 µg/mL), nifedipine (7.5, LOD 0.02 µg/mL), nikethamide (3.6, LOD <0.02 µg/mL), nitrazepam (6.5, LOD <0.02 µg/mL), nizatidine (1.7, LOD 1 µg/mL), nomifensine (4.6, LOD <0.02 µg/mL), nortriptyline (6.4, LOD <0.02 µg/mL), norverapamil (6.2, LOD 1 µg/mL), noscapine (5.0, LOD <0.02 µg/mL), olanzapine (3.0, LOD 0.05 µg/mL), ondansetron (4.6, LOD <0.02 µg/mL), orphenadrine (6.1, LOD <0.02 µg/mL), oxazepam (6.3, LOD <0.02 µg/mL), oxcarbazepine (5.3, LOD 0.02 µg/mL), oxprenolol (4.7, LOD 0.02 µg/mL), oxycodone (2.8, LOD 0.05 µg/mL), papaverine (4.8, LOD <0.02 µg/mL), paroxetine (6.2, LOD 0.02 µg/mL), pemoline (3.3, LOD 0.05 µg/mL), pentazocine (5.0, LOD <0.02 µg/mL), pentifylline (7.3, LOD <5 µg/mL), pentoxyverine (6.6, LOD <0.02 µg/mL), perphenazine (6.9, LOD 0.002 µg/mL), phenazone (3.9, LOD Acrivastine 9 0.05 µg/mL), phencyclidine (5.3, LOD 0.05 µg/mL), pheniramine (4.1, LOD 0.02 µg/mL), phenylbutazone (9.0, LOD <5 µg/mL), phenylpropanolamine (2.5, LOD 0.3 µg/mL), phenytoin (6.1, LOD 0.05 µg/mL), pindolol (3.3, LOD 0.05 µg/mL), piroxicam (6.6, LOD 0.02 µg/mL), pitofenone (5.4, LOD <0.02 µg/mL), pizotifen (6.5, LOD <0.02 µg/mL), practolol (1.8, LOD 0.1 µg/mL), prazosin (4.1, LOD 0.05 µg/mL), prilocaine (3.8, LOD <0.02 µg/mL), primidone (4.0, LOD <5 µg/mL), procainamide (2.2, LOD 0.05 µg/mL), prochlorperazine (7.5, LOD 0.02 µg/mL), promazine (6.2, LOD <0.02 µg/mL), promethazine (6.0, LOD 0.05 µg/mL), propafenone (6.3, LOD <0.02 µg/mL), propranolol (5.4, LOD 0.02 µg/mL), propyphenazone (6.6, LOD 0.50 µg/mL), pseudoephedrine (2.6, LOD 1 µg/mL), quinine (4.2, LOD 0.02 µg/mL), ranitidine (1.8, LOD 0.1 µg/mL), risperidone (4.9, LOD <0.02 µg/mL), rocurone (3.8, LOD 0.1 µg/mL), ropivacaine (4.6, LOD <0.02 µg/mL), salicylamide (4.2, LOD <5 µg/mL), selegiline (4.1, LOD 0.05 µg/mL), sertindole (7.2, LOD <0.02 µg/mL), sertraline (6.8, LOD 0.02 µg/mL), sulindac (6.5, LOD 0.02 µg/mL), simazine (6.0, LOD 0.1 µg/mL), sincocaine (6.5, LOD <0.02 µg/mL), sisapride (5.9, LOD <0.02 µg/mL), sotalol (2.1, LOD 0.1 µg/mL), strychnine (5.3, LOD 0.05 µg/mL), sulpiride (1.9, LOD 0.1 µg/mL), sulthiame (4.1, LOD 0.05 µg/mL), temazepam (7.2, LOD <0.02 µg/mL), terbutaline (2.3, LOD 0.1 µg/mL), terfenadine (8.1, LOD 0.002 µg/mL), terodiline (6.7, LOD <0.02 µg/mL), tetracaine (5.7, LOD <0.02 µg/mL), tetrahydrozoline (3.6, LOD 0.1 µg/mL), theobromine (2.3, LOD <5 µg/mL), theophylline (2.4, LOD <5 µg/mL), thioridazine (7.5, LOD 0.02 µg/mL), timolol (3.8, LOD 0.05 µg/mL), thiothixene (6.7, LOD 0.02 µg/mL), tolbutamide (7.1, LOD <5 µg/mL), toremifene (8.7, LOD 0.02 µg/mL), tramadol (4.2, LOD 0.02 µg/mL), trazodone (5.2, LOD <0.02 µg/mL), triamterene (3.2, LOD 0.1 µg/mL), triazolam (6.7, LOD 0.002 µg/mL), trimeprazine (6.4, LOD <0.02 µg/mL), trimethoprim (3.1, LOD 0.05 µg/mL), trimipramine (6.7, LOD <0.02 µg/mL), venlafaxine (4.9, LOD 0.02 µg/mL), verapamil (6.5, LOD <0.02 µg/mL), warfarin (7.9, LOD <0.02 µg/mL), yohimbine (4.5, LOD <0.02 µg/mL), zolpidem (4.7, LOD <0.02 µg/mL), zopiclone (4.0, LOD 0.1 µg/mL) KEY WORDS whole blood REFERENCE Gergov, M.; Ojanperä, I.; Vuori, E. Simultaneous screening for 238 drugs in blood by liquid chromatography-ionspray tandem mass spectrometry with multiple-reaction monitoring, J.Chromatogr.B, 2003, 795, 41–53. 10 Adapalene Adapalene COOH Molecular formula: C28 H28 O3 Molecular weight: 412.52 CAS Registry No: 106685-40-9 Merck Index: 13, 150 H3CO SAMPLE Matrix: formulations Sample preparation: Inject an aliquot of a 0.1% gel. HPLC VARIABLES Column: 250 × 4 ODS-RP18 (Merck) Mobile phase: MeCN:THF:water:trifluoroacetic acid 43:36:21:0.02 Flow rate: 1 Detector: UV 270 CHROMATOGRAM Retention time: 6.1 OTHER SUBSTANCES Noninterfering: tretinoin KEY WORDS gel REFERENCE Martin, B.; Meunier, C.; Montels, D.; Watts, O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation, Br.J.Dermatol., 1998, 139 (Suppl. 52), 8–11. 11 Adefovir dipivoxil Adefovir dipivoxil Molecular formula: C20 H32 N5 O8 P Molecular weight: 501.47 CAS Registry No: 142340-99-6 Merck Index: 13, 151 NH2 CH3 CH3 N N O N CH3 O N O P O O O O O CH3 CH3 CH3 SAMPLE Matrix: blood Sample preparation: Mix 100 µL plasma with 200 µL 0.1% trifluoroacetic acid in MeCN. Evaporate the supernatant to dryness under reduced pressure at room temperature. Reconstitute with 0.34% chloroacetaldehyde in 100 mM pH 4.5 sodium acetate, vortex, centrifuge. Heat the supernatant at 95◦ for 40 min, evaporate to dryness, reconstitute with 100 µL 25 mM pH 6.0 potassium phosphate buffer containing 5 mM tetrabutylammonium hydrogen phosphate, inject a 50 µL aliquot. HPLC VARIABLES Guard column: 15 × 3.2 Brownlee RP-18 Newguard Column: 150 × 4.6 Zorbax RX-C18 Column temperature: 35 Mobile phase: Gradient. A was MeCN:25 mM pH 6.0 potassium phosphate buffer containing 5 mM tetrabutylammonium hydrogen phosphate 2:98. B was MeCN:25 mM pH 6.0 potassium phosphate buffer containing 5 mM tetrabutylammonium hydrogen phosphate 65:35. A:B 100:0 for 2 min, to 0:100 over 13 min, re-equilibrate at initial conditions for 10 min. (Only adefovir is detected in blood. However, the method is reported to distinguish between adefovir and adefovir dipivoxil.) Flow rate: 1.5 Injection volume: 50 Detector: F ex 236 em 420 KEY WORDS derivatization; dog; pharmacokinetics; plasma REFERENCE Cundy, K.C.; Sue, I.-L.; Visor, G.C.; Marshburn, J.; Nakamura, C.; Lee, W.A.; Shaw, J.P. Oral formulations of adefovir dipivoxil: In vitro dissolution and in vivo bioavailability in dogs, J.Pharm.Sci., 1997, 86, 1334–1338. SAMPLE Matrix: blood Sample preparation: Vortex 200 µL plasma with 50 µL 20% trichloroacetic acid in water, centrifuge at 1300 g for 15 min. Remove 150 µL of the supernatant and mix it with 50 µL 160 mM chloroacetaldehyde in water containing 2 M sodium acetate, vortex, close the tube, heat at 98◦ for 30 min, cool to 2◦ , vortex, inject a 20 µL aliquot. HPLC VARIABLES Guard column: 10 × 3 R3 (Chrompack) Column: 150 × 4.6 5 µm Chromspher C8 Column temperature: 40 ± 2 Mobile phase: MeCN:buffer 10:90 (Buffer was 10 mM pH 7.0 sodium phosphate buffer containing 2 mM tetrabutylammonium hydrogen sulfate.) Flow rate: 1.5 12 Adefovir dipivoxil Injection volume: 20 Detector: F ex 254 em 425 CHROMATOGRAM Retention time: 4.5 Limit of quantitation: 10 ng/mL OTHER SUBSTANCES Extracted: adefovir (4) KEY WORDS derivatization; plasma REFERENCE Sparidans, R.W.; Veldkamp, A.; Hoetelmans, R.M.W.; Beijnen, J.H. Improved and simplified liquid chromatographic assay for adefovir, a novel antiviral drug, in human plasma using derivatization with chloroacetaldehyde, J.Chromatogr.B, 1999, 736, 115–121. Adrenocorticotropic hormone 13 Adrenocorticotropic hormone CAS Registry No: 9002-60-2 Merck Index: 13, 136 SAMPLE Matrix: blood Sample preparation: Condition a 1 mL Analytichem weak cation-exchange (carboxymethylhydrogen form, CBA) SPE cartridge with 1 mL 1% trifluoroacetic acid in MeOH, 1 mL MeOH, and 2 mL water. Add 1 mL plasma to the SPE cartridge, rinse the tube with 1 mL water, add the rinse to the SPE cartridge, wash with 1 mL 1% trifluoroacetic acid in water, wash with 2 mL water, wash with 2 mL MeOH, elute with 2 mL 1% trifluoroacetic acid in MeOH. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue in 100 µL MeOH:buffer 50:50, inject a 5–75 µL aliquot. (Buffer was 5.7 g monochloroacetic acid, 2.0 g NaOH, and 0.2 g disodium EDTA in 1 L water, pH 3.2.) (The procedure was not necessarily validated for this compound.) HPLC VARIABLES Column: 250 × 2 5 µm Ultrasphere octyl Column temperature: 60 Mobile phase: Gradient. A was MeOH containing 10 mM sodium octanesulfonate. B was buffer containing 10 mM sodium octanesulfonate. A:B from 45:55 to 70:30 over 30 min, maintain at 70:30 for 1 h. (The buffer was 5.7 g monochloroacetic acid, 2.0 g NaOH, and 0.2 g disodium EDTA in 1 L water, pH 3.2.) Flow rate: 0.3 Injection volume: 5–75 Detector: F ex 390 em 470 following post-column reaction. The column effluent mixed with 400 mM NaOH pumped at 0.15 mL/min and 0.05% ninhydrin pumped at 0.05 mL/min and the mixture flowed through a 12 m ×0.33 mm ID reaction coil at 70◦ to the detector. CHROMATOGRAM Retention time: 45 Limit of detection: 100 fmole OTHER SUBSTANCES Simultaneous: angiotensin I, angiotensin II, angiotensin III, atrial natriuretic peptide, bombesin, bradykinin, gonadorelin (LHRH), somatoliberin, vasopressin KEY WORDS plasma; post-column reaction; SPE REFERENCE Rhodes, G.R.; Boppana, V.K. High-performance liquid chromatographic analysis of arginine-containing peptides in biological fluids by means of a selective post-column reaction with fluorescence detection, J.Chromatogr., 1988, 444, 123–131. SAMPLE Matrix: solutions HPLC VARIABLES Column: 300 × 3.9 10 µm µBondapak C18 Mobile phase: Gradient. A was 0.08% trifluoroacetic acid. B was MeCN:0.08% trifluoroacetic acid 70:30. A:B from 70:30 to 50:50 over 30 min. 14 Adrenocorticotropic hormone Flow rate: 1 Detector: UV 206 CHROMATOGRAM Retention time: 25 OTHER SUBSTANCES Simultaneous: adrenocorticotropic hormone fragments, melanotropin KEY WORDS human REFERENCE McDermott, J.R.; Smith, A.I.; Biggins, J.A.; Al-Noaemi, M.C.; Edwardson, J.A. Characterization and determination of neuropeptides by high-performance liquid chromatography and radioimmunoassay, J.Chromatogr., 1981, 222, 371–379. SAMPLE Matrix: solutions Sample preparation: Dissolve in 100 mM NaH2 PO4 adjusted to pH 2.1 with orthophosphoric acid, inject a 100 µL aliquot. HPLC VARIABLES Column: 250 × 4 Aquapore RP 300 (Kontron) Mobile phase: Gradient. A was 100 mM NaH2 PO4 adjusted to pH 2.1 with orthophosphoric acid. B was MeOH. A:B from 90:10 to 35:65 over 180 min. Flow rate: 1 Injection volume: 100 Detector: UV 225 CHROMATOGRAM Retention time: 145 OTHER SUBSTANCES Simultaneous: adrenocorticotropin hormone fragments, lipotropic hormone and fragments, melanotropin, endorphins, prolactin, somatropin, menotropins KEY WORDS pig REFERENCE Richter, W.O.; Schwandt, P. Separation of neuropeptides by HPLC: evaluation of different supports, with analytical and preparative applications to human and porcine neurophysins, β-lipotropin, adrenocorticotropic hormone, and β-endorphin, J.Neurochem., 1985, 44, 1697–1703. ANNOTATED BIBLIOGRAPHY Capp, M.W.; Simonian, M.H. Separation of the major adrenal steroids by reversed-phase highperformance liquid chromatography, Anal.Biochem., 1985, 147, 374–381. Janssen, P.S.; van Nispen, J.W.; Hamelinck, R.L.; Melgers, P.A.; Goverde, B.C. Application of reversedphase HPLC in some critical peptide separations, J.Chromatogr.Sci., 1984, 22, 234–238. Smith, A.I.; McDermott, J.R. High-performance liquid chromatography of neuropeptides using radially compressed polythene cartridges, J.Chromatogr., 1984, 306, 99–108. 15 Afloqualone Afloqualone Molecular formula: C16 H14 FN3 O Molecular weight: 283.30 CAS Registry No: 56287-74-2 Merck Index: 13, 183 N H2N F N O H3C SAMPLE Matrix: solutions HPLC VARIABLES Column: Chiralpak AS Column temperature: 50 Mobile phase: Hexane:EtOH 95:5 Flow rate: 1.3 Detector: UV 254 CHROMATOGRAM Retention time: 30, 35 (enantiomers) KEY WORDS chiral REFERENCE Application Guide for Chiral Column Selection, Second Edition; Chiral Technologies: Exton PA, 1995, p. 43. 16 Alacepril Alacepril H O O Molecular formula: C20 H26 N2 O5 S Molecular weight: 406.50 CAS Registry No: 74258-86-9 Merck Index: 13, 200 N O COOH H3C S N CH3 SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 10 µm Cosmosil 5C18-MS Column temperature: 50 Mobile phase: Gradient. MeCN:10 mM pH 2.5 potassium phosphate buffer 0:100 for 2 min, to 75:25 over 7.5 min, maintain at 75:25 for 5.5 min. Isocratic. MeCN:buffer 40:60 Flow rate: 1.5 Detector: UV (wavelength not specified) CHROMATOGRAM Retention time: 10.9 (gradient) or 4.1 (isocratic) OTHER SUBSTANCES Simultaneous: acetaminophen (7.9), ampicillin (7.9), aspirin (10.0), caffeine (8.5), carbenicillin (9.5), cefotiam (7.2), chlorpromazine (10.8), cromolyn (8.9), enalapril (9.9), loperamide (11.6), ofloxacin (8.3), procainamide (7.4), procaine (7.9), propranolol (9.6), sultamicillin tosylate (8.3), tegafur (8.4), temocapril (12.3), theophylline (8.0), tulobuterol (8.9) (gradient retention times; isocratic conditions may differ) REFERENCE Sugiyama, T.; Matsuyama, R.; Usui, S.; Katagiri, Y.; Hirano, K. Selection of mobile phases in highperformance liquid chromatographic determination for medicines, Biol.Pharm.Bull., 2000, 23, 274–278. SAMPLE Matrix: enzyme reactions Sample preparation: Mix 40 µL enzyme reaction mixture with 200 µL MeCN, add 200 µL of a 20 µg/mL solution of n-propyl paraben, centrifuge, inject a 30 µL aliquot of the supernatant. HPLC VARIABLES Column: 250 × 4.6 Cosmosil 5-C18 MS Column temperature: 50 Mobile phase: MeCN:10 mM pH 2.5 potassium phosphate buffer 40:60 Flow rate: 1.5 Injection volume: 30 Detector: UV 220 CHROMATOGRAM Internal standard: n-propyl paraben Alacepril 17 OTHER SUBSTANCES Extracted: deacetylalacepril REFERENCE Usui, S.; Kubota, M.; Iguchi, K.; Kiho, T.; Sugiyama, T.; Katagiri, Y.; Hirano, K. Sialic acid 9-Oacetylesterase catalyzes the hydrolyzing reaction from alacepril to deacetylalacepril, Pharm.Res., 2003, 20, 1309–1316. 18 Alclometasone 17,21-dipropionate Alclometasone 17,21-dipropionate O Molecular formula: C28 H37 ClO7 Molecular weight: 521.05 CAS Registry No: 66734-13-2 Merck Index: 13, 219 CH3 HO CH3 H O H CH3 O O O O CH3 CH3 H Cl SAMPLE Matrix: formulations Sample preparation: Condition a 3 mL 500 mg Megabond MF C18 SPE cartridge (Varian) with 3 mL MeOH and 3 mL water. Sonicate 1 g cosmetic with 10 mL MeOH or MeOH:dichloromethane 10:90 (depending on what appears visually to give best solubility) at 40◦ for 10 min, centrifuge, collect the clear supernatant. Add 5 mL of the supernatant to the SPE cartridge, wash with 4 mL acetone:water 20:80, wash with 1 mL n-hexane, elute with 4 mL diethyl ether. Evaporate the eluate to dryness under reduced pressure, reconstitute the residue with 5 mL (or more) MeOH, inject a 10 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm endcapped Purospher RP-18 Column temperature: 25 Mobile phase: Isocratic. MeCN:water 60:40. Gradient. MeCN:water from 25:75 to 90:10 over 30 min, maintain at 90:10 for 10 min. Flow rate: 1 Injection volume: 10 Detector: UV 239 CHROMATOGRAM Retention time: k′ 2.55 (isocratic); 21.0 min (gradient) Limit of detection: 300 ng/mL OTHER SUBSTANCES Simultaneous: amcinonide (isocratic k′ 3.18; gradient retention time (min) 22.6; LOD 0.1 µg/mL), betamethasone (isocratic k′ 0.18; gradient retention time (min) 11.8; LOD 0.1 µg/mL), betamethasone-17-acetate (isocratic k′ 0.73; gradient retention time (min) 15.4; LOD 0.3 µg/mL), betamethasone-17-benzoate (isocratic k′ 2.04; gradient retention time (min) 20.6; LOD 0.3 µg/mL), betamethasone-17-propionate-21-stearate (isocratic k′ >13; gradient retention time (min) >35; LOD 0.5 µg/mL), betamethasone-17-propionate21-butyrate (isocratic k′ 5.91; gradient retention time (min) 26.1; LOD 0.4 µg/mL), betamethasone-17-valerate-21-acetate (isocratic k′ 4.41; gradient retention time (min) 23.1; LOD 0.4 µg/mL), betamethasone-17-valerate (isocratic k′ 2.32; gradient retention time (min) 21.4; LOD 0.3 µg/mL), betamethasone-17,21-dipropionate (isocratic k′ 4.00; gradient retention time (min) 24.2; LOD 0.4 µg/mL), betamethasone-17,21-diacetate (isocratic k′ 1.81; gradient retention time (min) 20.5; LOD 0.3 µg/mL), betamethasone17,21-divalerate (isocratic k′ 10.82; gradient retention time (min) 28.0; LOD 0.4 µg/mL), betamethasone-21-acetate (isocratic k′ 0.77; gradient retention time (min) 15.6; LOD 0.3 µg/mL), betamethasone propionate (isocratic k′ 0.82; gradient retention time (min) 17.1; LOD 0.3 µg/mL), clobetasol propionate (isocratic k′ 3.41; gradient retention time (min) 23.4; LOD 0.1 µg/mL), clobetasone butyrate (isocratic k′ 5.45; gradient retention time (min) 26.3; LOD 0.1 µg/mL), cortisone (isocratic k′ 0.18; gradient retention time Alclometasone 17,21-dipropionate 19 (min) 11.1; LOD 0.6 µg/mL), cortisone acetate (isocratic k′ 0.73; gradient retention time (min) 15.2; LOD 0.6 µg/mL), dehydrocorticosterone (isocratic k′ 4.27; gradient retention time (min) 22.3; LOD 0.5 µg/mL), deoxymethasone (isocratic k′ 0.64; gradient retention time (min) 14.2; LOD 0.2 µg/mL), dexamethasone (isocratic k′ 0.27; gradient retention time (min) 11.9; LOD 0.1 µg/mL), dexamethasone-21-acetate (isocratic k′ 0.91; gradient retention time (min) 16.1; LOD 0.2 µg/mL), dexamethasone isonicotinate (isocratic k′ 1.05; gradient retention time (min) 17.7; LOD 0.4 µg/mL), dexamethasone pivalate (isocratic k′ 3.45; gradient retention time (min) 24.1; LOD 0.3 µg/mL), dexamethasone valerate (isocratic k′ 3.00; gradient retention time (min) 21.6; LOD 0.3 µg/mL), diflucortolone valerate (isocratic k′ 4.73; gradient retention time (min) 23.3; LOD 0.3 µg/mL), fludrocortisone acetate (isocratic k′ 0.59; gradient retention time (min) 14.1; LOD 0.3 µg/mL), flumethasone pivalate (isocratic k′ 2.68; gradient retention time (min) 21.2; LOD 0.3 µg/mL), fluocinolone acetonide (isocratic k′ 0.91; gradient retention time (min) 13.4; LOD 0.3 µg/mL), fluocinonide (isocratic k′ 1.45; gradient retention time (min) 20.5; LOD 0.1 µg/mL), fluocortin butyl ester (isocratic k′ 5.59; gradient retention time (min) 24.6; LOD 0.3 µg/mL), fluocortolone caproate (isocratic k′ 6.59; gradient retention time (min) 25.1; LOD 0.3 µg/mL), fluocortolone pivalate (isocratic k′ 4.50; gradient retention time (min) 23.6; LOD 0.3 µg/mL), fluorometholone (isocratic k′ 0.59; gradient retention time (min) 14.4; LOD 0.1 µg/mL), 9-α-fluoroprednisolone (isocratic k′ 0.18; gradient retention time (min) 10.0; LOD 0.1 µg/mL), 9-α-fluoroprednisolone acetate (isocratic k′ 0.50; gradient retention time (min) 13.9; LOD 0.2 µg/mL), flurandrenolide (isocratic k′ 0.50; gradient retention time (min) 13.5; LOD 0.1 µg/mL), halcinonide (isocratic k′ 1.64; gradient retention time (min) 20.6; LOD 0.1 µg/mL), hydrocortisone (isocratic k′ 0.18; gradient retention time (min) 10.0; LOD 0.4 µg/mL), hydrocortisone17-butyrate (isocratic k′ 1.09; gradient retention time (min) 17.7; LOD 0.6 µg/mL), hydrocortisone-21-acetate (isocratic k′ 0.77; gradient retention time (min) 15.3; LOD 0.6 µg/mL), hydrocortisone pivalate (isocratic k′ 2.27; gradient retention time (min) 20.4; LOD 0.8 µg/mL), methylprednisolone (isocratic k′ 0.55; gradient retention time (min) 13.5; LOD 0.1 µg/mL), mometasone furoate (isocratic k′ 3.05; gradient retention time (min) 22.0; LOD 0.2 µg/mL), prednisolone-21-acetate (isocratic k′ 0.60; gradient retention time (min) 13.6; LOD 0.2 µg/mL), prednisolone acetonide (isocratic k′ 0.50; gradient retention time (min) 13.0; LOD 0.3 µg/mL), prednisolone pivalate (isocratic k′ 2.05; gradient retention time (min) 19.7; LOD 0.3 µg/mL), triamcinolone (isocratic k′ 0.14; gradient retention time (min) 7.2; LOD 0.1 µg/mL), triamcinolone acetonide (isocratic k′ 0.50; gradient retention time (min) 13.9; LOD 0.2 µg/mL), triamcinolone diacetate (isocratic k′ 0.45; gradient retention time (min) 13.9; LOD 0.3 µg/mL) KEY WORDS cosmetics; SPE REFERENCE Gagliardi, L.; De Orsi, D.; Del Giudice, M.R.; Gatta, F.; Porrà, R.; Chimenti, P.; Tonelli, D. Development of a tandem thin-layer chromatography-high-performance liquid chromatography method for the identification and determination of corticosteroids in cosmetic products, Anal.Chim.Acta, 2002, 457, 187–198. SAMPLE Matrix: formulations Sample preparation: Mix 1 g of a topical product, 5 mL 100 mM pH 4 citrate buffer saturated with NaCl, and 10 mL ethyl acetate, shake vigorously by hand to ensure that no large clumps stick to the tube, mix with the tube on its side on an oscillating shaker for 15 min. Remove the upper ethyl acetate layer and wash with citrate buffer as before. Dry the ethyl acetate over anhydrous sodium sulfate and evaporate to dryness. Dissolve the residue in a mixture of 10 mL heptane and 5 mL MeCN:water 90:10. Remove the upper heptane layer and extract it with 2 mL MeCN:water 90:10. Combine the MeCN/water layers and evaporate them to dryness, dissolve the residue in 300 µL MeOH, filter (0.45 µm nylon), inject a 5 µL aliquot. 20 Alclometasone 17,21-dipropionate HPLC VARIABLES Guard column: 15 × 3.2 7 µm Brownlee NewGuard C18 Column: 75 × 4.6 3.5 µm Symmetry C18 (Waters) Mobile phase: Gradient. MeCN:water 18:82 for 2 min, to 82:18 over 12 min, maintain at 82:18 for 3 min, re-equilibrate at initial conditions for 12 min. Flow rate: 1 Injection volume: 5 Detector: UV 240 CHROMATOGRAM Retention time: 10.93 Limit of detection: 0.001% OTHER SUBSTANCES Simultaneous: amcinonide (10.90), beclomethasone 17,21-dipropionate (11.90), betamethasone (6.52), betamethasone 21-acetate (8.47), betamethasone 17-benzoate (10.28), betamethasone 17,21-dipropionate (11.42), betamethasone 17-valerate (10.25), budesonide (8.55, 8.69 (epimers)), clobetasol 17-propionate (11.06), cortisone (5.62), cortisone 21-acetate (8.07), dexamethasone (6.57), dexamethasone 21-acetate (8.68), desonide (6.99), desoximetasone (7.60), desoxycorticosterone acetate (10.90), desoxycorticosterone pivalate (14.45), diflorasone 17,21-diacetate (9.81), fluocinolone acetonide (7.38), fluocinonide (9.79), flurandrenolide (7.36), fludrocortisone 21acetate (7.77), fluorometholone (7.67), flumethasone 21-pivalate (11.20), flunisolide (7.14), fluprednisolone (5.46), fluticasone 17-propionate (11.19), halcinonide (10.72), halobetasol propionate (10.98), hydrocortisone (5.50), hydrocortisone 21-acetate (7.65), hydrocortisone 17-butyrate (8.66), hydrocortisone 21-cypionate (12.54), hydrocortisone 17-valerate (9.53), mometasone 17-furoate (11.24), methylprednisolone (6.31), methylprednisolone 21-acetate (8.34), meprednisone (6.55), prednisolone (5.37), prednisolone 21-acetate (7.47), prednisolone 21-tebuate (11.01), paramethasone 21-acetate (8.64), prednicarbate (10.72), prednisone (5.46), triamcinolone (4.15), triamcinolone acetonide (7.04), triamcinolone 16,21-diacetate (7.49), triamcinolone hexacetonide (13.12) KEY WORDS body wash, cream, gel, lotion, shampoo, spray REFERENCE Reepmeyer, J.C. Screening for corticosteroids in topical pharmaceuticals by HPLC with a scanning ultraviolet detector, J.Liq.Chromatogr.Rel.Technol., 2001, 24, 693–709. Alitretinoin Alitretinoin H3C Molecular formula: C20 H28 O2 Molecular weight: 300.43 CAS Registry No: 5300-03-8 Merck Index: 13, 244 [9-cis-retinoic acid] CH3 21 CH3 CH3 H3C COOH SAMPLE Matrix: blood Sample preparation: 1 mL plasma + 50 µL 500 µg/mL IS in MeOH:MeCN 50:50 + 1 mL 1 M pH 6.0 phosphate buffer, mix, add 6 mL MTBE, shake on a horizontal shaker for 10 min, freeze the aqueous layer in a dry ice/acetone bath. Decant the organic layer and evaporate it to dryness under nitrogen at 25◦ , reconstitute the residue with 200 µL MeOH, add 100 µL 5 mM ammonium acetate, centrifuge at 13 000 g for 3 min, inject a 100 µL aliquot. (Use silanized glassware. Process under yellow light.) HPLC VARIABLES Guard column: 10 × 2 5 µm Hypersil BDS C18 Column: 100 × 4.6 3 µm Microsorb Short One C18 (Rainin) Column temperature: 36 Mobile phase: Gradient. A was 5 mM pH 2.7 ammonium acetate/acetic acid buffer. B was 1% acetic acid in MeOH. A:B 30:70 for 6.5 min, to 20:80 over 0.5 min, to 11:80 over 14.4 min, to 30:70 over 0.5 min, maintain at 30:70 for 10 min. Flow rate: 1 Injection volume: 100 Detector: UV 348 CHROMATOGRAM Retention time: 21 Internal standard: all-trans-3,7-dimethyl-9-(2,4,6-trimethylphenyl)-2,4,6,8-nonatetraenoic acid (Ro 11–5036) (19) Limit of detection: 2.5 ng/mL OTHER SUBSTANCES Extracted: isotretinoin (19.5), tretinoin (21.5), vitamin A (20.5) KEY WORDS plasma REFERENCE Dzerk, A.M.; Carlson, A.; Loewen, G.R.; Shirley, M.A.; Lee, J.W. A HPLC method for the determination of 9-cis retinoic acid (ALRT1057) and its 4-oxo metabolite in human plasma, J.Pharm.Biomed.Anal., 1998, 16, 1013–1019. SAMPLE Matrix: blood, food, formulations, tissue Sample preparation: Serum. Extract one volume (20–100 µL) serum with three volumes isopropanol:dichloromethane 2:1 containing about 6 nM IS and 1 mM butylated hydroxytoluene (BHT, antioxidant), add glacial acetic acid (1 µL/20 µL serum). Vortex for 30 s, centrifuge for 1 min, inject a 20–70 µL aliquot of the supernatant. Tissue, food. Homogenize 100–200 mg human or rat liver, 200 mg–2 g other tissues, or 2–5 g pulp of fruits and fresh vegetables with 3–5 mL isopropanol:dichloromethane 2:1, make up to 10 mL with isopropanol:dichloromethane 2:1. Vortex for 1 min, keep under argon 22 Alitretinoin at −20◦ overnight, vortex for 1 min, return to the freezer. On the third day, vortex the mixture, centrifuge or filter. Evaporate the supernatant or filtrate to dryness in a rotary evaporator. Dissolve the residue in 200 µL isopropanol:dichloromethane 2:1, inject a 20–40 µL aliquot. Multivitamin tablets. Grind tablet to a powder, add 10 mL isopropanol:dichloromethane 2:1. Vortex for 1 min, keep under argon at −20◦ overnight, vortex for 1 min, return to the freezer. On the third day, vortex the mixture, centrifuge about 500 µL solution, inject a 50 µL aliquot of the supernatant. HPLC VARIABLES Guard column: C18 (Upchurch) Column: 100 × 4.6 3 µm Microsorb MV Mobile phase: Gradient. A was MeOH:water 75:25 containing 10 mM ammonium acetate. B was MeOH:dichloromethane 80:20. A:B from 100:0 to 0:100 over 15 min, maintain at 0:100 for 15–20 min, to 100:0 over 5 min, re-equilibrate at initial conditions for 10 min. Flow rate: 0.8 Injection volume: 50 Detector: UV 340 CHROMATOGRAM Retention time: 10.2 Internal standard: retinyl acetate (13.8) OTHER SUBSTANCES Extracted: β-carotene (27.1), isotretinoin (9.9), all-trans retinal (13.8), all-trans retinyl palmitate (24.1), all-trans retinyl stearate (26.4), tretinoin (10.5), vitamin A (12.9), vitamin E (18.7), KEY WORDS human, ketchup, liver, mango, multivitamin tablets, papaya, rat, serum, spinach, tomato REFERENCE Barua, A.B.; Olson, J.A. Reversed-phase gradient high-performance liquid chromatographic procedure for simultaneous analysis of very polar to nonpolar retinoids, carotenoids and tocopherols in animal and plant samples, J.Chromatogr.B, 1998, 707, 69–79. SAMPLE Matrix: formulations Sample preparation: Capsules. Cut open 10 capsules, sonicate three times at 30◦ for 5 min with 40 mL portions of MeCN:EtOH:1% acetic acid 70:20:10, centrifuge at 3500 rpm for 6 min. Filter the supernatants, combine, make up to 250 mL. Dilute a 1 mL aliquot to 10 mL with mobile phase, filter (nylon 0.45 µm), inject an aliquot. Gel. Sonicate a portion with 8 mL mobile phase for 1 min, centrifuge at 3500 rpm for 10 min. Filter the supernatant and make up to 10 mL. Dilute a 1 mL aliquot to 5 mL with mobile phase, filter (nylon 0.45 µm), inject an aliquot. Cream. Sonicate an aliquot twice for 5 min with 4 mL portions of MeCN:EtOH:1% acetic acid 70:20:10, centrifuge at 3500 rpm for 6 min. Filter the supernatants, combine, make up to 10 mL with MeCN:EtOH:1% acetic acid 70:20:10. Dilute a 2 mL aliquot to 5 mL with mobile phase, filter (nylon 0.45 µm), inject an aliquot. HPLC VARIABLES Column: 250 × 3.2 Phenomenex Prodigy 5ODS Column temperature: 32 ± 2 Mobile phase: MeCN:EtOH:1% acetic acid 68:8:24 Flow rate: 0.4 Injection volume: 20 Detector: F ex 350 em 520 Alitretinoin 23 CHROMATOGRAM Retention time: 31 Limit of detection: 11.09 pmole (S/N = 3) OTHER SUBSTANCES Simultaneous: isotretinoin (28.5), tretinoin (33) KEY WORDS avoid exposure to light, use amber-colored glassware, capsules, cream, gel REFERENCE Gatti, R.; Gioia, M.G.; Cavrini, V. Analysis and stability study of retinoids in pharmaceuticals by LC with fluorescence detection, J.Pharm.Biomed.Anal., 2000, 23, 147–159. ANNOTATED BIBLIOGRAPHY Disdier, B.; Bun, H.; Placidi, M.; Durand, A. Excretion of oral 9-cis-retinoic acid in the rat, Drug Metab.Dispos., 1996, 24, 1279–1281. Disdier, B.; Bun, H.; Catalin, J.; Durand, A. Simultaneous determination of all-trans-, 13-cis, 9-cisretinoic acid and their 4-oxometabolites in plasma by high-performance liquid chromatography, J.Chromatogr.B, 1996, 683, 143–154. Gatti, R.; Gioia, M.G.; Di Pietra, A.M.; Cini, M. Determination of retinoids in galenicals by column liquid chromatography with fluorescence and diode-array detection, J.Chromatogr.A, 2001, 905, 345–350. Marchetti, M.-N.; Sampol, E.; Bun, H.; Scoma, H.; Lacarelle, B.; Durand, A. In vitro metabolism of three major isomers of retinoic acid in rats. Intersex and interstrain comparison, Drug Metab.Dispos., 1997, 25, 637–646. Miyagi, M.; Yokoyama, H.; Shiraishi, H.; Matsumoto, M.; Ishii, H. Simultaneous quantification of retinol, retinal, and retinoic acid isomers by high-performance liquid chromatography with a simple gradiation, J.Chromatogr.B, 2001, 757, 365–368. Rühl, R.; Schweigert, F.J. Automated solid-phase extraction and liquid chromatographic method for retinoid determination in biological samples, J.Chromatogr.B, 2003, 798, 309–316. Shih, T.-W.; Lin, T.-H.; Shealy, Y.F.; Hill, D.L. Nonenzymatic isomerization of 9-cis-retinoic acid catalyzed by sulfhydryl compounds, Drug Metab.Dispos., 1997, 25, 27–32. Van Merris, V.; Meyer, E.; De Wasch, K.; Burvenich, C. Simple quantification of endogenous retinoids in bovine serum by high-performance liquid chromatography – diode-array detection, Anal.Chim.Acta, 2002, 468, 237–244. Wyss, R.; Bucheli, F. Determination of endogenous levels of 13-cis-retinoic acid (isotretinoin), all-transretinoic acid (tretinoin) and their 4-oxo metabolites in human and animal plasma by high-performance liquid chromatography with automated column switching and ultraviolet detection, J.Chromatogr.B, 1997, 700, 31–47. Yamakoshi, Y.; Fukasawa, H.; Yamauchi, T.; Waki, H.; Kadowaki, T.; Shudo, K.; Kagechika, H. Determination of endogenous levels of retinoic acid isomers in type II diabetes mellitus patients. Possible correlation with HbA1c values, Biol.Pharm.Bull., 2002, 25, 1268–1271. 24 Allethrin Allethrin Molecular formula: C19 H26 O3 Molecular weight: 302.41 CAS Registry No: 584-79-2 Merck Index: 13, 256 H3C CH3 H3C H3C O O O H3C CH2 SAMPLE Matrix: fruit, vegetables Sample preparation: Prepare a cleanup column by placing 4 g Florisil, 1 g activated charcoal, and a 20 mm layer of anhydrous sodium sulfate in a 400 × 10 glass column, wash with 40 mL toluene, wash with 40 mL toluene:MeCN 99:1. Homogenize 25 g chopped fruit or vegetable with 70 mL MeOH at high speed for 3 min, filter, homogenize solid with 30 mL MeOH, and filter. Combine the filtrates and add them to 60 mL toluene and 300 mL 10% NaCl in water, shake well for 3 min, let layers separate. Dry the organic layer by passing it through 20 g anhydrous sodium sulfate in a 20 mm diameter column, concentrate to about 5 mL under reduced pressure at 80◦ , add to the cleanup column, elute with 40 mL toluene:MeCN 99:1. Evaporate the eluate just to dryness under reduced pressure at 80◦ , reconstitute with 1 mL MeOH, inject an aliquot. (Reflux activated charcoal (20–40 mesh) with 1 M HCl for 4 h, wash with water until the washings are neutral, dry at 95–100◦ (J.Assoc.Off.Anal.Chem. 1983, 66, 1013). Heat 60–100 mesh Florisil at 200◦ for 24 h, cool, add 4% water, mix thoroughly, store in a sealed jar (J.Assoc.Off.Anal.Chem. 1983, 66, 1003).) HPLC VARIABLES Column: 300 × 3.9 10 µm µBondapak C18 Column temperature: 50 Mobile phase: Gradient. MeCN:water from 62:38 to 78:22 over 32 min (Waters curve 6). Flow rate: 1.5 Detector: UV 206 CHROMATOGRAM Retention time: 11.55 Limit of detection: 50 ng/g OTHER SUBSTANCES Simultaneous: cypermethrin (21.05–22.08), permethrin (24.60, 27.01), tetramethrin (13.08) KEY WORDS apple, cabbage, cucumber; peach, pear, tomato, SPE REFERENCE Pang, G.-F.; Chao, Y.-Z.; Liu, X.-S.; Fan, C.-L. Multiresidue liquid chromatographic method for simultaneous determination of pyrethroid insecticides in fruits and vegetables, J.AOAC Int., 1995, 78, 1474–1480. SAMPLE Matrix: solutions HPLC VARIABLES Column: Two 250 × 4 Phase 3019 columns in series (Phenomenex) Mobile phase: Hexane:1,2-dichloroethane:EtOH 500:30:0.15 Allethrin 25 Flow rate: 0.8 Detector: UV 230 CHROMATOGRAM Retention time: 34, 36, 37, 39, 40, 42, 44, 46 (isomers) REFERENCE Phenomenex Catalogue, Phenomenex: Torrance CA, 1994, p. 1035. SAMPLE Matrix: solutions HPLC VARIABLES Guard column: 50 × 4 40 µm pellicular material Column: 250 × 4.6 5 µm Ultrasphere octadecylsilica Mobile phase: MeOH:water 80:20 Flow rate: 1 Injection volume: 10 Detector: UV 254 CHROMATOGRAM Retention time: k′ 4.68 (cis), k′ 5.32 (trans) OTHER SUBSTANCES Also analyzed: cyfluthrin (baythroid) (k′ 7.41 (cis, S), k′ 7.77 (trans, R), k′ 8.01 (cis, S), k′ 8.73 (trans, R)), permethrin (k′ 14.9 (trans), k′ 19.5 (cis)), resmethrin (k′ 13.5 (cis), k′ 15.0 (trans)), tetramethrin (k′ 4.05 (cis), k′ 4.68 (trans)) REFERENCE Abidi, S.L. Column selectivity in high-performance liquid chromatography of substituted gem-dimethylcyclopropanes, J.Chromatogr., 1986, 368, 59–76. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 5 µm Cyclobond I cyclodextrin-modified silica (Astec) Mobile phase: MeCN:water 22:78 Flow rate: 1 Detector: UV 220 CHROMATOGRAM Retention time: 7 (cis isomers), 9.5 (1R,trans, αS), 10.5 (1S,trans, αR), 13 (1R,trans, αR), 15 (1S,trans, αS) KEY WORDS comparison with GC REFERENCE Kutter, J.P.; Class, T.J. Diastereoselective and enantioselective chromatography of the pyrethroid insecticides allethrin and cypermethrin, Chromatographia, 1992, 33, 103–112. SAMPLE Matrix: solutions Sample preparation: Inject an aliquot of a 0.1–1 mg/mL solution in hexane. 26 Allethrin HPLC VARIABLES Guard column: 5 µm Spherisorb NH2 Column: 250 × 4.6 Pirkle ionic type 1-A column (Technicol) Mobile phase: Hexane:isopropanol 99.85:0.15 Flow rate: 0.8 Detector: UV 230 OTHER SUBSTANCES Also analyzed: cypermethrin, fenpropathrin, fenvalerate, tetramethrin KEY WORDS chiral REFERENCE Lisseter, S.G.; Hambling, S.G. Chiral high-performance liquid chromatography of synthetic pyrethroid insecticides, J.Chromatogr., 1991, 539, 207–210. SAMPLE Matrix: urine Sample preparation: Add 4 g solid NaCl, 3.5 mL MeCN, and 5 mL saturated NaCl solution to 5 mL MeCN, shake for 1 min. Remove the MeCN layer and extract the aqueous layer with 1 mL MeCN. Combine the MeCN layers and adjust to a known volume (0.5–1 mL), mix, filter (0.45 µm), inject a 40 µL aliquot. HPLC VARIABLES Column: 150 × 3 3 µm Luna C18(2) (Phenomenex) Column temperature: 30 Mobile phase: Gradient. MeCN:water 10:90 for 1 min, to 90:10 over 30 min, maintain at 90:10 for 4 min, to 100:0 over 1 min, maintain at 100:0 for 10 min, return to initial conditions over 1 min. Flow rate: 0.5 Injection volume: 40 Detector: UV 235 CHROMATOGRAM Retention time: 31.8 Limit of detection: 5 ng/mL OTHER SUBSTANCES Extracted: bifenthrin (37, LOD 5 ng/mL), cyfluthrin (34.3, LOD 5 ng/mL), fenvalerate (35.3, LOD 2 ng/mL), cis-permethrin (35.7, LOD 5 ng/mL), trans-permethrin (36.3, LOD 5 ng/mL), phenothrin (36.4, LOD 5 ng/mL), m-phenoxybenzyl alcohol (21, LOD 5 ng/mL), pyrethrin I (29.6, LOD 4 ng/mL), pyrethrin II (33.7, LOD 40 ng/mL), resmethrin (35.2, LOD 5 ng/mL), tetramethrin (31.4, LOD 5 ng/mL) REFERENCE Loper, B.L.; Anderson, K.A. Determination of pyrethrin and pyrethroid pesticides in urine and water matrices by liquid chromatography with diode array detection, J.AOAC Int., 2003, 86, 1236–1240. Almotriptan Almotriptan H O O Molecular formula: C17 H25 N3 O2 S Molecular weight: 335.47 CAS Registry No: 154323-57-6 Merck Index: 13, 301 27 N S N N SAMPLE Matrix: blood, urine Sample preparation: Condition a C2 SPE cartridge (Baker) with 2 mL MeCN and 2 mL water. Dilute 500 µL plasma or 100 µL urine with 1 mL water containing IS, mix, add to the SPE cartridge, wash with 750 µL MeCN:water 30:70, wash with 250 µL water, elute with mobile phase over 1 min (straight onto column (?)). HPLC VARIABLES Guard column: Guardpak µBondapak CN Column: 150 × 4 5 µm Spherisorb ODS-2 Mobile phase: MeCN:50 mM pH 4.0 sodium phosphate buffer:triethylamine 20:80:0.2 Flow rate: 1 Detector: UV 227 CHROMATOGRAM Retention time: 6.5 Internal standard: 4-[3-(2-aminoethyl)-1H-indol-5-ylmethylsulfonyl]piperazine-1-carboxylic acid ethyl ester (10) Limit of quantitation: 1 ng/mL (plasma), 50 ng/mL urine KEY WORDS plasma, SPE REFERENCE Jansat, J.M.; Costa, J.; Salvà, P.; Fernandez, F.J.; Martinez-Tobed, A. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers, J.Clin.Pharmacol., 2002, 42, 1303–1310. SAMPLE Matrix: microsomal incubations Sample preparation: Mix 500 µL microsomal incubation with 1 mL 200 mM pH 4 sodium acetate buffer, centrifuge, inject an aliquot. HPLC VARIABLES Guard column: GuardPak µBondapak CN Column: 300 × 3.9 10 µm µBondapak Mobile phase: Gradient. A:B from 80:20 to 40:60 over 30 min. A was buffer. B was MeCN:buffer 80:20. Buffer was 10 mM orthophosphoric acid containing 0.1% triethylamine, adjusted to pH 6.5 with NaOH. Flow rate: 1 Detector: UV 227 CHROMATOGRAM Retention time: 25 OTHER SUBSTANCES Extracted: metabolites 28 Almotriptan KEY WORDS human, liver REFERENCE Salva, M.; Jansat, J.M.; Martinez-Tobed, A.; Palacios, J.M. Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan, Drug Metab.Dispos., 2003, 31, 404–411. 29 Alosetron Alosetron H Molecular weight: 294.35 CAS Registry No: 122852-42-0, 122852-69-1 (HCl) Merck Index: 13, 305 N O Molecular formula: C17 H18 N4 O N N H3C N CH3 SAMPLE Matrix: blood Sample preparation: Condition a 100 mg LRC Bond Elut ethyl (C2) SPE cartridge with 1 mL isopropanol and 1 mL buffer. Mix 1.1 mL plasma or serum with 1 mL buffer containing 10 ng/mL IS, vortex, add 2 mL to the SPE cartridge, wash with 2 mL buffer, dry with nitrogen for 30 s, wash with 2 mL MeCN, elute with two 2 mL aliquots of MeCN:buffer 90:10. Evaporate the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 300 µL mobile phase, vortex, inject a 200 µL aliquot. (The buffer was 10 mM ammonium acetate adjusted to pH 4.0 with glacial acetic acid.) HPLC VARIABLES Guard column: 15 × 4.6 7 µm Spherisorb cyanopropyl Column: 100 × 4.6 5 µm Spheri cyanopropyl (Brownlee) Column temperature: 45 Mobile phase: MeOH:THF:10 mM pH 4.0 ammonium acetate buffer 24:6:70 Flow rate: 0.5 Injection volume: 200 Detector: F ex 295 em 370 CHROMATOGRAM Retention time: 10.1 Internal standard: GR87442, 6-fluoroalosetron (Glaxo) (13.7) Limit of quantitation: 0.1 ng/mL OTHER SUBSTANCES Noninterfering: amitriptyline, carbamazepine, carmustine, chlorpromazine, cimetidine, cisplatin, cyclophosphamide, dexamethasone, diazepam, digoxin, etoposide, furosemide, haloperidol, ibuprofen, imipramine, indomethacin, methotrexate, phenobarbital, phenytoin, propranolol, ranitidine, theophylline, triazolam, warfarin KEY WORDS plasma; serum; SPE REFERENCE Lloyd, T.L.; Gupta, S.K.; Gooding, A.E.; Alianti, J.R. Determination of alosetron in human plasma or serum by high-performance liquid chromatography with robotic sample preparation, J.Chromatogr.B, 1996, 678, 261–267. 30 Amcinonide Amcinonide O H3C Molecular formula: C28 H35 FO7 O Molecular weight: 502.57 CAS Registry No: 51022-69-6 Merck Index: 13, 387 O CH3 HO O CH3 F H O H O SAMPLE Matrix: formulations Sample preparation: Condition a 3 mL 500 mg Megabond MF C18 SPE cartridge (Varian) with 3 mL MeOH and 3 mL water. Sonicate 1 g cosmetic with 10 mL MeOH or MeOH:dichloromethane 10:90 (depending on what appears visually to give the best solubility) at 40◦ for 10 min, centrifuge, collect the clear supernatant. Add 5 mL of the supernatant to the SPE cartridge, wash with 4 mL acetone:water 20:80, wash with 1 mL n-hexane, elute with 4 mL diethyl ether. Evaporate the eluate to dryness under reduced pressure, reconstitute the residue with 5 mL (or more) MeOH, inject a 10 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm endcapped Purospher RP-18 Column temperature: 25 Mobile phase: Isocratic.MeCN:water 60:40. Gradient. MeCN:water from 25:75 to 90:10 over 30 min, maintain at 90:10 for 10 min. Flow rate: 1 Injection volume: 10 Detector: UV 239 CHROMATOGRAM Retention time: k′ 3.18 (isocratic); 22.6 min (gradient) Limit of detection: 100 ng/mL OTHER SUBSTANCES Simultaneous: alclometasone dipropionate (isocratic k′ 2.55; gradient retention time (min) 21.0; LOD 0.3 µg/mL), betamethasone (isocratic k′ 0.18; gradient retention time (min) 11.8; LOD 0.1 µg/mL), betamethasone-17-acetate (isocratic k′ 0.73; gradient retention time (min) 15.4; LOD 0.3 µg/mL), betamethasone-17-benzoate (isocratic k′ 2.04; gradient retention time (min) 20.6; LOD 0.3 µg/mL), betamethasone-17-propionate21-stearate (isocratic k′ >13; gradient retention time (min) >35; LOD 0.5 µg/mL), betamethasone-17-propionate-21-butyrate (isocratic k′ 5.91; gradient retention time (min) 26.1; LOD 0.4 µg/mL), betamethasone-17-valerate-21-acetate (isocratic k′ 4.41; gradient retention time (min) 23.1; LOD 0.4 µg/mL), betamethasone-17-valerate (isocratic k′ 2.32; gradient retention time (min) 21.4; LOD 0.3 µg/mL), betamethasone-17,21dipropionate (isocratic k′ 4.00; gradient retention time (min) 24.2; LOD 0.4 µg/mL), betamethasone-17,21-diacetate (isocratic k′ 1.81; gradient retention time (min) 20.5; LOD 0.3 µg/mL), betamethasone-17,21-divalerate (isocratic k′ 10.82; gradient retention time (min) 28.0; LOD 0.4 µg/mL), betamethasone-21-acetate (isocratic k′ 0.77; gradient retention time (min) 15.6; LOD 0.3 µg/mL), betamethasone propionate (isocratic k′ 0.82; gradient retention time (min) 17.1; LOD 0.3 µg/mL), clobetasol propionate (isocratic k′ 3.41; gradient retention time (min) 23.4; LOD 0.1 µg/mL), clobethasone butyrate (isocratic k′ 5.45; gradient retention time (min) 26.3; LOD 0.1 µg/mL), cortisone (isocratic k′ 0.18; gradient retention time (min) 11.1; LOD 0.6 µg/mL), cortisone acetate (isocratic k′ 0.73; gradient retention time (min) 15.2; LOD 0.6 µg/mL), dehydrocorticosterone (isocratic k′ 4.27; gradient retention time (min) 22.3; LOD 0.5 µg/mL), deoxymethasone (isocratic k′ 0.64; gradient retention time (min) 14.2; LOD 0.2 µg/mL), dexamethasone Amcinonide 31 (isocratic k′ 0.27; gradient retention time (min) 11.9; LOD 0.1 µg/mL), dexamethasone21-acetate (isocratic k′ 0.91; gradient retention time (min) 16.1; LOD 0.2 µg/mL), dexamethasone isonicotinate (isocratic k′ 1.05; gradient retention time (min) 17.7; LOD 0.4 µg/mL), dexamethasone pivalate (isocratic k′ 3.45; gradient retention time (min) 24.1; LOD 0.3 µg/mL), dexamethasone valerate (isocratic k′ 3.00; gradient retention time (min) 21.6; LOD 0.3 µg/mL), diflucortolone valerate (isocratic k′ 4.73; gradient retention time (min) 23.3; LOD 0.3 µg/mL), fludrocortisone acetate (isocratic k′ 0.59; gradient retention time (min) 14.1; LOD 0.3 µg/mL), flumethasone pivalate (isocratic k′ 2.68; gradient retention time (min) 21.2; LOD 0.3 µg/mL), fluocinolone acetonide (isocratic k′ 0.91; gradient retention time (min) 13.4; LOD 0.3 µg/mL), fluocinonide (isocratic k′ 1.45; gradient retention time (min) 20.5; LOD 0.1 µg/mL), fluocortin butyl ester (isocratic k′ 5.59; gradient retention time (min) 24.6; LOD 0.3 µg/mL), fluocortolone caproate (isocratic k′ 6.59; gradient retention time (min) 25.1; LOD 0.3 µg/mL), fluocortolone pivalate (isocratic k′ 4.50; gradient retention time (min) 23.6; LOD 0.3 µg/mL), fluorometholone (isocratic k′ 0.59; gradient retention time (min) 14.4; LOD 0.1 µg/mL), 9-α-fluoroprednisolone (isocratic k′ 0.18; gradient retention time (min) 10.0; LOD 0.1 µg/mL), 9-α-fluoroprednisolone acetate (isocratic k′ 0.50; gradient retention time (min) 13.9; LOD 0.2 µg/mL), flurandrenolide (isocratic k′ 0.50; gradient retention time (min) 13.5; LOD 0.1 µg/mL), halcinonide (isocratic k′ 1.64; gradient retention time (min) 20.6; LOD 0.1 µg/mL), hydrocortisone (isocratic k′ 0.18; gradient retention time (min) 10.0; LOD 0.4 µg/mL), hydrocortisone-17-butyrate (isocratic k′ 1.09; gradient retention time (min) 17.7; LOD 0.6 µg/mL), hydrocortisone-21-acetate (isocratic k′ 0.77; gradient retention time (min) 15.3; LOD 0.6 µg/mL), hydrocortisone pivalate (isocratic k′ 2.27; gradient retention time (min) 20.4; LOD 0.8 µg/mL), methylprednisolone (isocratic k′ 0.55; gradient retention time (min) 13.5; LOD 0.1 µg/mL), mometasone furoate (isocratic k′ 3.05; gradient retention time (min) 22.0; LOD 0.2 µg/mL), prednisolone-21-acetate (isocratic k′ 0.60; gradient retention time (min) 13.6; LOD 0.2 µg/mL), prednisolone acetonide (isocratic k′ 0.50; gradient retention time (min) 13.0; LOD 0.3 µg/mL), prednisolone pivalate (isocratic k′ 2.05; gradient retention time (min) 19.7; LOD 0.3 µg/mL), triamcinolone (isocratic k′ 0.14; gradient retention time (min) 7.2; LOD 0.1 µg/mL), triamcinolone acetonide (isocratic k′ 0.50; gradient retention time (min) 13.9; LOD 0.2 µg/mL), triamcinolone diacetate (isocratic k′ 0.45; gradient retention time (min) 13.9; LOD 0.3 µg/mL). KEY WORDS cosmetics; SPE REFERENCE Gagliardi, L.; De Orsi, D.; Del Giudice, M.R.; Gatta, F.; Porrà, R.; Chimenti, P.; Tonelli, D. Development of a tandem thin-layer chromatography-high-performance liquid chromatography method for the identification and determination of corticosteroids in cosmetic products, Anal.Chim.Acta, 2002, 457, 187–198. SAMPLE Matrix: formulations Sample preparation: Mix 1 g of a topical product, 5 mL 100 mM pH 4 citrate buffer saturated with NaCl, and 10 mL ethyl acetate, shake vigorously by hand to ensure that no large clumps stick to the tube, mix with the tube on its side on an oscillating shaker for 15 min. Remove the upper ethyl acetate layer and wash with citrate buffer as before. Dry the ethyl acetate over anhydrous sodium sulfate and evaporate to dryness. Dissolve the residue in a mixture of 10 mL heptane and 5 mL MeCN:water 90:10. Remove the upper heptane layer and extract it with 2 mL MeCN:water 90:10. Combine the MeCN/water layers and evaporate them to dryness, dissolve the residue in 300 µL MeOH, filter (0.45 µm nylon), inject a 5 µL aliquot. HPLC VARIABLES Guard column: 15 × 3.2 7 µm Brownlee NewGuard C18 Column: 75 × 4.6 3.5 µm Symmetry C18 (Waters) 32 Amcinonide Mobile phase: Gradient. MeCN:water 18:82 for 2 min, to 82:18 over 12 min, maintain at 82:18 for 3 min, re-equilibrate at initial conditions for 12 min. Flow rate: 1 Injection volume: 5 Detector: UV 240 CHROMATOGRAM Retention time: 10.90 Limit of detection: 0.001% OTHER SUBSTANCES Extracted: Simultaneous: alclometasone 17,21-dipropionate (10.93), beclomethasone 17,21-dipropionate (11.90), betamethasone (6.52), betamethasone 21-acetate (8.47), betamethasone 17-benzoate (10.28), betamethasone 17,21-dipropionate (11.42), betamethasone 17-valerate (10.25), budesonide (8.55, 8.69 (epimers)), clobetasol 17-propionate (11.06), cortisone (5.62), cortisone 21-acetate (8.07), dexamethasone (6.57), dexamethasone 21acetate (8.68), desonide (6.99), desoximetasone (7.60), desoxycorticosterone acetate (10.90), desoxycorticosterone pivalate (14.45), diflorasone 17,21-diacetate (9.81), fluocinolone acetonide (7.38), fluocinonide (9.79), flurandrenolide (7.36), fludrocortisone 21-acetate (7.77), fluorometholone (7.67), flumethasone 21-pivalate (11.20), flunisolide (7.14), fluprednisolone (5.46), fluticasone 17-propionate (11.19), halcinonide (10.72), halobetasol propionate (10.98), hydrocortisone (5.50), hydrocortisone 21-acetate (7.65), hydrocortisone 17-butyrate (8.66), hydrocortisone 21-cypionate (12.54), hydrocortisone 17-valerate (9.53), mometasone 17-furoate (11.24), methylprednisolone (6.31), methylprednisolone 21-acetate (8.34), meprednisone (6.55), prednisolone (5.37), prednisolone 21-acetate (7.47), prednisolone 21-tebuate (11.01), paramethasone 21-acetate (8.64), prednicarbate (10.72), prednisone (5.46), triamcinolone (4.15), triamcinolone acetonide (7.04), triamcinolone 16,21-diacetate (7.49), triamcinolone hexacetonide (13.12) KEY WORDS body wash, cream, gel, lotion, shampoo, spray REFERENCE Reepmeyer, J.C. Screening for corticosteroids in topical pharmaceuticals by HPLC with a scanning ultraviolet detector, J.Liq.Chromatogr.Rel.Technol., 2001, 24, 693–709. Aminolevulinic acid Aminolevulinic acid 33 O H2N COOH Molecular formula: C5 H9 NO3 Molecular weight: 131.13 CAS Registry No: 106-60-5 Merck Index: 13, 445 SAMPLE Matrix: blood, tissue Sample preparation: Deproteinize plasma by adding perchloric acid to a final concentration of 800 mM. Neutralize the supernatant by adding solid sodium bicarbonate until a pH of ca. 7.6 is reached. Homogenize tissue with 3 volumes of 10 mM pH 7.2 HEPES buffer containing 250 mM sucrose and 500 mM EDTA, centrifuge at 800 g for 5 min. Mix 10 µL sample with 5 µL reagent and 35 µL water, let stand at room temperature for 1 min, inject a 20 µL aliquot. (Prepare the reagent by dissolving 27 mg o-phthalaldehyde in 500 µL MeOH, add 5 mL 100 mM sodium tetraborate, add 20 µL mercaptoethanol, mix.) HPLC VARIABLES Column: 150 × 3.9 4 µm C18 (Waters) Mobile phase: MeCN:50 mM pH 7.0 phosphate buffer 10:90 containing 2.4 mM EDTA Flow rate: 1 Injection volume: 20 Detector: E, Shimadzu LECD 6A, glassy carbon working electrode at +0.45 V, Ag/AgCl reference electrode CHROMATOGRAM Retention time: 44.6 Limit of detection: 50 nM Limit of quantitation: 100 nM KEY WORDS brain; derivatization; human; liver; plasma; rat REFERENCE Costa, C.A.; Trivelato, G.C.; Demasi, M.; Bechara, E.J.H. Determination of 5-aminolevulinic acid in blood plasma, tissues and cell cultures by high-performance liquid chromatography with electrochemical detection, J.Chromatogr.B, 1997, 695, 245–250. SAMPLE Matrix: blood, urine Sample preparation: 50 µL Plasma or urine + 3.5 mL reagent + 450 µL 10% formaldehyde, vortex for 3 s, heat at 100◦ for 10 min, cool in an ice bath, filter (0.8 µm, plasma samples only), inject a 10 (urine) or 20 (plasma) µL aliquot. (Prepare the reagent by mixing 15 mL acetylacetone, 10 mL EtOH, and 75 mL water.) HPLC VARIABLES Column: 150 × 4.6 Shim-pack CLC-ODS (Shimadzu) Column temperature: 40 Mobile phase: MeOH:water:acetic acid 50:50:1 Flow rate: 0.7 Injection volume: 10–20 Detector: F ex 370 em 460 34 Aminolevulinic acid CHROMATOGRAM Retention time: 6.1 Limit of detection: 3 ng/mL KEY WORDS derivatization; plasma; protect from light REFERENCE Oishi, H.; Nomiyama, H.; Nomiyama, K.; Tomokuni, K. Fluorometric HPLC determination of deltaaminolevulinic acid (ALA) in the plasma and urine of lead workers: biological indicators of lead exposure, J.Anal.Toxicol., 1996, 20, 106–110. SAMPLE Matrix: urine Sample preparation: Centrifuge urine at 1000 g and store at −20◦ . 20 µL Urine + 5 mL acetylacetone:EtOH:4 g/L NaCl in water 15:10:75 + 450 µL 9.3% formaldehyde solution, mix, boil for 15 min, cool with water, store sample in the dark at 15◦ until injection, inject a 50 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm TSK-80 TM (Tosoh) Column temperature: 40 Mobile phase: Gradient. A was MeCN:MeOH:water:acetic acid 10:35:54:1. B was MeCN. A:B 100:0 for 7.5 min, to 50:50 over 1.5 min, return to initial conditions over 2 min, re-equilibrate for 2 min. Flow rate: 0.8 Injection volume: 50 Detector: F ex 246 em 458 CHROMATOGRAM Retention time: 7.3 Limit of detection: 10 ng/mL KEY WORDS derivatization; protect from light; improved version of A. Okayama et al. Clin.Chem. 1990, 36, 1494. REFERENCE Endo, Y.; Okayama, A.; Endo, G.; Ueda, T.; Nakazono, N.; Horiguchi, S. Improvement of urinary δ-aminolevulinic acid determination by HPLC and fluorescence detection using condensing reaction with acetylacetone and formaldehyde, Jap.J.Ind.Health, 1994, 36, 49–56. ANNOTATED BIBLIOGRAPHY Dalton, J.T.; Meyer, M.C.; Golub, A.L. Pharmacokinetics of aminolevulinic acid after oral and intravenous administration to dogs, Drug Metab.Dispos., 1999, 27, 432–435. [derivatization] Ho, J.; Guthrie, R.; Tieckelmann, H. Detection of δ-aminolevulinic acid, porphobilinogen and porphyrins related to heme biosynthesis by high-performance liquid chromatography, J.Chromatogr., 1986, 375, 57–63. [derivatization] Ho, J.W. Micro assay for urinary δ-aminolevulinic acid and porphobilinogen by high-performance liquid chromatography with pre-column derivatization, J.Chromatogr., 1990, 527, 134–139. Kondo, M.; Kimura, H.; Maekubo, T.; Tomita, T.; Senda, M.; Urata, G.; Kajiwara, M. Direct injection method for quantitation of δ-aminolevulinic acid in urine by high-performance liquid chromatography, Chem.Pharm.Bull., 1992, 40, 1948–1950. [derivatization] Lim, C.K.; Rideout, J.M.; Samson, D.M. Determination of 5-aminolaevulinic acid and porphobilinogen by high-performance liquid chromatography, J.Chromatogr., 1979, 185, 605–611. Aminolevulinic acid 35 Meisch, H.U.; Reinle, W.; Wolf, U. Determination of 5-aminolevulinic acid in biological samples by high-performance liquid chromatography, Anal.Biochem., 1985, 149, 29–34. Minder, E.I. Measurement of 5-aminolevulinic acid by reversed phase HPLC and fluorescence detection, Clin.Chim.Acta, 1986, 161, 11–18. [derivatization] Miyajima, K.; Hirata, M.; Yoshida, T.; Kosaka, H.; Okayama, A. Study on measurement of delta-aminolevulinic acid in plasma by high-performance liquid chromatography, J.Chromatogr.B, 1994, 654, 165–169. Okayama, A. Fluorimetric determination of urinary δ-aminolevulinic acid by high-performance liquid chromatography and post-column derivatization, J.Chromatogr., 1988, 426, 365–369. Okayama, A.; Fujii, S.; Miura, R. Optimized fluorometric determination of urinary delta-aminolevulinic acid by using pre-column derivatization, and identification of the derivative, Clin.Chem., 1990, 36, 1494–1497. Tomokuni, K.; Ichiba, M.; Hirai, Y.; Hasegawa, T. Optimized liquid-chromatographic method for fluorometric determination of urinary delta-aminolevulinic acid in workers exposed to lead, Clin.Chem., 1987, 33, 1665–1667. 36 Amprenavir Amprenavir NH2 O Molecular formula: C25 H35 N3 O6 S Molecular weight: 505.64 CAS Registry No: 161814-49-9 Merck Index: 13, 594 O O O N H N OH S O CH3 CH3 SAMPLE Matrix: blood Sample preparation: Condition a C18 SPE cartridge (Baker) with 3 mL MeOH and 3 mL water. Do not allow to run dry. Add 1 mL plasma to the SPE cartridge, wash with 2 mL water, suck dry for 1 min, elute with 2.6 mL MeOH. Evaporate a 1 mL aliquot of the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL mobile phase, inject a 100 µL aliquot. HPLC VARIABLES Guard column: GuardPak µBondapak C18 Column: 250 × 4.6 5 µm Symmetry C18 Column temperature: 37 Mobile phase: MeCN:40 mM disodium hydrogen phosphate containing 4% octanesulfonic acid 50:50. (At the end of each session, wash column with MeOH:water 50:50 and MeCN:water 80:20.) Flow rate: 1.3 Injection volume: 100 Detector: UV 261 for 9 min, UV 241 for 11 min, UV 254 for 12 min CHROMATOGRAM Retention time: 5.6 Limit of quantitation: 25 ng/mL OTHER SUBSTANCES Extracted: efavirenz (15.2, LOQ 50 ng/mL), indinavir (4.8, LOQ 50 ng/mL), nelfinavir (19.2, LOQ 50 ng/mL), ritonavir (12.8, LOQ 50 ng/mL), saquinavir (16.8, LOQ 5 ng/mL) acebutolol, acetaminophen, acetylcysteine, acyclovir, albendazole, alimemazine, alizapride, amikacin, amiodarone, amphotericin B, ampicillin, aspirin, bepridil, buprenorphine, butobarbital, caffeine, calcium folinate, captopril, carbamazepine, carbutamide, chloroquine, ciprofloxacin, clindamycin, clofazimine, clofibrate, clonazepam, clonidine, cloxacillin, clozapine, cocaine, codeine, cyamemazine, dantrolene, dexamethasone, dextropropoxyphene, diazepam, diclofenac, didanosine, digoxin, dihydroergotamine, diltiazem, doxycycline, ethambutol, flecainide, fluconazole, fluoxetine, fluvoxamine, foscarnet, furosemide, ganciclovir, gentamicin, glibenclamide, granisetron, halofantrine, haloperidol, hydrocortisone, imipramine, indomethacin, interferon alfa, isoniazid, itraconazole, josamycin, ketoconazole, lamivudine, levomepromazine, lidocaine, loperamide, loratadine, losartan, mefloquine, meprobamate, methadone, methylprednisolone, metoclopramide, metronidazole, mianserin, moclobemide, morphine, nevirapine, nifedipine, niflumic acid, nitrofurantoin, omeprazole, paroxetine, pentamidine, phenobarbital, phenytoin, piracetam, prazosin, prednisolone, prednisone, primidone, propranolol, quinidine, quinine, ranitidine, ribavirin, rifabutin, rifampin, roxithromycin, salicylic acid, simvastatin, stavudine, sulfadiazine, sulfamethoxazole, sulpiride, thalidomide, theophylline, trimethoprim, valproic acid, venlafaxine, vigabatrin, viloxazine, zidovudine, zolpidem, zopiclone Interfering: delavirdine, flunitrazepam Noninterfering: abacavir, Amprenavir 37 KEY WORDS plasma; SPE REFERENCE Aymard, G.; Legrand, M.; Trichereau, N.; Diquet, B. Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography, J.Chromatogr. B, 2000, 744, 227–240. SAMPLE Matrix: blood Sample preparation: Mix 250 µL plasma with 50 µL MeOH, add 100 µL 2 µg/mL IS in MeOH, add 250 µL 1 M NaOH, add 3 mL hexane:ethyl acetate 50:50, shake at high speed for 25 min, centrifuge at 3000 g for 15 min. Evaporate the organic layer to dryness under a stream of air, reconstitute the residue with 1 mL initial mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Guard column: 10 × 2.1 Symmetry Shield Column: 30 × 2.1 3.5 µm Symmetry C18 Mobile phase: Gradient. MeCN:5 mM pH 3.25 acetate buffer from 25:75 to 80:20 over 4 min using a nonlinear gradient (not specified). Flow rate: 0.35 Injection volume: 20 Detector: MS, PE Sciex API 3000, turbo ionspray source, column effluent split 1:1 before entering source CHROMATOGRAM Retention time: 2.7 Internal standard: Abbott A-86093 (3.2) Limit of detection: 380 pg/mL Limit of quantitation: 16.3 ng/mL OTHER SUBSTANCES Extracted: indinavir (2.0, LOQ 16.3 ng/mL, LOD 1.5 ng/mL), lopinavir (3.1, LOQ 16.3 ng/mL, LOD 750 pg/mL), nelfinavir (2.5, LOQ 16.3 ng/mL, LOD 330 pg/mL), ritonavir (2.9, LOQ 51.2 ng/mL, LOD 650 pg/mL), saquinavir (2.4, LOQ 16.3 ng/mL, LOD 780 pg/mL) KEY WORDS plasma REFERENCE Frerichs, V.A.; DiFrancesco, R.; Morse, G.D. Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry, J.Chromatogr.B, 2003, 787, 393–403. SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 200 µL 10 µg/mL IS in water, add 200 µL 100 mM NaOH, mix, add 4 mL diethyl ether, shake for 5 min, centrifuge at 2500 rpm for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 200 µL initial mobile phase, inject a 100 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 Stability RP18 (CIL, France) 38 Amprenavir Mobile phase: Gradient. MeCN:50 mM pH 5.65 phosphate buffer from 36:64 to 64:36 over 25 min, to 80:20 (step gradient), maintain at 80:20 for 10 min, re-equilibrate at initial conditions for 5 min. Flow rate: 1.5 Injection volume: 100 Detector: UV 240 for 5 min, UV 215 for 22 min, UV 260 for rest of the run CHROMATOGRAM Retention time: 11.2 Internal standard: JR051012 (Janssen Cilag) (28.2) Limit of quantitation: 50 ng/mL OTHER SUBSTANCES Extracted: efavirenz (19.9), indinavir (8.5), lopinavir (18.9), nelfinavir (24.1), nevirapine (3.3), ritonavir (17.6), saquinavir (16.7) Noninterfering: acetaminophen, amineptine, amphotericin B, aspirin, bromazepam, buspirone, citalopram, clobazam, diazepam, didanosine, fluconazole, flunitrazepam, fluvoxamine, hydroxyitraconazole, isoniazid, itraconazole, lamivudine, loprazolam, lorazepam, metronidazole, minalcipram, nordiazepam, omeprazole, paroxetine, pyrimethamine, rifampin, sertraline, stavudine, sulfadiazine, trimethoprim, venlafaxine, zalcitabine, zidovudine, zolpidem, zopiclone KEY WORDS plasma REFERENCE Titier, K.; Lagrange, F.; Péhourcq, F.; Edno-Mcheik, L.; Moore, N.; Molimard, M. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma, Ther.Drug Monit., 2002, 24, 417–424. SAMPLE Matrix: microsomal incubations Sample preparation: Extract 100 µL incubation mixture twice with 5 mL MTBE. Evaporate the organic layer to dryness, reconstitute the residue with 100 µL MeCN, inject a 30 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 Beckman ODS Ultrasphere Column temperature: 45 Mobile phase: Gradient. A was 0.1% formic acid in water. B was 0.1% formic acid in MeCN. A:B 100:0 for 1 min, to 30:70 over 3 min, to 5:95 over 3 min, maintain at 5:95 for 3 min, to 100:0 over 1 min. Flow rate: 0.35 Injection volume: 30 Detector: MS, Hewlett-Packard 5989B, electrospray ionization, selected ion monitoring, m/z 506.6 CHROMATOGRAM Limit of quantitation: 25 ng/mL OTHER SUBSTANCES Also analyzed: astemizole, indinavir, ketoconazole, methadone, nelfinavir, rifabutin, rifampin, ritonavir, saquinavir, terfenadine, trimethoprim KEY WORDS human; liver; rat Amprenavir 39 REFERENCE Decker, C.J.; Laitinen, L.M.; Bridson, G.W.; Raybuck, S.A.; Tung, R.D.; Chaturvedi, P.R. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions, J.Pharm.Sci., 1998, 87, 803–807. ANNOTATED BIBLIOGRAPHY Brophy, D.F.; Israel, D.S.; Pastor, A.; Gillotin, C.; Chittick, G.E.; Symonds, W.T.; Lou, Y.; Sadler, B.M.; Polk, R.E. Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers, Antimicrob.Agents Chemother., 2000, 44, 978–984. [no HPLC of clarithromycin] Chi, J.; Jayewardene, A.L.; Stone, J.A.; Motoya, T.; Aweeka, F.T. Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS, J.Pharm.Biomed.Anal., 2002, 30, 675–684. Cociglio, M.; Hillaire-Buys, D.; Peyrière, H.; Alric, R. Performance analysis of a rapid HPLC determination with the solvent demixing extraction of HIV antiproteases and efavirenz in plasma, J.Chromatogr.Sci., 2003, 41, 80–86. [efavirenz; indinavir; amprenavir; ritonavir; saquinavir; nelfinavir] Dailly, E.; Thomas, L.; Kergueris, M.F.; Jolliet, P.; Bourin, M. High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction, J.Chromatogr.B, 2001, 758, 129–135. Droste, J.A.H.; Verweij-van Wissen, C.P.W.G.M.; Burger, D.M. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography, Ther.Drug Monit., 2003, 25, 393–399. Edwards, J.E.; Brouwer, K.R.; McNamara, P.J. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats, Antimicrob.Agents Chemother., 2002, 46, 2284–2286. Faux, J.; Venisse, N.; Le Moal, G.; Dupuis, A.; Bouquet, S. Simultaneous determination of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography after solid-phase extraction, Chromatographia 2003, 58, 421–426. [amprenavir; indinavir; lopinavir; nelfinavir; ritonavir; saquinavir; efavirenz; nevirapine; prazepam] Gao, W.; Kishida, T.; Kimura, K.; Kageyama, M.; Sumi, M.; Yoshikawa, Y.; Shibata, N.; Takada, K. Sensitive and simultaneous determination of HIV protease inhibitors in rat biological samples by liquid chromatography-mass spectrometry, Biomed.Chromatogr., 2002, 16, 267–273. [indinavir; amprenavir; saquinavir; nelfinavir] Goujard, C.; Vincent, I.; Meynard, J.-L.; Choudet, N.; Bollens, D.; Rousseau, C.; Demarles, D.; Gillotin, C.; Bidault, R.; Taburet, A.-M. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients, Antimicrob.Agents Chemother., 2003, 47, 118–123. Gunawan, S.; Griswold, M.P.; Kahn, D.G. Liquid chromatographic-tandem mass spectrometric determination of amprenavir (agenerase) in serum/plasma of human immunodeficiency virus type-1 infected patients receiving combination antiretroviral therapy, J.Chromatogr.A, 2001, 914, 1–4. Huang, L.; Wring, S.A.; Woolley, J.L.; Brouwer, K.R.; Serabjit-Singh, C.; Polli, J.W. Induction of Pglycoprotein and cytochrome P450 3A by HIV protease inhibitors, Drug Metab.Dispos., 2001, 29, 754–760. [fosamprenavir; amprenavir; nelfinavir] Justesen, U.S.; Pedersen, C.; Klitgaard, N.A. Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography, J.Chromatogr.B, 2003, 783, 491–500. Keil, K.; Frerichs, V.A.; DiFrancesco, R.; Morse, G. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma, Ther.Drug Monit., 2003, 25, 340–346. Leibenguth, P.; Le Guellec, C.; Besnier, J.-M.; Bastides, F.; Macé, M.; Gaudet, M.-L.; Autret-Leca, E.; Paintaud, G. Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid chromatography with ultraviolet or photodiode array detection, Ther.Drug Monit., 2001, 23, 679–688. [indinavir; saquinavir; lopinavir; ritonavir; nelfinavir; amprenavir; carbamazepine] 40 Amprenavir Marzolini, C.; Telenti, A.; Buclin, T.; Biollaz, J.; Decosterd, L.A. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction, J.Chromatogr.B, 2000, 740, 43–58. Marzolini, C.; Béguin, A.; Telenti, A.; Schreyer, A.; Buclin, T.; Biollaz, J.; Decosterd, L.A. Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery, J.Chromatogr.B, 2002, 774, 127–140. [lopinavir; nevirapine; amprenavir; efavirenz; clozapine] Pereira, A.S.; Kenney, K.B.; Cohen, M.S.; Eron, J.J.; Tidwell, R.R.; Dunn, J.A. Determination of amprenavir, a HIV-1 protease inhibitor, in human seminal plasma using high-performance liquid chromatography-tandem mass spectrometry, J.Chromatogr.B, 2002, 766, 307–317. Poirier, J.-M.; Radembino, N.; Robidou, P.; Jaillon, P. Simultaneous determination of the five HIVprotease inhibitors: Amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by solid-phase extraction and column liquid chromatography, Ther.Drug Monit., 2000, 22, 465–473. Poirier, J.M.; Robidou, P.; Jaillon, P. Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography, Ther.Drug Monit., 2002, 24, 302–309. Polk, R.E.; Brophy, D.F.; Israel, D.S.; Patron, R.; Sadler, B.M.; Chittick, G.E.; Symonds, W.T.; Lou, Y.; Kristoff, D.; Stein, D.S. Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males, Antimicrob.Agents Chemother., 2001, 45, 502–508. Proust, V.; Toth, K.; Hulin, A.; Taburet, A.-M.; Gimenez, F.; Singlas, E. Simultaneous high-performance liquid chromatographic determination of the antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasma, J.Chromatogr.B, 2000, 742, 453–458. Rentsch, K.M. Sensitive and specific determination of eight antiretroviral agents in plasma by highperformance liquid chromatography-mass spectrometry, J.Chromatogr.B, 2003, 788, 339–350. [SPE; amprenavir; efavirenz; indinavir; lopinavir; nelfinavir; nevirapine; ritonavir; saquinavir] Sadler, B.M.; Hanson, C.D.; Chittick, G.E.; Symonds, W.T.; Roskell, N.S. Safety and pharmacokinetics of amprenavir (141 W94), a human immunodeficiency virus (HIV) type I protease inhibitor, following oral administration of single doses to HIV-infected adults, Antimicrob.Agents Chemother., 1999, 43, 1686–1692. Sadler, B.M.; Chittick, G.E.; Polk, R.E.; Slain, D.; Kerkering, T.M.; Studenberg, S.D.; Lou, Y.; Moore, K.H.P.; Woolley, J.L.; Stein, D.S. Metabolic disposition and pharmacokinetics of [14C]amprenavir, a human immunodeficiency virus Type 1 (HIV-1) protease inhibitor, administered as a single oral dose to healthy male subjects, J.Clin.Pharmacol., 2001, 41, 386–396. Sarasa-Nacenta, M.; López-Púa, Y.; Mallolas, J.; Blanco, J.L.; Gatell, J.M.; Carné, X. Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography, J.Chromatogr.B, 2001, 757, 325–332. Sparidans, R.W.; Hoetelmans, R.M.W.; Beijnen, J.H. Sensitive liquid chromatographic assay for amprenavir, a human immunodeficiency virus protease inhibitor, in human plasma, cerebrospinal fluid and semen, J.Chromatogr.B, 2000, 742, 185–192. Tran, J.Q.; Petersen, C.; Garrett, M.; Hee, B.; Kerr, B.M. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir, Clin.Pharmacol.Ther., 2002, 72, 615–626. Tréluyer, J.M.; Bowers, G.; Cazali, N.; Sonnier, M.; Rey, E.; Pons, G.; Cresteil, T. Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation, Drug Metab.Dispos., 2003, 31, 275–281. Tribut, O.; Arvieux, C.; Michelet, C.; Chapplain, J.-M.; Allain, H.; Bentué-Ferrer, D. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography, Ther.Drug Monit., 2002, 24, 554–562. [nevirapine; efavirenz; indinavir; amprenavir; nelfinavir; ritonavir; lopinavir; saquinavir] Turner, M.L.; Reed-Walker, K.; King, J.R.; Acosta, E.P. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography, J.Chromatogr.B, 2003, 784, 331–341. [indinavir; nelfinavir; saquinavir; ritonavir; amprenavir; delavirdine; efavirenz; lopinavir] van Heeswijk, R.P.G.; Hoetelmans, R.M.W.; Harms, R.; Meenhorst, P.L.; Mulder, J.W.; Lange, J.M.A.; Beijnen, J.H. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 1998, 719, 159–168. Amprenavir 41 Veronese, L.; Rautaureau, J.; Sadler, B.M.; Gillotin, C.; Petite, J.-P.; Pillegand, B.; Delvaux, M.; Masliah, C.; Fosse, S.; Lou, Y.; Stein, D.S. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function, Antimicrob.Agents Chemother., 2000, 44, 821–826. Villani, P.; Feroggio, M.; Gianelli, L.; Bartoli, A.; Montagna, M.; Maserati, R.; Regazzi, M.B. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography-mass spectrometry assay, Ther.Drug Monit., 2001, 23, 380–388. [saquinavir; indinavir; ritonavir; nelfinavir; amprenavir; nevirapine; delavirdine; efavirenz] Yamada, H.; Kotaki, H.; Nakamura, T.; Iwamoto, A. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by highperformance liquid chromatography, J.Chromatogr.B, 2001, 755, 85–89. Yu, L.; Bridgers, A.; Polli, J.; Vikers, A.; Long, S.; Roy, A.; Winnike, R.; Coffin, M. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability, Pharm.Res., 1999, 16, 1812–1817. 42 Anagrelide Anagrelide Molecular formula: C10 H7 Cl2 N3 O Molecular weight: 256.09 CAS Registry No: 68475-42-3 Merck Index: 13, 629 H N N N Cl O Cl SAMPLE Matrix: blood, urine Sample preparation: Mix 2 mL plasma or urine with 2 mL 200 mM pH 7.0 phosphate buffer, extract twice with 10 mL portions of ethyl acetate. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 60 µL DMSO, mix, sonicate, inject a 40 µL aliquot. HPLC VARIABLES Guard column: 40 mm long µBondapak phenyl corasil Column: 300 × 3.9 µBondapak phenyl Mobile phase: MeCN:10 mM pH 4 sodium acetate buffer 25:75 for 10 min, DMSO for 8 min, return to original mobile phase Flow rate: 2.5 for 13 min, 1 for 5 min, 2.5 for rest of the run Injection volume: 40 Detector: UV 254; Radioactivity (14 C) CHROMATOGRAM Retention time: 6–8 KEY WORDS plasma; radiolabeled REFERENCE Gaver, R.C.; Deeb, G.; Pittman, K.A.; Smyth, R.D. Disposition of anagrelide, an inhibitor of platelet aggregation, Clin.Pharmacol.Ther., 1981, 29, 381–386. Anakinra 43 Anakinra Molecular weight: 17 000 CAS Registry No: 143090-92-0 Merck Index: 13, 5022 SAMPLE Matrix: blood, tissue Sample preparation: Inject a 50 µL aliquot of plasma or tissue homogenate supernatant. HPLC VARIABLES Guard column: 40 × 6 Spherogel TSK PWHR (Beckman) Column: 300 × 7.8 5 µm Progel-TSK G2000 SWXL (Supelco) Mobile phase: 10 mM pH 6.5 citrate buffer containing 140 mM NaCl and 0.5 mM EDTA Flow rate: 0.5 Injection volume: 50 Detector: UV; Radioactivity (35 S); ELISA CHROMATOGRAM Retention time: 20 KEY WORDS brain; gut; heart; kidney; liver; lung; muscle; plasma; rat; spleen REFERENCE Kim, D.C.; Reitz, B.; Carmichael, D.F.; Bloedow, D.C. Kidney as a major clearance organ for recombinant human interleukin-1 receptor antagonist, J.Pharm.Sci., 1995, 84, 575–580. SAMPLE Matrix: solutions Sample preparation: Inject a 100 µL aliquot of a 2–5 mg/mL solution in 10 mM pH 6.5 citrate buffer containing 140 mM NaCl and 0.5 mM EDTA. HPLC VARIABLES Column: 75 × 7.5 Bio-Gel SP-5-PW (Bio-Rad) Mobile phase: Gradient. A:B from 99:1 to 40:60 over 60 min. A was 20 mM pH 5.5 2-(N-morpholino)ethanesulfonic acid monohydrate. B was 20 mM pH 5.5 2-(Nmorpholino)ethanesulfonic acid monohydrate containing 1.0 M NaCl. Flow rate: 0.5 Injection volume: 100 Detector: UV 280 REFERENCE Nahata, M.C.; Morosco, R.S.; Sabados, B.K.; Weber, T.R. Stability and compatibility of anakinra with intravenous cimetidine hydrochloride or famotidine in 0.9% sodium chloride injection, J.Clin.Pharm. Ther., 1995, 20, 97–99. ANNOTATED BIBLIOGRAPHY Chang, B.S.; Beauvais, R.M.; Arakawa, T.; Narhi, L.O.; Dong, A.; Aparisio, D.I.; Carpenter, J.F. Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution, Biophys.J., 1996, 71, 3399–3406. 44 Anakinra Chang, B.S.; Reeder, G.; Carpenter, J.F. Development of a stable freeze-dried formulation of recombinant human interleukin-1 receptor antagonist, Pharm.Res., 1996, 13, 243–249. Nahata, M.C.; Morosco, R.S.; Sabados, B.K.; Weber, T.R. Stability and compatibility of anakinra with ceftriaxone sodium injection in 0.9% sodium chloride or 5% dextrose injection, J.Clin.Pharm.Ther., 1997, 22, 167–169. 45 Apraclonidine Apraclonidine Molecular formula: C9 H10 Cl2 N4 Molecular weight: 245.11 CAS Registry No: 66711-21-5 Merck Index: 13, 756 Cl H N N NH Cl NH2 SAMPLE Matrix: solutions Sample preparation: Inject a 50 µL aliquot of a solution in glutathione bicarbonated Ringer’s solution (pH 7.4). HPLC VARIABLES Column: 150 × 4 5 µm Ultrasphere ODS Mobile phase: MeCN:water 20:80 to 60:40 (?) containing 5 mM sodium heptanesulfonic acid at pH 3.5 Flow rate: 1–1.5 Injection volume: 50 Detector: UV 254 OTHER SUBSTANCES Simultaneous: clonidine REFERENCE Chien, D.S.; Homsy, J.J.; Gluchowski, C.; Tang-Liu, D.D.-S. Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes, Current Eye Res., 1990, 9, 1051–1059. 46 Aprepitant Aprepitant O O Molecular formula: C23 H21 F7 N4 O3 Molecular weight: 534.43 CAS Registry No: 170729-80-3 N N H H H CH3 CF3 O N H N CF3 H F SAMPLE Matrix: blood, tissue Sample preparation: Mix 200 µL plasma with 20 ng IS and 1.7 mL water, add 500 µL MeCN, add to a 500 mg Bond Elut C18 SPE cartridge, wash with 6 mL water, elute with 3 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with 300 µL mobile phase, inject an aliquot. Alternatively, mix 50 µL plasma or brain homogenate with 5 ng IS and 100 µL MeCN, vortex, centrifuge at 3000 g for 10 min, inject a 5–25 µL aliquot of the supernatant. HPLC VARIABLES Column: 50 × 4.6 5 µm Spherisorb C8 Mobile phase: MeCN:10 mM ammonium acetate:formic acid 55:45:0.1 Flow rate: 1 Injection volume: 5–25 Detector: MS, Sciex API III+, heated nebulizer interface, dwell time 450 ms, m/z 535 to 179 CHROMATOGRAM Retention time: 1.5 Internal standard: desfluoroaprepitant (m/z 535 to 161) (1.5) KEY WORDS brain; ferret; plasma; SPE REFERENCE Huskey, S.-E.W.; Dean, B.J.; Bakhtiar, R.; Sanchez, R.I.; Tattersall, F.D.; Rycroft, W.; Hargreaves, R.; Watt, A.P.; Chicchi, G.G.; Keohane, C.; Hora, D.F.; Chiu, S.-H.L. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets, Drug Metab.Dispos., 2003, 31, 785–791. SAMPLE Matrix: blood, tissue Sample preparation: Mix 3 mL plasma with 6 mL MeCN, centrifuge at 3000 g, evaporate the supernatant to dryness under a stream of nitrogen, reconstitute the residue with 1 mL MeOH:water 40:60, inject a 250–400 µL aliquot of the supernatant. Homogenize the brain with 3 volumes of water. Vortex 10 mL homogenate with 90 mL MeCN, sonicate for 5 min, centrifuge at 3000 g for 10 min, re-extract the pellet with 10 mL MeOH. Combine the organic layers and add to a Bond Elut C18 SPE cartridge equipped with an Acrodisc glass filter, elute with 5 mL MeOH:MeCN:water 50:25:25. Collect all the cartridge effluent and evaporate to dryness under a stream of nitrogen, reconstitute the residue with 5 mL MeOH, vortex, sonicate, centrifuge. Evaporate the supernatant to dryness under a stream of nitrogen, reconstitute the residue with 1 mL MeOH:water 40:60, inject a 400 µL aliquot of the supernatant. HPLC VARIABLES Column: 250 × 4.6 Zorbax RX-C8 Aprepitant 47 Mobile phase: Gradient. A:B 65:35 to 20:80 over 40 min. A was 10 mM ammonium acetate. B was MeCN:MeOH 92.8:7.2 containing 7.2 mM ammonium acetate. (Alternatively, A 10 mM ammonium acetate in water containing 0.1% trifluoroacetic acid and B MeCN:MeOH 92.8:7.2 containing 7.2 mM ammonium acetate and 0.1% trifluoroacetic acid with the same gradient.) Flow rate: 1 Injection volume: 250–400 Detector: Radioactivity (14 C) CHROMATOGRAM Retention time: 26 Internal standard: desfluoroaprepitant (m/z 535 to 161) (1.5) OTHER SUBSTANCES Extracted: metabolites KEY WORDS brain; ferret; plasma; SPE REFERENCE Huskey, S.E.W.; Dean, B.J.; Bakhtiar, R.; Sanchez, R.I.; Tattersall, F.D.; Rycroft, W.; Hargreaves, R.; Watt, A.P.; Chicchi, G.G.; Keohane, C.; Hora, D.F.; Chiu, S.H.L. Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets, Drug Metab.Dispos., 2003, 31, 785–791. SAMPLE Matrix: solutions Sample preparation: Inject a 1 µL aliquot of a solution in MeOH:water 10:90. HPLC VARIABLES Column: 20 × 2 5 µm DASH BetaBasic C8 (ThermoHypersil Keystone) Mobile phase: Gradient. A was MeCN:water:formic acid 5:95:0.1. B was MeCN:water: formic acid 95:5:0.1. A:B 100:0 for 0.2 min, to 0:100 over 1.5 min. Flow rate: 1.5 Injection volume: 1 Detector: MS, PE Sciex API-3000, turbo ionspray, electrospray 4500 V, ring 290 V, orifice 60 V, drying gas 400◦ , 20% of column effluent entered the detector, m/z 535.3–277 CHROMATOGRAM Retention time: 1.4 OTHER SUBSTANCES Simultaneous: amitriptyline (m/z 278.3–233) (1.1), diclofenac (m/z 296.1–215) (1.35), enoxacin (m/z 321.2–234) (0.7), fenofibrate (m/z 360.9–233) (1.6), finasteride (m/z 373.2–317) (1.2), indinavir (m/z 614.4–421) (0.93), pioglitazone (357.2–134) (0.87), raloxifene (m/z 474.1–112) (0.97) REFERENCE Romanyshyn, L.A.; Tiller, P.R. Ultra-short columns and ballistic gradients: considerations for ultra-fast chromatographic liquid chromatographic-tandem mass spectrometric analysis, J.Chromatogr.A, 2001, 928, 41–51. 48 Aranidipine Aranidipine H O Molecular formula: C19 H20 N2 O7 Molecular weight: 388.37 CAS Registry No: 86780-90-7 Merck Index: 13, 772 CH3 H3C N CH3 O OCH3 O O NO2 SAMPLE Matrix: blood Sample preparation: Add 20 ng nifedipine and 500 µL 100 mM pH 9.0 borate buffer to 1 mL plasma, vortex for 10 s, add 6 mL toluene, shake mechanically for 10 min, centrifuge at 1000 g for 15 min. Evaporate the organic layer to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL mobile phase, inject a 50 µL aliquot. (Carry out all steps under yellow fluorescent lighting.) HPLC VARIABLES Column: 150 × 4.6 5 µm Inertsil ODS-2 Column temperature: 40 Mobile phase: MeOH:360 mM sodium perchlorate 45:55 Flow rate: 0.8 Injection volume: 50 Detector: E, BAS LC-4B/17AT, +0.92 V versus Ag/AgCl CHROMATOGRAM Retention time: 16 Internal standard: nifedipine (26) Limit of quantitation: 2.5 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS dog; pharmacokinetics; plasma REFERENCE Iida, Y.; Kinouchi, Y.; Takeichi, Y.; Imai, T.; Otagiri, M. Simultaneous determination of a new dihydropyridine calcium antagonist (MPC-1304) and its metabolite in dog plasma by high-performance liquid chromatography with electrochemical detection, J.Chromatogr., 1991, 571, 277–282. 49 Arotinolol Arotinolol O H2N Molecular formula: C15 H21 N3 O2 S3 CH3 CH3 S S N N S Molecular weight: 371.55 CAS Registry No: 68377-92-4, 68377-91-3 (HCl) Merck Index: 13, 797 OH CH3 H SAMPLE Matrix: blood Sample preparation: Add 100 µL 10 mg/mL IS in water to 500 µL plasma, make up to 1 mL with water, add 100 µL 3 M pH 9 ammonium acetate, vortex vigorously for 2 min, centrifuge at 3000 g for 10 min. Extract the aqueous layer three times with 1 mL portions of ether, evaporate the extracts to dryness under reduced pressure, reconstitute the residue with 100 µL 100 mM HCl, inject an aliquot. HPLC VARIABLES Column: 250 × 4.6 Chirobiotic T (Advanced Separation Technologies) Mobile phase: MeOH:acetic acid:triethylamine 100:0.1:0.1 Flow rate: 0.8 Detector: UV 317 CHROMATOGRAM Retention time: 17.25 (S-(+)), 20.06 (R-(–) ) Internal standard: labetalol hydrochloride (21.98, 23.43 (enantiomers)) Limit of detection: 50 ng/mL Limit of quantitation: 100 ng/mL KEY WORDS chiral; plasma REFERENCE Aboul-Enein, H.Y.; Hefnawy, M.M. Enantioselective determination of arotinolol in human plasma by HPLC using teicoplanin chiral stationary phase, Biomed.Chromatogr., 2003, 17, 453–457. SAMPLE Matrix: blood, urine Sample preparation: Condition a 1 mL C18 Bakerbond SPE cartridge with MeOH. Mix 1 mL plasma with 50 µL 5 µg/mL alpiropride in water. Mix 100 µL pure or diluted urine with 250 µL blank plasma and 100 µL 5 µg/mL alpiropride in water. Add the sample to the SPE cartridge, wash three times with 1 mL portions of water, wash three times with 1 mL portions of n-hexane:diethyl ether 50:50, elute with two 1 mL portions of chloroform:triethylamine 90:10 (Caution! Chloroform is a carcinogen!). Evaporate the eluate to dryness under reduced pressure, reconstitute the residue with 150 µL mobile phase, inject a 100 µL aliquot. HPLC VARIABLES Guard column: 15 × 4.6 7 µm C18 Column: 250 × 4.6 5 µm ODS Hypersil Column temperature: 25 Mobile phase: MeCN:MeOH:buffer 12.5:12.5:75 (The buffer was 67 mM pH 5.6 phosphate buffer containing 0.6 mM tetrabutylammonium chloride.) Flow rate: 1.2 Injection volume: 100 Detector: F ex 310 em 395; UV 310 50 Arotinolol CHROMATOGRAM Retention time: 10.0 Internal standard: alpiropride (4.7) Limit of detection: 0.11 ng/mL (plasma), 11 ng/mL (urine) OTHER SUBSTANCES Extracted: metabolites KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Moulin, A.; Maillet, E.; Truffer, D.; Dufour, A. High performance liquid chromatographic determination of arotinolol and AC 623, its main metabolite in biological samples, J.Liq.Chromatogr., 1992, 15, 151–164. SAMPLE Matrix: blood, urine Sample preparation: Condition a 1 mL C18 Bakerbond SPE cartridge with MeOH. Mix 1 mL plasma with 50 µL 5 µg/mL alpiropride in water. Mix 100 µL pure or diluted urine with 250 µL blank plasma and 100 µL 5 µg/mL alpiropride in water. Add the sample to the SPE cartridge, wash three times with 1 mL portions of water, wash three times with 1 mL portions of n-hexane:diethyl ether 50:50, elute with two 1 mL portions of chloroform:triethylamine 90:10 (Caution! Chloroform is a carcinogen!). Evaporate the eluate to dryness under reduced pressure, reconstitute the residue with 150 µL mobile phase, inject a 100 µL aliquot. HPLC VARIABLES Guard column: 15 × 4.6 7 µm diol Column: 200 × 4.6 5 µm Lichrosorb diol Column temperature: 25 Mobile phase: Dichloromethane containing 10 mM Z-glycyl-L-proline:MeOH 100:1 Flow rate: 2 Injection volume: 100 Detector: F ex 320 em 425 CHROMATOGRAM Retention time: 12 (R-(–) ), 15 (S-(+)) Internal standard: alpiropride (7.5) Limit of detection: 2 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS chiral; plasma; SPE REFERENCE Moulin, A.; Truffer, D.; Maillet, E.; Dufour, A. High performance liquid chromatographic determination of the optical isomers of arotinolol and AC 623, its main metabolite, in biological samples, J.Liq.Chromatogr., 1992, 15, 165–181. Arotinolol 51 ANNOTATED BIBLIOGRAPHY Nakamura, K.; Fujima, H.; Kitagawa, H.; Wada, H.; Makino, K. Preparation and chromatographic characteristics of a chiral-recognizing perphenylated cyclodextrin column, J.Chromatogr.A, 1995, 694, 111–118. [ibuprofen; chlorpheniramine; acetylpheneturide; alprenolol; arotinolol; atenolol; benzoin; biperiden; bunitrolol; chlormezanone; chlorphenesin; eperisone; flavanone; oxprenolol; phenylethyl alcohol; phenylethylamine; pindolol; proglumide; propranolol; trihexyphenidyl] 52 Arteether Arteether Molecular formula: C17 H28 O5 Molecular weight: 312.40 CAS Registry No: 75887-54-6 Merck Index: 13, 822 H H3C CH3 O O O H H H CH3 O H O CH3 SAMPLE Matrix: blood Sample preparation: Add 5 µL 10 µg/mL artemisinin in MeOH to 200 µL serum, vortex, add 2 mL hexane, vortex for 1 min, centrifuge at 1000 g for 5 min, freeze in liquid nitrogen. Repeat the extraction. Combine the organic layers and evaporate to dryness, reconstitute the residue with 40 µL MeOH, inject a 20 µL aliquot. HPLC VARIABLES Column: 300 × 4.6 5 µm Ultracarb 5 ODS 20 (Phenomenex) Mobile phase: MeOH:100 mM sodium acetate 80:20 Flow rate: 1 Injection volume: 20 Detector: MS, Quattro II triple quadrupole, electrospray, nebulizing gas nitrogen 10 L/h, curtain gas nitrogen 250 L/h, ESI capillary at 3.5 kV, cone voltage 52 V, positive mode, m/z 335 [M + Na]+, one tenth of column effluent was allowed into MS CHROMATOGRAM Retention time: 1.73 (α), 2.81 (β) Internal standard: artemisinin (m/z 305) (1.02) Limit of detection: 5 ng/mL Limit of quantitation: 20 ng/mL KEY WORDS rat; serum REFERENCE Rajanikanth, M.; Madhusudanan, K.P.; Gupta, R.C. Liquid chromatographic-mass spectrometric method for the determination of α-, β-arteether in rat serum, J.Chromatogr.B, 2003, 783, 391–399. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 5 µm IBO-SIL C18 (Phenomenex) Mobile phase: MeOH:water 80:20 Flow rate: 0.9 Detector: UV 260 REFERENCE Illapakurthy, A.C.; Sabnis, Y.A.; Avery, B.A.; Avery, M.A.; Wyandt, C.M. Interaction of artemisinin and its related compounds with hydroxypropyl-β-cyclodextrin in solution state: experimental and molecular-modeling studies, J.Pharm.Sci., 2003, 92, 649–655. Arteether 53 ANNOTATED BIBLIOGRAPHY Baker, J.K.; Yarber, R.H.; Hufford, C.D.; Lee, I.-S.; ElSohly, H.N.; McChesney, J.D. Thermospray mass spectroscopy/high performance liquid chromatographic identification of the metabolites formed from arteether using a rat liver microsome preparation, Biomed.Environ.Mass Spectrom., 1989, 18, 337–351. Baker, J.K.; McChesney, J.D.; Chi, H.T. Decomposition of arteether in simulated stomach acid yielding compounds retaining antimalarial activity, Pharm.Res., 1993, 10, 662–666. Benakis, A.; Schopfer, C.; Paris, M.; Plessas, C.; Karayannakos, P.E.; Dondas, I.; Kotsarelis, D.; Plessas, S.T.; Skalkeas, G. Pharmacokinetics of arteether in dog, Eur.J.Drug Metab.Pharmacokinet., 1991, 16, 325–328. Chi, H.T.; Ramu, K.; Baker, J.K.; Hufford, C.D.; Lee, I.S.; Zeng, Y.-L.; McChesney, J.D. Identification of the in vivo metabolites of the antimalarial arteether by thermospray high-performance liquid chromatography/mass spectrometry, Biol.Mass Spectrom., 1991, 20, 609–628. Idowu, O.R.; Edwards, G.; Ward, S.A.; Orme, M.L’E.; Breckenridge, A.M. Determination of arteether in blood plasma by high-performance liquid chromatography with ultraviolet detection after hydrolysis with acid, J.Chromatogr., 1989, 493, 125–136. Leo, K.U.; Grace, J.M.; Li, Q.; Peggins, J.; Mitchell, A.L.; Aguilar, T.; Brewer, T.G. Effects of Plasmodium berghei infection on arteether metabolism and disposition, Pharmacology, 1997, 54, 276–284. Leskovac, V.; Theoharides, A.D. Hepatic metabolism of artemisinin drugs – I. Drug metabolism in rat liver microsomes, Comp.Biochem.Physiol.C, 1991, 99, 383–390. [arteether; dihydroartemisinin] Li, Q.G.; Brueckner, R.P.; Peggins, J.O.; Trotman, K.M.; Brewer, T.G. Arteether toxicokinetics and pharmacokinetics in rats after 25 mg/kg/day single and multiple doses, Eur.J.Drug Metab.Pharmacokinet., 1999, 24, 213–223. Melendez, V.; Peggins, J.O.; Brewer, T.G.; Theoharides, A.D. Determination of the antimalarial arteether and its deethylated metabolite dihydroartemisinin in plasma by high-performance liquid chromatography with reductive electrochemical detection, J.Pharm.Sci., 1991, 80, 132–138. Rajanikanth, M.; Madhusudanan, K.P.; Gupta, R.C. An HPLC-MS method for simultaneous estimation of α,β-arteether and its metabolite dihydroartemisinin, in rat plasma for application to pharmacokinetic study, Biomed.Chromatogr., 2003, 17, 440–446. Ramu, K.; Baker, J.K. Identification of the glucuronides of the hydroxylated metabolites of the antimalarial arteether in rat plasma and urine by thermospray high-performance liquid chromatography/mass spectrometry, J.Pharm.Sci., 1997, 86, 915–920. 54 Articaine Articaine Molecular formula: C13 H20 N2 O3 S Molecular weight: 284.38 CAS Registry No: 23964-58-1, 23964-57-0 (HCl) Merck Index: 13, 1884 O OCH3 O H S H3C N H N CH3 CH3 SAMPLE Matrix: blood Sample preparation: 1 mL Plasma + 50 µL 2 µg/mL etidocaine in water + 100 µL 1 M NaOH + 3 mL heptane:ethyl acetate 90:10, shake for 2 min, centrifuge at 1200 g for 10 min. Remove the organic phase and add it to 50 µL 50 mM sulfuric acid, shake for 2 min, centrifuge at 1200 g for 5 min. Remove the aqueous phase and add it to 820 µg sodium acetate, inject a 40 µL aliquot. (The sodium acetate was measured out by adding 50 µL 200 mM sodium acetate in MeOH to the tube and evaporating the MeOH.) HPLC VARIABLES Column: 250 × 4 10 µm µBondapak C18 Column temperature: 30 Mobile phase: MeCN:10 mM sodium dihydrogen phosphate 7:93, adjusted to pH 2.1 Flow rate: 1 Injection volume: 40 Detector: UV 205 CHROMATOGRAM Retention time: 19 Internal standard: etidocaine (10) Limit of detection: 5 ng/mL OTHER SUBSTANCES Extracted: mepivacaine (15) KEY WORDS plasma; rabbit REFERENCE Le Guévello, P.; Le Corre, P.; Chevanne, P.; Le Verge, R. High-performance liquid chromatographic determination of bupivacaine in plasma samples for biopharmaceutical studies and application to seven other local anaesthetics, J.Chromatogr., 1993, 622, 284–290. SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 4 mm SDB-RPS SPE disk cartridge (3M Empore) with 500 µL MeOH, 500 µL air, 500 µL water, and 1 mL air. Mix 1 mL serum with 50 µL perchloric acid, let stand for 10 min, mix, centrifuge at 16 000 g for 10 min. Add 800 µL to the cartridge followed by 2 mL air. Wash with 800 µL 0.5% phosphoric acid in MeOH:water 20:80, push through 1.5 mL air, wash with 700 µL water, push through 2 mL air, elute with 500 µL MeOH containing 1% ammonia, push through 1.2 mL air. Evaporate the eluate to dryness under a stream of air at 70◦ and reconstitute the residue with 50 µL mobile phase, inject a 40 µL aliquot. HPLC VARIABLES Column: 125 × 3 5 µm Nucleosil 50-5 endcapped RP-8 Articaine 55 Column temperature: 35 Mobile phase: MeCN:buffer 12:88 (Buffer was 880 mL 20 mM potassium dihydrogen phosphate containing 500 µL phosphoric acid, pH 3.) Flow rate: 1 Injection volume: 40 Detector: UV 274 CHROMATOGRAM Retention time: 9.5 Limit of quantitation: 10 ng/mL OTHER SUBSTANCES Extracted: articainic acid (3.5) KEY WORDS serum; SPE REFERENCE Richter, K.; Oertel, R. Solid-phase extraction and high-performance liquid chromatographic determination of articaine and its metabolite articainic acid in human serum, J.Chromatogr.B, 1999, 724, 109–115. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 10 µm Chiralcel OD Mobile phase: n-Hexane:isopropanol 80:20 Flow rate: 0.4 Injection volume: 5 Detector: UV 274 CHROMATOGRAM Retention time: 12, 14 (enantiomers) KEY WORDS chiral REFERENCE Rustichelli, C.; Ferioli, V.; Gamberini, G.; Stancanelli, R. Enantiomeric separation of local anaesthetic drug by HPLC on chiral stationary phases, Chromatographia, 2001, 54, 731–736. ANNOTATED BIBLIOGRAPHY Chankvetadze, B.; Chankvetadze, L.; Sidamonidze, S.; Yashima, E.; Okamoto, Y. High performance liquid chromatography enantioseparation of chiral pharmaceuticals using tris(chloro-methylphenylcarbamate)s of cellulose, J.Pharm.Biomed.Anal., 1996, 14, 1295–1303. [oxazepam; oxazolam; hexobarbital; phenobarbital; thiopental; lorazepam; lopirazepam; camazepam; cloxazolam; ketazolam; pindolol; propranolol; sotalol; alprenolol; bupranolol; acebutolol; penbutolol; toliprolol; enilconazole; econazole; miconazole; bifonazole; ornidazole; bayleton; metomidate; nisoldipine; nimodipine; isradipine; nicardipine; triadimefon; pheniramine; doxylamine; chlorphenoxamine; carbinoxamine; azelastine; mequitazine; paramethadione; norgestrel; tesicam; mesuximide; metofoline; tramadol; clofedanol; lofexidine; clenbuterol; piprozolin; etozolin; doxapram; chlormezanone; aminoglutethimide; articaine; etidocaine; nefopam] Oertel, R.; Richter, K.; Weile, K.; Gramatte, T.; Berndt, A.; Feller, K. A simple method for the determination of articaine and its metabolite articainic acid in dentistry: application to a comparison of articaine and lidocaine concentrations in alveolus blood, Methods Find.Exp.Clin.Pharmacol., 1993, 15, 541–547. 56 Articaine Oertel, R.; Richter, K.; Gramatté, T.; Kirch, W. Determination of drugs in biological fluids by highperformance liquid chromatography with on-line sample processing, J.Chromatogr.A, 1998, 797, 203–209. [metoprolol; talinolol; celiprolol; tiracizine; triamterene; ajmaline; articaine; lamotrigine] Rop, P.P.; Grimaldi, F.; Bresson, M.; Fornaris, M.; Viala, A. Liquid chromatographic analysis of cocaine, benzoylecgonine, local anaesthetic agents and some of their metabolites in biological fluids, J.Liq.Chromatogr., 1993, 16, 2797–2811. [cocaine; benzoylecgonine; procaine; p-aminobenzoic acid; butacaine; tetracaine; articaine; prilocaine; o-toluidine; lidocaine; monoethylglycine xylidide; bupivacaine; pipecolylxylidene; etidocaine; dibucaine; caffeine; amphetamine; ephedrine; epinephrine; morphine; monoacetylmorphine; diamorphine; ethylmorphine; codeine; acetylcodeine; fluorescence detection; UV detection; SPE] Vree, T.B.; Baars, A.M.; van Oss, G.E.; Booij, L.H. High-performance liquid chromatography and preliminary pharmacokinetics of articaine and its 2-carboxy metabolite in human serum and urine, J.Chromatogr., 1988, 424, 440–444. Asparaginase 57 Asparaginase Molecular weight: ca. 136 000 CAS Registry No: 9015-68-3 Merck Index: 13, 841 SAMPLE Matrix: reaction mixtures Sample preparation: Adjust to pH 7 with 2 M NaOH, inject a 20 µL aliquot. HPLC VARIABLES Column: 250 × 4 10 µm HEMA-BIO 1000 (Tessek, Prague) (hydroxyethyl methacrylate–type column) Mobile phase: 100 mM Potassium dihydrogen phosphate adjusted to pH 6.9 with 2 M NaOH Flow rate: 0.8 Injection volume: 20 Detector: UV 210 CHROMATOGRAM Retention time: 2.1 Limit of detection: 0.51 U/mL REFERENCE Barek, J.; Cvacka, J.; Zima, J.; De Méo, M.; Laget, M.; Michelon, J.; Castegnaro, M. Chemical degradation of wastes of antineoplastic agents amsacrine, azathioprine, asparaginase and thiotepa, Ann.Occup.Hyg., 1998, 42, 259–266. 58 Atazanavir sulfate Atazanavir sulfate N Molecular formula: C38 H52 N6 O7 .H2 O4 S H2SO4 Molecular weight: 802.93 CAS Registry No: 229975-97-7 H3C O H3CO CH3 CH3 H N N H O OH O N N H H3C H N OCH3 O CH3 CH3 SAMPLE Matrix: blood Sample preparation: Condition each well of a 3M Empore C2-SD 96 well plate with 250 µL MeOH and 500 µL 0.1% acetic acid, do not allow to go dry. Add 50 µL 200 ng/mL IS in MeOH:water 60:40 to 200 µL MeOH:water 60:40 containing 5 million cells, sonicate for 10 min, centrifuge at 2600 g for 10 min. Evaporate the supernatant to dryness, reconstitute with 50 µL MeOH, add 200 µL water, add 250 µL 0.1% acetic acid, mix, add to a well on the SPE plate, allow to pass through under vacuum over 2 min, wash with 500 µL 0.1% acetic acid, dry under vacuum for 2 min, elute twice with 200 µL portions of MeCN:MeOH 50:50, pulling to dryness after each portion. Evaporate the eluate to dryness under a stream of nitrogen at 60◦ over ca. 40 min, reconstitute the residue with 200 µL mobile phase, vortex, inject a 20 µL aliquot. HPLC VARIABLES Guard column: 10 × 2 5 µm YMC Basic Column: 50 × 2 5 µm YMC Basic Mobile phase: MeCN:MeOH:water:88% formic acid 30:30:40:0.025 Flow rate: 0.25 Injection volume: 20 Detector: MS, Sciex API 3000 turbo ionspray, electrospray, positive mode at 400◦ , m/z 705 to 335, IonSpray 4600 V, declustering potential 56 V, entrance potential −10 V, focusing potential 220 V, TurboIon gas nitrogen 8 L/min, collision energy 42 V, collision cell exit potential 24 V, dwell time 500 ms, pause time 5 ms CHROMATOGRAM Retention time: <4 Internal standard: 13 C6 -atazanavir Limit of quantitation: 5 fmole/million cells KEY WORDS peripheral blood mononuclear cells; SPE REFERENCE Jemal, M.; Rao, S.; Gatz, M.; Whigan, D. Liquid chromatography-tandem mass spectrometric quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human peripheral blood mononuclear cells (PBMC): practical approaches to PBMC preparation and PBMC assay design for high-throughput analysis, J.Chromatogr.B, 2003, 795, 273–289. SAMPLE Matrix: blood Sample preparation: Condition each well of a10 mg Oasis HLB 96 well SPE plate with 1 mL MeOH and 1 mL 0.1% acetic acid. Add 40 µL 5 µg/mL IS in water and 300 µL 0.1% Atazanavir sulfate 59 acetic acid to 250 µL plasma, mix, add to a well of the SPE plate, wash with 500 µL 0.1% acetic acid, wash with 500 µL MeOH:water 20:80, elute with 300 µL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 500 µL MeCN:MeOH:10 mM pH 5.5 ammonium acetate 30:30:40, inject a 15 µL aliquot. HPLC VARIABLES Column: 33 × 4.6 3 µm Uptisphere HDO C18 (Interchim) Mobile phase: Gradient. MeCN:5 mM ammonium acetate 50:50 for 0.5 min, to 60:40 over 0.1 min, maintain at 60:40 for 1.7 min, return to initial conditions over 0.1 min, re-equilibrate for 2.1 min. Flow rate: 0.8 Injection volume: 15 Detector: MS, Micromass Quattro Ultima, atmospheric pressure electrospray ionization, column effluent split 1:20 before entering MS, positive ion mode, capillary sprayer voltage 3.2 kV, sample cone voltage 80 V, source temperature 100◦ , desolvation temperature 350◦ , nebulizing gas nitrogen, cone gas nitrogen at 37 L/h, desolvation gas nitrogen at 500 L/h, collision gas argon at 2.6 µbar, collision energy was set at 40 eV, resolution set at 0.7 mass units at half height for the first and third quadrupoles. CHROMATOGRAM Retention time: 2.3 Internal standard: 13 C6 -atazanavir Limit of quantitation: 1 ng/mL KEY WORDS plasma; SPE REFERENCE Schuster, A.; Burzawa, S.; Jemal, M.; Loizillon, E.; Couerbe, P.; Whigan, D. Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatographytandem mass spectrometry following automated solid-phase extraction, J.Chromatogr.B, 2003, 788, 377–386. 60 Atipamezole Atipamezole CH3 H N Molecular formula: C14 H16 N2 Molecular weight: 212.29 CAS Registry No: 104054-27-5 Merck Index: 13, 866 N SAMPLE Matrix: blood Sample preparation: Condition a Sep-Pak C18 SPE cartridge with water, MeOH, and 100 mM ammonium acetate. 5 mL Plasma + 250 ng detomidine, add to the SPE cartridge, wash with 100 mM ammonium acetate, elute with MeOH:100 mM ammonium acetate 75:25. Evaporate the eluate to dryness under reduced pressure, reconstitute the residue in 200 µL mobile phase, inject a 50 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Hitachi gel #3056 Mobile phase: MeOH:100 mM ammonium acetate 65:35 Flow rate: 1 Injection volume: 50 Detector: MS, Hitachi M-1000, APCI interface, drift voltage 21 V, nebulizer 260◦ , vaporizer 399◦ , multiplier voltage 1500 VF, m/z 213 CHROMATOGRAM Retention time: 8 Internal standard: detomidine (m/z 187) (6.5) Limit of quantitation: 1–2 ng/mL OTHER SUBSTANCES Extracted: medetomidine (7.5, m/z 201), midazolam (10.5, m/z 326) KEY WORDS pharmacokinetics; pig; plasma; SPE REFERENCE Kanazawa, H.; Nishimura, R.; Sasaki, N.; Takeuchi, A.; Takai, N.; Nagata, Y.; Matsushima, Y. Determination of medetomidine, atipamazole and midazolam by liquid chromatography-mass spectrometry, Biomed.Chromatogr., 1995, 9, 188–191. SAMPLE Matrix: blood Sample preparation: Mix 200 µL 250 mM NaOH with 500 µL plasma, add 6 mL dichloromethane, mix gently for 10 min, centrifuge at 1700 g for 10 min. Evaporate 4 mL of the lower organic layer to dryness under a stream of nitrogen, reconstitute the residue with 100 µL 50 mM pH 3.2 phosphate buffer, vortex for 1.5 min, centrifuge at 1700 g for 10 min, inject a 50 µL aliquot. HPLC VARIABLES Guard column: 20 × 4.6 5 µm Supelguard LC-DP Column: 250 × 4.6 5 µm Supelcosil LC-DP Mobile phase: MeCN:50 mM phosphate buffer:triethylamine 27:73:0.05, adjusted to pH 3.2 Flow rate: 1 Injection volume: 50 Atipamezole 61 Detector: UV 215 CHROMATOGRAM Retention time: 16.2 Limit of detection: 5 ng/mL OTHER SUBSTANCES Extracted: medetomidine (14.6) KEY WORDS pharmacokinetics; plasma; reindeer REFERENCE Ranheim, B.; Horsberg, T.E.; Nymoen, U.; Soli, N.E.; Tyler, N.J.; Arnemo, J.M. Reversal of medetomidine-induced sedation in reindeer (Rangifer tarandus tarandus) with atipamezole increases the medetomidine concentration in plasma, J.Vet.Pharmacol.Ther., 1997, 20, 350–354. ANNOTATED BIBLIOGRAPHY Kanazawa, H.; Nagata, Y.; Matsushima, Y.; Takai, N.; Uchiyama, H.; Nishimura, R.; Takeuchi, A. Liquid chromatography-mass spectrometry for the determination of medetomidine and other anaesthetics in plasma, J.Chromatogr., 1993, 631, 215–220. 62 Atomoxetine hydrochloride Atomoxetine hydrochloride Molecular formula: C17 H21 NO.HCl Molecular weight: 291.82 CAS Registry No: 82248-59-7 H H3C N H O CH3 HCl SAMPLE Matrix: blood Sample preparation: Add 500 µL plasma to a Varian SDB-XC SPE cartridge, wash with 1 mL MeOH:water 15:85, elute with 750 µL MeCN containing 0.1% trifluoroacetic acid. Evaporate the eluate to dryness under a stream of nitrogen at 45◦ , reconstitute the residue with 100 µL MeCN, mix with 25 µL water, inject an aliquot. HPLC VARIABLES Column: 100 × 4.6 5 µm Brownlee Spheri-5 ODS Mobile phase: MeCN:water 85:15 containing 5 mM ammonium acetate, 0.2% formic acid, and 0.03% trifluoroacetic acid Flow rate: 1 Detector: MS, PE Sciex API III, MS/MS, positive atmospheric pressure chemical ionization, heated nebulizer interface, m/z 256 to 44 CHROMATOGRAM Limit of quantitation: 0.25 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS dog; plasma; rat; SPE REFERENCE Mattiuz, E.L.; Ponsler, G.D.; Barbuch, R.J.; Wood, P.G.; Mullen, J.H.; Shugert, R.L.; Li, Q.; Wheeler, W.J.; Kuo, F.; Conrad, P.C.; Sauer, J.-M. Disposition and metabolic fate of atomoxetine hydrochloride: Pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog, Drug Metab.Dispos., 2003, 31, 88–97. SAMPLE Matrix: blood, urine Sample preparation: Plasma. Mix 3 mL MeCN with 1.5 mL plasma, centrifuge, evaporate the supernatant to dryness under a stream of nitrogen, reconstitute the residue with 200 µL MeCN:water 10:90, inject an aliquot. Urine. Lyophilize urine, reconstitute with MeCN:water 10:90 to one-tenth original volume, vortex, filter (0.45 µm), inject an aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Zorbax Eclipse XDB-C18 Column temperature: 30 Mobile phase: Gradient. MeCN:50 mM ammonium acetate from 10:90 to 60:40 over 30 min. (Use 25 mM ammonium acetate for MS detector.) Flow rate: 1 Atomoxetine hydrochloride 63 Detector: Radioactivity (14 C); MS, Finnigan TSQ 700 or TSQ 7000, positive electrospray, collision gas argon, 0.2 mL/min of column effluent entered MS CHROMATOGRAM Retention time: 20 OTHER SUBSTANCES Extracted: metabolites KEY WORDS plasma REFERENCE Sauer, J.-M.; Ponsler, G.D.; Mattiuz, E.L.; Long, A.J.; Witcher, J.W.; Thomasson, H.R.; Desante, K.A. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism, Drug Metab.Dispos., 2003, 31, 98–107. 64 Atorvastatin Atorvastatin H3C O Molecular formula: C33 H35 FN2 O5 N Molecular weight: 558.64 CAS Registry No: 134523-00-5 Merck Index: 13, 868 H CH3 OH OH COOH N F SAMPLE Matrix: blood Sample preparation: Mix 500 µL serum with IS, acidify to pH 6 with sodium acetate buffer, extract with MTBE, centrifuge. Remove the organic layer and evaporate it to dryness, reconstitute the residue, inject an aliquot. HPLC VARIABLES Column: YMC Basic Mobile phase: Gradient. A:B from 70:30 to 45:55 over 1 min, maintain at 45:55 for 0.5 min, return to initial conditions over 0.1 min, maintain at 70:30 for 1.9 min. A was MeOH:water:88% formic acid 5:95:0.0043. B was MeCN:MeOH:88% formic acid 95:5:0.0043. Detector: MS, Finnigan TSQ-7000, electrospray, m/z 559-440 CHROMATOGRAM Internal standard: deuterated atorvastatin Limit of quantitation: 500 pg/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS pharmacokinetics; serum REFERENCE Kantola, T.; Kivistö, K.T.; Neuvonen, P.J. Effect of itraconazole on the pharmacokinetics of atorvastatin, Clin.Pharmacol.Ther., 1998, 64, 58–65. SAMPLE Matrix: formulations Sample preparation: Shake 10 tablets with 50 mL MeCN:THF:50 mM pH 4 ammonium citrate buffer 27:20:53 at 450 rpm for 1 h, make up to 100 mL with the same solution, filter, dilute a 2 mL aliquot to 10 mL, inject an aliquot. HPLC VARIABLES Guard column: 4 × 3 5 µm C18 Luna (Phenomenex) Column: 250 × 4.6 5 µm C18 Luna (Phenomenex) Mobile phase: Gradient. MeCN:THF:20 mM pH 4.0 ammonium acetate buffer from 25:5:70 to 70:5:25 over 50 min, maintain at 70:5:25 for 10 min. Flow rate: 1 Injection volume: 100 Detector: UV 248 CHROMATOGRAM Retention time: 30 Atorvastatin 65 Limit of detection: 13 ng/mL Limit of quantitation: 130 ng/mL OTHER SUBSTANCES Simultaneous: impurities KEY WORDS tablets REFERENCE Ertürk, S.; Aktas, E.S.; Ersoy, L.; Fiçicioglu, S. An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets, J.Pharm.Biomed.Anal., 2003, 33, 1017–1023. ANNOTATED BIBLIOGRAPHY Al-Rawithi, S.; Hussein, R.F.; Alzahrani, A. Sensitive assay for the determination of fluvastatin in plasma utilizing high-performance liquid chromatography with fluorescence detection, Ther.Drug Monit., 2003, 25, 88–92. [atorvastatin is IS] Jacobsen, W.; Kuhn, B.; Soldner, A.; Kirchner, G.; Sewing, K.-F.; Kollman, P.A.; Benet, L.Z.; Christians, U. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin, Drug Metab.Dispos., 2000, 28, 1369–1378. [microsomal incubations] Mazzu, A.L.; Lasseter, K.C.; Shamblen, E.C.; Agarwal, V.; Lettieri, J.; Sundaresen, P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin, Clin.Pharmacol.Ther., 2000, 68, 391–400. [SPE] Miao, X.-S.; Metcalfe, C.D. Determination of cholesterol-lowering statin drugs in aqueous samples using liquid chromatography-electrospray ionization tandem mass spectrometry, J.Chromatogr.A, 2003, 998, 133–141. [atorvastatin; lovastatin; pravastatin; simvastatin] Prueksaritanont, T.; Tang, C.; Qiu, Y.; Mu, L.; Subramanian, R.; Lin, J.H. Effects of fibrates on metabolism of statins in human hepatocytes, Drug Metab.Dispos., 2002, 30, 1280–1287. [cerivastatin; simvastatin; atorvastatin; rosuvastatin; pravastatin] 66 Atosiban Atosiban O O Molecular formula: C43 H67 N11 O12 S2 Molecular weight: 994.20 CAS Registry No: 90779-69-4 Merck Index: 13, 869 CH3 S N H Ile-Thr-Asn-Cys-Pro-Orn-GlyNH2 O SAMPLE Matrix: solutions HPLC VARIABLES Guard column: Kromasil C8 pre-column Column: 100 × 2.1 KR 100-5 C8 1572 (Hichrom) Mobile phase: MeCN:water:triethylammonium phosphate 27:72.9:0.1 Flow rate: 0.2 Detector: UV 190 REFERENCE Lundin, S.; Svedman, P.; Höglund, P.; Jönsson, K.; Broeders, A.; Melin, P. Absorption of an oxytocin antagonist (antocin) and a vasopressin analogue (dDAVP) through a standardized skin erosion in volunteers, Pharm.Res., 1995, 12, 2024–2029. SAMPLE Matrix: solutions Sample preparation: Inject an aliquot of a solution in mobile phase. HPLC VARIABLES Column: 250 × 4.6 5 µm Spherisorb NH2 (Before use flush column with isopropanol at 60◦ (to remove hexane-shipping solvent) and then with aqueous trifluoroacetic acid (pH 2.0) at 75◦ (to protonate amino groups).) Column temperature: 40 Mobile phase: MeCN:water 92.35:7.65 containing 2.5 mM ammonium acetate and 250 mM sodium perchlorate Flow rate: 0.5–1.2 Detector: UV 210 CHROMATOGRAM Retention time: 230 (0.5 mL/min), 130 (1.2 mL/min) OTHER SUBSTANCES Simultaneous: impurities REFERENCE Oyler, A.R.; Armstrong, B.L.; Cha, J.Y.; Zhou, M.X.; Yang, Q.; Robinson, R.I.; Dunphy, R.; Burinsky, D.J. Hydrophilic interaction chromatography on amino-silica phases complements reversed-phase highperformance liquid chromatography and capillary electrophoresis for peptide analysis, J.Chromatogr.A, 1996, 724, 378–383. Balofloxacin Molecular formula: C20 H24 FN3 O4 OCH3 H3C N H Molecular weight: 389.42 CAS Registry No: 127294-70-6 Merck Index: 13, 946 N N F COOH O SAMPLE Matrix: bile, blood, urine Sample preparation: Dilute urine and bile 100-fold with 100 mM pH 7.4 sodium phosphate buffer. Mix 100 µL plasma or diluted urine or bile with 100 µL IS solution, 100 µL 100 mM pH 7.4 sodium phosphate buffer, and 5 mL dichloromethane, shake for 10 min, centrifuge at 3000 rpm for 3 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen, reconstitute the residue with 100 µL mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 Capcell Pak C18 Mobile phase: MeCN:10 mM pH 2.5 potassium phosphate buffer containing 5 mM PIC B-5 22:78 Flow rate: 1 Injection volume: 20 Detector: F ex 295 em 500 CHROMATOGRAM Internal standard: l-cyclopropyl-6,8-difluoro-l,4-dihydro-7-(3-methylaminopiperidin-lyl)-4-oxoquinoline-3-carboxylic acid Limit of quantitation: 10 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS plasma; rat REFERENCE Nakagawa, T.; Ishigai, M.; Hiramatsu, Y.; Kinoshita, H.; Ishitani, Y.; Ohkubo, K.; Okazaki, A. Determination of the new fluoroquinolone balofloxacin and its metabolites in biological fluids by high performance liquid chromatography, Arzneimittelforschung, 1995, 45, 716–718. SAMPLE Matrix: tissue Sample preparation: Homogenize 100 mg mouse ears with 100 mM pH 7.2 phosphate buffered saline. HPLC VARIABLES Column: Capcell Pak C18 Mobile phase: MeCN:10 mM potassium dihydrogen phosphate 22:78 containing 5 mM 1-pentanesulfonic acid Detector: F ex 295 em 500 CHROMATOGRAM Retention time: 7 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 67 68 Balofloxacin KEY WORDS ear; mouse REFERENCE Marutani, K.; Matsumoto, M.; Otabe, Y.; Nagamuta, M.; Tanaka, K.; Miyoshi, A.; Hasegawa, T.; Nagano, H.; Matsubara, S.; Kamide, R.; Yokota, T.; Matsumoto, F.; Ueda, Y. Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light, Antimicrob.Agents Chemother., 1993, 37, 2217–2223. ANNOTATED BIBLIOGRAPHY Kozawa, O.; Uematsu, T.; Matsuno, H.; Niwa, M.; Nagashima, S.; Kanamaru, M. Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects, Antimicrob.Agents Chemother., 1996, 40, 2824–2828. Uematsu, T.; Ohsawa, Y.; Mizuno, A.; Nakashima, M. Analysis of a new fluoroquinolone derivative (Q35) in human scalp hair as an index of drug exposure and as a time marker in hair, Int.J.Legal Med., 1994, 106, 237–243. Bambermycins 69 Bambermycins CAS Registry No: 11015-37-5 Merck Index: 13, 954 SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4 Superspher-100 RP18 endcapped Mobile phase: MeCN:MeOH:buffer 25:35:40 (The buffer was 10 mg potassium dihydrogen phosphate in 1 L water, adjusted to pH 7.8 with dipotassium hydrogen phosphate.) Flow rate: 0.4 Detector: UV 258 CHROMATOGRAM Retention time: 24.6 (moenomycins A and C3) KEY WORDS According to the paper, moenomycins A and C3 can be separated using 100 × 2 5 µm Nucleosil C18 with a 10 min gradient from 0.09% trifluoroacetic acid in MeCN to 0.1% trifluoroacetic acid (sic) at 0.2 mL/min using electrospray MS triple quadrupole detection (8.2 and 8.5 min, respectively). REFERENCE Subramaniam-Niehaus, B.; Schneider, T.; Metzger, J.W.; Wohlleben, W. Isolation and analysis of moenomycin and its biosynthetic intermediates from Streptomyces ghanaensis (ATCC 14672) wildtype and selected mutants, Z.Naturforsch.C, 1997, 52, 217–226. 70 Befunolol Befunolol CH3 H3C Molecular formula: C16 H21 NO4 N H O OH Molecular weight: 291.34 CAS Registry No: 39552-01-7, 39543-79-8 (HCl), 66717-59-7 ((S)-(–) HCl), 66685-79-8 ((R)-(+) HCl) Merck Index: 13, 1023 O O CH3 SAMPLE Matrix: blood Sample preparation: Condition a Sep-Pak C18 SPE cartridge with 5 mL MeOH, 5 mL water, and 5 mL MeOH:water 30:70. Mix 1 mL plasma with 450 µL 3 µg/mL IS in MeOH, centrifuge at 1700 g for 10 min, add the supernatant to the SPE cartridge, wash with 5 mL MeOH:water 30:70, wash with 50 µL MeOH, suck dry under reduced pressure for 1 min, elute with 5 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 50◦ , reconstitute the residue with 200 µL mobile phase, inject a 150 µL aliquot. HPLC VARIABLES Column: 250 × 4 LiChrosorb RP-Select B Mobile phase: MeCN:20 mM potassium dihydrogen phosphate 20:80 Flow rate: 1 Injection volume: 150 Detector: UV 290 CHROMATOGRAM Retention time: 11 Internal standard: levobunolol (13) Limit of quantitation: 1 ng/mL OTHER SUBSTANCES Extracted: dihydrobefunolol (UV 245, LOQ 10 ng/mL) (10) KEY WORDS pharmacokinetics; plasma; rabbit REFERENCE Nozaki, Y.; Imai, T.; Goto, K.; Imamura, Y.; Underberg, W.J.M.; Otagiri, M. Simultaneous determination of befunolol and its major metabolite, dihydrobefunolol, in plasma by high performance liquid chromatography, Anal.Sci., 1989, 5, 395–397. 71 Benzalkonium chloride Benzalkonium chloride CH3 Molecular formula: C21 H38 ClN (C12), C23 H42 ClN (C14) CH3 Molecular weight: 339.99 (C12), 368.04 (C14) CAS Registry No: 8001-54-5 Merck Index: 13, 1058 N+ Cl− R n = C8H17 to C18H37 SAMPLE Matrix: blood Sample preparation: Mix 2 mL plasma with 4 mL water, add to a 3 mL Baker C18 SPE cartridge, wash with three 3 mL portions of water, wash with two 3 mL portions of MeOH, wash with two 3 mL portions of ethyl acetate, elute with 4 mL MeOH:ethyl acetate 50:50 containing 0.01% ammonium chloride, and evaporate the eluate to dryness under a stream of nitrogen. Reconstitute the residue with 1 mL ethyl acetate, 1 mL 10% sodium carbonate, and 200 µL 0.1% bromophenol blue. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 50 µL mobile phase, and inject an aliquot. (The ammonium chloride is eliminated in the aqueous layer and the benzalkonium forms an ion pair with the bromophenol blue and goes into the organic layer.) HPLC VARIABLES Column: Spherisorb CN Mobile phase: MeCN:buffer 90:10 (The buffer was a 161 mM pH 5.4 propionate buffer made by mixing 75 mL 10% sodium carbonate, 1.5 L water, and 12 mL propionic acid. Make up to 2 L with water.) Flow rate: 2 Detector: UV 214, UV 254 CHROMATOGRAM Retention time: 5.8 (C14), 6.2 (C12) Limit of detection: 5 ng/mL (UV 214) KEY WORDS dog; human; plasma; SPE REFERENCE Bleau, G.; Desaulniers, M. High-performance liquid chromatographic assay of benzalkonium in plasma, J.Chromatogr., 1989, 487, 221–227. 72 Betaine Betaine Molecular formula: C5 H11 NO2 O −O CH3 N+ CH3 CH3 Molecular weight: 117.15 CAS Registry No: 107-43-7 Merck Index: 13, 1182 SAMPLE Matrix: blood, urine Sample preparation: Dilute urine 10-fold with water. Mix 50 µL plasma or diluted urine with 50 µL 100 mM potassium dihydrogen phosphate, vortex, add 900 µL reagent, vortex, heat at 80◦ for 1 h, cool to room temperature, vortex, centrifuge at 1000 g, inject a 15 µL aliquot of the supernatant. (Prepare the reagent by dissolving 66 mg 18-crown-6 and 1.39 g 4-bromophenacyl bromide in 100 mL MeCN.) HPLC VARIABLES Column: 250 × 4.6 5 µm Supelcosil LC-SCX Mobile phase: MeCN:water 90:10 containing 22 mM choline Flow rate: 1.5 Injection volume: 15 Detector: UV 254 CHROMATOGRAM Retention time: 14.8 Limit of detection: 5 µM OTHER SUBSTANCES Extracted: N, N-dimethylglycine (12.7) KEY WORDS derivatization; plasma REFERENCE Laryea, M.D.; Steinhagen, F.; Pawliczek, S.; Wendel, U. Simple method for the routine determination of betaine and N, N-dimethylglycine in blood and urine, Clin.Chem., 1998, 44, 1937–1941. SAMPLE Matrix: blood, urine Sample preparation: Vortex 100 µL plasma or urine with 1 mL MeCN:MeOH 90:10, add 300–400 mg drying mixture, mix thoroughly with occasional inversion for 1 h, centrifuge at 1000 g for 2 min. Remove a 200 µL portion of the supernatant and mix with 20 µL of a 10% suspension of magnesium oxide in water, vortex, add 50 µL 100 mM 4-bromophenacyl triflate in MeCN, continue mixing for 5 min, centrifuge at 1000 g for 2 min (Lever,M. et al. Anal.Biochem. 1992, 205, 14–21), add 10 µL of a suspension of Dowex 1 in the dichloroacetate form (to eliminate excess derivatization reagent), inject a 20 µL aliquot. (Drying mixture was 90% anhydrous disodium hydrogen phosphate and 10% argentous oxide. Prepare 4′ -bromophenacyl trifluoromethanesulfonate as follows. Add 8.8 g p-bromobenzoyl chloride in 40 mL dry ether over 20–30 min to 100 mmol diazomethane stirred in an ice bath, stir in an ice bath for 8–9 h, let stand at room temperature for 3 h, evaporate the solvent under reduced pressure, recrystallize 4′ -bromo-2-diazoacetophenone from ether/hexane (mp 123.5–124◦ d) (J.Am.Chem.Soc. 1951, 73, 5301). Condense 50 mL anhydrous sulfur dioxide in a flask fitted with a calcium sulfate drying tube, cool in a dry ice/acetone bath, add 2.25 g 4′ -bromo-2diazoacetophenone, stir for 5 min, add 900 µL anhydrous trifluoromethanesulfonic acid Betaine 73 from a freshly opened bottle in one portion, stir for 15 min, remove the cooling bath, after 30 min use an ice/water bath to evaporate the solvent. Dissolve the residue in 100 mL boiling dichloromethane, treat twice with 5 g portions of decolorizing carbon, filter, evaporate the filtrate, recrystallize the residue from pentane:dichloromethane 80:20 to give 4′ -bromophenacyl trifluoromethanesulfonate as colorless plates (mp 137–8◦ ) (J.Chromatogr. 1984, 299, 365.) HPLC VARIABLES Column: 250 × 4 5 µm silica (Merck) Mobile phase: MeCN:dichloromethane:water 80:10:10 containing 9 mM triethylamine and 6 mM citric acid Flow rate: 1 Injection volume: 20 KEY WORDS normal phase; plasma REFERENCE Lever, M.; Sizeland, P.C.; Bason, L.M.; Hayman, C.M.; Chambers, S.T. Glycine betaine and proline betaine in human blood and urine, Biochim.Biophys.Acta, 1994, 1200, 259–264. 74 Bethanechol chloride Bethanechol chloride Molecular formula: C7 H17 ClN2 O2 CH3 H2N O O N+ CH3 Cl− CH3 CH3 Molecular weight:: 196.68 CAS Registry No: 590-63-6 Merck Index: 13, 1189 SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 5 µm Bakerbond phenylethyl Mobile phase: MeCN:water 33:67 Flow rate: 0.7 Detector: UV 200 CHROMATOGRAM Retention time: 3.0 OTHER SUBSTANCES Simultaneous: degradants KEY WORDS stability-indicating REFERENCE Allen, L.V. Jr.; Erickson,M.A. III. Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids, Am.J.Health Syst.Pharm., 1998, 55, 1804–1809. Bexarotene Bexarotene H3C CH3 H3C CH3 Molecular formula: C24 H28 O2 Molecular weight: 348.48 CAS Registry No: 153559-49-0 Merck Index: 13, 1196 75 CH2 CH3 COOH SAMPLE Matrix: bile, blood, microsomal incubation Sample preparation: Mix plasma with 5 vol of MeOH, cool to −20◦ , centrifuge at 4◦ , evaporate the supernatant to dryness under reduced pressure, reconstitute the residue with MeCN:10 mM ammonium acetate 40:60 containing 1% acetic acid, inject an aliquot. Mix 1 mL (?) microsomal incubation with 1.5 mL ice-cold EtOH, cool at <5◦ for 1 h, centrifuge, evaporate the supernatant to dryness under reduced pressure, reconstitute the residue with MeCN:10 mM ammonium acetate 40:60 containing 1% acetic acid, inject an aliquot. Dilute bile twofold with 10 mM ammonium acetate, centrifuge, inject an aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Microsorb MV C18 Column temperature: 40 Mobile phase: Gradient. A:B from 20:80 to 80:20 over 20 min, maintain at 80:20 for 15 min. A was MeCN:acetic acid 100:1. B was 10 mM ammonium acetate:acetic acid 100:1. Detector: UV 262 CHROMATOGRAM Retention time: 32 OTHER SUBSTANCES Extracted: metabolites KEY WORDS dog; plasma; rat REFERENCE Howell, S.R.; Shirley, M.A.; Grese, T.A.; Neel, D.A.; Wells, K.E.; Ulm, E.H. Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors, Drug Metab.Dispos., 2001, 29, 990–998. SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 20 µL 2.5 µg/mL IS, vortex for 10 s, add five 250 µL portions of MeCN and one 1 mL portion of 500 mM HCl with each addition followed by vortexing for a short period. Add 5 mL n-hexane:isoamyl alcohol 98:2, rotate at 45 rpm for 20 min, centrifuge at 3200 g for 10 min, freeze, remove the organic layer. Evaporate the organic layer to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 400 µL MeCN, vortex for 30 s, sonicate for 2 min, add 100 µL 10 mM ammonium acetate, centrifuge at 13 000 g for 5 min, inject a 50 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Inertsil ODS-2 Column temperature: 35 Mobile phase: MeCN:10 mM ammonium acetate:acetic acid 80:20:0.8 76 Bexarotene Injection volume: 50 Detector: F ex 260 em 430 CHROMATOGRAM Retention time: 8.5 Internal standard: LG100130 (4-[1-(5,6,7,8-tetrahydro-3-(1-methyl)ethyl-5,5,8,8-tetramethyl-2-naphthalenyl)ethenyl]benzoic acid, Ligand Pharmaceuticals, San Diego) (11) Limit of detection: 0.3 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS pharmacokinetics; plasma REFERENCE Van de Merbel, N.C.; van Veen, J.H.; Wilkens, G.; Loewen, G. Validated liquid chromatographic method for the determination of bexarotene in human plasma, J.Chromatogr.B, 2002, 775, 189–195. 77 Biapenem Biapenem OH H H H3C Molecular formula: C15 H18 N4 O4 S Molecular weight: 350.40 CAS Registry No: 120410-24-4 Merck Index: 13, 1200 N O CH3 S N N+ N COO− SAMPLE Matrix: blood, urine Sample preparation: Mix plasma or urine with an equal volume of 1 M pH 7.0 MOPS (3-(N-morpholino)propanesulfonic acid) buffer. Dilute plasma with 30% ammonium sulfate solution, centrifuge at 3000 rpm. HPLC VARIABLES Column: 150 × 4.6 TSK gel ODS 80TM (Tosoh) Mobile phase: MeCN:100 mM acetate buffer 1.5:98.5 (plasma) or MeCN:MeOH:sodium 1-octanesulfonate solution:acetic acid 110:12:480:3 (urine) Flow rate: 1.2 (plasma), 1.1 (urine) Detector: UV 300 (plasma), UV 310 (urine) CHROMATOGRAM Internal standard: 5-hydroxyindole-3-acetic acid (plasma), o-nitroacetanilide (urine) Limit of detection: 100 ng/mL (plasma), 1 µg/mL (urine) KEY WORDS plasma REFERENCE Kozawa, O.; Uematsu, T.; Matsuno, H.; Niwa, M.; Takiguchi, Y.; Matsumoto, S.; Minamoto, M.; Niida, Y.; Yokokawa, M.; Nagashima, S.; Kanamaru, M. Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects, Antimicrob.Agents Chemother., 1998, 42, 1433–1436. SAMPLE Matrix: solutions Sample preparation: Mix an aliquot of a solution in 50 mM pH 7.0 MOPS (3-(Nmorpholino)propanesulfonic acid) buffer with 2 aliquots of MeCN, vortex. Add a volume of chloroform equal to 50% of the total volume (Caution! Chloroform is a carcinogen!), mix well, centrifuge at 5000 g for 10 min, inject a 20 µL aliquot of the supernatant. HPLC VARIABLES Guard column: 100 × 4.6 Inertsil ODS-2 Column: 150 × 4.6 Inertsil ODS-2 Mobile phase: MeCN:50 mM pH 5.5 acetate buffer 2:100 Flow rate: 0.9 Injection volume: 20 Detector: UV 295 78 Biapenem CHROMATOGRAM Retention time: 6.3 REFERENCE Hikida, M.; Kawashima, K.; Nishiki, K.; Furukawa, Y.; Nishizawa, K.; Saito, I.; Kuwao, S. Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic, Antimicrob.Agents Chemother., 1992, 36, 481–483. 79 Bimatoprost Bimatoprost H H OH H N Molecular formula: C25 H37 NO4 Molecular weight: 415.57 CAS Registry No: 155206-00-1 CH3 O HO H H H OH SAMPLE Matrix: solutions HPLC VARIABLES Column: 150 × 4.6 5 µm Ultrasphere IP Mobile phase: Gradient. A:B 100:0 for 1 min, to 40:60 over 16 min (+ curved), maintain at 40:60 for 4 min, return to initial conditions over 1 min, re-equilibrate at initial conditions for 8 min. A was MeCN:20 mM pH 2.8 potassium phosphate buffer 20:80. B was MeCN:20 mM pH 2.8 potassium phosphate buffer 50:50. Flow rate: 1 Injection volume: 20–100 Detector: UV, Radioactivity (3 H) CHROMATOGRAM Retention time: 16 OTHER SUBSTANCES Simultaneous: metabolites REFERENCE Woodward, D.F.; Krauss, A.H.-P.; Chen, J.; Liang, Y.; Li, C.; Protzman, C.E.; Bogardus, A.; Chen, R.; Kedzie, K.M.; Krauss, H.A.; Gil, D.W.; Kharlamb, A.; Wheeler, L.A.; Babusis, D.; Welty, D.; TangLiu, D.D.-S.; Cherukury, M.; Andrews, S.W.; Burk, R.M.; Garst, M.E. Pharmacological characterization of a novel antiglaucoma agent, bimatoprost (AGN 192024), J.Pharmacol.Exp.Ther., 2003, 305, 772–785. 80 Bioresmethrin Bioresmethrin Molecular formula: C22 H26 O3 Molecular weight: 338.44 CAS Registry No: 28434-01-7 Merck Index: 13, 1230 H3C CH3 O H3C H H H3C O O SAMPLE Matrix: urine Sample preparation: Add 4 g solid NaCl, 3.5 mL MeCN, and 5 mL saturated NaCl solution to 5 mL MeCN, shake for 1 min. Remove the MeCN layer and extract the aqueous layer with 1 mL MeCN. Combine the MeCN layers and adjust to a known volume (0.5–1 mL), mix, filter (0.45 µm), inject a 40 µL aliquot. HPLC VARIABLES Column: 150 × 3 3 µm Luna C18(2) (Phenomenex) Column temperature: 30 Mobile phase: Gradient. MeCN:water 10:90 for 1 min, to 90:10 over 30 min, maintain at 90:10 for 4 min, to 100:0 over 1 min, maintain at 100:0 for 10 min, return to initial conditions over 1 min. Flow rate: 0.5 Injection volume: 40 Detector: UV 235 CHROMATOGRAM Retention time: 35.2 Limit of detection: 5 ng/mL OTHER SUBSTANCES Extracted: allethrin (31.8, LOD 5 ng/mL), bifenthrin (37, LOD 5 ng/mL), cyfluthrin (34.3, LOD 5 ng/mL), fenvalerate (35.3, LOD 2 ng/mL), cis-permethrin (35.7, LO 5 ng/mL), trans-permethrin (36.3, LOD 5 ng/mL), phenothrin (36.4, LOD 5 ng/mL), m-phenoxybenzyl alcohol (21, LOD 5 ng/mL), pyrethrin I (29.6, LOD 4 ng/mL), pyrethrin II (33.7, LOD 40 ng/mL), tetramethrin (31.4, LOD 5 ng/mL) REFERENCE Loper, B.L.; Anderson, K.A. Determination of pyrethrin and pyrethroid pesticides in urine and water matrices by liquid chromatography with diode array detection, J.AOAC Int., 2003, 86, 1236–1240. Bivalirudin 81 Bivalirudin Molecular formula: C98 H138 N24 O33 Molecular weight: 2180.28 CAS Registry No: 128270-60-0 Merck Index: 13, 1306 SAMPLE Matrix: blood, urine Sample preparation: Condition a 1 mL 30 mg Oasis HLB SPE cartridge with 1 mL MeCN:trifluoroacetic acid 98:2 and 1 mL water. Plasma. Mix 200 µL plasma with 100 µL of a solution of IS in water, make up to 1100 µL with water, add 1 mL to the SPE cartridge, wash with 500 µL water, wash with 500 µL MeOH:water 30:70, elute with 1 mL MeCN:trifluoroacetic acid 98:2, evaporate the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 100 µL MeOH:water 50:50, centrifuge at 10 000 rpm at 4◦ for 10 min, inject a 30 µL aliquot. Urine. Mix 50 µL urine with 400 µL of a solution of IS in water, make up to 500 µL with water, inject a 10 µL aliquot. HPLC VARIABLES Column: 30 × 4.6 5 µm Hypersil BDS C18 Mobile phase: Gradient. A:B from 30:70 to 100:0 over 0.5 min, maintain at 100:0 for 2 min, return to initial conditions over 0.2 min, re-equilibrate at initial conditions for 1.5 min. A was MeCN:0.1% formic acid 60:40. B was 0.1% formic acid. Injection volume: 10–30 Detector: MS, Perkin Elmer, positive ion mode, TurboIonSpray heater 400◦ , m/z 1090.9 to 227.1, dwell time 400 ms, ionspray voltage 5.2 kV, ring voltage 230 V, nebulizer gas nitrogen at 12 units, TurboIonSpray gas nitrogen at 7.0 L/min, collision gas nitrogen at 3 units, curtain gas nitrogen at 10 units, deflector −100 V, electron multiplier 2400–2700 V, collision energy −83 V CHROMATOGRAM Internal standard: Gln-9-hirulog (Polypeptide Laboratories, Torrance CA) (m/z 1097.9 to 199.1) KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Robson, R.; White, H.; Aylward, P.; Frampton, C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender, Clin.Pharmacol.Ther., 2002, 71, 433–439. 82 Boldenone Boldenone CH3 OH CH3 H Molecular formula: C19 H26 O2 Molecular weight:: 286.41 CAS Registry No: 846-48-0 Merck Index: 13, 1315 H H O SAMPLE Matrix: blood, urine Sample preparation: Adjust the pH of 3 mL serum to 9.6, add to an Extrelut 3 SPE column, extract with 15 mL diethyl ether, evaporate the ether to dryness, reconstitute the residue with 50 µL mobile phase containing 10 ng IS, inject an aliquot. Adjust the pH of 3 mL urine to 9.6 with sodium bicarbonate:sodium carbonate 2:1, add to an Extrelut 3 SPE column, extract with 15 mL diethyl ether, evaporate the ether to dryness, reconstitute the residue with 50 µL mobile phase containing 10 ng IS, inject the whole amount of aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Ultrasphere ODS Mobile phase: MeCN:water 37:63 (A) or THF:water 30:70 (B) Flow rate: 1 Detector: ELISA (collect 300 µL fractions) CHROMATOGRAM Retention time: 13 (A), 10 (B) Internal standard: methandienone (17 (A), 12 (B)) OTHER SUBSTANCES Extracted: testosterone (20 (A), 15 (B)) KEY WORDS horse; serum; SPE REFERENCE Hagedorn, H.-W.; Schulz, R.; Jaeschke, G. Identification and verification of the anabolic steroid boldenone in equine blood and urine by HPLC/ELISA, Biomed.Chromatogr., 1994, 8, 63–68. Bosentan Bosentan O O S Molecular formula: C27 H29 N5 O6 S H3C Molecular weight: 551.62 CAS Registry No: 147536-97-8, 150726-52-6 (Na salt) Merck Index: 13, 1341 H3C H N N OCH3 O N CH3 83 N N O OH SAMPLE Matrix: blood Sample preparation: Mix 500 µL plasma with 10 µL 5 µg/mL IS in EtOH, add 750 µL MeCN, vortex, store at 5◦ for 10 min. Add the supernatant at pH 11 to 7 mL dichloromethane, shake on a rotating shaker for 20 min, centrifuge for 5 min. Evaporate the organic layer to dryness under reduced pressure, reconstitute the residue with 1 mL MeCN, centrifuge for 5 min. Evaporate the supernatant to dryness under reduced pressure, reconstitute the residue with 100 µL MeCN:5 mM ammonium acetate:acetic acid 30:70:1, inject a 30–90 µL aliquot. HPLC VARIABLES Guard column: 10 × 2 4 µm Superspher RP-18 Column: 125 × 2 4 µm Superspher RP-18 Column temperature: 35 Mobile phase: MeCN:5 mM ammonium acetate:acetic acid 75:25:1 or 70:30:1 Injection volume: 30–90 Detector: UV 270; MS, Perkin-Elmer SCIEX API III plus triple quadrupole, ionspray, collision gas argon, collision energy 50 eV CHROMATOGRAM Retention time: 3.2 Internal standard: tetradeutero bosentan; Ro 47–8761 (4-cyclopropyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2′ -bipyrimidin]-4-yl]benzenesulfonamide) Limit of quantitation: 0.5 ng/mL (MS) KEY WORDS plasma REFERENCE Lausecker, B.; Hopfgartner, G. Determination of an endothelin receptor antagonist in human plasma by narrow-bore liquid chromatography and ionspray tandem mass spectrometry, J.Chromatogr.A, 1995, 712, 75–83. SAMPLE Matrix: blood, tissue Sample preparation: Homogenize (Polytron) liver with 2 vol of 100 mM phosphate buffer at 8000 rpm for 10–15 s. Mix 250 µL plasma or liver homogenate with 50 µL 2 µg/mL IS in MeCN:5 mM ammonium acetate:acetic acid 10:90:1, add 1 mL MeCN:EtOH 50:50, mix, centrifuge at 14 000 g for 10 min. Remove the supernatant and add it to 1 mL pH 4.0 buffer (Merck Tetrisol citrate/HCl), mix, add 6 mL n-chlorobutane:dichloromethane 80:20, rotate at 40 rpm for 20 min. Evaporate the organic layer to dryness under reduced pressure, reconstitute the residue with 1 mL MeCN:5 mM ammonium acetate:acetic acid 10:90:1, inject a 950 µL aliquot onto column A and elute to waste with mobile phase A. After 2 min, elute the contents of column A onto column B with mobile phase B. (After the elution of the analytes, flush column B with MeCN:acetic acid 99:1 at 0.35 mL/min for 1 min and then re-equilibrate with initial mobile phase B at 0.35 mL/min for 30 s. Wash column A in backflush and forward flush 84 Bosentan mode with MeCN:MeOH:5 mM ammonium acetate:acetic acid 45:45:10:1 at 1 mL/min for 3.5 min, then re-equilibrate with mobile phase A at 1 mL/min for 2.5 min.) HPLC VARIABLES Column: A 25 × 4 5 µm Superspher RP-Select B; B 10 × 2 Superspher RP−18 + 150 × 2.1 Symmetry RP-18 Mobile phase: A 5 mM ammonium acetate containing 1% acetic acid; B Gradient. C:D from 50:50 to 10:90 over 4.5 min. C was MeCN:MeOH:5 mM ammonium acetate:acetic acid 25:25:50:1. D was MeCN:MeOH:5 mM ammonium acetate:acetic acid 45:45:10:1. Flow rate: A 1; B 0.25 Injection volume: 950 Detector: MS, Perkin-Elmer SCIEX API 300 triple quadrupole, ionspray, collision gas argon, collision energy 50 eV, m/z 552 to 202 CHROMATOGRAM Retention time: 6.8 Internal standard: tetradeutero bosentan Limit of quantitation: 1 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS column-switching; dog; human; liver; plasma; rat REFERENCE Lausecker, B.; Hess, B.; Fischer, G.; Mueller, M.; Hopfgartner, G. Simultaneous determination of bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chromatography with ion spray tandem mass spectrometric detection, J.Chromatogr.B, 2000, 749, 67–83. SAMPLE Matrix: blood Sample preparation: Mix 250 µL plasma with 50 µL 2 µg/mL IS in MeCN:5 mM ammonium acetate:acetic acid 10:90:1, add 750 µL MeOH. Mix the supernatant with 2 mL 50 mM pH 10 ammonium acetate buffer, add to a 30 mg Oasis SPE cartridge, wash with 1 mL water, wash with 2 mL 20 mM phosphoric acid, wash with 2.1 mL MeOH:water 20:80, wash with 1 mL water, elute with MeCN:MeOH:triethylamine 30:70:2. Evaporate the eluate to dryness, reconstitute the residue with 150 µL MeCN:5 mM ammonium acetate:acetic acid 10:90:1, inject an aliquot. HPLC VARIABLES Column: 125 × 2 Superspher Mobile phase: MeCN:MeOH:5 mM ammonium acetate:acetic acid 37.5:37.5:25:1 Flow rate: 0.25 Detector: MS, Perkin-Elmer SCIEX API 300 triple quadrupole, ionspray, collision gas argon, collision energy 50 eV, m/z 552 to 202 CHROMATOGRAM Retention time: 3 Internal standard: tetradeutero bosentan Limit of quantitation: 1 ng/mL OTHER SUBSTANCES Extracted: metabolites Bosentan 85 KEY WORDS human; plasma; rat; SPE REFERENCE Lausecker, B.; Hess, B.; Fischer, G.; Mueller, M.; Hopfgartner, G. Simultaneous determination of bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chromatography with ion spray tandem mass spectrometric detection, J.Chromatogr.B, 2000, 749, 67–83. ANNOTATED BIBLIOGRAPHY Dell, D.; Lausecker, B.; Hopfgartner, G.; van Giersbergen, P.L.M.; Dingemanse, J. Evolving bioanalytical methods for the cardiovascular drug bosentan, Chromatographia, 2002, 55, S115–S119. [review] Ubeaud, G.; Schmitt, C.; Jaeck, D.; Lave, T.; Coassolo, P. Bosentan, a new endothelin receptor antagonist: prediction of the systemic plasma clearance in man from combined in vivo and in vitro data, Xenobiotica, 1995, 25, 1381–1390. [gradient; microsomal incubations; rat; mouse; dog; rabbit; metabolites] Weber, C.; Schmitt, R.; Birnboeck, H.; Hopfgartner, G.; van Marle, S.P.; Peeters, P.A.M.; Jonkman, J.H.G.; Jones, C.-R. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects, Clin.Pharmacol.Ther., 1996, 60, 124–137. [LC-MS; UV detection; urine; plasma; LOQ 50 ng/mL] 86 β-Boswellic acid β-Boswellic acid CH3 H3C CH3 Molecular formula: C30 H48 O3 Molecular weight: 456.70 CAS Registry No: 631-69-6 Merck Index: 13, 1343 CH3 H CH3 H CH3 HO H HOOC CH3 SAMPLE Matrix: blood Sample preparation: Add 1 mL plasma to an Extrelut NT SPE cartridge, let stand for 15 min, elute with THF:hexane:ethyl acetate:isopropanol 32:32:32:3. Evaporate the eluate to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 80 µL DMSO, add this solution to a 4 mL 150 mg Carbograph SPE cartridge (Alltech, preconditioned with 6 mL MeOH). Rinse the vial twice with 1 mL portions of MeOH:isopropanol 95:5 and add the rinses to the Carbograph SPE cartridge, wash with 3 mL MeOH:isopropanol 95:5, apply a vacuum for 5 s, elute with 2.5 mL cyclohexane:acetone 50:50. Evaporate the eluate to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 80 µL DMSO, inject an aliquot. HPLC VARIABLES Column: 250 × 3 5 µm ReproSil-Pur 120 ODS-3 (Dr Maisch, Ammerbuch, Germany) Column temperature: 28 Mobile phase: Gradient. A:B from 62:38 to 51:49 over 20 min, to 39:61 over 15 min, to 32:68 over 5 min, to 31:69 over 5 min, to 0:100 over 5 min, maintain at 0:100 for 10 min, re-equilibrate at initial conditions for 6 min. A was MeOH:water:acetic acid 80:20:0.2. B was MeOH:acetic acid 100:0.2. Flow rate: 0.56 for 50 min, 0.9 for 10 min, 0.56 for 6 min Detector: UV 210 CHROMATOGRAM Retention time: 32 OTHER SUBSTANCES Extracted: similar triterpenic acids KEY WORDS plasma; SPE REFERENCE Büchele, B.; Simmet, T. Analysis of 12 different pentacyclic triterpenic acids from frankincense in human plasma by high-performance liquid chromatography and photodiode array detection, J.Chromatogr.B, 2003, 795, 355–362. SAMPLE Matrix: plant resin Sample preparation: Sonicate 100–500 mg resin in 3 mL MeOH for 10 min, centrifuge, repeat extraction twice more. Combine the supernatants and make up to 10 mL with MeOH, filter (0.45 µm), inject a 10 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 4 µm Synergi MAX-RP 80 A (Phenomenex) Column temperature: 60 β-Boswellic acid 87 Mobile phase: Gradient. A:B 65:35 for 7 min, to 90:10 over 21 min, maintain at 90:10 for 5 min, to 100:0 (step gradient), maintain at 100:0 for 5 min, re-equilibrate at initial conditions for 10 min. A was MeCN containing 0.05% phosphoric acid. B was water containing 0.05% phosphoric acid. Flow rate: 1 Injection volume: 10 Detector: UV 210 CHROMATOGRAM Retention time: 25 Limit of detection: 270 ng/mL OTHER SUBSTANCES Simultaneous: similar triterpenic acids REFERENCE Ganzera, M.; Khan, I.A. A reversed phase high-performance liquid chromatography method for the analysis of boswellic acids in Boswellia serrata, Planta Med., 2001, 67, 778–780. 88 Brimonidine Brimonidine Molecular formula: C11 H10 BrN5 Molecular weight: 292.14 CAS Registry No: 59803-98-4 Merck Index: 13, 1361 H H N N N Br N N SAMPLE Matrix: aqueous humor, blood Sample preparation: Mix 100–300 µL serum or aqueous humor with 2 vol buffer, centrifuge at 11 000 g for 10 min,, add the supernatant to a Sep-Pak C18 SPE cartridge, wash with 5 mL buffer, elute with 5 mL MeCN:buffer 50:50. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with 100 µL mobile phase, inject a 10–20 µL aliquot. (The buffer was 10 mM triethylamine adjusted to pH 3.2 with phosphoric acid.) HPLC VARIABLES Guard column: 20 × 4.6 RP-18 (Supelco) Column: 250 × 4.6 5 µm Supelcosil LC-18 Mobile phase: MeCN:buffer 10:90 (The buffer was 10 mM triethylamine adjusted to pH 3.2 with phosphoric acid.) Flow rate: 1 Injection volume: 10–20 Detector: UV 248 CHROMATOGRAM Retention time: 7 Limit of detection: 30 pg/mL OTHER SUBSTANCES Noninterfering: benzalkonium chloride, cyclopentolate, phenylephrine, tropicamide KEY WORDS serum; SPE REFERENCE Karamanos, N.K.; Lamari, F.; Katsimpris, J.; Gartaganis, S. Development of an HPLC method for determining the alpha2-adrenergic receptor agonist brimonidine in blood serum and aqueous humor of the eye, Biomed.Chromatogr., 1999, 13, 86–88. SAMPLE Matrix: tissue Sample preparation: Vortex <3–25 mg ocular tissue with 200 µL MeOH for 3 min, centrifuge at 3000 g for 10 min. Mix a 35 µL aliquot of the supernatant with 65 µL 0.01% trifluoroacetic acid in water, inject the whole amount. HPLC VARIABLES Column: 300 × 3.9 15 µm Delta PAK C18 (Waters) Mobile phase: MeOH:water:trifluoroacetic acid 35:65:0.01 Flow rate: 1 Injection volume: 100 Detector: UV 360 Brimonidine 89 CHROMATOGRAM Retention time: 3.5 Limit of detection: 20 ng/mL OTHER SUBSTANCES Extracted: mitomycin C (6, LOD 10 ng/mL), timolol (10, LOD 50 ng/mL) KEY WORDS eye REFERENCE Xiong, X.; Lim, B.A.; Lat-Luna, M.; Chew, P.; Tan, D. Quantitation of mitomycin C in human ocular tissues by high-performance liquid chromatography-photo-diode array detection, J.Chromatogr.B, 2001, 755, 65–72. ANNOTATED BIBLIOGRAPHY Acheampong, A.A.; Shackleton, M.; Tang-Liu, D.D.-S. Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits, Drug Metab.Dispos., 1995, 23, 708–712. [UV detection; radioactivity detection] Acheampong, A.A.; Chien, D.-S.; Lam, S.; Vekich, S.; Breau, A.; Usansky, J.; Harcourt, D.; Munk, S.A.; Nguyen, H.; Garst, M.; Tang-Liu, D. Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit liver aldehyde oxidase, Xenobiotica, 1996, 26, 1035–1055. Acheampong, A.A.; Shackleton, M.; John, B.; Burke, J.; Wheeler, L.; Tang-Liu, D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes, Drug Metab.Dispos., 2002, 30, 421–429. 90 Bromfenac Bromfenac Molecular formula: C15 H12 BrNO3 Molecular weight: 334.17 CAS Registry No: 91714-94-2 Merck Index: 13, 1374 O NH2 COOH Br SAMPLE Matrix: blood, urine Sample preparation: Mix 1 mL plasma with 1 mL MeCN, filter (0.2 µm) by centrifuging at 800 g for 15 min, inject a 500 µL aliquot of the filtrate. Mix 1 mL urine with 1 mL 100 mM pH 5 ammonium acetate buffer and 100 µL Glusulase (40 000 units), heat at 37◦ for 16 h, centrifuge at 800 g for 15 min, inject a 500 µL aliquot of the supernatant. HPLC VARIABLES Column: 150 × 4.6 5 µm HiChrom (Regis) (for electrospray negative ion MS (FinniganMAT TSQ 700) detection use 250 × 2 C18 DB (Supelco) column with the gradient below at 0.2 mL/min) Mobile phase: Gradient. MeCN:100 mM pH 4.9 ammonium acetate buffer from 10:90 to 45:55 over 50 min, maintain at 45:55 for 10 min, re-equilibrate at initial conditions for 15 min. Flow rate: 1 Injection volume: 500 Detector: UV 270 CHROMATOGRAM Retention time: 42 OTHER SUBSTANCES Extracted: metabolites KEY WORDS plasma REFERENCE Osman, M.; Chandrasekaran, A.; Chan, K.; Scatina, J.; Ermer, J.; Cevallos, W.; Sisenwine, S.F. Metabolic disposition of 14 C-bromfenac in healthy male volunteers, J.Clin.Pharmacol., 1998, 38, 744–752. SAMPLE Matrix: blood Sample preparation: Mix 500 µL plasma with 200 µL 1 µg/mL IS in water, add 7 mL hexane, add 500 µL 5% ammonium hydroxide, shake rapidly on a reciprocating shaker for 10 min, centrifuge at 550 g for 5 min, discard the organic layer. Add 1 mL 2 M HCl to the aqueous layer, mix briefly, let stand for 20 min. Add 7 mL hexane, shake rapidly for 10 min, centrifuge at 550 g for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 200 µL mobile phase, inject a 100 µL aliquot. HPLC VARIABLES Column: 300 × 3.9 10 µm µBondapak C18 Mobile phase: MeCN:THF:50 mM pH 6.5 sodium acetate buffer 39:6:55 Flow rate: 1.5 Injection volume: 100 Detector: UV 270 Bromfenac 91 CHROMATOGRAM Retention time: 9.5 Internal standard: 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid (chloro analogue) (8.5) Limit of quantitation: 30 ng/mL KEY WORDS pharmacokinetics; plasma; rat REFERENCE Osman, M.A.; Dunning, L.K.; Cheng, L.K.; Wright, G.J. Determination of bromfenac in plasma by highperformance liquid chromatography, J.Chromatogr., 1989, 489, 452–458. 92 Brovincamine Brovincamine Molecular formula: C21 H25 BrN2 O3 Molecular weight: 433.35 CAS Registry No: 57475-17-9 Merck Index: 13, 1436 H Br HO CH3O O N N CH3 SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 40 µL 10 µg/mL IS in MeCN, add 500 µL ammonia (0.88):water 1:10, mix, add 5 mL diethyl ether, rotate for 10 min, centrifuge at 2000 g for 10 min. Evaporate the organic layer to dryness under a stream of nitrogen at 37◦ , rinse the walls of the tube with ether, again evaporate to dryness, reconstitute the residue with 50 µL mobile phase, centrifuge at 2000 g for 10 min, inject an aliquot. HPLC VARIABLES Guard column: 70 × 2 25–37 µm Co:Pell ODS (Whatman) Column: 300 × 4 10 µm µBondapak C18 Mobile phase: MeCN:buffer 35:65 (The buffer was 0.1% sodium dihydrogen phosphate adjusted to pH 3.5 with phosphoric acid.) Flow rate: 2 Detector: UV 232 CHROMATOGRAM Retention time: 6.8 Internal standard: vincamine (3.6) Limit of detection: 10 ng/mL KEY WORDS plasma REFERENCE Brodie, R.R.; Chasseaud, L.F. Determination of 11-bromovincamine in human plasma by highperformance liquid chromatography, J.Chromatogr., 1982, 228, 413–417. Bucillamine Bucillamine Molecular formula: C7 H13 NO3 S2 O H3C H3C COOH N SH 93 SH H Molecular weight: 223.32 CAS Registry No: 65002-17-7 Merck Index: 13, 1445 SAMPLE Matrix: blood Sample preparation: Mix 50 µL blood with 50 µL buffer, immediately add 300 µL 0.167 mM N-(1-pyrenyl)maleimide in MeCN, vortex, let stand at room temperature for 15 min, add 5 µL 167 mM HCl, centrifuge at 12 000 rpm for 2 min, inject an aliquot of the supernatant. (The buffer was 10 mM pH 8.0 Tris-HCl containing 1 mM EDTA.) HPLC VARIABLES Column: 150 × 4.6 5 µm C18 (Kanto, Japan) Mobile phase: MeCN:EtOH:water:orthophosphoric acid:acetic acid 210:250:290:0.5:0.5 Flow rate: 0.5 Injection volume: 20 Detector: F ex 330 em 380 CHROMATOGRAM Retention time: 10 Limit of detection: 2.5 nM (S/N 3) Limit of quantitation: 3 nM KEY WORDS derivatization; whole blood REFERENCE Higashi, Y.; Yamashiro, M.; Yamamoto, R.; Fujii, Y. HPLC analysis of bucillamine by derivatization with N-(1-pyrenyl)maleimide in human blood, J.Liq.Chromatogr.Rel.Technol., 2003, 26, 3265–3275. 94 Budipine Budipine Molecular formula: C21 H27 N N CH3 CH3 CH3 Molecular weight: 293.44 CAS Registry No: 57982-78-2 Merck Index: 13, 1455 SAMPLE Matrix: urine Sample preparation: Adjust pH of urine to 5.0 with acetic acid, add 1300 U/mL glusulase and 50 U/mL sulfatase, heat at 37◦ for 24 h, adjust pH to 9, pass through a column of Amberlite XAD-2 resin, wash with 3 vol of water, elute with MeOH. Evaporate the eluate to dryness, reconstitute the residue with water, adjust to pH 8, extract with ethyl acetate. Wash the ethyl acetate extract with one-tenth the volume of saturated NaCl, dry over anhydrous sodium sulfate, reconstitute with MeOH, inject an aliquot. Alternatively, adjust pH of urine to 5.0 with acetic acid, add glusulase/sulfatase, heat at 37◦ , adjust pH to 9, extract with dichloromethane:isopropanol 90:10. Evaporate the extract to dryness under reduced pressure, reconstitute, inject an aliquot. (Both the procedures are given.) HPLC VARIABLES Column: 10 µm Viosfer C8 Mobile phase: MeCN:water:isopropylamine 79.96:20:0.04 Detector: UV 220 OTHER SUBSTANCES Extracted: metabolites KEY WORDS rat; SPE REFERENCE Caputo, O.; Grosa, G.; Ceruti, M.; Rocco, F.; Biglino, G. The metabolic fate of the anti-parkinsonian drug budipine in rats, Eur.J.Drug Metab.Pharmacokinet., 1991, 16, 113–118. 95 Bulaquine Bulaquine Molecular formula: C21 H27 N3 O3 Molecular weight: 369.46 CAS Registry No: 223661-25-4 O O H H N CH3 H N CH3 N H3CO SAMPLE Matrix: formulations Sample preparation: Extract capsule fill containing 5 mg bulaquine three times with 3 mL MeOH:dimethyloctylamine 99:1. Combine the extracts and make up to 10 mL with the same solvent, filter, dilute 500 µL of the filtrate to 25 mL with MeOH, inject an aliquot. HPLC VARIABLES Column: 250 × 4 5 µm Lichrospher RP select-B C8 Mobile phase: MeCN:10 mM pH 5.6 sodium acetate buffer 55:45 Flow rate: 1 Injection volume: 20 Detector: UV 265 CHROMATOGRAM Retention time: 17.26 Limit of detection: 400 ng/mL Limit of quantitation: 2 µg/mL OTHER SUBSTANCES Simultaneous: chloroquine (4.22), primaquine (5.72) KEY WORDS capsules; comparison with HPTLC REFERENCE Dwivedi, A.K.; Saxena, D.; Singh, S. HPLC and HPTLC assays for the antimalarial agents chloroquine, primaquine and bulaquine, J.Pharm.Biomed.Anal., 2003, 33, 851–858. SAMPLE Matrix: blood Sample preparation: Mix 500 µL plasma with 50 µL 1 M KOH, add 25 µL 20 µg/mL IS in MeCN, add 3 mL extraction solvent, vortex for 1 min, centrifuge at 1000 g for 10 min, freeze the aqueous layer, remove the organic layer, repeat the extraction. Evaporate the combined organic layers to dryness under reduced pressure, reconstitute the residue with 200 µL MeCN:50 mM pH 7.0 ammonium acetate buffer 50:50, centrifuge, inject an aliquot of the supernatant. (Extraction solvent was nhexane:isopropanol:dimethyloctylamine 98:2:0.1.) HPLC VARIABLES Guard column: 30 × 4.6 5 µm Spheri-5 cyano Column: 220 × 4.6 5 µm Spheri-5 cyano Mobile phase: Gradient. A:B from 55:45 to 90:10 over 15 min, maintain at 90:10 for 2 min, return to initial conditions over 2 min. A was MeCN:50 mM pH 6.0 ammonium acetate buffer 65:35. B was 50 mM pH 6.0 ammonium acetate buffer. 96 Bulaquine Flow rate: 1 Injection volume: 50 Detector: UV 261 CHROMATOGRAM Retention time: 8 Internal standard: 3-bromoprimaquine diphosphate (13.5) Limit of detection: 10 ng/mL Limit of quantitation: 20 ng/mL OTHER SUBSTANCES Extracted: primaquine (11) KEY WORDS pharmacokinetics; plasma; rabbit REFERENCE Lal, J.; Mehrotra, N.; Gupta, R.C. Analysis and pharmacokinetics of bulaquine and its major metabolite primaquine in rabbits using an LC-UV method – a pilot study, J.Pharm.Biomed.Anal., 2003, 32, 141–150. ANNOTATED BIBLIOGRAPHY Nitin, M.; Rajanikanth, M.; Lal, J.; Madhusudanan, K.P.; Gupta, R.C. Liquid chromatography-tandem mass spectrometric assay with a novel method of quantitation for the simultaneous determination of bulaquine and its metabolite, primaquine, in monkey plasma, J.Chromatogr.B, 2003, 793, 253–263. Butacaine Butacaine Molecular formula: C18 H30 N2 O2 Molecular weight: 306.44 CAS Registry No: 149-16-6 Merck Index: 13, 1495 97 O O H2N N CH3 CH3 SAMPLE Matrix: blood Sample preparation: Buffer plasma with 100 mM pH 7.0 phosphate buffer, inject a 300 µL aliquot onto column A and elute to waste with mobile phase A; after 11 min, backflush the contents of column A onto column B with mobile phase B. (Re-equilibrate column A with mobile phase A at 1.8 mL/min for 3.3 min.) HPLC VARIABLES Column: A 25 × 4 LiChrospher RP-18 ADS; B 4 × 4 5 µm LiChrospher 100 RP−18 + 125 × 3 5 µm LiChrospher 100 RP-18 Column temperature: 35 Mobile phase: A 100 mM pH 7.0 phosphate buffer; B MeCN:50 mM pH 7.0 phosphate buffer 50:50 Flow rate: 0.6 Injection volume: 300 Detector: UV 210 KEY WORDS column-switching; plasma REFERENCE Baeyens, W.R.G.; Van Der Weken, G.; Haustraete, J.; Smet, E. Application of the ADS precolumnswitching technique to the separation of some drugs from plasma, Biomed.Chromatogr., 2000, 14, 61–63. SAMPLE Matrix: blood, urine Sample preparation: 2 mL Whole blood, plasma, or urine + 1 mL saturated sodium carbonate + 20 µL 100 µg/mL tetracaine, add to a 3 mL Extrelut SPE cartridge, elute with 15 mL dichloromethane. Evaporate eluate to dryness under a stream of nitrogen at 40◦ , reconstitute in 100 µL mobile phase, inject a 40 µL aliquot. HPLC VARIABLES Guard column: 5 × 6 µBondapak Guard Pak Column: 300 × 3.9 10 µm µBondapak C18 Mobile phase: MeCN:100 mM ammonium acetate 50:50 Flow rate: 1.5 Injection volume: 40 Detector: UV 280; F ex 280 em 350 CHROMATOGRAM Retention time: 10 Internal standard: tetracaine (14) Limit of detection: 20 ng/mL OTHER SUBSTANCES Extracted: p-aminobenzoic acid (4), procaine (5) 98 Butacaine Also analyzed: articaine, prilocaine, o-toluidine, lidocaine, bupivacaine, etidocaine, dibucaine, caffeine, amphetamine, ephedrine, epinephrine, morphine, monoacetylmorphine, diamorphine, ethylmorphine, codeine, acetylcodeine KEY WORDS plasma; SPE; whole blood REFERENCE Rop, P.P.; Grimaldi, F.; Bresson, M.; Fornaris, M.; Viala, A. Liquid chromatographic analysis of cocaine, benzoylecgonine, local anaesthetic agents and some of their metabolites in biological fluids, J.Liq.Chromatogr., 1993, 16, 2797–2811. Butamben Butamben Molecular formula: C11 H15 NO2 Molecular weight: 193.24 CAS Registry No: 94-25-7 Merck Index: 13, 1502 99 O O CH3 H2N SAMPLE Matrix: blood Sample preparation: Mix 500 µL plasma with 600 µL 100 mM KOH, add 1 mL 8.0 M urea, vortex gently, add 4 mL ethyl acetate, vortex for 1 min, centrifuge at 3000 g for 10 min. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 200 µL MeOH, inject a 20 µL aliquot. (Perform the analyses under yellow light.) HPLC VARIABLES Guard column: Corasil Column: 250 × 4.6 5 µm Spherisorb ODS 2 Mobile phase: MeOH:10 mM pH 6.1 ammonium acetate buffer 62:38 Flow rate: 1 Injection volume: 20 Detector: UV 247 CHROMATOGRAM Retention time: 8.45 OTHER SUBSTANCES Extracted: nifedipine (7.14) KEY WORDS butamben is IS; plasma REFERENCE Thongnopnua, P.; Viwatwongsa, K. Quantitative analysis of nifedipine in plasma by high-performance liquid chromatography, J.Pharm.Biomed.Anal., 1994, 12, 119–125. 100 Butoconazole Butoconazole N Molecular formula: C19 H17 Cl3 N2 S Molecular weight: 411.78 CAS Registry No: 64872-76-0; 64872-77-1 (nitrate) Merck Index: 13, 1525 N Cl S Cl Cl SAMPLE Matrix: solutions Sample preparation: Extract swab with MeOH or MeOH:THF 95:5, add IS, filter, inject an aliquot. HPLC VARIABLES Column: 250 × 4.6 Partisil 10 SCX (Whatman) Mobile phase: MeOH:135 mM pH 4.35 potassium acetate buffer 61:39 Flow rate: 1 Detector: UV 230 CHROMATOGRAM Internal standard: 1-benzylimidazole REFERENCE Weinstein, L.; Henzel, M.R.; Tsina, I.W. Vaginal retention of 2% butoconazole nitrate cream: comparison of a standard and a sustained-release preparation, Clin.Ther., 1994, 16, 930–934. Butyl flufenamate Butyl flufenamate CH3 O O 101 H N CF3 Molecular formula: C18 H18 F3 NO2 Molecular weight: 337.34 CAS Registry No: 67330-25-0 Merck Index: 13, 4158 SAMPLE Matrix: formulations Sample preparation: Add 100–300 mg gel ointment to 3 mL MeOH, mix vigorously, filter (0.2 µm), inject a 10 µL aliquot. HPLC VARIABLES Column: 300 × 3.9 10 µm µBondapak C18 Mobile phase: MeOH Flow rate: 1 Injection volume: 10 Detector: UV 280 CHROMATOGRAM Retention time: 4.3 KEY WORDS ointment REFERENCE Yamamura, K.; Yamada, J.-I.; Yotsuyanagi, T. High-performance liquid chromatographic assay of antiinflammatory drugs incorporated in gel ointments. Separation and stability testing, J.Chromatogr., 1985, 331, 383–388. Cambendazole Molecular formula: C14 H14 N4 O2 S Molecular weight: 302.36 H CH3 H3C O N O N N S N H CAS Registry No: 26097-80-3 Merck Index: 13, 1733 SAMPLE Matrix: abomasal fluid, blood, duodenal fluid, rumen fluid Sample preparation: Shake 4 mL plasma, rumen fluid, abomasal fluid, or duodenal fluid with 4 mL pH 7.4 phosphate buffer and 20 mL ether on a rotary mixer for 10 min, remove 16 mL of the ether layer, add 20 mL ether, shake on a rotary mixer for 10 min, remove 20 mL of the ether layer. Combine the ether layers and evaporate them under a stream of nitrogen at 60◦ to dryness, reconstitute in 50 µL MeOH, sonicate, inject a 5 µL aliquot. HPLC VARIABLES Column: 100 × 8 ODS Hypersil Mobile phase: MeOH:50 mM ammonium carbonate 65:35 Flow rate: 1.5 Injection volume: 5 Detector: UV 292 CHROMATOGRAM Retention time: 4.3 Limit of detection: 20 ng/mL OTHER SUBSTANCES Extracted: albendazole (7.5), fenbendazole (10), mebendazole (5), oxfendazole (3), oxibendazole (5.2), parbendazole (11), thiabendazole (3.7) KEY WORDS plasma; sheep REFERENCE Bogan, J.A.; Marriner, S. Analysis of benzimidazoles in body fluids by high-performance liquid chromatography, J.Pharm.Sci., 1980, 69, 422–423. SAMPLE Matrix: egg, tissue Sample preparation: Condition an SDB (styrol-divinyl-benzene) SPE cartridge (Baker) with 3 mL MeOH and 3 mL water. Vortex 3 g muscle or liver with ? µL 10 µg/mL IS in MeOH, 1.5 g sodium sulfate, 500 µL 4 M potassium carbonate, and 5 mL ethyl acetate. Centrifuge at 2500 g for 5 min and remove the organic layer. Repeat the extraction. Combine the organic layers and evaporate them to dryness under a stream of nitrogen at 50◦ or under reduced pressure. Add 5 mL n-hexane to the residue, shake to get a good mixture, add 1 mL EtOH/HCl, vortex, centrifuge at 1000 g for 2 min, discard the upper layer. Evaporate the lower layer to dryness under reduced pressure, reconstitute the residue with 500 µL 10 mM pH 5.5 ammonium acetate and 500 µL MeOH, add to the SPE cartridge, wash with 3 mL water, wash with two 3 mL portions of MeOH:water 50:50, dry under vacuum, elute with 3 mL MeOH:ethyl acetate 20:80. Evaporate the eluate to dryness under reduced pressure, reconstitute the residue with 250 µL mobile phase, inject a 4 (ion spray) or 15 (turbo ion spray) µL aliquot. Preparation of egg samples is similar except that the mixture is vortexed for 10 s and sonicated for 15 min 102 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 Cambendazole 103 after the addition of the ethyl acetate. (EtOH/HCl was made by mixing 66 mL EtOH with 33 mL 200 mM HCl.) HPLC VARIABLES Column: 150 × 2.1 5 µm Zorbax RX Mobile phase: MeCN:10 mM ammonium acetate containing 0.5% acetic acid 60:40 Flow rate: 0.04 (ion spray), 0.2 (turbo ion spray) Injection volume: 4–15 Detector: MS, Perkin-Elmer SCIEX API 365 tandem, ion spray or turbo ion spray, m/z 303–261 CHROMATOGRAM Retention time: 1.9 Internal standard: 2-n-butylmercaptobenzimidazole (2.7) (m/z 207–151) Limit of detection: 4 ng/g Limit of quantitation: 6 ng/g OTHER SUBSTANCES Extracted: albendazole (2.5, m/z 266–233, LOD 19 ng/g, LOQ 305 ng/g), febantel (4, m/z 447–382, LOD 10 ng/g, LOQ 15 ng/g), fenbendazole (2.9, m/z 300–268, LOD 5 ng/g, LOQ 7 ng/g), flubendazole (2.1, m/z 314–281, LOD 3 ng/g, LOQ 5 ng/g), mebendazole (2, m/z 296–264, LOD 3 ng/g, LOQ 5 ng/g), oxfendazole (1.7, m/z 316–159, LOD 5 ng/g, LOQ 8 ng/g), oxibendazole (2.2, m/z 250–176, LOD 4 ng/g, LOQ 6 ng/g), thiabendazole (2, m/z 202–175, LOD 3 ng/g, LOQ 5 ng/g), triclabendazole (5.5, m/z 359–343, LOD 6 ng/g, LOQ 9 ng/g) KEY WORDS cow; egg; liver; muscle; pig; sheep; SPE REFERENCE Balizs, G. Determination of benzimidazole residues using liquid chromatography and tandem mass spectrometry, J.Chromatogr.B, 1999, 727, 167–177. ANNOTATED BIBLIOGRAPHY Danaher, M.; O’Keeffe, M.; Glennon, J.D. Development and optimisation of a method for the extraction of benzimidazoles from animal liver using supercritical carbon dioxide, Anal.Chim.Acta, 2003, 483, 313–324. [albendazole; fenbendazole; mebendazole; thiabendazole; oxibendazole; flubendazole; oxfendazole; netobimin; triclabendazole; cambendazole] 104 Candesartan cilexetil Candesartan cilexetil N N Molecular formula: C33 H34 N6 O6 Molecular weight: 610.66 CAS Registry No: 145040-37-5, 139481-59-7 (candesartan only) Merck Index: 13, 1747 CH3 O N N N O O O O N H CH3 O SAMPLE Matrix: blood, formulations Sample preparation: Mix 1 mL plasma with 2 mL MeCN, vortex briefly, let stand at room temperature for 5 min, centrifuge at 4000 g for 20 min, inject a 20 µL aliquot of the supernatant. Mechanically shake a pulverized tablet with 100 mL MeOH for 10 min, centrifuge an aliquot at 4000 rpm for 5 min, filter (0.45 µm), dilute, inject a 20 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Supelcosil C18 Mobile phase: MeCN:MeOH:10 mM potassium dihydrogen phosphate 18:80:2 Flow rate: 1 Injection volume: 20 Detector: UV 260 CHROMATOGRAM Retention time: 3.5 Limit of detection: 2 ng/mL Limit of quantitation: 11 ng/mL OTHER SUBSTANCES Extracted: hydrochlorothiazide (6.5, LOD 3.58 ng/mL, LOQ 6.75 ng/mL) Simultaneous: benazepril (4.5), cilazapril (2.5), hydroflumethiazide (11), lisinopril (7.3) Noninterfering: amiloride, losartan, valsartan KEY WORDS plasma; tablets REFERENCE Erk, N. Simultaneous analysis of candesartan cilexetil and hydrochlorothiazide in human plasma and dosage forms using HPLC with a photodiode array detector, J.Liq.Chromatogr.Rel.Technol., 2003, 26, 2581–2591. SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg Bond Elut C8 SPE cartridge with 2 mL MeOH and 1 mL 100 mM pH 2 phosphate buffer. Mix 250 µL plasma with IS, add 250 µL 1 M phosphoric acid, shake, centrifuge at 10000 g at 4◦ for 5 min, add the supernatant to the SPE cartridge, wash with 500 µL MeOH:100 mM pH 2 phosphate buffer 50:50, dry at full vacuum for 20 min, elute with 500 µL MeOH. Add 100 µL MeOH:ethylene glycol 90:10 to the eluate (to prevent adsorption of the drug), vortex, evaporate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 250 µL of the initial mobile phase, inject a 20 µL aliquot. Candesartan cilexetil 105 HPLC VARIABLES Guard column: 20 × 3.9 4 µm Novapak C18 (Waters) Column: 300 × 3.9 10 µm µBondapak C18 Mobile phase: Gradient. MeCN:5 mM pH 4 acetate buffer from 30:70 to 60:40 over 15 min, to 95:5 over 6 min, return to initial conditions over 3 min, re-equilibrate at initial conditions for 1 min. Flow rate: From 1 to 1.2 over 15 min, maintain at 1.2 for 6 min, to 1 over 3 min, maintain at 1 for 1 min Injection volume: 20 Detector: F ex 250 em 375 CHROMATOGRAM Retention time: 22.6 Internal standard: bumetanide (13.5) Limit of quantitation: 3 ng/mL OTHER SUBSTANCES Extracted: metabolites, irbesartan (12.6, LOQ 50 ng/mL), losartan (11.5, LOQ 16 ng/mL), valsartan (14.4, LOQ 50 ng/mL) KEY WORDS plasma; SPE REFERENCE González, L.; López, J.A.; Alonso, R.M.; Jiménez, R.M. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection, J.Chromatogr.A, 2002, 949, 49–60. ANNOTATED BIBLIOGRAPHY González, L.; Alonso, R.M.; Jiménez, R.M. A high-performance liquid chromatographic method for screening angiotensin II receptor antagonists in human urine, Chromatographia, 2000, 52, 735–740. [losartan; irbesartan; valsartan; candesartan; SPE] Stenhoff, H.; Lagerström, P.O.; Andersen, C. Determination of candesartan cilexetil, candesartan and a metabolite in human plasma and urine by liquid chromatography and fluorometric detection, J.Chromatogr.B, 1999, 731, 411–417. 106 Capecitabine Capecitabine O H N Molecular formula: C15 H22 FN3 O6 Molecular weight: 359.35 CAS Registry No: 154361-50-9 Merck Index: 13, 1759 O CH3 F N H3C O N O OH OH SAMPLE Matrix: blood Sample preparation: Add 50 µL 50 µg/mL IS in MeOH to a tube, evaporate to dryness under reduced pressure at 30◦ for 20 min, add 500 µL plasma, add 500 µL 5 mM pH 6.8 ammonium acetate, vortex, let stand on ice for 15 min, centrifuge at 3000 g at 41◦ (sic) for 10 min. Inject a 20 µL aliquot of the supernatant onto column A and elute to waste with the mobile phase; after 0.8 min, divert the effluent from column A onto column B; after another 19.1 min, elute only column A to waste. HPLC VARIABLES Column: A 20 × 2.1 Oasis HLB (Waters); B SecurityGuard C18 (Phenomenex) + 150 × 2 5 µm YMC ODS-AQ Column temperature: 30 (column B only) Mobile phase: Gradient. MeCN:5 mM pH 6.8 ammonium acetate 0:100 for 2 min, to 10:90 over 0.2 min, to 30:70 over 7.8 min, to 70:30 over 2 min, maintain at 70:30 for 3 min, to 0:100 over 0.2 min, maintain at 0:100 for 4.8 min, to 95:5 over 0.2 min, maintain at 95:5 for 1 min, return to initial conditions over 0.2 min, re-equilibrate for 2.6 min. Flow rate: 3 for 0.8 min, 0.2 for 19.2 min, then 3 Injection volume: 20 Detector: MS, electrospray, m/z 360, cone voltage 20 V, 33% of column effluent went to MS CHROMATOGRAM Retention time: 18 Internal standard: 5-chloro-2′ -deoxyuridine (11.5, m/z 261, cone voltage 35 V) Limit of quantitation: 1.4 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS column-switching; pharmacokinetics; plasma REFERENCE Xu, Y.; Grem, J.L. Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma, J.Chromatogr.B, 2003, 783, 273–285. SAMPLE Matrix: blood Sample preparation: Mix plasma and IS with MeCN, centrifuge, add the supernatant to a Bond Elut C18 SPE cartridge, elute with MeOH. Capecitabine 107 HPLC VARIABLES Column: 150 × 6 5 µm YMC-Pack C8-AM Mobile phase: MeCN:buffer 40:60 (The buffer was 50 mL pH 4.0 citrate buffer (Titrisol, Merck) diluted to 1200 mL with water.) Flow rate: 1 Detector: UV 310 CHROMATOGRAM Retention time: 6.2 Internal standard: Ro 09–1977 (8.8) Limit of quantitation: 50 ng/mL KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Reigner, B.; Verweij, J.; Dirix, L.; Cassidy, J.; Twelves, C.; Allman, D.; Weidekamm, E.; Roos, B.; Banken, L.; Utoh, M.; Osterwalder, B. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients, Clin.Cancer Res., 1998, 4, 941–948. 108 Casanthranol Casanthranol CAS Registry No: 8024-48-4 Merck Index: 13, 1893 SAMPLE Matrix: solutions Sample preparation: Inject a 20 µL aliquot of a solution in MeOH. HPLC VARIABLES Guard column: 4 × 4 5 µm LiChrospher 100 RP18 Column: 125 × 4 5 µm LiChrospher 100 RP18 Column temperature: 40 Mobile phase: MeCN:MeOH:water:acetic acid 5:55:39:1 Flow rate: 1 Injection volume: 20 Detector: UV 254 CHROMATOGRAM Retention time: 6.1 (aloe-emodin), 20.8 (emodin) OTHER SUBSTANCES Extracted: rhein (9.1), sennidin A (16.4), sennidin B (24.8) REFERENCE Grimminger, W.; Witthohn, K. Analytics of senna drugs with regard to the toxicological discussion of anthranoids, Pharmacology, 1993, 47(Suppl. 1), 98–109. ANNOTATED BIBLIOGRAPHY Matthees, D. Determination of emodin in feeds, J.Agric.Food Chem., 1983, 31, 453–454. Koch, A. Metabolism of aloin – the influence of nutrition, J.Pharm.Biomed.Anal., 1996, 14, 1335–1338. 109 Caspofungin Caspofungin H2N H N Molecular formula: C52 H88 N10 O15 Molecular weight: 1093.31 HO H2N O N H CAS Registry No: 162808-62-0 Merck Index: 13, 1899 OH O N H O O H N HO H H O H N O H N H HO N H O OH N H OH H C 3 CH3 CH3 CH3 OH HO SAMPLE Matrix: blood Sample preparation: Condition a 3 mL diol SPE cartridge (Baker) with 3 mL MeOH and 3 mL water. Mix 1 mL plasma with 10 µL 50 µg/mL IS in MeCN:0.1% trifluoroacetic acid adjusted to pH 3.0 with triethylamine 35:65 and 250 µL 1 M pH 4.9 potassium acetate buffer, add to SPE cartridge, wash with 3 mL water, wash with 3 mL MeOH, elute with 1 mL MeOH containing 250 mM ammonium hydroxide and 0.1% trifluoroacetic acid. Evaporate the eluate to dryness under reduced pressure at 50◦ , reconstitute the residue with 100 µL mobile phase, inject a 50 µL aliquot. (See also Schwartz,M. et al. Anal.Chim.Acta 1997, 352, 299–307.) HPLC VARIABLES Column: 150 × 4.6 5 µm Zorbax SB C80 Mobile phase: MeCN:buffer 35:65. After 5.5 min, wash column with MeCN:buffer 90:10 for 0.9 min, re-equilibrate at initial conditions for 5 min. (The buffer was 675 µL trifluoroacetic acid in 1 L water, adjusted to pH 3.0 with ammonium hydroxide.) Flow rate: 1.2 Injection volume: 50 Detector: MS, PE Sciex API III plus triple quadrupole, ion spray, 5% of column effluent entered MS, m/z 1093.7 CHROMATOGRAM Retention time: 5.5 Internal standard: isostere (oxygen replaces nitrogen at 5 position, m/z 1094.7) (6.8) Limit of quantitation: 10 ng/mL (LOQ was 2.5 ng/mL using a 75 µL injection and turbo ion spray, but precision and accuracy was less good) KEY WORDS plasma; SPE REFERENCE Chavez-Eng, C.M.; Schwartz, M.; Constanzer, M.L.; Matuszewski, B.K. Determination of a cyclic hexapeptide, a novel antifungal agent, in human plasma by high-performance liquid chromatography with ion spray and turbo ion spray tandem mass spectrometric detection, J.Chromatogr.B, 1999, 721, 229–238. SAMPLE Matrix: blood 110 Caspofungin Sample preparation: Mix plasma with MeCN/MeOH containing 0.1% trifluoroacetic acid, vortex, centrifuge. Evaporate the supernatant to dryness under reduced pressure, reconstitute the residue with 0.1% trifluoroacetic acid, vortex, centrifuge, inject an aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Zorbax RX C8 Mobile phase: Gradient. MeCN:0.1% trifluoroacetic acid 18:82 for 4 min, to 50:50 over 36 min. Detector: Radioactivity (3 H) CHROMATOGRAM Retention time: 32 OTHER SUBSTANCES Extracted: metabolites KEY WORDS plasma REFERENCE Balani, S.K.; Xu, X.; Arison, B.H.; Silva, M.V.; Gries, A.; deLuna, F.A.; Cui, D.; Kari, P.H.; Ly, T.; Hop, C.E.C.A.; Singh, R.; Wallace, M.A.; Dean, D.C.; Lin, J.H.; Pearson, P.G.; Baillie, T.A. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine, Drug Metab.Dispos., 2000, 28, 1274–1278. SAMPLE Matrix: urine Sample preparation: Evaporate to dryness under reduced pressure, reconstitute, inject an aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Luna C18 (Phenomenex) + 250 × 4.6 5 µm Zorbax SAX in series Mobile phase: Gradient. MeCN:0.1% trifluoroacetic acid 0:100 for 15 min, to 80:20 over 25 min Detector: Radioactivity (3 H) CHROMATOGRAM Retention time: 35 OTHER SUBSTANCES Extracted: metabolites REFERENCE Balani, S.K.; Xu, X.; Arison, B.H.; Silva, M.V.; Gries, A.; deLuna, F.A.; Cui, D.; Kari, P.H.; Ly, T.; Hop, C.E.C.A.; Singh, R.; Wallace, M.A.; Dean, D.C.; Lin, J.H.; Pearson, P.G.; Baillie, T.A. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine, Drug Metab.Dispos., 2000, 28, 1274–1278. ANNOTATED BIBLIOGRAPHY Groll, A.H.; Gullick, B.M.; Petraitiene, R.; Petraitis, V.; Candelario, M.; Piscitelli, S.C.; Walsh, T.J. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits, Antimicrob.Agents Chemother., 2001, 45, 596–600. Caspofungin 111 Petraitiene, R.; Petraitis, V.; Groll, A.H.; Sein, T.; Schaufele, R.L.; Francesconi, A.; Bacher, J.; Avila, N.A.; Walsh, T.J. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia, Antimicrob.Agents Chemother., 2002, 46, 12–23. Schwartz, M.; Kline, W.; Matuszewski, B. Determination of a cyclic hexapeptide (L-743 872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detection, Anal.Chim.Acta, 1997, 352, 299–307. 112 Castor oil Castor oil CAS Registry No: 8001-79-4 Merck Index: 13, 1908 SAMPLE Matrix: cosmetics Sample preparation: Inject a 5–50 µL aliquot of a solution of the lipstick in MeCN. HPLC VARIABLES Column: 300 × 3.9 Bondapak C18 Mobile phase: Gradient. MeCN:water 50:50 for 5 min, to 100:0 (step gradient) Flow rate: 2 Injection volume: 5–50 Detector: UV 254 CHROMATOGRAM Retention time: 8, 20, 27 (multiple peaks) OTHER SUBSTANCES Simultaneous: lanolin (13, 14), propyl paraben (4) KEY WORDS lipstick REFERENCE Reuland, D.J.; Trinler, W.A. A comparison of lipstick smears by high performance liquid chromatography, J.Forensic Sci.Soc., 1980, 20, 111–120. 113 Cefbuperazone Cefbuperazone Molecular formula: C22 H29 N9 O9 S2 Molecular weight: 627.66 H3C H N N O O O HO OCH3 H O N H N H CH3 O S N CAS Registry No: 76610-84-9 Merck Index: 13, 1930 CH3 S COOH N N N N SAMPLE Matrix: blood Sample preparation: Condition a 3 mL 200 mg Bond Elut C18 SPE cartridge with two 3 mL portions of MeOH and two 3 mL portions of 5% acetic acid. Mix 500 µL serum with 500 µL 10% acetic acid, add to the SPE cartridge, wash with 3 mL water, elute with four 500 µL portions of MeOH:water 60:40. Evaporate the combined eluates to dryness under a stream of nitrogen, reconstitute the residue with 250 µL water, filter (0.22 µm). Inject a 100 µL aliquot onto column A and elute to waste with mobile phase A. After an unspecified time, backflush the contents of column A onto column B using mobile phase B. Monitor the effluent from column B. (Sato,K.; Kobayashi,K.; Moore,C.M.; Mizuno,Y.; Katsumata,Y. Semi-quantitative analysis of cefaclor in human serum by capillary high performance liquid chromatography/fast atom bombardment mass spectrometry. Forensic Sci.Int. 1993, 59, 71–77.) HPLC VARIABLES Column: A 30 × 0.5 10 µm Develosil PhA (phenethyl); B 150 × 0.5 5 µm Develosil PhA (phenethyl) Mobile phase: A 10 mM ammonium acetate:glycerol 99.5:0.5, adjusted to pH 5 with acetic acid; B MeOH:water:acetic acid:glycerol 40:59:0.5:0.5 (pH ca. 3) Flow rate: A 0.05; B 0.004 Injection volume: 100 Detector: MS, JMS DX303 double focusing, xenon FAB ion source, gun current 10 mA, voltage 3 kV, positive ion mode CHROMATOGRAM Retention time: 20.8 Limit of detection: 50–200 ng OTHER SUBSTANCES Extracted: cefaclor (14.4), cefamandole (31.0), cefazolin (19.7), cefixime (19.2), cefmenoxime (18.8), cefmetazole (21.4), cefoperazone (24.2), cefotaxime (16.1), cefotetan (16.8), cefotiam (11.7), cefpiramide (20.9), cefsulodin (12.2), ceftazidime (12.0), ceftizoxime (15.6), ceftriaxone (16.7), cefuroxime (16.9), cefuzonam (32.0), cephalexin (14.8), cephaloglycine (15.7), cephaloridine (15.6), cephalothin (34.7), flomoxef (18.3), latamoxef (15.1) KEY WORDS column-switching; serum; SPE REFERENCE Kobayashi, K.; Sato, K.; Mizuno, Y.; Katsumata, Y. Capillary high-performance liquid chromatographyfast atom bombardment mass spectrometry of 24 cephem antibiotics, J.Chromatogr.B, 1996, 677, 275–290. 114 Cefditoren Cefditoren S O H H H2N N Molecular formula: C19 H18 N6 O5 S3 Molecular weight: 506.59 CAS Registry No: 104145-95-1, 117467-28-4 (pivoxil) Merck Index: 13, 1934 N N H O OCH3 N S S CH3 N COOH SAMPLE Matrix: blood Sample preparation: Mix 200 µL serum or urine with 200 µL 5 µg/mL IS in MeCN, centrifuge at 3500 rpm for 10 min, inject a 20 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 ODS C18 Column temperature: 30 Mobile phase: MeOH:5% amine acetate (sic) 30:70 Flow rate: 1 Injection volume: 20 Detector: UV 295 CHROMATOGRAM Retention time: 11.5 Internal standard: not specified (15.8) KEY WORDS pharmacokinetics; serum REFERENCE Li, J.T.; Hou, F.; Lu, H.; Li, T.Y.; Li, H. Phase I clinical trial of cefditoren pivoxil (ME 1207): pharmacokinetics in healthy volunteers, Drugs Exp.Clin.Res., 1997, 23, 145–150. SAMPLE Matrix: blood Sample preparation: Mix 500 µL MeCN with ? µL plasma and ? µL 2 µg/mL IS in MeCN:water 50:50, vortex at high speed for 30 s, centrifuge at 1180 g for 5 min. Evaporate the supernatant to dryness, reconstitute the residue with 100–200 µL mobile phase (?), inject a 10–25 µL aliquot. HPLC VARIABLES Column: 100 × 2 4 µm YMC J’sphere M80 Mobile phase: MeOH:10 mM pH 4.5 ammonium acetate 40:60 Flow rate: 0.2 Injection volume: 10–25 Detector: MS, PE-Sciex API-365 triple quadrupole, turbo ion spray source 450◦ , nitrogen 7 L/min, m/z 506.9–240.8 CHROMATOGRAM Retention time: 6.2 Internal standard: cefotaxime (m/z 455.9–324) (2.2) Limit of quantitation: 10 ng/mL KEY WORDS plasma Cefditoren 115 REFERENCE Zhu, T.; Cheung, B.W.Y.; Cartier, L.L.; Giebink, G.S.; Sawchuk, R.J. Simultaneous intravenous and intramiddle-ear dosing to determine cefditoren influx and efflux clearances in middle ear fluid in freely moving chinchillas, J.Pharm.Sci., 2003, 92, 1947–1956. SAMPLE Matrix: dialysate Sample preparation: Inject a 10 µL aliquot of artificial middle ear fluid (pH 7.45 phosphate-buffered saline-containing 15 mM phosphate and 150 mM sodium) containing 200 ng/mL IS. HPLC VARIABLES Column: 100 × 4.6 YMC ODS-A S-5 C18 Mobile phase: MeOH:50 mM pH 4.0 ammonium acetate buffer 35:65 Flow rate: 0.5 Injection volume: 10 Detector: UV 295 CHROMATOGRAM Retention time: 9.6 Internal standard: (+)-(6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-methoxyiminoacetamido]-3-[(Z)-2-(4-methylthiazol-5-yl)ethenyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2carboxylic acid (Meiji Seika Kaisha, Tokyo) (8.2) Limit of quantitation: 5 ng/mL OTHER SUBSTANCES Extracted: metabolites REFERENCE Zhu, T.; Cheung, B.W.Y.; Cartier, L.L.; Giebink, G.S.; Sawchuk, R.J. Simultaneous intravenous and intramiddle-ear dosing to determine cefditoren influx and efflux clearances in middle ear fluid in freely moving chinchillas, J.Pharm.Sci., 2003, 92, 1947–1956. 116 Cefoselis Cefoselis Molecular formula: C19 H22 N8 O6 S2 Molecular weight: 522.57 CAS Registry No: 122841-10-5, 122841-12-7 (sulfate) Merck Index: 13, 1945 S O H H H2N N N N S + N H N O OCH3 COO− N NH2 OH SAMPLE Matrix: blood, CSF, tissue Sample preparation: Mix 100 µL serum with 10 µL 100 mg/mL (sic) IS in 100 mM pH 7.0 phosphate buffer and 100 µL MeCN, vortex for 10 s, centrifuge at 13000 rpm for 2 min. Remove 100 µL of the supernatant and mix it with 400 µL 20 mM pH 2.5 phosphate buffer, vortex for 10 s, inject a 5 µL aliquot. Mix 30 µL CSF with 1 mg/mL IS in 100 mM pH 7.0 phosphate buffer (?), inject a 50 µL aliquot. Homogenize brain tissue with 5 vol of saline. Mix 200 µL homogenate with 20 µL 1 mg/mL IS in 100 mM pH 7.0 phosphate buffer and 200 µL MeCN, vortex for 10 s, inject a 50 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm TSKgel ODS-80TM Mobile phase: MeCN:20 mM pH 2.5 phosphate buffer 0.065:99.935 Flow rate: 1 Injection volume: 5–50 Detector: UV 254 CHROMATOGRAM Internal standard: cefpirome sulfate KEY WORDS brain; rat; serum REFERENCE Nagata, M.; Yasuhara, M. Effect of experimental renal failure on the pharmacodynamics of cefoselisinduced seizures in rats, Biol.Pharm.Bull., 2001, 24, 1049–1052. 117 Cefozopran Cefozopran Molecular formula: C19 H17 N9 O5 S2 Molecular weight: 515.53 H2N O N H H S N N N CAS Registry No: 113359-04-9 Merck Index: 13, 1950 S + N H N N N O OCH3 COO− SAMPLE Matrix: blood, urine Sample preparation: Serum. Mix 300 µL serum with 300 µL 5 mM pH 3.2 sodium phosphate buffer and 800 µL MeCN, shake mechanically for 2 min, centrifuge at 13000 g for 5 min. Remove 1.4 mL of the supernatant and add it to 2 mL dichloromethane, agitate for 1 min, centrifuge at 2000 g for 5 min. Remove a 300 µL aliquot of the supernatant and add it to 600 µL mobile phase, inject a 20 µL aliquot. Urine. Mix 100 µL urine with 900 µL of the aqueous portion of the mobile phase, inject a 5 µL aliquot. HPLC VARIABLES Guard column: 30 × 4 30–40 µm Perisorb RP18 Column: 125 × 4 5 µm Nucleosil 5C18 Mobile phase: MeCN:buffer 4.5:95.5 (Make mobile phase by adding 45 mL MeCN and 3 bottles of PIC B7 solution (15 M heptanesulfonic acid, pH 3.2 (Waters)) to water and making up to 1 L with water.) Flow rate: 1.5 Injection volume: 5 (urine), 20 (serum) Detector: UV 235 CHROMATOGRAM Retention time: 5.3 Limit of detection: 600 ng/mL (serum), 3.5 µg/mL (urine) Limit of quantitation: 1 µg/mL (serum), 5 µg/mL (urine) KEY WORDS serum REFERENCE Borner, K.; Borner, E.; Lode, H. Determination of a new cephalosporin, SCE-2787, in serum and urine by high-performance liquid chromatography, J.Chromatogr., 1993, 615, 174–179. 118 Cefuzonam Cefuzonam Molecular formula: C16 H15 N7 O5 S4 Molecular weight: 513.60 CAS Registry No: 82219-78-1 Merck Index: 13, 1967 S O H H H2N N N N H O OCH3 S N S S N COOH N SAMPLE Matrix: blood Sample preparation: Condition a 3 mL 200 mg Bond Elut C18 SPE cartridge with two 3 mL portions of MeOH and two 3 mL portions of 5% acetic acid. Mix 500 µL serum with 500 µL 10% acetic acid, add to the SPE cartridge, wash with 3 mL water, elute with four 500 µL portions of MeOH:water 60:40. Evaporate the combined eluates to dryness under a stream of nitrogen, reconstitute the residue with 250 µL water, filter (0.22 µm). Inject a 100 µL aliquot onto column A and elute to waste with mobile phase A. After an unspecified time, backflush the contents of column A onto column B using mobile phase B. Monitor the effluent from column B. (Sato,K.; Kobayashi,K.; Moore,C.M.; Mizuno,Y.; Katsumata,Y. Semi-quantitative analysis of cefaclor in human serum by capillary high performance liquid chromatography/fast atom bombardment mass spectrometry. Forensic Sci.Int. 1993, 59, 71–77.) HPLC VARIABLES Column: A 30 × 0.5 10 µm Develosil PhA (phenethyl); B 150 × 0.5 5 µm Develosil PhA (phenethyl) Mobile phase: A 10 mM ammonium acetate:glycerol 99.5:0.5, adjusted to pH 5 with acetic acid; B MeOH:water:acetic acid:glycerol 40:59:0.5:0.5 (pH ca .3) Flow rate: A 0.05; B 0.004 Injection volume: 100 Detector: MS, JMS DX303 double focusing, xenon FAB ion source, gun current 10 mA, voltage 3 kV, positive ion mode CHROMATOGRAM Retention time: 32.0 Limit of detection: 200–1000 ng OTHER SUBSTANCES Extracted: cefaclor (14.4), cefamandole (31.0), cefazolin (19.7), cefbuperazone (20.8), cefixime (19.2), cefmenoxime (18.8), cefmetazole (21.4), cefoperazone (24.2), cefotaxime (16.1), cefotetan (16.8), cefotiam (11.7), cefpiramide (20.9), cefsulodin (12.2), ceftazidime (12.0), ceftizoxime (15.6), ceftriaxone (16.7), cefuroxime (16.9), cephalexin (14.8), cephaloglycine (15.7), cephaloridine (15.6), cephalothin (34.7), flomoxef (18.3), latamoxef (15.1) KEY WORDS column-switching; serum; SPE REFERENCE Kobayashi, K.; Sato, K.; Mizuno, Y.; Katsumata, Y. Capillary high-performance liquid chromatographyfast atom bombardment mass spectrometry of 24 cephem antibiotics, J.Chromatogr.B, 1996, 677, 275–290. 119 Celecoxib Celecoxib O O S H2N Molecular formula: C17 H14 F3 N3 O2 S Molecular weight: 381.38 N N CF3 CAS Registry No: 169590-42-5 Merck Index: 13, 1968 H3C SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg Chromabond C18 SPE cartridge with two 1 mL portions of MeCN and two 1 mL portions of water. Mix 200 µL plasma with 200 µL 100 mM pH 4.0 phosphate buffer and 25 µL 450 ng/mL IS in MeCN:water 50:50, add to the SPE cartridge, wash with two 1 mL portions of water, dry under vacuum for at least 5 min, elute with two 1 mL portions of dichloromethane. Evaporate the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL mobile phase, inject a 10 µL aliquot. HPLC VARIABLES Column: 30 × 2 5 µm Nucleosil C18 Mobile phase: MeCN:water:25% ammonium hydroxide 85:15:0.1 Flow rate: 0.2 Injection volume: 10 Detector: MS, PE Sciex API 3000 triple quadrupole, turbo ion spray interface, neg- ative ion mode at -3700 V and 400◦ , auxiliary gas nitrogen 4.5 L/min, nebulizer gas nitrogen 1.23 L/min, curtain gas nitrogen 1.08 L/min, collision gas nitrogen 2.92 × 1015 molecules/cm2 , m/z 380–316 (–32 eV) CHROMATOGRAM Retention time: 0.8 Internal standard: 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (The IS is celecoxib lacking the methyl group. Preparation is as follows. Reflux 200 mL EtOH containing 16 mmol 4,4,4-trifluoro-1-phenyl-1,3-butadiene and 17.6 mmol 4-sulfonamidophenylhydrazine hydrochloride with stirring for 22 h, evaporate under reduced pressure. Take up the residue in ethyl acetate, wash with water, wash with saline, evaporate the organic solvent, recrystallize from n-hexane:ethyl acetate 50:50 to obtain the IS as white needles.) (m/z 366–302 (–30 eV)) (0.8) Limit of quantitation: 0.25 ng/mL KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Bräutigam, L.; Vetter, G.; Tegeder, I.; Heinkele, G.; Geisslinger, G. Determination of celecoxib in human plasma and rat microdialysis samples by liquid chromatography tandem mass spectrometry, J.Chromatogr.B, 2001, 761, 203–212. SAMPLE Matrix: blood Sample preparation: Mix 500 µL serum with 25 µL 30 µg/mL IS in MeCN, add 500 µL saturated NaCl, add 1 mL MeCN, mix, add 8 mL chloroform (Caution! Chloroform is a carcinogen!), extract for 15 min, centrifuge at 1500 g for 15 min. Evaporate the organic 120 Celecoxib layer to dryness under a stream of nitrogen, reconstitute the residue with 100 µL mobile phase, sonicate for 5 min, vortex, centrifuge for 15 min, inject a 10 µL aliquot. HPLC VARIABLES Column: 150 × 3 3 µm Prontosil C18 AQ Column temperature: 15 Mobile phase: MeCN:water 60:40 Flow rate: 0.35 Injection volume: 10 Detector: F ex 240 em 380 CHROMATOGRAM Retention time: 9.1 Internal standard: 4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (The IS is celecoxib lacking the methyl group. Preparation is as follows. Reflux 200 mL EtOH containing 16 mmol 4,4,4-trifluoro-1-phenyl-1,3-butadiene and 17.6 mmol 4-sulfonamidophenylhydrazine hydrochloride with stirring for 22 h, evaporate under reduced pressure. Take up the residue in ethyl acetate, wash with water, wash with saline, evaporate the organic solvent, recrystallize from n-hexane:ethyl acetate 50:50 to obtain the IS as white needles.) (11.7) Limit of quantitation: 12.5 ng/mL KEY WORDS pharmacokinetics; serum REFERENCE Schönberger, F.; Heinkele, G.; Mürdter, T.E.; Brenner, S.; Klotz, U.; Hofmann, U. Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection, J.Chromatogr.B, 2002, 768, 255–260. SAMPLE Matrix: blood Sample preparation: Condition a 1 mL Oasis HLB SPE cartridge with 1 mL MeOH and 1 mL water. Mix 500 µL plasma with 15 µL 10 µg/mL IS in MeOH and 300 µL 200 mM pH 5.0 sodium acetate buffer, add 1.8 mL MeCN, vortex, centrifuge at 15000 g for 5 min. Evaporate the organic part of the supernatant under a stream of nitrogen at 50◦ , dilute the remaining aqueous phase with 2 mL water, add to the SPE cartridge at 0.07 mL/min, wash with two 1.5 mL portions of MeOH:water 5:95, elute with 2 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 50◦ , reconstitute the residue with 75 µL MeOH, inject a 50 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Luna C18 (Phenomenex) Column temperature: 60 Mobile phase: Gradient. A:B 90:10 for 10 min, to 62:38 over 37 min, to 27:73 over 16 min, maintain at 27:73 for 5 min, return to initial conditions over 0.1 min, reequilibrate for 6.9 min. A was MeCN:10 mM pH 5.4 sodium phosphate buffer 10:90. B was MeCN:10 mM pH 5.4 sodium phosphate buffer 80:20. Flow rate: 1.5 Injection volume: 50 Detector: UV 254 CHROMATOGRAM Retention time: 61 Internal standard: phenacetin (12) Limit of quantitation: 10 ng/mL Celecoxib 121 OTHER SUBSTANCES Extracted: metabolites KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Störmer, E.; Bauer, S.; Kirchheiner, J.; Brockmöller, J.; Roots, I. Simultaneous determination of celecoxib, hydroxycelecoxib, and carboxycelecoxib in human plasma using gradient reversed-phase liquid chromatography with ultraviolet absorbance detection, J.Chromatogr.B, 2003, 783, 207–212. SAMPLE Matrix: formulations Sample preparation: Weigh out capsule contents containing 5 mg celecoxib, dissolve in 25 mL mobile phase, filter (Whatman No 1 paper), dilute with mobile phase, inject an aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Inertsil C8 Mobile phase: MeCN:water 65:35 Flow rate: 1.25 Injection volume: 20 Detector: UV 230 CHROMATOGRAM Retention time: 8.05 Limit of detection: 25 ng/mL Limit of quantitation: 75 ng/mL KEY WORDS capsules REFERENCE Saha, R.N.; Sajeev, C.; Jadhav, P.R.; Patil, S.P.; Srinivasan, N. Determination of celecoxib in pharmaceutical formulations using UV spectrophotometry and liquid chromatography, J.Pharm.Biomed.Anal., 2002, 28, 741–751. ANNOTATED BIBLIOGRAPHY Abdel-Hamid, M.; Novotny, L.; Hamza, H. Liquid chromatographic-mass spectrometric determination of celecoxib in plasma using single-ion monitoring and its use in clinical pharmacokinetics, J.Chromatogr.B, 2001, 753, 401–408. Abdel-Hamid, M.E. LC-MS analysis of selected sulfur-containing non-steroid antiinflammatory agents: Applications to pharmaceutical products, J.Liq.Chromatogr.Rel.Technol., 2000, 23, 3095–3107. [rofecoxib; sulindac; celecoxib; piroxicam; tenoxicam] Chow, H.-H.S.; Anavy, N.; Salazar, D.; Frank, D.H.; Alberts, D.S. Determination of celecoxib in human plasma using solid-phase extraction and high-performance liquid chromatography, J.Pharm.Biomed.Anal., 2004, 34, 167–174. Jayasagar, G.; Kumar, M.K.; Chandrasekhar, K.; SivaPrasad, P.; Madhusudan Rao, Y. Validated HPLC method for the determination of celecoxib in human serum and its application in a clinical pharmacokinetic study, Pharmazie, 2002, 57, 619–621. [tolbutamide is internal standard] Mamidi, R.N.V.S.; Mullangi, R.; Kota, J.; Bhamidipati, R.; Khan, A.A.; Katneni, K.; Datla, S.; Singh, S.K.; Rao, K.Y.; Rao, C.S.; Srinivas, N.R.; Rajagopalan, R. Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats, Biopharm.Drug Dispos., 2002, 23, 273–282. Mamidi, R.N.V.S.; Benjamin, B.; Ramesh, M.; Srinivas, N.R. Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard, Biomed.Chromatogr., 2003, 17, 417–420. 122 Celecoxib Paulson, S.K.; Engel, L.; Reitz, B.; Bolten, S.; Burton, E.G.; Maziasz, T.J.; Yan, B.; Schoenhard, G.L. Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib, Drug Metab.Dispos., 1999, 27, 1133–1142. Paulson, S.K.; Kaprak, T.A.; Gresk, C.J.; Fast, D.M.; Baratta, M.T.; Burton, E.G.; Breau, A.P.; Karim, A. Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human, Biopharm.Drug Dispos., 1999, 20, 293–299. Paulson, S.K.; Hribar, J.D.; Liu, N.W.K.; Hajdu, E.; Bible, R.H. Jr.; Piergies, A.; Karim, A. Metabolism and excretion of [14 C]celecoxib in healthy male volunteers, Drug Metab.Dispos., 2000, 28, 308–314. [SPE] Paulson, S.K.; Zhang, J.Y.; Breau, A.P.; Hribar, J.D.; Liu, N.W.K.; Jessen, S.M.; Lawal, Y.M.; Cogburn, J.N.; Gresk, C.J.; Markos, C.S.; Maziasz, T.J.; Schoenhard, G.L.; Burton, E.G. Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats, Drug Metab.Dispos., 2000, 28, 514–521. Rao, D.S.; Srinivasu, M.K.; Narayana, C.L.; Reddy, G.O. LC separation of ortho and meta isomers of celecoxib in bulk and formulations using a chiral column, J.Pharm.Biomed.Anal., 2001, 25, 21–30. Rose, M.J.; Woolf, E.J.; Matuszewski, B.K. Determination of celecoxib in human plasma by normal-phase high-performance liquid chromatography with column switching and ultraviolet absorbance detection, J.Chromatogr.B, 2000, 738, 377–385. Srinivasu, M.K.; Narayana, C.L.; Rao, D.S.; Reddy, G.O. A validated LC method for the quantitative determination of celecoxib in pharmaceutical dosage forms and purity evaluation in bulk drugs, J.Pharm.Biomed.Anal., 2000, 22, 949–956. Stempak, D.; Gammon, J.; Klein, J.; Koren, G.; Baruchel, S. Single-dose and steady-state pharmacokinetics of celecoxib in children, Clin.Pharmacol.Ther., 2002, 72, 490–497. Tang, C.; Shou, M.; Mei, Q.; Rushmore, T.H.; Rodrigues, A.D. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor, J.Pharmacol.Exp.Ther., 2000, 293, 453–459. Tang, C.; Shou, M.; Rodrigues, A.D. Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity, Drug Metab.Dispos., 2000, 28, 567–572. [diclofenac; phenytoin; celecoxib; tolbutamide; flurbiprofen; chlorpropamide] Werner, U.; Werner, D.; Mundkowski, R.; Gillich, M.; Brune, K. Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans, J.Chromatogr.B, 2001, 760, 83–90. Werner, U.; Werner, D.; Pahl, A.; Mundkowski, R.; Gillich, M.; Brune, K. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry, Biomed.Chromatogr., 2002, 16, 56–60. [rofecoxib is internal standard] Yener, G.; Gonullu, U.; Uner, M.; Degim, T.; Araman, A. Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of celecoxib through human skin, Pharmazie, 2003, 58, 330–333. Cerivastatin Cerivastatin F Molecular formula: C26 H34 FNO5 Molecular weight: 459.55 CAS Registry No: 145599-86-6 Merck Index: 13, 2004 123 OH OH COOH H3CO H3C N CH3 CH3 CH3 SAMPLE Matrix: blood Sample preparation: Add 50 µL serum to 500 µL chilled (4◦ ) 100 mM pH 5.0 sodium acetate buffer, mix, add 50 µL IS in MeCN:water 50:50, vortex, add 5 mL MTBE, shake mechanically for 15 min, centrifuge for 5 min, freeze in dry ice/MeOH. Remove the organic layer, evaporate to dryness under reduced pressure with nitrogen at 35◦ , reconstitute the residue with 50 µL MeCN:10 mM pH 4.0 ammonium formate buffer 50:50, centrifuge, inject a 25 µL aliquot. HPLC VARIABLES Guard column: 10 × 2 YMC Basic Column: 50 × 2 5 µm YMC Basic Mobile phase: Gradient. MeCN:10 mM pH 4.0 ammonium formate buffer from 60:40 to 100:0 over 0.3 min, maintain at 100:0 for 0.7 min, return to initial conditions over 0.1 min, re-equilibrate for 2.4 min. Flow rate: 0.3 Injection volume: 25 Detector: MS, Sciex API 365, positive turbo ion spray at 400◦ , ion spray +5.5 kV, orifice voltage 45 V, nebulizer gas nitrogen 5.5 bar, turbo ion spray gas at 7 L/min, dwell time 200 ms, collision cell energy 45 eV, m/z 460.4-356.0 (acid), m/z 442.2–354.0 (lactone) CHROMATOGRAM Retention time: 1.52 (acid), 1.75 (lactone) Internal standard: d3 -cerivastatin acid (1.49), d3 -cerivastatin lactone (1.72) Limit of quantitation: 0.01 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS serum REFERENCE Jemal, M.; Rao, S.; Salahudeen, I.; Chen, B.-C.; Kates, R. Quantitation of cerivastatin and its seven acid and lactone biotransformation products in human serum by liquid chromatography-electrospray tandem mass spectrometry, J.Chromatogr.B, 1999, 736, 19–41. SAMPLE Matrix: blood, formulations Sample preparation: Vortex 2 mL serum and 500 µL MeCN for 2 min, centrifuge at 4000 g for 10 min, inject a 50 µL aliquot of the supernatant. Crush tablets and weigh out an amount corresponding to 10 mg cerivastatin, sonicate with MeOH for 10 min, make up to 10 mL with MeOH, filter, add IS to the filtrate, dilute with mobile phase, inject a 50 µL aliquot. 124 Cerivastatin HPLC VARIABLES Column: 250 × 4.6 5 µm LC18 (Waters) Mobile phase: MeCN:buffer 35:65 (Buffer was 10 mM potassium dihydrogen phosphate adjusted to pH 3.1 with phosphoric acid.) Flow rate: 1 Injection volume: 50 Detector: UV 232 CHROMATOGRAM Retention time: 6.90 Internal standard: losartan (8.78) Limit of detection: 0.62 ng/mL Limit of quantitation: 207 ng/mL KEY WORDS serum; tablets REFERENCE Ozkan, S.A.; Ozkan, Y.; Aboul-Enein, H.Y. Quality control and drug dissolution studies of pharmaceutical preparations containing cerivastatin sodium by means of RP-HPLC, J.Liq.Chromatogr.Rel.Technol., 2002, 25, 251–262. ANNOTATED BIBLIOGRAPHY Boberg, M.; Angerbauer, R.; Fey, P.; Kanhai, W.K.; Karl, W.; Kern, A.; Ploschke, J.; Radtke, M. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved, Drug Metab.Dispos., 1997, 25, 321–331. [LC-MS] Krol, G.J.; Beck, G.W.; Ritter, W.; Lettieri, J.T. LC separation and induced fluorometric detection of rivastatin in blood plasma, J.Pharm.Biomed.Anal., 1993, 11, 1269–1275. Mazzu, A.L.; Lasseter, K.C.; Shamblen, E.C.; Agarwal, V.; Lettieri, J.; Sundaresen, P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin, Clin.Pharmacol.Ther., 2000, 68, 391–400. [SPE] Prueksaritanont, T.; Tang, C.; Qiu, Y.; Mu, L.; Subramanian, R.; Lin, J.H. Effects of fibrates on metabolism of statins in human hepatocytes, Drug Metab.Dispos., 2002, 30, 1280–1287. [cerivastatin; simvastatin; atorvastatin; rosuvastatin; pravastatin] Cetrorelix Cetrorelix Cl Molecular formula: C70 H92 ClN17 O14 Molecular weight: 1431.06 CAS Registry No: 120287-85-6 Merck Index: 13, 2036 125 H O N N H N H O O O Ser-Tyr-D-Cit-Leu-Arg-Pro-D-AlaNH 2 N H3C SAMPLE Matrix: bile, feces, urine Sample preparation: Bile. Dilute bile with 2 vol of 30% acetic acid, inject a 50–100 µL aliquot. After each run, regenerate column with a water injection. Feces. Homogenize feces with 1.5 vol of water. Extract 5 g homogenized feces three times with 5 mL aliquots of MeOH:ethyl acetate 2:1 using an ultra turrax (TP 18–10; IKA, Staufen, Germany) at about 10000 rpm with three 30 s applications, centrifuge at 10000 g for 15 min. Combine the supernatants, evaporate to dryness under reduced pressure at 40◦ , reconstitute the residue with 2 mL 30% acetic acid in water, filter (minisart GF and minisart NML, 0.8 µm, Sartorius), inject a 50–100 µL aliquot. Urine. Directly inject a 50–100 µL aliquot of urine. HPLC VARIABLES Guard column: 30 × 3 Merck Column: 250 × 3 5 µm LiChrospher WP 300 RP-18 Mobile phase: Gradient. A:B from 95:5 to 20:80 over 180 min, to 0:100 over 2 min, maintain at 0:100 for 10 min, return to initial conditions over 3 min. A was 0.1% trifluoroacetic acid in water, adjusted to pH 2.0 with 1 M NaOH. B was MeCN:water:trifluoroacetic acid 90:10:0.1, adjusted to pH 2.0 with 1 M NaOH. Flow rate: 0.5 Injection volume: 50–100 Detector: Radioactivity (14 C); UV 226 CHROMATOGRAM Retention time: 82 OTHER SUBSTANCES Extracted: metabolites KEY WORDS dog; rat REFERENCE Schwahn, M.; Schupke, H.; Gasparic, A.; Krone, D.; Peter, G.; Hempel, R.; Kronbach, T.; Locher, M.; Jahn, W.; Engel, J. Disposition and metabolism of cetrorelix, a potent luteinizing hormone-releasing hormone antagonist, in rats and dogs, Drug Metab.Dispos., 2000, 28, 10–20. SAMPLE Matrix: blood, urine Sample preparation: Plasma. Condition a 500 mg Sep-Pak Vac C8 with 20 mL MeOH and 20 mL water. Vortex 1 mL plasma with 10 µL 20 µg/mL IS in mobile phase, add 10 mL MeOH:water 10:90, mix, add to the SPE cartridge, wash with 10 mL MeOH:water 10:90, wash with 10 mL MeOH:water 50:50, elute with 10 mL MeOH:water:trifluoroacetic acid 90:10:0.1. Evaporate the eluate to dryness under 126 Cetrorelix reduced pressure, reconstitute the residue with 100 µL mobile phase, vortex, add to an Ultrafree-MC/LCR filter (0.2 µm, area 0.2 cm2 ), filter while centrifuging at 3500 g at 4◦ for 20 min, inject a 40 µL aliquot of the filtrate. Urine. Condition a 500 mg SepPak Vac C8 with 20 mL MeOH and 20 mL water. Mix 2 mL urine with 200 µL blank human plasma, add 10 µL 20 µg/mL IS in mobile phase, mix, add 8 mL MeOH:water 10:70, mix, add to the SPE cartridge, wash with 10 mL MeOH:water 10:90, wash with 10 mL MeOH:water 50:50, elute with 10 mL MeOH:water:trifluoroacetic acid 90:10:0.1. Evaporate the eluate to dryness under reduced pressure, reconstitute the residue with 100 µL mobile phase, vortex, add to an Ultrafree-MC/LCR filter (0.2 µm, area 0.2 cm2 ), filter while centrifuging at 3500 g at 4◦ for 20 min, inject a 40 µL aliquot of the filtrate. HPLC VARIABLES Column: 150 × 2.1 5 µm µ-Bondasphere C18 Mobile phase: MeCN:water:trifluoroacetic acid 35:65:0.1 Flow rate: 0.2 Injection volume: 40 Detector: MS, Micromass Platform single-stage quadrupole, electrospray, negative ion detection, nebulizer gas nitrogen at 30 L/h, drying gas nitrogen at 300 L/h, source temperature 120◦ , capillary voltage 3 kV, m/z 1429, 1543, 1657 CHROMATOGRAM Retention time: 6 Internal standard: brominated cetrorelix (dissolve 10 mg cetrorelix in 1 mL glacial acetic acid, slowly add 15 µL 10% bromine in acetic acid while slowly stirring at room temperature, stir for 1 h, evaporate to dryness under a stream of nitrogen, reconstitute the residue with glacial acetic acid, store at 4◦ .) (m/z 1586, 1700, 1813) (8) Limit of quantitation: 1 ng/mL KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Niwa, M.; Enomoto, K.; Yamashita, K. Measurement of the novel decapeptide cetrorelix in human plasma and urine by liquid chromatography-electrospray ionization mass spectrometry, J.Chromatogr.B, 1999, 729, 245–253. SAMPLE Matrix: blood Sample preparation: Mix 4 mL plasma with 200 µL 1 M HCl, add 100 µL 1 µg/mL IS in 10 mM acetic acid, add 9 mL ethyl acetate:1-butanol 90:10, extract on a Reax mixer for 15 min, centrifuge at 1000 g for 3 min, remove 5 mL of the organic layer, add 5 mL ethyl acetate:1-butanol 90:10, extract for 15 min, centrifuge at 1000 g for 3 min, remove 5 mL of the organic layer. Combine the organic layers and extract with 150 µL 10 mM HCl, centrifuge at 1000 g for 3 min, inject a 150 µL aliquot of the aqueous layer. HPLC VARIABLES Column: 250 × 4 5 µm LiChrospher 60 RP-Select B Mobile phase: MeCN:MeOH:50 mM pH 4 ammonium acetate buffer 25.5:25.5:49 Flow rate: 0.4 Injection volume: 150 Detector: F ex 227 em 340 CHROMATOGRAM Retention time: 25 Internal standard: D-21740 (Ac-D-Nal1 -(p-Cl)-D-Phe2 -D-Pal3 -Ser4 -Tyr5 -D-Cit6 -Leu7 Arg8 -Ala9 -D-Ala10 -NH2 trifluoroacetate) (23) Limit of quantitation: 2 ng/mL Cetrorelix 127 KEY WORDS plasma REFERENCE Raffel, H.H.; Locher, M.; Borbe, H.O. High-performance liquid chromatographic assay for the determination of the decapeptide cetrorelix, a novel luteinizing hormone-releasing hormone antagonist, in human plasma, J.Chromatogr.B, 1994, 653, 102–105. 128 Cetyl alcohol Cetyl alcohol Molecular formula: C16 H34 O Molecular weight: 242.44 CH3(CH2)14CH2OH CAS Registry No: 36653-82-4 Merck Index: 13, 2037 SAMPLE Matrix: solutions Sample preparation: Prepare a solution of the alcohol by dissolving 10 mg alcohol in 200 µL pyridine and diluting to 10 mL in MeCN. Mix 1 mL solution with 100 µL reagent and 100 µL 2% 1-isopropyl-3-(3-dimethylaminopropyl)carbodiimide perchlorate in MeCN, heat at 80◦ for 20 min, cool to room temperature, add 1 mL water, add 2 mL isopropanol:water 50:50, add to a Sep-Pak ODS SPE cartridge, rinse the tube with 3 mL isopropanol:water 50:50, add the rinse to the SPE cartridge, wash with 3 mL isopropanol:water 50:50, elute with 2 mL isopropanol, inject a 20 µL aliquot of the eluate. (The reagent was 10 mg 2-(4-carboxyphenyl)-5,6-dimethylbenzimidazole in 1 mL pyridine, add 700 mg 4-piperidinopyridine, dilute to 10 mL with MeCN. Prepare 2-(4carboxyphenyl)-5,6-dimethylbenzimidazole as follows. Add 13 g 4-carboxybenzaldehyde (terephthalaldehydic acid) in 400 mL EtOH dropwise to 4,5-dimethyl-1,2-phenylenediamine in 400 mL EtOH in an ice bath, after 1 h reflux for 8 h, cool to room temperature, collect the precipitate, recrystallize three times from MeOH:water 50:50 to give 2-(4carboxyphenyl)-5,6-dimethylbenzimidazole as a white amorphous product (mp >300◦ ). 4-Piperidinopyridine is not commercially available but 4-dimethylaminopyridine or 4-pyrrolidinopyridine can be used instead although interferences are greater. Alternatively, 4-piperidinopyridine can be synthesized as follows. Add 200 mmol piperidine dropwise with stirring to 15 g phosphorus pentoxide and 9.51 g 4-hydroxypyridine, heat at 250◦ for 7 h, cautiously pour onto 200 g ice, add 400 mL 1 M NaOH, add 200 mL ether. Remove the ether layer and extract the aqueous layer three times with 100 mL portions of ether. Combine the organic layers and dry them over anhydrous potassium carbonate, evaporate, distill the residue, recrystallize from petroleum ether (bp 80–100◦ ) to give 4-piperidinopyridine (bp 167–170◦ /11 mm Hg; mp 79–80◦ ) (Synthesis 1978, 844). Alternatively, add 1.94 g 4-bromopyridine hydrochloride to 5 mL 50% NaOH, add 5 mL piperidine, add 2.72 g benzyltriethylammonium bromide, heat at 100◦ for 5 h, remove excess piperidine by distillation, add 25 mL water, extract four times with 25 mL portions of benzene. Combine the organic layers and dry them over anhydrous sodium sulfate, boil the residue with petroleum ether to give 4-piperidinopyridine (mp 80◦ ) (Syn.Commun. 1979, 9, 251). Prepare 1-isopropyl-3-(3dimethylaminopropyl)carbodiimide perchlorate as follows. Stir 1.41 mol isopropylisocyanate in 750 mL dichloromethane at 5◦ , add 144 g 3-dimethylaminopropylamine (N, N-dimethyl-1,3-propanediamine) in 250 mL dichloromethane at such a rate that the temperature does not exceed 10◦ , add 500 mL triethylamine, add 300 g p-toluenesulfonyl chloride in 300 mL dichloromethane at such a rate that the temperature does not exceed 10◦ , reflux for 3 h, add 400 g anhydrous sodium carbonate, add 3.5 L ice water, stir vigorously for 30 min, remove the organic phase. Extract the aqueous phase three times with 500 mL portions of dichloromethane. Combine the organic layers and dry them over anhydrous sodium sulfate, evaporate under reduced pressure, distil the residue to give 1-isopropyl-3-(3-dimethylaminopropyl)carbodiimide (bp 91–92◦ /10 mm Hg (Ber. 1941, 74B, 1285)) (cf. Org.Syn. 1973, Coll Vol. V, 555). Prepare pyridine perchlorate from pyridine and 20% perchloric acid, crystallize from EtOH (Ber. 1926, 59, 446). Add 18 g pyridine perchlorate in portions to 100 mmol 1-isopropyl-3-(3dimethylaminopropyl)carbodiimide stirred in 200 mL dichloromethane at 0◦ , let stand for 30 min, filter, add 200 mL anhydrous diethyl ether to the filtrate. Filter off the precipitate and recrystallize it from dichloromethane/diethyl ether to give 1-isopropyl- Cetyl alcohol 129 3-(3-dimethylaminopropyl)carbodiimide perchlorate (mp 88–90◦ ) (Chem.Pharm.Bull. 1985, 33, 5375).) HPLC VARIABLES Guard column: 50 × 4.6 7 µm Zorbax ODS Column: 250 × 4.6 7 µm Zorbax ODS Mobile phase: MeOH:isopropanol 85:15 Flow rate: 1 Injection volume: 20 Detector: F ex 338 em 428 CHROMATOGRAM Retention time: 9.4 Limit of detection: 10–20 pg/mL OTHER SUBSTANCES Simultaneous: dodecyl alcohol (6.2), tetradecyl alcohol (7.2), stearyl alcohol (12.5), eicosyl alcohol (16.5) KEY WORDS derivatization; SPE REFERENCE Katayama, M.; Masuda, Y.; Taniguchi, H. Determination of alcohols by high-performance liquid chromatography after pre-column derivatization with 2-(4-carboxyphenyl)-5,6-dimethylbenzimidazole, J.Chromatogr., 1991, 585, 219–224. 130 Cevimeline hydrochloride Cevimeline hydrochloride N O Molecular formula: C10 H17 NOS.HCl.1/2H2 O Molecular weight: 244.78 CAS Registry No: 153504-70-2, 107233-08-9 (free base) S HCl CH3 H 1/2 H2O SAMPLE Matrix: blood Sample preparation: Condition a Bond Elut Certify SPE cartridge with 3 mL MeOH and 3 mL 100 mM pH 6.0 phosphate buffer. Mix 1 mL plasma with 100 µL water, 100 µL 1 µg/mL IS, and 2 mL 100 mM pH 6.0 phosphate buffer, add to the SPE cartridge, wash with 4 mL 10 µM acetic acid, wash with 5 mL MeOH, elute with 6 mL dichloromethane:isopropanol 80:20 containing 2% ammonia water. Concentrate the eluate under a stream of nitrogen at 40◦ for 10 min, add 200 µL 0.02% DL-tartaric acid in MeOH, evaporate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL MeOH, evaporate to dryness again, reconstitute the residue with 50 µL MeOH:water 20:80, inject an aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Capcell pak C18 UG120 Mobile phase: Gradient. MeCN:0.075% heptafluorobutyric acid in water from 5:95 to 25:75 over 25 min. Detector: MS, JEOL AX-505 W, 1% glycerol in MeOH is added post-column at 0.3 mL/min, chamber temperature 60◦ , emission current 5 mA, collision gas xenon, FAB positive ion CHROMATOGRAM Limit of quantitation: 5 ng/mL KEY WORDS dog; pharmacokinetics; plasma; rat REFERENCE Washio, T.; Kohsaka, K.; Arisawa, H.; Masunaga, H. Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs, Arzneimittelforschung, 2003, 53, 26–33. SAMPLE Matrix: urine Sample preparation: Freeze-dry urine and reconstitute with 0.05% trifluoroacetic acid, inject an aliquot. HPLC VARIABLES Column: 250 × 4.6 Inertsil ODS-2 Mobile phase: Gradient. MeCN:0.05% trifluoroacetic acid from 0:100 to 20:80 over 40 min. Flow rate: 1 Detector: Radioactivity (14 C); Refractive Index CHROMATOGRAM Retention time: 29 OTHER SUBSTANCES Extracted: metabolites Cevimeline hydrochloride 131 REFERENCE Washio, T.; Kohsaka, K.; Arisawa, H.; Masunaga, H.; Nagatsuka, S.-i.; Satoh, Y. Pharmacokinetics and metabolism of radiolabelled SNI-2011, a novel muscarinic receptor agonist, in healthy volunteers, Arzneimittelforschung, 2003, 53, 80–86. 132 Chlorobutanol Chlorobutanol Molecular formula: C4 H7 Cl3 O Molecular weight: 177.46 CH3 H3C HO CCl3 CAS Registry No: 57-15-8 Merck Index: 13, 2148 SAMPLE Matrix: formulations Sample preparation: Dissolve ophthalmic ointment containing 20 mg chlorobutanol in 50 mL hexane, extract 3 times with 15 mL portions of MeOH:water 75:25. Combine the extracts, make up to 50 mL with MeOH:water 75:25, inject a 100 µL aliquot. HPLC VARIABLES Guard column: 10 × 2 47 µm Bondapak C18/Corasil Column: 250 × 4 10 µm ODS-10 (Bio-Rad) Mobile phase: MeOH:water 50:50 Flow rate: 1.8 Injection volume: 100 Detector: UV 210 CHROMATOGRAM Retention time: 6 KEY WORDS ophthalmic ointment REFERENCE Dunn, D.L.; Jones, W.J.; Dorsey, E.D. Analysis of chlorobutanol in ophthalmic ointments and aqueous solutions by reverse-phase high-performance liquid chromatography, J.Pharm.Sci., 1983, 72, 277–280. 133 Chloroprocaine Chloroprocaine Molecular formula: C13 H19 ClN2 O2 Molecular weight: 270.76 CH3 O O H2N N CH3 Cl CAS Registry No: 3858-89-7 (HCl) Merck Index: 13, 2177 SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 50 µL 50 µg/mL lidocaine in water and 200 µL 2 M NaOH, extract with diethyl ether. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute with 150 µL mobile phase, inject a 50 µL aliquot. HPLC VARIABLES Column: 150 × 3.9 µBondapak C18 Mobile phase: MeCN:50 mM pH 5.8 sodium phosphate buffer 30:70 Flow rate: 1 Injection volume: 50 Detector: UV 210 CHROMATOGRAM Retention time: 4 Internal standard: lidocaine (5) Limit of detection: 100 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS dog; pharmacokinetics; plasma REFERENCE Janicki, P.K.; Johnson, R.; Kambam, J.R. Rapid determination of chloroprocaine and its major metabolite, 2-chloroaminobenzoic acid, in plasma by high-performance liquid chromatography, J.Chromatogr.B, 1996, 675, 336–341. 134 Chorionic gonadotropin Chorionic gonadotropin CAS Registry No: 9002-61-3 (human), 9002-70-4 (horse) Merck Index: 13, 2237 SAMPLE Matrix: solutions Sample preparation: Inject a 20 µL aliquot of a 1 mg/mL solution. HPLC VARIABLES Column: 250 × 4.6 10 µm Vydac 214TP Mobile phase: Gradient. A:B from 30:70 to 0:100 over 40 min. A was 100 mM pH 6.8 sodium phosphate buffer. B was MeCN:100 mM pH 6.8 sodium phosphate buffer 50:50. Flow rate: 2 Injection volume: 20 Detector: UV 220 CHROMATOGRAM Retention time: 19 OTHER SUBSTANCES Simultaneous: luteinizing hormone (20), thyroid-stimulating hormone (16) REFERENCE Chlenov, M.A.; Kandyba, E.I.; Nagornaya, L.V.; Orlova, I.L.; Volgin, Y.V. High-performance liquid chromatography of human glycoprotein hormones, J.Chromatogr., 1993, 631, 261–267. SAMPLE Matrix: solutions HPLC VARIABLES Guard column: 40 × 4.1 SynChropak RSC (SynChrom) Column: 250 × 4.1 SynChropak RP-P (SynChrom) Mobile phase: Gradient. A:B 85:15 for 6 min, to 75:25 over 1 min, maintain at 75:25 for 5 min, return to initial conditions over 1 min, re-equilibrate for 13 min. A was water:ethylene glycol dimethyl ether:trifluoroacetic acid 93:7:0.012. B was isopropanol. Flow rate: 1 Detector: UV 220 CHROMATOGRAM Retention time: 11 REFERENCE Wilks, J.W.; Butler, S.S. Biologic activity of human chorionic gonadotropin following reversed-phase high-performance liquid chromatography, J.Chromatogr., 1984, 298, 123–130. ANNOTATED BIBLIOGRAPHY Pask-Hughes, R.A. Characterisation and purification of some glycoproteins by high-performance liquid chromatography, J.Chromatogr., 1987, 393, 273–284. Cilnidipine Cilnidipine Molecular formula: C27 H28 N2 O7 Molecular weight: 492.52 135 H H3C H3CO CAS Registry No: 132203-70-4 Merck Index: 13, 2297 N CH3 O O O O NO2 SAMPLE Matrix: blood Sample preparation: Condition a Bond Elut C18 SPE cartridge with 5 mL MeCN and 10 mL water. Mix 10 µL 10 µg/mL IS in MeCN with 1 mL plasma, add 2 mL MeCN, vortex for 30 s, centrifuge at 1670 g at 4◦ for 10 min, remove the supernatant, repeat the extraction with 1 mL MeCN. Add the supernatants to 6 mL water, vortex for 30 s, add to the SPE cartridge, wash with 2 mL MeCN:water 40:60, elute with 2 mL MeCN. Evaporate the eluate to dryness under reduced pressure at 40◦ , reconstitute the residue with 100 µL MeCN, inject a 10 µL aliquot. HPLC VARIABLES Column: 60 × 4.6 3 µm Hypersil ODS Mobile phase: MeCN:100 mM ammonium acetate 60:40 Flow rate: 1 Injection volume: 10 Detector: MS, Hewlett-Packard Model 5988A thermospray quadrupole, vaporizer stem 95◦ , ion source 275◦ , negative ion filament on mode, m/z 375 CHROMATOGRAM Retention time: 3.7 Internal standard: d3 -cilnidipine (m/z 378) (3.7) Limit of quantitation: 0.5 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS plasma; SPE REFERENCE Hatada, K.; Kimura, M.; Ono, I.; Ozaki, M. Determination of a new calcium antagonist and its main metabolite in plasma by thermospray liquid chromatography-mass spectrometry, J.Chromatogr., 1992, 583, 116–121. 136 Cimetropium bromide Cimetropium bromide Molecular formula: C21 H28 BrNO4 Molecular weight: 438.36 CAS Registry No: 51598-60-8 Merck Index: 13, 2301 N+ CH3 Br− O OH O O SAMPLE Matrix: microsomal incubations Sample preparation: Condition a Sep-Pak C18 SPE cartridge (unspecified). Mix 3.5 mL microsomal incubation with 1 mL 1% zinc sulfate solution, centrifuge at 3000 g for 15 min, add to the SPE cartridge, wash with 500 µL water, elute with 5 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 37◦ , reconstitute the residue with 100 µL MeOH, inject an aliquot. HPLC VARIABLES Column: 250 × 4.6 10 µm Spherisorb ODS-2 Mobile phase: MeCN:MeOH:water 20:20:55 or 10:5:55 containing 20 or 35 mM sodium heptanesulfonate and 100 mM triethylamine, pH 3.7 Flow rate: 1 Detector: MS, VG 70-SEQ, positive ion FAB, collision gas xenon at 8.5 keV CHROMATOGRAM Internal standard: glycopyrrolate or benzyl alcohol REFERENCE Kajbaf, M.; Jahanshahi, M.; Pattichis, K.; Gorrod, J.W.; Naylor, S. Rapid and efficient purification of cimetropium bromide and mifentidine drug metabolite mixtures derived from microsomal incubates for analysis by mass spectrometry, J.Chromatogr., 1992, 575, 75–85. Cisatracurium besylate 137 Cisatracurium besylate CH3O Molecular formula: C65 H82 N2 O18 S2 Molecular weight: 1243.50 CAS Registry No: 96946-42-8 Merck Index: 13, 872 (See also atracurium besylate in Volume 2) O N+ CH3O O O O CH3 2 OCH3 N+ OCH3 H3C SO3− CH3O OCH3 OCH3 OCH3 SAMPLE Matrix: blood, gastric contents Sample preparation: Immediately vortex 500 µL plasma, serum, whole blood, or gastric contents with 20 µL 50 mM sulfuric acid, store at -20◦ (if required), add 20 µL 10 µg/mL IS in MeOH, add 1 mL MeCN, vortex, let stand for 10 min, centrifuge at 2000 g for 5 min. Evaporate the supernatant to 100–150 µL under a stream of nitrogen, inject a 3 µL aliquot. HPLC VARIABLES Column: 150 × 1 3.5 µm X-Terra MS C18 Mobile phase: Gradient. A was 2 mM pH 3 ammonium formate buffer. B was MeCN:2 mM pH 3 ammonium formate buffer 90:10. A:B 85:15 for 2 min, to 57:43 over 8 min, re-equilibrate at initial conditions for 1 min. Flow rate: 0.05 Injection volume: 3 Detector: MS, PE Sciex API-100, electrospray, ion spray 5800 V, positive ion mode, nebulizer gas nitrogen, curtain gas nitrogen, collision gas argon, m/z 464.6, 358.4 CHROMATOGRAM Retention time: 9.1 Internal standard: ambenonium besylate (m/z 125.0, 411.6) Limit of detection: 5 ng/mL Limit of quantitation: 10 ng/mL OTHER SUBSTANCES Extracted: laudanosine (m/z 206.1, 358.4) (7.0), mivacurium (m/z 446.6, 402.5) (6.3), pancuronium (m/z 430.5, 472.5) (6.4), rocuronium (m/z 529.4, 358.4) (5.3), vecuronium (m/z 557.4, 398.4) (6.8) KEY WORDS plasma; serum; whole blood REFERENCE Sayer, H.; Quintela, O.; Marquet, P.; Dupuy, J.-L.; Gaulier, J.M.; Lachâtre, G. Identification and quantitation of six non-depolarizing neuromuscular blocking agents by LC-MS in biological fluids, J.Anal.Toxicol., 2004, 28, 105–110. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 5 µm Spherisorb ODS-2 Column temperature: 40 138 Cisatracurium besylate Mobile phase: Gradient. A was MeCN:buffer 50:50. B was MeOH. A:B 100:0 for 9 min, to 0:100 over 2 min, maintain at 0:100 for 4 min. (The buffer was 300 mM ammonium formate adjusted to pH 5.6 with formic acid.) Flow rate: 1 Injection volume: 20 Detector: UV 280; MS, Micromass Quattro II, triple quadrupole, ESI, source 150◦ , source capillary voltage 2500–3500 V, cone voltage 25–50 V or APCI, positive ion mode to negative ion mode at 11 min, source 150◦ , probe 550◦ , corona voltage 2500 V, cone voltage 35 V CHROMATOGRAM Retention time: 9.3 Limit of detection: 100 pg/mL (positive ion mode) OTHER SUBSTANCES Simultaneous: degradation products, propofol (negative ion mode) (13) REFERENCE Wang, P.; Zhang, H.; Stewart, J.T.; Bartlett, M.G. Simultaneous detection of cisatracurium, its degradation products and propofol using positive ion detection followed by negative ion detection in a single LC/MS run, J.Pharm.Biomed.Anal., 1998, 17, 547–554. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 5 µm Spherisorb ODS-2 Mobile phase: MeCN:buffer 50:50 (The buffer was 300 mM ammonium formate adjusted to pH 5.2 with formic acid.) Flow rate: 1 Injection volume: 20 Detector: UV 280; MS, Micromass Quattro II, EI positive ion mode or APCI, scan m/z 150–600, m/z 464 CHROMATOGRAM Retention time: 8.8 OTHER SUBSTANCES Simultaneous: degradation products, laudanosine (5, m/z 358), propofol (13, m/z 178) KEY WORDS stability-indicating REFERENCE Zhang, H.; Wang, P.; Bartlett, M.G.; Stewart, J.T. HPLC determination of cisatracurium besylate and propofol mixtures with LC-MS identification of degradation products, J.Pharm.Biomed.Anal., 1998, 16, 1241–1249. ANNOTATED BIBLIOGRAPHY Bryant, B.J.; James, C.D. Jr.; Cook, D.R.; Harrelson, J.C. High performance liquid chromatographic assay for cisatracurium and its metabolites in human urine, J.Liq.Chromatogr.Rel.Technol., 1997, 20, 2041–2051. Xu, Q.A.; Zhang, Y.-P.; Trissel, L.A.; Gilbert, D.L.; Martinez, J.F.; Fox, J.L. Stability of cisatracurium besylate in vials, syringes, and infusion admixtures, Am.J.Health-Syst.Pharm., 1998, 55, 1037–1041. Citric acid Citric acid Molecular formula: C6 H8 O7 Molecular weight: 192.12 139 COOH HO COOH COOH CAS Registry No: 77-92-9 Merck Index: 13, 2350 SAMPLE Matrix: blood Sample preparation: Condition a 30 × 10 column of DEAE-cellulose (Serva) with 10 vol of 100 mM pH 7.0 sodium perchlorate and 15 vol of water. Mix 6 mL plasma with 6 mL MeCN, centrifuge at 4000 g for 10 min, suspend the pellet in 6 mL MeCN:water 50:50, centrifuge at 4000 g for 10 min. Combine the supernatants, adjust the pH of a 10 mL aliquot to 7.0 with 100 mM NaOH, add to the DEAE-cellulose column, wash with 10 mL water, elute with 10 mL 100 mM perchloric acid. Freeze-dry the eluate overnight at 0◦ , reconstitute the residue with 500 µL mobile phase, centrifuge at 12000 g for 2 min, inject a 100 µL aliquot. HPLC VARIABLES Guard column: 50 × 4 micro-Guard-NH2 Column: 300 × 7.8 Aminex HPX-87 cation-exchange (Bio-Rad) Mobile phase: 6.5 mM sulfuric acid Flow rate: 0.5 Injection volume: 100 Detector: UV 210 CHROMATOGRAM Retention time: 5 OTHER SUBSTANCES Extracted: adipic acid (12), meglutol (8), 2-oxoglutaric acid (6.4), KEY WORDS plasma; SPE REFERENCE Lippe, G.; Trevisan, R.; Nosadini, R.; Fabris, R.; Deana, R. 3-Hydroxy-3-methylglutaric, adipic, and 2-oxoglutaric acids measured by HPLC in the plasma from diabetic patients, Clin.Biochem., 1987, 20, 275–279. SAMPLE Matrix: plants Sample preparation: Extract 20 g leaves with 250 mL water at 15 psi for 20 min, filter, repeat extraction and filtration twice more. Combine the extracts, concentrate to 50 mL under reduced pressure, add 200 mL EtOH, centrifuge, concentrate the supernatant to 25 mL under reduced pressure, inject a 20 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 µBondapak C18 Mobile phase: 8 mM sulfuric acid Flow rate: 1 Injection volume: 20 Detector: UV 210 140 Citric acid CHROMATOGRAM Retention time: 5.7 Limit of quantitation: 1.4 µg KEY WORDS leaves REFERENCE Jayaprakasha, G.K.; Sakariah, K.K. Determination of organic acids in leaves and rinds of Garcinia indica (Desr.) by LC, J.Pharm.Biomed.Anal., 2002, 28, 379–384. SAMPLE Matrix: solutions Sample preparation: Inject a 5 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm LC-18 Mobile phase: 0.5% Ammonium dihydrogen phosphate adjusted to pH 2.80 with 1 M phosphoric acid Flow rate: 1 Injection volume: 5 Detector: UV 214 CHROMATOGRAM Retention time: 5 Limit of detection: 30 ng OTHER SUBSTANCES Simultaneous: ascorbic acid (3.3, LOD 10 ng), malic acid (2.5, LOD 50 ng), oxalic acid (1, LOD 10 ng), succinic acid (5.7, 100 ng), tartaric acid (1.7, LOD 10 ng) REFERENCE Zhanguo, C.; Jiuru, L. Simultaneous and direct determination of oxalic acid, tartaric acid, malic acid, vitamin C, citric acid, and succinic acid in Fructus mume by reversed-phase high-performance liquid chromatography, J.Chromatogr.Sci., 2002, 40, 35–39. ANNOTATED BIBLIOGRAPHY Jayaprakasha, G.K.; Jena, B.S.; Sakariah, K.K. Improved liquid chromatographic method for determination of organic acids in leaves, pulp, fruits, and rinds of Garcinia, J.AOAC Int., 2003, 86, 1063–1068. [SPE] Nozal, M.J.; Bernal, J.L.; Diego, J.C.; Gómez, L.A.; Higes, M. HPLC determination of low molecular weight organic acids in honey with series-coupled ion-exclusion columns, J.Liq.Chromatogr.Rel. Technol., 2003, 26, 1231–1253. [oxalic acid; glucuronic acid; citric acid; galacturonic acid; propionic acid; pyruvic acid; malic acid; citramalic acid; quinic acid; gluconic acid; lactic acid; formic acid; glutaric acid; fumaric acid; succinic acid; butyric acid] Pérez-Ruiz, T.; Martı́nez-Lozano, C.; Tomás, V.; Martı́n, J. High-performance liquid chromatographic separation and quantification of citric, lactic, malic, oxalic and tartaric acids using a post-column photochemical reaction and chemiluminescence detection, J.Chromatogr.A, 2004, 1026, 57–64. Podgornik, A.; Barut, M.; Jaksa, S.; Jancar, J.; Strancar, A. Application of very short monolithic columns for separation of low and high molecular mass substances, J.Liq.Chromatogr.Rel.Technol., 2002, 25, 3099–3116. [citric acid; malic acid; ketoglutaric acid] Qiu, J.; Jin, X. Development and optimization of organic acid analysis in tobacco with ion chromatography and suppressed conductivity detection, J.Chromatogr.A, 2002, 950, 81–88. [citric acid; malonic acid; malic acid; succinic acid; lactic acid; formic acid; acetic acid; pyroglutamic acid] Citric acid 141 Sanarico, D.; Motta, S.; Bertolini, L.; Antonelli, A. HPLC determination of organic acids in traditional balsamic vinegar of Reggio Emilia, J.Liq.Chromatogr.Rel.Technol., 2003, 26, 2177–2187. [dextrose; fructose; citric acid; tartaric acid; gluconic acid; malic acid; succinic acid; lactic acid; acetic acid] Shui, G.; Leong, L.P. Separation and determination of organic acids and phenolic compounds in fruit juices and drinks by high-performance liquid chromatography, J.Chromatogr.A, 2002, 977, 89–96. [vitamin C; catechin; epicatechin; myricetin; quercetin; eugenol; kaempferol; tartaric acid; oxalic acid; malic acid; ascorbic acid; malonic acid; lactic acid; acetic acid; citric acid; fumaric acid; gallic acid; hydroxybenzoic acid; p-hydroxybenzoic acid; chlorogenic acid; caffeic acid; syringic acid; ferulic acid; benzoic acid; ellagic acid; salicylic acid; cinnamic acid] Skelly, N.E. Separation of aliphatic and aromatic acids, aromatic sulfonates, quaternary ammonium compounds, and chelating agents on a reversed-phase column without ion pairing, J.Chromatogr.Sci., 2003, 41, 22–25. [nonoxynol-9; citric acid; benzenesulfonic acid; phthalic acid; hydrobromic acid; nitrilotriacetic acid; oxalic acid; nitric acid; hydriodic acid; glycolic acid; formic acid; nitrous acid; cyanuric acid; lactic acid; acetic acid; NTA; benzalkonium; EDTA] Suárez-Luque, S.; Mato, I.; Huidobro, J.F.; Simal-Lozano, J. Solid-phase extraction procedure to remove organic acids from honey, J.Chromatogr.B, 2002, 770, 77–82. [malic acid; maleic acid; citric acid; succinic acid; fumaric acid] Suárez-Luque, S.; Mato, I.; Huidobro, J.F.; Simal-Lozano, J.; Sancho, M.T. Rapid determination of minority organic acids in honey by high-performance liquid chromatography, J.Chromatogr.A, 2002, 955, 207–214. [malic acid; maleic acid; citric acid; succinic acid; fumaric acid; SPE] Wei, M.-C.; Chang, C.-T.; Jen, J.-F. Determination of organic acids in fermentation products of milk with high performance liquid chromatography/on-lined micro-dialysis, Chromatographia, 2001, 54, 601–605. [citric acid; acetic acid; lactic acid; formic acid] Yamamoto, A.; Kodama, S.; Matsunaga, A.; Inoue, Y.; Aoyama, T.; Kumagai, Y. Characteristics of a column suitable for capacity gradient chromatography with a borate eluent, The Analyst, 2001, 126, 465–468. 142 Clioquinol Clioquinol Molecular formula: C9 H5 ClINO Molecular weight: 305.50 CAS Registry No: 130-26-7 Merck Index: 13, 5053 OH I N Cl SAMPLE Matrix: bile, blood, tissue, urine Sample preparation: Mix 200 µL plasma, bile, urine, or kidney with 20 µL IS in MeOH, 200 µL 200 mM disodium EDTA, and 800 µL water. Add 4 mL benzene:pyridine 90:10 (Caution! Benzene is a carcinogen!), shake vigorously for 1 min, centrifuge at 3500 g for 5 min. Evaporate the organic layer to dryness under reduced pressure, reconstitute the residue with 200 µL mobile phase, inject a 2–20 µL aliquot. This sample measures free clioquinol. To measure the glucuronide conjugate, wash the aqueous phase left over from the previous extraction twice with 6 mL portions of benzene. Discard the benzene. Add IS in MeOH, β-glucuronidase (final concentration 200 U/mL), and 150 µL 1 M pH 5 acetate buffer to the aqueous phase. Shake at 37◦ for 2 h. Add 4 mL benzene:pyridine 90:10, shake vigorously for 1 min, centrifuge at 3500 g for 5 min. Evaporate the organic layer to dryness under reduced pressure, reconstitute the residue with 200 µL mobile phase, inject a 2–20 µL aliquot. This sample measures clioquinol glucuronide. To measure the sulfate conjugate, wash the aqueous phase left over from the previous extraction twice with 6 mL portions of benzene. Discard the benzene. Add 6 M HCl to achieve an HCl concentration of 1 M, add IS, heat at 40◦ for 2 h, almost (sic) neutralize with 3 M NaOH, add 4 mL benzene:pyridine 90:10, shake vigorously for 1 min, centrifuge at 3500 g for 5 min. Evaporate the organic layer to dryness under reduced pressure, reconstitute the residue with 200 µL mobile phase, inject a 2–20 µL aliquot. This sample measures clioquinol sulfate. HPLC VARIABLES Column: 300 × 3 10 µm Iatrobeads 6cp-2010 (polystyrene-type porous polymer) in a Pyrex glass column Column temperature: 37 ± 0.5 Mobile phase: MeOH:n-hexane:100 mM citric acid 86:6:8 Flow rate: 0.75 Injection volume: 2–20 Detector: UV 254 CHROMATOGRAM Retention time: 9.6 Internal standard: 5,7-dichloro-8-hydroxyquinoline (6.8) Limit of quantitation: 600 ng/mL KEY WORDS kidney; plasma; rabbit REFERENCE Hayakawa, K.; Kitada, K.; Hamaki, M.; Miyazaki, M. High-performance liquid chromatographic determination of clioquinol and its conjugates in biological materials, J.Chromatogr., 1982, 229, 159–165. Clobetasol 17-propionate 143 Clobetasol 17-propionate O O Cl Molecular formula: C25 H32 ClFO5 Molecular weight: 466.98 CAS Registry No: 25122-46-7 Merck Index: 13, 2387 CH3 HO CH3 O CH3 F H CH3 H O SAMPLE Matrix: formulations Sample preparation: Condition a 3 mL 500 mg Megabond MF C18 SPE cartridge (Varian) with 3 mL MeOH and 3 mL water. Sonicate 1 g cosmetic with 10 mL MeOH or MeOH:dichloromethane 10:90 (depending on what appears visually to give the best solubility) at 40◦ for 10 min, centrifuge, collect the clear supernatant. Add 5 mL of the supernatant to the SPE cartridge, wash with 4 mL acetone:water 20:80, wash with 1 mL n-hexane, elute with 4 mL diethyl ether. Evaporate the eluate to dryness under reduced pressure, reconstitute the residue with 5 mL (or more) MeOH, inject a 10 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm endcapped Purospher RP-18 Column temperature: 25 Mobile phase: Isocratic.MeCN:water 60:40. Gradient. MeCN:water from 25:75 to 90:10 over 30 min, maintain at 90:10 for 10 min. Flow rate: 1 Injection volume: 10 Detector: UV 239 CHROMATOGRAM Retention time: k′ 3.41 (isocratic); 23.4 min (gradient) Limit of detection: 100 ng/mL OTHER SUBSTANCES Simultaneous: alclometasone dipropionate (isocratic k′ 2.55; gradient retention time (min) 21.0; LOD 0.3 µg/mL), amcinonide (isocratic k′ 3.18; gradient retention time (min) 22.6; LOD 0.1 µg/mL), betamethasone (isocratic k′ 0.18; gradient retention time (min) 11.8; LOD 0.1 µg/mL), betamethasone-17-acetate (isocratic k′ 0.73; gradient retention time (min) 15.4; LOD 0.3 µg/mL), betamethasone-17-benzoate (isocratic k′ 2.04; gradient retention time (min) 20.6; LOD 0.3 µg/mL), betamethasone-17-propionate-21-stearate (isocratic k′ >13; gradient retention time (min) >35; LOD 0.5 µg/mL), betamethasone17-propionate-21-butyrate (isocratic k′ 5.91; gradient retention time (min) 26.1; LOD 0.4 µg/mL), betamethasone-17-valerate-21-acetate (isocratic k′ 4.41; gradient retention time (min) 23.1; LOD 0.4 µg/mL), betamethasone-17-valerate (isocratic k′ 2.32; gradient retention time (min) 21.4; LOD 0.3 µg/mL), betamethasone-17,21-dipropionate (isocratic k′ 4.00; gradient retention time (min) 24.2; LOD 0.4 µg/mL), betamethasone17,21-diacetate (isocratic k′ 1.81; gradient retention time (min) 20.5; LOD 0.3 µg/mL), betamethasone-17,21-divalerate (isocratic k′ 10.82; gradient retention time (min) 28.0; LOD 0.4 µg/mL), betamethasone-21-acetate (isocratic k′ 0.77; gradient retention time (min) 15.6; LOD 0.3 µg/mL), betamethasone propionate (isocratic k′ 0.82; gradient retention time (min) 17.1; LOD 0.3 µg/mL), clobetasone butyrate (isocratic k′ 5.45; gradient retention time (min) 26.3; LOD 0.1 µg/mL), cortisone (isocratic k′ 0.18; gradient retention time (min) 11.1; LOD 0.6 µg/mL), cortisone acetate (isocratic k′ 0.73; gradient retention time (min) 15.2; LOD 0.6 µg/mL), dehydrocorticosterone (isocratic k′ 4.27; gradient 144 Clobetasol 17-propionate retention time (min) 22.3; LOD 0.5 µg/mL), deoxymethasone (isocratic k′ 0.64; gradient retention time (min) 14.2; LOD 0.2 µg/mL), dexamethasone (isocratic k′ 0.27; gradient retention time (min) 11.9; LOD 0.1 µg/mL), dexamethasone-21-acetate (isocratic k′ 0.91; gradient retention time (min) 16.1; LOD 0.2 µg/mL), dexamethasone isonicotinate (isocratic k′ 1.05; gradient retention time (min) 17.7; LOD 0.4 µg/mL), dexamethasone pivalate (isocratic k′ 3.45; gradient retention time (min) 24.1; LOD 0.3 µg/mL), dexamethasone valerate (isocratic k′ 3.00; gradient retention time (min) 21.6; LOD 0.3 µg/mL), diflucortolone valerate (isocratic k′ 4.73; gradient retention time (min) 23.3; LOD 0.3 µg/mL), fludrocortisone acetate (isocratic k′ 0.59; gradient retention time (min) 14.1; LOD 0.3 µg/mL), flumethasone pivalate (isocratic k′ 2.68; gradient retention time (min) 21.2; LOD 0.3 µg/mL), fluocinolone acetonide (isocratic k′ 0.91; gradient retention time (min) 13.4; LOD 0.3 µg/mL), fluocinonide (isocratic k′ 1.45; gradient retention time (min) 20.5; LOD 0.1 µg/mL), fluocortin butyl ester (isocratic k′ 5.59; gradient retention time (min) 24.6; LOD 0.3 µg/mL), fluocortolone caproate (isocratic k′ 6.59; gradient retention time (min) 25.1; LOD 0.3 µg/mL), fluocortolone pivalate (isocratic k′ 4.50; gradient retention time (min) 23.6; LOD 0.3 µg/mL), fluorometholone (isocratic k′ 0.59; gradient retention time (min) 14.4; LOD 0.1 µg/mL), 9-α-fluoroprednisolone (isocratic k′ 0.18; gradient retention time (min) 10.0; LOD 0.1 µg/mL), 9-α-fluoroprednisolone acetate (isocratic k′ 0.50; gradient retention time (min) 13.9; LOD 0.2 µg/mL), flurandrenolide (isocratic k′ 0.50; gradient retention time (min) 13.5; LOD 0.1 µg/mL), halcinonide (isocratic k′ 1.64; gradient retention time (min) 20.6; LOD 0.1 µg/mL), hydrocortisone (isocratic k′ 0.18; gradient retention time (min) 10.0; LOD 0.4 µg/mL), hydrocortisone17-butyrate (isocratic k′ 1.09; gradient retention time (min) 17.7; LOD 0.6 µg/mL), hydrocortisone-21-acetate (isocratic k′ 0.77; gradient retention time (min) 15.3; LOD 0.6 µg/mL), hydrocortisone pivalate (isocratic k′ 2.27; gradient retention time (min) 20.4; LOD 0.8 µg/mL), methylprednisolone (isocratic k′ 0.55; gradient retention time (min) 13.5; LOD 0.1 µg/mL), mometasone furoate (isocratic k′ 3.05; gradient retention time (min) 22.0; LOD 0.2 µg/mL), prednisolone-21-acetate (isocratic k′ 0.60; gradient retention time (min) 13.6; LOD 0.2 µg/mL), prednisolone acetonide (isocratic k′ 0.50; gradient retention time (min) 13.0; LOD 0.3 µg/mL), prednisolone pivalate (isocratic k′ 2.05; gradient retention time (min) 19.7; LOD 0.3 µg/mL), triamcinolone (isocratic k′ 0.14; gradient retention time (min) 7.2; LOD 0.1 µg/mL), triamcinolone acetonide (isocratic k′ 0.50; gradient retention time (min) 13.9; LOD 0.2 µg/mL), triamcinolone diacetate (isocratic k′ 0.45; gradient retention time (min) 13.9; LOD 0.3 µg/mL) KEY WORDS cosmetics; SPE REFERENCE Gagliardi, L.; De Orsi, D.; Del Giudice, M.R.; Gatta, F.; Porrà, R.; Chimenti, P.; Tonelli, D. Development of a tandem thin-layer chromatography-high-performance liquid chromatography method for the identification and determination of corticosteroids in cosmetic products, Anal.Chim.Acta, 2002, 457, 187–198. SAMPLE Matrix: formulations Sample preparation: Mix 1 g of a topical product, 5 mL 100 mM pH 4 citrate buffer saturated with NaCl, and 10 mL ethyl acetate, shake vigorously by hand to ensure that no large clumps stick to the tube, mix with the tube on its side on an oscillating shaker for 15 min. Remove the upper ethyl acetate layer and wash with citrate buffer as before. Dry the ethyl acetate over anhydrous sodium sulfate and evaporate to dryness. Dissolve the residue in a mixture of 10 mL heptane and 5 mL MeCN:water 90:10. Remove the upper heptane layer and extract it with 2 mL MeCN:water 90:10. Combine the MeCN/water layers and evaporate them to dryness, dissolve the residue in 300 µL MeOH, filter (0.45 µm nylon), inject a 5 µL aliquot. HPLC VARIABLES Guard column: 15 × 3.2 7 µm Brownlee NewGuard C18 Clobetasol 17-propionate 145 Column: 75 × 4.6 3.5 µm Symmetry C18 (Waters) Mobile phase: Gradient. MeCN:water 18:82 for 2 min, to 82:18 over 12 min, maintain at 82:18 for 3 min, re-equilibrate at initial conditions for 12 min. Flow rate: 1 Injection volume: 5 Detector: UV 240 CHROMATOGRAM Retention time: 11.06 Limit of detection: 0.001% OTHER SUBSTANCES Simultaneous: alclometasone 17,21-dipropionate (10.93), amcinonide (10.90), beclomethasone 17,21-dipropionate (11.90), betamethasone (6.52), betamethasone 21-acetate (8.47), betamethasone 17-benzoate (10.28), betamethasone 17,21-dipropionate (11.42), betamethasone 17-valerate (10.25), budesonide (8.55, 8.69 (epimers)), cortisone (5.62), cortisone 21-acetate (8.07), dexamethasone (6.57), dexamethasone 21-acetate (8.68), desonide (6.99), desoximetasone (7.60), desoxycorticosterone acetate (10.90), desoxycorticosterone pivalate (14.45), diflorasone 17,21-diacetate (9.81), fluocinolone acetonide (7.38), fluocinonide (9.79), flurandrenolide (7.36), fludrocortisone 21-acetate (7.77), fluorometholone (7.67), flumethasone 21-pivalate (11.20), flunisolide (7.14), fluprednisolone (5.46), fluticasone 17-propionate (11.19), halcinonide (10.72), halobetasol propionate (10.98), hydrocortisone (5.50), hydrocortisone 21-acetate (7.65), hydrocortisone 17-butyrate (8.66), hydrocortisone 21-cypionate (12.54), hydrocortisone 17-valerate (9.53), mometasone 17-furoate (11.24), methylprednisolone (6.31), methylprednisolone 21-acetate (8.34), meprednisone (6.55), prednisolone (5.37), prednisolone 21-acetate (7.47), prednisolone 21-tebuate (11.01), paramethasone 21-acetate (8.64), prednicarbate (10.72), prednisone (5.46), triamcinolone (4.15), triamcinolone acetonide (7.04), triamcinolone 16,21-diacetate (7.49), triamcinolone hexacetonide (13.12) KEY WORDS body wash, cream, gel, lotion, shampoo, spray REFERENCE Reepmeyer, J.C. Screening for corticosteroids in topical pharmaceuticals by HPLC with a scanning ultraviolet detector, J.Liq.Chromatogr.Rel.Technol., 2001, 24, 693–709. SAMPLE Matrix: solutions Sample preparation: The receptor solution for skin diffusion experiments consisted of 4% bovine serum albumin (BSA) in phosphate-buffered saline. Mix receptor solution with an equal volume of 2 µg/mL IS in MeCN, let stand for 3 h, centrifuge for 20 min, inject a 50 µL aliquot of the supernatant. HPLC VARIABLES Guard column: 4 × 3 C18 (ODS) (Phenomenex) Column: 150 × 4.6 5 µm Luna C18 (2) (Phenomenex) Mobile phase: MeCN:MeOH:100 mM pH 3 potassium dihydrogen phosphate 50:10:40 Flow rate: 1 Injection volume: 50 Detector: UV 239 CHROMATOGRAM Internal standard: propyl paraben 146 Clobetasol 17-propionate REFERENCE Mueller, B.; Anissimov, Y.G.; Roberts, M.S. Unexpected clobetasol propionate profile in human stratum corneum after topical application in vitro, Pharm.Res., 2003, 20, 1835–1837. ANNOTATED BIBLIOGRAPHY Marini, R.D.; Pantella, A.; Bimazubute, M.A.; Chiap, P.; Hubert, P.; Crommen, J. Optimisation and validation of a generic method for the LC assay of six corticosteroids and salicylic acid in dermopharmaceutical forms, Chromatographia, 2002, 55, 263–269. [salicylic acid; methyl paraben; propyl paraben; triamcinolone acetonide; hydrocortisone acetate; betamethasone valerate; clobetasol propionate; clobetasone butyrate; betamethasone dipropionate] Reepmeyer, J.C.; Revelle, L.K.; Vidavsky, I. Detection of clobetasol propionate as an undeclared steroid in zinc pyrithione formulations by high-performance liquid chromatography with rapid-scanning ultraviolet spectroscopy and mass spectrometry, J.Chromatogr.A, 1998, 828, 239–246. Tsai, J.-C.; Cheng, C.-L.; Tsai, Y.-F.; Sheu, H.-M.; Chou, C.-H. Evaluation of in vivo bioequivalence methodology for topical clobetasol 17-propionate based on pharmacodynamic modeling using Chinese skin, J.Pharm.Sci., 2004, 93, 207–217. [betamethasone dipropionate is internal standard] 147 Clopidogrel Clopidogrel Molecular formula: C16 H16 ClNO2 S Molecular weight: 321.83 O OCH3 N S Cl CAS Registry No: 113665-84-2 Merck Index: 13, 2421 SAMPLE Matrix: microsomal incubations Sample preparation: Add 200 µL microsomal incubation to 100 µL ice-cold MeCN, centrifuge, inject a 200 µL aliquot of the supernatant. HPLC VARIABLES Column: 150 × 4.6 5 µm Resolve C18 (Waters) Mobile phase: Gradient. A:B from 17:83 to 43:57 over 30 min, to 100:0 over 15 min. A was MeCN. B was MeCN:10 mM ammonium acetate 10:90. Flow rate: 1 Injection volume: 200 Detector: UV 220; MS, Micromass VG Fisons Platform single quadrupole electrospray, m/z 322.2 CHROMATOGRAM Retention time: 26 REFERENCE Clarke, T.A.; Waskell, L.A. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin, Drug Metab.Dispos., 2003, 31, 53–59. SAMPLE Matrix: formulations Sample preparation: Weigh out an amount of pulverized tablet containing 75 mg of clopidogrel, sonicate with 40 mL MeCN for 20 min, make up to 50 mL with MeCN, centrifuge at 2890 g for 5 min, dilute a 1 mL aliquot to 100 mL with water. Remove a 1 mL aliquot of this solution and dilute to 10 mL with 100 ng/mL IS in mobile phase, inject a 5 µL aliquot. HPLC VARIABLES Column: 250 × 2.1 5 µm BDS C8 Mobile phase: MeCN:10 mM pH 3.0 sodium phosphate buffer 65:35 Flow rate: 0.3 Injection volume: 5 Detector: UV 235 CHROMATOGRAM Retention time: 3.08 Internal standard: naproxen (6.28) Limit of detection: 120 ng/mL Limit of quantitation: 390 ng/mL KEY WORDS stability-indicating; tablets 148 Clopidogrel REFERENCE Mitakos, A.; Panderi, I. A validated LC method for the determination of clopidogrel in pharmaceutical preparations, J.Pharm.Biomed.Anal., 2002, 28, 431–438. ANNOTATED BIBLIOGRAPHY Reist, M.; Roy-De Vos, M.; Montseny, J.P.; Mayer, J.M.; Carrupt, P.-A.; Berger, Y.; Testa, B. Very slow chiral inversion of clopidogrel in rats: a pharmacokinetic and mechanistic investigation, Drug Metab.Dispos., 2000, 28, 1405–1410. [The metabolite clopidogrel acid is measured in rat plasma by chiral HPLC with derivatization.] 149 Clopidol Clopidol Molecular formula: C7 H7 Cl2 NO Molecular weight: 192.05 H3C N Cl CH3 Cl OH CAS Registry No: 2971-90-6 Merck Index: 13, 2422 SAMPLE Matrix: feed Sample preparation: Moisten 10 g pulverized feed with 5 mL water for 1 min, add 45 mL DMF:water 95:5, shake horizontally for 1 h. Remove a 10 mL aliquot of the supernatant and centrifuge at 3000 rpm for 5 min. Add 5 mL of the supernatant to a non-pretreated 6 mL 1 g Isolute A1-B SPE cartridge, discard the first 1 mL, collect the next 2 mL, inject a 10 µL aliquot. HPLC VARIABLES Guard column: 20 × 4.6 5 µm Supelguard LC-18 Column: 250 × 4.6 5 µm Supelcosil LC-18 Mobile phase: Gradient. MeCN:10 mM pH 4.6 acetate buffer from 0:100 to 30:70 over 10 min, to 80:20 over 5 min, maintain at 80:20 for 4 min, return to initial conditions over 1 min, re-equilibrate for 4 min. Flow rate: 1.2 Injection volume: 10 Detector: UV 265 for 12 min, UV 345 for rest of the run CHROMATOGRAM Retention time: 9 Limit of quantitation: 2 µg/g OTHER SUBSTANCES Extracted: nicarbazin (17.5) KEY WORDS SPE REFERENCE Dusi, G.; Faggionato, E.; Gamba, V.; Baiguera, A. Determination of nicarbazin and clopidol in poultry feeds by liquid chromatography, J.Chromatogr.A, 2000, 882, 79–84. SAMPLE Matrix: tissue Sample preparation: Fill a 400 × 20 glass tube fitted with a glass wool plug and a PTFE stopcock about a third full with MeOH, add 15 g neutral alumina (70–230 mesh), drain the solvent to the top of the column. Fill a 200 × 12 glass tube fitted with a glass wool plug and a PTFE stopcock with a slurry of Dowex 1-X8 anion-exchange resin (acetate form, 100–200 mesh) in MeOH to a bed height of 15 mm after settling, drain the solvent to the top of the bed. Place the alumina column on top of the Dowex column. Homogenize 10 g minced tissue, 20 g anhydrous sodium sulfate, and 50 mL MeCN at 10000 rpm for 2 min, add the supernatant to the alumina tube. Re-extract the residue with 50 mL MeCN, centrifuge, add to the columns, rinse the centrifuge tube with 20 mL MeOH, and add the rinse to the columns. Allow the liquid to flow through the columns at 3 mL/min. When the various solutions have passed through, discard the alumina column and elute the Dowex column with 20 mL 0.5% acetic acid in MeOH. Evaporate 150 Clopidol the eluate to dryness under reduced pressure at 60◦ , reconstitute the residue with 1 mL MeOH, inject an aliquot. HPLC VARIABLES Column: 150 × 4.6 Inertsil ODS Mobile phase: MeCN:water 20:80 Flow rate: 0.8 Injection volume: Detector: MS, Finnigan MAT TSQ-7000 quadrupole, atmospheric pressure chemical ionization, m/z 190, corona voltage 1.8 kV, corona current 5.0 µA, capillary temperature 220◦ , electron multiplier 1400 V, vaporizer temperature 400◦ CHROMATOGRAM Retention time: 3.47 Limit of detection: 5 ng/g Limit of quantitation: 10 ng/g KEY WORDS chicken; muscle; SPE REFERENCE Pang, G.-F.; Cao, Y.-Z.; Fan, C.-L.; Zhang, J.-J.; Li, X.-M.; Wang, C. Determination of clopidol residues in chicken tissues by high-performance liquid chromatography-mass spectrometry, J.Chromatogr.A, 2000, 882, 85–88. ANNOTATED BIBLIOGRAPHY Malisch, R. Multimethode zur Bestimmung der Ruckstande von Chemotherapeutica, Antiparasitica und Wachstumsforderern in Lebensmitt tierischer Herkunft. 3. Mitteilung: Bestimmung von Chloramphenicol und Meticlorpindol [Method for the simultaneous determination of residues of chemotherapeutic agents, antiparasitic agents and growth promoters in food of animal origin. 3. Determination of chloramphenicol and meticlorpindol], Z.Lebensm.-Unters.-Forsch., 1987, 184, 467–477. [clopidol; chloramphenicol] Mattern, E.M.; Kan, C.A.; van Gend, H.W. An automated HPLC determination of meticlorpindol in eggs with UV absorbance detection, using on-line dialysis and pre-concentration as sample clean-up; occurrence in and carry over to eggs, Z.Lebensm.-Unters.-Forsch., 1990, 190, 25–30. Pang, G.-F.; Cao, Y.-Z.; Fan, C.-L.; Zhang, J.-J.; Li, X.-M.; Jia, X.; Song, W.-B. Determination of clopidol residues in chicken tissues by liquid chromatography: Part I. Optimization of analytical conditions and comparison with AOAC gas chromatography method, J.AOAC Int., 2001, 84, 1337–1342. [SPE] Pang, G.-F.; Cao, Y.-Z.; Fan, C.-L.; Zhang, J.-J.; Li, X.-M.; Zhang, Z.-Y. Determination of clopidol residues in chicken tissues by liquid chromatography: Part II. Distribution and depletion of clopidol in chicken tissues, J.AOAC Int., 2001, 84, 1343–1346. [SPE] Pang, G.-F.; Cao, Y.-Z.; Fan, C.-L.; Zhang, J.-J.; Li, X.-M.; MacNeil, J.D. Determination of clopidol residues in chicken tissues by liquid chromatography : collaborative study, J.AOAC Int., 2003, 86, 685–693. 151 Cloricromen Cloricromen Molecular formula: C20 H26 ClNO5 Molecular weight: 395.88 CAS Registry No: 68206-94-0 Merck Index: 13, 2431 O H3C O Cl O O O N CH3 CH3 CH3 SAMPLE Matrix: aqueous humor Sample preparation: Vortex 100 µL aqueous humor with 100 µL 4.8 µg/mL IS in MeCN containing 0.6% perchloric acid for 1 min, centrifuge at 10000 g for 5 min, filter (0.2 µm) the supernatant, inject a 20 µL aliquot of the supernatant. HPLC VARIABLES Guard column: 7.5 × 4.6 5 µm Hypersil ODS C18 Column: 150 × 4.6 5 µm Hypersil ODS C18 Column temperature: 25 Mobile phase: Gradient. MeCN:buffer from 10:90 to 53:47 over 13 min, return to initial conditions over 5 min, re-equilibrate for 3 min. (The buffer was 1% triethylamine adjusted to pH 3.5 with phosphoric acid.) Flow rate: 1 Injection volume: 20 Detector: UV 318 CHROMATOGRAM Retention time: 11.25 Internal standard: timolol maleate (6.48) Limit of quantitation: 10 ng/mL OTHER SUBSTANCES Extracted: metabolite KEY WORDS pharmacokinetics; rabbit REFERENCE Maltese, A.; Bucolo, C. Simultaneous determination of cloricromene and its active metabolite in rabbit aqueous humor by high-performance liquid chromatography, J.Chromatogr.B, 2002, 767, 153–158. 152 Clorsulon Clorsulon Molecular formula: C8 H8 Cl3 N3 O4 S2 Molecular weight: 380.66 O Cl O S NH2 Cl Cl CAS Registry No: 60200-06-8 Merck Index: 13, 2435 S NH2 O NH2 O SAMPLE Matrix: milk Sample preparation: Matrix Solid-Phase Dispersion (MSPD) – Blend 500 µL milk with 2 g 40 µm Bondesil octadecylsilyl silica (Analytichem) in a mortar and pestle until a homogeneous mixture is obtained, place the mixture in the barrel of an 8 mL syringe fitted with a frit, compress the matrix using the syringe plunger, wash with 3 mL hexane; when all the hexane has eluted, place under vacuum for 5 s. Place this column on top of a 6 mL 1 g Supelclean LC-Florisil SPE cartridge (prewashed with diethyl ether), elute with three 3 mL portions of diethyl ether. Remove the C18 column and elute the Florisil with 2 mL ether. Combine all the ether eluates, evaporate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 1 mL mobile phase, vortex, filter, inject a 200 µL aliquot. Solid-Phase Extraction (SPE) – Condition a 6 mL 1 g Mega Bond Elut cyclohexyl SPE cartridge with two 3 mL portions of MeOH and two 3 mL portions of water. Vortex 6 g milk with 6 mL 200 mg/mL hydroxylamine hydrochloride in water, add 4 mL MeOH, shake on a rotating shaker at 180 rpm for 30 min, centrifuge at 8000 rpm for 30 min. Add 10 mL of the supernatant to the SPE cartridge, elute at not more than 2 drops/s, discard the effluent, wash with two 4 mL portions of water, elute with two 4 mL portions of MeCN. Evaporate the eluate to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 1 mL mobile phase, vortex for 5 s, filter (0.2 µm PTFE), inject a 50 µL aliquot. (SPE method found in Schenck,F.J.; Wagner,R.; Bargo,W. Determination of clorsulon residues in milk using a solid-phase extraction cleanup and liquid chromatographic determination. J.Liq.Chromatogr. 1993, 16, 513–520, other details are identical.) HPLC VARIABLES Column: 150 × 4.6 3 µm Econosphere ODS Mobile phase: MeCN:10 mM pH 7.0 potassium phosphate buffer 25:75 Flow rate: 1 Injection volume: 50–200 Detector: UV 265 CHROMATOGRAM Retention time: 11.5 Limit of detection: 5 ng/g (SPE, S/N = 4) Limit of quantitation: 50 ng/g (MSPD), 15 ng/g (SPE) KEY WORDS matrix solid-phase dispersion; SPE REFERENCE Schenck, F.J.; Barker, S.A.; Long, A.R. Matrix solid phase dispersion (MSPD) isolation and liquid chromatographic determination of clorsulon in milk, J.Liq.Chromatogr., 1991, 14, 2827–2834. Colistin 153 Colistin Molecular formula: C58 H105 N16 Na5 O28 S5 (colistin A sodium methanesulfonate) Molecular weight: 1749.82 CAS Registry No: 1066-17-7, 8068-28-8 (sodium methanesulfonate), 1264-72-8 (sulfate) Merck Index: 13, 2503 SAMPLE Matrix: blood Sample preparation: Condition a 100 mg C18 SPE cartridge (Baker) with 1 mL MeOH and 1 mL carbonate buffer. Mix 20 µL 5 µg/mL IS in water with 250 µL plasma, add 50 µL MeOH:10% trichloroacetic acid 50:50, vortex for 1 min, centrifuge at 1000 g at 4◦ for 10 min. Remove the supernatant, add 10 µL 1 M NaOH, vortex for 1 min, add 250 µL MeOH:10 mM HCl 50:50, vortex for 1 min, add to the SPE cartridge, wash with 1 mL carbonate buffer, add 30 µL 100 mM 9-fluorenylmethyl chloroformate in MeCN, let stand for 10 min, dry by drawing air through the cartridge, elute with 900 µL acetone. Add the eluate to 600 µL 200 mM boric acid solution, vortex for 2 min, inject a 50 µL aliquot. (Prepare the carbonate buffer by adjusting the pH of 1% sodium bicarbonate solution to 10 with 10% NaOH.) HPLC VARIABLES Column: 250 × 4.6 5 µm Ultrasphere C18 Mobile phase: MeCN:THF:water 87:4:13 Flow rate: 1 Injection volume: 50 Detector: F ex 260 em 315 CHROMATOGRAM Retention time: 21.8 (colistin B), 26.1 (colistin A) Internal standard: netilmicin sulfate (17.1) Limit of quantitation: 100 ng/mL OTHER SUBSTANCES Noninterfering: aztreonam, ceftazidime, ciprofloxacin, meropenem, piperacillin, ticarcillin, tobramycin KEY WORDS derivatization; plasma; SPE REFERENCE Li, J.; Milne, R.W.; Nation, R.L.; Turnidge, J.D.; Coulthard, K.; Johnson, D.W. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography, J.Chromatogr.B, 2001, 761, 167–175. SAMPLE Matrix: blood, sputum, urine Sample preparation: Plasma, sputum. Add 1 mL plasma or sonicated sputum to 1.1 mL water and 200 µL 3 M perchloric acid, vortex for 10 s, centrifuge at 3000 g at 4◦ for 25 min. Remove 1.4 mL of the supernatant and add it to 200 µL 1.5 M KOH, vortex, add 200 µL 100 mM HCl, vortex, add 100 µL 9% sodium carbonate, vortex, add 400 µL 20 mg/mL dansyl chloride, vortex, heat at 54◦ ; after 5 min, add 100 µL 150 mg/mL 154 Colistin proline, heat at 54◦ for another 55 min, vortex, heat at 54◦ for 1 h, cool. Remove a 2 mL aliquot and add it to 1 mL ethyl acetate, rotate for 10 min (Roto-torque Model 7637 setting #5), centrifuge at 3000 rpm for 10 min, inject an aliquot of the top layer. Urine. Dilute urine 0–20 fold with 100 mM pH 6.8 sodium phosphate buffer. Add 1 mL diluted urine to 1 mL water and 200 µL 3 M perchloric acid, vortex for 10 s. Remove 1.4 mL and add it to 200 µL 1.5 M KOH, vortex, add 200 µL 100 mM HCl, vortex, add 100 µL 9% sodium carbonate, vortex, add 400 µL 20 mg/mL dansyl chloride, vortex, heat at 57◦ ; after 5 min, add 100 µL 300 mg/mL proline, heat at 57◦ for another 55 min, vortex, heat at 57◦ for 1 h, cool. Remove a 2 mL aliquot and add it to 1 mL ethyl acetate, rotate for 10 min (Roto-torque Model 7637 setting #5), centrifuge at 3000 rpm for 2 min, inject an aliquot of the top layer. HPLC VARIABLES Guard column: 40 µm Vydac pellicular resin Column: 150 × 4.6 Eclipse XDB-C8 Mobile phase: Gradient. A:B from 40:60 to 80:20 over 15 min, maintain at 80:20 for 3 min. A was 0.1% trifluoroacetic acid in MeCN. B was 0.1% trifluoroacetic acid in water. Flow rate: 1 Injection volume: 50 Detector: F ex 350 em 500 CHROMATOGRAM Limit of quantitation: 5 µg/mL KEY WORDS derivatization; pharmacokinetics; plasma REFERENCE Reed, M.D.; Stern, R.C.; O’Riordan, M.A.; Blumer, J.L. The pharmacokinetics of colistin in patients with cystic fibrosis, J.Clin.Pharmacol., 2001, 41, 645–654. ANNOTATED BIBLIOGRAPHY Cabanes, A.; Cajal, Y.; Haro, I.; Garcia Anton, J.M.; Arboix, M.; Reig, F. Gentamicin determination in biological fluids by HPLC, using tobramycin as internal standard, J.Liq.Chromatogr., 1991, 14, 1989–2010. [gentamicin; tobramycin is internal standard; plasma; urine; rabbit; derivatization with o-phthalaldehyde; fluorescence detection; LOD 300 ng/mL; kanamycin; colistin] Gmur, D.J.; Bredl, C.R.; Steele, S.J.; Cai, S.; VanDevanter, D.R.; Nardella, P.A. Determination of polymyxin E1 in rat plasma by high-performance liquid chromatography, J.Chromatogr.B, 2003, 789, 365–372. [SPE; derivatization; fluorescence detection; LOQ 50 ng/mL; rat; dog] Le Brun, P.P.H.; de Graaf, A.I.; Vinks, A.A.T.M.M. High-performance liquid chromatographic method for the determination of colistin in serum, Ther.Drug Monit., 2000, 22, 589–593. [colistin; derivatization; polymyxin] 155 Cypermethrin Cypermethrin Molecular formula: C22 H19 Cl2 NO3 Molecular weight: 416.30 CH3 CH3 Cl Cl O O O CN CAS Registry No: 52315-07-8 Merck Index: 13, 2796 SAMPLE Matrix: blood, milk Sample preparation: Activate silica gel 60 in air at 130◦ for 5 h, hydrate by adding water equivalent to 10% of its weight, keep in a sealed container for 30 min before use. Prepare a chromatographic column with 4 g of this material and wash with 1 mL n-hexane:diethyl ether 90:10. Acidify 10 mL or 10 g whole blood or whole milk with 1.0 M HCl to approximately pH 4.0, add 50 mL MeCN, shake mechanically for 30 min, filter (Whatman paper No. 42 or 44). Add 25 mL MeCN to the residue, shake for 15 min, filter (Whatman paper No. 42 or 44). Combine the filtrates and add them to 15 mL n-hexane, shake for 1 min, repeat twice. Retain the acetonitrile phases. Add 45 mL MeCN to the hexane phases, shake for 1 min. Combine all the acetonitrile layers, evaporate to dryness under a stream of nitrogen at 50◦ . Dissolve the residue in 10 mL n-hexane. Add to the silica column, elute with 7 mL n-hexane:diethyl ether 90:10, evaporate the eluate to dryness at room temperature, dissolve the residue in 1.0 mL MeCN, filter (0.45 µm cellulose membrane), inject an aliquot of the filtrate. (All diethyl ether should be peroxide free.) HPLC VARIABLES Column: 250 × 4.6 Nucleosil 120-5 C18 Mobile phase: MeCN:water 80:20 Flow rate: 1 Injection volume: 20 Detector: UV 266 CHROMATOGRAM Retention time: 8.6, 8.9 Limit of detection: 1 ng/g OTHER SUBSTANCES Extracted: cyhalothrin (7.7), deltamethrin (9.8), flumethrin (3.8, 4.1) KEY WORDS cow; SPE; whole blood REFERENCE Bissacot, D.Z.; Vassilieff, I. HPLC determination of flumethrin, deltamethrin, cypermethrin, and cyhalothrin residues in the milk and blood of lactating dairy cows, J.Anal.Toxicol., 1997, 21, 397–402. Dalfopristin H N Molecular formula: C34 H50 N4 O9 S Molecular weight: 690.86 CAS Registry No: 112362-50-2 Merck Index: 13, 2831 CH3 O CH3 OH CH3 O CH3 CH3 CH3 N O H S O O N O O N O SAMPLE Matrix: blood Sample preparation: Condition a CN SPE cartridge (Lida-Interchim) with 1 mL MeOH, 1 mL water, and 1 mL buffer. Add 1 mL 3.8% sodium citrate and 2.5 mL 250 mM HCl to 10 mL whole blood. Shake gently by hand and centrifuge at 2000 g at 4◦ for 15 min. Add 1 mL buffer and 50 µL 100 µg/mL IS in MeOH to 1.35 mL acidified plasma. Vortex for a few seconds, centrifuge at 4000 g at 4◦ for 5 min. Add either supernatant to the SPE cartridge and dry the SPE cartridge with 3 mL air. Elute with 500 µL MeOH:water 70:30 containing 3.5 mM pentane sulfonic acid, inject an aliquot. (The buffer was a mixture of 85 mM pH 3.0 citric acid monohydrate containing 81 mM NaOH and 60 mM HCl.) HPLC VARIABLES Guard column: 10 µm µBondapak C18 Column: 125 × 4.6 5 µm Kromasil C18 (Higgins Analytical) Mobile phase: Gradient. MeCN:buffer 30:70 for 11 min, then 32:68 for 4 min (step gradient), to 40:60 over 0.6 min, maintain at 40:60 for 0.4 min, at 38:62 for 18 min (step gradient), at 80:20 for 2 min (step gradient), re-equilibrate at 30:70 for 9 min. (Prepare buffer by adding 800 µL 70% perchloric acid to 1 L water.) Flow rate: 0.5 for 11 min, 1 for 25 min, 0.5 for 9 min Injection volume: 500 Detector: UV 235 CHROMATOGRAM Retention time: 12.7 Internal standard: dimethylamino-3-propyl thiomethylene-5 virginiamycin S (31.0) Limit of quantitation: 25 pg/mL OTHER SUBSTANCES Extracted: metabolites, pristinamycin II A (24.1), quinupristin (22.1) KEY WORDS plasma; SPE; whole blood REFERENCE Le Liboux, A.; Pasquier, O.; Montay, G. Simultaneous high-performance liquid chromatographic determination of quinupristin, dalfopristin and their main metabolites in human plasma, J.Chromatogr.B, 1998, 708, 161–168. SAMPLE Matrix: formulations Sample preparation: Inject a 5–10 µL aliquot of the infusion solution. 156 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 Dalfopristin 157 HPLC VARIABLES Column: 125 × 4 5 µm LiChrospher-100 RP18 Column Temperature: 40 ± 1 Mobile phase: Gradient. A:B from 0:100 to 66:34 over 42.5 min, return to initial conditions over 1.5 min, re-equilibrate for 5 min. A was MeCN:buffer 65:35. B was MeCN:buffer 20:80. The buffer was 30 mM potassium dihydrogen phosphate adjusted to pH 2.9 with phosphoric acid. Flow rate: 1.1 Injection volume: 5–10 Detector: UV 254 CHROMATOGRAM Retention time: 8.5 Limit of quantitation: 0.05% OTHER SUBSTANCES Simultaneous: impurities, quinupristin (LOQ 0.12%) (23.9, 23.1, 27.0) KEY WORDS infusion; injection; stability-indicating REFERENCE Vasselle, B.; Gousset, G.; Bounine, J.-P. Development and validation of a high-performance liquid chromatographic stability-indicating method for the analysis of Synercid in quality control, stability and compatibility studies, J.Pharm.Biomed.Anal., 1999, 19, 641–657. ANNOTATED BIBLIOGRAPHY Abdel-Hamid, M.E.; Phillips, O.A. LC-MS/MS determination of Synercid injections, J.Pharm.Biomed. Anal., 2003, 32, 1167–1174. [pristinamycin; quinupristin; dalfopristin] 158 Dalteparin Dalteparin Molecular weight: 4000–6000 CAS Registry No: 9041-08-1 (Na salt) Merck Index: 13, 2832 SAMPLE Matrix: solutions Sample preparation: Prepare a 10 mg/mL solution in mobile phase, stir for 4 h, filter (0.2 µm) while centrifuging, inject a 200 µL aliquot. HPLC VARIABLES Guard column: Ohpak SB-G Column: 300 × 8 Shodex Ohpak SB-803 HQ Mobile phase: 100 mM pH 7 ammonium acetate buffer containing 0.05% sodium azide (Caution! Sodium azide is highly toxic and can form shock-sensitive and highly explosive azides when it comes in contact with heavy metals! Sodium azide should not be discharged to the plumbing system!) Flow rate: 0.8 Injection volume: 200 Detector: Refractive Index; Light Scattering Detector (miniDAWN, Wyatt Technology, Santa Barbara CA) (detector measures scattered light intensity (690 nm) at three angles (45◦ , 90◦ , 135◦ ) CHROMATOGRAM Retention time: 10 REFERENCE Knobloch, J.E.; Shaklee, P.N. Absolute molecular weight distribution of low-molecular-weight heparins by size-exclusion chromatography with multiangle laser light scattering detection, Anal.Biochem., 1997, 245, 231–241. Daptomycin 159 Daptomycin Molecular formula: C72 H101 N17 O26 Molecular weight: 1620.67 CAS Registry No: 103060-53-3 SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 mm long DuPont C8 Mobile phase: MeCN:0.5% pH 3.5 ammonium dihydrogen phosphate 38:62 Flow rate: 1.5 Detector: UV 214 CHROMATOGRAM Retention time: 25 OTHER SUBSTANCES Simultaneous: anhydrodaptomycin (35), β-asp daptomycin (23) REFERENCE Kirsch, L.E.; Molloy, R.M.; Debono, M.; Baker, P.; Farid, K.Z. Kinetics of the aspartyl transpeptidation of daptomycin, a novel lipopeptide antibiotic, Pharm.Res., 1989, 6, 387–393. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 5 µm Zorbax 300SB-C8 Mobile phase: MeCN:50 mM pH 5 phosphate buffer 29:71 Flow rate: 1 Injection volume: 10 Detector: UV 214 CHROMATOGRAM Retention time: <30 OTHER SUBSTANCES Simultaneous: degradation products REFERENCE Muangsiri, W.; Kirsch, L.E. The kinetics of the alkaline degradation of daptomycin, J.Pharm.Sci., 2001, 90, 1066–1075. SAMPLE Matrix: blood Sample preparation: Precipitate proteins before analysis (no other details) HPLC VARIABLES Guard column: Xterra RP18 (Waters) Column: Hypersil C8 Mobile phase: MeCN:0.5% ammonium phosphate 32.6:67.4 160 Daptomycin Flow rate: 1.5 Detector: UV 214 CHROMATOGRAM Retention time: 14–16 Internal standard: ethyl paraben Limit of quantitation: 7.5 µg/mL KEY WORDS plasma REFERENCE Sakoulas, G.; Eliopoulos, G.M.; Alder, J. Thauvin-Eliopoulos,C. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant staphylococcus aureus, Antimicrob.Agents Chemother., 2003, 47, 1714–1718. 161 Deferiprone Deferiprone CH3 N CH3 Molecular formula: C7 H9 NO2 Molecular weight: 139.15 CAS Registry No: 30652-11-0 Merck Index: 13, 2878 OH O SAMPLE Matrix: blood, urine Sample preparation: Add IS to a final concentration of 100 µM and perchloric acid to a final concentration of 500 mM to plasma or serum, centrifuge at 11 600 g for 10 min, inject a 50 µL aliquot. Centrifuge urine at 960 g for 20 min, filter (0.45 µm), dilute 10-fold with 50 mM pH 2.0 potassium phosphate buffer, inject a 50 µL aliquot. HPLC VARIABLES Guard column: LiChrosorb RP Select B Column: 5 µm LiChrosorb RP Select B Mobile phase: Gradient MeOH:50 mM pH 2.0 potassium phosphate buffer 27:73 containing 10 mM octanesulfonic acid for 16 min, to 70:30 over 2 min, maintain at 70:30 for 2 min, return to initial conditions over 2 min, re-equilibrate for 8 min. (Methanol wash not necessary for urine samples.) Flow rate: 1.6 Injection volume: 50 Detector: UV 280 CHROMATOGRAM Retention time: 8.2 Internal standard: 1-ethyl-2-methyl-3-hydroxypyrid-4-one (13.2) Limit of quantitation: 25 µM KEY WORDS plasma; serum REFERENCE Goddard, J.G.; Kontoghlorghes, G.J. Development of an HPLC method for measuring orally administered 1-substituted 2-alkyl-3-hydroxypyrid-4-one iron chelators in biological fluids, Clin.Chem., 1990, 36, 5–8. 162 Deflazacort Deflazacort O CH3 O Molecular formula: C25 H31 NO6 Molecular weight: 441.52 CAS Registry No: 14484-47-0 Merck Index: 13, 2881 O CH3 N HO CH3 H CH3 O H H O SAMPLE Matrix: blood, formulations Sample preparation: Mix 1 mL serum with 1 µg IS and 1 mL MeOH, vortex for 5 min, centrifuge at 5000 g for 5 min, inject a 20 µL aliquot of the supernatant. Weigh out amount of crushed tablets containing 10 mg deflazacort, add 7 mL mobile phase, sonicate for 10 min, make up to 10 mL with mobile phase, centrifuge. Mix an aliquot of the supernatant with an aliquot of 2 µg/mL IS in mobile phase, dilute with mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Spherisorb C18 Mobile phase: MeCN:MeOH:67 mM potassium dihydrogen phosphate 27:20:53, adjusted to pH 6.5 with 3 M NaOH Flow rate: 0.75 Injection volume: 20 Detector: UV 244 CHROMATOGRAM Retention time: 12.3 Internal standard: etodolac (5.5) Limit of detection: 4 ng/mL Limit of quantitation: 13.6 ng/mL KEY WORDS plasma; tablets REFERENCE Ozkan, Y.; Savaser, A.; Tas, C.; Uslu, B.; Ozkan, S.A. Drug dissolution studies and determination of deflazacort in pharmaceutical formulations and human serum samples by RP-HPLC, J.Liq.Chromatogr. Rel.Technol., 2003, 26, 2141–2156. SAMPLE Matrix: blood Sample preparation: Condition a 3 mL 200 mg Clean-Up C18 SPE cartridge (Worldwide Monitoring) with two 2 mL portions of MeOH and two 2 mL portions of water. Centrifuge plasma at 2000 rpm for 5 min prior to analysis. Mix 2 mL plasma with 20 µL 5 µg/mL IS in MeCN and 20 µL MeCN, add 1 mL water, vortex until homogeneous, add to the SPE cartridge, wash with two 2 mL portions of acetone:water 20:80, wash with 1 mL 50 mM pH 2.7 phosphate buffer, place under vacuum for 3 min, elute with two 2.5 mL portions of ethyl acetate. Evaporate the eluate to dryness under reduced pressure at 40◦ , reconstitute the residue with 75 µL mobile phase B, vortex, add 100 µL 50 mM pH 3 phosphate buffer, centrifuge at 5000 rpm for 5 min, inject a 145 µL aliquot. HPLC VARIABLES Column: 100 × 2 5 µm YMC Basic Deflazacort 163 Column temperature: 50 Mobile phase: Gradient. A:B 20:80 for 1 min, to 50:50 over 7 min, to 65:35 over 3 min, to 100:0 (step gradient), maintain at 100:0 for 1 min, return to initial conditions, reequilibrate for 4 min. A was MeCN:50 mM pH 3.0 potassium dihydrogen phosphate buffer 50:50. B was MeOH:50 mM pH 3.0 potassium dihydrogen phosphate buffer 20:80. Flow rate: 0.3 Injection volume: 145 Detector: UV 246 CHROMATOGRAM Retention time: 13.8 Internal standard: fludrocortisone acetate (12.4) OTHER SUBSTANCES Extracted: 21-hydroxydeflazacort (10) Simultaneous: cortisone, hydrocortisone KEY WORDS plasma; SPE; method validated for 21-hydroxydeflazacort rather than deflazacort REFERENCE Reynolds, D.L.; Burmaster, S.D.; Eichmeier, L.S. Quantitative determination of 21-hydroxy-deflazacort in human plasma using gradient semi-microbore liquid chromatography, Biomed.Chromatogr., 1994, 8, 230–235. ANNOTATED BIBLIOGRAPHY Ozkan, S.A.; Uslu, B. Rapid HPLC assay for lamivudine in pharmaceuticals and human serum, J.Liq.Chromatogr.Rel.Technol., 2002, 25, 1447–1456. [deflazacort is internal standard] 164 Desloratadine Desloratadine H N Molecular formula: C19 H19 ClN2 Molecular weight: 310.83 CAS Registry No: 100643-71-8 Merck Index: 13, 2939 N Cl SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma, 100 µL MeOH, 50 µL MeOH containing 20 ng/mL d3 -loratadine and 100 ng/mL d3 -desloratadine, and 50 µL 0.1% ammonium hydroxide, vortex for 30 s, add 5 mL hexane, vortex for 2 min, centrifuge at 1200 g for 5 min, freeze in dry ice acetone. Evaporate the organic layer to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL 0.1% trifluoroacetic acid in MeCN, vortex for 2 min, inject a 35 µL aliquot. HPLC VARIABLES Column: 50 × 3 5 µm Betasil silica (Keystone) Mobile phase: MeCN:water:trifluoroacetic acid 90:10:0.1 Flow rate: 0.5 Injection volume: 35 Detector: MS, PE Sciex API 3000 turbo ionspray, positive ion mode, ionspray needle 5 kV, turbo gas temperature 300◦ , auxiliary gas flow 8 L/min, m/z 311–259 CHROMATOGRAM Retention time: 2 Internal standard: d3 -loratadine (m/z 388–342), d3 -desloratadine (m/z 316–262) Limit of quantitation: 25 pg/mL OTHER SUBSTANCES Extracted: loratadine (LOQ 10 pg/mL, m/z 383–337) (1.2) Noninterfering: acetaminophen, albuterol, aspirin, caffeine, clonidine, fentanyl, ibuprofen, naltrexone, ritonavir KEY WORDS plasma REFERENCE Naidong, W.; Addison, T.; Schneider, T.; Jiang, X.; Halls, T.D.J. A sensitive LC/MS/MS method using silica column and aqueous-organic mobile phase for the analysis of loratadine and descarboethoxyloratadine in human plasma, J.Pharm.Biomed.Anal., 2003, 32, 609–617. SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 20 µL 7.5 µg/mL IS in MeOH:50 mM HCl 20:80 and 200 µL 1 M NaOH, vortex, add 3 mL toluene, shake for 20 min, centrifuge at 2000 g for 10 min, freeze, remove organic layer, repeat extraction. Combine the organic layers and evaporate to dryness under a stream of nitrogen at 50◦ , reconstitute the residue with 200 µL MeOH:50 mM HCl 20:80, vortex, mobile phase, inject a 100 µL aliquot. HPLC VARIABLES Column: 150 × 3.9 5 µm Symmetry C18 (Waters) Desloratadine 165 Column temperature: 35 Mobile phase: Gradient. MeCN:MeOH:50 mM pH 2.0 potassium phosphate buffer from 14:5:81 to 24:3:7.3 over 5.5 min, to 40:3:57 over 4.5 min, return to initial conditions over 4 min, re-equilibrate for 6 min. Flow rate: 1.2 Injection volume: 100 Detector: F ex 290 em 480 CHROMATOGRAM Retention time: 3.4 Internal standard: propranolol hydrochloride (8.6) Limit of detection: 0.25 ng/mL Limit of quantitation: 0.5 ng/mL OTHER SUBSTANCES Extracted: loratadine (11.2) KEY WORDS pharmacokinetics; plasma REFERENCE Yin, O.Q.P.; Shi, X.; Chow, M.S.S. Reliable and specific high-performance liquid chromatographic method for simultaneous determination of loratadine and its metabolite in human plasma, J.Chromatogr.B, 2003, 796, 165–172. ANNOTATED BIBLIOGRAPHY Rupérez, F.J.; Fernández, H.; Barbas, C. LC determination of loratadine and related impurities, J.Pharm. Biomed.Anal., 2002, 29, 35–41. Sutherland, F.C.W.; de Jager, A.D.; Badenhorst, D.; Scanes, T.; Hundt, H.K.L.; Swart, K.J.; Hundt, A.F.. Sensitive liquid chromatography-tandem mass spectrometry method for the determination of loratadine and its major active metabolite descarboethoxyloratadine in human plasma. J.Chromatogr.A 2001, 914, 37–43. 166 Desogestrel Desogestrel Molecular formula: C22 H30 O Molecular weight: 310.47 CAS Registry No: 54024-22-5 Merck Index: 13, 2943 H3C OH H2C H H H H H SAMPLE Matrix: blood Sample preparation: Add plasma to a Bakerbond C18 SPE cartridge, wash with 100 mM pH 4.2 ammonium acetate buffer, elute with MeOH. Evaporate the eluate to dryness under reduced pressure, reconstitute the residue with MeOH, inject an aliquot. HPLC VARIABLES Column: 300 × 3.9 µBondapak C18 Column temperature: 50 Mobile phase: Gradient. MeOH:100 mM pH 4.2 ammonium acetate from 10:90 to 90:10 over 30 min Flow rate: 1.7 Detector: Radioactivity (3 H); UV 254 CHROMATOGRAM Retention time: 32 OTHER SUBSTANCES Extracted: metabolites KEY WORDS dog; plasma; SPE REFERENCE Verhoeven, C.H.J.; Krebbers, S.F.M.; Wagenaars, G.N.; Vos, R.M.E. In vitro and in vivo metabolism of desogestrel in several species, Drug Metab.Dispos., 1998, 26, 927–936. Desoximetasone Desoximetasone O CH3 HO CH3 Molecular formula: C22 H29 FO4 Molecular weight: 376.46 CAS Registry No: 382-67-2 Merck Index: 13, 2947 167 F H OH CH3 H O SAMPLE Matrix: formulations Sample preparation: Mix 1 g of a topical product, 5 mL 100 mM pH 4 citrate buffer saturated with NaCl, and 10 mL ethyl acetate, shake vigorously by hand to ensure that no large clumps stick to the tube, mix with the tube on its side on an oscillating shaker for 15 min. Remove the upper ethyl acetate layer and wash with citrate buffer as before. Dry the ethyl acetate over anhydrous sodium sulfate and evaporate to dryness. Dissolve the residue in a mixture of 10 mL heptane and 5 mL MeCN:water 90:10. Remove the upper heptane layer and extract it with 2 mL MeCN:water 90:10. Combine the MeCN/water layers and evaporate them to dryness, dissolve the residue in 300 µL MeOH, filter (0.45 µm nylon), inject a 5 µL aliquot. HPLC VARIABLES Guard column: 15 × 3.2 7 µm Brownlee NewGuard C18 Column: 75 × 4.6 3.5 µm Symmetry C18 (Waters) Mobile phase: Gradient. MeCN:water 18:82 for 2 min, to 82:18 over 12 min, maintain at 82:18 for 3 min, re-equilibrate at initial conditions for 12 min. Flow rate: 1 Injection volume: 5 Detector: UV 240 CHROMATOGRAM Retention time: 7.60 Limit of detection: 0.001% OTHER SUBSTANCES Simultaneous: alclometasone 17,21-dipropionate (10.93), amcinonide (10.90), beclomethasone 17,21-dipropionate (11.90), betamethasone (6.52), betamethasone 21-acetate (8.47), betamethasone 17-benzoate (10.28), betamethasone 17,21-dipropionate (11.42), betamethasone 17-valerate (10.25), budesonide (8.55, 8.69 (epimers)), clobetasol 17propionate (11.06), cortisone (5.62), cortisone 21-acetate (8.07), dexamethasone (6.57), dexamethasone 21-acetate (8.68), desonide (6.99), desoximetasone (7.60), desoxycorticosterone acetate (10.90), desoxycorticosterone pivalate (14.45), diflorasone 17,21-diacetate (9.81), fluocinolone acetonide (7.38), fluocinonide (9.79), flurandrenolide (7.36), fludrocortisone 21-acetate (7.77), fluorometholone (7.67), flumethasone 21-pivalate (11.20), flunisolide (7.14), fluprednisolone (5.46), fluticasone 17-propionate (11.19), halcinonide (10.72), halobetasol propionate (10.98), hydrocortisone (5.50), hydrocortisone 21-acetate (7.65), hydrocortisone 17-butyrate (8.66), hydrocortisone 21-cypionate (12.54), hydrocortisone 17-valerate (9.53), mometasone 17-furoate (11.24), methylprednisolone (6.31), methylprednisolone 21-acetate (8.34), meprednisone (6.55), prednisolone (5.37), prednisolone 21-acetate (7.47), prednisolone 21-tebuate (11.01), paramethasone 21-acetate (8.64), prednicarbate (10.72), prednisone (5.46), triamcinolone (4.15), triamcinolone acetonide (7.04), triamcinolone 16,21-diacetate (7.49), triamcinolone hexacetonide (13.12) KEY WORDS body wash, cream, gel, lotion, shampoo, spray 168 Desoximetasone REFERENCE Reepmeyer, J.C. Screening for corticosteroids in topical pharmaceuticals by HPLC with a scanning ultraviolet detector, J.Liq.Chromatogr.Rel.Technol., 2001, 24, 693–709. SAMPLE Matrix: urine Sample preparation: Mix 5 mL urine with 100 ng IS and 400 µL 1 M pH 4.1 sodium acetate buffer, adjust pH to 5.0, add 600 µL β-glucuronidase solution (10800 U), heat at 65◦ for 3.5 h or at 37◦ overnight, cool, add 6 mL ethyl acetate, rotate for 10 min. Remove the organic layer and wash it with 3 mL 1 M NaOH containing 150 mM NaCl by rotating for 5 min, centrifuge at 1900 g for 30 s. Remove the organic layer and pass it through an anhydrous sodium sulfate drying column. Evaporate the eluate to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 30 µL MeOH, vortex, inject a 10 µL aliquot. HPLC VARIABLES Column: 75 × 4.6 3 µm DB-8 (Supelco) Column temperature: 25 Mobile phase: Gradient. MeOH:1% acetic acid from 0:100 to 100:0 over 15 min, maintain at 100:0 for 3 min. Flow rate: 1 Injection volume: 10 Detector: MS, Finnigan MAT LCQ Classic, APCI, source 450◦ , capillary 150◦ , source +5 kV for positive ions and – 5 kV for negative ions, collision gas helium, m/z 377 CHROMATOGRAM Retention time: 27.6 Internal standard: d4 -hydrocortisone (24.4) Limit of detection: 5 ng/mL OTHER SUBSTANCES Extracted: beclomethasone (m/z 409) (26.4), betamethasone (m/z 393) (25.9), deoxycortone (m/z 331) (28.1), 21-deoxydexamethasone (m/z 377) (26.8), dexamethasone (m/z 393) (25.9), dichlorisone (m/z 413) (26.4), fluclorolone acetonide (m/z 487) (27.8), fludrocortisone (m/z 381) (24.2), flumethasone (m/z 411) (25.4), fluocinolone acetonide (m/z 453) (26.4), fluocinonide (m/z 495) (28.5), fluocortolone (m/z 377) (26.8), fluorometholone (m/z 3.77) (26.6), fluprednisolone (m/z 379) (23.9), flurandrenolide (m/z 437) (26.8), hydrocortisone (m/z 363) (24.4), isoflupredone (m/z 379) (23.9), methylprednisolone (m/z 375) (26.1), prednisolone (m/z 361) (24.4), prednisone (m/z 359) (23.4), triamcinolone (m/z 395) (19), triamcinolone acetonide (m/z 435) (29.3) KEY WORDS horse REFERENCE Tang, P.W.; Law, W.C.; Wan, T.S.M. Analysis of corticosteroids in equine urine by liquid chromatographymass spectrometry, J.Chromatogr.B, 2001, 754, 229–244. Desoxycorticosterone Desoxycorticosterone O CH3 CH3 Molecular formula: C21 H30 O3 Molecular weight: 330.46 CAS Registry No: 64-85-7 Merck Index: 13, 2917 169 H OH H H O SAMPLE Matrix: blood Sample preparation: Vortex 500 µL serum with 5 mL diethyl ether for 3 min, cen- trifuge at 3500 rpm for 5 min. Evaporate the organic layer to dryness at 50◦ , reconstitute the residue with 50 µL MeOH:water 60:40, vortex for 1 min, sonicate for 1 min, centrifuge at 4000 rpm for 2 min, inject a 20 µL aliquot of the supernatant. HPLC VARIABLES Guard column: 50 × 2.1 unspecified Column: 150 × 6 Shimpack CLC-ODS Column temperature: 48 Mobile phase: MeOH:THF:water 26:18:56 Flow rate: 1 Injection volume: 20 Detector: UV 254 CHROMATOGRAM Retention time: 10 Limit of detection: 1 pmol OTHER SUBSTANCES Extracted: androstenedione (9.5), corticosterone (7), cortisone (5), 11-deoxycortisol (7.5), dexamethasone acetate (13), estradiol (F ex 285 em 310) (15), estriol (F ex 285 em 310) (5), estrone (F ex 285 em 310) (17), hydrocortisone (6), hydroxyprogesterone (14), prednisone acetate (8), progesterone (23), testosterone (11) KEY WORDS serum; SPE REFERENCE Wei, J.-q.; Wei, J.-l.; Zhou, X.-t.; Cheng, J.-p. Isocratic reversed phase high performance liquid chromatography determination of twelve natural corticosteroids in serum with on-line ultraviolet and fluorescence detection, Biomed.Chromatogr., 1990, 4, 161–164. SAMPLE Matrix: formulations Sample preparation: Mix 1 g of a topical product, 5 mL 100 mM pH 4 citrate buffer saturated with NaCl, and 10 mL ethyl acetate, shake vigorously by hand to ensure that no large clumps stick to the tube, mix with the tube on its side on an oscillating shaker for 15 min. Remove the upper ethyl acetate layer and wash with citrate buffer as before. Dry the ethyl acetate over anhydrous sodium sulfate and evaporate to dryness. Dissolve the residue in a mixture of 10 mL heptane and 5 mL MeCN:water 90:10. Remove the upper heptane layer and extract it with 2 mL MeCN:water 90:10. Combine the MeCN/water layers and evaporate them to dryness, dissolve the residue in 300 µL MeOH, filter (0.45 µm nylon), inject a 5 µL aliquot. 170 Desoxycorticosterone HPLC VARIABLES Guard column: 15 × 3.2 7 µm Brownlee NewGuard C18 Column: 75 × 4.6 3.5 µm Symmetry C18 (Waters) Mobile phase: Gradient. MeCN:water 18:82 for 2 min, to 82:18 over 12 min, maintain at 82:18 for 3 min, re-equilibrate at initial conditions for 12 min. Flow rate: 1 Injection volume: 5 Detector: UV 240 CHROMATOGRAM Retention time: 10.90 (acetate), 14.45 (pivalate) Limit of detection: 0.001% OTHER SUBSTANCES Simultaneous: alclometasone 17,21-dipropionate (10.93), amcinonide (10.90), beclomethasone 17,21-dipropionate (11.90), betamethasone (6.52), betamethasone 21-acetate (8.47), betamethasone 17-benzoate (10.28), betamethasone 17,21-dipropionate (11.42), betamethasone 17-valerate (10.25), budesonide (8.55, 8.69 (epimers)), clobetasol 17propionate (11.06), cortisone (5.62), cortisone 21-acetate (8.07), dexamethasone (6.57), dexamethasone 21-acetate (8.68), desonide (6.99), desoximetasone (7.60), diflorasone 17,21-diacetate (9.81), fluocinolone acetonide (7.38), fluocinonide (9.79), flurandrenolide (7.36), fludrocortisone 21-acetate (7.77), fluorometholone (7.67), flumethasone 21-pivalate (11.20), flunisolide (7.14), fluprednisolone (5.46), fluticasone 17-propionate (11.19), halcinonide (10.72), halobetasol propionate (10.98), hydrocortisone (5.50), hydrocortisone 21-acetate (7.65), hydrocortisone 17-butyrate (8.66), hydrocortisone 21cypionate (12.54), hydrocortisone 17-valerate (9.53), mometasone 17-furoate (11.24), methylprednisolone (6.31), methylprednisolone 21-acetate (8.34), meprednisone (6.55), prednisolone (5.37), prednisolone 21-acetate (7.47), prednisolone 21-tebuate (11.01), paramethasone 21-acetate (8.64), prednicarbate (10.72), prednisone (5.46), triamcinolone (4.15), triamcinolone acetonide (7.04), triamcinolone 16,21-diacetate (7.49), triamcinolone hexacetonide (13.12) KEY WORDS body wash, cream, gel, lotion, shampoo, spray REFERENCE Reepmeyer, J.C. Screening for corticosteroids in topical pharmaceuticals by HPLC with a scanning ultraviolet detector, J.Liq.Chromatogr.Rel.Technol., 2001, 24, 693–709. SAMPLE Matrix: cell cultures Sample preparation: Extract cell medium twice with two volumes of ethyl acetate for 5 min. Evaporate the combined extracts to dryness under a stream of nitrogen, reconstitute the residue with 100 µL MeCN, inject an aliquot. HPLC VARIABLES Guard column: 15 × 3.2 Newguard 7 µm RP-C18 Column: 220 × 4.6 5 µm RP-C18 Spheri (Kontron) Column temperature: 30 Mobile phase: Gradient. MeCN:water 30:70 for 12 min, to 70:30 over 33 min. Flow rate: 1.2 Injection volume: 20 Detector: UV 254 CHROMATOGRAM Retention time: 16.9 Limit of quantitation: 50 ng Desoxycorticosterone 171 OTHER SUBSTANCES Extracted: corticosterone (8.3), 18-hydroxydeoxycorticosterone (6.9), progesterone (29.6) REFERENCE Matilla, M.J.; Jimenez, M.M.; Montiel, M. Deoxycorticosterone, 18-OH-deoxycorticosterone and corticosterone determination by high performance liquid chromatography in monolayer adrenal cell culture, Biochem.Int., 1991, 24, 951–957. ANNOTATED BIBLIOGRAPHY Sheikh, S.U.; Touchstone, J. HPLC of steroids in non-aqueous mobile phase at subambient temperature, J.Liq.Chromatogr., 1987, 10, 2489–2496. [column temperature −50◦ ; desoxycorticosterone; estrone; estradiol; cortisone; hydrocortisone] Smith, E. Liquid chromatographic determination of desoxycorticosterone acetate in oil injections, J.Assoc.Off.Anal.Chem., 1979, 62, 812–817. Wei, J.Q.; Wei, J.L.; Lucarelli, C.; Zhou, X.T.; Wang, D.Q.; Dai, W.J.; Li, S.; Li, S.M.; Liu, R.T. Serum steroid hormonal profiles by reversed-phase liquid chromatography in patients with 17-hydroxylase deficiency and in an affected family, Clin.Chem., 1992, 38, 76–82. [cortisone; hydrocortisone; deoxycortisol; androstenedione; testosterone; progesterone; hydroxyprogesterone; desoxycorticosterone] 172 Dexrazoxane Dexrazoxane Molecular formula: C11 H16 N4 O4 Molecular weight: 268.27 CAS Registry No: 24584-09-6, 21416-87-5 (racemic) Merck Index: 13, 8208 O H N O N N N O CH3 H O SAMPLE Matrix: blood Sample preparation: Condition a Sep-Pak Plus C18 SPE cartridge with MeCN and water. Acidify 1 mL plasma with 50 µL 43% phosphoric acid. Add 70 µL 6 M HCl to 260 µL acidified plasma, centrifuge, remove the supernatant, wash the pellet three times with 250 µL portions of 10 mM HCl. Combine the supernatant and the washings and adjust the pH to 6.0 with 80 µL 5 M NaOH, add to the SPE cartridge, wash with 5 mL water, wash with 1 mL hexane, elute with 7.5 mL MeCN. Evaporate the eluate to dryness under a stream of argon, reconstitute the residue with 130 µL mobile phase EtOH:MeOH:isopropanol 90:5:5, inject a 50 µL aliquot. HPLC VARIABLES Guard column: 3.2 × 1.5 NewGuard silica (Brownlee) Column: 250 × 4.6 10 µm Chiralcel OD Mobile phase: EtOH:MeOH:isopropanol:n-hexane 76.5:4.25:4.25:15 Flow rate: 0.5 Injection volume: 50 Detector: UV 207 CHROMATOGRAM Retention time: 18.5 Limit of quantitation: 2 µM OTHER SUBSTANCES Extracted: levrazoxane (16.5) KEY WORDS chiral; plasma; pharmacokinetics; rat; SPE REFERENCE Hasinoff, B.B.; Aoyama, R.G. Stereoselective metabolism of dexrazoxane (ICRF-187) and levrazoxane (ICRF-186), Chirality, 1999, 11, 286–290. SAMPLE Matrix: blood, urine Sample preparation: Plasma. Mix 1 mL plasma with 25 µg/mL IS, 100 µL water, and 2 mL MeCN, shake for 10 min, centrifuge at 2500 g for 10 min. Remove the supernatant, add 20 mL chloroform:2-methyl-2-propanol 90:10 (Caution! Chloroform is a carcinogen!), shake for 30 min, centrifuge at 2500 g for 10 min. Remove a 15 mL portion of the organic layer and evaporate it to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 500 µL MeOH:100 mM HCl 20:80, inject a 50 µL aliquot. Urine. Mix 1 mL urine with 250 µg/mL IS, make up to 100 mL with water. Remove a 1 mL portion of this mixture, add 20 mL chloroform:2-methyl-2-propanol 90:10, shake for 30 min, centrifuge at 2500 g for 10 min. Remove 15 mL of the organic layer and evaporate it to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 500 µL MeOH:100 mM HCl 20:80, inject a 50 µL aliquot. Dexrazoxane 173 HPLC VARIABLES Guard column: 10 × 3 reverse phase (Chrompack) Column: 300 × 4.6 10 µm µBondapak Phenyl Mobile phase: MeOH:10 mM pH 4.7 potassium phosphate buffer 20:80 Flow rate: 1 Injection volume: 50 Detector: UV 208 CHROMATOGRAM Retention time: 6.2 Internal standard: 8-chlorotheophylline (16) Limit of quantitation: 100 ng/mL (plasma), 10 µg/mL (urine) OTHER SUBSTANCES Simultaneous: acetaminophen, 5-bromouracil, caffeine, 5-chlorouracil, 5-fluorocytosine, 5-fluorouracil, phenylethyleneglycol, theophylline Noninterfering: codeine, cyclophosphamide, doxorubicin, indomethacin, methylparaben, phenacetin, phenazone, prednisone, triamcinolone acetate, triamcinolone KEY WORDS plasma; pharmacokinetics REFERENCE Rosing, H.; van Gijn, R.; ten Bokkel Huinink, W.W.; Beijnen, J.H. High performance liquid chromatographic analysis of the cardioprotective agent dexrazoxane in human plasma and urine, J.Liq.Chromatogr.Rel.Technol., 1997, 20, 583–601. ANNOTATED BIBLIOGRAPHY Hasinoff, B.B.; Aoyama, R.G. Relative plasma levels of the cardioprotective drug dexrazoxane and its two active ring-opened metabolites in the rat, Drug Metab.Dispos., 1999, 27, 265–268. 174 Dextran Dextran CAS Registry No: 9004-54-0 Merck Index: 13, 2965 SAMPLE Matrix: blood Sample preparation: Dilute plasma 4 times with 100 mM pH 12 sodium glycinate buffer, filter (Amicon Centrifree) while centrifuging. Lyophilize the ultrafiltrate and reconstitute the residue with 125 µL pH 7 ammonium phosphate buffer, inject a 100 µL aliquot. HPLC VARIABLES Column: Tosohaas 2000SWXL + Tosohaas 2500PWXL in series Mobile phase: 100 mM pH 6 sodium acetate buffer Flow rate: 0.8 Injection volume: 100 Detector: Radioactivity (3 H) CHROMATOGRAM Retention time: 18 KEY WORDS plasma; rat REFERENCE Hartman, N.R.; Johns, D.G.; Mitsuya, H. Pharmacokinetic analysis of dextran sulfate in rats as pertains to its clinical usefulness for therapy of HIV infection, AIDS Res.Hum.Retroviruses, 1990, 6, 805–812. SAMPLE Matrix: blood Sample preparation: Filter serum (0.45 µm), inject an aliquot. HPLC VARIABLES Guard column: 48 × 4.6 (ES Industries) Column: 300 × 7.8 5 µm Chromega diol size-exclusion (ES Industries) Column temperature: 40 Mobile phase: Buffer containing 25 mM potassium dihydrogen phosphate, 25 mM dipotassium hydrogen phosphate, and 50 mM potassium chloride, pH ca. 6.8 Flow rate: 1 Injection volume: 10 Detector: UV 525 following post-column reaction with an 18.5 µg/mL solution of 1,9dimethylmethylene blue in water pumped at 0.5 mL/min. The column effluent mixed with the dye solution in a 3.1 µL mixing tee and flowed through a 28.8 cm length of 0.254 mm ID tubing to the detector. CHROMATOGRAM Retention time: 7 Limit of detection: 300 ng/mL Limit of quantitation: 8 µg/mL KEY WORDS post-column reaction; rat; serum Dextran 175 REFERENCE Maderich, A.B.; Sugita, E.T. Size-exclusion chromatographic determination of dextran sulfate in rat serum, J.Chromatogr., 1993, 620, 137–142. ANNOTATED BIBLIOGRAPHY Hemmelder, M.H.; de Jong, P.E.; De Zeeuw, D. A comparison of analytic procedures for measurement of fractional dextran clearances, J.Lab.Clin.Med., 1998, 132, 390–403. [RI detection; detection by reaction of fractions with anthrone reagent] 176 Diacerein Diacerein O COOH Molecular formula: C19 H12 O8 Molecular weight: 368.29 CAS Registry No: 13739-02-1 Merck Index: 13, 2979 CH3 O O O O CH3 O SAMPLE Matrix: blood, urine Sample preparation: Mix 1 mL plasma or urine with 1 mL MeCN, centrifuge, inject a 40 µL aliquot of the supernatant. HPLC VARIABLES Column: Nucleosil C18 Mobile phase: MeCN:pH 2.2 McIlvaine buffer 47:53 Flow rate: 1 Injection volume: 40 Detector: UV 432 CHROMATOGRAM Limit of detection: 100 ng/mL KEY WORDS determined as rhein, the active metabolite; pharmacokinetics; plasma REFERENCE Debord, P.; Louchahi, K.; Tod, M.; Cournot, A.; Perret, G.; Petitjean, O. Influence of renal function on the pharmacokinetics of diacerein after a single oral dose, Eur.J.Drug Metab.Pharmacokinet., 1994, 19, 13–19. Dichloroacetic acid 177 Dichloroacetic acid Molecular formula: C2 H2 Cl2 O2 Cl2CHCOOH Molecular weight: 128.94 CAS Registry No: 79-43-6 Merck Index: 13, 3075 SAMPLE Matrix: blood Sample preparation: Inject 15–25 µL serum directly. HPLC VARIABLES Column: Asahipak GS-320 gel permeation Mobile phase: MeCN:10 mM pH 4.0 ammonium acetate buffer 10:90 Flow rate: 2 Injection volume: 15–25 Detector: UV 220 CHROMATOGRAM Retention time: 12 Limit of detection: 5 µg/mL KEY WORDS pharmacokinetics; serum REFERENCE Sakakihara, Y.; Nakamura, G.; Tokoeda, Y.; Abe, T.; Kamoshita, S. A rapid microassay for dichloroacetate in serum by gel-permeation chromatography, Eur.J.Clin.Chem.Clin.Biochem., 1994, 32, 79–83. 178 Dichlorophen Dichlorophen OH OH Cl Cl Molecular formula: C13 H10 Cl2 O2 Molecular weight: 269.13 CAS Registry No: 97-23-4 Merck Index: 13, 3096 SAMPLE Matrix: solutions Sample preparation: Inject a 10–40 µL aliquot of a 500 µg/mL solution in MeOH. HPLC VARIABLES Column: Zorbax C8 Column temperature: 31 Mobile phase: Gradient. A:B from 0:100 to 100:0 over 30 min. A was MeCN:water:phosphoric acid 89.9:10:0.1. B was 0.1% phosphoric acid. Flow rate: 2 Injection volume: 10–40 Detector: UV 230 CHROMATOGRAM Retention time: 21.9 OTHER SUBSTANCES Simultaneous: acetaminophen (8.2), acetophenetidine (14.6), aminophylline (8.8), amobarbital (15.5), antipyrine (12.9), aprobarbital (12.3), aspirin (13.6), barbital (9.4), benzoic acid (13.2), butabarbital (13.1), butethal (14.2), caffeine (10.2), chloramphenicol (14.4), chlorothiazide (9.1), chlorpropamide (17.7), colchicine (15.3), cortisone (15.0), coumarin (15.1), cyclothiazide (18.6), cyheptamide (17.8), danazol (19.3), danthron (22.3), dapsone (13.1), diethylstilbestrol (21.5), dronabinol (26.3), estradiol (19.4), estriol, 15.0), estrone (20.3), ethosuximide (9.8), eugenol (18.8), fenoprofen (19.2), fluorouracil, 3.0), fluoxymesterone (15.0), furosemide (17.0), gitoxigenin (16.0), glutethimide (16.3), guaiacol (11.4), hexobarbital (15.1), hippuric acid (9.6), hydrocortisone (14.4), hydroquinone (3.3), ibuprofen (22.4), indomethacin (22.00, isocarbostyril (11.8), mefenamic acid (23.7), methocarbamol (12.6), methyl salicylate (19.3), methyldopa (6.4), methylparaben (12.8), methyltestosterone (19.6), niacin (3.9), nitrofurantoin (11.2), normethsuximide (14.5), oxyphenbutazone (19.8), paraxanthine (8.7), pentobarbital (15.2), phenylbutazone (23.4), piperonyl butoxide (26.1), prednisolone (15.2), prednisone (15.5), primidone (11.3), probenecid (20.5), progesterone (21.8), propylparaben (18.3), pyrithydione (11.2), pyrocatechol (l4.6), reserpine (22.5), resorcinol (4.3), saccharin (8.0), salicylamide (11.0), salicylic acid (15.0), secobarbital (15.7), stanozolol (19.2), sulfacetamide (8.4), sulfadimethoxine (7.7), sulfaethidole (13.4), sulfamerazine (10.1), sulfamethazine (7.0), sulfamethizole (11.5), sulfamethoxazole (13.6), sulfanilamide (4.0), sulfapyridine (9.6), sulfisoxazole (14.2), sulindac (19.1), testosterone acetate (20.5), testosterone 17 β-cypionate (25.2), testosterone enanthate (25.0), testosterone propionate, 24.1), theobromine (8.3), thiobarbituric acid (2.4), thiosalicylic acid (15.4), tolbutamide, 18.8), tolmetin (18.7), triamcinolone (13.8), triamcinolone acetonide (17.8), warfarin (20.0) REFERENCE Hill, D.W.; Langner, K.J. HPLC photodiode array UV detection for toxicological drug analysis, J.Liq. Chromatogr., 1987, 10, 377–409. 179 Diclazuril Diclazuril Molecular formula: C17 H9 Cl3 N4 O2 Molecular weight: 407.64 CAS Registry No: 101831-37-2 Merck Index: 13, 3106 CN Cl O H Cl Cl N N N O SAMPLE Matrix: blood Sample preparation: Condition a Mega Bond Elut C18 SPE cartridge with 2 mL MeOH and 2 mL 100 mM pH 6.0 phosphate buffer. Mix 20 µL 100 µg/mL IS in DMF:water 50:50 with ? mL plasma, add 2 mL 100 mM pH 6.0 phosphate buffer, mix, adjust pH to 6.0, add to the SPE cartridge, allow to pass through taking at least 2 min, wash with 2 mL 100 mM pH 6.0 phosphate buffer, wash with 2 mL 1 M acetic acid, wash with 2 mL hexane (allow cartridge to dry for 5–10 min after each wash). Elute with 4 mL MeOH:conc. HCl 95:5. Evaporate the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 100 µL DMF, vortex, sonicate, add 100 µL water, vortex, sonicate, inject a 20 µL aliquot. HPLC VARIABLES Guard column: Alltech C18 Column: 150 × 4.6 5 µm Ultrasphere ODS Mobile phase: MeCN:MeOH:buffer 20:43.2:36.8 (The buffer was 0.5% ammonium acetate containing 10 mM tetrabutylammonium hydrogen sulfate.) Flow rate: 1 Injection volume: 20 Detector: UV 280 CHROMATOGRAM Retention time: 13 Internal standard: R062646 (diclazuril with methyl α to cyano group, Janssen) (14.5) Limit of detection: 10 ng/mL KEY WORDS horse; pharmacokinetics; plasma; SPE; use silanized glassware REFERENCE Dirikolu, L.; Lehner, F.; Nattrass, C.; Bentz, B.G.; Woods, W.E.; Carter, W.G.; Karpiesiuk, W.; Jacobs, J.; Boyles, J.; Harkins, J.D.; Granstrom, D.E.; Tobin, T. Diclazuril in the horse: its identification and detection and preliminary pharmacokinetics, J.Vet.Pharmacol.Ther., 1999, 22, 374–379. SAMPLE Matrix: feed Sample preparation: Mix 50 g ground feed with 1 mL 50 µg/mL IS in DMF and 200 mL acidified MeOH, stir overnight. Remove 20 mL of the supernatant and dilute with 20 mL water, add to a Mega Bond C18 SPE cartridge, wash with 25 mL acidified MeOH:water 65:35, elute with 25 mL acidified MeOH:water 80:20. Evaporate the eluate to dryness at 60◦ , reconstitute the residue with 1 mL DMF and 1.5 mL water, filter (0.45 µm), inject a 20 µL aliquot. (Acidified MeOH was 5 mL conc. HCl in 1 L MeOH.) HPLC VARIABLES Column: 100 × 4.6 3 µm Hypersil ODS or BDS Mobile phase: Gradient. MeCN:MeOH:10 mM tetrabutylammonium hydrogen sulfate 20:20:60 for 10 min, to 20:35:45 over 30 min, flush column with MeCN for 10 min. 180 Diclazuril Flow rate: 2 Injection volume: 20 Detector: UV 280 CHROMATOGRAM Retention time: 24 Internal standard: R062646 (diclazuril with methyl α to cyano group, Janssen) (26) Limit of quantitation: 1 µg/g OTHER SUBSTANCES Simultaneous: degradant KEY WORDS SPE REFERENCE De Kock, J.; de Smet, M.; Sneyers, R. Determination of diclazuril in animal feed by liquid chromatography, J.Chromatogr., 1992, 606, 141–146. ANNOTATED BIBLIOGRAPHY Fontaine, A.; Haustraete, K. Liquid-chromatographic determination of diclazuril in premix and supplemented feed: Interlaboratory study, J.AOAC Int., 1994, 77, 1359–1361. [SPE] Mortier, L.; Daeseleire, E.; Delahaut, P. Simultaneous detection of five coccidiostats in eggs by liquid chromatography-tandem mass spectrometry, Anal.Chim.Acta, 2003, 483, 27–37. [diclazuril; dimetridazole; halofuginone; nicarbazin; robenidine] 181 Dihydrotachysterol Dihydrotachysterol CH3 H3C CH3 Molecular formula: C28 H46 O Molecular weight: 398.66 CAS Registry No: 67-96-9 Merck Index: 13, 3202 CH3 H CH3 H H3C OH SAMPLE Matrix: blood Sample preparation: Mix 1 mL serum with 2 mL 50 ng/mL IS in EtOH, centrifuge at 1500 g for 15 min, add to an activated (by an unspecified method) Chromabond C18 ec SPE cartridge, wash with 3 mL EtOH:500 mM ammonium acetate 2:1, wash with 1 mL water, elute with 5 mL MeCN. Evaporate the eluate to dryness under a stream of nitrogen at 45◦ , reconstitute the residue with 90 µL MeCN, inject a 50 µL aliquot. HPLC VARIABLES Column: 250 × 3 Nucleosil 100-5 C18 AB Mobile phase: MeCN:water:acetic acid 95:5:5 Flow rate: 0.75 Injection volume: 50 Detector: UV 252 CHROMATOGRAM Retention time: 15.4 Internal standard: vitamin D2 (17) Limit of quantitation: 0.5 ng/mL KEY WORDS pharmacokinetics; serum REFERENCE Koytchev, R.; Alken, R.G.; Vagaday, M.; Kunter, U.; Kirkov, V. Differences in the bioavailability of dihydrotachysterol preparations, Eur.J.Clin.Pharmacol., 1994, 47, 81–84. SAMPLE Matrix: blood Sample preparation: Condition a Sep-Pak C18 SPE cartridge with 20 mL MeOH and 10 mL water. Mix 5 mL plasma with 5 mL freshly charcoal-washed MeCN, let stand for 1 h with occasional vortexing, centrifuge at 7000 g for 15 min. Add the supernatant to 2.5 mL 200 mM pH 5.6 acetate buffer, add to the SPE cartridge, wash with 3 mL MeOH:water 60:40, elute with 6 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen or under reduced pressure, reconstitute the residue with hexane:isopropanol:MeOH 91:7:2, inject an aliquot. (SPE procedure from: Coldwell,R.D.; Trafford,D.J.H.; Makin,H.L.J.; Varley,M.J.; Kirk,D.N. Specific mass fragmentographic assay for 25,26-dihydroxyvitamin D in human plasma using a deuterated internal standard. J.Chromatogr. 1985, 338, 289–302.) HPLC VARIABLES Column: 250 × 6.2 Zorbax-SIL 182 Dihydrotachysterol Mobile phase: Hexane:isopropanol:MeOH 91:7:2 Flow rate: 1.8–2 Detector: UV 254 KEY WORDS normal phase; plasma; rat; SPE REFERENCE Qaw, F.; Calverley, M.J.; Schroeder, N.J.; Trafford, D.J.; Makin, H.L.; Jones, G. In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1α,25- and 1β,25-dihydroxydihydrotachysterol metabolites and studies of their biological activity, J.Biol.Chem., 1993, 268, 282–292. ANNOTATED BIBLIOGRAPHY Taylor, A.; Bikle, D.D.; Norman, M.E. Serum dihydrotachysterol levels and biological action in normal man, J.Clin.Endocrinol.Metab., 1988, 67, 198–202. [normal phase] Dimethyl sulfoxide 183 Dimethyl sulfoxide Molecular formula: C2 H6 OS (CH3)2SO Molecular weight: 78.13 CAS Registry No: 67-68-5 Merck Index: 13, 3285 SAMPLE Matrix: bulk Sample preparation: Dissolve 40 mg bisnafide drug substance in 20 mL water with sonication and gentle heating, inject a 200 µL aliquot. (Dimethyl sulfoxide is determined as an impurity in bisnafide drug substance.) HPLC VARIABLES Column: Zorbax Rx C8 Column temperature: 45 ± 2 Mobile phase: Gradient. A:B 100:0 for 10 min, to 0:100 (step gradient) maintain at 0:100 for 5 min, 100:0 for 15 min. A was 10 mM NaCl containing 0.10% phosphoric acid. B was MeCN:10 mM NaCl containing 0.10% phosphoric acid 90:10. Flow rate: 0.8 Injection volume: 200 Detector: UV 215 CHROMATOGRAM Retention time: 7 Limit of detection: 51 ng/mL Limit of quantitation: 219 ng/mL REFERENCE Walker, J.T.; Paolini, D.L.; Segretario, J. Quantitation of residual dimethylsulfoxide in a drug substance (bisnafide) by reversed-phase high-performance liquid chromatography, J.Chromatogr.Sci., 1996, 34, 513–516. SAMPLE Matrix: tissue Sample preparation: Extract 1 g tissue with 10 mL MeOH:water 10:90 for at least 6 h (no other details), dilute an aliquot 10 fold with MeOH:water 10:90, centrifuge for 5 min, inject an aliquot. HPLC VARIABLES Guard column: 5 µm Spheri-18 C18 (Brownlee) Column: 250 × 4.6 5 µm Spherisorb ODS2 C18 Mobile phase: MeOH:water 10:90 Flow rate: 1 Injection volume: 20 Detector: UV 214 CHROMATOGRAM Retention time: 3.5 Limit of quantitation: 500 ng/mL 184 Dimethyl sulfoxide KEY WORDS myocardium; pig REFERENCE Carpenter, J.F.; Dawson, P.E. Quantitation of dimethyl sulfoxide in solutions and tissues by highperformance liquid chromatography, Cryobiology, 1991, 28, 210–215. Dinitolmide Dinitolmide O 185 NH2 CH3 Molecular formula: C8 H7 N3 O5 Molecular weight: 225.16 CAS Registry No: 148-01-6 Merck Index: 13, 3297 O2 N NO2 SAMPLE Matrix: feed Sample preparation: Mix 5 g ground feed with 50 mL MeCN:water 85:15, heat at 50◦ with frequent shaking for 10 min, shake on a wrist-action shaker at room temperature for 10 min, filter, inject a 20 µL aliquot of the filtrate. HPLC VARIABLES Column: 250 × 4.9 5 µm Partisil Mobile phase: MeCN:dichloromethane 50:50 Flow rate: 2 Injection volume: 20 Detector: UV 270 CHROMATOGRAM Retention time: 3.5 Limit of quantitation: 20 µg/g OTHER SUBSTANCES Noninterfering: amprolium, avoparcin, decoquinate, dimetridazole, ethopabate, furazolidone, halquinol, monensin, nifursol, nitrovin, robenidine, vitamin A, vitamin D3 , vitamin E, zinc bacitracin Interfering: sulfaquinoxaline (can be resolved using MeCN:dichloromethane 30:70) KEY WORDS normal phase REFERENCE Burns, I.W.; Jones, A.D. Determination of 3,5-dinitro-o-toluamide in poultry feedstuffs and pre-mixes by high-performance liquid chromatography, The Analyst, 1980, 105, 509–512. 186 Dipivefrin Dipivefrin Molecular formula: C19 H29 NO5 Molecular weight: 351.44 CAS Registry No: 52365-63-6 Merck Index: 13, 3372 OH H N O CH3 CH3 CH3 CH3 O O CH3 CH3 CH3 O SAMPLE Matrix: solutions HPLC VARIABLES Column: reversed phase Mobile phase: MeOH:20 mM pH 7.9 Tris buffer 80:20 Flow rate: 1.6 Injection volume: 30 Detector: UV ? CHROMATOGRAM Retention time: 12–16 REFERENCE Tamaru, R.D.; Davis, W.L.; Anderson, J.A. Comparison of ocular disposition of free pivalic acid and pivalic acid esterified in dipivefrin, Arch.Ophthalmol., 1983, 101, 1127–1129. Dithiazanine iodide Dithiazanine iodide Molecular formula: C23 H23 IN2 S2 Molecular weight: 518.49 CAS Registry No: 514-73-8 Merck Index: 13, 3405 S S 187 I− N+ N CH3 H3C SAMPLE Matrix: solutions HPLC VARIABLES Column: 150 × 4.6 5 µm TSKgel ODS 80TM Mobile phase: MeCN:25 mM pH 6.5 imidazole buffer 60:40 containing 10 mM sodium 1-propanesulfonate Flow rate: 1 Injection volume: Detector: Chemiluminescence, the column effluent mixed with MeCN containing 0.25 mM bis(4-nitro-2-(3,6,9-trioxadecyloxycarbonyl)phenyl) oxalate (TDPO) and 25 mM hydrogen peroxide pumped at 1.3 mL/min and the mixture flowed into the flow cell and the chemiluminescence was measured using a red-sensitive photomultiplier (Hamamatsu R2228) CHROMATOGRAM Retention time: 14 Limit of detection: 0.19 fmole OTHER SUBSTANCES Simultaneous: methylene blue (3.5) REFERENCE Kimoto, K.; Gohda, R.; Murayama, K.; Santa, T.; Fukushima, T.; Homma, H.; Imai, K. Sensitive detection of near-infrared fluorescent dyes using high-performance liquid chromatography with peroxalate chemiluminescence detection system, Biomed.Chromatogr., 1996, 10, 189–190. 188 Docarpamine Docarpamine O H3C O Molecular formula: C21 H30 N2 O8 S Molecular weight: 470.54 CAS Registry No: 74639-40-0 Merck Index: 13, 3430 O H3C O O O O H H N N CH3 SCH3 O SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 10 µm Cosmosil 5C18-MS Column temperature: 50 Mobile phase: Gradient. MeCN:10 mM pH 4.2 potassium phosphate buffer 0:100 for 2 min, to 75:25 over 7.5 min, maintain at 75:25 for 5.5 min. Isocratic. MeCN:buffer 40:60 Flow rate: 1.5 Detector: UV (wavelength not specified) CHROMATOGRAM Retention time: 11.4 (gradient) or 6.5 (isocratic) OTHER SUBSTANCES Simultaneous: acetazolamide (7.9), acyclovir (7.0), allopurinol (7.3), aniracetam (8.6), benazepril (11.5), betamethasone (10.8), camostat mesylate (8.8), carbamazepine (10.8), cilazapril (10.7), cimetidine (7.5), clofibrate (15.0), clonazepam (11.3), cyclophosphamide (9.9), delapril (11.9), dexamethasone (10.9), diazepam (12.5), digoxin (9.0), dilazep (10.6), diltiazem (10.2), eperisone (8.7), ethosuximide (9.0), fenbufen (11.8), fluconazole (9.2), flutamide (12.7), fominoben (12.6), hydrocortisone acetate (12.1), imidapril (10.1), indomethacin (12.6), irinotecan (9.2), maprotiline (10.5), methotrexate (8.0), nefiracetam (9.7), nifedipine (11.9), nitrazepam (11.2), pentobarbital (10.9), phenobarbital (10.0), phenytoin (10.8), pindolol (8.3), pranlukast (13.4), pranoprofen (10.4), prednisolone (10.3), primidone (8.9), quinapril (10.5), spironolactone (12.4), sulpiride (7.6), sulthiame (9.3), tolbutamide (11.6), tranilast (10.5), triamcinolone (11.2), warfarin (12.0), zonisamide (9.5) (gradient retention times; isocratic conditions may differ) REFERENCE Sugiyama, T.; Matsuyama, R.; Usui, S.; Katagiri, Y.; Hirano, K. Selection of mobile phases in highperformance liquid chromatographic determination for medicines, Biol.Pharm.Bull., 2000, 23, 274–278. 189 Dofetilide Dofetilide H N S Molecular formula: C19 H27 N3 O5 S2 Molecular weight: 441.57 CAS Registry No: 115256-11-6 Merck Index: 13, 3443 O O O S H3C N O CH3 O N CH3 H SAMPLE Matrix: blood Sample preparation: Dilute plasma with an equal volume of MeOH:water 10:90 containing 1 M monochloroacetic acid, centrifuge at 4◦ at 3000 rpm for 1 h, inject a 200 µL aliquot onto column A and elute to waste with mobile phase A, backflush column A with mobile phase A, backflush the contents of column A onto column B with mobile phase C, elute column B with mobile phase C. Wash column A with mobile phase B and wash column B with mobile phase D HPLC VARIABLES Column: A 50 × 1 50 µm HTLC Turbo C18 (Cohesive Technologies); B 33 × 2.1 HTLC HiRes C18 (Cohesive Technologies) (Fit a 5 µm filter before column A and a 2 µm filter before column B.) Mobile phase: A 0.01% trifluoroacetic acid in water; B MeCN:0.1% aqueous ammonia 90:10; C MeCN:MeOH:20 mM ammonium acetate 45:45:10; D MeCN:THF 50:50 Flow rate: A 5; B 1 Injection volume: 200 Detector: MS, PE Sciex API 2000 triple quadrupole, positive ion mode, TurboIonspray, nebulizer gas nitrogen at 25 psi, applied voltage 5200 V, collision energy 50 V, turbo gas 100◦ and 40 psi, a flow splitter was used to deliver 50 µL/mL to the detector, m/z 442–198 CHROMATOGRAM Retention time: 1.1 Limit of quantitation: 5 ng/mL OTHER SUBSTANCES Extracted: doxazosin (m/z 452–344) (1.1) KEY WORDS column-switching; dog; plasma REFERENCE Chassaing, C.; Luckwell, J.; Macrae, P.; Saunders, K.; Wright, P.; Venn, R. Direct analysis of crude plasma samples by turbulent flow chromatography/tandem mass spectrometry, Chromatographia, 2001, 53, 122–130. SAMPLE Matrix: urine Sample preparation: Mix 1 mL urine with 20 µL 5 µg/mL IS in MeOH, add 1 mL 100 mM pH 7.4 phosphate buffer, mix, add 5 mL MTBE, rotate at 30 rpm for 10 min, centrifuge at 1730 g for 5 min. Remove the organic layer and extract it with 1 mL 20 mM phosphoric acid, centrifuge at 1730 g for 5 min. Add the aqueous layer to 2 mL 100 mM pH 7.4 phosphate buffer, extract with 5 mL MTBE, centrifuge at 1730 g for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 100 µL mobile phase, inject an 80 µL aliquot. 190 Dofetilide HPLC VARIABLES Column: 250 × 4.6 5 µm Spherisorb silica Mobile phase: MeCN:20 mM pH 7.0 ammonium phosphate buffer 35:65 Flow rate: 1 Injection volume: 80 Detector: UV 230 CHROMATOGRAM Retention time: 8.5 Internal standard: UK-69,308 (N,N-bis(4-methanesulfonamidophenethyl)methyl- amine) (10) Limit of quantitation: 2.5 ng/mL OTHER SUBSTANCES Extracted: metabolite REFERENCE Walker, D.K.; Smith, D.A.; Stopher, D.A. Liquid-liquid extraction and high-performance liquid chromatography for the determination of a novel antidysrhythmic agent (UK-68,798) in human urine, J.Chromatogr., 1991, 568, 475–480. 191 Dolasetron Dolasetron O N Molecular formula: C19 H20 N2 O3 Molecular weight: 324.37 CAS Registry No: 115956-12-2 Merck Index: 13, 3445 O O N H SAMPLE Matrix: blood, urine Sample preparation: Plasma. Mix 1 mL plasma with IS and 100 µL 5 M citric acid, add 1 mL 2 M sodium carbonate, extract with 4 mL ethyl acetate:n-hexane 75:25 for 30 min. Remove the organic layer and extract it with 1 mL 100 mM HCL for 15 min, centrifuge, discard the organic layer. Add 1 mL 2 M sodium carbonate to the aqueous layer, extract with 4 mL ethyl acetate:n-hexane 75:25, evaporate the organic layer to dryness under a stream of nitrogen, reconstitute with 150 µL mobile phase, inject a 100 µL aliquot. Urine. Dilute urine 1:100 with water. Mix 1 mL diluted urine with IS and 1 mL 2 M sodium carbonate, extract with 4 mL ethyl acetate:n-hexane 75:25 for 30 min. Remove the organic layer and extract it with 1 mL 100 mM HCL for 15 min, centrifuge, discard the organic layer. Add 1 mL 2 M sodium carbonate to the aqueous layer, extract with 4 mL ethyl acetate:n-hexane 75:25, evaporate the organic layer to dryness under a stream of nitrogen, reconstitute with 150 µL mobile phase, inject a 100 µL aliquot. HPLC VARIABLES Guard column: 4 × 6 10 µm µBondapak C18 Column: 150 × 4.6 5 µm Ultrasphere IP C18 Column temperature: 30 Mobile phase: MeCN:n-butanol:buffer 5:6:89 (The buffer was 50 mM sodium dihydrogen phosphate adjusted to pH 2.5 with orthophosphoric acid.) Flow rate: 0.7 Injection volume: 100 Detector: F ex 285 em 345 CHROMATOGRAM Retention time: 7.6 Internal standard: trans-octahydro-3-hydroxy-2,6-methano-2H-quinolizin-8-yl-1H-5methyl-indole-3-carboxylate (MDL 101,8588; Marion Merrell Dow Research Institute, Strasbourg) (17.0) Limit of quantitation: 10 nM (plasma), 50 nM (urine) OTHER SUBSTANCES Extracted: metabolite KEY WORDS pharmacokinetics; plasma 192 Dolasetron REFERENCE Huebert, N.D.; Schwartz, J.J.; Zeidler, L.; Schwach, V.; Haegele, K.D. Simultaneous measurement of dolasetron and its major metabolite, MDL 74,156, in human plasma and urine, J.Chromatogr.B, 1996, 685, 291–297. SAMPLE Matrix: formulations Sample preparation: Prepare a liquid suspension by crushing twelve 50 mg tablets, slowly add 60 mL of Ora-Plus:Ora-Sweet SF 50:50, dilute to 10 µg/mL with MeCN:water 24:76, shake for 15 s, centrifuge at 1000 rpm for 2 min, inject a 5 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 3 µm Spherisorb CN Column temperature: 30 Mobile phase: MeCN:buffer 24:76 (The buffer was 50 mM ammonium acetate adjusted to pH 7.5 with dilute ammonium hydroxide.) Flow rate: 0.8 Injection volume: 5 Detector: UV 280 CHROMATOGRAM Retention time: 6.9 KEY WORDS stability-indicating; suspension REFERENCE Johnson, C.E.; Wagner, D.S.; Bussard, W.E. Stability of dolasetron in two oral liquid vehicles, Am.J. Health-Syst.Pharm., 2003, 60, 2242–2244. ANNOTATED BIBLIOGRAPHY McElvain, J.S.; Vandiver, V.J.; Eichemeier, L.S. Validation of a reversed-phase HPLC method for directly quantifying the enantiomers of MDL 74,156, the primary metabolite of dolasetron mesylate, in human plasma, J.Pharm.Biomed.Anal., 1997, 15, 513–521. [HPLC of metabolites only] Reith, M.K.; Sproles, G.D.; Cheng, L.K. Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist, Drug Metab.Dispos., 1995, 23, 806–812. [column temp 30; metabolites; urine] Sanwald, P.; Huebert, N.D.; Haegele, K.D. Simultaneous measurement of the major metabolites of dolasetron mesilate in human urine using solid-phase extraction and high-performance liquid chromatography, J.Chromatogr.B, 1994, 661, 101–107. Donepezil Donepezil Molecular formula: C24 H29 NO3 Molecular weight: 379.49 CAS Registry No: 120014-06-4 Merck Index: 13, 3453 O 193 N H3CO H3CO SAMPLE Matrix: blood Sample preparation: Add 100 µL 200 ng/mL IS in 1 mM HCl and 5 mL n-hexane:isopropanol 97:3 to 1 mL plasma, shake for 5 min, centrifuge at 1800 g for 1 min. Remove the organic layer and add it to 200 µL 1 mM HCl, shake for 1 min, centrifuge at 1800 g for 1 min, inject a 75 µL aliquot of the aqueous layer. HPLC VARIABLES Column: 150 × 2.1 5 µm Bioptick AV-1 (GL Sciences) Mobile phase: MeOH:10 mM formic acid 25:75 Flow rate: 0.2 Injection volume: 75 Detector: MS, Finnigan MAT TSQ7000, source 4.5 kV, capillary 200◦ , sheath gas nitrogen 70 psi, auxiliary gas nitrogen, collision gas argon 1.5 mtorr 40 eV, m/z 380–91 CHROMATOGRAM Retention time: 8 (R-enantiomer), 13 (S-enantiomer) Internal standard: d7 -donepezil (m/z 387–98) Limit of detection: 7.7 pg Limit of quantitation: 20 pg/mL KEY WORDS chiral; pharmacokinetics; plasma REFERENCE Matsui, K.; Oda, Y.; Nakata, H.; Yoshimura, T. Simultaneous determination of donepezil (aricept) enantiomers in human plasma by liquid chromatography-electrospray tandem mass spectrometry, J.Chromatogr.B, 1999, 729, 147–155. SAMPLE Matrix: blood Sample preparation: Add 100 µL 3 µg/mL IS in 1 mM HCl and 500 µL 100 mM NaOH to 1 mL plasma, vortex for 10 s, add 4 mL n-hexane:isopropanol 97:3, shake for 10 min, centrifuge at 620 g at 4◦ for 10 min. Remove the organic layer and add it to 75 µL 100 mM HCl, mix at 100 cycles/min for 10 min, centrifuge at 1710 g at 4◦ for 5 min. Carefully remove the upper organic layer, then remove traces of organic solvent with a stream of air, inject a 50 µL aliquot of the aqueous layer. HPLC VARIABLES Column: 150 × 4.6 5 µm STR ODS-II (Shinwa) Column temperature: 30 (in body of paper) or 40 (in abstract) Mobile phase: MeCN:20 mM pH 4.6 phosphate buffer:6 M perchloric acid 40:59.5:0.5 Flow rate: 1 Injection volume: 50 Detector: UV 315 194 Donepezil CHROMATOGRAM Retention time: 5.1 Internal standard: cisapride (7.1) Limit of quantitation: 3 ng/mL OTHER SUBSTANCES Simultaneous: alprazolam, chlorpromazine, diazepam, levomepromazine, nitrazepam Noninterfering: haloperidol, risperidone KEY WORDS pharmacokinetics; plasma REFERENCE Yasui-Furukori, N.; Furuya, R.; Takahata, T.; Tateishi, T. Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection, J.Chromatogr.B, 2002, 768, 261–265. ANNOTATED BIBLIOGRAPHY Kaddoumi, A.; Mori, M.; Nanashima, K.; Kono, M.; Nakashima, K. High performance liquid chromatographic determination of mazindol in human plasma, The Analyst, 2001, 126, 1963–1968. [donepezil is internal standard] Matsui, K.; Mishima, M.; Nagai, Y.; Yuzuriha, T.; Yoshimura, T. Absorption, distribution, metabolism, and excretion of donepezil (Aricept) after a single oral administration to rat, Drug Metab.Dispos., 1999, 27, 1406–1414. Pappa, H.; Farrú, R.; Vilanova, P.O.; Palacios, M.; Pizzorno, M.T. A new HPLC method to determine Donepezil hydrochloride in tablets, J.Pharm.Biomed.Anal., 2002, 27, 177–182. 195 Doxefazepam Doxefazepam HO Molecular formula: C17 H14 ClFN2 O3 Molecular weight: 348.76 CAS Registry No: 40762-15-0 Merck Index: 13, 3467 O N OH N Cl F SAMPLE Matrix: blood Sample preparation: Condition a Supelclean LC-18 SPE cartridge with 1 mL MeOH and 2 mL water. Mix 1 mL plasma with 100 µL 2 µg/mL IS in MeOH, add to the SPE cartridge, wash with 2 column volumes of water, wash with 100 µL MeOH, elute with 400 µL MeOH. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with 200 µL mobile phase, inject a 25 µL aliquot. HPLC VARIABLES Guard column: 20 × 4 Supelguard C18 Column: 300 × 4 µBondapak C18 Mobile phase: MeOH:water 20:80 Flow rate: 2 Injection volume: 25 Detector: UV 280 CHROMATOGRAM Retention time: 5.2 Internal standard: diazepam (3.1) Limit of quantitation: 100 ng/mL KEY WORDS plasma; SPE REFERENCE Carlucci, G. A high-performance liquid chromatographic method for the determination of doxefazepam in human plasma using a solid-phase extraction column, J.Liq.Chromatogr., 1988, 11, 1559–1568. 196 Doxercalciferol Doxercalciferol CH3 H3C CH3 CH3 Molecular formula: C28 H44 O2 CH3 Molecular weight: 412.65 CAS Registry No: 54573-75-0 Merck Index: 13, 3470 H [1α-Hydroxyergocalciferol] CH2 HO OH SAMPLE Matrix: blood Sample preparation: Condition a 60 mg Oasis HLB SPE cartridge with 2 mL ethyl acetate, 2 mL MeOH, and 2 mL water. Condition a 500 mg Bond Elut silica SPE cartridge with 4 mL chloroform:MeOH 30:1 (Caution! Chloroform is a carcinogen!) and 4 mL chloroform. Mix 10 µL 40 ng/mL IS in EtOH with 1 mL plasma, let stand for 15 min, add this mixture to 1 mL MeCN in another tube, rinse the first tube with 250 µL MeCN and add it to the plasma/MeCN mixture. Vortex for 30 s, centrifuge at 1500 g for 10 min. Add 2 mL water to the supernatant and pass the mixture through the Oasis SPE cartridge. Wash with 2 mL water, wash with 2 mL MeOH:water 70:30, wash with 1 mL hexane, elute with 1 mL ethyl acetate. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with two 200 µL portions of chloroform. Add the chloroform layers to the silica SPE cartridge, wash with 3 mL chloroform, wash with 2.2 mL chloroform:MeOH 40:1, elute with 2 mL chloroform:MeOH 30:1. Evaporate the eluate to dryness, place the residue under reduced pressure for 10 min, reconstitute the residue with 25 µL 100 µg/mL DMEQTAD in ethyl acetate, let stand at room temperature for 30 min, add another 25 µL 100 µg/mL DMEQTAD in ethyl acetate, let stand at room temperature for 1 h, add 40 µL EtOH, evaporate to dryness, reconstitute with 10 µL acetic anhydride and 20 µL pyridine, heat at 50◦ for 1 h, add 40 µL EtOH, evaporate the solvent, dissolve the residue in 40 µL mobile phase, inject a 15 µL aliquot. (DMEQTAD is 4-[2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalyl)ethyl]-1,2,4triazoline-3,5-dione and can be purchased from Wako.) HPLC VARIABLES Column: 150 × 4.6 4 µm YMC J’sphere ODS H-80 Column temperature: 40 Mobile phase: MeCN:water 92:8 Flow rate: 1 Injection volume: 15 Detector: MS, ThermoQuest LCQ, APCI, positive ion mode, collision gas helium, source current 5 µA, heated capillary 225◦ , vaporizer 475◦ , capillary 3 V, tube lens offset 15 V CHROMATOGRAM Retention time: 6.8 Internal standard: d4 -doxercalciferol (6.7) Limit of detection: 6.3 fmol Limit of quantitation: 25 pg/mL KEY WORDS derivatization; plasma; SPE; Doxercalciferol can be determined without derivatization using MeOH:water 95:5, retention time 5.4 min, LOD 200 pg/injection. Doxercalciferol 197 REFERENCE Higashi, T.; Awada, D.; Shimada, K. Liquid chromatography-mass spectrometric method combined with derivatization for determination of 1α-hydroxyvitamin D3 in human plasma, J.Chromatogr.B, 2002, 772, 229–238. SAMPLE Matrix: cell cultures Sample preparation: Precipitate cells with MeOH. Homogenize 1 vol of cells with 2 vol of MeOH, add 1 vol of chloroform (Caution! Chloroform is a carcinogen!), homogenize (blender or Polytron) for 2 min, add 1 vol of chloroform, homogenize for 30 s, add 1 vol of water, homogenize for 30 s, centrifuge, extract solids with 0.4 vol chloroform:MeOH 50:50. Combine the liquids and separate the chloroform layer. Pass the chloroform layer through anhydrous sodium sulfate and evaporate under reduced pressure at 40◦ , reconstitute, inject an aliquot. (Current Protocols in Food Analytical Chemistry, Wrolstad,R.E. (ed), Wiley, New York, 2003, page D.1.1.5; after Bligh,E.G.; Dyer,W.J. A rapid method of total lipid extraction and purification. Can.J.Biochem.Physiol. 1959, 37, 911–917.)) HPLC VARIABLES Column: 80 × 6.2 3 µm Zorbax SIL Mobile phase: Hexane:isopropanol:MeOH 91:7:2 Flow rate: 1.5 Detector: UV 265 CHROMATOGRAM Retention time: 5.6 OTHER SUBSTANCES Simultaneous: metabolites KEY WORDS normal phase REFERENCE Strugnell, S.; Byford, V.; Makin, H.L.; Moriarty, R.M.; Gilardi, R.; LeVan, L.W.; Knutson, J.C.; Bishop, C.W.; Jones, G. 1α,24(S)-dihydroxyvitamin D2 : a biologically active product of 1α-hydroxyvitamin D2 made in the human hepatoma, Hep3B, Biochem.J., 1995, 310, 233–241. 198 Dropropizine Dropropizine N N OH OH Molecular formula: C13 H20 N2 O2 Molecular weight: 236.31 CAS Registry No: 17692-31-8, 99291-24-4 (levodropropizine) Merck Index: 13, 3486 SAMPLE Matrix: blood Sample preparation: Mix 200 µL plasma or serum with 10 ng IS and 200 µL 100 mM pH 8.9 disodium hydrogen phosphate, add 5 mL chloroform:isopropanol 90:10 (Caution! Chloroform is a carcinogen!), vortex for 2 min, centrifuge at 700 g for 10 min. Evaporate 4 mL of the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 500 µL water, inject a 100 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Bio-Gel PRP 70-5 poly(styrene-divinylbenzene) (Bio-Rad) Mobile phase: MeOH:THF:100 mM pH 3 potassium phosphate buffer 30:0.5:70 Flow rate: 0.5 Injection volume: 100 Detector: F ex 240 em 350 (slits 18 and 30 nm, respectively) CHROMATOGRAM Retention time: 10 Internal standard: p-methoxylevodropropizine (15) Limit of detection: 1–2 ng/mL Limit of quantitation: 3.1 ng/mL OTHER SUBSTANCES Noninterfering: acetaminophen, amitriptyline, amobarbital, amphetamine, aprobarbital, atropine, barbital, benzoylecgonine, benztropine, butabarbital, caffeine, carbamazepine, carisoprodol, chlorpheniramine, chlorpromazine, chlorprothixene, cimetidine, cocaine, codeine, dextromethorphan, diazepam, dihydrocodeine, diphenhydramine, diphenoxylate, diphenylhydantoin, disopyramide, doxepin, doxylamine, emetine, erythromycin, ethinamate, ethylmorphine, flurazepam, glutethimide, hydrocodone, hydrocortisone, hydromorphone, hydroxyzine, imipramine, lidocaine, loxapine, meperidine, meprobamate, methadone, methamphetamine, methapyrilene, methaqualone, methocarbamol, methylphenidate, morphine, naloxone, nicotine, nordiazepam, nortriptyline, orphenadrine, oxycodone, papaverine, pentazocine, pentobarbital, phenacetin, phencyclidine, phenmetrazine, phenobarbital, phenolphthalein, phentermine, phenylpropanolamine, phenytoin, phetidine, prazepam, procainamide, procaine, propoxyphene, propranolol, protriptyline, pseudoephedrine, pyrilamine, quinine, salicylamide, secobarbital, spironolactone, strychnine, terpin hydrate, thioridazine, thiothixene, triamterene, trifluperazine, triflupromazine, trihexyphenidyl, trimeprazine, trimethoprim, trimetobenzamide KEY WORDS plasma; serum REFERENCE Tagliaro, F.; Moffa, M.; De Battisti, Z.; Smith, F.P.; Gentile, M. High-performance liquid chromatographic determination of levodropropizine in human plasma with fluorometric detection, J.Chromatogr.B, 1996, 685, 165–170. 199 Drospirenone Drospirenone O H3C Molecular formula: C24 H30 O3 Molecular weight: 366.49 CAS Registry No: 67392-87-4 Merck Index: 13, 3488 CH3 H O H H O SAMPLE Matrix: blood Sample preparation: Vortex 3 mL plasma with 3 mL n-hexane:toluene 50:50 for 1 min, centrifuge at 1200 g for 5 min, repeat the extraction. Combine the organic layers, evaporate them to dryness under a stream of nitrogen, reconstitute the residue with 200 µL mobile phase, inject a 150 µL aliquot. To increase sensitivity, extract 5 mL plasma twice with 2 mL aliquots of n-hexane:toluene 50:50. HPLC VARIABLES Column: 250 × 4.6 10 µm LiChrosorb RP-18 Mobile phase: MeOH:water 60:40 Flow rate: 2 Injection volume: 150 Detector: UV 254 CHROMATOGRAM Retention time: 13.4 Limit of detection: <5 ng/mL OTHER SUBSTANCES Extracted: spirenone (9.2) KEY WORDS pharmacokinetics; plasma REFERENCE Krause, W.; Jakobs, U. Determination of plasma levels of spirorenone, a new aldosterone antagonist, and one of its metabolites by high-performance liquid chromatography, J.Chromatogr., 1982, 230, 37–45. 200 Droxicam Droxicam O O N N Molecular formula: C16 H11 N3 O5 S Molecular weight: 357.35 CAS Registry No: 90101-16-9 Merck Index: 13, 3491 O S O N CH3 O SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4 5 µm LiChrospher 60 RP-Select B Mobile phase: MeOH:water:acetic acid 48:45:7 Flow rate: 1.1 Injection volume: 20 Detector: UV 340 OTHER SUBSTANCES Simultaneous: isoxicam, piroxicam KEY WORDS Droxicam cannot be detected in plasma, but it can be chromatographed under the above conditions. REFERENCE Maya, M.T.; Pais, J.P.; Morais, J.A. A rapid method for the determination of piroxicam in plasma by high-performance liquid chromatography, J.Pharm.Biomed.Anal., 1995, 13, 319–322. 201 Droxidopa Droxidopa Molecular formula: C9 H11 NO5 Molecular weight: 213.19 CAS Registry No: 23561-95-8 Merck Index: 13, 3492 OH HO HO COOH NH2 SAMPLE Matrix: solutions HPLC VARIABLES Guard column: 50 × 4 Develosil ODS-10 Column: 250 × 4 Develosil ODS-5 Mobile phase: MeCN:buffer 10:90 (The buffer was 50 mM pH 3.4 sodium dihydrogen phosphate containing 50 mM trichloroacetic acid, 200 µg/mL sodium dodecylsulfate, and 10 µg/mL disodium EDTA.) Flow rate: 0.6 Detector: E, Coulochem 5100A, conditioning cell Model 5021 + 400 mV, analytical cell Model 5011, first electrode −100 mV, second electrode (recording electrode) −400 mV CHROMATOGRAM Retention time: 4 REFERENCE Naoi, M.; Nagatsu, T. Uptake of L-threo-dihydroxyphenylserine into human brain synaptosomes, J.Neural Transm., 1987, 70, 51–61. Ebrotidine Br H H2N Molecular formula: C14 H17 BrN6 O2 S3 Molecular weight: 477.43 CAS Registry No: 100981-43-9 Merck Index: 13, 3518 N N NH2 S N S N S O O SAMPLE Matrix: bulk Sample preparation: Inject a 20 µL aliquot of an 0.2% solution in MeOH. HPLC VARIABLES Column: 250 × 4 10 µm Spherisorb CN Column temperature: 30 Mobile phase: MeCN:10 mM sodium dihydrogen phosphate 35:65 Flow rate: 1.5 Injection volume: 20 Detector: UV 245 CHROMATOGRAM Retention time: 11 OTHER SUBSTANCES Simultaneous: impurities REFERENCE Albet, C.; Fernandez, J.M.; Castello, J.M.; Sacristan, A.; Ortiz, J.A. Physicochemical properties, analytical determinations and stability of ebrotidine, Arzneimittelforschung, 1997, 47, 435–438. SAMPLE Matrix: urine Sample preparation: Vortex 1 mL urine with 100 µL 1 M NaOH, add 5 mL dichloromethane:isopropanol 90:10, shake mechanically for 15 min, centrifuge at 2700 g for 5 min. Evaporate 4 mL of the organic layer to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL MeOH, vortex, filter (0.45 µm), inject a 25 µL aliquot. HPLC VARIABLES Column: 300 × 3.9 10 µm µBondapak C18 Mobile phase: Gradient. MeCN:buffer from 20:80 to 35:65 over 30 min (The buffer was 5 mM 1-hexanesulfonic acid adjusted to pH 3 with glacial acetic acid.) Flow rate: 1.5 Injection volume: 25 Detector: UV 235 CHROMATOGRAM Retention time: 24 Limit of detection: 97 ng/mL OTHER SUBSTANCES Extracted: metabolites Simultaneous: acetaminophen, amoxicillin, aspirin, caffeine, cimetidine, codeine, diazepam, omeprazole, ranitidine, theophylline Interfering: imipramine 202 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 Ebrotidine 203 KEY WORDS SPE REFERENCE Rozman, E.; Galcerán, M.T.; Albet, C. Determination of ebrotidine and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography, J.Chromatogr.B, 1997, 688, 107–115. ANNOTATED BIBLIOGRAPHY Rozman, E.; Galceran, M.T.; Anglada, L.; Albet, C. Investigation of the metabolism of ebrotidine in human urine by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry, Drug Metab.Dispos., 1995, 23, 976–981. [APCI]. Rozman, E.; Galcerán, M.T.; Albet, C. Ebrotidine and its metabolites studied by mass spectrometry with electrospray ionization. Comparison of tandem and in-source fragmentation, Rapid Commun.Mass Spectrom., 1995, 9, 1492–1498. 204 Edaravone Edaravone Molecular formula: C10 H10 N2 O Molecular weight: 174.20 CAS Registry No: 89-25-8 Merck Index: 13, 6746 O N N CH3 SAMPLE Matrix: blood, urine Sample preparation: Plasma. Add 25 µL 15 µg/mL IS in MeOH, 500 µL 750 mM pH 5.0 sodium acetate buffer containing 40 mg/mL sodium metabisulfite, and 10 mg β-glucuronidase/arylsulfatase (Limpet acetone powder type 1:Platela vulgata (Sigma)) to 500 µL plasma, heat at 37◦ for 2 h, add 100 mg NaCl, add 1.2 mL chloroform:EtOH 90:10 (Caution! Chloroform is a carcinogen!), vortex for 2 min, centrifuge at 1800 g for 20 min. Remove the organic layer and add it to 50 µL 100 mM HCl. Evaporate to dryness under a stream of nitrogen at room temperature, reconstitute the residue with 75 µL mobile phase, wash with 25 µL n-hexane, inject a 20 µL aliquot of the lower layer. Urine. Add 25 µL 500 µg/mL IS in MeOH, 500 µL 750 mM pH 5.0 sodium acetate buffer containing 40 mg/mL sodium metabisulfite, and 10 mg β-glucuronidase/arylsulfatase (Limpet acetone powder type 1: Platela vulgata (Sigma)) to 500 µL urine, heat at 37◦ for 2 h, add 200 mg NaCl, add 2 mL dichloromethane:isopropanol 90:10, vortex for 1.5 min, centrifuge at 1800 g for 30 min. Remove the organic layer, evaporate to dryness under a stream of nitrogen at room temperature, reconstitute the residue with 200 µL mobile phase (keep in a dry ice bath), vortex for 15 s, inject a 20 µL aliquot. (Wash NaCl with extraction mixture before use.) HPLC VARIABLES Column: 150 × 3.9 Nova-Pak C18 Mobile phase: MeOH:250 mM pH 5.0 sodium acetate buffer 30:70 Flow rate: 1 Injection volume: 20 Detector: UV 254 CHROMATOGRAM Retention time: 7 Internal standard: phenacetin (10) Limit of quantitation: 50 ng/mL OTHER SUBSTANCES Extracted: antipyrine (5) Noninterfering: albuterol, aspirin, chlorpropamide, chlorthalidone, codeine, diazepam, diclofenac, dipyrone, enalapril, furosemide, heparin, nifedipine, phenytoin, ranitidine, warfarin Interfering: aminophylline, dapsone KEY WORDS plasma REFERENCE Lanchote, V.L.; Ping, W.C.; Santos, S.R.C.J. Determination of antipyrine and metabolites in plasma of a patient with mild renal failure, Ther.Drug Monit., 1997, 19, 705–710. SAMPLE Matrix: urine Edaravone 205 Sample preparation: Centrifuge urine, mix a 100 µL aliquot with 1 mL acetate buffer and 50 µL water containing 5000–6000 IU β-glucuronidase and 150–200 IU sulfatase from Helix pomatia, Sigma) (hydrolysis conditions not specified but 3 h at 37◦ is recommended by St.Peter,J.V.; Awni,W.M. J.Chromatogr. 1989, 494, 424–427), add 8 mL dichloromethane, add 1 g NaCl, extract on a linear agitator for 10 min, centrifuge at 1500 g for 5 min, remove the organic layer and add it to 1 mL washing buffer, extract on a linear agitator for 5 min, centrifuge at 1500 g for 5 min, remove the organic layer and add it to 500 µL water. Evaporate the dichloromethane to dryness under a stream of nitrogen at 37◦ , add 500 µL MeOH, homogenize, inject a 20 µL aliquot. (Stock acetate buffer was 27 g/L sodium acetate trihydrate containing 3 mL/L glacial acetic acid. Store at 4◦ . Prepare the working acetate buffer (pH 4.9) fresh each day by adding 2% sodium metabisulfite to the stock solution. Washing buffer was 500 mM disodium hydrogen phosphate containing 35 g/L NaCl adjusted to pH 7.8 with 38% KOH.) HPLC VARIABLES Guard column: 20 × 4.6 10 µm C8 Column: 150 × 4.6 5 µm Ultrasphere C8 Mobile phase: MeCN:buffer 15:85 (The buffer was 5 mL/L glacial acetic acid containing 3 g/L sodium acetate trihydrate and 0.1 mM (20 µL/L) n-decylamine, pH 3.8–3.9.) Flow rate: 1 Injection volume: 20 Detector: UV 242 CHROMATOGRAM Retention time: 11 Internal standard: pyramidon (5) Limit of detection: 1 µg/mL Limit of quantitation: 15 µg/mL REFERENCE Palette, C.; Cordonnier, P.; Naline, E.; Advenier, C.; Pays, M. High-performance liquid chromatographic method for the determination of the three main oxidative and 3-carboxylic antipyrine metabolites in human urine, J.Chromatogr., 1991, 563, 103–113. ANNOTATED BIBLIOGRAPHY Ali, H.A.; el-Yazigi, A.; Sieck, J.O.; Dossing, M.; Saour, J.; Raines, D.A.; Ernst, P. Elimination studies of antipyrine and its metabolites in healthy Saudi Arabians, Hum.Exp.Toxicol., 1994, 13, 658–662. Mikati, M.A.; Szabo, G.K.; Pylilo, R.J.; LeDuc, B.W.; Browne, T.R.; Greenblatt, D.J. Improved highperformance liquid chromatographic assay of antipyrine, hydroxymethylantipyrine, 4-hydroxyantipyrine and norantipyrine in urine, J.Chromatogr., 1988, 433, 305–311. Nakagawa, A.; Nakamura, K.; Ishizaki, T.; Chiba, K. Automated high-performance liquid chromatographic method for the determination of antipyrine and its metabolites in urine. Some preliminary results obtained from smokers and non-smokers, J.Chromatogr., 1982, 231, 349–360. St.Peter, J.V.; Awni, W.M. Modified high-performance liquid chromatographic assay for antipyrine and its three major metabolites in urine, J.Chromatogr., 1989, 494, 424–427. 206 EDTA EDTA Molecular formula: C10 H16 N2 O8 COOH HOOC N N COOH HOOC Molecular weight: 292.24 CAS Registry No: 60-00-4 Merck Index: 13, 3546 SAMPLE Matrix: blood Sample preparation: Place 0.5 cm2 of a dried blood stain in 50–100 µL 25 mM copper(II) sulfate, let stand for 3 h, vortex, centrifuge at 3000–9000 rpm for 10 min, filter (0.2 µm), inject a 25 µL aliquot. Alternatively, dilute 200 µL whole blood with 2 mL water, mix with an equal volume of 50 mM copper(II) sulfate, centrifuge for 7 min, inject an aliquot of the supernatant. HPLC VARIABLES Column: Hamilton PRP X-100 Mobile phase: MeOH:3 mM sulfuric acid 5:95 Flow rate: 2 Injection volume: 25 Detector: UV 243 CHROMATOGRAM Retention time: 6 Limit of detection: 5 ppm KEY WORDS complexation; derivatization; dried blood; whole blood REFERENCE Miller, M.L.; McCord, B.R.; Martz, R.; Budowle, B. The analysis of EDTA in dried bloodstains by electrospray LC-MS-MS and ion chromatography, J.Anal.Toxicol., 1997, 21, 521–528. SAMPLE Matrix: blood Sample preparation: Place 0.5 cm2 of a dried blood stain with 25 µL water in an Ultrafree-MC centrifugal filter with a PTTK polysulfone membrane (cutoff 30 000 Da), let stand for 45 min, centrifuge for 10 min, inject an aliquot of the filtrate. HPLC VARIABLES Column: 150 × 2.1 Hamilton PRP-1 Mobile phase: MeCN:water:ammonium hydroxide 80:20:0.03 Flow rate: 0.3 Detector: MS, Finnigan MAT TSQ700, triple-stage quadrupole, electrospray, collision gas argon, positive ion mode, spray voltage 4 kV, sheath gas 90 psi, interface capillary 200◦ , collision offset – 20 V, m/z 293 CHROMATOGRAM Retention time: 0.9 EDTA 207 KEY WORDS dried blood REFERENCE Miller, M.L.; McCord, B.R.; Martz, R.; Budowle, B. The analysis of EDTA in dried bloodstains by electrospray LC-MS-MS and ion chromatography, J.Anal.Toxicol., 1997, 21, 521–528. 208 Efavirenz Efavirenz H N Molecular formula: C14 H9 ClF3 NO2 Molecular weight: 315.68 CAS Registry No: 154598-52-4 Merck Index: 13, 3552 Cl O O F3C SAMPLE Matrix: blood Sample preparation: Condition an Extrasep C18 SPE cartridge (Lida) with 2 mL MeOH and 2 mL water. Dilute 500 µL serum with 500 µL water, add to the SPE cartridge, wash with 500 µL water, elute with 1 mL MeOH. Evaporate the eluate to dryness with vortexing under reduced pressure at 40◦ and reconstitute the residue with 300 µL MeOH, inject a 10 µL aliquot. HPLC VARIABLES Column: two 150 × 4.6 3 µm Luna C18 columns in series Column temperature: 60 Mobile phase: Gradient. MeCN:4 mM sulfuric acid from 8:92 to 63:37 over 45 min, maintain at 63:37 for 5 min. Flow rate: 0.85 Injection volume: 10 Detector: UV 265 for 31 min then UV 240 CHROMATOGRAM Retention time: 51 Limit of detection: 62 ng/mL OTHER SUBSTANCES Extracted: delavirdine (25.5, LOD 110 ng/mL), indinavir (24.5, LOD 210 ng/mL), nelfinavir (33.5, LOD 400 ng/mL), nevirapine (23.5, LOD 84 ng/mL), ritonavir (50.5, LOD 510 ng/mL), saquinavir (35, LOD 100 ng/mL) KEY WORDS serum; SPE REFERENCE Simon, V.A.; Thiam, M.D.; Lipford, L.C. Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography, J.Chromatogr.A, 2001, 913, 447–453. SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 200 µL 10 µg/mL IS in water, add 200 µL 100 mM NaOH, mix, add 4 mL diethyl ether, shake for 5 min, centrifuge at 2500 rpm for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 200 µL initial mobile phase, inject a 100 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 Stability RP18 (CIL, France) Mobile phase: Gradient. MeCN:50 mM pH 5.65 phosphate buffer from 36:64 to 64:36 over 25 min, to 80:20 (step gradient), maintain at 80:20 for 10 min, re-equilibrate at initial conditions for 5 min. Flow rate: 1.5 Efavirenz 209 Injection volume: 100 Detector: UV 240 for 5 min, UV 215 for 22 min, UV 260 for rest of run CHROMATOGRAM Retention time: 19.9 Internal standard: JR051012 (Janssen Cilag) (28.2) Limit of quantitation: 50 ng/mL OTHER SUBSTANCES Extracted: amprenavir (11.2), indinavir (8.5), lopinavir (18.9), nelfinavir (24.1), nevirapine (3.3), ritonavir (17.6), saquinavir (16.7) Noninterfering: acetaminophen, amineptine, amphotericin B, aspirin, bromazepam, buspirone, citalopram, clobazam, diazepam, didanosine, fluconazole, flunitrazepam, fluvoxamine, hydroxyitraconazole, isoniazid, itraconazole, lamivudine, loprazolam, lorazepam, metronidazole, minalcipram, nordiazepam, omeprazole, paroxetine, pyrimethamine, rifampin, sertraline, stavudine, sulfadiazine, trimethoprim, venlafaxine, zalcitabine, zidovudine, zolpidem, zopiclone KEY WORDS plasma REFERENCE Titier, K.; Lagrange, F.; Péhourcq, F.; Edno-Mcheik, L.; Moore, N.; Molimard, M. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma, Ther.Drug Monit., 2002, 24, 417–424. SAMPLE Matrix: bulk, formulations Sample preparation: Inject a 35 µL aliquot of a solution in MeCN:water 52.5:47.5. HPLC VARIABLES Column: 150 × 4.6 Zorbax SB-CN Column temperature: 40 Mobile phase: Gradient. A:B from 40:60 to 50:50 over 16 min, to 65:35 over 7 min, to 70:30 over 5 min, to 80:20 over 1 min, maintain at 80:20 for 2 min, return to initial conditions over 1 min, re-equilibrate for 8 min. A was MeOH:water:trifluoroacetic acid 90:10:0.05. B was MeOH:water:trifluoroacetic acid 10:90:0.05. Flow rate: 1.5 Injection volume: 35 Detector: UV 250 CHROMATOGRAM Retention time: 15 Limit of detection: 0.01% Limit of quantitation: 0.05% OTHER SUBSTANCES Simultaneous: impurities KEY WORDS capsules; stability-indicating 210 Efavirenz REFERENCE Montgomery, E.R.; Edmanson, A.L.; Cook, S.C.; Hovsepian, P.K. Development and validation of a reverse-phase HPLC method for analysis of efavirenz and its related substances in the drug substance and in a capsule formulation, J.Pharm.Biomed.Anal., 2001, 25, 267–284. ANNOTATED BIBLIOGRAPHY Aarnoutse, R.E.; Grintjes, K.J.T.; Telgt, D.S.C.; Stek, M. Jr.; Hugen, P.W.H.; Reiss, P.; Koopmans, P.P.; Hekster, Y.A.; Burger, D.M. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers, Clin.Pharmacol.Ther., 2002, 71, 57–67. Aymard, G.; Legrand, M.; Trichereau, N.; Diquet, B. Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography, J.Chromatogr.B, 2000, 744, 227–240. [amprenavir; efavirenz; indinavir; nelfinavir; ritonavir; saquinavir; abacavir; didanosine; lamivudine; stavudine; nevirapine; zidovudine] Balani, S.K.; Kauffman, L.R.; deLuna, F.A.; Lin, J.H. Nonlinear pharmacokinetics of efavirenz (DMP266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys, Drug Metab.Dispos., 1999, 27, 41–45. Cociglio, M.; Hillaire-Buys, D.; Peyriègre, H.; Alric, R. Performance analysis of a rapid HPLC determination with the solvent demixing extraction of HIV antiproteases and efavirenz in plasma, J.Chromatogr.Sci., 2003, 41, 80–86. [efavirenz; indinavir; amprenavir; ritonavir; saquinavir; nelfinavir] Fan, B.; Bartlett, M.G.; Stewart, J.T. Determination of lamivudine/stavudine/efavirenz in human serum using liquid chromatography/electrospray tandem mass spectrometry with ionization polarity switch, Biomed.Chromatogr., 2002, 16, 383–389. [aprobarbital is internal standard; SPE] Faux, J.; Venisse, N.; Le Moal, G.; Dupuis, A.; Bouquet, S. Simultaneous determination of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography after solid-phase extraction, Chromatographia, 2003, 58, 421–426. [amprenavir; indinavir; lopinavir; nelfinavir; ritonavir; saquinavir; efavirenz; nevirapine; prazepam is internal standard; SPE] Keil, K.; Frerichs, V.A.; DiFrancesco, R.; Morse, G. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma, Ther.Drug Monit., 2003, 25, 340–346. Langmann, P.; Schirmer, D.; Väth, T.; Zilly, M.; Klinker, H. High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy, J.Chromatogr.B, 2001, 755, 151–156. Lavison, G.; Thiébaut, D. Evaluation of a ristocetin bonded stationary phase for subcritical fluid chromatography of enantiomers, Chirality, 2003, 15, 630–636. [warfarin; efavirenz; chiral; thalidomide] Marzolini, C.; Telenti, A.; Buclin, T.; Biollaz, J.; Decosterd, L.A. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction, J.Chromatogr.B, 2000, 740, 43–58.. [SPE] Marzolini, C.; Béguin, A.; Telenti, A.; Schreyer, A.; Buclin, T.; Biollaz, J.; Decosterd, L.A. Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery, J.Chromatogr.B, 2002, 774, 127–140. [SPE; clozapine is internal standard] Matthews, C.Z.; Woolf, E.J.; Mazenko, R.S.; Haddix-Wiener, H.; Chavez-Eng, C.M.; Constanzer, M.L.; Doss, G.A.; Matuszewski, B.K. Determination of efavirenz, a selective non-nucleoside reverse transcriptase inhibitor, in human plasma using HPLC with post-column photochemical derivatization and fluorescence detection, J.Pharm.Biomed.Anal., 2002, 28, 925–934. Maurin, M.B.; Rowe, S.M.; Blom, K.; Pierce, M.E. Kinetics and mechanism of hydrolysis of efavirenz, Pharm.Res., 2002, 19, 517–521. Mutlib, A.E.; Chen, H.; Nemeth, G.; Gan, L.; Christ, D.D. Liquid chromatography/mass spectrometry and high-field nuclear magnetic resonance characterization of novel mixed diconjugates of the non-nucleoside human immunodeficiency virus-1 reverse transcriptase inhibitor, efavirenz, Drug Metab.Dispos., 1999, 27, 1045–1056. Poirier, J.-M.; Robidou, P.; Jaillon, P. Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite Efavirenz 211 and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography, Ther.Drug Monit., 2002, 24, 302–309. Proust, V.; Toth, K.; Hulin, A.; Taburet, A.-M.; Gimenez, F.; Singlas, E. Simultaneous high-performance liquid chromatographic determination of the antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasma, J.Chromatogr.B, 2000, 742, 453–458. Rentsch, K.M. Sensitive and specific determination of eight antiretroviral agents in plasma by highperformance liquid chromatography-mass spectrometry, J.Chromatogr.B, 2003, 788, 339–350. [SPE; amprenavir; efavirenz; indinavir; lopinavir; nelfinavir; nevirapine; ritonavir; saquinavir] Rezk, N.L.; Tidwell, R.R.; Kashuba, A.D.M. Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using highperformance liquid chromatography with ultraviolet absorbance detection, J.Chromatogr.B, 2002, 774, 79–88. [SPE] Sarasa-Nacenta, M.; López-Púa, Y.; López-Cortés, L.F.; Mallolas, J.; Gatell, J.M.; Carné, X. Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 2001, 763, 53–59. Simon, V.A.; Thiam, M.D.; Lipford, L.C. Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography, J.Chromatogr.A, 2001, 913, 447–453. [zalcitabine; lamivudine; stavudine; didanosine; zidovudine; nevirapine; abacavir; indinavir; delavirdine; nelfinavir; saquinavir; ritonavir; efavirenz] Störmer, E.; von Moltke, L.L.; Perloff, M.D.; Greenblatt, D.J. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture, Pharm.Res., 2002, 19, 1038–1045. [verapamil; efavirenz; nevirapine; delavirdine] Tribut, O.; Arvieux, C.; Michelet, C.; Chapplain, J.-M.; Allain, H.; Bentué-Ferrer, D. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography, Ther.Drug Monit., 2002, 24, 554–562. [nevirapine; efavirenz; indinavir; amprenavir; nelfinavir; ritonavir; lopinavir; saquinavir] Turner, M.L.; Reed-Walker, K.; King, J.R.; Acosta, E.P. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography, J.Chromatogr.B, 2003, 784, 331–341. [indinavir; nelfinavir; saquinavir; ritonavir; amprenavir; delavirdine; efavirenz; lopinavir] Usami, Y.; Oki, T.; Nakai, M.; Sagisaka, M.; Kaneda, T. A simple HPLC method for simultaneous determination of lopinavir, ritonavir and efavirenz, Chem.Pharm.Bull., 2003, 26, 715–718. Veldkamp, A.I.; van Heeswijk, R.P.G.; Meenhorst, P.L.; Mulder, J.W.; Lange, J.M.A.; Beijnen, J.H.; Hoetelmans, R.M.W. Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 1999, 734, 55–61. Villani, P.; Pregnolato, M.; Banfo, S.; Rettani, M.; Burroni, D.; Seminari, E.; Maserati, R.; Regazzi, M.B. High-performance liquid chromatography method for analyzing the antiretroviral agent efavirenz in human plasma, Ther.Drug Monit., 1999, 21, 346–350. [saquinavir is internal standard] Villani, P.; Feroggio, M.; Gianelli, L.; Bartoli, A.; Montagna, M.; Maserati, R.; Regazzi, M.B. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography-mass spectrometry assay, Ther.Drug Monit., 2001, 23, 380–388. [saquinavir; indinavir; ritonavir; nelfinavir; amprenavir; nevirapine; delavirdine; efavirenz] Ward, B.A.; Gorski, J.C.; Jones, D.R.; Hall, S.D.; Flockhart, D.A.; Desta, Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity, J.Pharmacol.Exp.Ther., 2003, 306, 287–300. Weissburg, R.P.; Montgomery, E.R.; Junnier, L.A.; Segretario, J.; Cook, S.; Hovsepian, P.K. Investigation of critical factors for the resolution of SR695, a key impurity, from efavirenz in the reversed-phase assay of efavirenz dosage forms, J.Pharm.Biomed.Anal., 2002, 28, 45–56. Xu, J.Q.; Aubry, A.-F. Impurity profiling of non-nucleoside reverse transcriptase inhibitors by HPLC using a porous graphitic carbon stationary phase, Chromatographia, 2003, 57, 67–71. 212 Efrotomycin Efrotomycin Molecular formula: C59 H88 N2 O20 Molecular weight: 1145.33 CAS Registry No: 56592-32-6 Merck Index: 13, 3556 HO CH3O H3C OCH3 O O H3C O OCH3 OH O CH3 CH3 CH3 OH CH3 H OCH3 O N O OH O CH3 CH3 OH OH O CH3 HO O N CH3 SAMPLE Matrix: feed Sample preparation: Condition a 2.8 mL Bond-Elut NH2 SPE cartridge with 1 mL MeCN:dichloromethane 50:50 saturated with 50 mM pH 7.5 potassium phosphate buffer. Shake 100 g blended homogenized feed with 320 mL 50 mM pH 7.5 potassium phosphate buffer in a 950 mL amber bottle for 30 min, add 280 mL MeCN, shake for 15 min, centrifuge a 30 mL aliquot at 2500 rpm for 10 min. Remove a 5 mL aliquot and add it to 10 mL dichloromethane and 20 mL MeCN:dichloromethane 50:50 saturated with 50 mM pH 7.5 potassium phosphate buffer, shake for 30 min, centrifuge at 2500 rpm for 10 min. Add 10 mL of the lower phase to the SPE cartridge, wash with 2 mL MeOH, wash with 2 mL ethyl acetate, wash with 2 mL hexane, draw air through the cartridge for 5 min, elute with 1 mL elution solvent, inject a 100 µL aliquot of the eluate. (The elution solvent was 250 mM pH 5 phosphate buffer containing 1.5 M LiCl saturated with MeCN. Prepare by mixing 500 mL of this aqueous phase with 250 mL MeCN.) HPLC VARIABLES Column: 150 × 4.6 Zorbax C8 Column temperature: 55 Mobile phase: MeCN:MeOH:water:85% phosphoric acid 32.5:22.5:57.5:1 (Adjust with MeCN or water to give a k’ of 19–22.) Flow rate: 2 Injection volume: 100 Detector: UV 335 CHROMATOGRAM Retention time: 10 Limit of quantitation: 2 ppm KEY WORDS SPE REFERENCE Stong, J.D. Determination of efrotomycin in feeds by high-performance liquid chromatography, Analyst, 1986, 111, 853–855. Egualen Egualen 213 CH3 CH3 SO3H Molecular formula: C15 H18 O3 S Molecular weight: 278.37 CAS Registry No: 99287-30-6 CH3 SAMPLE Matrix: blood Sample preparation: Prepare plasma using a Sep-Pak C18 SPE cartridge (no further details). HPLC VARIABLES Column: 250 × 4.6 TSK-gel ODS-80TM Mobile phase: Gradient. MeCN:20 mM pH 6.0 phosphate buffer 20:80 for 10 min, to 30:70 over 10 min, maintain at 30:70 for 15 min. Flow rate: 1 Detector: Radioactivity (14 C) OTHER SUBSTANCES Extracted: metabolites KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Sato, M.; Suzaka, H.; Miyazaki, H. Sex-related differences in urinary excretion of egualen sodium in rats, Drug Metab.Dispos., 2000, 28, 21–27. 214 Eletriptan Eletriptan H N Molecular formula: C22 H26 N2 O2 S Molecular weight: 382.53 CAS Registry No: 143322-58-1 Merck Index: 13, 3577 N S O O CH3 SAMPLE Matrix: blood, saliva Sample preparation: Mix 570 µL plasma or saliva with 130 µL 1 (plasma) or 0.1 (saliva) M monochloroacetic acid containing 500 ng/mL IS. Place 690 µL of this mixture in the donor channel of a dialyzer fitted with a15 kDa cuprophan membrane (regenerated cellulose, Enka, Germany), pass 3500 µL recipient solvent in 500 µL pulsed bursts through the acceptor channel over 4 min, pass the recipient solvent through column A, wash column A with 200 µL MeCN:water 60:40, wash with 800 µL donor solvent, backflush the contents of column A onto column B with the mobile phase, monitor the effluent from column B. (The donor solvent was 10 mM pH 7.0 potassium phosphate buffer. Recipient solvent was MeOH:10 mM pH 7.0 potassium phosphate buffer 10:90. After each run, purge the donor channel with 1.5 mL donor solvent. Purge the HPLC system with 14 mL of donor and recipient solvent. Condition column A with 200 µL recipient solvent.) HPLC VARIABLES Column: A 5 × 4.6 10 µm Hypersil C1; B 100 × 4.6 5 µm Kromasil C1 Mobile phase: MeCN:500 mM pH 3.5 potassium phosphate buffer:water 30:6:64 (Add 20 mM diethylamine hydrochloride to the buffer/water mixture before adding the MeCN.) Flow rate: 1 Detector: UV 225 CHROMATOGRAM Retention time: 5 Internal standard: UK-136,509 (7) Limit of quantitation: 0.5 ng/mL OTHER SUBSTANCES Extracted: metabolite KEY WORDS column-switching; dialysis; pharmacokinetics; plasma REFERENCE Cooper, J.D.H.; Muirhead, D.C.; Taylor, J.E. Determination of eletriptan in plasma and saliva using automated sequential trace enrichment of dialysate and high-performance liquid chromatography, J.Pharm.Biomed.Anal., 1999, 21, 787–796. 215 Emtricitabine Emtricitabine Molecular formula: C8 H10 FN3 O3 S Molecular weight: 247.25 CAS Registry No: 143491-57-0 Merck Index: 13, 3597 NH2 F HO S N N O O SAMPLE Matrix: blood, CSF, urine Sample preparation: Plasma. Mix 100 µL serum, 50 µL 20 µg/mL IS, and 50 µL 2 M perchloric acid, centrifuge at 5000 g for 5 min, add 50 µL 2 M KOH, mix well, centrifuge at 5000 g for 5 min, inject a 15–200 µL aliquot. CSF. Mix 100 µL CSF with 20 µL IS solution and 80 µL water, inject a 100 µL aliquot. Urine. Dilute 50 µL urine and 100 µL IS solution to 1 mL with water, inject a 15–100 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Hypersil octadecanoylsulfate (sic) (Alltech) Mobile phase: MeOH:40 mM pH 2.5 potassium phosphate buffer 5.5:94.5 Flow rate: 2 Injection volume: 15–200 Detector: UV 279 CHROMATOGRAM Retention time: 5.5 Internal standard: 3′ deoxy-2′ ,3′ -didehydrothymidine (9.5) Limit of quantitation: 100 ng/mL OTHER SUBSTANCES Extracted: 2,3′ -dideoxy-5-fluoro-3′ -thiauridine (FTU) (8.3) KEY WORDS monkey; pharmacokinetics; plasma REFERENCE Schinazi, R.F.; Boudinot, F.D.; Ibrahim, S.S.; Manning, C.; McClure, H.M.; Liotta, D.C. Pharmacokinetics and metabolism of racemic 2′ ,3′ -dideoxy-5-fluoro-3′ -thiacytidine in rhesus monkeys, Antimicrob.Agents Chemother., 1992, 36, 2432–2438. SAMPLE Matrix: cell cultures Sample preparation: Extract cells twice with 4 mL portions of MeOH:water 60:40 at – 70◦ overnight, centrifuge at 2000 g for 10 min. Evaporate the methanol from a 500 µL aliquot under a stream of nitrogen, adjust the volume to 200 µL with water, inject a 180 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 10 µm Partisil SAX Mobile phase: Gradient. A:B 100:0 for 10 min, to 0:100 over 65 min. A was 8 mM pH 3.5 potassium phosphate buffer. B was 1 M pH 3.5 potassium phosphate buffer. Flow rate: 1 Injection volume: 180 Detector: Radioactivity (3 H) 216 Emtricitabine CHROMATOGRAM Retention time: 5 OTHER SUBSTANCES Extracted: emtricitabine monophosphate (25), emtricitabine diphosphate (40), emtricitabine triphosphate (57) KEY WORDS peripheral blood mononuclear cells REFERENCE Darque, A.; Valette, G.; Rousseau, F.; Wang, L.H.; Sommadossi, J.-P.; Zhou, X.-J. Quantitation of intracellular triphosphate for emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients, Antimicrob.Agents Chemother., 1999, 43, 2245–2250. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 10 µm Chiralpak AS Mobile phase: Isopropanol Flow rate: 0.8 Detector: UV 270 CHROMATOGRAM Retention time: 5.9 (emtricitabine), 9.5 ((+)-enantiomer) KEY WORDS chiral REFERENCE Schinazi, R.F.; McMillan, A.; Cannon, D.; Mathis, R.; Lloyd, R.M.; Peck, A.; Sommadossi, J.-P.; St. Clair, M.; Wilson, J.; Furman, P.A.; Painter, G.; Choi, W.-B.; Liotta, D.C. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3oxathiolan-5-yl]cytosine, Antimicrob.Agents Chemother., 1992, 36, 2423–2431. ANNOTATED BIBLIOGRAPHY Cass, Q.B.; Watanabe, C.S.F.; Rabi, J.A.; Bottari, P.Q.; Costa, M.R.; Nascimento, R.M.; Cruz, J.E.D.; Ronald, R.C. Polysaccharide-based chiral phase under polar organic mode of elution in the determination of the enantiomeric purity of emtricitabine an anti-HIV analogue nucleoside, J.Pharm.Biomed. Anal., 2003, 33, 581–587. Paff, M.T.; Averett, D.R.; Prus, K.L.; Miller, W.H.; Nelson, D.J. Intracellular metabolism of (-) and (+)cis-5-fluoro-1-[2-(hydroxymethyl)- 1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (Subclone P5A) cells, Antimicrob.Agents Chemother., 1994, 38, 1230–1238. Enoxaparin sodium 217 Enoxaparin sodium Molecular weight: ca. 4500 CAS Registry No: 9041-08-1 Merck Index: 13, 3621 SAMPLE Matrix: solutions HPLC VARIABLES Column: 300 × 3.2 Superdex (Pharmacia PC 3.2/30) Mobile phase: 200 mM NaCl Flow rate: 0.1 Detector: Refractive Index CHROMATOGRAM Retention time: 12–16 REFERENCE Intes, O.; Renault, J.-H.; Sinquin, C.; Zèches-Hanrot, M.; Nuzillard, J.-M. Fractionation of low-molecularmass heparin by centrifugal partition chromatography in the ion-exchange displacement mode, J.Chromatogr.A, 2001, 918, 47–57. 218 Entacapone Entacapone Molecular formula: C14 H15 N3 O5 Molecular weight: 305.29 CAS Registry No: 130929-57-6 Merck Index: 13, 3626 O HO N CN HO CH3 CH3 NO2 SAMPLE Matrix: blood, urine Sample preparation: Plasma. Add 50 µL 50 mM pH 7.2 phosphate buffer to 1 mL plasma, vortex, add 100 µL 2 M HCl, add 6 mL n-hexane:ethyl acetate 50:50, vortex for 2 min, centrifuge at 3500 g for 5 min. Remove 5 mL of the organic layer, evaporate it to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 500 µL DMSO, inject a 20 µL aliquot. Urine. Add 50 µL 50 mM pH 7.2 phosphate buffer to 1 mL urine, vortex, add 100 µL 2 M HCl, vortex, add 5 mL n-hexane:ethyl acetate 75:25, vortex for 2 min, centrifuge at 3500 g for 5 min. Remove 4 mL of the organic layer and add it to 1 mL 50 mM pH 7.2 phosphate buffer, vortex for 2 min, centrifuge at 3500 g for 5 min, inject a 30 µL aliquot of the aqueous layer. (Protect from light during preparation.) HPLC VARIABLES Guard column: µBondapak Guard-PAC C18 Column: 250 × 4 10 µm Lichrosorb C18 Column temperature: 35 (plasma), 28 (urine) Mobile phase: MeOH:THF:buffer A 50:5:63 (plasma) or MeCN:THF:buffer B 50:5:125 (urine) (Buffer A was 50 mM sodium dihydrogen phosphate containing 20 mM citric acid and 0.25 mM EDTA, adjusted to pH 2.0 with phosphoric acid. Buffer B was 50 mM sodium dihydrogen phosphate containing 20 mM citric acid and 0.25 mM EDTA, adjusted to pH 3.0 with 10 M NaOH.) Flow rate: 1.5 Injection volume: 20 (plasma), 30 (urine) Detector: E, Bioanalytical Systems LC-4B, glassy carbon electrode 700 mV, Ag/AgCl reference electrode CHROMATOGRAM Retention time: 7.5 (plasma), 10.7 (urine) Limit of quantitation: 10 ng/mL OTHER SUBSTANCES Extracted: Z-isomer (5.3 (plasma), 9.1 (urine)) Noninterfering: carbidopa, 3,4-dihydroxyphenylacetic acid, homovanillic acid, levodopa, 3-O-methyldopa KEY WORDS pharmacokinetics; plasma REFERENCE Karlsson, M.; Wikberg, T. Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine, J.Pharm.Biomed.Anal., 1992, 10, 593–600. ANNOTATED BIBLIOGRAPHY Keski-Hynnilä, H.; Kurkela, M.; Elovaara, E.; Antonio, L.; Magdalou, J.; Luukkanen, L.; Taskinen, J.; Kostiainen, R. Comparison of electrospray, atmospheric pressure chemical ionization, and atmospheric pressure photoionization in the identification of apomorphine, dobutamine, and entacapone phase II Entacapone 219 metabolites in biological samples, Anal.Chem., 2002, 74, 3449–3457. [urine; microsomal incubations; entacapone metabolites only] Luukkanen, L.; Kilpelainen, I.; Kangas, H.; Ottoila, P.; Elovaara, E.; Taskinen, J. Enzyme-assisted synthesis and structural characterization of nitrocatechol glucuronides, Bioconjug.Chem., 1999, 10, 150–154. [HPLC of metabolites only] Wikberg, T.; Ottoila, P.; Taskinen, J. Identification of major urinary metabolites of the catechol-Omethyltransferase inhibitor entacapone in the dog, Eur.J.Drug Metab.Pharmacokinet., 1993, 18, 359–367. Wikberg, T.; Vuorela, A.; Ottoila, P.; Taskinen, J. Identification of major metabolites of the catechol-Omethyltransferase inhibitor entacapone in rats and humans, Drug Metab.Dispos., 1993, 21, 81–92. Wikberg, T.; Vuorela, A. Metabolite profiles of two [14 C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile, Eur.J.Drug Metab.Pharmacokinet., 1994, 19, 125–135. [HPLC of metabolites only] 220 Eperisone Eperisone Molecular formula: C17 H25 NO O N H3C CH3 Molecular weight: 259.39 CAS Registry No: 64840-90-0 Merck Index: 13, 3637 SAMPLE Matrix: blood Sample preparation: Mix 1 mL water, 100 µL 1 µg/mL IS in MeOH, and 1 mL 1 M pH 7.2 phosphate buffer with 100 µL plasma, add 4 mL diethyl ether, extract, repeat extraction. Combine the organic layers and add them to 200 µL 100 mM HCl, extract, inject a 70 µL aliquot of the aqueous layer. HPLC VARIABLES Column: 250 × 4.6 YMC pack A-303 Mobile phase: MeCN:5 mM pH 2.5 sodium dodecyl sulfate 50:50 Flow rate: 1 Injection volume: 70 Detector: UV 256 CHROMATOGRAM Internal standard: tolperisone HCl Limit of quantitation: 2 ng/mL KEY WORDS plasma REFERENCE Matsunaga, M.; Uemura, Y.; Yonemoto, Y.; Kanai, K.; Etoh, H.; Tanaka, S.; Atsuta, Y.; Nishizawa, Y.; Yamanishi, Y. Long-lasting muscle relaxant activity of eperisone hydrochloride after percutaneous administration in rats, Jpn.J.Pharmacol., 1997, 73, 215–220. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 10 µm Cosmosil 5C18-MS Column temperature: 50 Mobile phase: Gradient. MeCN:10 mM pH 4.2 potassium phosphate buffer 0:100 for 2 min, to 75:25 over 7.5 min, maintain at 75:25 for 5.5 min. Isocratic. MeCN:buffer 20:80 Flow rate: 1.5 Detector: UV (wavelength not specified) CHROMATOGRAM Retention time: 8.7 (gradient) or 5.8 (isocratic) OTHER SUBSTANCES Simultaneous: acetazolamide (7.9), acyclovir (7.0), allopurinol (7.3), aniracetam (8.6), benazepril (11.5), betamethasone (10.8), camostat mesylate (8.8), carbamazepine (10.8), cilazapril (10.7), cimetidine (7.5), clofibrate (15.0), clonazepam (11.3), cyclophosphamide (9.9), delapril (11.9), dexamethasone (10.9), diazepam (12.5), digoxin (9.0), dilazep (10.6), diltiazem (10.2), docarpamine (11.4), ethosuximide (9.0), fenbufen (11.8), fluconazole (9.2), flutamide (12.7), fominoben (12.6), hydrocortisone acetate (12.1), imidapril Eperisone 221 (10.1), indomethacin (12.6), irinotecan (9.2), maprotiline (10.5), methotrexate (8.0), nefiracetam (9.7), nifedipine (11.9), nitrazepam (11.2), pentobarbital (10.9), phenobarbital (10.0), phenytoin (10.8), pindolol (8.3), pranlukast (13.4), pranoprofen (10.4), prednisolone (10.3), primidone (8.9), quinapril (10.5), spironolactone (12.4), sulpiride (7.6), sulthiame (9.3), tolbutamide (11.6), tranilast (10.5), triamcinolone (11.2), warfarin (12.0), zonisamide (9.5) (gradient retention times; isocratic conditions may differ) REFERENCE Sugiyama, T.; Matsuyama, R.; Usui, S.; Katagiri, Y.; Hirano, K. Selection of mobile phases in highperformance liquid chromatographic determination for medicines, Biol.Pharm.Bull., 2000, 23, 274–278. ANNOTATED BIBLIOGRAPHY Nakamura, K.; Fujima, H.; Kitagawa, H.; Wada, H.; Makino, K. Preparation and chromatographic characteristics of a chiral-recognizing perphenylated cyclodextrin column, J.Chromatogr.A, 1995, 694, 111–118. [ibuprofen; chlorpheniramine; acetylpheneturide; alprenolol; arotinolol; atenolol; benzoin; biperiden; bunitrolol; chlormezanone; chlorphenesin; eperisone; flavanone; oxprenolol; phenylethyl alcohol; phenylethylamine; pindolol; proglumide; propranolol; trihexyphenidyl] 222 Eplerenone Eplerenone CH3 CH3 OH Molecular formula: C24 H30 O6 Molecular weight: 414.49 CAS Registry No: 107724-20-9 O O H O CO2CH3 SAMPLE Matrix: urine Sample preparation: Urine. Condition a 1 mL 100 mg Bond Elut C18 SPE cartridge with 2 mL MeCN and 2 mL water. Vortex 500 µL urine and 500 µL 1 µg/mL IS in 20 mM pH 7.4 ammonium acetate, add to the SPE cartridge, wash with 3 mL water, elute with 250 µL MeCN. Vortex the eluate with 250 µL 20 mM pH 7.4 ammonium acetate buffer, inject a 20 µL aliquot. Plasma. Condition a 1 mL 100 mg Bond Elut C18 SPE cartridge with 2 mL MeOH and 2 mL water. Centrifuge plasma at 2000 g at 4◦ for 10 min. Vortex 400 µL of the supernatant and 400 µL 500 ng/mL IS in water, add to the SPE cartridge, wash with 2 mL water, elute with 500 µL MeCN. Evaporate the eluate to dryness under a stream of nitrogen at room temperature, reconstitute the residue with 100 µL mobile phase, inject a 10 µL aliquot. (Plasma preparation from Zhang,J.Y.; Fast,D.M.; Breau,A.P. Development and validation of a liquid chromatography-tandem mass spectrometric assay for Eplerenone and its hydrolyzed metabolite in human plasma. J.Chromatogr.B 2003, 787, 333–344.) HPLC VARIABLES Column: 50 × 2.1 5 µm Zorbax XDB-C8 Mobile phase: MeCN:water 40:60 containing 10 mM ammonium acetate, pH 7.4 Flow rate: 0.1 Injection volume: 20 (urine), 10 (plasma) Detector: MS, PE Sciex API-III Plus quadrupole, ionspray, positive ionization, ionspray interface 4400 V, orifice 67 V, nebulizer gas nitrogen at 60 psi, curtain gas nitrogen at 1.8 L/min, collision gas argon, m/z 415–163 CHROMATOGRAM Retention time: 3.2 Internal standard: 13 C2 H3 -eplerenone (m/z 419–163) Limit of quantitation: 50 ng/mL (urine), 10 ng/mL (plasma) OTHER SUBSTANCES Extracted: metabolite KEY WORDS pharmacokinetics; SPE REFERENCE Zhang, J.Y.; Fast, D.M.; Breau, A.P. A validated SPE-LC-MS/MS assay for Eplerenone and its hydrolyzed metabolite in human urine, J.Pharm.Biomed.Anal., 2003, 31, 103–115. ANNOTATED BIBLIOGRAPHY Cook, C.S.; Berry, L.M.; Kim, D.H.; Burton, E.G.; Hribar, J.D.; Zhang, L. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: Differential metabolism by CYP3A4 and CYP3A5, Drug Metab.Dispos., 2002, 30, 1344–1351. [radioactivity detection (14 C); LC-MS] Cook, C.S.; Zhang, L. Atypical dose-route-dependent food effects of eplerenone in the dog: Presence of food effects following intravenous dosing and lack of food effects of following oral dosing, J.Pharm.Sci., 2002, 91, 607–614. Eplerenone 223 Cook, C.S.; Berry, L.M.; Bible, R.H.; Hribar, J.D.; Hajdu, E.; Liu, N.W. Pharmacokinetics and metabolism of [14 C]eplerenone after oral administration to humans, Drug Metab.Dispos., 2003, 31, 1448–1455. [radioactivity detection; LC-MS] Cook, C.S.; Zhang, L.; Ames, G.B.; Fischer, J.; Zhang, J.; Levin, S. Single-and repeated-dose pharmacokinetics of eplerenone, a selective aldosterone receptor blocker, in rats, Xenobiotica, 2003, 33, 305–321. [LC-MS; SPE] 224 Epoprostenol Epoprostenol HOOC O Molecular formula: C20 H32 O5 Molecular weight: 352.46 CAS Registry No: 35121-78-9, 61849-14-7 (Na salt) Merck Index: 13, 7967 H H CH3 OH OH SAMPLE Matrix: blood Sample preparation: Pack a polypropylene column with 1 g Hi-Flosil (80/100) C18 material (Applied Science) in an MeCN slurry, add 5 mL 10% dimethyldichlorosilane in toluene, wash with 15 mL toluene, wash with 15 mL MeCN. Just prior to use, equilibrate with 15 mL 2 mM sodium borate adjusted to pH 10 with NaOH. Mix 1 mL whole blood with 10 mg/mL sodium carbonate solution, keep on ice, centrifuge at 2000 g at 4◦ for 10 min, add a 500 µL aliquot to the SPE column, wash with two 3 mL portions of 2 mM pH 10 sodium borate, elute with three 3 mL portions of MeCN:2 mM pH 10 sodium borate 40:60. Collect the eluate in a container containing 200 µL 200 mM NaOH. Evaporate the eluate to dryness under reduced pressure at 40◦ , reconstitute the residue with 1 mL 2 mM pH 9.1 sodium borate, inject a 100 µL aliquot. HPLC VARIABLES Column: 250 × 4 MCH-10 Mobile phase: Gradient. MeCN:2 mM pH 9.1 sodium borate from 12:88 to 27:73 over 7 min. Flow rate: 2 Injection volume: 100 Detector: UV 200; Radioactivity (3 H) CHROMATOGRAM Retention time: 6 OTHER SUBSTANCES Extracted: 6-ketoprostaglandin F1α (2) KEY WORDS SPE; whole blood REFERENCE Skrinska, V.; Lucas, F.V. Isolation of prostacyclin from whole blood, Prostaglandins, 1981, 22, 365–375. Eprosartan Eprosartan 225 N H3C Molecular formula: C23 H24 N2 O4 S Molecular weight: 424.52 CAS Registry No: 133040-01-4 Merck Index:: 13, 3664 S N COOH COOH SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg phenyl SPE cartridge (Analytichem) with 2 mL MeOH and 2 mL water. Add 500 µL 100 mM pH 3.5 citrate buffer to 500 µL plasma containing 200 ng IS, vortex briefly, centrifuge at 8800 g for 5 min. Add the supernatant to the SPE cartridge, wash with 2 mL 50 mM acetic acid, dry the cartridge by passing air through it for 45 s, wash with 1 mL ethyl acetate containing 0.1% triethylamine, dry with air for 45 s, elute with 2 mL MeOH:50 mM acetic acid 90:10. Evaporate the eluate to dryness under nitrogen at 45◦ , reconstitute the residue with 125 µL mobile phase, vortex, centrifuge at 1875 g for 10 min, inject a 50 µL aliquot of the supernatant. HPLC VARIABLES Guard column: 20 × 2 5 µm BDS-Hypersil C18 Column: 150 × 2 5 µm BDS-Hypersil C18 Mobile phase: THF:50 mM pH 3.5 citrate buffer 32:68 Flow rate: 0.25 Injection volume: 50 Detector: UV 300 CHROMATOGRAM Retention time: 9 Internal standard: SB-200062 [(E)-3-[2-butyl-1-[(4-carboxy-phenyl)methyl]-1H-imidazol-5-yl]-2-[(2-thienyl)-ethyl]propenoic acid] (12.3) Limit of quantitation: 10 ng/mL KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Lundberg, D.E. Jr.; Person, C.R.; Knox, S.; Cyronak, M.J. Determination of SK&F 108566 (Teveten) in human plasma by reversed-phase high-performance liquid chromatography, J.Chromatogr.B, 1998, 707, 328–333. SAMPLE Matrix: urine Sample preparation: Mix 100 µL urine with 200 µL 500 ng/mL IS in MeCN, vortex, centrifuge at 11 000 g, inject a 1 µL aliquot of the supernatant. HPLC VARIABLES Column: 20 × 2 3 µm Hypersil APS-2 amino Mobile phase: MeCN:10 mM pH 3.0 ammonium formate 80:20 Flow rate: 0.25 Injection volume: 1 Detector: MS, PE Sciex API-III Plus, ionspray, positive ion mode, split column effluent so 50 µL/min enters MS 226 Eprosartan CHROMATOGRAM Retention time: 0.42 Internal standard: unspecified (0.44) Limit of quantitation: 50 ng/mL KEY WORDS SPE REFERENCE Martin, D.E.; Chapelsky, M.C.; Ilson, B.; Tenero, D.; Boike, S.C.; Zariffa, N.; Jorkasky, D.K. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment, J.Clin.Pharmacol., 1998, 38, 129–137. 227 Eptazocine Eptazocine Molecular formula: C15 H21 NO Molecular weight:: 231.33 CAS Registry No: 72522-13-5 Merck Index:: 13, 3668 H N CH3 HO CH3 SAMPLE Matrix: blood Sample preparation: Add 100 µL 100 ng/mL IS in MeOH to 50 µL plasma, add 300 µL water, add 20 µL 25% ammonium hydroxide, vortex gently for 1 min, add 400 µL ethyl acetate, vortex for 5 min, centrifuge at 10 000 g for 10 min. Evaporate the organic layer to dryness under a stream of nitrogen at 38◦ , reconstitute the residue with 200 µL MeOH, inject a 20 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Cosmosil 5C18-MS Column temperature: 25 Mobile phase: MeOH:70 mM pH 3.0 sodium phosphate buffer containing 5 mM sodium heptylsulfonate 45:55 Flow rate: 0.8 Injection volume: 20 Detector: F ex 278 em 324 CHROMATOGRAM Retention time: 4.9 Internal standard: 7-methyleptazocine (7.2) Limit of detection: 5 ng/mL Limit of quantitation: 10 ng/mL KEY WORDS pharmacokinetics; plasma; rat REFERENCE Suzuki, T.; Shimizu, R.; Suganuma, T.; Nishino, J.; Tomono, K.; Hanano, M.; Watanabe, J. Pharmacokinetic/pharmacodynamic relationship of eptazocine, a narcotic-antagonist analgesic, in rats, Biol.Pharm. Bull., 2000, 23, 1504–1510. 228 Eptifibatide Eptifibatide Molecular formula: C35 H49 N11 O9 S2 Molecular weight: 831.98 CAS Registry No: 188627-80-7 Merck Index: 13, 3670 SAMPLE Matrix: formulations Sample preparation: Dilute oral solution with MeCN:water 70:30, inject a 100 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Pinnacle octyl amine (C8) (Restek) Mobile phase: Gradient. MeCN:buffer 17:83 for 15 min, to 100:0 over 5 min, return to initial conditions over 2 min. (The buffer was 0.1% trifluoroacetic acid in water containing 0.1% triethylamine.) Flow rate: 1 Injection volume: 100 Detector: UV 220 CHROMATOGRAM Retention time: 10.1 Limit of quantitation: 500 ng/mL OTHER SUBSTANCES Simultaneous: degradants KEY WORDS oral solution REFERENCE Zhao, L.; Yalkowsky, S.H. Stabilization of eptifibatide by cosolvents, Int.J.Pharm., 2001, 218, 43–56. SAMPLE Matrix: solutions HPLC VARIABLES Column: 30 mm long C18 (Perkin-Elmer) Mobile phase: Gradient. MeCN:water:trifluoroacetic acid from 80:20:0.1 to 75:25:0.1 (sic) over 5 min. Detector: UV 280 REFERENCE Schachter, D.M.; Kohn, J. A synthetic polymer matrix for the delayed or pulsatile release of water-soluble peptides, J.Control.Rel., 2002, 78, 143–153. Erdosteine Erdosteine Molecular formula: C8 H11 NO4 S2 O S 229 H N S COOH O Molecular weight: 249.31 CAS Registry No: 84611-23-4 Merck Index: 13, 3677 SAMPLE Matrix: blood Sample preparation: Mix 100 µL plasma, 500 µL water, 560 µL 100 mM pH 9.3 borate buffer, 10 µL 100 µM IS in water, and 420 µL 762 µg/mL DBD-F in MeCN, let stand at room temperature for 30 min (to derivatize thiol in metabolites and IS), evaporate the MeCN under reduced pressure, add 2 mL ethyl acetate to the remaining solution, mix vigorously, centrifuge at 3000 rpm for 2 min. Wash the aqueous layer three more times with ethyl acetate. Adjust the pH of the aqueous layer to 1–2 with ca. 1.5 mL 100 mM HCl, extract three times with 2 mL portions of ethyl acetate. Combine the organic layers and evaporate them to dryness under reduced pressure, reconstitute the residue with 100 µL MeCN. Remove a 50 µL aliquot, add 5 µL DPPA, add 45 µL 17.8 mg/mL R-(−)-DBD-Apy in MeCN, let stand at room temperature for 2 h (to derivatize carboxylic acid), inject an aliquot. (DBD-F is 4-(N, N-dimethylaminosulfonyl)-7fluoro-2,1,3-benzoxadiazole. R-(−)-DBD-Apy is R-(−)-4-(N, N-dimethylaminosulfonyl)7-(3-aminopyrrolidin-1-yl)-2,1,3-benzoxadiazole. DPPA is diphenyl phosphoryl azide. They are all available from Tokyo Kasei or TCI America (www.tciamerica.com).) HPLC VARIABLES Column: 150 × 4.6 5 µm Ultron VX-ODS Column temperature: 40 Mobile phase: Gradient. MeCN:water:trifluoroacetic acid 30:70:0.1 for 10 min, to 37:63:0.1 over 25 min, to 43:57:0.1 over 30 min. Flow rate: 1 Detector: F ex 468 em 563 CHROMATOGRAM Retention time: 11 Internal standard: captopril (41) Limit of detection: 0.22 pmol OTHER SUBSTANCES Extracted: metabolites KEY WORDS derivatization; plasma; rat REFERENCE Muramatsu, N.; Toyo’oka, T.; Yamaguchi, K.; Kobayashi, S. High-performance liquid chromatographic determination of erdosteine and its optical active metabolite utilizing a fluorescent chiral tagging reagent, R-(−)-4-(N,N-dimethylaminosulfonyl)-7-(3-aminopyrrolidin-1-yl)-2,1,3-benzoxadiazole, J. Chromatogr.B, 1998, 719, 177–189. 230 Ergotamine Ergotamine H O Molecular formula: C33 H35 N5 O5 Molecular weight: 581.66 CAS Registry No: 113-15-5 Merck Index: 13, 3696 HO N H3C O H N N O O N H CH3 N H SAMPLE Matrix: blood Sample preparation: Mix 1 mL whole blood with 20 µL 1 µg/mL dibenzepin in MeOH:water 50:50, add 300 µL pH 11 Tris buffer, mix, add 500 µL butyl acetate, vortex for 2 min, centrifuge. Preserve the aqueous layer (A). Remove the organic layer and add it to 75 µL 10 mM ammonium acetate buffer containing 0.1% formic acid (pH 3.2), evaporate (?). Add 75 µL MeCN, sonicate for 5 min, centrifuge at 5000 rpm for 5 min, keep the extract as B. Add 20 µL 1 µg/mL enalapril in MeOH:water 50:50 and 120 mg NaCl to the aqueous layer (A), mix, add 500 µL pH 3 phosphate buffer, add 600 µL 8.5% phosphoric acid, add 5 mL dichloromethane:isopropanol 95:5, shake at 250 cycles/min in a bench-top shaker for 30 min, centrifuge at 5000 rpm for 5 min. Remove the lower organic layer and evaporate it to dryness under a stream of air at 45◦ . Reconstitute the residue with 150 µL initial mobile phase, sonicate, centrifuge, combine with extract B, inject a 30 µL aliquot. (Sample preparation from Gergov,M.; Robson,J.N.; Ojanperä,I.; Heinonen,O.P.; Vuori,E. Simultaneous screening and quantitation of 18 antihistamine drugs in blood by liquid chromatography ionspray tandem mass spectrometry. Forensic Sci.Inter. 2001, 121, 108–115.) HPLC VARIABLES Guard column: 40 mm long 4 µm Purospher RP-18 LiChro Cart 4-4 Column: 100 × 2.1 4 µm Genesis C18 (Jones Chromatography) Column temperature: 35 Mobile phase: Gradient. MeCN:buffer from 20:80 to 100:0 over 10 min, maintain at 0:100 for 3 min, re-equilibrate at initial conditions for 5 min. (The buffer was 10 mM ammonium acetate containing 0.1% formic acid (pH 3.2).) Flow rate: 0.2 Injection volume: 30 Detector: MS, PE Sciex API 365 triple-stage quadrupole LC-MS-MS, PE Sciex TurboIonSpray interface, positive ion mode, needle voltage 5.2 kV, nebulizer gas air at 60 psi, curtain gas nitrogen at 40 psi, collision cell gas nitrogen at 40 psi, turbo ionspray heater 375◦ , heater gas flow 7 L/min CHROMATOGRAM Retention time: 5.5 Internal standard: dibenzepin, enalapril Limit of detection: 5 ng/mL OTHER SUBSTANCES Extracted: acebutolol (3.8, LOD 0.1 µg/mL), acrivastine (5.7, LOD <0.02 µg/mL), alprazolam (6.1, LOD <0.02 µg/mL), alprenolol (5.4, LOD 0.01 µg/mL), amantadine (3.4, LOD 0.1 µg/mL), amiloride (2.0, LOD 0.1 µg/mL), aminophenazone (2.8, LOD <5 µg/mL), amiodarone (10.2, LOD 0.05 µg/mL), amitriptyline (6.6, LOD <0.02 µg/mL), Ergotamine 231 astemizole (5.8, LOD <0.02 µg/mL), atenolol (1.7, LOD 0.30 µg/mL), azacyclonol (5.1, LOD 0.02 µg/mL), benzhexol (6.6, LOD <0.02 µg/mL), benzoylecgonine (3.3, LOD 0.01 µg/mL), betaxolol (5.5, LOD 0.01 µg/mL), biperidine (6.2, LOD <0.02 µg/mL), bisoprolol (5.0, LOD <0.02 µg/mL), brompheniramine (5.3, LOD 0.002 µg/mL), bupivacaine (5.1, LOD <0.02 µg/mL), buprenorphine (5.9, LOD 0.01 µg/mL), buspirone (5.1, LOD 0.002 µg/mL), caffeine (2.8, LOD 1 µg/mL), carbamazepine (6.1, LOD <0.02 µg/mL), carbinoxamine (5.1, LOD 0.002 µg/mL), carisoprodol (6.7, LOD <5 µg/mL), carvedilol (6.2, LOD <0.02 µg/mL), celiprolol (4.3, LOD 0.05 µg/mL), cetirizine (6.3, LOD 0.05 µg/mL), chlorcyclizine (6.6, LOD <0.02 µg/mL), chlordiazepoxide (5.7, LOD <0.02 µg/mL), chlormezanone (5.8, LOD <5 µg/mL), chloroquine (2.7, LOD 0.02 µg/mL), chlorpheniramine (5.1, LOD 0.002 µg/mL), chlorpromazine (7.0, LOD 0.02 µg/mL), chlorpropamide (6.7, LOD <5 µg/mL), chlorprothixene (7.0, LOD <0.02 µg/mL), cinnarizine (7.9, LOD <0.02 µg/mL), citalopram (5.7, LOD <0.02 µg/mL), clemastine (7.7, LOD 0.02 µg/mL), clobazam (7.3, LOD <0.02 µg/mL), clobutinol (5.3, LOD 0.02 µg/mL), clomethiazole (6.2, LOD 0.5 µg/mL), clomipramine (7.1, LOD <0.02 µg/mL), clonazepam (6.6, LOD <0.02 µg/mL), clonidine (2.8, LOD 0.1 µg/mL), clozapine (5.6, LOD <0.02 µg/mL), cocaine (4.6, LOD <0.02 µg/mL), codeine (2.5, LOD 0.1 µg/mL), coumatetralyl (8.4, LOD 0.05 µg/mL), cyclizine (5.8, LOD <0.02 µg/mL), dextropropoxyphene (6.6, LOD 0.05 µg/mL), demoxepam (5.8, LOD 0.02 µg/mL), dextromethorphan (5.5, LOD <0.02 µg/mL), diazepam (8.1, LOD 0.02 µg/mL), diltiazem (5.8, LOD <0.02 µg/mL), diphenhydramine (5.7, LOD <0.02 µg/mL), dipyridamole (5.4, LOD 0.005 µg/mL), disopyramine (4.4, LOD <0.02 µg/mL), dixyrazine (6.8, LOD 0.005 µg/mL), doxapram (4.8, LOD <0.02 µg/mL), doxepin (5.9, LOD <0.02 µg/mL), ebastine (9.6, LOD 0.005 µg/mL), embutramide (6.7, LOD 0.005 µg/mL), ethenzamide (5.0, LOD 0.05 µg/mL), ethylmorphine (3.2, LOD 0.05 µg/mL), ethylparathion (9.7, LOD <5 µg/mL), etodroxizine (6.4, LOD <0.02 µg/mL), felodipine (9.6, LOD 0.02 µg/mL), fenazepam (7.5, LOD <0.02 µg/mL), fenfluramine (5.3, LOD <0.02 µg/mL), fenkamfamine (5.1, LOD <0.02 µg/mL), fentanyl (5.5, LOD <0.02 µg/mL), fexofenadine (6.3, LOD <0.02 µg/mL), flecainide (5.9, LOD <0.02 µg/mL), fluconazole (4.0, LOD 0.1 µg/mL), flumazenil (5.2, LOD <0.02 µg/mL), flunitrazepam (7.1, LOD 0.002 µg/mL), fluoxetine (6.8, LOD 0.1 µg/mL), flupentixol (7.5, LOD 0.18 µg/mL), fluvoxamine (6.3, LOD 0.02 µg/mL), glibenclamide (8.5, LOD <0.02 µg/mL), glipizide (6.8, LOD <0.05 µg/mL), haloperidol (6.1, LOD <0.02 µg/mL), histapyrrodine (6.3, LOD 0.02 µg/mL), hydrocodone (3.0, LOD 0.05 µg/mL), hydroxychloroquine (2.4, LOD <0.3 µg/mL), hydroxyzine (6.3, LOD <0.02 µg/mL), imipramine (6.4, LOD 0.05 µg/mL), indomethacin (8.6, LOD 0.05 µg/mL), isoniazid (2.2, LOD 3 µg/mL), isradipine (8.6, LOD 0.05 µg/mL), ketamine (3.6, LOD <0.05 µg/mL), ketobemidone (3.3, LOD <0.05 µg/mL), ketoprofen (7.3, LOD 0.1 µg/mL), ketorolac (6.2, LOD 0.05 µg/mL), labetalol (4.9, LOD 0.05 µg/mL), lamotrigine (4.0, LOD 0.1 µg/mL), levocabastine (5.8, LOD 0.01 µg/mL), levomepromazine (6.5, LOD 0.02 µg/mL), lidocaine (3.7, LOD <0.05 µg/mL), loratadine (9.3, LOD 0.002 µg/mL), lorazepam (6.6, LOD 0.02 µg/mL), lormetazepam (7.4, LOD <0.02 µg/mL), LSD (4.7, LOD <0.02 µg/mL), malathion (8.9, LOD 10 µg/mL), maprotiline (6.4, LOD <0.02 µg/mL), MDMA (3.3, LOD 0.02 µg/mL), meclozine (8.5, LOD <0.02 µg/mL), medazepam (6.3, LOD <0.02 µg/mL), meloxicam (7.1, LOD 0.01 µg/mL), melperone (5.0, LOD <0.02 µg/mL), meperidine (4.7, LOD <0.02 µg/mL), mepivacaine (3.7, LOD <0.02 µg/mL), meprobamate (4.9, LOD 0.1 µg/mL), mesoridazine (5.4, LOD <0.02 µg/mL), methamphetamine (3.3, LOD 0.05 µg/mL), methadone (6.7, LOD <0.02 µg/mL), methylparathion (8.6, LOD 10 µg/mL), methylphenidate (4.2, LOD <0.02 µg/mL), metoclopramide (3.8, LOD <0.02 µg/mL), metoprolol (4.1, LOD 0.02 µg/mL), metronidazole (2.6, LOD 1 µg/mL), mexiletine (4.4, LOD 0.05 µg/mL), mianserin (5.7, LOD <0.02 µg/mL), midazolam (5.9, LOD <0.02 µg/mL), mirtazapine (4.4, LOD <0.02 µg/mL), mizolastine (5.5, LOD 0.01 µg/mL), moclobemide (3.7, LOD 0.05 µg/mL), molindone (4.0, LOD <0.02 µg/mL), monoacetylmorphine (2.7, LOD 0.1 µg/mL), morphine (2.0, LOD 0.1 µg/mL), nicotine (2.2, LOD 0.05 µg/mL), nifedipine (7.5, LOD 0.02 µg/mL), nikethamide (3.6, LOD <0.02 µg/mL), nitrazepam (6.5, LOD <0.02 µg/mL), nizatidine (1.7, LOD 1 µg/mL), nomifensine (4.6, LOD <0.02 µg/mL), nortriptyline (6.4, LOD <0.02 µg/mL), norverapamil (6.2, LOD 1 µg/mL), noscapine (5.0, LOD <0.02 µg/mL), olanzapine (3.0, LOD 0.05 µg/mL), ondansetron (4.6, LOD <0.02 µg/mL), orphenadrine (6.1, LOD <0.02 µg/mL), oxazepam (6.3, LOD 232 Ergotamine <0.02 µg/mL), oxcarbazepine (5.3, LOD 0.02 µg/mL), oxprenolol (4.7, LOD 0.02 µg/mL), oxycodone (2.8, LOD 0.05 µg/mL), papaverine (4.8, LOD <0.02 µg/mL), acetaminophen (2.5, LOD <5 µg/mL), paroxetine (6.2, LOD 0.02 µg/mL), pemoline (3.3, LOD 0.05 µg/mL), pentazocine (5.0, LOD <0.02 µg/mL), pentifylline (7.3, LOD <5 µg/mL), pentoxyverine (6.6, LOD <0.02 µg/mL), perphenazine (6.9, LOD 0.002 µg/mL), phenazone (3.9, LOD 0.05 µg/mL), phencyclidine (5.3, LOD 0.05 µg/mL), pheniramine (4.1, LOD 0.02 µg/mL), phenylbutazone (9.0, LOD <5 µg/mL), phenylpropanolamine (2.5, LOD 0.3 µg/mL), phenytoin (6.1, LOD 0.05 µg/mL), pindolol (3.3, LOD 0.05 µg/mL), piroxicam (6.6, LOD 0.02 µg/mL), pitofenone (5.4, LOD <0.02 µg/mL), pizotifen (6.5, LOD <0.02 µg/mL), practolol (1.8, LOD 0.1 µg/mL), prazosin (4.1, LOD 0.05 µg/mL), prilocaine (3.8, LOD <0.02 µg/mL), primidone (4.0, LOD <5 µg/mL), procainamide (2.2, LOD 0.05 µg/mL), prochlorperazine (7.5, LOD 0.02 µg/mL), promazine (6.2, LOD <0.02 µg/mL), promethazine (6.0, LOD 0.05 µg/mL), propafenone (6.3, LOD <0.02 µg/mL), propranolol (5.4, LOD 0.02 µg/mL), propyphenazone (6.6, LOD 0.50 µg/mL), pseudoephedrine (2.6, LOD 1 µg/mL), quinine (4.2, LOD 0.02 µg/mL), ranitidine (1.8, LOD 0.1 µg/mL), risperidone (4.9, LOD <0.02 µg/mL), rocurone (3.8, LOD 0.1 µg/mL), ropivacaine (4.6, LOD <0.02 µg/mL), salicylamide (4.2, LOD <5 µg/mL), selegiline (4.1, LOD 0.05 µg/mL), sertindole (7.2, LOD <0.02 µg/mL), sertraline (6.8, LOD 0.02 µg/mL), sulindac (6.5, LOD 0.02 µg/mL), simazine (6.0, LOD 0.1 µg/mL), sincocaine (6.5, LOD <0.02 µg/mL), sisapride (5.9, LOD <0.02 µg/mL), sotalol (2.1, LOD 0.1 µg/mL), strychnine (5.3, LOD 0.05 µg/mL), sulpiride (1.9, LOD 0.1 µg/mL), sulthiame (4.1, LOD 0.05 µg/mL), temazepam (7.2, LOD <0.02 µg/mL), terbutaline (2.3, LOD 0.1 µg/mL), terfenadine (8.1, LOD 0.002 µg/mL), terodiline (6.7, LOD <0.02 µg/mL), tetracaine (5.7, LOD <0.02 µg/mL), dronabinol (12.3, LOD 0.05 µg/mL), tetrahydrozoline (3.6, LOD 0.1 µg/mL), theobromine (2.3, LOD <5 µg/mL), theophylline (2.4, LOD <5 µg/mL), thioridazine (7.5, LOD 0.02 µg/mL), timolol (3.8, LOD 0.05 µg/mL), thiothixene (6.7, LOD 0.02 µg/mL), tolbutamide (7.1, LOD <5 µg/mL), toremifene (8.7, LOD 0.02 µg/mL), tramadol (4.2, LOD 0.02 µg/mL), trazodone (5.2, LOD <0.02 µg/mL), triamterene (3.2, LOD 0.1 µg/mL), triazolam (6.7, LOD 0.002 µg/mL), trimeprazine (6.4, LOD <0.02 µg/mL), trimethoprim (3.1, LOD 0.05 µg/mL), trimipramine (6.7, LOD <0.02 µg/mL), venlafaxine (4.9, LOD 0.02 µg/mL), verapamil (6.5, LOD <0.02 µg/mL), warfarin (7.9, LOD <0.02 µg/mL), yohimbine (4.5, LOD <0.02 µg/mL), zolpidem (4.7, LOD <0.02 µg/mL), zopiclone (4.0, LOD 0.1 µg/mL) KEY WORDS whole blood REFERENCE Gergov, M.; Ojanperä, I.; Vuori, E. Simultaneous screening for 238 drugs in blood by liquid chromatography-ionspray tandem mass spectrometry with multiple-reaction monitoring, J.Chromatogr.B, 2003, 795, 41–53. SAMPLE Matrix: blood Sample preparation: Rotate 2 mL plasma and 5 mL diethyl ether for 30 min, centrifuge, repeat the extraction. Combine the organic layers and evaporate them to dryness under a stream of nitrogen at room temperature, reconstitute the residue with 100 µL MeOH, inject a 50 µL aliquot. HPLC VARIABLES Guard column: 15 × 3.2 7 µm silica Newguard Column: 100 × 4.6 5 µm Spheri-5 silica Mobile phase: MeOH:water:acetic acid:MeCN 40:2:10 (sic) Flow rate: 1 Injection volume: 50 Detector: F ex 322 em 405 Ergotamine 233 CHROMATOGRAM Retention time: 7.5 Internal standard: ergotamine OTHER SUBSTANCES Extracted: lisuride (12) KEY WORDS ergotamine is IS in original paper; plasma; protect from light REFERENCE Wolthers, B.G.; Verhagen Kamerbeek, W.D.J.; van Beusekom, C.M.; Elshof, F.; de Ruyter Buitenhuis, A.W.; Brunt, E.P.R.; Lakke, J.P.W.F. Quantitative determination of the dopamine agonist lisuride in plasma using high-performance liquid chromatography with fluorescence detection, J.Chromatogr., 1993, 622, 33–38. SAMPLE Matrix: blood Sample preparation: Vortex 500 µL plasma, 200 µL 2.5 M potassium carbonate, and 3 mL diethyl ether. Remove a 2 mL aliquot of the organic layer and add it to 100 µL 50 mM sulfuric acid, vortex for 1 min, inject a 50 µL aliquot of the aqueous layer. HPLC VARIABLES Column: 250 × 4 5 µm Hypersil ODS RP-C18 Mobile phase: MeCN:MeOH:water 8:56:36 containing 200 mg (per 500 mL (?)) sodium heptanesulfonate Flow rate: 1 Injection volume: 50 Detector: UV 254 CHROMATOGRAM Retention time: 7 Internal standard: ergotamine OTHER SUBSTANCES Extracted: bromocriptine (13) KEY WORDS ergotamine is IS in original paper; plasma; rabbit REFERENCE Degim, I.T.; Acartürk, F.; Erdogan, D.; Lortlar, N.D. Transdermal administration of bromocriptine, Biol.Pharm.Bull., 2003, 26, 501–505. 234 Ertapenem Ertapenem Molecular formula: C22 H25 N3 O7 S Molecular weight: 475.52 CAS Registry No: 153832-46-3 Merck Index: 13, 3706 OH H H H N CH3 H3C S O N COOH O N COOH H SAMPLE Matrix: blood Sample preparation: Filter (Amicon Centrifree) 1 mL plasma while centrifuging at 1500 g for 15 min, mix an aliquot of the filtrate with an equal volume of buffer, inject a 50 µL aliquot. (Prepare the buffer by dissolving 15.5 g sodium 2-[N-morpholino]ethane sulfonate (MES) and 5.58 g 2-[N-morpholino]ethane sulfonic acid in 100 mL water. Dilute this stock solution 10-fold before use, pH 6.5.) HPLC VARIABLES Column: 100 × 4.6 5 µm Hypersil C18 Mobile phase: MeOH:25 mM phosphate buffer 10:90, apparent pH 6.5 Flow rate: 2 Injection volume: 50 Detector: UV 300 CHROMATOGRAM Retention time: 5.6 Limit of quantitation: 250 ng/mL KEY WORDS pharmacokinetics; plasma; ultrafiltrate REFERENCE Musson, D.G.; Birk, K.L.; Kitchen, C.J.; Zhang, J.; Hsieh, J.Y.K.; Fang, W.; Majumdar, A.K.; Rogers, J.D. Assay methodology for the quantitation of unbound ertapenem, a new carbapenem antibiotic, in human plasma, J.Chromatogr.B, 2003, 783, 1–9. SAMPLE Matrix: blood Sample preparation: Mix 50 µL 50 µg/mL IS with 200 µL serum, add 800 µL MeCN, vortex briefly, centrifuge at 2600 g for 10 min. remove the supernatant and add it to 2.5 mL dichloromethane, vortex briefly, centrifuge, inject an aliquot of the aqueous layer. HPLC VARIABLES Column: 100 × 4.6 5 µm C18 (Keystone) Mobile phase: MeOH:25 mM pH 6.5 phosphate buffer 9.5:100 Flow rate: 1 Detector: UV 300 CHROMATOGRAM Retention time: 10.5 Internal standard: meropenem (14.9) Limit of quantitation: 150 ng/mL Ertapenem 235 KEY WORDS mouse; pharmacokinetics; serum REFERENCE Xuan, D.; Banevicius, M.; Capitano, B.; Kim, M.-K.; Nightingale, C.; Nicolau, D. Pharmacodynamic assessment of ertapenem (MK-0826) against streptococcus pneumoniae in a murine neutropenic thigh infection model, Antimicrob.Agents Chemother., 2002, 46, 2990–2995. ANNOTATED BIBLIOGRAPHY Kitchen, C.J.; Musson, D.G.; Fisher, A.L. Column-switching technique for the sensitive determination of ertapenem in human cerebrospinal fluid using liquid chromatography and ultraviolet absorbance detection, J.Chromatogr.B, 2004, 799, 9–14. McQuade, M.S.; Van Nostrand, V.; Schariter, J.; Kanike, J.D.; Forsyth, R.J. Stability and compatibility of reconstituted ertapenem with commonly used i.v. infusion and coinfusion solutions, Am.J.HealthSyst.Pharm., 2004, 61, 38–45. Musson, D.G.; Kitchen, C.J.; Hsieh, J.Y.-K.; Birk, K.L. Modified high-performance liquid chromatographic method for the determination of ertapenem in human urine: enhanced selectivity and automation, J.Chromatogr.B, 2002, 779, 341–346. Musson, D.G.; Majumdar, A.; Birk, K.; Holland, S.; Wickersham, P.; Li, S.X.; Mistry, G.; Fisher, A.; Waldman, S.; Greenberg, H.; Deutsch, P.; Rogers, J.D. Pharmacokinetics of intramuscularly administered ertapenem, Antimicrob.Agents Chemother., 2003, 47, 1732–1735. Sajonz, P.; Natishan, T.K.; Wu, Y.; Williams, J.M.; Pipik, B.; DiMichele, L.; Novak, T.; Pitzenberger, S.; Dubost, D.; Almarsson, O. Preparation, isolation, and characterization of dimeric degradation products of the 1β-methylcarbapenem antibiotic, ertapenem, J.Liq.Chromatogr.Rel.Technol., 2001, 24, 2999–3015. 236 Ethopabate Ethopabate Molecular formula: C12 H15 NO4 Molecular weight: 237.25 CAS Registry No: 59-06-3 Merck Index: 13, 3781 O O H3C OCH3 N O CH3 H SAMPLE Matrix: blood Sample preparation: Vortex 100 µL MeOH:water 80:20 and 400 µL trichloroacetic acid solution with 500 µL plasma, centrifuge at 4000 rpm for 4 min, filter (Spin-X) the supernatant. Mix the filtrate with an equal quantity of water and inject a 30 µL aliquot. (Prepare trichloroacetic acid solution as follows. Dissolve 85 g trichloroacetic acid in 15 mL water. Store this solution in the refrigerator. Dilute 150 µL of this solution with 100 mL acetone.) HPLC VARIABLES Column: 250 × 4.6 5 µm Supelcosil LC-ABZ + Plus Mobile phase: MeCN:10 mM ammonium acetate 35:65 Flow rate: 1 Injection volume: 30 Detector: MS, PE Sciex API 100 single quadrupole, turbo ionspray, 50 µL/min flowed into detector, m/z 238.2 CHROMATOGRAM Retention time: 7.5 Limit of quantitation: 15 ng/mL KEY WORDS chicken; plasma REFERENCE Hormazábal, V.; Yndestad, M. Determination of amprolium, ethopabate, lasalocid, monensin, narasin, and salinomycin in chicken tissues, plasma, and egg using liquid chromatography-mass spectrometry, J.Liq.Chromatogr.Rel.Technol., 2000, 23, 1585–1598. Ethyl icosapentate 237 Ethyl icosapentate Molecular formula: C22 H34 O2 Molecular weight: 330.51 CAS Registry No: 73310-10-8 CO2Et SAMPLE Matrix: solutions Sample preparation: Inject a 2 µL aliquot. HPLC VARIABLES Column: 125 × 4 4 µm Supersphere Si 60 Column temperature: 27 Mobile phase: n-Hexane:diethyl ether 98:2 Flow rate: 1.8 Injection volume: 2 Detector: UV 213 CHROMATOGRAM Retention time: 2 Internal standard: 2,4-dinitrochlorobenzene (6) KEY WORDS normal phase REFERENCE Teraoka, R.; Otsuka, M.; Matsuda, Y. Chemical stability of ethyl icosapentate against autoxidation. I. Effect of temperature on oxidation kinetics, Pharm.Res., 1992, 9, 1673–1676. 238 Etonogestrel Etonogestrel H3C H Molecular formula: C22 H28 O2 Molecular weight: 324.46 CAS Registry No: 54048-10-1 Merck Index: 13, 3916 OH H H2C H H H O SAMPLE Matrix: cell culture Sample preparation: Extract medium twice with 2 mL diethyl ether. Evaporate the extracts to dryness, reconstitute the residue with MeOH, inject an aliquot. HPLC VARIABLES Column: 250 × 4.6 Ultratech 5-ODS (HPLC Technology) Mobile phase: MeCN:MeOH:0.5% pH 3.0 ammonium dihydrogen phosphate 15:47:38 Flow rate: 1.2 Detector: UV 214 CHROMATOGRAM Retention time: 13 OTHER SUBSTANCES Extracted: metabolites REFERENCE Wild, M.J.; Rudland, P.S.; Back, D.J. Metabolism of the oral contraceptive steroids ethynylestradiol, norgestimate and 3-ketodesogestrel by a human endometrial cancer cell line (HEC-1A) and endometrial tissue in vitro, J.Steroid Biochem.Mol.Biol., 1993, 45, 407–420. SAMPLE Matrix: microsomal incubations HPLC VARIABLES Guard column: Novapak C18 Column: 150 × 3.9 Novapak C18 Column temperature: 50 Mobile phase: Gradient. MeCN:MeOH:water from 5:20:75 to 8:32:60 over 5 min, to 14:56:30 over 10 min, to 18:72:10 over 2 min. Flow rate: 1 Detector: Radioactivity (3 H); UV 254 CHROMATOGRAM Retention time: 16 OTHER SUBSTANCES Extracted: metabolites KEY WORDS dog; human; liver; rabbit, rat REFERENCE Verhoeven, C.H.J.; Krebbers, S.F.M.; Wagenaars, G.N.; Vos, R.M.E. In vitro and in vivo metabolism of desogestrel in several species, Drug Metab.Dispos., 1998, 26, 927–936. Etonogestrel 239 SAMPLE Matrix: solutions Sample preparation: Extract 15 mL aqueous solution with dichloromethane, evaporate the extract to dryness, take up the residue in 3 mL mobile phase, inject a 50 µL aliquot. HPLC VARIABLES Column: C18 Mobile phase: MeOH:water 82:18 Injection volume: 50 Detector: UV 242 CHROMATOGRAM Internal standard: progesterone Limit of quantitation: 50 ng/mL OTHER SUBSTANCES Simultaneous: ethinyl estradiol (F ex 200 em 300), mestranol (F ex 200 em 300) REFERENCE de Leede, L.G.; Govers, C.P.M.; de Nijs, H. A multi-compartment vaginal ring system for independently adjustable release of contraceptive steroids, Contraception, 1986, 34, 589–602. SAMPLE Matrix: solutions HPLC VARIABLES Column: 150 × 3.9 Novapak C18 Column temperature: 30 Mobile phase: MeCN:water 30:70 Flow rate: 1.5 Injection volume: 10 Detector: UV 205 OTHER SUBSTANCES Simultaneous: ethinyl estradiol REFERENCE van Laarhoven, J.A.H.; Kruft, M.A.B.; Vromans, H. In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring, Int.J.Pharm., 2002, 232, 163–173. 240 Etoricoxib Etoricoxib CH3 N Molecular formula: C18 H15 ClN2 O2 S Molecular weight: 358.84 CAS Registry No: 202409-33-4 O O S CH3 N Cl SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 30 mg Oasis HLB SPE cartridge with 1 mL MeOH and 1 mL water. Mix 200 µL plasma with 20 µL 500 ng/mL IS in water, centrifuge at 12 000 g, add to the SPE cartridge, wash with 1 mL MeOH:water 5:95, dry under reduced pressure for 5 min, elute with 2 mL MeCN:ethyl acetate 50:50. Evaporate the eluate to dryness under reduced pressure at 45◦ , reconstitute the residue with 200 µL mobile phase, inject a 15 µL aliquot. HPLC VARIABLES Column: 30 × 2 5 µm Nucleodur C18 Mobile phase: MeCN:water 90:10 Flow rate: 0.3 Injection volume: 15 Detector: MS, PE Sciex API 3000 triple quadrupole, turbo ionspray, positive ion mode 5400 V and 400◦ , nebulizer gas nitrogen at 1.49 L/min, curtain gas nitrogen at 1.25 L/min, collision gas nitrogen, collision energy 43 eV, m/z 359.0–280.1 CHROMATOGRAM Retention time: 0.5 Internal standard: phenazone (m/z 189.0–104.0, 33 eV) (0.5) Limit of quantitation: 0.2 ng/mL KEY WORDS pharmacokinetics; plasma REFERENCE Bräutigam, L.; Nefflen, J.U.; Geisslinger, G. Determination of etoricoxib in human plasma by liquid chromatography-tandem mass spectrometry with electrospray ionisation, J.Chromatogr.B, 2003, 788, 309–315. SAMPLE Matrix: solutions Sample preparation: Inject a 10 µL aliquot of a 100 µg/mL solution in MeCN:water 50:50. HPLC VARIABLES Column: 150 × 4.6 3 µm YMC AQ-ODS Column temperature: 35 Mobile phase: Gradient. MeCN:buffer 28:72 for 11 min, to 70:30 over 19 min, to 90:10 over 5 min. (The buffer was 10 mM potassium dihydrogen phosphate adjusted to pH 3.1 with 2.2 mM phosphoric acid.) Flow rate: 1 Injection volume: 10 Detector: UV 220 Etoricoxib 241 CHROMATOGRAM Retention time: 12 Limit of detection: 0.02% Limit of quantitation: 0.04% OTHER SUBSTANCES Simultaneous: degradants, impurities KEY WORDS stability-indicating; robust REFERENCE Hartman, R.; Abrahim, A.; Clausen, A.; Mao, B.; Crocker, L.S.; Ge, Z. Development and validation of an HPLC method for the impurity and quantitative analysis of etoricoxib, J.Liq.Chromatogr.Rel.Technol., 2003, 26, 2551–2566. ANNOTATED BIBLIOGRAPHY Kassahun, K.; McIntosh, I.S.; Shou, M.; Walsh, D.J.; Rodeheffer, C.; Slaughter, D.E.; Geer, L.A.; Halpin, R.A.; Agrawal, N.; Rodrigues, A.D. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor, Drug Metab.Dispos., 2001, 29, 813–820. Niederberger, E.; Tegeder, I.; Schäfer, C.; Seegel, M.; Grösch, S.; Geisslinger, G. Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation, J.Pharmacol.Exp.Ther., 2003, 304, 1153–1160. [etoricoxib is internal standard; post-column photochemical derivatization] Rodrigues, A.D.; Halpin, R.A.; Geer, L.A.; Cui, D.; Woolf, E.J.; Matthews, C.Z.; Gottesdiener, K.M.; Larson, P.J.; Lasseter, K.C.; Agrawal, N.G.B. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers, Drug Metab.Dispos., 2003, 31, 224–232. Rose, M.J.; Agrawal, N.; Woolf, E.J.; Matuszewski, B.K. Simultaneous determination of unlabeled and carbon-13-labeled etoricoxib, a new cyclooxygenase-2 inhibitor, in human plasma using HPLC-MS/MS, J.Pharm.Sci., 2002, 91, 405–416. [SPE] 242 Etorphine Etorphine Molecular formula: C25 H33 NO4 Molecular weight: 411.53 CAS Registry No: 14521-96-1 Merck Index: 13, 3919 HO O N H3CO H3C HO CH3 CH3 SAMPLE Matrix: blood, urine Sample preparation: Add 3 mL 200 mM sodium carbonate solution containing 100 ng/mL IS and 3 mL 1-chlorobutane to 3 mL blood or urine, shake for 3 min, centrifuge at 4500 rpm for 5 min, repeat the extraction. Combine the organic layers and add them to 100 µL 50 mM sulfuric acid, shake for 3 min, centrifuge at 3500 rpm for 3 min, inject a 20 µL aliquot of the aqueous layer. HPLC VARIABLES Guard column: 10 × 4 Spherisorb S5ODS2 Column: 150 × 4.6 Spherisorb S50D/CN Mobile phase: MeCN:water 20:80 Flow rate: 2 Injection volume: 20 Detector: UV 220 CHROMATOGRAM Retention time: 3.77 Internal standard: pentazocine (6.31) Limit of quantitation: 2 ng/mL KEY WORDS whole blood REFERENCE Elliott, S.P.; Hale, K.A. Analysis of etorphine in postmortem samples by HPLC with UV diode-array detection, Forensic Sci.Int., 1999, 101, 9–16. 243 Exemestane Exemestane CH3 O CH3 H Molecular formula: C20 H24 O2 Molecular weight: 296.40 CAS Registry No: 107868-30-4 Merck Index: 13, 3944 H H O CH2 SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 100 µL 1 µg/mL IS in water, add 600 µL 500 mM pH 7.4 potassium phosphate buffer, mix, add 3 mL dichloromethane:isooctane 40:60, shake for 10 min, centrifuge at 1200 g for 15 min, repeat the extraction. Combine the organic layers and evaporate them to dryness under a stream of nitrogen at 37◦ , reconstitute the residue with 200 µL MeCN:water 50:50, inject a 150 µL aliquot. HPLC VARIABLES Guard column: 37–53 µm pellicular ODS Column: 125 × 4.6 5 µm Lichrocart RP18 Mobile phase: MeCN:50 mM pH 4.5 potassium phosphate buffer 35:65 Flow rate: 1.5 Injection volume: 150 Detector: UV 247 CHROMATOGRAM Retention time: 14 Internal standard: norgestrel (17) Limit of detection: 2 ng Limit of quantitation: 10 ng/mL OTHER SUBSTANCES Extracted: metabolite KEY WORDS pharmacokinetics; plasma REFERENCE Breda, M.; Pianezzola, E.; Strolin Benedetti, M.S. Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection, J.Chromatogr., 1993, 620, 225–231. SAMPLE Matrix: blood Sample preparation: Condition a 2 mL 50 mg C2 end-capped SPE cartridge (in a 96 well plate format) with two 1 mL portions of MeCN and two 1 mL portions of water. Vortex 500 µL plasma with 50 µL 1.11 µg/mL IS in MeOH:water 50:50 and 500 µL water, add to the SPE cartridge, wash with 1 mL MeCN:water 10:90, dry under vacuum for 30 min, elute with two 150 µL portions of MeCN containing 0.1% trifluoroacetic acid. Centrifuge the eluate at 1500 rpm for 2 min and inject an 80 µL aliquot of the supernatant. HPLC VARIABLES Guard column: 15 × 3.2 7 µm New Guard RP8 Aquapore Octyl Column: 150 × 4.6 5 µm Zorbax SB C8 Column temperature: 45 244 Exemestane Mobile phase: MeCN Flow rate: 1 Injection volume: 80 Detector: MS, PE Sciex API 300 triple quadrupole, APCI, nebulizer probe 375◦ , collision energy 30 eV, m/z 297–121 CHROMATOGRAM Retention time: 2.3 Internal standard: 13 C3 -exemestane (m/z 300–123) (2.3) Limit of quantitation: 50 pg/mL KEY WORDS plasma; SPE REFERENCE Cenacchi, V.; Barattè, S.; Cicioni, P.; Frigerio, E.; Long, J.; James, C. LC-MS-MS determination of exemestane in human plasma with heated nebulizer interface following solid-phase extraction in the 96 well plate format, J.Pharm.Biomed.Anal., 2000, 22, 451–460. ANNOTATED BIBLIOGRAPHY Del Nero, S.; Di Somma, M.; Vigevani, A. High-performance liquid chromatographic analysis of FCE 24304 (6-methylenandrosta-1,4-diene-3,17-dione) and FCE 24928 (4-aminoandrosta-1,4,6-triene-3,17dione), two new aromatase inhibitors, J.Chromatogr., 1992, 593, 25–28. Ezetimibe Ezetimibe 245 OH OH Molecular formula: C24 H21 F2 NO3 Molecular weight: 409.42 CAS Registry No: 163222-33-1 Merck Index: 13, 3949 F N O F SAMPLE Matrix: bile Sample preparation: Extract bile with 1.5 vol of MeCN. HPLC VARIABLES Column: 150 × 4.6 5 µm Inertsil C8 Mobile phase: Gradient. MeCN:100 mM pH 6 ammonium acetate from 30:70 to 100:0 over 40 min (concave gradient (Waters Expert-Ease Curve #10)). Flow rate: 1 Detector: UV 245; Radioactivity (3 H) CHROMATOGRAM Retention time: 40 OTHER SUBSTANCES Extracted: metabolites KEY WORDS rat REFERENCE Van Heek, M.; Farley, C.; Compton, D.S.; Hoos, L.; Alton, K.B.; Sybertz, E.J.; Davis, H.R. Jr. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br.J.Pharmacol., 2000, 129, 1748–1754. SAMPLE Matrix: blood Sample preparation: For unconjugated ezetimibe, add 100 µL 513 ng/mL IS in water and 1 mL water to 200 µL plasma, add 8 mL 1-chlorobutane. For total ezetimibe, add 100 µL 513 ng/mL IS in water, 500 µL 500 mM pH 5.0 sodium acetate buffer, and 50 µL β-glucuronidase (100 000 U/mL) to 200 µL plasma, heat at 50◦ for 1 h, add 500 µL 1 M sodium borate solution, add 8 mL 1-chlorobutane. Shake each mixture for 15 min and centrifuge at 491 g for 10 min. Evaporate the organic layer to dryness under reduced pressure, reconstitute the residue with 500 µL MeOH, evaporate to dryness, reconstitute with 50 µL MeOH, inject an aliquot. HPLC VARIABLES Column: 100 × 4.6 10 µm Spherisorb ODS-2 Mobile phase: MeOH:25 mM ammonium acetate 90:10 Flow rate: 1.5 Detector: MS, PE Sciex API-III, positive ion mode, m/z 392.3–133.1 246 Ezetimibe CHROMATOGRAM Internal standard: SCH 58053 ((+)-7-(4-chlorophenyl)-2-(4-fluorophenyl)-7-hydroxy3(R)-4-hydroxyphenyl)-2-azaspiro[3.5]nonan-1-one (enantiomer A)) (m/z 434.2–216.1) Limit of quantitation: 1 ng/mL (unconjugated), 5.02 ng/mL (total) KEY WORDS pharmacokinetics; plasma REFERENCE Patrick, J.E.; Kosoglou, T.; Stauber, K.L.; Alton, K.B.; Maxwell, S.E.; Zhu, Y.; Statkevich, P.; Iannucci, R.; Chowdhury, S.; Affrime, M.; Cayen, M.N. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects, Drug Metab.Dispos., 2002, 30, 430–437. Fadrozole N N CN Molecular formula: C14 H13 N3 Molecular weight: 223.27 CAS Registry No: 102676-47-1 Merck Index: 13, 3958 SAMPLE Matrix: solutions HPLC VARIABLES Column: Chiralcel OD Mobile phase: Hexane:isopropanol 70:30 Detector: UV CHROMATOGRAM Retention time: (+)-enantiomer elutes first, α = 1.40 KEY WORDS chiral REFERENCE Furet, P.; Batzl, C.; Bhatnagar, A.; Francotte, E.; Rihs, G.; Lang, M. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds, J.Med.Chem., 1993, 36, 1393–1400. HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 247 248 Falecalcitriol Falecalcitriol H3C H CH3 CF3 H Molecular formula: C27 H38 F6 O3 Molecular weight: 524.58 CAS Registry No: 83805-11-2 OH CF3 H CH2 HO H H OH SAMPLE Matrix: cell suspensions Sample preparation: Condition a Sep-Pak silica SPE cartridge with n-hexane:isopro- panol 80:20. Sonicate 2 (?) mL cell suspension at 0◦ for 2 min, add 1 mL THF, add 4 mL ethyl acetate, vortex, centrifuge at 2200 rpm at 4◦ for 5 min, extract the aqueous layer four times with 4 mL portions of ethyl acetate. Dry the combined organic layers over anhydrous sodium sulfate, evaporate to dryness, reconstitute with n-hexane:isopropanol 96:4, pass through the SPE cartridge. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with 200 µL toluene:EtOH 50:50, inject an aliquot. HPLC VARIABLES Column: 150 × 6 Sumipax ODS A212 Mobile phase: MeCN:THF:water 45:5:50 Flow rate: 1.5 Detector: Radioactivity (3 H) CHROMATOGRAM Retention time: 60 OTHER SUBSTANCES Extracted: metabolites KEY WORDS SPE REFERENCE Miyahara, T.; Gomyo, S.; Ueda, Y.; Ohyama, Y.; Sigeno, C.; Kozakai, A.; Takamura, T.; Yamazaki, R.; Higuchi, S.; Yamamoto, M.; Sakuma, T.; Nemoto, N. Metabolism of 26,27-hexafluoro-1α,25-dihydroxyvitamin D3 and 26,27-hexafluoro-1α,23(S)25−trihydroxyvitamin D3 in ROS17/2.8 cells transfected with a plasmid expressing CYP24, Xenobiotica, 2000, 30, 1055–1062. SAMPLE Matrix: enzyme incubations Sample preparation: Extract enzyme incubation with 3 vol dichloromethane, evaporate the extract to dryness, dissolve the residue in MeCN, inject an aliquot. HPLC VARIABLES Column: 300 × 4 µBondapak C18 Column temperature: 50 Mobile phase: Gradient. MeCN:water from 50:50 to 100:0 over 15 (?) min. Flow rate: 1 Detector: UV 265 Falecalcitriol 249 CHROMATOGRAM Retention time: 12 OTHER SUBSTANCES Extracted: metabolites REFERENCE Hayashi, K.; Akiyoshi-Shibata, M.; Sakaki, T.; Yabusaki, Y. Rat CYP24 catalyses 23S-hydroxylation of 26,26,26,27,27,27-hexafluorocalcitriol in vitro, Xenobiotica, 1998, 28, 457–463. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 Zorbax Sil Mobile phase: n-Hexane:dichloromethane:methanol 49:48:3 Flow rate: 1.5 Detector: UV 254 CHROMATOGRAM Retention time: 12 OTHER SUBSTANCES Simultaneous: metabolites KEY WORDS normal phase REFERENCE Imanishi, Y.; Inaba, M.; Seki, H.; Koyama, H.; Nishizawa, Y.; Morii, H.; Otani, S. Increased biological potency of hexafluorinated analogs of 1,25-dihydroxyvitamin D3 on bovine parathyroid cells, J.Steroid Biochem.Mol.Biol., 1999, 70, 243–248. ANNOTATED BIBLIOGRAPHY Harada, M.; Miyahara, T.; Kajita-Kondo, S.; Kozakai, A.; Higuchi, S.; Otomo, S.; Kozuka, H. Differences in metabolism between 26,26,26,27,27,27-hexafluoro-1α,25-dihydroxyvitamin D3 and 1α,25dihydroxyvitamin D3 in cultured neonatal mouse calvaria, Res.Commun.Mol.Pathol.Pharmacol., 1994, 86, 183–193. Miyahara, T.; Harada, M.; Kozakai, A.; Matsumoto, M.; Hashimoto, K.; Inoue, H.; Yoda, K.; Nakatsu, T.; Kajita, S.; Yamazaki, R.; Higuchi, S.; Kozuka, H.; Nemoto, N. Comparison of 26,27-hexafluoro-1α,25dihydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3 on the resorption of bone explants ex vivo. J.Nutr.Sci.Vitaminol., 1999, 45, 239–249. 250 Fenoxycarb Fenoxycarb O Molecular formula: C17 H19 NO4 H O Molecular weight: 301.34 CAS Registry No: 72490-01-8 Merck Index: 13, 4013 N O CH3 O SAMPLE Matrix: fruit, vegetables Sample preparation: Blend 500 mg chopped fruit or vegetable with 500 mg 45–55 µm C8 reversed-phase material in a mortar and pestle for 5 min, place in a 100 × 9 glass column, elute with 10 mL MeCN:dichloromethane 40:60. Concentrate the eluate to 500 µL under a stream of nitrogen, inject a 5 µL aliquot. HPLC VARIABLES Guard column: 10 × 4.6 5 µm LiChrosorb RP-8 Column: 150 × 4.6 3 µm Spherisorb C8 Mobile phase: Gradient. MeOH:water 50:50 for 15 min, to 70:30 over 5 min, maintain at 70:30 for 5 min, to 90:10 over 5 min, maintain at 90:10 for 5 min. Flow rate: 0.5 Injection volume: 5 Detector: MS, HP, electrospray, positive mode, gas 350◦ , drying gas flow 13 L/min, nebulizer gas pressure 30 psi, capillary 4000 V, m/z 302.1 CHROMATOGRAM Retention time: 30 Limit of detection: 5 ng/g OTHER SUBSTANCES Extracted: carbaryl (19), carbofuran (17), diethofencarb (24), ethiofencarb (20), fenobucarb (24), isoprocarb (21), methiocarb (26), metholcarb (13.5), oxamyl (4.5), pirimicarb (22), propoxur (16), thiobencarb (32.5) KEY WORDS matrix solid phase dispersion REFERENCE Fernández, M.; Picó, Y.; Mañes, J. Determination of carbamate residues in fruits and vegetables by matrix solid-phase dispersion and liquid chromatography-mass spectrometry, J.Chromatogr.A, 2000, 871, 43–56. ANNOTATED BIBLIOGRAPHY Fernández, M.; Picó, Y.; Mañes, J. Simultaneous determination of carbamate and organophosphorus pesticides in honeybees by liquid chromatography-mass spectrometry, Chromatographia, 2003, 58, 151–158. [very similar to above method] 251 Fenticonazole Fenticonazole Molecular formula: C24 H20 Cl2 N2 OS N Cl N S Molecular weight: 455.41 CAS Registry No: 72479-26-6 Merck Index: 13, 4033 O Cl SAMPLE Matrix: blood Sample preparation: Vortex 50 µL plasma with 100 µL 2 ng/mL IS in MeCN, centrifuge at 12 000 rpm for 2 min, inject a 20 µL aliquot of the supernatant. HPLC VARIABLES Guard column: 15 × 3.2 Brownlee C18 Column: 50 × 4.6 3 µm Shandon BDS C8 Column temperature: 45 Mobile phase: MeCN:buffer 70:30 (The buffer was 10 mM ammonium formate adjusted to pH 3.5 with formic acid.) Flow rate: 1 Injection volume: 20 Detector: MS, PE Sciex API-III+ triple quadrupole, APCI, positive ion, heated nebulizer interface, nebulizer probe 500◦ , nebulizer gas nitrogen 0.6 L/min, curtain gas nitrogen at 0.8 L/min, auxiliary gas nitrogen 2.0 L/min, nebulizer gas pressure 70 psi, m/z 455–199 CHROMATOGRAM Retention time: 2.25 Internal standard: econazole (m/z 381–125) (1.5) Limit of quantitation: 0.49 ng/mL OTHER SUBSTANCES Simultaneous: clindamycin (1) KEY WORDS plasma REFERENCE Speed, W.; Long, J.M.; Simmonds, R.J.; Enos, T.A. The development and validation of a high performance liquid chromatography (HPLC)/tandem mass spectrometry assay for fenticonazole in human plasma and comparison with an HPLC-UV method, Rapid Commun.Mass Spectrom., 1995, 9, 1452–1456. SAMPLE Matrix: blood Sample preparation: Liquid–liquid extraction of 1 mL basified plasma (not otherwise specified), inject an 80 µL aliquot of the supernatant. HPLC VARIABLES Guard column: Guard Pak µBondapak C18 Column: 150 × 4.6 4 µm phenyl Column temperature: 40 Mobile phase: MeCN:buffer 76:24 (The buffer was 120 mM acetic acid containing 0.02 mM sodium bisulfate.) Flow rate: 1.5 Injection volume: 80 Detector: UV 254 252 Fenticonazole CHROMATOGRAM Retention time: 12.9 Internal standard: miconazole (9.9) Limit of quantitation: 5 ng/mL OTHER SUBSTANCES Simultaneous: clindamycin (1) KEY WORDS plasma REFERENCE Speed, W.; Long, J.M.; Simmonds, R.J.; Enos, T.A. The development and validation of a high performance liquid chromatography (HPLC)/tandem mass spectrometry assay for fenticonazole in human plasma and comparison with an HPLC-UV method, Rapid Commun.Mass Spectrom., 1995, 9, 1452–1456. Fexofenadine Fexofenadine CH3 CH3 COOH Molecular formula: C32 H39 NO4 Molecular weight: 501.65 CAS Registry No: 83799-24-0 Merck Index: 13, 4101 253 N OH OH SAMPLE Matrix: blood Sample preparation: Mix 1 mL whole blood with 20 µL 1 µg/mL dibenzepin in MeOH:water 50:50, add 300 µL pH 11 Tris buffer, mix, add 500 µL butyl acetate, vortex for 2 min, centrifuge. Preserve the aqueous layer (A). Remove the organic layer and add it to 75 µL 10 mM ammonium acetate buffer containing 0.1% formic acid (pH 3.2), evaporate (?). Add 75 µL MeCN, sonicate for 5 min, centrifuge at 5000 rpm for 5 min, keep the extract as B. Add 20 µL 1 µg/mL enalapril in MeOH:water 50:50 and 120 mg NaCl to the aqueous layer (A), mix, add 500 µL pH 3 phosphate buffer, add 600 µL 8.5% phosphoric acid, add 5 mL dichloromethane:isopropanol 95:5, shake at 250 cycles/min in a bench-top shaker for 30 min, centrifuge at 5000 rpm for 5 min. Remove the lower organic layer and evaporate it to dryness under a stream of air at 45◦ . Reconstitute the residue with 150 µL initial mobile phase, sonicate, centrifuge, combine with extract B, inject a 30 µL aliquot. (Sample preparation from Gergov,M.; Robson,J.N.; Ojanperä,I.; Heinonen,O.P.; Vuori,E. Simultaneous screening and quantitation of 18 antihistamine drugs in blood by liquid chromatography ionspray tandem mass spectrometry. Forensic Sci.Inter. 2001, 121, 108–115.) HPLC VARIABLES Guard column: 40 mm long 4 µm Purospher RP-18 LiChro Cart 4-4 Column: 100 × 2.1 4 µm Genesis C18 (Jones Chromatography) Column temperature: 35 Mobile phase: Gradient. MeCN:buffer from 20:80 to 100:0 over 10 min, maintain at 0:100 for 3 min, re-equilibrate at initial conditions for 5 min. (The buffer was 10 mM ammonium acetate containing 0.1% formic acid (pH 3.2).) Flow rate: 0.2 Injection volume: 30 Detector: MS, PE Sciex API 365 triple-stage quadrupole LC-MS-MS, PE Sciex Turbo Ion Spray interface, positive ion mode, needle voltage 5.2 kV, nebulizer gas air at 60 psi, curtain gas nitrogen at 40 psi, collision cell gas nitrogen at 40 psi, turbo ionspray heater 375◦ , heater gas flow 7 L/min CHROMATOGRAM Retention time: 6.3 Internal standard: dibenzepin, enalapril Limit of detection: <20 ng/mL OTHER SUBSTANCES Extracted: acebutolol (3.8, LOD 0.1 µg/mL), acrivastine (5.7, LOD <0.02 µg/mL), alprazolam (6.1, LOD <0.02 µg/mL), alprenolol (5.4, LOD 0.01 µg/mL), amantadine (3.4, LOD 0.1 µg/mL), amiloride (2.0, LOD 0.1 µg/mL), aminophenazone (2.8, LOD <5 µg/mL), amiodarone (10.2, LOD 0.05 µg/mL), amitriptyline (6.6, LOD <0.02 µg/mL), astemizole (5.8, LOD <0.02 µg/mL), atenolol (1.7, LOD 0.30 µg/mL), azacyclonol (5.1, LOD 0.02 µg/mL), benzhexol (6.6, LOD <0.02 µg/mL), benzoylecgonine (3.3, LOD 0.01 µg/mL), betaxolol (5.5, LOD 0.01 µg/mL), biperidine (6.2, LOD <0.02 µg/mL), bisoprolol (5.0, LOD <0.02 µg/mL), brompheniramine (5.3, LOD 0.002 µg/mL), 254 Fexofenadine bupivacaine (5.1, LOD <0.02 µg/mL), buprenorphine (5.9, LOD 0.01 µg/mL), buspirone (5.1, LOD 0.002 µg/mL), caffeine (2.8, LOD 1 µg/mL), carbamazepine (6.1, LOD <0.02 µg/mL), carbinoxamine (5.1, LOD 0.002 µg/mL), carisoprodol (6.7, LOD <5 µg/mL), carvedilol (6.2, LOD <0.02 µg/mL), celiprolol (4.3, LOD 0.05 µg/mL), cetirizine (6.3, LOD 0.05 µg/mL), chlorcyclizine (6.6, LOD <0.02 µg/mL), chlordiazepoxide (5.7, LOD <0.02 µg/mL), chlormezanone (5.8, LOD <5 µg/mL), chloroquine (2.7, LOD 0.02 µg/mL), chlorpheniramine (5.1, LOD 0.002 µg/mL), chlorpromazine (7.0, LOD 0.02 µg/mL), chlorpropamide (6.7, LOD <5 µg/mL), chlorprothixene (7.0, LOD <0.02 µg/mL), cinnarizine (7.9, LOD <0.02 µg/mL), citalopram (5.7, LOD <0.02 µg/mL), clemastine (7.7, LOD 0.02 µg/mL), clobazam (7.3, LOD <0.02 µg/mL), clobutinol (5.3, LOD 0.02 µg/mL), clomethiazole (6.2, LOD 0.5 µg/mL), clomipramine (7.1, LOD <0.02 µg/mL), clonazepam (6.6, LOD <0.02 µg/mL), clonidine (2.8, LOD 0.1 µg/mL), clozapine (5.6, LOD <0.02 µg/mL), cocaine (4.6, LOD <0.02 µg/mL), codeine (2.5, LOD 0.1 µg/mL), coumatetralyl (8.4, LOD 0.05 µg/mL), cyclizine (5.8, LOD <0.02 µg/mL), dextropropoxyphene (6.6, LOD 0.05 µg/mL), demoxepam (5.8, LOD 0.02 µg/mL), dextromethorphan (5.5, LOD <0.02 µg/mL), diazepam (8.1, LOD 0.02 µg/mL), diltiazem (5.8, LOD <0.02 µg/mL), diphenhydramine (5.7, LOD <0.02 µg/mL), dipyridamole (5.4, LOD 0.005 µg/mL), disopyramine (4.4, LOD <0.02 µg/mL), dixyrazine (6.8, LOD 0.005 µg/mL), doxapram (4.8, LOD <0.02 µg/mL), doxepin (5.9, LOD <0.02 µg/mL), ebastine (9.6, LOD 0.005 µg/mL), embutramide (6.7, LOD 0.005 µg/mL), ergotamine (5.5, LOD 0.005 µg/mL), ethenzamide (5.0, LOD 0.05 µg/mL), ethylmorphine (3.2, LOD 0.05 µg/mL), ethylparathion (9.7, LOD <5 µg/mL), etodroxizine (6.4, LOD <0.02 µg/mL), felodipine (9.6, LOD 0.02 µg/mL), fenazepam (7.5, LOD <0.02 µg/mL), fenfluramine (5.3, LOD <0.02 µg/mL), fenkamfamine (5.1, LOD <0.02 µg/mL), fentanyl (5.5, LOD <0.02 µg/mL), flecainide (5.9, LOD <0.02 µg/mL), fluconazole (4.0, LOD 0.1 µg/mL), flumazenil (5.2, LOD <0.02 µg/mL), flunitrazepam (7.1, LOD 0.002 µg/mL), fluoxetine (6.8, LOD 0.1 µg/mL), flupentixol (7.5, LOD 0.18 µg/mL), fluvoxamine (6.3, LOD 0.02 µg/mL), glibenclamide (8.5, LOD <0.02 µg/mL), glipizide (6.8, LOD <0.05 µg/mL), haloperidol (6.1, LOD <0.02 µg/mL), histapyrrodine (6.3, LOD 0.02 µg/mL), hydrocodone (3.0, LOD 0.05 µg/mL), hydroxychloroquine (2.4, LOD <0.3 µg/mL), hydroxyzine (6.3, LOD <0.02 µg/mL), imipramine (6.4, LOD 0.05 µg/mL), indomethacin (8.6, LOD 0.05 µg/mL), isoniazid (2.2, LOD 3 µg/mL), isradipine (8.6, LOD 0.05 µg/mL), ketamine (3.6, LOD <0.05 µg/mL), ketobemidone (3.3, LOD <0.05 µg/mL), ketoprofen (7.3, LOD 0.1 µg/mL), ketorolac (6.2, LOD 0.05 µg/mL), labetalol (4.9, LOD 0.05 µg/mL), lamotrigine (4.0, LOD 0.1 µg/mL), levocabastine (5.8, LOD 0.01 µg/mL), levomepromazine (6.5, LOD 0.02 µg/mL), lidocaine (3.7, LOD <0.05 µg/mL), loratadine (9.3, LOD 0.002 µg/mL), lorazepam (6.6, LOD 0.02 µg/mL), lormetazepam (7.4, LOD <0.02 µg/mL), LSD (4.7, LOD <0.02 µg/mL), malathion (8.9, LOD 10 µg/mL), maprotiline (6.4, LOD <0.02 µg/mL), MDMA (3.3, LOD 0.02 µg/mL), meclozine (8.5, LOD <0.02 µg/mL), medazepam (6.3, LOD <0.02 µg/mL), meloxicam (7.1, LOD 0.01 µg/mL), melperone (5.0, LOD <0.02 µg/mL), meperidine (4.7, LOD <0.02 µg/mL), mepivacaine (3.7, LOD <0.02 µg/mL), meprobamate (4.9, LOD 0.1 µg/mL), mesoridazine (5.4, LOD <0.02 µg/mL), methamphetamine (3.3, LOD 0.05 µg/mL), methadone (6.7, LOD <0.02 µg/mL), methylparathion (8.6, LOD 10 µg/mL), methylphenidate (4.2, LOD <0.02 µg/mL), metoclopramide (3.8, LOD <0.02 µg/mL), metoprolol (4.1, LOD 0.02 µg/mL), metronidazole (2.6, LOD 1 µg/mL), mexiletine (4.4, LOD 0.05 µg/mL), mianserin (5.7, LOD <0.02 µg/mL), midazolam (5.9, LOD <0.02 µg/mL), mirtazapine (4.4, LOD <0.02 µg/mL), mizolastine (5.5, LOD 0.01 µg/mL), moclobemide (3.7, LOD 0.05 µg/mL), molindone (4.0, LOD <0.02 µg/mL), monoacetylmorphine (2.7, LOD 0.1 µg/mL), morphine (2.0, LOD 0.1 µg/mL), nicotine (2.2, LOD 0.05 µg/mL), nifedipine (7.5, LOD 0.02 µg/mL), nikethamide (3.6, LOD <0.02 µg/mL), nitrazepam (6.5, LOD <0.02 µg/mL), nizatidine (1.7, LOD 1 µg/mL), nomifensine (4.6, LOD <0.02 µg/mL), nortriptyline (6.4, LOD <0.02 µg/mL), norverapamil (6.2, LOD 1 µg/mL), noscapine (5.0, LOD <0.02 µg/mL), olanzapine (3.0, LOD 0.05 µg/mL), ondansetron (4.6, LOD <0.02 µg/mL), orphenadrine (6.1, LOD <0.02 µg/mL), oxazepam (6.3, LOD <0.02 µg/mL), oxcarbazepine (5.3, LOD 0.02 µg/mL), oxprenolol (4.7, LOD 0.02 µg/mL), oxycodone (2.8, LOD 0.05 µg/mL), papaverine (4.8, LOD <0.02 µg/mL), acetaminophen (2.5, LOD <5 µg/mL), paroxetine (6.2, LOD 0.02 µg/mL), pemoline (3.3, LOD 0.05 µg/mL), pentazocine (5.0, LOD <0.02 µg/mL), pentifylline (7.3, LOD <5 µg/mL), Fexofenadine 255 pentoxyverine (6.6, LOD <0.02 µg/mL), perphenazine (6.9, LOD 0.002 µg/mL), phenazone (3.9, LOD 0.05 µg/mL), phencyclidine (5.3, LOD 0.05 µg/mL), pheniramine (4.1, LOD 0.02 µg/mL), phenylbutazone (9.0, LOD <5 µg/mL), phenylpropanolamine (2.5, LOD 0.3 µg/mL), phenytoin (6.1, LOD 0.05 µg/mL), pindolol (3.3, LOD 0.05 µg/mL), piroxicam (6.6, LOD 0.02 µg/mL), pitofenone (5.4, LOD <0.02 µg/mL), pizotifen (6.5, LOD <0.02 µg/mL), practolol (1.8, LOD 0.1 µg/mL), prazosin (4.1, LOD 0.05 µg/mL), prilocaine (3.8, LOD <0.02 µg/mL), primidone (4.0, LOD <5 µg/mL), procainamide (2.2, LOD 0.05 µg/mL), prochlorperazine (7.5, LOD 0.02 µg/mL), promazine (6.2, LOD <0.02 µg/mL), promethazine (6.0, LOD 0.05 µg/mL), propafenone (6.3, LOD <0.02 µg/mL), propranolol (5.4, LOD 0.02 µg/mL), propyphenazone (6.6, LOD 0.50 µg/mL), pseudoephedrine (2.6, LOD 1 µg/mL), quinine (4.2, LOD 0.02 µg/mL), ranitidine (1.8, LOD 0.1 µg/mL), risperidone (4.9, LOD <0.02 µg/mL), rocurone (3.8, LOD 0.1 µg/mL), ropivacaine (4.6, LOD <0.02 µg/mL), salicylamide (4.2, LOD <5 µg/mL), selegiline (4.1, LOD 0.05 µg/mL), sertindole (7.2, LOD <0.02 µg/mL), sertraline (6.8, LOD 0.02 µg/mL), sulindac (6.5, LOD 0.02 µg/mL), simazine (6.0, LOD 0.1 µg/mL), sincocaine (6.5, LOD <0.02 µg/mL), sisapride (5.9, LOD <0.02 µg/mL), sotalol (2.1, LOD 0.1 µg/mL), strychnine (5.3, LOD 0.05 µg/mL), sulpiride (1.9, LOD 0.1 µg/mL), sulthiame (4.1, LOD 0.05 µg/mL), temazepam (7.2, LOD <0.02 µg/mL), terbutaline (2.3, LOD 0.1 µg/mL), terfenadine (8.1, LOD 0.002 µg/mL), terodiline (6.7, LOD <0.02 µg/mL), tetracaine (5.7, LOD <0.02 µg/mL), dronabinol (12.3, LOD 0.05 µg/mL), tetrahydrozoline (3.6, LOD 0.1 µg/mL), theobromine (2.3, LOD <5 µg/mL), theophylline (2.4, LOD <5 µg/mL), thioridazine (7.5, LOD 0.02 µg/mL), timolol (3.8, LOD 0.05 µg/mL), thiothixene (6.7, LOD 0.02 µg/mL), tolbutamide (7.1, LOD <5 µg/mL), toremifene (8.7, LOD 0.02 µg/mL), tramadol (4.2, LOD 0.02 µg/mL), trazodone (5.2, LOD <0.02 µg/mL), triamterene (3.2, LOD 0.1 µg/mL), triazolam (6.7, LOD 0.002 µg/mL), trimeprazine (6.4, LOD <0.02 µg/mL), trimethoprim (3.1, LOD 0.05 µg/mL), trimipramine (6.7, LOD <0.02 µg/mL), venlafaxine (4.9, LOD 0.02 µg/mL), verapamil (6.5, LOD <0.02 µg/mL), warfarin (7.9, LOD <0.02 µg/mL), yohimbine (4.5, LOD <0.02 µg/mL), zolpidem (4.7, LOD <0.02 µg/mL), zopiclone (4.0, LOD 0.1 µg/mL) KEY WORDS whole blood REFERENCE Gergov, M.; Ojanperä, I.; Vuori, E. Simultaneous screening for 238 drugs in blood by liquid chromatography-ion spray tandem mass spectrometry with multiple-reaction monitoring, J.Chromatogr.B, 2003, 795, 41–53. SAMPLE Matrix: formulations Sample preparation: Extract tablets with MeOH, centrifuge, dilute the supernatant with mobile phase, inject an aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Eclipse XDB C8 Mobile phase: MeCN:MeOH:buffer 20:20:60 (The buffer was 1% triethylamine adjusted to pH 3.7 with concentrated orthophosphoric acid.) Flow rate: 1.2 Injection volume: 10 Detector: UV 210 CHROMATOGRAM Retention time: 14 Internal standard: 5-methyl-2-nitrophenol (12) Limit of detection: 0.12–0.18 µg/mL Limit of quantitation: 0.5–0.6 µg/mL 256 Fexofenadine OTHER SUBSTANCES Simultaneous: impurities KEY WORDS robust; tablets; validated REFERENCE Radhakrishna, T.; Reddy, G.O. Simultaneous determination of fexofenadine and its related compounds by HPLC, J.Pharm.Biomed.Anal., 2002, 29, 681–690. ANNOTATED BIBLIOGRAPHY Dresser, G.K.; Bailey, D.G.; Leake, B.F.; Schwarz, U.I.; Dawson, P.A.; Freeman, D.J.; Kim, R.B. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine, Clin.Pharmacol.Ther., 2002, 71, 11–20. Hamman, M.A.; Bruce, M.A.; Haehner-Daniels, D.; Hall, S.D. The effect of rifampin administration on the disposition of fexofenadine, Clin.Pharmacol.Ther., 2001, 69, 114–121. [SPE] Hofmann, U.; Seiler, M.; Drescher, S.; Fromm, M.F. Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry, J.Chromatogr.B, 2002, 766, 227–233. [SPE] Kim, R.B.; Leake, B.F.; Choo, E.F.; Dresser, G.K.; Kubba, S.V.; Schwarz, U.I.; Taylor, A.; Xie, H.-G.; McKinsey, J.; Zhou, S.; Lan, L.-B.; Schuetz, J.D.; Schuetz, E.G.; Wilkinson, G.R. Identification of functionally variant MDR1 alleles among European Americans and African Americans, Clin.Pharmacol.Ther., 2001, 70, 189–199. Milne, R.W.; Larsen, L.A.; Jorgensen, K.L.; Bastlund, J.; Stretch, G.R.; Evans, A.M. Hepatic disposition of fexofenadine: Influence of the transport inhibitors erythromycin and dibromosulphothalein, Pharm.Res., 2000, 17, 1511–1515. Putnam, W.S.; Ramanathan, S.; Pan, L.; Takahashi, L.H.; Benet, L.Z. Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells, J.Pharm.Sci., 2002, 91, 2622–2635. [column-switching] Robbins, D.K.; Castles, M.A.; Pack, D.J.; Bhargava, V.O.; Weir, S.J. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers, Biopharm.Drug Dispos., 1998, 19, 455–463. Soldner, A.; Christians, U.; Susanto, M.; Wacher, V.J.; Silverman, J.A.; Benet, L.Z. Grapefruit juice activates P-glycoprotein-mediated drug transport, Pharm.Res., 1999, 16, 478–485. [losartan; felodipine; nifedipine; fexofenadine; column-switching] Tannergren, C.; Petri, N.; Knutson, L.; Hedeland, M.; Bondesson, U.; Lennernäs, H. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine, Clin.Pharmacol.Ther., 2003, 74, 423–436. [SPE; LC-MS; UV detection] 257 Flomoxef Flomoxef Molecular formula: C15 H18 F2 N6 O7 S2 Molecular weight: 496.47 CAS Registry No: 99665-00-6 Merck Index: 13, 4132 OCH3 H O S F F N O N H S O COOH N N N N HO SAMPLE Matrix: blood Sample preparation: Condition a 3 mL 200 mg Bond-Elut C18 SPE cartridge with two 3 mL portions of MeOH and two 3 mL portions of 5% acetic acid. Mix 500 µL serum with 500 µL 10% acetic acid, add to the SPE cartridge, wash with 3 mL water, elute with four 500 µL portions of MeOH:water 60:40. Evaporate the combined eluates to dryness under a stream of nitrogen, reconstitute the residue with 250 µL water, filter (0.22 µm). Inject a 100 µL aliquot onto column A and elute to waste with mobile phase A. After an unspecified time, backflush the contents of column A onto column B using mobile phase B. Monitor the effluent from column B. (Sato,K.; Kobayashi,K.; Moore,C.M.; Mizuno,Y.; Katsumata,Y. Semi-quantitative analysis of cefaclor in human serum by capillary high performance liquid chromatography/fast atom bombardment mass spectrometry. Forensic Sci.Int. 1993, 59, 71–77.) HPLC VARIABLES Column: A 30 × 0.5 10 µm Develosil PhA (phenethyl); B 150 × 0.5 5 µm Develosil PhA (phenethyl) Mobile phase: A 10 mM ammonium acetate:glycerol 99.5:0.5, adjusted to pH 5 with acetic acid; B MeOH:water:acetic acid:glycerol 40:59:0.5:0.5 (pH ca. 3) Flow rate:: A 0.05; B 0.004 Injection volume: 100 Detector: MS, JMS DX303 double focusing, xenon FAB ion source, gun current 10 mA, voltage 3 kV, positive ion mode CHROMATOGRAM Retention time: 18.3 LIMIT OF DETECTION: 200–1000 ng OTHER SUBSTANCES Extracted: cefaclor (14.4), cefamandole (31.0), cefazolin (19.7), cefbuperazone (20.8), cefixime (19.2), cefmenoxime (18.8), cefmetazole (21.4), cefoperazone (24.2), cefotaxime (16.1), cefotetan (16.8), cefotiam (11.7), cefpiramide (20.9), cefsulodin (12.2), ceftazidime (12.0), ceftizoxime (15.6), ceftriaxone (16.7), cefuroxime (16.9), cefuzonam (32.0), cephalexin (14.8), cephaloglycine (15.7), cephaloridine (15.6), cephalothin (34.7), latamoxef (15.1) KEY WORDS column-switching; serum; SPE REFERENCE Kobayashi, K.; Sato, K.; Mizuno, Y.; Katsumata, Y. Capillary high-performance liquid chromatographyfast atom bombardment mass spectrometry of 24 cephem antibiotics, J.Chromatogr.B, 1996, 677, 275–290. 258 Florfenicol Florfenicol OH H Cl N Cl Molecular formula: C12 H14 Cl2 FNO4 S Molecular weight: 358.22 CAS Registry No: 73231-34-2 Merck Index: 13, 4135 H3C S O F O O SAMPLE Matrix: blood, CSF Sample preparation: Condition a 3 mL 500 mg Bond-Elut C18 SPE cartridge with 2 mL MeOH and 2 mL water. Mix 250 µL plasma or CSF with 750 µL water and 40 µL 8 µg/mL IS in MeOH:water 2:98 or 400 µg/mL IS in MeOH, vortex. Add to the SPE cartridge, wash with 2 mL MeCN:water 15:85, wash with 3 mL hexane, elute with 3 mL MeCN. Evaporate the eluate to dryness under reduced pressure. Dissolve the residue in 500 µL MeCN:water 22:78, filter (0.45 µm polyvinylidene difluoride), inject a 100 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Hypersil ODS Column temperature: 40 Mobile phase: MeCN:50 mM ammonium acetate 22:78 Flow rate: 1.5 Injection volume: 100 Detector: UV 224 CHROMATOGRAM Retention time: 6 Internal standard: chloramphenicol (7.50) Limit of detection: 20 ng/mL Limit of quantitation: 30 ng/mL KEY WORDS calf; cow; pharmacokinetics; plasma; SPE REFERENCE de Craene, B.A.; Deprez, P.; D’Haese, E.; Nelis, H.J.; Van den Bossche, W.; De Leenheer, P. Pharmacokinetics of florfenicol in cerebrospinal fluid and plasma of calves, Antimicrob.Agents Chemother., 1997, 41, 1991–1995. SAMPLE Matrix: water Sample preparation: Inject a 25 µL aliquot. HPLC VARIABLES Column: 150 × 3.9 4 µm Nova-Pak C18 Column temperature: 30 Mobile phase: MeCN:buffer 15:85 (The buffer was 3.28 g sodium acetate and 1.01 g sodium 1-heptanesulfonate in 1 L water, adjusted to pH 4.6 with phosphoric acid.) Flow rate: 1 Injection volume: 25 Detector: UV 224 CHROMATOGRAM Retention time: 8 Florfenicol 259 Limit of detection: 0.1 µg/mL Limit of quantitation: 0.2 µg/mL OTHER SUBSTANCES Simultaneous: degradants, thiamphenicol (3.3) REFERENCE Hayes, J.M.; Eichman, J.; Katz, T.; Gilewicz, R. Stability of florfenicol in drinking water, J.AOAC Int., 2003, 86, 22–29. ANNOTATED BIBLIOGRAPHY De Wasch, K.; Van Hoof, N.; Poelmans, S.; Okerman, L.; Courtheyn, D.; Ermens, A.; Cornelis, M.; De Brabander, H.F. Identification of ‘‘unknown analytes’’ in injection sites: a semi-quantitative interpretation, Anal.Chim.Acta, 2003, 483, 387–399. Hormazabal, V.; Steffenak, I.; Yndestad, M. Simultaneous determination of residues of florfenicol and the metabolite florfenicol amine in fish tissues by high-performance liquid chromatography, J.Chromatogr., 1993, 616, 161–165. Hormazabal, V.; Steffenak, I.; Yndestad, M. Simultaneous extraction and determination of florfenicol and the metabolite florfenicol amine in sediment by high-performance liquid chromatography, J.Chromatogr.A, 1996, 724, 364–366. Liu, J.; Fung, K.-F.; Chen, Z.; Zeng, Z.; Zhang, J. Pharmacokinetics of florfenicol in healthy pigs and in pigs experimentally infected with Actinobacillus pleuropneumoniae, Antimicrob.Agents Chemother., 2003, 47, 820–823. Lobell, R.D.; Varma, K.J.; Johnson, J.C.; Sams, R.A.; Gerken, D.F.; Ashcraft, S.M. Pharmacokinetics of florfenicol following intravenous and intramuscular doses to cattle, J.Vet.Pharmacol.Ther., 1994, 17, 253–258. [thiamphenicol is internal standard] Nagata, T.; Saeki, M. Simultaneous determination of thiamphenicol, florfenicol and chloramphenicol residues in muscles of animals and cultured fish by liquid chromatography, J.Liq.Chromatogr., 1992, 15, 2045–2056. [LOD 0.01 ppm; column temp 55◦ ; SPE] Vue, C.; Schmidt, L.J.; Stehly, G.R.; Gingerich, W.H. Liquid chromatographic determination of florfenicol in the plasma of multiple species of fish, J.Chromatogr.B, 2002, 780, 111–117. 260 Fludrocortisone Fludrocortisone O HO Molecular formula: C21 H29 FO5 Molecular weight: 380.45 CAS Registry No: 127-31-1, 514-36-3 (21-acetate) Merck Index: 13, 4156 CH3 OH OH CH3 F H H O SAMPLE Matrix: blood Sample preparation: Condition a 3 mL 500 mg Sep-Pak Vac C18 SPE cartridge with 3 mL MeOH and 3 mL water. Mix 500 µL 200 mM pH 3.85 acetate buffer with 1 mL serum, add 400 µL 2.5 µM IS in mobile phase, centrifuge, add to the SPE cartridge, wash with 3 mL acetone:water 20:80, wash with 3 mL water, wash with 3 mL hexane, elute with 3 mL diethyl ether. Vortex the eluate with 1 mL 200 mM NaOH, centrifuge. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 250 µL mobile phase, place on a rotary mixer for 5 min, inject a 60 µL aliquot. (Fludrocortisone is IS. Extraction from serum has not been strictly demonstrated.) HPLC VARIABLES Column: 250 × 4.6 5 µm Spherex C18 (Phenomenex) Mobile phase: MeOH:THF:water 3:25:72 Flow rate: 1 Injection volume: 60 Detector: UV 254 CHROMATOGRAM Retention time: 15.90 Internal standard: fludrocortisone (15.90) Limit of detection: 5 nM Limit of quantitation: 10 nM OTHER SUBSTANCES Extracted: 11-deoxycortisol (22.10), dexamethasone (29.85), hydrocortisone (12.85), methylprednisolone (21.00), prednisolone (12.00) KEY WORDS fludrocortisone is IS in original method; serum; SPE REFERENCE McWhinney, B.C.; Ward, G.; Hickman, P.E. Improved HPLC method for simultaneous analysis of cortisol, 11-deoxycortisol, prednisolone, methylprednisolone, and dexamethasone in serum and urine, Clin.Chem., 1996, 42, 979–981. SAMPLE Matrix: blood Sample preparation: Condition a 3 mL 200 mg Clean-Up C18 SPE cartridge (Worldwide Monitoring) with two 2 mL portions of MeOH and two 2 mL portions of water. Centrifuge plasma at 2000 rpm for 5 min prior to analysis. Mix 2 mL plasma with 40 µL MeCN, add 1 mL water, vortex until homogeneous, add to the SPE cartridge, wash with two 2 mL portions of acetone:water 20:80, wash with 1 mL 50 mM pH 2.7 phosphate buffer, place under vacuum for 3 min, elute with two 2.5 mL portions of ethyl acetate. Evaporate the eluate to dryness under reduced pressure at 40◦ , reconstitute the residue with 75 µL mobile phase B, vortex, add 100 µL 50 mM pH 3 phosphate buffer, centrifuge at 5000 rpm for 5 min, inject a 145 µL aliquot. Fludrocortisone 261 HPLC VARIABLES Column: 100 × 2 5 µm YMC Basic Column temperature: 50 Mobile phase: Gradient. A:B 20:80 for 1 min, to 50:50 over 7 min, to 65:35 over 3 min, to 100:0 (step gradient), maintain at 100:0 for 1 min, return to initial conditions, reequilibrate for 4 min. A was MeCN:50 mM pH 3.0 potassium dihydrogen phosphate buffer 50:50. B was MeOH:50 mM pH 3.0 potassium dihydrogen phosphate buffer 20:80. Flow rate: 0.3 Injection volume: 145 Detector: UV 246 CHROMATOGRAM Retention time: 12.4 Internal standard: fludrocortisone acetate OTHER SUBSTANCES Extracted: deflazacort (13.8), 21-hydroxydeflazacort (10) Simultaneous: cortisone, hydrocortisone KEY WORDS fludrocortisone acetate is internal standard; plasma; SPE REFERENCE Reynolds, D.L.; Burmaster, S.D.; Eichmeier, L.S. Quantitative determination of 21-hydroxy-deflazacort in human plasma using gradient semi-microbore liquid chromatography, Biomed.Chromatogr., 1994, 8, 230–235. 262 Fluprostenol Fluprostenol HO COOH Molecular formula: C23 H29 F3 O6 Molecular weight: 458.47 CAS Registry No: 40666-16-8 Merck Index: 13, 4220 O HO OH CF3 SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg IST Isolute ODS SPE cartridge (Jones Chromatography) with 1 mL MeOH and 1 mL MeOH:water:formic acid 3:97:0.1. Vortex 200 µL plasma with 200 pg IS for 30 s, add to the SPE cartridge, wash with 1 mL MeOH:water:formic acid 3:97:0.1, wash with 1 mL MeOH:water 25:75, elute with 1 mL MeOH:water 90:10. Evaporate the eluate to dryness under a stream of nitrogen at 35◦ , reconstitute the residue with 120 µL MeOH:water 30:70, inject a 25 µL aliquot. HPLC VARIABLES Column: 10 × 2.1 3 µm Symmetry Sentry Guard C18 (Waters) Mobile phase: MeOH:water:formic acid 38:62:0.1 containing 70 µg/mL ammonium acetate Flow rate: 0.4 Injection volume: 25 Detector: MS, PE Sciex API-III Plus triple quadrupole, TurboIonSpray, positive ionization, ESI 3800 V, orifice 40 V, nebulizer gas nitrogen at 62 psi, TurboProbe 475◦ , TurboProbe nitrogen at 8 L/min, collision gas argon, m/z 476–279 CHROMATOGRAM Retention time: 0.63 Internal standard: 3,3,4,4-2 H4 -fluprostenol (m/z 480–283) (0.63) Limit of quantitation: 25 pg/mL KEY WORDS pharmacokinetics; plasma; rat; SPE REFERENCE Eichhold, T.H.; Kuhlenbeck, D.L.; Baker, T.R.; Stella, M.E.; Amburgey, J.S.; deLong, M.A.; Hartke, J.R.; Cruze, C.A.; Pierce, S.A.; Wehmeyer, K.R. Use of short high-performance liquid chromatography columns and tandem-mass spectrometry for the rapid analysis of a prostaglandin analog, fluprostenol, in rat plasma, J.Chromatogr.B, 2000, 741, 213–220. SAMPLE Matrix: blood Sample preparation: Condition a SPEC 3 mL 15 mg MP1 nonpolar reversed-phase/ strong cation exchange SPE Cartridge (Ansys) with 500 µL MeOH and 500 µL 40 mM formic acid. Mix 1 mL plasma with 15 µL 20 ng/mL IS and 1 mL 100 mM formic acid, add to the SPE cartridge, rinse tube with 0.5–1 mL water, add rinse to the SPE cartridge, wash with 500 µL water, dry under vacuum, wash with two 500 µL portions of toluene:dichloromethane 60:40, dry under vacuum, elute with 600 µL toluene:methylformate 20:80. Evaporate the eluate to dryness under a stream of nitrogen at 30◦ , reconstitute the residue with 125 µL MeOH:water 50:50, inject a 35 µL aliquot. HPLC VARIABLES Column: 150 × 2 5 µm Phenomenex Columbus C18 Fluprostenol 263 Mobile phase: MeOH:5 mM pH 6.3 ammonium formate 70:30 Flow rate: 0.2 Injection volume: 35 Detector: MS, Micromass Quattro LC, electrospray, capillary 3.0 kV, sample cone 40 V, extraction cone 2 V, RF lens 0.3 V, source temperature 125◦ , drying gas 250◦ , MS1 parameters LM resolution 14, HM resolution 14, ion energy, 1.2 V, entrance and exit set to 0 and 1, collision energy 30 eV, MS2 parameters LM resolution 15.0, HM resolution 15.0, ion energy 1.2 V, multiplier 650 V, nebulizing gas 75 L/h, drying gas 570 L/h, collision gas argon, m/z 457–161 CHROMATOGRAM Retention time: 5.3 Internal standard: AL-5848X (tetradeutero travoprost free acid) (m/z 461–161) Limit of quantitation: 10 pg/mL KEY WORDS plasma; SPE REFERENCE McCue, B.A.; Cason, M.M.; Curtis, M.A.; Faulkner, R.D.; Dahlin, D.C. Determination of travoprost and travoprost free acid in human plasma by electrospray HPLC/MS/MS, J.Pharm.Biomed.Anal., 2002, 28, 199–208. 264 Flurandrenolide Flurandrenolide HO Molecular formula: C24 H33 FO6 Molecular weight: 436.51 CAS Registry No: 1524-88-5 Merck Index: 13, 4223 CH3 HO CH3 H H O CH3 O CH3 O H O F SAMPLE Matrix: formulations Sample preparation: Mix 1 g of a topical product, 5 mL 100 mM pH 4 citrate buffer saturated with NaCl, and 10 mL ethyl acetate, shake vigorously by hand to ensure that no large clumps stick to the tube, mix with the tube on its side on an oscillating shaker for 15 min. Remove the upper ethyl acetate layer and wash with citrate buffer as before. Dry the ethyl acetate over anhydrous sodium sulfate and evaporate to dryness. Dissolve the residue in a mixture of 10 mL heptane and 5 mL MeCN:water 90:10. Remove the upper heptane layer and extract it with 2 mL MeCN:water 90:10. Combine the MeCN/water layers and evaporate them to dryness, dissolve the residue in 300 µL MeOH, filter (0.45 µm nylon), inject a 5 µL aliquot. HPLC VARIABLES Guard column: 15 × 3.2 7 µm Brownlee NewGuard C18 Column: 75 × 4.6 3.5 µm Symmetry C18 (Waters) Mobile phase: Gradient. MeCN:water 18:82 for 2 min, to 82:18 over 12 min, maintain at 82:18 for 3 min, re-equilibrate at initial conditions for 12 min. Flow rate: 1 Injection volume: 5 Detector: UV 240 CHROMATOGRAM Retention time: 7.36 Limit of detection: 0.001% OTHER SUBSTANCES Simultaneous: alclometasone 17,21-dipropionate (10.93), amcinonide (10.90), beclomethasone 17,21-dipropionate (11.90), betamethasone (6.52), betamethasone 21acetate (8.47), betamethasone 17-benzoate (10.28), betamethasone 17,21-dipropionate (11.42), betamethasone 17-valerate (10.25), budesonide (8.55, 8.69 (epimers)), clobetasol 17-propionate (11.06), cortisone (5.62), cortisone 21-acetate (8.07), dexamethasone (6.57), dexamethasone 21-acetate (8.68), desonide (6.99), desoximetasone (7.60), desoxycorticosterone acetate (10.90), desoxycorticosterone pivalate (14.45), diflorasone 17,21-diacetate (9.81), fluocinolone acetonide (7.38), fluocinonide (9.79), fludrocortisone 21-acetate (7.77), fluorometholone (7.67), flumethasone 21-pivalate (11.20), flunisolide (7.14), fluprednisolone (5.46), fluticasone 17-propionate (11.19), halcinonide (10.72), halobetasol propionate (10.98), hydrocortisone (5.50), hydrocortisone 21-acetate (7.65), hydrocortisone 17-butyrate (8.66), hydrocortisone 21-cypionate (12.54), hydrocortisone 17-valerate (9.53), mometasone 17-furoate (11.24), methylprednisolone (6.31), methylprednisolone 21-acetate (8.34), meprednisone (6.55), prednisolone (5.37), prednisolone 21-acetate (7.47), prednisolone 21-tebuate (11.01), paramethasone 21-acetate (8.64), prednicarbate (10.72), prednisone (5.46), triamcinolone (4.15), triamcinolone acetonide (7.04), triamcinolone 16,21-diacetate (7.49), triamcinolone hexacetonide (13.12) KEY WORDS body wash, cream, gel, lotion, shampoo, spray Flurandrenolide 265 REFERENCE Reepmeyer, J.C. Screening for corticosteroids in topical pharmaceuticals by HPLC with a scanning ultraviolet detector, J.Liq.Chromatogr.Rel.Technol., 2001, 24, 693–709. SAMPLE Matrix: urine Sample preparation: Mix 5 mL urine with 100 ng IS and 400 µL 1 M pH 4.1 sodium acetate buffer, adjust pH to 5.0, add 600 µL β-glucuronidase solution (10800 U), heat at 65◦ for 3.5 h or at 37◦ overnight, cool, add 6 mL ethyl acetate, rotate for 10 min. Remove the organic layer and wash it with 3 mL 1 M NaOH containing 150 mM NaCl by rotating for 5 min, centrifuge at 1900 g for 30 s. Remove the organic layer and pass it through an anhydrous sodium sulfate drying column. Evaporate the eluate to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 30 µL MeOH, vortex, inject a 10 µL aliquot. HPLC VARIABLES Column: 75 × 4.6 3 µm DB-8 (Supelco) Column temperature: 25 Mobile phase: Gradient. MeOH:1% acetic acid from 0:100 to 100:0 over 15 min, maintain at 100:0 for 3 min. Flow rate: 1 Injection volume: 10 Detector: MS, Finnigan MAT LCQ Classic, APCI, source 450◦ , capillary 150◦ , source +5 kV for positive ions and – 5 kV for negative ions, collision gas helium, m/z 437 CHROMATOGRAM Retention time: 26.8 Internal standard: d4 -hydrocortisone (24.4) Limit of detection: 5 ng/mL OTHER SUBSTANCES Extracted: beclomethasone (m/z 409) (26.4), betamethasone (m/z 393) (25.9), deoxycortone (m/z 331) (28.1), 21-deoxydexamethasone (m/z 377) (26.8), desoximetasone (m/z 377) (27.6), dexamethasone (m/z 393) (25.9), dichlorisone (m/z 413) (26.4), fluclorolone acetonide (m/z 487) (27.8), fludrocortisone (m/z 381) (24.2), flumethasone (m/z 411) (25.4), fluocinolone acetonide (m/z 453) (26.4), fluocinonide (m/z 495) (28.5), fluocortolone (m/z 377) (26.8), fluorometholone (m/z 3.77) (26.6), fluprednisolone (m/z 379) (23.9), hydrocortisone (m/z 363) (24.4), isoflupredone (m/z 379) (23.9), methylprednisolone (m/z 375) (26.1), prednisolone (m/z 361) (24.4), prednisone (m/z 359) (23.4), triamcinolone (m/z 395) (19), triamcinolone acetonide (m/z 435) (29.3) KEY WORDS horse REFERENCE Tang, P.W.; Law, W.C.; Wan, T.S.M. Analysis of corticosteroids in equine urine by liquid chromatographymass spectrometry, J.Chromatogr.B, 2001, 754, 229–244. ANNOTATED BIBLIOGRAPHY Gagliardi, L.; De Orsi, D.; Del Giudice, M.R.; Gatta, F.; Porrà, R.; Chimenti, P.; Tonelli, D. Development of a tandem thin-layer chromatography-high-performance liquid chromatography method for the identification and determination of corticosteroids in cosmetic products, Anal.Chim.Acta, 2002, 457, 187–198. [hydrocortisone; hydrocortisone acetate; hydrocortisone butyrate; hydrocortisone pivalate; prednisolone pivalate; prednisolone acetonide; prednisolone acetate; fluorocortolone pivalate; clobetasone butyrate; flumethasone pivalate; fluorocortolone caproate; prednisolone; fluorocortolone; clobetasone; flumethasone; triamcinolone; triamcinolone diacetate; triamcinolone acetonide; clobetasol 266 Flurandrenolide propionate; clobetasol; fluocortin; fluocortin butyl ester; fludrocortisone; fludrocortisone acetate; dexamethasone; dexamethasone acetate; dexamethasone pivalate; dexamethasone isonicotinate; dexamethasone valerate; betamethasone; betamethasone acetate; betamethasone benzoate; betamethasone propionate butyrate; betamethasone propionate stearate; betamethasone propionate; betamethasone dipropionate; betamethasone valerate; betamethasone divalerate; betamethasone valerate acetate; fluocinolone; fluocinolone acetonide; fluocinonide; cortisone; cortisone acetate; amcinonide; flurandrenolide; fluorometholone; methylprednisolone; halcinonide; deoxymethasone; diflucortolone; valerate; dehydrocorticosterone; fluoroprednisolone; beclomethasone; alclometasone; mometasone; fluoroprednisolone acetate; beclomethasone dipropionate; alclometasone dipropionate; mometasone furoate] Tang, P.W.; Law, W.C.; Wan, T.S.M. Analysis of corticosteroids in equine urine by liquid chromatographymass spectrometry, J.Chromatogr.B, 2001, 754, 229–244. [triamcinolone; prednisone; fluprednisolone; isoflupredone; fludrocortisone; hydrocortisone; prednisolone; flumethasone; betamethasone; dexamethasone; methylprednisolone; dichlorisone; beclomethasone; fluocinolone acetonide; fluocinolone; fluorometholone; fluocortolone; desoximetasone; triamcinolone acetonide; flurandrenolide; fluclorolone acetonide; fluclorolone; deoxycortone; fluocinonide; flucloronide] 267 Flurithromycin Flurithromycin Molecular formula: C37 H66 FNO13 O H3C H3C F OH CH3 OH O O N O HO H3C O CH3 H3C CH3 OH Molecular weight: 751.92 CAS Registry No: 82664-20-8 O CH3 CH3 OCH3 CH3 O CH3 OH CH3 SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 10 µm Lichrosorb RP18 Column temperature: 35 Mobile phase: MeCN:buffer 68:32 (The buffer was 10 mM potassium dihydrogen phosphate adjusted to pH 7 with 20% NaOH.) Flow rate: 1.5 Detector: UV 214 CHROMATOGRAM Retention time: 3.9 (hemiketal), 5.6 (ketone) REFERENCE Colombo, N.; Depaoli, A.; Gobetti, M.; Saorin, M.G. Analytical-physical profile of the novel macrolide antibiotic flurithromycin ethylsuccinate, Arzneimittelforschung, 1994, 44, 850–855. SAMPLE Matrix: solutions HPLC VARIABLES Column: 125 × 4 3 µm LKB Spherisorb ODS-2 Mobile phase: MeCN:MeOH:100 mM pH 7.0 ammonium acetate 65:20:15 Flow rate: 0.5 Injection volume: 10–50 Detector: UV 235 CHROMATOGRAM Retention time: 5.1 OTHER SUBSTANCES Simultaneous: azithromycin (4.5), clarithromycin (7.6), erythromycin (5.4), oleandomycin (4.4), roxithromycin (7.9) REFERENCE Lingerfelt, B.; Champney, W.S. Macrolide and ketolide antibiotic separation by reversed phase high performance liquid chromatography, J.Pharm.Biomed.Anal., 1999, 20, 459–469. 268 Flurogestone acetate Flurogestone acetate O HO Molecular formula: C23 H31 FO5 Molecular weight: 406.49 CAS Registry No: 2529-45-5 Merck Index: 13, 4226 CH3 CH3 O CH3 CH3 H O F H O SAMPLE Matrix: solutions HPLC VARIABLES Column: 300 × 3.9 10 µm µBondapak C18 Mobile phase: MeOH:water 50:50 Flow rate: 2 Detector: UV 254 CHROMATOGRAM Retention time: 21 Internal standard: testosterone (32) OTHER SUBSTANCES Simultaneous: degradants REFERENCE Kabadi, M.B.; Valia, K.H.; Chien, Y.W. Intravaginal controlled administration of flurogestone acetate I: development of a stability-indicating liquid chromatographic method and stability kinetics of flurogestone acetate, J.Pharm.Sci., 1984, 73, 1461–1464. SAMPLE Matrix: tissue Sample preparation: Condition a 100 mg C18 SPE cartridge (Varian) with MeOH and 10 mM pH 8.5 Tris buffer. Fill a 22 mL vessel (from bottom to top) with 5 g alumina (dried at 120◦ for 48 h before use), 6 g anhydrous sodium sulfate, and 2 g melted (microwave) kidney fat. There is filter paper between the alumina and sodium sulfate. Pass hexane down through the layers at 60◦ at 1500 psi followed by MeCN at 50◦ at 1500 psi. Store the MeCN at – 20◦ for 30 min to precipitate fat, filter through a plug of glass wool, evaporate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 2 mL MeOH, mix with 5 mL water, add to the SPE cartridge, wash with 2 mL 20 mM pH 8.5 Tris buffer, wash with 2 mL MeOH:water 40:60, elute with 2 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 75 µL MeCN, add 75 µL 0.5% formic acid, mix, inject a 75 µL aliquot. (The extraction is done in a Dionex ASE system (advanced solvent extraction).) HPLC VARIABLES Column: 150 × 3 5 µm Symmetry (Waters) Column temperature: 40 Mobile phase: Gradient. A:B from 45:55 to 100:0 over 12 min. A was MeCN:water:formic acid 10:90:0.5. B was MeCN:water:formic acid 90:10:0.5. Flow rate: 0.4 Injection volume: 75 Detector: MS, Micromass Quattro Ultima, positive electrospray, capillary 2.5 kV, cone 40 V, source 120◦ , cone gas 189 L/h, desolvation gas 652 L/h, m/z 407.2–267.4–225.4 Flurogestone acetate 269 CHROMATOGRAM Retention time: 4.5 Limit of detection: <2 ng/g OTHER SUBSTANCES Extracted: chloromadinone acetate (m/z 405.2–309.2–345.3) (8.6), chlorotestosterone acetate (m/z 365.2–305.2–323.3) (12.2), delmadinone acetate (m/z 403.2–205.1–181.1) (7.8), medroxyprogesterone acetate (m/z 387.2–327.3–285.3) (8.8), megestrol acetate (m/z 385.2–267.3–325.3) (8.4), melengestrol acetate (m/z 397.2–279.3–279.3) (8.8) KEY WORDS fat; kidney; SPE REFERENCE Hooijerink, H.; van Bennekom, E.O.; Nielen, M.W.F. Screening for gestagens in kidney fat using accelerated solvent extraction and liquid chromatography electrospray tandem mass spectrometry, Anal.Chim.Acta, 2003, 483, 51–59. ANNOTATED BIBLIOGRAPHY Kabadi, M.B.; Chien, Y.W. Intravaginal controlled administration of flurogestone acetate II: development of an in vitro system for studying the intravaginal release and permeation of flurogestone acetate, J.Pharm.Sci., 1984, 73, 1464–1468. 270 Fluticasone propionate Fluticasone propionate S F Molecular formula: C25 H31 F3 O5 S Molecular weight: 500.58 CAS Registry No: 80474-14-2 Merck Index: 13, 4237 CH3 HO CH3 F H O O CH3 O CH3 H O F SAMPLE Matrix: blood Sample preparation: The SPE cartridges were contained in 96 well MicroLute II SPE blocks (Porvair Sciences) with each cell packed with 50 mg Varian C18. Condition each cell with 400 µL MeOH and 400 µL water. Centrifuge plasma at 1000 g for 10 min. Mix 500 µL plasma with 500 µL 1 ng/mL IS in 100 mM pH 7.4 ammonium formate buffer, wash with 400 µL water, wash with 400 µL MeOH:water 40:60 (40% aqueous methanol), elute with 200 µL MeOH. Evaporate the eluate to dryness under a stream of heated nitrogen, reconstitute the residue with 100 µL MeOH:25 mM pH 5 ammonium formate 50:50, inject an 80 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm ResElut C8 BD (Varian) Column temperature: 40 Mobile phase: MeOH:25 mM pH 5 ammonium formate 80:20 Flow rate: 1 Injection volume: 80 Detector: MS, PE Sciex API-III Plus triple quadrupole, column effluent split 1:30 so that 336 µL/min enters MS (?), TurboIonspray 500◦ , positive ion electrospray 5000 V, nebulizer gas nitrogen at 400 kPa, auxiliary gas nitrogen at 2.0 L/min, collision gas argon, collision energy 25 eV, m/z 501–313 CHROMATOGRAM Retention time: 3.0 Internal standard: 13 C3 -fluticasone propionate (m/z 504–313) Limit of quantitation: 20 pg/mL KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Callejas, S.L.; Biddlecombe, R.A.; Jones, A.E.; Joyce, K.B.; Pereira, A.I.; Pleasance, S. Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry, J.Chromatogr.B, 1998, 718, 243–250. SAMPLE Matrix: bulk Sample preparation: Inject a 200 µL aliquot of a 6.7 mg/mL solution in mobile phase. HPLC VARIABLES Column: 250 × 4.6 5 µm Inertsil ODS-2 Column temperature: 40 Fluticasone propionate 271 Mobile phase: Gradient. A:B from 45:55 to 60:40 over 25 min, to 75:25 over 25 min. A was MeCN. B was deuterated water containing 0.05% trifluoroacetic acid. Flow rate: 1 Injection volume: 200 Detector: UV 239 connected with NMR, Bruker AMX-600, stop-flow mode, 600.14 MHz; MS, Trio 1000 single quadrupole, thermospray, source 200◦ , orifice 200◦ , source ion repeller 100 V CHROMATOGRAM Retention time: 14 OTHER SUBSTANCES Simultaneous: impurities REFERENCE Mistry, N.; Ismail, I.M.; Smith, M.S.; Nicholson, J.K.; Lindon, J.C. Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC-NMR spectroscopy and HPLC-MS, J.Pharm.Biomed.Anal., 1997, 16, 697–705. SAMPLE Matrix: formulations Sample preparation: Mix 1 g of a topical product, 5 mL 100 mM pH 4 citrate buffer saturated with NaCl, and 10 mL ethyl acetate, shake vigorously by hand to ensure that no large clumps stick to the tube, mix with the tube on its side on an oscillating shaker for 15 min. Remove the upper ethyl acetate layer and wash with citrate buffer as before. Dry the ethyl acetate over anhydrous sodium sulfate and evaporate to dryness. Dissolve the residue in a mixture of 10 mL heptane and 5 mL MeCN:water 90:10. Remove the upper heptane layer and extract it with 2 mL MeCN:water 90:10. Combine the MeCN/water layers and evaporate them to dryness, dissolve the residue in 300 µL MeOH, filter (0.45 µm nylon), inject a 5 µL aliquot. HPLC VARIABLES Guard column: 15 × 3.2 7 µm Brownlee NewGuard C18 Column: 75 × 4.6 3.5 µm Symmetry C18 (Waters) Mobile phase: Gradient. MeCN:water 18:82 for 2 min, to 82:18 over 12 min, maintain at 82:18 for 3 min, re-equilibrate at initial conditions for 12 min. Flow rate: 1 Injection volume: 5 Detector: UV 240 CHROMATOGRAM Retention time: 11.19 (17-propionate) Limit of detection: 0.001% OTHER SUBSTANCES Simultaneous: alclometasone 17,21-dipropionate (10.93), amcinonide (10.90), beclomethasone 17,21-dipropionate (11.90), betamethasone (6.52), betamethasone 21acetate (8.47), betamethasone 17-benzoate (10.28), betamethasone 17,21-dipropionate (11.42), betamethasone 17-valerate (10.25), budesonide (8.55, 8.69 (epimers)), clobetasol 17-propionate (11.06), cortisone (5.62), cortisone 21-acetate (8.07), dexamethasone (6.57), dexamethasone 21-acetate (8.68), desonide (6.99), desoximetasone (7.60), desoxycorticosterone acetate (10.90), desoxycorticosterone pivalate (14.45), diflorasone 17,21-diacetate (9.81), fluocinolone acetonide (7.38), fluocinonide (9.79), flurandrenolide (7.36), fludrocortisone 21-acetate (7.77), fluorometholone (7.67), flumethasone 21pivalate (11.20), flunisolide (7.14), fluprednisolone (5.46), halcinonide (10.72), halobetasol propionate (10.98), hydrocortisone (5.50), hydrocortisone 21-acetate (7.65), hydrocortisone 17-butyrate (8.66), hydrocortisone 21-cypionate (12.54), 272 Fluticasone propionate hydrocortisone 17-valerate (9.53), mometasone 17-furoate (11.24), methylprednisolone (6.31), methylprednisolone 21-acetate (8.34), meprednisone (6.55), prednisolone (5.37), prednisolone 21-acetate (7.47), prednisolone 21-tebuate (11.01), paramethasone 21-acetate (8.64), prednicarbate (10.72), prednisone (5.46), triamcinolone (4.15), triamcinolone acetonide (7.04), triamcinolone 16,21-diacetate (7.49), triamcinolone hexacetonide (13.12) KEY WORDS body wash; cream; gel; lotion; shampoo; spray REFERENCE Reepmeyer, J.C. Screening for corticosteroids in topical pharmaceuticals by HPLC with a scanning ultraviolet detector, J.Liq.Chromatogr.Rel.Technol., 2001, 24, 693–709. ANNOTATED BIBLIOGRAPHY Bernal, J.L.; Del Nozal, M.J.; Martı́n, M.T.; Diez-Masa, J.C.; Cifuentes, A. Quantitation of active ingredients and excipients in nasal sprays by high-performance liquid chromatography, capillary electrophoresis and UV spectroscopy, J.Chromatogr.A, 1998, 823, 423–431. [beclomethasone dipropionate; fluticasone dipropionate; beclomethasone; fluticasone; benzalkonium; benzalkonium chloride; phenylethyl alcohol] Borchard, G.; Cassará, M.L.; Roemelé, P.E.H.; Florea, B.I.; Junginger, H.E. Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3), J.Pharm. Sci., 2002, 91, 1561–1567. Krishnaswami, S.; Möllmann, H.; Derendorf, H.; Hochhaus, G. A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma, J.Pharm.Biomed.Anal., 2000, 22, 123–129. [SPE] Laugher, L.; Noctor, T.G.; Barrow, A.; Oxford, J.M.; Phillips, T. An improved method for the determination of fluticasone propionate in human plasma, J.Pharm.Biomed.Anal., 1999, 21, 749–758. [SPE] Li, Y.N.; Tattam, B.N.; Brown, K.F.; Seale, J.P. A sensitive method for the quantification of fluticasone propionate in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionisation mass spectrometry, J.Pharm.Biomed.Anal., 1997, 16, 447–452. Li, Y.N.; Tattam, B.; Brown, K.F.; Seale, J.P. Quantification of epimeric budesonide and fluticasone propionate in human plasma by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry, J.Chromatogr.B, 2001, 761, 177–185. [SPE] 273 Flutrimazole Flutrimazole N F N Molecular formula: C22 H16 F2 N2 Molecular weight: 346.37 CAS Registry No: 119006-77-8 Merck Index: 13, 4241 F SAMPLE Matrix: blood, feces, urine Sample preparation: Mix 500 µL plasma or urine with 500 µL MeOH, shake, centrifuge, inject a 50 µL aliquot. Homogenize feces with an equal volume of MeOH, centrifuge at 5000 rpm for 20 min, inject a 100 µL aliquot. HPLC VARIABLES Guard column: µBondapak C18 Column: 300 × 3.9 10 µm µBondapak C18 Mobile phase: MeOH:5 mM pH 7 phosphate buffer 75:25 Flow rate: 1 Injection volume: 50–100 Detector: UV 225 CHROMATOGRAM Retention time: 10 OTHER SUBSTANCES Extracted: clotrimazole (11.2), imidazole (3.3) KEY WORDS dog; plasma REFERENCE Conte, L.; Ramis, J.; Mis, R.; Vilageliu, J.; Basi, N.; Forn, J. Pharmacokinetic study of [14 C]flutrimazole after oral and intravenous administration in dogs. Comparison with clotrimazole, Arzneimittelforschung, 1992, 42, 854–858. 274 Fomepizole Fomepizole H N N Molecular formula: C4 H6 N2 Molecular weight: 82.10 CAS Registry No: 7554-65-6 Merck Index: 13, 4252 H3C SAMPLE Matrix: blood Sample preparation: Condition a 100 mg Bond Elut SCX SPE cartridge with two 1 mL portions of MeOH and two 1 mL portions of 5 mM HCl. Mix 200 µL plasma with 800 µL 6.25 µM IS in 5 mM HCl, add to the SPE cartridge, wash with 1 mL MeOH:5 mM HCl 5:95, elute with 1 mL MeOH:250 mM pH 7.4 potassium phosphate buffer, inject a 100 µL aliquot. HPLC VARIABLES Guard column: 30 × 4 Nucleosil 120-5C18 Column: 100 × 4 Nucleosil 120-5C18 Mobile phase: MeOH:5 mM pH 6.0 potassium phosphate buffer 20:80 Flow rate: 0.8 Injection volume: 100 Detector: UV 220 CHROMATOGRAM Retention time: 7 Internal standard: 3-methylpyrazole (6) Limit of quantitation: 2.5 µM KEY WORDS plasma; SPE REFERENCE Diczfalusy, U.; Eklöf, R. Determination of 4-methylpyrazole in plasma using solid phase extraction and HPLC, Biomed.Chromatogr., 1987, 2, 226–227. SAMPLE Matrix: blood, dialysate Sample preparation: Mix 200 µL plasma with 10 µL 300 µg/mL IS in water, add 100 µL 15% trichloroacetic acid, mix, centrifuge at 10 000 g for 4 min. Mix a 150 µL aliquot of the supernatant with 100 µL 500 mM disodium hydrogen phosphate solution (pH ca. 7), inject a 50 µL aliquot. Inject a 200 µL aliquot of dialysate directly. HPLC VARIABLES Guard column: 4 × 4 5 µm LiChrospher 60 RP-select B Column: 125 × 4 5 µm LiChrospher 100 RP-18 Column temperature: 40 Mobile phase: MeCN:5 mM pH 6 potassium phosphate buffer 7.5:92.5 Flow rate: 1.5 Injection volume: 50–200 Detector: UV 220 CHROMATOGRAM Retention time: 4.9 Internal standard: 3-methylpyrazole (4.1) Fomepizole 275 Limit of quantitation: 300 ng/mL (plasma), 50 ng/mL (dialysate) KEY WORDS plasma REFERENCE Jobard, E.; Turcant, A.; Harry, P.; Le Bouil, A.; Allain, P. High-performance liquid chromatographic determination of 4-methylpyrazole in plasma and in dialysate, J.Chromatogr.B, 1997, 695, 444–447. ANNOTATED BIBLIOGRAPHY McMartin, K.E.; Collins, T.D.; Hewlett, T.P. High pressure liquid chromatographic assay of 4-methylpyrazole. Measurements of plasma and urine levels, J.Toxicol.Clin.Toxicol., 1984, 22, 133–148. 276 Fomivirsen Fomivirsen Molecular formula: C204 H263 N63 O114 P20 S20 Molecular weight: 6682.46 CAS Registry No: 144245-52-3, 160369-77-7 (Na salt) Merck Index: 13, 4254 SAMPLE Matrix: tissue, vitreous humor Sample preparation: Heat retina sample with 2 mg/mL proteinase K in buffer at 37◦ for 16–24 h, wash twice with phenol:chloroform 50:50 (Caution! Chloroform is a carcinogen!), wash with chloroform, evaporate to dryness under reduced pressure, suspend in water, inject an aliquot. Vitreous humor is similar, but buffer is not used. (Caution! Chloroform is a carcinogen! Buffer was 20 mM pH 8.0 Tris-HCl containing 0.5% Non-Idet P-40 (NP-40), 20 mM EDTA, and 100 mM NaCl.) HPLC VARIABLES Column: 100 × 4.6 Gen Pak Fax strong anion exchange Mobile phase: Gradient. A was MeOH:86 mM pH 8.0 Tris-HCl 20:80. B was 86 mM pH 8.0 Tris-HCl containing 1.5 M NaBr. A:B 100:0 for 5 min, to 40:60 over 45 min. Flow rate: 0.5 Detector: Radioactivity (14 C) CHROMATOGRAM Retention time: 50 OTHER SUBSTANCES Extracted: metabolites KEY WORDS retina REFERENCE Leeds, J.M.; Henry, S.P.; Truong, L.; Zutshi, A.; Levin, A.A.; Kornbrust, D. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothioate oligonucleotide, after intravitreal injection in the rabbit, Drug Metab.Dispos., 1997, 25, 921–926. 277 Fondaparinux Fondaparinux SO3Na Molecular formula: C31 H43 N3 Na10 O49 S8 Molecular weight: 1728.08 CAS Registry No: 114870-03-0 Merck Index: 13, 4257 O O SO3Na OH O O SO3Na O OSO3Na COONa O O O HO H SO3Na O N H O OCH3 N O OH OH O COONa OH O SO3Na SO3Na OH N H SO3Na SAMPLE Matrix: solutions HPLC VARIABLES Column: HR 5/5 mono-Q (Pharmacia) Mobile phase: Gradient. A was 500 mM NaCl. B was 2 M NaCl. A:B from 100:0 to 0:100 over 25 min. Flow rate: 1 Detector: Radioactivity (35 S) CHROMATOGRAM Retention time: 18 REFERENCE Lieu, C.; Shi, J.; Donat, F.; Van Horn, R.; Brian, W.; Newton, J.; Delbressine, L.; Vos, R. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs, Clin.Pharmacokinet., 2002, 41(Suppl. 2), 19–26. 278 Formestane Formestane CH3 O CH3 H Molecular formula: C19 H26 O3 Molecular weight: 302.41 CAS Registry No: 566-48-3 Merck Index: 13, 4264 H H O OH SAMPLE Matrix: urine Sample preparation: Add 500 µL β-glucuronidase (Boehringer Mannheim) to 5 mL urine, heat at 37◦ for 22 h, extract three times with 10 mL portions of ethyl acetate. Combine the extracts and evaporate to dryness, reconstitute the residue with 100 µL MeOH, inject a 20 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 Apex II 5ODS (Jones) Mobile phase: MeOH:water:formic acid 60:40:0.01 Flow rate: 1.2 Injection volume: 20 Detector: MS, Finnigan MAT TSQ 700 triple quadrupole, thermospray, discharge-on mode (1000 V), positive ion mode, source block 200◦ , vaporizer 100◦ , repeller 50 V, m/z 303 CHROMATOGRAM Retention time: 8.1 OTHER SUBSTANCES Extracted: metabolites REFERENCE Poon, G.K.; Jarman, M.; McCague, R.; Davies, J.H.; Heeremans, C.E.M.; van der Hoeven, R.A.M.; Niessen, W.M.A.; van der Greef, J. Identification of 4-hydroxyandrost-4-ene-3,17-dione metabolites in prostatic cancer patients by liquid chromatography-mass spectrometry, J.Chromatogr., 1992, 576, 235–244. Formoterol Formoterol Molecular formula: C19 H24 N2 O4 279 O H N HO Molecular weight: 344.40 CAS Registry No: 73573-87-2 Merck Index: 13, 4269 CH3 OCH3 N OH H SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg polysulfonic sorbent strong cationexchange SPE cartridge with 2 mL MeOH, 500 µL water, 3 mL 25 mM pH 6.6 phosphate buffer, and 1 mL water. Mix 1 mL plasma with 50 µL 5 ng/mL IS in water, 750 µL 50 mM pH 6.6 buffer, and 50 µL water, vortex for 5 s. Add to the SPE cartridge, wash with 2.5 mL 25 mM pH 6.6 phosphate buffer, wash with 500 µL water, wash with 250 µL MeOH:water 20:80, dry with 2 mL air, elute with two 150 µL portions of MeOH:pH 6.0 buffer 30:70, dilute the eluate with 200 µL water, mix, filter (0.45 µm nylon), inject a 300 µL aliquot. (50 mM pH 6.6 Buffer was 50 mM potassium dihydrogen phosphate:50 mM disodium hydrogen phosphate 62.7:37.3. Prepare 25 mM pH 6.6 buffer by dilution. The pH 6.0 buffer was 30 mM potassium dihydrogen phosphate:30 mM disodium hydrogen phosphate 87.7:12.3 containing 15 g/L KCl.) HPLC VARIABLES Guard column: 10 × 2 R2 Chromsep Column: 200 × 3 5 µm Hypersil ODS Column temperature: 33 Mobile phase: MeCN:MeOH:buffer 5:25:70 (The buffer was 35 mM potassium dihydrogen phosphate:35 mM disodium hydrogen phosphate 87.7:12.3 containing 20 mg/L EDTA, pH 6.) Flow rate: 0.4 Injection volume: 300 Detector: E, Model Decade (Antec, Leiden, Netherlands), VT-03 flowcell, working electrode with a 50 µm thickness spacer, potential +0.63 V in DC mode CHROMATOGRAM Retention time: 15.6 Internal standard: 3-acetylamino-4-hydroxy-α-[N-[1-methyl-2-(p-methoxyphenyl) ethyl]aminomethyl]benzyl alcohol (CGP 47086A) (19) Limit of detection: 4 pM Limit of quantitation: 3 pg/mL KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Campestrini, J.; Lecaillon, J.B.; Godbillon, J. Automated and sensitive method for the determination of formoterol in human plasma by high-performance liquid chromatography and electrochemical detection, J.Chromatogr.B, 1997, 704, 221–229. SAMPLE Matrix: blood Sample preparation: Condition an Isolute weak cation-exchange SPE cartridge with MeOH, water, and 100 mM pH 5.0 ammonium acetate buffer. Add plasma to the SPE cartridge, wash with 100 mM pH 5.0 ammonium acetate buffer, wash with MeOH, elute with MeOH:water:formic acid 75:23.75:1.25. Evaporate the eluate to dryness, 280 Formoterol reconstitute the residue with MeOH:water:acetic acid 10:89.5:0.5, inject an 80 µL aliquot onto column A, elute to waste with mobile phase A, divert the mobile phase containing formoterol onto column B, elute the contents of column B onto column C with mobile phase B, monitor the effluent from column C. HPLC VARIABLES Column: A 10 × 2.1 Hypersil NH2 + 33 × 2.1 4 µm Genesis CN; B 10 × 2.1 4 µm Genesis C18; C Hichrom ACE C18 Mobile phase: A MeOH:water:acetic acid 15:84.5:0.5; B MeOH:water:acetic acid 35:64.5: 0.5 Flow rate: 0.22 Injection volume: 80 Detector: MS, Finnigan TSQ 7000, atmospheric pressure ionization, positive ion electrospray CHROMATOGRAM Limit of quantitation: 5 pM KEY WORDS column-switching; pharmacokinetics; plasma; SPE REFERENCE Tronde, A.; Nordén, B.; Marchner, H.; Wendel, A.-K.; Lennernäs, H.; Bengtsson, U.H. Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs, J.Pharm.Sci., 2003, 92, 1216–1233. ANNOTATED BIBLIOGRAPHY Rosenborg, J.; Larsson, P.; Tegnér, K.; Hallström, G. Mass balance and metabolism of [3 H]formoterol in healthy men after combined i.v. and oral administration-mimicking inhalation, Drug Metab.Dispos., 1999, 27, 1104–1116. Fosamprenavir calcium 281 Fosamprenavir calcium Molecular formula: C25 H36 CaN3 O9 PS Molecular weight: 625.68 CAS Registry No: 226700-81-8 NH2 O O O S O N H O N O P CH3 O− O− O Ca++ CH3 SAMPLE Matrix: blood Sample preparation: Vortex 100 µL plasma with 200 µL 1 µg/mL IS in MeCN, centrifuge. Mix a 100 µL aliquot of the supernatant with 100 µL 0.1% formic acid and 400 µL MeCN:water 50:50, inject a 10–20 µL aliquot. HPLC VARIABLES Column: 50 × 2 3 µm Phenomenex Aqua C18 or 30 × 2 3 µm Phenomenex Aqua C18 Mobile phase: Gradient. A was MeOH:10 mM pH 3.5 ammonium formate 1.5:98.5. B was MeCN. A:B 99:1 for 3 min, to 5:95 over 1.5 min, maintain at 5:95 for 1.4 min, return to initial conditions over 0.1 min, re-equilibrate for 3 min. Flow rate: 0.325 Injection volume: 10–20 Detector: MS, PE Sciex API2000 turbo ion spray, electrospray ionization, positive ion mode CHROMATOGRAM Internal standard: 13 C6 -amprenavir OTHER SUBSTANCES Extracted: amprenavir, nelfinavir KEY WORDS plasma REFERENCE Huang, L.; Wring, S.A.; Woolley, J.L.; Brouwer, K.R.; Serabjit-Singh, C.; Polli, J.W. Induction of Pglycoprotein and cytochrome P450 3A by HIV protease inhibitors, Drug Metab.Dispos., 2001, 29, 754–760. SAMPLE Matrix: blood Sample preparation: Mix 100 µL plasma with 500 µL EtOH:MeCN 50:50, centrifuge at 15 800 g at 4◦ for 5 min. Evaporate the supernatant to dryness, reconstitute the residue with 100 µL initial mobile phase, inject a 10 µL aliquot. HPLC VARIABLES Column: 100 × 2 5 µm Luna C18 (Phenomenex) Mobile phase: Gradient. MeCN:buffer from 20:80 to 95:5 over 5 min, maintain at 95:5 for 4 min. (The buffer was 0.1% aqueous acetic acid adjusted to pH 5.4 with ammonium hydroxide.) Flow rate: 0.2 Injection volume: 10 282 Fosamprenavir calcium Detector: MS, PE Sciex API-365, triple quadrupole, collision energy 30 eV, m/z 586.3– 418.2 CHROMATOGRAM Retention time: 5.5 Limit of quantitation: 300 pg/mL OTHER SUBSTANCES Extracted: amprenavir (506.3–245.2) (7.0) KEY WORDS dog; plasma; rat REFERENCE Furfine, E.S.; Baker, C.T.; Hale, M.R.; Reynolds, D.J.; Salisbury, J.A.; Searle, A.D.; Studenberg, S.D.; Todd, D.; Tung, R.D.; Spaltenstein, A. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir, Antimicrob.Agents Chemother., 2004, 48, 791–798. Fosinopril Fosinopril O Molecular formula: C30 H46 NO7 P P Molecular weight: 563.66 CAS Registry No: 98048-97-6 Merck Index: 13, 4279 O H3C O O O 283 N COOH CH3 CH3 SAMPLE Matrix: blood Sample preparation: Condition a 3 mL 200 mg Bond Elut cyclohexyl SPE cartridge with 3 mL MeOH and 3 mL 0.1 N phosphoric acid. Vortex 1 mL serum with 2 mL 0.2 N phosphoric acid and an aliquot of EtOH containing 1.5 µg/mL SQ-33055 and 1.5 µg/mL SQ-27133, add to the SPE cartridge, wash with 3 mL 0.1 N phosphoric acid, wash with 3 mL 10 mM pH 4.6 ammonium acetate buffer, dry under vacuum, elute with 1.5 mL MeOH containing 10 mM ammonium acetate. Evaporate the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 75 µL initial mobile phase, inject a 5 µL aliquot. (Use silanized glass or polypropylene containers. Silanize glass vials by immersing in Prosil-28 working solution (10 mL concentrate diluted to 1 L with water) for 10 min, rinsing with water several times, drying in air.) HPLC VARIABLES Column: 50 × 2 5 µm Asahipak ODP PVA-C18 Mobile phase: Gradient. A was 770 mg ammonium acetate in 750 mL water and 250 mL MeOH, adjusted to pH 5.5 with glacial acetic acid. B was 770 mg ammonium acetate in MeOH. A:B from 70:30 to 5:95 over 1 min, maintain at 5:95 for 2 min, return to initial conditions over 2 min, re-equilibrate for 5 min. Flow rate: 0.2 Injection volume: 5 Detector: MS, PE Sciex API-III Plus triple quadrupole, turbo ion spray, positive ion, sprayer 4200 V, orifice 35 V, declustering 4 V, nebulizer gas nitrogen at 65 psi, curtain gas nitrogen at 1.2 L/min, turbo ion spray nitrogen 4 L/min, collision gas argon 23 eV, m/z 581.3–436.2 CHROMATOGRAM Retention time: 4.2 Internal standard: SQ-33055 ((4S)-4-phenyl-1-[[(R)-[(1S)-2-methyl-1-(1-oxopropoxy) propoxy](4-phenylbutyl)phosphinyl]acetyl]-L-proline) (m/z 575.3–430.2) (4), SQ-27133 ((4S)-4-phenylthio-1-[[(R)-(4-phenylbutyl)phosphinyl]acetyl]-L-proline) (m/z 479.2– 416.2) (3.3) Limit of quantitation: 1.17 ng/mL OTHER SUBSTANCES Extracted: fosinoprilat (m/z 453.2–390.2) (3.5) KEY WORDS serum; SPE REFERENCE Jemal, M.; Mulvana, D.E. Liquid chromatographic-electrospray tandem mass spectrometric method for the simultaneous quantitation of the prodrug fosinopril and the active drug fosinoprilat in human serum, J.Chromatogr.B, 2000, 739, 255–271. 284 Fosphenytoin Fosphenytoin H N Molecular formula: C16 H15 N2 O6 P Molecular weight: 362.27 CAS Registry No: 93390-81-9 Merck Index: 13, 4280 N O O O OH P OH O SAMPLE Matrix: blood Sample preparation: Vortex 1 mL plasma, 3 mL MeCN, and 5 µg IS, centrifuge for 10 min, inject an aliquot of the supernatant. HPLC VARIABLES Column: 150 × 3.9 µBondapak C18 Mobile phase: MeOH:10 mM pH 4.0 tetrabutylammonium dihydrogen phosphate 47:53 Flow rate: 1.7 Detector: UV 214 CHROMATOGRAM Internal standard: diphenylphosphate Limit of quantitation: 100 ng/mL KEY WORDS pharmacokinetics; plasma REFERENCE Boucher, B.A.; Bombassaro, A.M.; Rasmussen, S.N.; Watridge, C.B.; Achari, R.; Turlapaty, P. Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration, J.Pharm.Sci., 1989, 78, 929–932. SAMPLE Matrix: blood Sample preparation: Vortex 100 µL plasma, 100 µL 30 µg/mL IS in MeCN:water 3:97, and 100 µL 85% phosphoric acid for 10 s, add 2 mL diethyl ether, shake horizontally at 120 cycles/min for 20 min, centrifuge at 1300 g for 10 min, evaporate the supernatant to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL mobile phase, inject a 50 µL aliquot. Alternatively, filter (Amicon Centrifree with YMT membrane) 1 mL plasma at 1000 g for 20 min, collect ca. 150 µL, inject a 50 µL aliquot of the ultrafiltrate. HPLC VARIABLES Guard column: Guard-Pak Resolve C18 (Waters) Column: 150 × 3.9 5 µm Resolve C18 (Waters) Column temperature: 30 Mobile phase: MeCN:water 20:80 containing 5 mM tetrabutylammonium hydrogen sulfate, adjusted to pH 2.2–2.5 with 800 µL/L 85% phosphoric acid Flow rate: 2 Injection volume: 50 Detector: UV 210 CHROMATOGRAM Retention time: 8.8 Internal standard: 5-(p-methylphenyl)-5-phenylhydantion (11.3) Limit of detection: 100 ng/mL (extraction), 15 ng/mL (ultrafiltrate) Fosphenytoin 285 Limit of quantitation: 400 ng/mL (extraction), 30 ng/mL (ultrafiltrate) OTHER SUBSTANCES Extracted: phenytoin (5.8) Noninterfering: N-acetylprocainamide, carbamazepine, diazepam, digoxin, ethosuximide, gentamicin, lithium, lorazepam, phenobarbital, primidone, procainamide, quinidine, theophylline, valproic acid KEY WORDS pharmacokinetics; plasma; ultrafiltrate REFERENCE Cwik, M.J.; Liang, M.; Deyo, K.; Andrews, C.; Fischer, J. Simultaneous rapid high-performance liquid chromatographic determination of phenytoin and its prodrug, fosphenytoin in human plasma and ultrafiltrate, J.Chromatogr.B, 1997, 693, 407–414. ANNOTATED BIBLIOGRAPHY Kugler, A.R.; Annesley, T.M.; Nordblom, G.D.; Koup, J.R.; Olson, S.C. Cross-reactivity of fosphenytoin in two human plasma phenytoin assays, Clin.Chem., 1998, 44, 1474–1480. 286 Frovatriptan Frovatriptan Molecular formula: C14 H17 N3 O Molecular weight: 243.30 CAS Registry No: 158747-02-5, 158930-17-7 (succinate) O H CH3 N H NH2 N H SAMPLE Matrix: blood Sample preparation: Mix 200 µL blood with 40 µL 10 µg/mL IS and 100 µL 100 mM sodium carbonate, extract with 3 mL chloroform:isopropanol 50:50 (Caution! Chloroform is a carcinogen!). Evaporate the organic layer to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 150 µL mobile phase, inject an aliquot. HPLC VARIABLES Guard column: 10 × 4.6 4 µm µBondapak C18 Column: 150 × 4.6 5 µm Hypersil BDS C18 Mobile phase: MeCN:10 mM ammonium acetate 6:94, adjusted to pH 4 with glacial acetic acid Flow rate: 1 Detector: UV 244 CHROMATOGRAM Retention time: 5.5 Internal standard: 5,6,7,8-Tetrahydro-6-(ethylamino)carbazole-3-carboxamide (8) Limit of quantitation: 10 ng/mL KEY WORDS dog; mouse; rat; whole blood REFERENCE Laugher, L.; Briggs, R.; Doughty, J. Development of an analytical methodology from toxicokinetic to clinical studies for the anti-migraine drug frovatriptan, Chromatographia, 2000, 52, S113–S119. SAMPLE Matrix: blood Sample preparation: Human. Mix 1 mL blood with 100 µL 200 ng/mL IS and 2 mL MeCN, centrifuge. Evaporate the supernatant to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL mobile phase, inject an aliquot. Rabbit. Mix 250 µL blood with 100 µL 500 ng/mL IS and 2 mL MeCN, centrifuge. Evaporate the supernatant to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 250 µL mobile phase, inject an aliquot. HPLC VARIABLES Guard column: 10 × 3.2 5 µm Kromasil C8 Column: 50 × 4.6 3 µm Hypersil BDS C8 Mobile phase: MeCN:10 mM pH 4 ammonium acetate buffer 13:87 Flow rate: 1 Injection volume: Detector: MS, PE Sciex API-III, ionspray, 40 µL/min entered the detector, m/z 244.3–213.0 CHROMATOGRAM Retention time: 1 Frovatriptan 287 Internal standard: 5,6,7,8-Tetrahydro-6-(ethylamino)carbazole-3-carboxamide (m/z 258.3–213.0) (1) Limit of quantitation: 200 pg/mL (human), 10 ng/mL (rabbit) KEY WORDS human; rabbit; whole blood REFERENCE Laugher, L.; Briggs, R.; Doughty, J. Development of an analytical methodology from toxicokinetic to clinical studies for the anti-migraine drug frovatriptan, Chromatographia, 2000, 52, S113–S119. 288 Fumagillin Fumagillin CH3 HO Molecular formula: C26 H34 O7 Molecular weight: 458.54 CAS Registry No: 23110-15-8 Merck Index: 13, 4307 CH3 H3C O OCH3 O COOH O SAMPLE Matrix: formulations Sample preparation: Mix 100 µL of a 70 µg/mL solution in 0.9% sodium chloride with 900 µL MeOH, vortex for 15 s, centrifuge for 10 min. Mix 100 µL of the supernatant with 900 µL MeOH, vortex for 15 s, centrifuge for 10 min, inject a 20 µL aliquot. HPLC VARIABLES Column: Zorbax C18 Mobile phase: MeCN:MeOH:water:phosphoric acid 50:20:30:0.1 Flow rate: 0.5 Injection volume: 20 Detector: UV 350 CHROMATOGRAM Retention time: 3.7 Limit of quantitation: 200 ng/mL KEY WORDS ophthalmic solutions; stability-indicating REFERENCE Abdel-Rahman, S.M.; Nahata, M.C. Stability of fumagillin in an extemporaneously prepared ophthalmic solution, Am.J.Health-Syst.Pharm., 1999, 56, 547–550. SAMPLE Matrix: tissue Sample preparation: Mix 2 g cut up tissue with dichloromethane:dioxane:isopropanol 75:16:9 (Caution! Dioxane is a carcinogen!), sonicate, shake, try to divide solid into smaller pieces with a glass rod, sonicate for 15 min, centrifuge at 5000 rpm for 10 min, filter. Evaporate the filtrate to 1–1.5 mL under a stream of nitrogen at 55◦ , make up to 2 mL with mobile phase, inject an aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm silica (Perkin Elmer) (Before use, wash column with dichloromethane:acetic acid 95:5.) Mobile phase: n-Hexane:dichloromethane:dioxane:isopropanol:acetic acid 43:43:9:5:0.1 Flow rate: 2 Detector: UV 340 CHROMATOGRAM Retention time: 10 Limit of detection: 5 ng/g Limit of quantitation: 15 ng/g Fumagillin 289 KEY WORDS fat; fish; kidney; liver; muscle; normal phase; protect from light REFERENCE Fekete, J.; Romvári, Z.; Gebefügi, I.; Kettrup, A. Comparative study on determination of fumagillin in fish by normal and reversed phase chromatography, Chromatographia, 1998, 48, 48–52. SAMPLE Matrix: tissue Sample preparation: Condition a Sep-Pak C18 SPE cartridge with 5 mL dichloromethane and 10 mL MeOH. Mix 2 g cut up tissue with dichloromethane:dioxane:isopropanol 75:16:9 (Caution! Dioxane is a carcinogen!), sonicate, shake, try to divide solid into smaller pieces with a glass rod, sonicate for 15 min, centrifuge at 5000 rpm for 10 min, filter. Evaporate the filtrate to 0.1–0.2 mL under a stream of nitrogen at 55◦ , make up to 2 mL with mobile phase, add to the SPE cartridge, discard the first 0.5 mL (?), collect the second 0.5 mL, inject a 100 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Spherisorb ODS Mobile phase: MeCN:water:bicyclohexylamine 70:30:0.05, adjusted to pH 5.0 with 1 M phosphoric acid Flow rate: 2 Injection volume: 100 Detector: UV 340 CHROMATOGRAM Retention time: 5 Limit of detection: 5 ng/g Limit of quantitation: 15 ng/g KEY WORDS fat; fish; kidney; liver; muscle; protect from light; SPE REFERENCE Fekete, J.; Romvári, Z.; Gebefügi, I.; Kettrup, A. Comparative study on determination of fumagillin in fish by normal and reversed phase chromatography, Chromatographia, 1998, 48, 48–52. ANNOTATED BIBLIOGRAPHY Fekete, J.; Romvári, Z.; Szepesi, I.; Morovján, G. Liquid chromatographic determination of the antibiotic fumagillin in fish meat samples, J.Chromatogr.A, 1995, 712, 378–381. [trout; LOQ 5 ng/g] Guyonnet, J.; Richard, M.; Hellings, P. Determination of fumagillin in muscle tissue of rainbow trout using automated ion-pairing liquid chromatography, J.Chromatogr.B, 1995, 666, 354–359. [SPE; LOQ 20 ng/g] Galantamine OH Molecular formula: C17 H21 NO3 Molecular weight: 287.35 O CAS Registry No: 357-70-0 Merck Index: 13, 4361 H3CO N CH3 SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 100 µL 10 µg/mL IS in MeOH, 1 mL saturated KCl solution, and 100 µL 1 M NaOH, vortex, extract twice with 2.5 mL portions of toluene. Combine the organic layers and evaporate to dryness under a stream of nitrogen at 65◦ , reconstitute the residue with 100 µL MeOH:10 mM ammonium acetate:diethylamine 90:10:1, inject an aliquot. HPLC VARIABLES Column: 100 × 4.6 3 µm Hypersil C18 BDS Mobile phase: MeCN:10 mM pH 7 ammonium acetate 15:85 Flow rate: 0.8 Detector: F ex 280 em 310 CHROMATOGRAM Internal standard: codeine phosphate Limit of quantitation: 2–10 ng/mL OTHER SUBSTANCES Extracted: norgalantamine KEY WORDS dog; mouse; pharmacokinetics; plasma; rabbit; rat REFERENCE Monbaliu, J.; Verhaeghe, T.; Willems, B.; Bode, W.; Lavrijsen, K.; Meuldermans, W. Pharmacokinetics of galantamine, a cholinestrase inhibitor, in several animal species, Arzneimittelforschung, 2003, 53, 486–495. SAMPLE Matrix: blood Sample preparation: Mix 200 µL plasma with 100 µL 50 ng/mL IS in 2% bovine serum albumin in 50 mM pH 7.5 phosphate buffer, add 1 mL 100 mM NaOH, add 500 µL saturated KCl, add 5 mL toluene, extract by over-the-top mixing at 15 rpm for 10 min, centrifuge at 2000 g for 10 min. Evaporate the organic layer to dryness under a stream of nitrogen at 65◦ , reconstitute the residue with 200 µL mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Column: 50 × 4.6 3.5 µm Symmetry Shield C18 (Waters) Mobile phase: MeCN:10 mM ammonium acetate 15:85 Flow rate: 1.5 Injection volume: 20 Detector: MS, PE Sciex API 3000 triple quadrupole, TurboIonspray, positive ion mode, ionspray 4500 V, turbo gas nitrogen 350◦ 6.5 L/min, nebulizing gas air, collision gas nitrogen, orifice 31 V, ring potential 230 V, m/z 288.1–213.0 290 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 Galantamine 291 CHROMATOGRAM Retention time: 1.12 Internal standard: 13 C2 H3 -galantamine (292.1–217.0) (1.10) Limit of quantitation: 1 ng/mL OTHER SUBSTANCES Extracted: epigalantamine KEY WORDS pharmacokinetics; plasma REFERENCE Verhaeghe, T.; Diels, L.; De Vries, R.; De Meulder, M.; de Jong, J. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the determination of galantamine in human heparinized plasma, J.Chromatogr.B, 2003, 789, 337–346. ANNOTATED BIBLIOGRAPHY Huang, F.; Lasseter, K.C.; Janssens, L.; Verhaeghe, T.; Lau, H.; Zhao, Q. Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together, J.Clin.Pharmacol., 2002, 42, 1341–1351. Mannens, G.S.J.; Snel, C.A.W.; Hendrickx, J.; Verhaeghe, T.; Le Jeune, L.; Bode, W.; van Beijsterveldt, L.; Lavrijsen, K.; Leempoels, J.; Van Osselaer, N.; Van Peer, A.; Meuldermans, W. The metabolism and excretion of galantamine in rats, dogs, and humans, Drug Metab.Dispos., 2002, 30, 553–563. Zhao, Q.; Brett, M.; Van Osselaer, N.; Huang, F.; Raoult, A.; Van Peer, A.; Verhaeghe, T.; Hust, R. Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects, J.Clin.Pharmacol., 2002, 42, 1002–1010. Zhao, Q.; Iyer, G.R.; Verhaeghe, T.; Truyen, L. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers, J.Clin.Pharmacol., 2002, 42, 428–436. 292 Ganirelix Ganirelix Molecular formula: C80 H113 ClN18 O13 Molecular weight: 1570.35 CAS Registry No: 124904-93-4 Merck Index: 13, 4380 SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 5 µm Zorbax Rx octyl Mobile phase: MeCN:50 mM pH 2 ammonium phosphate buffer 27.5:72.5 Flow rate: 1 Detector: UV 225 REFERENCE Strickley, R.G.; Brandl, M.; Chan, K.W.; Straub, K.; Gu, L. High-performance liquid chromatographic (HPLC) and HPLC-mass spectrometric (MS) analysis of the degradation of the luteinizing hormonereleasing hormone (LH-RH) antagonist RS-26306 in aqueous solution, Pharm.Res., 1990, 7, 530–536. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 5 µm Zorbax Rx octyl Mobile phase: MeCN:100 mM pH 6 ammonium acetate buffer 42:58 Flow rate: 1.2 Injection volume: 100 Detector: UV 230; MS, Finnigan-MAT TSQ-70, thermospray, vaporizer 65–94◦ , jet 240◦ , collector 75–80 V, m/z 1570 CHROMATOGRAM Retention time: 23 OTHER SUBSTANCES Simultaneous: degradants REFERENCE Strickley, R.G.; Brandl, M.; Chan, K.W.; Straub, K.; Gu, L. High-performance liquid chromatographic (HPLC) and HPLC-mass spectrometric (MS) analysis of the degradation of the luteinizing hormonereleasing hormone (LH-RH) antagonist RS-26306 in aqueous solution, Pharm.Res., 1990, 7, 530–536. Gatifloxacin Gatifloxacin 293 CH3 H N OCH3 Molecular formula: C19 H22 FN3 O4 Molecular weight: 375.39 N CAS Registry No: 112811-59-3 Merck Index: 13, 4388 F N COOH O SAMPLE Matrix: blood, urine Sample preparation: Serum. Mix 200 µL serum with 200 µL 500 µg/mL IS in MeCN: 100 mM phosphoric acid 90:10 and 400 µL MeCN, centrifuge. Mix 200 µL of the supernatant with 800 µL PIC A solution, inject a 20 µL aliquot. Urine. Dilute 10 µL urine with 990 µL PIC A solution, inject a 5 µL aliquot. (PIC A solution was 10 mM tetrabutylammonium phosphate (Waters PIC A) adjusted to pH 3.48.) HPLC VARIABLES Guard column: 30 × 4 30–40 µm Perisorb RP-18 Column: 125 × 4 5 µm Nucleosil-100 5C18 Mobile phase: MeCN:10 mM tetrabutylammonium phosphate (Waters PIC A) 17:83, adjusted to pH 3.48 with ca. 1.3 mL concentrated phosphoric acid. Flow rate: 1 Injection volume: 5–20 Detector: F ex 295 em 480 CHROMATOGRAM Retention time: 4.5 Internal standard: trovafloxacin (12.6) Limit of detection: 30 ng/mL (serum), 1.7 µg/mL (urine) Limit of quantitation: 60 ng/mL (serum), 3.5 µg/mL (urine) OTHER SUBSTANCES Simultaneous: ciprofloxacin (3.6), grepafloxacin (11.1), moxifloxacin (7.7), ofloxacin (2.7), salicylic acid (22.2), tryptophan (1.9) Noninterfering: furosemide, sparfloxacin KEY WORDS pharmacokinetics; serum REFERENCE Borner, K.; Hartwig, H.; Lode, H. Determination of gatifloxacin in human serum and urine by HPLC, Chromatographia, 2000, 52, S105–S107. SAMPLE Matrix: blood, urine Sample preparation: Serum. Add 50 µL water to 450 µL serum, vortex for 30 s, add 450 µL MeCN:75 mM pH 7.5 phosphate buffer containing 500 µg/mL sodium dodecyl sulfate 20:80, add 50 µL 30 µg/mL IS solution, vortex for 30 s, filter (Amicon Centrifree) while centrifuging at 1500 g for 30 min, inject a 20 µL aliquot of the ultrafiltrate. Urine. Dilute 50 µL urine with 1 mL mobile phase, add 50 µL 30 µg/mL IS solution, vortex for 30 s, inject a 20 µL aliquot. HPLC VARIABLES Guard column: 7.5 × 4.6 5 µm Adsorbosphere HS C18 294 Gatifloxacin Column: 250 × 4.6 5 µm Adsorbosphere HS C18 Mobile phase: MeCN:buffer 50:50 (The buffer was 25 mM citric acid containing 10 mM sodium dodecyl sulfate and 10 mM tetrabutylammonium acetate.) Flow rate: 1 Injection volume: 20 Detector: UV 293 CHROMATOGRAM Retention time: 6.3 Internal standard: ciprofloxacin (5.5) Limit of quantitation: 100 ng/mL KEY WORDS pharmacokinetics; serum; ultrafiltrate REFERENCE Overholser, B.R.; Kays, M.B.; Sowinski, K.M. Determination of gatifloxacin in human serum and urine by high-performance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 2003, 798, 167–173. ANNOTATED BIBLIOGRAPHY Grant, E.M.; Nicolau, D.P.; Nightingale, C.; Quintiliani, R. Minimal interaction between gatifloxacin and oxycodone, J.Clin.Pharmacol., 2002, 42, 928–932. [no HPLC of oxycodone] Liang, H.; Kays, M.B.; Sowinski, K.M. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma, J.Chromatogr.B, 2002, 772, 53–63. Wallace, A.W.; Victory, J.M.; Amsden, G.W. Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers, J.Clin.Pharmacol., 2003, 43, 92–96. [moxifloxacin is internal standard; fluorescence detection] 295 Gefitinib Gefitinib Molecular formula: C22 H24 ClFN4 O3 Molecular weight: 446.90 H3CO N N N O N O Cl H CAS Registry No: 184475-35-2 F SAMPLE Matrix: blood Sample preparation: Vortex 500 µL plasma, 25 µL of 1 µg/mL IS in MeOH, 500 µL 1 M NaOH, and 6 mL MTBE for 2 min, centrifuge for 30 s. Remove 5.5 mL of the organic layer and evaporate it to dryness under a stream of nitrogen at 20◦ , reconstitute the residue with 250 µL mobile phase, inject a 15–100 µL aliquot. HPLC VARIABLES Guard column: Inertsil ODS3 Column: 150 × 4.6 Inertsil ODS3 Mobile phase: MeCN:1% ammonium acetate 80:20 Flow rate: 1 Injection volume: 15–100 Detector: MS, PE Sciex API-III tandem, APCI, m/z 447.2–128 CHROMATOGRAM Retention time: 2.5 Internal standard: d8 -gefitinib (m/z 455.4–136) (2.5) Limit of quantitation: 0.5 ng/mL KEY WORDS pharmacokinetics; plasma REFERENCE Jones, H.K.; Stafford, L.E.; Swaisland, H.C.; Payne, R. A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials, J.Pharm.Biomed.Anal., 2002, 29, 221–228. 296 Gemcitabine Gemcitabine Molecular formula: C9 H11 F2 N3 O4 Molecular weight: 263.20 CAS Registry No: 95058-81-4 Merck Index: 13, 4397 NH2 N O HO N O F OH F SAMPLE Matrix: blood Sample preparation: Mix 6 mL blood with 100 µL 10 mg/mL tetrahydrouridine, a cytidine deaminase inhibitor, centrifuge at 1200 g for 15 min to obtain plasma. Vortex 100 µL plasma and 10 µL 40% trichloroacetic acid for 1 min, centrifuge at 10 000 g at 4◦ for 5 min, inject a 25 µL aliquot of the supernatant. HPLC VARIABLES Column: 250 × 4.6 5 µm Thermo Hypersil BDS C18 Mobile phase: MeOH:buffer 17:83 (The buffer was 20 mM pH 3.1 ammonium dihydrogen phosphate buffer containing 10 mM sodium 1-heptanesulfonate.) Flow rate: 0.8 Injection volume: 25 Detector: UV 272 CHROMATOGRAM Retention time: 24 Limit of detection: 50 ng/mL Limit of quantitation: 80 ng/mL OTHER SUBSTANCES Extracted: 2′ ,2′ -difluorodeoxyuridine (dFdU) (6) KEY WORDS pharmacokinetics; plasma REFERENCE Wang, L.-Z.; Goh, B.-C.; Lee, H.-S.; Noordhuis, P.; Peters, G.J. An expedient assay for determination of gemcitabine and its metabolite in human plasma using isocratic ion-pair reversed-phase highperformance liquid chromatography, Ther.Drug Monit., 2003, 25, 552–557. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 5 µm Zorbax Rx-C8 Mobile phase: 13.8 g/L sodium dihydrogen phosphate containing 2.5 mL/L phosphoric acid Flow rate: 1.2 Injection volume: 5 Detector: UV 275 Gemcitabine 297 REFERENCE Jansen, P.J.; Akers, M.J.; Amos, R.M.; Baertschi, S.W.; Cooke, G.G.; Dorman, D.E.; Kemp, C.A.J.; Maple, S.R.; McCune, K.A. The degradation of the antitumor agent gemcitabine hydrochloride in an acidic aqueous solution at pH 3.2 and identification of degradation products, J.Pharm.Sci., 2000, 89, 885–891. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 5 µm Zorbax Rx-C8 Mobile phase: Gradient. A was MeOH:buffer 3:97. B was MeOH:buffer 50:50. A:B 100:0 for 8 min, to 0:100 over 5 min, maintain at 0:100 for 7 min. (The buffer was 13.8 g/L sodium dihydrogen phosphate containing 2.5 mL/L phosphoric acid.) Flow rate: 1.2 Injection volume: 5 Detector: UV 205 CHROMATOGRAM Retention time: 7.5 OTHER SUBSTANCES Simultaneous: degradants Interfering: 6-hydroxy-5,6-dihydro-2′ -deoxy-2′ ,2′ -difluorouridine REFERENCE Jansen, P.J.; Akers, M.J.; Amos, R.M.; Baertschi, S.W.; Cooke, G.G.; Dorman, D.E.; Kemp, C.A.J.; Maple, S.R.; McCune, K.A. The degradation of the antitumor agent gemcitabine hydrochloride in an acidic aqueous solution at pH 3.2 and identification of degradation products, J.Pharm.Sci., 2000, 89, 885–891. ANNOTATED BIBLIOGRAPHY Floridia, L.; Pietropaolo, A.M.; Tavazzani, M.; Rubino, F.M.; Colombi, A. Measurement of surface contamination from nucleoside analogue antineoplastic drugs by high-performance liquid chromatography in occupational hygiene studies of oncologic hospital departments, J.Chromatogr.B, 1999, 724, 325–334. [fluorouracil; bromouracil; iodouracil; cytarabine; gemcitabine; methotrexate; aminopterin; doxorubicin; daunorubicin; epirubicin; idarubicin] Freeman, K.B.; Anliker, S.; Hamilton, M.; Osborne, D.; Dhahir, P.H.; Nelson, R.; Allerheiligen, S.R.B. Validated assays for the determination of gemcitabine in human plasma and urine using highperformance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 1995, 665, 171–181. [normal phase; LOQ 50 ng/mL; pharmacokinetics] Keith, B.; Xu, Y.; Grem, J.L. Measurement of the anti-cancer agent gemcitabine in human plasma by high-performance liquid chromatography, J.Chromatogr.B, 2003, 785, 65–72. Sparidans, R.W.; Crul, M.; Schellens, J.H.M.; Beijnen, J.H. Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells, J.Chromatogr.B, 2002, 780, 423–430. Yilmaz, B.; Kadioglu, Y.; Aksoy, Y. Simultaneous determination of gemcitabine and its metabolite in human plasma by high-performance liquid chromatography, J.Chromatogr.B, 2003, 791, 103–109. 298 Gemifloxacin Gemifloxacin Molecular formula: C18 H20 FN5 O4 Molecular weight: 389.38 H2N H3CO N CAS Registry No: 175463-14-6 Merck Index: 13, 4400 N N N F COOH O SAMPLE Matrix: blood Sample preparation: Vortex 50 µL plasma and 250 µL 250 ng/mL IS in MeCN for 10 s, shake for 30 min, let stand at room temperature for 10 min, centrifuge at 14 000 g for 15 min, add the supernatant to 200 µL buffer in a silanized tube, inject a 10 µL aliquot. (The buffer was 10 mM ammonium acetate adjusted to pH 2.5 with trifluoroacetic acid.) HPLC VARIABLES Column: 500 × 4.6 5 µm 100 Å PLRP-S Column temperature: 40 Mobile phase: MeCN:buffer 30:70 (The buffer was 10 mM ammonium acetate adjusted to pH 2.5 with trifluoroacetic acid.) Flow rate: 1 Injection volume: 10 Detector: MS, PE Sciex API 300 tandem, heat-assisted nebulization, electrospray, positive ion mode, nebulizer gas at 60 psi, curtain gas at 40 psi, collision gas thickness 4, auxiliary gas 7 L/min, dwell 400 ms, pause 5 ms, m/z 390–313 CHROMATOGRAM Retention time: 1 Internal standard: 13 C2 H3 -gemifloxacin (m/z 394–313) Limit of quantitation: 10 ng/mL KEY WORDS pharmacokinetics; plasma REFERENCE Doyle, E.; Fowles, S.E.; McDonnell, D.F.; McCarthy, R.; White, S.A. Rapid determination of gemifloxacin in human plasma by high-performance liquid chromatography-tandem mass spectrometry, J.Chromatogr.B, 2000, 746, 191–198. SAMPLE Matrix: solutions Sample preparation: Inject a 1–3 µL aliquot of a 2 mg/mL solution. HPLC VARIABLES Column: 150 × 4 5 µm Crownpak CR(+) (Daicel) Mobile phase: MeOH:water 15:85 containing 10 mM sulfuric acid Flow rate: 1.2 Injection volume: 1–3 Detector: UV 272 CHROMATOGRAM Retention time: 38.88, 58.86 (enantiomers) Gemifloxacin 299 KEY WORDS chiral REFERENCE Lee, W.; Hong, C.Y. Direct liquid chromatographic enantiomer separation of new fluoroquinolones including gemifloxacin, J.Chromatogr.A, 2000, 879, 113–120. ANNOTATED BIBLIOGRAPHY Edelstein, P.H.; Shinzato, T.; Doyle, E.; Edelstein, M.A.C. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L-pneumophila pneumonia, Antimicrob.Agents Chemother., 2001, 45, 2204–2209. [LC-MS] Hyun, M.H.; Han, S.C. Liquid chromatographic separation of the enantiomers of fluoroquinolone antibacterials on a chiral stationary phase based on a chiral crown ether, J.Biochem.Biophys.Methods, 2002, 54, 235–243. Hyun, M.H.; Han, S.C.; Cho, Y.J.; Jin, J.S.; Lee, W. Liquid chromatographic resolution of gemifloxacin mesylate on a chiral stationary phase derived from crown ether, Biomed.Chromatogr., 2002, 16, 356–360. Naber, C.K.; Hammer, M.; Kinzig-Schippers, M.; Sauber, C. Söurgel, F.; Bygate, E.A.; Fairless, A.J.; Machka, K.; Naber, K.G. Urinary excretion and bactericidal activities of gemifloxacin and ofloxacin after a single oral dose in healthy volunteers, Antimicrob.Agents Chemother., 2001, 45, 3524–3530. [LC-MS; no HPLC of ofloxacin] Ramji, J.V.; Austin, N.E.; Boyle, G.W.; Chalker, M.H.; Duncan, G.; Fairless, A.J.; Hollis, F.J.; McDonnell, D.F.; Musick, T.J.; Shardlow, P.C. The disposition of gemifloxacin, a new fluoroquinolone antibiotic, in rats and dogs, Drug Metab.Dispos., 2001, 29, 435–442. 300 Gestodene Gestodene H3C H H Molecular formula: C21 H26 O2 Molecular weight: 310.43 CAS Registry No: 60282-87-3 Merck Index: 13, 4425 OH H H H O SAMPLE Matrix: formulations Sample preparation: Powder 2 tablets, sonicate with 10 mL EtOH for 15 min, shake mechanically for 20 min, centrifuge. Dilute a 2.5 mL aliquot of the supernatant to 10 mL with water, inject a 20 µL aliquot. HPLC VARIABLES Column: 150 × 3.9 4 µm Nova-Pak C18 Mobile phase: MeCN:MeOH:water 35:15:45 Flow rate: 1 Injection volume: 20 Detector: UV 215 OTHER SUBSTANCES Extracted: ethinyl estradiol KEY WORDS tablets REFERENCE Berzas, J.J.; Rodrı́guez, J.; Gastañeda, G. Determination of ethinylestradiol and gestodene in pharmaceuticals by a partial least-squares and principal component regression multivariate calibration, Anal.Sci., 1997, 13, 1029–1032. SAMPLE Matrix: solutions HPLC VARIABLES Column: 150 × 4.6 3 µm Hypersil ODS Mobile phase: Gradient. MeCN:water from 35:65 to 65:35 (time not given). Injection volume: 50 Detector: UV 242, UV 227 OTHER SUBSTANCES Simultaneous: gestodene esters REFERENCE Lipp, R.; Laurent, H.; Günther, C.; Riedl, J.; Esperling, P.; Täuber, U. Prodrugs of gestodene for matrixtype transdermal drug delivery systems, Pharm.Res., 1998, 15, 1419–1424. 301 Gestrinone Gestrinone H3C H H Molecular formula: C21 H24 O2 Molecular weight: 308.41 CAS Registry No: 16320-04-0 Merck Index: 13, 4427 OH H O SAMPLE Matrix: blood Sample preparation: Mix 200 µL serum with 50 µL 100 ng/mL IS in MeOH, add 2 mL diethyl ether, vortex for 2 min, freeze in dry ice/acetone, repeat the extraction. Combine the organic layers and evaporate to dryness, reconstitute the residue with 200 µL mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Kromasil C18 Mobile phase: 0.2% Formic acid in MeOH Flow rate: 1 Injection volume: 20 Detector: MS, PE Sciex API 3000, 100 µL/min entered the MS, electrospray, positive ion mode, source 200◦ , ionspray 5000 V, nebulizer gas nitrogen at 1 L/min, curtain gas at 1.25 L/min, orifice 45 V, collision gas nitrogen 30 µtorr, collision energy 45 eV, m/z 309–241 CHROMATOGRAM Retention time: 3 Internal standard: mifepristone (m/z 430–372) (2.7) Limit of detection: 0.8 ng/mL (S/N = 3) Limit of quantitation: 3.5 ng/mL KEY WORDS pharmacokinetics; serum; UV 340 can be used with MeOH:water 70:30 REFERENCE Wang, Q.; Wu, Z.; Wang, Y.; Luo, G.; Wu, E.; Gao, X. Determination of gestrinone in human serum by liquid chromatography-electrospray tandem mass spectrometry, J.Chromatogr.B, 2000, 746, 151–159. 302 Glycerin Glycerin Molecular formula: C3 H8 O3 Molecular weight: 92.09 HO OH OH CAS Registry No: 56-81-5 Merck Index: 13, 4497 SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 2 mL 10% trichloroacetic acid, centrifuge at 2500 rpm for 20 min. Wash the clear supernatant several times with ether until the aqueous layer becomes neutral. Dry the aqueous layer under a stream of air, reconstitute with 50 µL water containing 5 µg ethylene glycol, inject a 25 µL aliquot. HPLC VARIABLES Column: 20 × 7 5 µm IEX 215 cation-exchange (Toyo Soda) Mobile phase: Gradient. MeCN:water 76:24 for 30 min, to 0:100 (time not specified) Flow rate: 0.6 Injection volume: 25 Detector: F ex 412 em 475 following post-column reaction. The column effluent mixed with 25 mM periodic acid pumped at 0.1 mL/min and the resulting mixture flowed through an 0.4 mm ID reaction coil at 145◦ for 3 min. The effluent from this coil mixed with 8% acetylacetone in 2 M ammonium acetate (allowed to stand overnight before use) pumped at 0.2 mL/min and the mixture flowed through a similar coil at 64◦ to the detector. CHROMATOGRAM Retention time: 26 OTHER SUBSTANCES Extracted: anhydroglucitol (29), dexteros (43), erythritol (32), ethylene glycol (20) KEY WORDS plasma; post-column reaction REFERENCE Akanuma, H.; Ogawa, K.; Lee, Y.; Akanuma, Y. Reduced levels of plasma 1,5-anhydroglucitol in diabetic patients, J.Biochem.(Tokyo), 1981, 90, 157–162. SAMPLE Matrix: blood Sample preparation: Add 2 mL of a slurry of an anion-exchange resin (AG1-X8, 200–400 mesh, hydroxide form, Bio-Rad) in an equal volume of water to an 80 × 10 column. Add 2 mL of a slurry of a cation-exchange resin (AG50-WX8, 200–400 mesh, hydrogen form, Bio-Rad) in an equal volume of water to an 80 × 10 column. Place the anion column on top of the cation column. Vortex 1 mL plasma briefly, add 1 mL 0.3 N barium hydroxide, add 1.1 mL 0.3 N zinc sulfate, vortex, centrifuge at 2000 rpm for 10 min. Add the supernatant to the columns, vortex the pellet with 1 mL water, centrifuge at 2000 rpm, add the supernatant to the columns, repeat the extraction of the pellet, add two 1 mL portions of water to the columns. Collect all the eluate from the columns, add 100 µL 100 mM sucrose, vortex, lyophilize at – 20◦ for 15 h. Add 5 drops 2,2-dimethoxypropane, mix, dry under air (it is critical that the sample be completely dry), add 1 mL 30 mg/mL 4-dimethylaminopyridine in pyridine, vortex, sonicate at 45◦ for 5 min (no longer than 5 min), add 100 µL 25% benzoyl peroxide in Glycerin 303 butyl acetate, vortex until a white precipitate appears, heat at 45◦ for 15 min, cool to room temperature, add 50 µL MeOH, vortex at 45◦ for 5 min. Evaporate to dryness under a stream of air at 45◦ for 1 h, reconstitute the residue with 4 mL chloroform with vortexing and sonicating (Caution! Chloroform is a carcinogen!), add 2 mL 1 M HCl, vortex for 15 s, centrifuge at 2000 rpm for 5 min, discard the aqueous layer. Repeat the HCl wash. Evaporate the chloroform layer to dryness under a stream of air, reconstitute the residue with 172.8 µL MeCN and 67.2 µL water, vortex, centrifuge for 2 min, inject a 200 µL aliquot. HPLC VARIABLES Column: 250 mm long 5 µm Apex C18 (Jones) Mobile phase: Gradient. MeCN:water 56:44 for 30 min, to 95:5 (step gradient), maintain at 95:5 for 10 min, re-equilibria at initial conditions for 20 min. Flow rate: 1.3 Injection volume: 200 Detector: UV 254 CHROMATOGRAM Retention time: 26 OTHER SUBSTANCES Extracted: dextrose (28), sucrose (30) KEY WORDS derivatization; plasma; SPE REFERENCE Akanuma, H.; Ogawa, K.; Lee, Y.; Akanuma, Y. Reduced levels of plasma 1,5-anhydroglucitol in diabetic patients, J.Biochem., 1981, 90, 157–162. 304 Guanabenz Guanabenz Molecular formula: C8 H8 Cl2 N4 Molecular weight: 231.09 Cl NH N N Cl NH2 H CAS Registry No: 5051-62-7 Merck Index: 13, 4574 SAMPLE Matrix: blood Sample preparation: Mix 2 mL serum with 10 µL 10 µg/mL IS in MeOH, add 200 µL concentrated ammonium hydroxide, add 5 mL dichloromethane, shake on a reciprocating shaker for 30 min, centrifuge at 730 g for 20 min. (If excessive emulsion is present, mix by inversion and centrifuge again.). Evaporate the organic layer to dryness in a silanized glass tube under a stream of nitrogen below 40◦ , reconstitute the residue with 80 µL mobile phase, vortex, inject a 25 µL aliquot. HPLC VARIABLES Column: 250 × 2 5 µm Luna phenyl hexyl (Phenomenex) Column temperature: 30 Mobile phase: Gradient. MeCN:water:formic acid 5:95:0.05 for 1 min, to 90:10:0.05 over 4 min, maintain at 90:10:0.05 for 5 min, return to initial conditions over 0.5 min, re-equilibrate for 4.5 min. Flow rate: 0.45 Injection volume: 25 Detector: MS, Micromass Quattro II, positive ion mode, collision gas argon 3 µbar, photomultiplier 750–800 V, source cone 26 V, collision energy – 23 ± 1 V, capillary + 3.1 kV, HV lens 520 V, source 120◦ , m/z 231–172 CHROMATOGRAM Retention time: 6.19 Internal standard: clenbuterol (277–203) (6.12) Limit of detection: 0.3 ng/mL Limit of quantitation: 3 ng/mL KEY WORDS horse; pharmacokinetics; serum REFERENCE Harkins, J.D.; Dirikolu, L.; Lehner, A.F.; Hughes, C.; Schroedter, D.; Mayer, B.; Bratton, C.; Fisher, M.V.; Tobin, T. The detection and biotransformation of guanabenz in horses: a preliminary report, Vet.Ther., 2003, 4, 197–209. 305 Guanadrel Guanadrel NH O Molecular formula: C10 H19 N3 O2 Molecular weight: 213.28 O N NH2 H CAS Registry No: 40580-59-4 Merck Index: 13, 4575 SAMPLE Matrix: feed Sample preparation: Vortex 1 g pulverized feed with 5 mL 50 mM ammonium dihydrogen phosphate, let stand for 15 min, add 1 mL IS solution, add 3 mL MeCN, shake on a reciprocating shaker at 2000 rpm for 20 min. Add 3 mL supernatant to 1 mL 1 M sodium bicarbonate, add 2.5 mL MeOH, add 2 mL acetylacetone, mix, heat at 120 ± 5◦ for 100 min, cool, mix, centrifuge at 2000 rpm for 10 min, inject an aliquot of the supernatant. HPLC VARIABLES Column: 250 × 4.6 10 µm LiChrosorb RP-8 Mobile phase: MeCN:THF:50 mM ammonium dihydrogen phosphate 40:10:50 Flow rate: 0.8 Injection volume: 40 Detector: F ex 238 em 360 CHROMATOGRAM Retention time: 10.5 Internal standard: cyclohexymethylguanidine (18) Limit of detection: 1 ppm KEY WORDS derivatization REFERENCE Bombardt, P.A.; Adams, W.J. Liquid chromatographic determination of guanadrel in laboratory animal diet as the fluorescent acetylacetone derivative, Anal.Chem., 1982, 54, 1087–1090. Halobetasol propionate Molecular formula: C25 H31 ClF2 O5 Molecular weight: 484.97 CAS Registry No: 66852-54-8 Merck Index: 13, 4608 Cl HO O O CH3 CH3 O CH3 F H CH3 H O F SAMPLE Matrix: formulations Sample preparation: Mix 1 g of a topical product, 5 mL 100 mM pH 4 citrate buffer saturated with NaCl, and 10 mL ethyl acetate; shake vigorously by hand to ensure that no large clumps stick to the tube, mix with the tube on its side on an oscillating shaker for 15 min. Remove the upper ethyl acetate layer and wash with citrate buffer as before. Dry the ethyl acetate over anhydrous sodium sulfate and evaporate to dryness. Dissolve the residue in a mixture of 10 mL heptane and 5 mL MeCN:water 90:10. Remove the upper heptane layer and extract it with 2 mL MeCN:water 90:10. Combine the MeCN/water layers and evaporate them to dryness, dissolve the residue in 300 µL MeOH, filter (0.45 µm nylon), inject a 5 µL aliquot. HPLC VARIABLES Guard column: 15 × 3.2 7 µm Brownlee NewGuard C18 Column: 75 × 4.6 3.5 µm Symmetry C18 (Waters) Mobile phase: Gradient. MeCN:water 18:82 for 2 min, to 82:18 over 12 min, maintain at 82:18 for 3 min, re-equilibrate at initial conditions for 12 min. Flow rate: 1 Injection volume: 5 Detector: UV 240 CHROMATOGRAM Retention time: 10.98 Limit of detection: 0.001% OTHER SUBSTANCES Simultaneous: alclometasone 17,21-dipropionate (10.93), amcinonide (10.90), beclomethasone 17,21-dipropionate (11.90), betamethasone (6.52), betamethasone 21-acetate (8.47), betamethasone 17-benzoate (10.28), betamethasone 17,21-dipropionate (11.42), betamethasone 17-valerate (10.25), budesonide (8.55, 8.69 (epimers)), clobetasol 17propionate (11.06), cortisone (5.62), cortisone 21-acetate (8.07), dexamethasone (6.57), dexamethasone 21-acetate (8.68), desonide (6.99), desoximetasone (7.60), desoxycorticosterone acetate (10.90), desoxycorticosterone pivalate (14.45), diflorasone 17,21-diacetate (9.81), fluocinolone acetonide (7.38), fluocinonide (9.79), flurandrenolide (7.36), fludrocortisone 21-acetate (7.77), fluorometholone (7.67), flumethasone 21-pivalate (11.20), flunisolide (7.14), fluprednisolone (5.46), fluticasone 17-propionate (11.19), halcinonide (10.72), hydrocortisone (5.50), hydrocortisone 21-acetate (7.65), hydrocortisone 17-butyrate (8.66), hydrocortisone 21-cypionate (12.54), hydrocortisone 17-valerate (9.53), mometasone 17-furoate (11.24), methylprednisolone (6.31), methylprednisolone 21-acetate (8.34), meprednisone (6.55), prednisolone (5.37), prednisolone 21-acetate (7.47), prednisolone 21-tebuate (11.01), paramethasone 21-acetate (8.64), prednicarbate (10.72), prednisone (5.46), triamcinolone (4.15), triamcinolone acetonide (7.04), triamcinolone 16,21-diacetate (7.49), triamcinolone hexacetonide (13.12) 306 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 Halobetasol propionate 307 KEY WORDS body wash, cream, gel, lotion, shampoo, spray REFERENCE Reepmeyer, J.C. Screening for corticosteroids in topical pharmaceuticals by HPLC with a scanning ultraviolet detector, J.Liq.Chromatogr.Rel.Technol., 2001, 24, 693–709. 308 Halofuginone Halofuginone Molecular formula: C16 H17 BrClN3 O3 Molecular weight: 414.69 CAS Registry No: 55837-20-2 Merck Index: 13, 4611 Br N HO O N Cl O N H SAMPLE Matrix: blood Sample preparation: Condition a 1 mL Bond Elut C8 SPE cartridge with 2 mL MeOH and 8 mL water adjusted to pH 4.3 with acetic acid. Mix 4 mL serum with 8 mL 10% acetic acid, add to the SPE cartridge, wash with 5 mL water adjusted to pH 4.3 with acetic acid, wash with 1 mL MeOH:water 35:65 adjusted to pH 4.3 with acetic acid, wash with 1 mL water adjusted to pH 4.3 with acetic acid, elute with 1 mL MeCN:water:acetic acid 20:79.9:0.1 containing 2.104 µL/mL decylamine (pH ca. 4.3), inject a 50 µL aliquot of the eluate. (Use silanized glassware.) HPLC VARIABLES Guard column: 30–38 µm CO:PELL Column: 250 × 4.6 5 µm Supelcosil LC-DB18 Mobile phase: MeCN:buffer:water 22:15:63 containing 210.4 µL/L decylamine, pH ca. 4.75 (The buffer was 250 mM pH 4.3 ammonium acetate.) Injection volume: 50 Detector: UV 243 CHROMATOGRAM Retention time: 8 Limit of detection: 1.5 ng/mL KEY WORDS chicken; serum; SPE REFERENCE Beier, R.C.; Rowe, L.D.; Abd El-Aziz Nasr, M.I.; Elissalde, M.H.; Stanker, L.H. Extraction and HPLC analysis of halofuginone in chicken serum, J.Liq.Chromatogr., 1994, 17, 2961–2970. SAMPLE Matrix: eggs, tissue Sample preparation: Condition a 3 mL 60 mg Oasis HLB SPE cartridge with 3 mL MeOH, 3 mL water, and 3 mL 125 mM pH 4.9 ammonium acetate buffer. Mix 2 g minced liver or homogenized egg with 2 mL 25 mg/mL trypsin in water, vortex, adjust pH to 7–8 with 10% sodium carbonate, shake on an orbital shaker at 40◦ overnight, cool, add 1 mL 10% sodium carbonate, add 10 (liver) or 15 (eggs) mL ethyl acetate, shake on a mechanical shaker for 3 min, centrifuge at 600 g at 4◦ for 2 min, extract the aqueous layer again with 10 mL ethyl acetate. Combine the ethyl acetate layers and add to 5 mL 125 mM pH 4.9 ammonium acetate buffer, shake mechanically for 1 min. Shake the aqueous layer with 5 mL hexane for 20 s, discard the hexane layer. Add the aqueous layer to the SPE cartridge, wash with 2 mL toluene, push air through the SPE cartridge at 19 mL/min, elute with 2 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 500 µL 125 mM pH 4.9 ammonium acetate buffer, vortex for 30 s, inject a 25 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Prodigy C18 (Phenomenex) Halofuginone 309 Mobile phase: MeOH:water:acetic acid 40:59.5:0.5 Flow rate: 1 Injection volume: 25 Detector: MS, Micromass Quattro LC, 0.2 mL/min entered the detector, source 150◦ , drying gas nitrogen 500 L/h, nebulizing gas nitrogen 80 L/h, positive mode, collision cell entrance 0 eV, collision cell exit 2 eV, cone 30 V, collision gas argon 2.3310 mbar, m/z 416–398–138–120–100 CHROMATOGRAM Retention time: 6.3 Limit of quantitation: 15 ng/g (liver), 5 ng/g (eggs) KEY WORDS chicken; liver; SPE REFERENCE Yakkundi, S.; Cannavan, A.; Elliott, C.T.; Lövgren, T.; Kennedy, D.G. Development and validation of a method for the confirmation of halofuginone in chicken liver and eggs using electrospray tandem mass spectrometry, J.Chromatogr.B, 2003, 788, 29–36. ANNOTATED BIBLIOGRAPHY Anderson, A.; Christopher, D.H.; Woodhouse, R.N. Analysis of the anti-coccidial drug, halofuginone, in chicken feed using gas-liquid chromatography and high-performance liquid chromatography, J.Chromatogr., 1979, 168, 471–480. Anderson, A.; Goodall, E.; Bliss, G.W.; Woodhouse, R.N. Analysis of the anti-coccidial drug, halofuginone, in chicken tissue and chicken feed using high-performance liquid chromatography, J.Chromatogr., 1981, 212, 347–355. Holland, D.C.; Manns, R.K.; Roybal, J.E.; Hurlbut, J.A.; Long, A.R. Liquid chromatographic determination of the anticoccidial drug halofuginone hydrobromide in eggs, J.AOAC Int., 1995, 78, 37–40. Kinabo, L.D.B.; McKellar, Q.A.; Murray, M. Determination of halofuginone in bovine plasma by competing-ion high performance liquid chromatography after solid phase extraction, Biomed.Chromatogr., 1989, 3, 136–138. Mortier, L.; Daeseleire, E.; Delahaut, P. Simultaneous detection of five coccidiostats in eggs by liquid chromatography-tandem mass spectrometry, Anal.Chim.Acta, 2003, 483, 27–37. [diclazuril; dimetridazole; halofuginone; nicarbazin; robenidine] Tillier, C.; Cagniant, E.; Devaux, P. Determination of halofuginone in poultry feeds by high-performance liquid chromatography, J.Chromatogr., 1988, 441, 406–416. Yamamoto, Y.; Kondo, F. Determination of halofuginone and amprolium in chicken muscle and egg by liquid chromatography, J.AOAC Int., 2001, 84, 43–46. [SPE] 310 Hetastarch Hetastarch CAS Registry No: 9004-62-0 Merck Index: 13, 4692 OR′ O OR H O OH OR n R or R′ = H or CH2CH2OH SAMPLE Matrix: blood, lymph Sample preparation: Mix 2 mL plasma or lymph with 150 µL 85% trichloroacetic acid, centrifuge. Add 100 µL Tris buffer and 25µL phenol red to 1.5 mL of the supernatant, neutralize excess acid with 5–25 µL 5 M KOH, inject an aliquot of the supernatant HPLC VARIABLES Column: SEC-60 (TosoHaas) + SEC-50 (TosoHaas) + SEC-10 (Bio-Rad) Mobile phase: pH 4.0 acetate buffer Detector: Refractive Index KEY WORDS plasma; sheep REFERENCE Korent, V.A.; Conhaim, R.L.; McGrath, A.M.; DeAngeles, D.A.; Harms, B.A. Molecular distribution of hetastarch in plasma and lung lymph of unanesthetized sheep, Am.J.Respir.Crit.Care Med., 1997, 155, 1302–1308. Hydroquinone 311 Hydroquinone Molecular formula: C6 H6 O2 HO OH Molecular weight: 110.11 CAS Registry No: 123-31-9 Merck Index: 13, 4833 SAMPLE Matrix: blood Sample preparation: Filter (Amicon Centrifree) whole blood while centrifuging at 3◦ at 3000 g for 1 h, inject a 100 µL aliquot of the ultrafiltrate. HPLC VARIABLES Column: 170 × 4.6 5 µm Supelcosil LC-18 Mobile phase: 50 mM pH 4.5 formate buffer Flow rate: 1 Injection volume: 100 Detector: Radioactivity (14 C); UV (wavelength not specified, other papers have recommended 220–280) CHROMATOGRAM Retention time: 7 OTHER SUBSTANCES Extracted: hydroquinone glucuronide (3), hydroquinone sulfate (5) KEY WORDS ultrafiltrate; whole blood REFERENCE Deisinger, P.J.; English, J.C. Bioavailability and metabolism of hydroquinone after intratracheal instillation in male rats, Drug Metab.Dispos., 1999, 27, 442–448. 312 Hygromycin B Hygromycin B OH OH OH O Molecular formula: C20 H37 N3 O13 Molecular weight: 527.52 CAS Registry No: 31282-04-9 Merck Index: 13, 4878 NH2 HO OH O H3C OH O O N H NH2 HO O HO SAMPLE Matrix: tissue Sample preparation: Mix 500 mg homogenized kidney with 2 g 40 µm Bondesil preparative-grade end-capped cyanopropyl bulk packing material (Analytichem), blend with mortar and pestle for 2 min. (For a higher degree of purification, use 3 g Bondesil CN and blend for 3 min.) Place in a chromatography column, wash with 3 mL hexane, wash with 5 mL ethyl acetate, wash with 5 mL MeOH, wash with 5 mL MeOH:water 50:50, elute with 1 mL water and then with 8 mL 100 mM formic acid, filter (0.45 µm) a 4.5 mL aliquot of the eluate. Concentrate 4 mL of the filtrate to 75 µL under reduced pressure, add 7.5 µL 10% pentafluoropropionic acid in water, vortex, filter (0.20 µm), inject a 22 µL aliquot of the filtrate. HPLC VARIABLES Guard column: 10 × 2 3 µm YMCbasic Column: 100 × 2 3 µm YMCbasic Mobile phase: Gradient. A was MeCN:water 60:40 containing 20 mM pentafluoropropionic acid. B was MeCN:water 5:95 containing 20 mM pentafluoropropionic acid. A:B 0:100 for 5.1 min, to 32:68 over 0.1 min, maintain at 32:68 for 13.3 min, to 100:0 over 0.1 min, maintain at 100:0 for 5.5 min, return to initial conditions over 0.1 min, re-equilibrate for 21.8 min. Flow rate: 0.2 for 18.5 min, 0.22 for 0.1 min, 0.25 for 22.3 min, then 0.2 Injection volume: 22 Detector: MS, PE Sciex API III triple quadrupole, atmospheric pressure ion source, positive ion, laboratory-constructed ionspray interface (details provided), nebulizer gas nitrogen at 67 psi, curtain gas nitrogen, collision gas argon, 40 µL/min entered the detector, m/z 265–177 or 528–352–177 CHROMATOGRAM Retention time: 5.5 Limit of detection: 0.02 ppm OTHER SUBSTANCES Extracted: dihydrostreptomycin (7), gentamicin (13.5–15), neomycin (16), spectinomycin (5), streptomycin (6.5), tobramycin (12) KEY WORDS cow; kidney; MSPD REFERENCE McLaughlin, L.G.; Henion, J.D.; Kijak, P.J. Multi-residue confirmation of aminoglycoside antibiotics and bovine kidney by ion spray high-performance liquid chromatography/tandem mass spectrometry, Biol.Mass Spectrom., 1994, 23, 417–429. Iloprost HOOC Molecular formula: C22 H32 O4 Molecular weight: 360.49 CAS Registry No: 78919-13-8 Merck Index: 13, 4925 CH3 OH CH3 OH SAMPLE Matrix: blood Sample preparation: Mix 200 µL plasma with 200 µL 100 ppm 2-naphthoic acid and 300 µL MeCN, shake well, centrifuge for 10 min, inject a 20 µL aliquot of the supernatant. HPLC VARIABLES Column: 250 × 4.6 5 µm Zorbax C8 Mobile phase: MeCN:MeOH:20 mM pH 3.0 potassium phosphate buffer 30:24:46 Flow rate: 1.7 Injection volume: 20 Detector: UV 210; radioactivity (3 H) CHROMATOGRAM Retention time: 14.7, 15.9 (diastereomers) Internal standard: 2-naphthoic acid (6) Limit of quantitation: 500 ng (UV), 42 pg (radioactivity detector) OTHER SUBSTANCES Extracted: misoprostol (LOQ 1 µg (UV), 12 pg (radioactivity detector)) (18.5, diastereomers not resolved) KEY WORDS plasma; rat REFERENCE Womack, I.M.; Lee, A.S.; Kamath, B.; Agrawal, K.C.; Kishore, V. A high performance liquid radiochromatographic assay for the simultaneous analysis of iloprost and misoprostol, Prostaglandins, 1996, 52, 249–259. HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 313 314 Imatinib Imatinib Molecular formula: C29 H31 N7 O N H3C N Molecular weight: 493.60 CAS Registry No: 152459-95-5, 220127-57-1 (mesylate) Merck Index: 13, 4926 O H H N N N N N CH3 SAMPLE Matrix: blood Sample preparation: Mix 200 µL plasma with 10 µL 10 µg/mL IS in MeOH, add 1 mL MeCN, vortex briefly, centrifuge at 12000 g for 5 min. Evaporate a 1 mL aliquot of the supernatant to dryness under a stream of nitrogen at 27◦ , reconstitute the residue with 100 µL MeOH:water 20:80, vortex briefly, inject a 3 µL aliquot. HPLC VARIABLES Column: 50 × 4.6 5 µm Phenomenex Luna C18(2) Mobile phase: Gradient. MeOH:water:formic acid from 20:80:0.1 to 60:40:0.1 over 6 min, to 100:0:0.1 over 1 min, maintain at 100:0:0.1 for 2 min, return to initial conditions over 1 min, re-equilibrate for 4 min. Flow rate: 1 for 6 min, to 2 over 1 min, maintain at 2 for 6 min, to 1 over 0.1 min, maintain at 1 for 0.9 min Injection volume: 3 Detector: MS, ThermoFinnigan aQa, electrospray, positive single-ion, 10% of column effluent entered detector, insert probe 250◦ , ionspray 5000 V, orifice 10 V, nitrogen 75 psi, m/z 493.7 CHROMATOGRAM Retention time: 4.0 Internal standard: d8 -imatinib (m/z 501.7) (3.9) Limit of quantitation: 30 ng/mL OTHER SUBSTANCES Extracted: CGP 74588 (metabolite) (m/z 479.7) (3.7) KEY WORDS pharmacokinetics; plasma REFERENCE Parise, R.A.; Ramanathan, R.K.; Hayes, M.J.; Egorin, M.J. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma, J.Chromatogr.B, 2003, 791, 39–44. SAMPLE Matrix: formulations Sample preparation: Dissolve capsules in MeOH:water 25:75 containing 40 µg/mL acetaminophen so as to achieve an imatinib concentration of 2 mg/mL, inject an aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm XTerra C18 Column temperature: 25 Mobile phase: MeOH:water:triethylamine 25:74:1 (Mix 740 mL water with 10 mL triethylamine, adjust pH to 2.4 with 85% phosphoric acid, add 250 mL MeOH, adjust pH to 2.6 with 85% phosphoric acid, if necessary.) Imatinib 315 Flow rate: 1 Injection volume: 20 Detector: UV 267 CHROMATOGRAM Retention time: 7.7 Internal standard: acetaminophen (2.9) Limit of detection: 10 ng/mL Limit of quantitation: 100 ng/mL OTHER SUBSTANCES Simultaneous: impurity STI 509-00 KEY WORDS capsules; robust REFERENCE Ivanovic, D.; Medenica, M.; Jancic, B.; Malenovic, A. Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec capsules, J.Chromatogr.B, 2004, 800, 253–258. ANNOTATED BIBLIOGRAPHY Bakhtiar, R.; Khemani, L.; Hayes, M.; Bedman, T.; Tse, F. Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry, J.Pharm.Biomed.Anal., 2002, 28, 1183–1194. [SPE; LOQ 1 ng/mL] Bakhtiar, R.; Lohne, J.; Ramos, L.; Khemani, L.; Hayes, M.; Tse, F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry, J.Chromatogr.B, 2002, 768, 325–340. [LOQ 4 ng/mL] Hamada, A.; Miyano, H.; Watanabe, H.; Saito, H. Interaction of imatinib mesilate with human P-glycoprotein, J.Pharmacol.Exp.Ther., 2003, 307, 824–828. [cell cultures; UV detection] Vivekanand, V.V.; Rao, D.S.; Vaidyanathan, G.; Sekhar, N.M.; Kelkar, S.A.; Puranik, P.R. A validated LC method for imatinib mesylate, J.Pharm.Biomed.Anal., 2003, 33, 879–889. [bulk; UV detection] 316 Imidocarb Imidocarb Molecular formula: C19 H20 N6 O Molecular weight: 348.40 CAS Registry No: 27885-92-3 Merck Index: 13, 4938 O H N N H N N H H N N SAMPLE Matrix: blood Sample preparation: Condition a 100 mg Supelclean LC-18 SPE cartridge with 3 mL MeOH and 2 mL water. Vortex 1 mL plasma with 3 mL 50 mM disodium EDTA solution for 30 s, add to the SPE cartridge, wash with 2 mL MeOH:water 10:90, dry under vacuum for 5 min, elute with 3 mL MeCN:2% acetic acid in water containing 25 mM sodium octanesulfonate 90:10. Evaporate the eluate to dryness under reduced pressure at 40◦ , reconstitute the residue with 350 µL mobile phase, vortex, filter (0.45 µm), inject a 50 µL aliquot. HPLC VARIABLES Column: 100 × 8 4 µm Nova Pak C18 radial compression Mobile phase: MeCN:buffer 30:70 (The buffer was 5 mM sodium octanesulfonate containing 0.1% triethylamine adjusted to pH 3.2 with glacial acetic acid.) Flow rate: 1.5 Detector: UV 254 CHROMATOGRAM Retention time: 5.4 OTHER SUBSTANCES Extracted: diminazene (UV 370) (3.7) KEY WORDS cow; plasma; SPE; imidocarb is IS in original paper REFERENCE Gummow, B.; Du Preez, J.L.; Swan, G.E. Paired-ion extraction and high-performance liquid chromatographic determination of diminazene in cattle plasma: a modified method, Onderstepoort J.Vet.Res., 1995, 62, 1–4. SAMPLE Matrix: tissue Sample preparation: Homogenize (Ultra-Turrax) 10 g thinly sliced kidney with 2 mL 1 M sodium carbonate and 25 mL acetone for 2 min, sonicate for 3 min, centrifuge at 4 200 g for 5 min, extract the residue again with 2 mL 1 M sodium carbonate, 25 mL acetone, and 8 mL water. Combine the supernatants, add 50 mL chloroform (Caution! Chloroform is a carcinogen!), add 20 mL saturated aqueous NaCl, add 2 mL 40% NaOH, shake for 1 min. Filter the lower organic layer through anhydrous sodium sulfate and phase-separating filter paper (Whatman PS-1), evaporate to dryness under reduced pressure at 50◦ , reconstitute with three 3 mL portions of MeOH:10 mM pH 7 sodium acetate containing 10 mM sodium trifluoroacetate 80:20, centrifuge at 1860 g for 5 min, add the supernatant to a pre-washed (not otherwise described) Bond Elut CBA (carboxylic acid, weak cation exchange) SPE cartridge. Wash the residue with 1 mL MeOH:10 mM pH 7 sodium acetate containing 10 mM sodium trifluoroacetate 80:20 and add the supernatant to the SPE cartridge. Wash the SPE cartridge with 4 mL MeOH, elute with 5 mL MeOH:trifluoroacetic acid 95:5. Evaporate the eluate to dryness under Imidocarb 317 reduced pressure at 50◦ , reconstitute the residue with 500 µL mobile phase, vortex for 15 s, sonicate for 3 min, centrifuge at 1860 g for 5 min, filter (0.45 µm), inject a 50 µL aliquot. (Use silanized glassware.) HPLC VARIABLES Column: 100 × 4.6 3 µm Spherisorb S3W-C18 Mobile phase: Gradient. A was MeCN:10 mM pH 7 sodium acetate containing 10 mM sodium trifluoroacetate 15:85. B was MeCN:10 mM pH 2 sodium acetate containing 10 mM trifluoroacetic acid and 10 mM tetramethylammonium chloride 10:90. A:B 100:0 for 5 min, to 0:100 (step gradient), maintain at 0:100 for 15 min, return to initial conditions (step gradient), re-equilibrate for 10 min. Flow rate: 1 Injection volume: 50 Detector: UV 260 CHROMATOGRAM Retention time: 14 Limit of detection: 1–2 ng/g KEY WORDS cow; kidney; SPE REFERENCE Tarbin, J.A.; Shearer, G. High-performance liquid chromatographic determination of imidocarb in cattle kidney with cation-exchange clean-up, J.Chromatogr., 1992, 577, 376–381. ANNOTATED BIBLIOGRAPHY Coldham, N.G.; Moore, A.S.; Sivapathasundaram, S.; Sauer, M.J. Imidocarb depletion from cattle liver and mechanism of retention in isolated bovine hepatocytes, Analyst, 1994, 119, 2549–2552. [LOD 74 ng/g] Coldham, N.G.; Moore, A.S.; Dave, M.; Graham, P.J.; Sivapathasundaram, S.; Lake, B.G.; Sauer, M.J. Imidocarb residues in edible bovine tissues and in vitro assessment of imidocarb metabolism and cytotoxicity, Drug Metab.Dispos., 1995, 23, 501–505. 318 Iobenguane Iobenguane Molecular formula: C8 H10 IN3 H I N NH2 NH Molecular weight: 275.09 CAS Registry No: 80663-95-2 Merck Index: 13, 5028 SAMPLE Matrix: blood, urine Sample preparation: Inject a 200 µL aliquot of serum or urine onto column A and elute to waste with mobile phase A; after 5 min, backflush the contents of column A onto column B with mobile phase B, monitor the effluent from column B. After 15 min, re-equilibrate column A with mobile phase A for 5 min. After 5 determinations, flush column A with MeOH. HPLC VARIABLES Column: A 30 × 4 5 µm LiChrosorb C8; B 250 × 4 5 µm LiChrosorb C8 Mobile phase: A 60 mM pH 6.0 phosphate buffer; B MeCN:60 mM pH 6.0 phosphate buffer containing 1% sodium heptanesulfonate 35:65 Flow rate: 1 Injection volume: 200 Detector: UV 232 (urine), UV 254 (serum) CHROMATOGRAM Retention time: 14 Limit of detection: 50 ng/mL (S/N = 3) OTHER SUBSTANCES Extracted: metoclopramide (13), sulfamethoxazole/trimethoprim (?) (11) Noninterfering: acetaminophen, diazepam, dimenhydrinate, etoposide, prolonium iodide KEY WORDS column-switching; serum REFERENCE Schwabe, D.; Rohrbach, E.; Köhl, U. Determination of m-iodobenzylguanidine in serum and urine by high-performance liquid chromatography, J.Chromatogr., 1989, 487, 177–182. SAMPLE Matrix: blood Sample preparation: Plasma. Condition a 1 mL 100 mg Bakerbond cyano SPE cartridge with 1 mL MeOH and 2 mL water. Add 500 µL plasma to the SPE cartridge, wash with 2 mL water, wash with 2 mL MeOH, elute with 1 mL 100 mM HCl in MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 200 µL mobile phase, vortex for 15 s, centrifuge at 9 500 g for 2 min, inject a 100 µL aliquot. Whole blood. Condition a 1 mL 100 mg Bakerbond cyano SPE cartridge with 1 mL MeOH and 2 mL water, retaining 0.5 mL water above the sorbent. Place a 3 mL Bakerbond SPE filtration column above the SPE cartridge. Mix 500 µL whole blood with 1.5 mL water, add to the filtration column, wash with 1 mL water, remove the filtration column. Wash the SPE cartridge with 1 mL water, wash with 2 mL MeOH, elute with 1 mL 100 mM HCl in MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 200 µL mobile phase, vortex for 15 s, centrifuge at 9 500 g for 2 min, inject a 100 µL aliquot. Iobenguane 319 HPLC VARIABLES Column: 300 × 3.9 10 µm µBondapak C18 Mobile phase: MeCN:25 mM pH 4.0 ammonium phosphate buffer 20:80 Flow rate: 1 Injection volume: 100 Detector: UV 254 CHROMATOGRAM Limit of detection: 75 ng/mL Limit of quantitation: 100 ng/mL KEY WORDS plasma; SPE; whole blood REFERENCE Wafelman, A.R.; Konings, M.C.P.; Rosing, H.; Hoefnagel, C.A.; Taal, B.G.; Maes, R.A.A.; Beijnen, J.H. High-performance liquid chromatographic determination of metaiodobenzylguanidine in whole blood and plasma of cancer patients, J.Pharm.Biomed.Anal., 1994, 12, 1173–1179. ANNOTATED BIBLIOGRAPHY Sparidans, R.W.; Taal, B.G.; Beijnen, J.H. Bioanalysis of m-iodobenzylguanidine in plasma by highperformance liquid chromatography after derivatization with benzoin, J.Chromatogr.B, 1999, 730, 193–199. [SPE; fluorescence detection; LOQ 2 ng/mL] Wafelman, A.R.; Nortier, Y.L.M.; Rosing, H.; Underberg, W.J.M.; Maes, R.A.A.; Beijnen, J.H. Highperformance liquid chromatographic determination of m-iodobenzylguanidine in urine of cancer patients, J.Chromatogr., 1993, 622, 71–77. [SPE; LOQ 200 ng/mL] 320 Iodixanol Iodixanol OH Molecular formula: C35 H44 I6 N6 O15 Molecular weight: 1550.18 CAS Registry No: 92339-11-2 Merck Index: 13, 5045 H HO OH HO H N H O I O I N I N O I H3C OH N OH I N N O OH O H I OH OH O CH3 SAMPLE Matrix: blood Sample preparation: Dialyze 110 µL plasma against 175 µL water in the recipient channel using a Cuprophane cellulose dialysis membrane (molecular weight cut-off 15 000), pump 4 mL water in a pulsed fashion through the recipient channel, pass the water through column A, elute the contents of column A onto column B using the mobile phase, monitor the effluent from column B. (Purge the system with 0.01% Triton X-100 in water.) (ASTED XL system) HPLC VARIABLES Column: A 5 × 1.6 10 µm Hypersil ODS; B 15 × 3.2 7 µm Brownlee RP-18 Newguard + 250 × 4.6 5 µm Brownlee OD-5A, Spheri-5, RP-18 Mobile phase: MeCN:water 9:91 Flow rate: 1 Detector: UV 244 CHROMATOGRAM Retention time: 7 (exo isomer), 9 (endo isomer) Limit of detection: 19–130 ng/mL Limit of quantitation: 52–340 ng/mL KEY WORDS dialysis; monkey; human; plasma; rat REFERENCE Jacobsen, P.B. On-line dialysis and quantitative high-performance liquid chromatography analysis of iodixanol in human, rat and monkey plasma, J.Chromatogr.B, 2000, 749, 135–142. SAMPLE Matrix: urine Sample preparation: Dilute urine 1:20 with water, inject an aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm C18 (Becton Dickinson) Mobile phase: Gradient. MeCN:water 8:92 for 5 min, to 16:84 (step gradient), maintain at 16:84 for 10 min, return to initial conditions (step gradient), re-equilibrate for 5 min. Detector: UV 250 CHROMATOGRAM Retention time: 11.6 (exo), 13.8 (endo) Limit of detection: 640 ng/mL Iodixanol 321 REFERENCE Kerr, S.W.; Wolyniec, W.W.; Filipovic, Z.; Nodop, S.G.; Braza, F.; Winquist, R.J.; Noonan, T.C. Repeated measurement of intestinal permeability as an assessment of colitis severity in HLA-B27 transgenic rats, J.Pharmacol.Exp.Ther., 1999, 291, 903–910. ANNOTATED BIBLIOGRAPHY Molander, P.; Theodorsen, M.; Lundanes, E.; Soerenssen, D.M.; Greibrokk, T. Temperature effects on packed-capillary liquid chromatography of the X-ray contrast agent iodixanol, J.Chromatogr.Sci., 2000, 38, 157–161. Nomura, H.; Teshima, E.; Hakusui, H. Simple isocratic high-performance liquid chromatographic method for measurement of iodixanol in human plasma, J.Chromatogr., 1991, 572, 333–338. [size exclusion chromatography] 322 Iopanoic acid Iopanoic acid Molecular formula: C11 H12 I3 NO2 Molecular weight: 570.93 CAS Registry No: 96-83-3 Merck Index: 13, 5074 I CH3 I I COOH NH2 SAMPLE Matrix: blood Sample preparation: Mix 50 µL plasma with 50 µL 4 mM IS in MeOH, centrifuge at 14 000 rpm for 4 min, inject a 1–5 µL aliquot of the supernatant. HPLC VARIABLES Guard column: Present but not specified Column: 150 × 4.6 Hisep shielded hydrophobic phase Mobile phase: Gradient. MeOH:50 mM pH 3.4 phosphate buffer from 12:88 to 70:30 over 2 min, maintain at 70:30 for 30 min, return to initial conditions over 5 min. Flow rate: 1.5 Injection volume: 1–5 Detector: UV 231, UV 254 CHROMATOGRAM Retention time: 7.1 Internal standard: 2,4,6-triiodobenzoic acid (23.5) Limit of detection: 6.25 ng KEY WORDS dog; plasma REFERENCE Andeejani, A.M.; Hughes, H.; Feuchuk, D.M.; Aboul-Enein, H.Y. Rapid assay of iopanoic acid in dog plasma using a Hisep column, Biomed.Chromatogr., 1994, 8, 26–28. SAMPLE Matrix: blood, tissue Sample preparation: Blood. Shake 500 µL whole blood with 5 mL MeOH for 30 s, centrifuge at 2000 rpm for 2 min, inject a 20 µL aliquot of the supernatant. Liver. Shake 1 g liver homogenate with 10 mL MeOH for 30 s, centrifuge at 2000 rpm for 2 min, inject a 20 µL aliquot of the supernatant. HPLC VARIABLES Column: 300 × 4 10 µm LiChrosorb RP-18 Mobile phase: MeOH:water 60:40 containing 5 mM tetrabutylammonium phosphate Flow rate: 2 Injection volume: 20 Detector: UV 232 CHROMATOGRAM Retention time: 7.15 Limit of detection: 1 µg/mL OTHER SUBSTANCES Extracted: diatrizoic acid (UV 242) (1.30), iothalamic acid (UV 242) (1.30), ioxaglic acid (UV 242) (1.33) Iopanoic acid 323 KEY WORDS whole blood; liver REFERENCE Crowley, R.; Kacprzak, J. The determination of commonly used iodinated contrast media in postmortem samples using HPLC and TLC, J.Anal.Toxicol., 1986, 10, 53–55. 324 Iopromide Iopromide CH3 O Molecular formula: C18 H24 I3 N3 O8 Molecular weight: 791.11 CAS Registry No: 73334-07-3 Merck Index: 13, 5078 O H3CO OH I I H N N H OH N I OH OH O SAMPLE Matrix: blood Sample preparation: Mix plasma with 4 vol 5% perchloric acid, centrifuge, inject a 20 µL aliquot of the supernatant. HPLC VARIABLES Column: 250 × 4 LiChrosorb C18 Mobile phase: MeCN:water 4:96 adjusted to pH 2.5 with phosphoric acid Flow rate: 1.5 Injection volume: 20 Detector: UV 254 CHROMATOGRAM Retention time: 11, 13 (isomers) Limit of detection: 500 ng/mL OTHER SUBSTANCES Extracted: iohexol (4.5, 5.5 (isomers)) KEY WORDS plasma REFERENCE Gaspari, F.; Perico, N.; Ruggenenti, P.; Mosconi, L.; Amuchastegui, C.S.; Guerini, E.; Daina, E.; Remuzzi, G. Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate, J.Am.Soc. Nephrol., 1995, 6, 257–263. SAMPLE Matrix: water Sample preparation: Condition a 3 mL 200 mg LiChrolut EN SPE cartridge with water, 9 mL MeOH, and 9 mL water adjusted to pH 3.5 with nitric acid. Condition a 3 mL 250 mg LiChrolut Envi-Carb SPE cartridge (Supelco) with water, 9 mL MeOH, and 9 mL water adjusted to pH 2 with nitric acid. Adjust pH of 500–1000 mL water to 3.5 with nitric acid, pass through the EN cartridge at 200 mL/h. Adjust the pH of the eluate to 2 with nitric acid and pass through the Envi-Carb SPE cartridge at 300 mL/h. Dry cartridges under vacuum for 1 min. Elute the EN cartridge with 6 mL MeOH. Elute the Envi-Carb cartridge with 8 mL MeCN:water 50:50 containing a trace of ammonium acetate in the reverse direction. Combine the eluates and evaporate to dryness under a stream of nitrogen, reconstitute the residue with 500 µL mobile phase A, inject a 10 µL aliquot. HPLC VARIABLES Column: 150 × 2 3 µm Luna C18(2) Column temperature: 45 Iopromide 325 Mobile phase: Gradient. A was 0.05% trifluoroacetic acid in water. B was 0.05% trifluoroacetic acid in MeOH. A:B from 100:0 to 95:5 over 10 min, to 75:25 over 15 min, return to initial conditions over 2 min, re-equilibrate for 5 min. Flow rate: 0.25 Injection volume: 10 Detector: MS, Micromass Quattro-LC, electrospray, positive ion mode, drying gas nitrogen, nebulizing gas nitrogen, collision gas argon, m/z 792–573; UV 242 CHROMATOGRAM Retention time: 21.5, 22.5 (isomers) Limit of detection: ca. 50 pg/mL OTHER SUBSTANCES Extracted: diatrizoate (m/z 615–361) (11), iohexol (m/z 822–803) (16), iotrolan (m/z 814) (18) KEY WORDS SPE REFERENCE Putschew, A.; Schittko, S.; Jekel, M. Quantification of triiodinated benzene derivatives and X-ray contrast media in water samples by liquid chromatography-electrospray tandem mass spectrometry, J.Chromatogr.A, 2001, 930, 127–134. ANNOTATED BIBLIOGRAPHY Putschew, A.; Wischnack, S.; Jekel, M. Occurrence of triiodinated X-ray contrast agents in the aquatic environment, Sci.Total Environ., 2000, 255, 129–134. [iopromide; diatrizoate; iotrolan; iotroxin acid; iotroxin] Sacher, F.; Lange, F.T.; Brauch, H.-J.; Blankenhorn, I. Pharmaceuticals in groundwaters. Analytical methods and results of a monitoring program in Baden-Württemberg, Germany, J.Chromatogr.A, 2001, 938, 199–210. [amidotrizoic acid; amoxicillin; anhydro-erythromycin; atenolol; betaxolol; bezafibrate; bisoprolol; carbamazepine; chloramphenicol; clarithromycin; clenbuterol; clofibric acid; cloxacillin; cyclophosphamide; dapsone; diazepam; diclofenac; dicloxacillin; dimethylaminophenazone; erythromycin; etofibrate; fenofibrate; fenoprofen; furazolidone; gemfibrozil; ibuprofen; ifosfamide; indomethacin; iomeprol; iopamidol; iopromide; ketoprofen; metoprolol; metronidazole; nafcillin; naproxen; oleandomycin; oxacillin; penicillin G; penicillin V; pentoxifylline; phenazone; pindolol; propranolol; propyphenazone; ronidazole; roxithromycin; albuterol; simvastatin; sotalol; spiramycin; sulfadiazine; sulfadimidine; sulfamerazine; sulfamethoxazole; terbutaline; trimethoprim; tylosin; virginiamycin; sulfamethazine] Vanderford, B.J.; Pearson, R.A.; Rexing, D.J.; Snyder, S.A. Analysis of endocrine disruptors, pharmaceuticals, and personal care products in water using liquid chromatography/tandem mass spectrometry, Anal.Chem., 2003, 75, 6265–6274. [hydrocodone; trimethoprim; acetaminophen; caffeine; erythromycin; sulfamethoxazole; fluoxetine; pentoxifylline; meprobamate; phenytoin; carbamazepine; DEET; diazepam; oxybenzone; progesterone; iopromide; naproxen; ibuprofen; diclofenac; triclosan; gemfibrozil; ethinyl estradiol; estradiol; testosterone; SPE] 326 Ioversol Ioversol H O Molecular formula: C18 H24 I3 N3 O9 Molecular weight: 807.11 CAS Registry No: 87771-40-2 Merck Index: 13, 5085 O HO HO OH N OH I I H N N I OH OH O SAMPLE Matrix: blood, CSF, tissue, urine Sample preparation: Blood. Mix plasma or serum with 1 vol of MeCN:EtOH:water 60:38.4:1.6 or 20% trifluoroacetic acid at 4◦ , let stand overnight at 4◦ , centrifuge at 13 000 g at 4◦ for 10 min, inject an aliquot of the supernatant. Brain. Homogenize (Janke & Kunkel Ikawerk homogenizer) with an equal volume of saline at 20 000 rpm at room temperature for 3 min, centrifuge at 12 000 g at 4◦ for 30 min, filter (Centrisart 1) while centrifuging at 4◦ , inject an aliquot of the ultrafiltrate. CSF. Dilute 50–200-fold with water, inject an aliquot. Urine. Dilute with 4 vol of water. Mix with 1 vol of MeCN:EtOH:water 60:38.4:1.6 at 4◦ , let stand overnight at 4◦ , centrifuge at 13 000 g at 4◦ for 10 min, inject an aliquot of the supernatant. Alternatively, filter (Centrisart 1 with 5000 Da cut-off) while centrifuging at 4◦ , inject an aliquot of the ultrafiltrate. HPLC VARIABLES Column: 250 × 4.6 Spheri-5 RP-18 Mobile phase: Gradient. MeCN:water from 1:99 to 30:70 over 20 min Flow rate: 1 Injection volume: 10 Detector: UV 220–280 CHROMATOGRAM Retention time: 9.9 OTHER SUBSTANCES Extracted: iohexol (11.1 (endo), 11.3 (exo)) Noninterfering: diatrizoate, iothalamate KEY WORDS brain; plasma; serum; ultrafiltrate REFERENCE Jacobsen, P.B. High performance liquid chromatography with multiwavelength detection: a technique for identification of iodinated x-ray contrast agents in human body fluids and brain tissue, Am.J.Neuroradiol., 1992, 13, 1521–1525. Ipratropium bromide Ipratropium bromide Molecular formula: C20 H30 BrNO3 Molecular weight: 412.37 CAS Registry No: 22254-24-6 Merck Index: 13, 5092 327 CH3 H3C N+ CH3 Br− O OH O SAMPLE Matrix: blood Sample preparation: Inject 100 µL plasma onto column A and elute to waste with mobile phase A; after 10 min, backflush the contents of column A onto column B with mobile phase B; after 2 min, remove column A from the circuit, elute column B with mobile phase B, monitor the effluent from column B, re-equilibrate column A with mobile phase A for 5 min. HPLC VARIABLES Column: A 25 × 4 25 µm LiChrospher 60 XDS (SO3 /diol); B 250 × 4 5 µm LiChrospher 60 RP-Select B Column temperature: 25 ± 0.1 Mobile phase: A MeOH:2 mM lithium perchlorate adjusted to pH 3.0 with 1 M perchloric acid 3:97; B MeCN:50 mM pH 3.0 phosphate buffer containing 0.5 mM sodium butanesulfonate 20:80 Flow rate: 1 Injection volume: 100 Detector: UV 220 OTHER SUBSTANCES Extracted: atropine (16) KEY WORDS column-switching; plasma REFERENCE Chiap, P.; Rbeida, O.; Christiaens, B.; Hubert, P.; Lubda, D.; Boos, K.-S.; Crommen, J. Use of a novel cation-exchange restricted-access material for automated sample clean-up prior to the determination of basic drugs in plasma by liquid chromatography, J.Chromatogr.A, 2002, 975, 145–155. 328 Ipriflavone Ipriflavone O CH3 Molecular formula: C18 H16 O3 Molecular weight: 280.32 CAS Registry No: 35212-22-7 Merck Index: 13, 5093 H3C O O SAMPLE Matrix: blood, tissue, urine Sample preparation: Homogenize (Ultra-Turrax T25) tissue with 4 vol of water. Vortex 50 µL plasma, urine, or tissue homogenate with 125 µL 1 µg/mL IS in MeCN, centrifuge at 14 000 g for 1 min, inject a 50 µL aliquot of the supernatant. HPLC VARIABLES Column: 250 × 4.6 10 µm LiChrosorb RP-18 Mobile phase: MeCN:MeOH:50 mM pH 3 acetate buffer 35:25:40 Flow rate: 1.5 Injection volume: 50 Detector: UV 254 CHROMATOGRAM Retention time: 12 Internal standard: testosterone (6) Limit of detection: 20 ng/mL (plasma), 50 ng/mL (tissue), 100 ng/mL (urine) KEY WORDS brain; fat; heart; intestine; kidney; liver; lung; muscle; plasma; rat; spleen; stomach REFERENCE Kim, S.H.; Lee, J.S.; Lee, M.G. Determination of a isoflavone derivative, ipriflavone, and its metabolites, M1 and M5, in rat plasma, urine, and tissue homogenate by high-performance liquid chromatography, Res.Commun.Mol.Pathol.Pharmacol., 1997, 98, 313–324. 329 Isoflupredone Isoflupredone O OH CH3 Molecular formula: C21 H27 FO5 Molecular weight: 378.43 CAS Registry No: 338-95-4, 338-98-7 (21-acetate) Merck Index: 13, 5192 OH CH3 HO F H H O SAMPLE Matrix: blood, synovial fluid Sample preparation: Mix 500 µL plasma or synovial fluid with 4 mL pH 4 potassium phosphate buffer and 5 mL dichloromethane, centrifuge at 3000 g. Evaporate the organic layer to dryness, reconstitute the residue with 1 mL mobile phase, inject a 70 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 CR-J01 C18 (Shimadzu) Mobile phase: MeCN:50 mM pH 3.5 potassium phosphate buffer (ratio not given) Flow rate: 0.5 Injection volume: 70 Detector: UV 240 CHROMATOGRAM Limit of quantitation: 10 ng/mL KEY WORDS horse; plasma; for isoflupredone and isoflupredone acetate REFERENCE Lillich, J.D.; Bertone, A.L.; Schmall, L.M.; Ruggles, A.J.; Sams, R.A. Plasma, urine, and synovial fluid disposition of methylprednisolone acetate and isoflupredone acetate after intra-articular administration in horses, Am.J.Vet.Res., 1996, 57, 187–192. 330 Isopropamide iodide Isopropamide iodide H3C H3C Molecular formula: C23 H33 IN2 O Molecular weight: 480.42 CAS Registry No: 71-81-8 Merck Index: 13, 5222 CH3 I− N+ NH2 CH3 CH3 O SAMPLE Matrix: blood Sample preparation: Condition a 3 mL diol SPE cartridge (Baker) with 2 mL MeOH and 2 mL water. Add 1 mL plasma to the SPE cartridge, wash with 2 mL water, wash with 2 mL MeOH, elute with 3 mL 60 mM KBr in MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 200 µL mobile phase, inject an aliquot. (Prepare 60 mM KBr in MeOH by sonicating for 45 min.) HPLC VARIABLES Column: 250 × 4 LiChrosorb RP18 Mobile phase: MeOH:water 55:45 containing 4.325 g/L sodium octanesulfonate and 2 mL/L N, N-dimethyloctylamine, adjusted to pH 3.0 with phosphoric acid Flow rate: 1 Detector: UV 220 CHROMATOGRAM Retention time: 5 OTHER SUBSTANCES Extracted: clidinium bromide (9.5), mepenzolate bromide (8) KEY WORDS plasma; SPE REFERENCE Russ-Kirschenbaum, R.; Koziol, T.; Woolf, E. Solid phase extraction of quaternary ammonium compounds on diol columns: Application to the HPLC determination of CK-1649 in plasma, J.Liq.Chromatogr., 1989, 12, 3051–3059. SAMPLE Matrix: formulations Sample preparation: Sonicate a tablet in 35 mL MeOH:water 45:55 and 10 mL 40 µg/mL IS in MeOH:water 45:55, make up to 50 mL with MeOH:water 45:55, centrifuge at 3020 g for 10 min, inject an aliquot of the supernatant. Mix 1 mL oral solution with 10 mL 40 µg/mL IS in MeOH:water 45:55, make up to 50 mL with MeOH:water 45:55, inject an aliquot. HPLC VARIABLES Column: 150 × 4.1 5 µm Rsil C18 (RSL, Belgium) Column temperature: 25 Mobile phase: MeOH:water 55:45 containing 20 mM sodium 1-octanesulfonate and 10 mM N,N-dimethyloctylamine, adjusted to pH 3.0 with orthophosphoric acid Flow rate: 1 Injection volume: 10 Detector: UV 220 Isopropamide iodide 331 CHROMATOGRAM Retention time: 4 Internal standard: fenpiverinium bromide (6) OTHER SUBSTANCES Simultaneous: chlorpheniramine (10), glycopyrrolate (10), mepenzolate bromide (6), methyl paraben (2.5), pentienate bromide (7), phenylpropanolamine (3), tiemonium iodide (5) Noninterfering: cinnarizine, haloperidol KEY WORDS tablets; oral solutions; stability-indicating REFERENCE De Schutter, J.A.; Van den Bossche, W.; De Moerloose, P. Separation and determination of isopropamide iodide in pharmaceutical formulations by reversed-phase ion-pair high-performance liquid chromatography, J.Chromatogr., 1986, 366, 321–328. SAMPLE Matrix: solutions HPLC VARIABLES Column: 150 × 4.1 5 µm PRP-1 (Hamilton) Mobile phase: Gradient. MeCN:50 mM ammonium acetate from 10:90 to 50:50 over 30 min. Flow rate: 0.5 Injection volume: 20 Detector: MS, Finnigan MAT TSQ-70, thermospray, discharge-off mode, vaporizer 90◦ , ion-source 250◦ , repeller 50–100 V, make-up flow MeCN:50 mM ammonium acetate 10:90 at 1 mL/min, collision gas pressure 0.5 Pa, collision energy 20 eV, m/z 353–238 CHROMATOGRAM Limit of detection: 50 pg OTHER SUBSTANCES Simultaneous: antrenyl, clidinium, mepenzolate (14.5), methylbenacyzine, neostigmine, pipenzolate (15.5), propantheline (22), valethamate REFERENCE van der Hoeven, R.A.M.; Reeuwijk, H.J.E.M.; Tjaden, U.R.; van der Greef, J. Analysis of quaternary ammonium drugs by thermospray liquid chromatography-mass spectrometry using a resin-based stationary phase, J.Chromatogr.A, 1996, 741, 75–84. 332 Itopride Itopride H O O N N Molecular formula: C20 H26 N2 O4 Molecular weight: 358.43 CAS Registry No: 122898-67-3 H3CO OCH3 SAMPLE Matrix: blood, urine Sample preparation: Inject 200 µL serum or urine onto column A and elute to waste with mobile phase A. After 4 min, backflush the contents of column A onto column B with mobile phase B; after 1 min, remove column A from the circuit, elute column B with mobile phase B, monitor the effluent from column B. Re-equilibrate column A with mobile phase A. HPLC VARIABLES Column: A 10 × 4 25–40 µm Nucleosil CN (Macherey-Nagel); B 10 × 4.6 5 µm TSKgel ODS-80TM + 150 × 4.6 5 µm TSKgel ODS-80TM (Tosoh) Mobile phase: A 100 mM pH 7.0 phosphate buffer; B MeCN:50 mM pH 5.5 phosphate buffer 20:80 Flow rate: 1 Injection volume: 200 Detector: F ex 308 em 344 CHROMATOGRAM Retention time: 13 Limit of quantitation: 5 ng/mL (serum), 20 ng/mL (urine) OTHER SUBSTANCES Extracted: metabolites KEY WORDS column-switching; pharmacokinetics; serum REFERENCE Takahara, E.; Fukuoka, H.; Takagi, T.; Nagata, O.; Kato, H. Simultaneous determination of a new gastrointestinal prokinetic agent (HSR-803) and its metabolites in human serum and urine by highperformance liquid chromatography using automated column-switching, J.Chromatogr., 1992, 576, 174–178. Kinetin H O N N Molecular formula: C10 H9 N5 O Molecular weight: 215.21 CAS Registry No: 525-79-1 Merck Index: 13, 5329 H N N N SAMPLE Matrix: solutions Sample preparation: Inject an aliquot of a solution in 200 mM HCl. HPLC VARIABLES Guard column: present but not specified Column: 150 × 3.3 Vydac Mobile phase: MeOH:buffer 4:96 (The buffer was 12.5 mM citric acid containing 25 mM sodium acetate, 30 mM NaOH, and 10 mM acetic acid.) Detector: E, ESA Coulochem II, 650 mV; UV 260 CHROMATOGRAM Retention time: 8 REFERENCE Barciszewski, J.; Siboska, G.E.; Pedersen, B.O.; Clark, B.F.C.; Rattan, S.I.S. Evidence for the presence of kinetin in DNA and cell extracts, FEBS Lett., 1996, 393, 197–200. HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 333 Lafutidine H O Molecular formula: C22 H29 N3 O4 S O Molecular weight: 431.56 CAS Registry No: 118288-08-7 Merck Index: 13, 5362 N S O O N N SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 500 µL 1 M NaOH, extract with 3 mL ethyl acetate. Evaporate the extract to dryness under reduced pressure, reconstitute the residue with 100 µL 100 mM HCl, wash with 1 mL ethyl acetate. Add 750 µL 100 mM NaOH to the aqueous layer, extract with 3 mL ethyl acetate containing 20 ng IS. Evaporate the organic layer to dryness, reconstitute the residue with 200 µL mobile phase, inject an aliquot. HPLC VARIABLES Guard column: Guard-Pak Column: Cosmosil 5C18-AR Column temperature: 40 Mobile phase: MeCN:10 mM pH 5.9 phosphate buffer 20:80 Flow rate: 1 Detector: UV 230 CHROMATOGRAM Internal standard: 4-amino-3-nitroanisole KEY WORDS plasma REFERENCE Itoh, H.; Naito, T.; Takeyama, M. Lafutidine changes levels of somatostatin, calcitonin gene-related peptide, and secretin in human plasma, Biol.Pharm.Bull., 2002, 25, 379–382. 334 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 335 Lamivudine Lamivudine NH2 N Molecular formula: C8 H11 N3 O3 S Molecular weight: 229.26 CAS Registry No: 134678-17-4 Merck Index: 13, 5367 HO O N O S SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg Bond Elut-C SPE cartridge with 1 mL MeOH and 1 mL 100 mM pH 7.0 ammonium acetate buffer. Heat plasma at 58◦ for 1 h to inactivate HIV. Vortex 800 µL plasma with 300 µL 2 µg/mL hexobarbital in 25 mM pH 7.0 ammonium acetate buffer for 30 s and centrifuge at 18 000 g for 5 min. Add 1 mL of the supernatant to the SPE cartridge, wash with 1 mL 100 mM pH 7.0 ammonium acetate buffer, suck dry for 1 min, elute with 800 µL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 40◦ and reconstitute the residue with 100 µL mobile phase. Vortex for 30 s, centrifuge at 18 000 g for 3 min, and inject an 80 µL aliquot. HPLC VARIABLES Guard column: 20 × 3.9 5 µm Polarity dC18 (Waters) Column: 150 × 3.9 5 µm Polarity dC18 (Waters) Column temperature: 40 Mobile phase: Gradient. A was 10 mM pH 6.5 ammonium acetate buffer. B was 10 mM pH 6.5 ammonium acetate buffer:MeCN:MeOH 20:50:30. A:B 96:4 for 15 min, to 36:64 over 15 min, maintain at 36:64 for 3 min, re-equilibrate at initial conditions for 7 min. Flow rate: 1.1 Injection volume: 80 Detector: UV 269 for 11 min, UV 250 for 3 min, UV 271 for 10 min, UV 230 for 9 min CHROMATOGRAM Retention time: 8.6 Internal standard: hexobarbital (30.6) Limit of quantitation: 10.0 ng/mL OTHER SUBSTANCES Extracted: abacavir (25.1), didanosine (13.6), nevirapine (27.3), stavudine (15.7), zalcitabine (5.9), zidovudine (23.8) Noninterfering: tenofovir KEY WORDS plasma; SPE REFERENCE Rezk, N.L.; Tidwell, R.R.; Kashuba, A.D.M. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection, J.Chromatogr.B, 2003, 791, 137–147. SAMPLE Matrix: blood Sample preparation: Condition a 100 mg Dual Zone C18 SPE cartridge (Diazem) with 2 mL MeOH and 2 mL water. Dilute 500 µL serum with 1 mL water, add to the SPE cartridge, wash with 500 µL water, elute with 1 mL MeOH. Evaporate the eluate to 336 Lamivudine dryness with vortexing under reduced pressure at 40◦ and reconstitute the residue with 300 µL MeOH, inject a 10 µL aliquot. HPLC VARIABLES Column: two 150 × 4.6 3 µm Luna C18 columns in series Column temperature: 60 Mobile phase: Gradient. MeCN:water from 5:95 to 45:55 over 20 min. Flow rate: 0.85 Injection volume: 10 Detector: UV 250 CHROMATOGRAM Retention time: 9.5 Limit of detection: 260 ng/mL OTHER SUBSTANCES Extracted: abacavir (17, LOD 75 ng/mL), didanosine (10.5, LOD 120 ng/mL), stavudine (11.5, LOD 40 ng/mL), zalcitabine (7.5, LOD 440 ng/mL), zidovudine (16, LOD 30 ng/mL) KEY WORDS serum; SPE REFERENCE Simon, V.A.; Thiam, M.D.; Lipford, L.C. Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography, J.Chromatogr.A, 2001, 913, 447–453. SAMPLE Matrix: blood Sample preparation: Vortex 100 µL serum with 20 µL 20% trichloroacetic acid for 10 s, centrifuge at 16 000 g for 5 min, inject an aliquot of the supernatant. HPLC VARIABLES Column: 250 × 4.6 5 µm Hypersil C18 Mobile phase: MeOH: buffer 11.7:88.3 (The buffer was 43 mM orthophosphoric acid containing 10 mM triethylammonium acetate, adjusted to pH 7.0 with 5 M KOH.) Flow rate: 1 Injection volume: 100 Detector: UV 280 CHROMATOGRAM Retention time: 9.5 Limit of detection: 5 ng/mL Limit of quantitation: 20 ng/mL KEY WORDS pharmacokinetics; serum REFERENCE Zhou, X.-J.; Sommadossi, J.-P. Rapid quantitation of (−)-2′ -deoxy-3′ -thiacytidine in human serum by high-performance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 1997, 691, 417–424. ANNOTATED BIBLIOGRAPHY Aboul-Enein, H.Y.; Hefnawy, M.M. High throughput analysis of lamivudine in pharmaceutical preparations using monolithic silica HPLC column, Anal.Lett., 2003, 36, 2527–2538. [LOD 12.5 ng/mL] Lamivudine 337 Aymard, G.; Legrand, M.; Trichereau, N.; Diquet, B. Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography, J.Chromatogr.B, 2000, 744, 227–240. [column-switching; LOQ 20 ng/mL for lamivudine; amprenavir; efavirenz; indinavir; nelfinavir; ritonavir; saquinavir; abacavir; didanosine; lamivudine; stavudine; nevirapine; zidovudine] Fan, B.; Bartlett, M.G.; Stewart, J.T. Determination of lamivudine/stavudine/efavirenz in human serum using liquid chromatography/electrospray tandem mass spectrometry with ionization polarity switch, Biomed.Chromatogr., 2002, 16, 383–389. [SPE; LOQ 1.1 ng/mL for lamivudine] Fan, B.; Stewart, J.T. Determination of zidovudine/lamivudine/nevirapine in human plasma using ionpair HPLC, J.Pharm.Biomed.Anal., 2002, 28, 903–908. [SPE; LOQ 59 ng/mL for lamivudine] Gibbs, J.E.; Rashid, T.; Thomas, S.A. Effect of transport inhibitors and additional anti-HIV drugs on the movement of lamivudine (3TC) across the guinea pig brain barriers, J.Pharmacol.Exp.Ther., 2003, 306, 1035–1041. Harker, A.J.; Evans, G.L.; Hawley, A.E.; Morris, D.M. High-performance liquid chromatographic assay for 2′ -deoxy-3′ -thiacytidine in human serum, J.Chromatogr.B, 1994, 657, 227–232. [SPE; carbovir is internal standard] Hoetelmans, R.M.; Profijt, M.; Mennhorst, P.L.; Mulder, J.W.; Beijnen, J.H. Quantitative determination of (−)-2′ -deoxy-3′ -thiacytidine (lamivudine) in human plasma, saliva and cerebrospinal fluid by highperformance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 1998, 713, 387–394. [SPE; LOQ 10 ng/mL] Hsyu, P.-H.; Lloyd, T.L. Automated high-performance liquid chromatographic analysis of (−)- 2′ -deoxy-3′ thiacytidine in biological fluids using the automated sequential trace enrichment of dialysate systems, J.Chromatogr.B, 1994, 655, 253–259. [dialysate; serum; urine; column-switching] Kakuda, T.N.; Page, L.M.; Anderson, P.L.; Henry, K.; Schacker, T.W.; Rhame, F.S.; Acosta, E.P.; Brundage, R.C.; Fletcher, C.V. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir, Antimicrob.Agents Chemother., 2001, 45, 236–242. [SPE; no HPLC of indinavir] Kenney, K.B.; Wring, S.A.; Carr, R.M.; Wells, G.N.; Dunn, J.A. Simultaneous determination of zidovudine and lamivudine in human serum using HPLC with tandem mass spectrometry, J.Pharm.Biomed.Anal., 2000, 22, 967–983. [ultrafiltration; LOQ 2.5 ng/mL] Morris, D.; Selinger, K. Determination of 2′ -deoxy-3′ -thiacytidine (3TC) in human urine by liquid chromatography: direct injection with column switching, J.Pharm.Biomed.Anal., 1994, 12, 255–264. [LOQ 500 ng/mL] Moyer, T.P.; Temesgen, Z.; Enger, R.; Estes, L.; Charlson, J.; Oliver, L.; Wight, A. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study, Clin.Chem., 1999, 45, 1465–1476. [SPE; LOQ 100 ng/mL for lamivudine; didanosine; lamivudine; stavudine; zalcitabine; zidovudine; delavirdine; nevirapine; indinavir; nelfinavir; ritonavir; saquinavir] Ozkan, S.A.; Uslu, B. Rapid HPLC assay for lamivudine in pharmaceuticals and human serum, J.Liq.Chromatogr.Rel.Technol., 2002, 25, 1447–1456. [LOQ 14 ng/mL; deflazacort is internal standard] Pereira, A.S.; Kenney, K.B.; Cohen, M.S.; Hall, J.E.; Eron, J.J.; Tidwell, R.R.; Dunn, J.A. Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using highperformance liquid chromatography and tandem mass spectrometry, J.Chromatogr.B, 2000, 742, 173–183. [ultrafiltration; LOQ 5 ng/mL] Rajagopalan, P.; Boudinot, F.D.; Chu, C.K.; Tennant, B.C.; Baldwin, B.H.; Schinazi, R.F. Pharmacokinetics of (−)-2′ -3′ -dideoxy-3′ -thiacytidine in woodchucks, Antimicrob.Agents Chemother., 1996, 40, 642–645. [LOQ 250 ng/mL] Rezk, N.L.; Tidwell, R.R.; Kashuba, A.D.M. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection, J.Chromatogr.B, 2003, 791, 137–147. [plasma; LOQ 10 ng/mL; zalcitabine; lamivudine; didanosine; stavudine; zidovudine; abacavir; hexobarbital is internal standard; SPE] Rodriguez, J.F.; Rodriguez, J.L.; Santana, J.; Garcı́a, H.; Rosario, O. Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals, Antimicrob.Agents Chemother., 2000, 44, 3097–3100. [LC-MS] Santos-Magalhaes, N.S.; Pontes, A.; Cavalcante, R.M.; Costa, R.M.R.; Rangel, F.A.; Guimaraes, M.I.V.; de Carvalho, J.N.L.; de Souza, S.D.F.; de Oliveira, H.M.; Esteves, I.L.C.; Ramalho, M.S.; Vieira, S.L.A.; Alves, A.J. Bioequivalence of two lamivudine tablet formulations, Arzneimittelforschung, 2001, 51, 310–314. Simon, V.A.; Thiam, M.D.; Lipford, L.C. Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography, J.Chromatogr.A, 2001, 338 Lamivudine 913, 447–453. [SPE; LOD 260 ng/mL for lamivudine; zalcitabine; lamivudine; stavudine; didanosine; zidovudine; nevirapine; abacavir; indinavir; delavirdine; nelfinavir; saquinavir; ritonavir; efavirenz] Solas, C.; Li, Y.-F.; Xie, M.-Y.; Sommadossi, J.-P.; Zhou, X.-J. Intracellular nucleotides of (−)-2′ ,3′ -deoxy3′ -thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus, Antimicrob.Agents Chemother., 1998, 42, 2989–2995. Uslu, B.; Ozkan, S.A. Determination of lamivudine and zidovudine in binary mixtures using first derivative spectrophotometric, first derivative of the ratio-spectra and high-performance liquid chromatography-UV methods, Anal.Chim.Acta, 2002, 466, 175–185. [LOQ 25 ng/mL for lamivudine; finasteride is internal standard] Wang, L.H.; Chittick, G.E.; McDowell, J.A. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection, Antimicrob.Agents Chemother., 1999, 43, 1708–1715. Williams, L.D.; Von Tungeln, L.S.; Beland, F.A.; Doerge, D.R. Liquid chromatographic-mass spectrometric determination of the metabolism and disposition of the anti-retroviral nucleoside analogs zidovudine and lamivudine in C57BL/6N and B6C3F1 mice, J.Chromatogr.B, 2003, 798, 55–62. [SPE; LC-MS] Zheng, J.J.; Wu, S.T.; Emm, T.A. High-performance liquid chromatographic assay for the determination of 2′ -deoxy-3′ -thiacytidine (lamivudine) in human plasma, J.Chromatogr.B, 2001, 761, 195–201. [SPE; LOQ 10 ng/mL] 339 Latanoprost Latanoprost HO O O Molecular formula: C26 H40 O5 Molecular weight: 432.59 CAS Registry No: 130209-82-4 Merck Index: 13, 5391 HO CH3 CH3 OH SAMPLE Matrix: aqueous humor, tissue Sample preparation: Homogenize (Polytron) rabbit eye tissue with 3 mL EtOH, centrifuge, evaporate the supernatant under a stream of nitrogen, reconstitute with EtOH, inject an aliquot. Acidify aqueous humor to pH 3.4 with 1 M formic acid, extract with 3 mL ethyl acetate. Evaporate the ethyl acetate to dryness under a stream of nitrogen, reconstitute with EtOH, inject an aliquot. HPLC VARIABLES Column: 5 µm Nucleosil C18 Mobile phase: Gradient. MeCN:water:acetic acid 35:65:0.1 for 11 min, to 46:54:0.1 over 1 min, maintain at 46:54:0.1 for 6 min, return to initial conditions over 3 min, re-equilibrate for about 10 min. Alternatively, MeCN:water:acetic acid 25:75:0.1 for 15 min, to 40:60:0.1 over 10 min, return to initial conditions over 5 min, re-equilibrate for 5 min. Flow rate: 1 Detector: Radioactivity (3 H) CHROMATOGRAM Retention time: 22 OTHER SUBSTANCES Extracted: metabolites KEY WORDS ciliary body; cornea; eye; pharmacokinetics; rabbit REFERENCE Sjöquist, B.; Basu, S.; Byding, P.; Bergh, K.; Stjernschantz, J. The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit, Drug Metab.Dispos., 1998, 26, 745–754. SAMPLE Matrix: blood, feces, urine Sample preparation: Blood, urine. Condition a Sep-Pak C18 with 10 mL EtOH and 10 mL water. Centrifuge plasma or urine at 800 g for 10 min, acidify to pH 3.5–4.0 with 1 M HCl, add to the SPE cartridge, wash with 10 mL water, wash with 10 mL petroleum ether, elute with 10 mL methyl formate. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with EtOH, inject an aliquot. Homogenize feces with 3 volumes of EtOH, centrifuge at 800 g for 15 min, evaporate 2 mL of the supernatant to dryness, reconstitute with 200 µL EtOH, add 1.8 mL water, acidify to pH 3.5–4.0 with 1 M HCl, extract twice with 4 mL portions of ethyl acetate. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with EtOH, inject an aliquot. HPLC VARIABLES Guard column: 30 × 4 30–40 µm Presorb RP-18 340 Latanoprost Column: 125 × 4.6 5 µm Nucleosil C18 Mobile phase: Gradient. MeCN:water:acetic acid 20:80:0.1 for 20 min, to 40:60:0.1 over 20 min, return to initial conditions over 5 min, re-equilibrate for 10 min. Flow rate: 1 Detector: Radioactivity (3 H) CHROMATOGRAM Retention time: 20 OTHER SUBSTANCES Extracted: metabolites KEY WORDS monkey; pharmacokinetics; plasma REFERENCE Sjöquist, B.; Tajallaei, S.; Stjernschantz, J. Pharmacokinetics of latanoprost in the cynomolgus monkey. 1st communication: single intravenous, oral or topical administration on the eye, Arzneimittelforschung, 1999, 49, 225–233. 341 Leflunomide Leflunomide F3C Molecular formula: C12 H9 F3 N2 O2 Molecular weight: 270.21 CAS Registry No: 75706-12-6 Merck Index: 13, 5451 O CH3 N H O N SAMPLE Matrix: blood Sample preparation: Mix 75 µL plasma with 200 µL 50 ng/mL IS in MeCN, centrifuge, inject. HPLC VARIABLES Column: 150 × 4.6 Zorbax Eclipse XDB-C8 Mobile phase: Gradient. MeCN:10 mM ammonium formate containing 0.1% formic acid 0:100 for 3 min, to 90:10 over 17 min, return to initial conditions over 5 min. Flow rate: 1 Detector: MS, PE Sciex API 2000 triple quadrupole, 50 µL/min entered the detector, negative ionization, ionspray interface 150◦ , ionspray 4.5 kV, orifice 30 eV, nebulizer gas nitrogen, m/z 269–82; UV 254 CHROMATOGRAM Retention time: 16.5 Internal standard: indomethacin OTHER SUBSTANCES Extracted: metabolite A771726 (82) (12.7), 3-methylleflunomide (16.5) KEY WORDS human; plasma; rat REFERENCE Kalgutkar, A.S.; Nguyen, H.T.; Vaz, A.D.N.; Doan, A.; Dalvie, D.K.; McLeod, D.G.; Murray, J.C. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent leflunomide to its active α-cyanoenol metabolite A771726: Mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes, Drug Metab.Dispos., 2003, 31, 1240–1250. SAMPLE Matrix: blood Sample preparation: Mix 250 µL plasma, 500 µL 100 mM pH 5 sodium acetate buffer, and 100 µL 25 µg/mL IS in water, add 10 mL ethyl acetate, shake for 15 min, centrifuge at 4000 rpm for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen at room temperature, reconstitute the residue with 200 µL mobile phase, vortex for 1 min, inject a 50 µL aliquot. HPLC VARIABLES Guard column: C18 Column: 125 × 3 Nucleosil 100-5C18 Column temperature: 21 Mobile phase: MeCN:water:formic acid 40:59.8:0.2 Flow rate: 0.5 Injection volume: 50 Detector: UV 261 342 Leflunomide CHROMATOGRAM Retention time: 16.2 Internal standard: warfarin (12.2) Limit of quantitation: 50 ng/mL OTHER SUBSTANCES Extracted: metabolite A771726 (8.2) KEY WORDS plasma REFERENCE Schmidt, A.; Schwind, B.; Gillich, M.; Brune, K.; Hinz, B. Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography, Biomed.Chromatogr., 2003, 17, 276–281. Lercanidipine Lercanidipine Molecular formula: C36 H41 N3 O6 Molecular weight: 611.73 CAS Registry No: 100427-26-7 Merck Index: 13, 5465 343 H H3C N CH3O CH3 O O O H3C N CH3 CH3 NO2 SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 25 µL 660 ng/mL IS in MeOH and 50 µL 100 mM NaOH, add 4.5 mL hexane:isopropanol 99:1, vortex for 2 min, centrifuge at 2000 g for 10 min. Evaporate the organic layer to dryness under reduced pressure at 25◦ , reconstitute the residue with 50 µL mobile phase, vortex for 20 s, inject a 20 µL aliquot. (Carry out all manipulations under yellow light.) HPLC VARIABLES Guard column: 4 × 4 5 µm 100 RP-18 Column: 250 × 4.6 10 µm Chiralpak AD Column temperature: 30 ± 1 Mobile phase: Hexane:EtOH:diethylamine 95:5:0.1 Flow rate: 1.3 Injection volume: 20 Detector: MS, Micromass Quatro Micro LC triple quadrupole, electrospray interface, positive ion mode, capillary voltage 3.5 kV, source 100◦ , desolvation 150◦ , nebulizing gas nitrogen at 365 L/h, collision gas argon at 3.5 µbar, cone 40 V, collision energy 38.0 eV, m/z 612.40–100.10 (The make-up liquid was EtOH:10 mM ammonium acetate 95:5 pumped at 0.25 mL/min, which mixed with the column effluent. A splitter was used so that 0.2 mL/min entered the detector.) CHROMATOGRAM Retention time: 5.98 (S), 6.50 (R) Internal standard: amiodarone (collision energy 30.0 eV) (m/z 646.30–100.30) (3.47) Limit of quantitation: 25 pg/mL KEY WORDS chiral; pharmacokinetics; plasma REFERENCE Jabor, V.A.P.; Coelho, E.B.; Ifa, D.R.; Bonato, P.S.; dos Santos, N.A.G.; Lanchote, V.L. Enantioselective determination of lercanidipine in human plasma for pharmacokinetic studies by normal-phase liquid chromatography-tandem mass spectrometry, J.Chromatogr.B, 2003, 796, 429–437. SAMPLE Matrix: formulations Sample preparation: Sonicate tablet in 5 mL EtOH, make up to 10 mL with mobile phase, centrifuge at 2700 g for 10 min. Dilute a 500 µL aliquot of the supernatant to 10 mL with mobile phase, inject an aliquot. HPLC VARIABLES Guard column: 30 × 4.6 Bondapak C18 Column: 150 × 3.9 5 µm Symmetry C18 Column temperature: 25 ± 1 Mobile phase: MeCN:10 mM pH 4.0 phosphate buffer 45:55 344 Lercanidipine Flow rate: 1 Injection volume: 20 Detector: UV 356; E, glassy carbon working electrode 1000 mV, Ag/AgCl reference electrode, platinum rod auxiliary electrode CHROMATOGRAM Retention time: 5 Limit of detection: 930 nM (UV), 750 nM (E) Limit of quantitation: 1.2 µM (UV), 3.2 µM (E) KEY WORDS tablets REFERENCE Alvarez-Lueje, A.; Pujol, S.; Squella, J.A.; Núñz-Vergara, L.J. A selective HPLC method for determination of lercanidipine in tablets, J.Pharm.Biomed.Anal., 2003, 31, 1–9. ANNOTATED BIBLIOGRAPHY Boatto, G.; Nieddu, M.; Faedda, M.V.; De Caprariis, P. Enantiomeric separation by HPLC of 1,4dihydropyridines with vancomycin as chiral selector, Chirality, 2003, 15, 494–497. [isradipine; nimodipine; nisoldipine; felodipine; lercanidipine; amlodipine] Calleri, E.; De Lorenzi, E.; Siluk, D.; Markuszewski, M.; Kaliszan, R.; Massolini, G. Column liquid chromatography riboflavin binding protein-chiral stationary phase: Investigation of retention mechanism, Chromatographia, 2002, 55, 651–658. [fenfluramine; dichloroisoproterenol; propranolol; oxprenolol; alprenolol; acebutolol; ketoprofen; indoprofen; warfarin; lorazepam; oxazepam; isradipine; nimodipine; amlodipine; nicardipine; lercanidipine; gallopamil; verapamil; bepridil] Garzotti, M.; Hamdan, M. Supercritical fluid chromatography coupled to electrospray mass spectrometry: a powerful tool for the analysis of chiral mixtures, J.Chromatogr.B, 2002, 770, 53–61. [alprenolol; lercanidipine; disopyramide; propafenone; tropicamide; atenolol; ofloxacin; albuterol; econazole; miconazole; homatropine; nicardipine; sulpiride; verapamil; pindolol; flecainide; atropine; clenbuterol; sulconazole; ketoconazole] Letrozole Letrozole 345 N N N Molecular formula: C17 H11 N5 Molecular weight: 285.30 CAS Registry No: 112809-51-5 Merck Index: 13, 5469 NC CN SAMPLE Matrix: blood, urine Sample preparation: Condition a 1 mL 100 mg Bond Elut C8 SPE cartridge with 1 mL MeOH and 1 mL 100 mM HCl. Dilute urine with an equal volume of water. Mix 1 mL plasma or diluted urine with 100 µL IS in water and 1 mL 100 mM HCl, add to the SPE cartridge, wash with 2 mL 10 mM pH 7 phosphate buffer, wash with 500 µL MeCN:10 mM pH 7 phosphate buffer 20:80, elute with 2 mL MeCN:10 mM pH 7 phosphate buffer 40:60, inject a 100 µL aliquot of the eluate. HPLC VARIABLES Guard column: 20 × 4.6 5 µm Supelguard LC Column: 250 × 4.6 5 µm ODS Hypersil C18 Mobile phase: MeCN:10 mM pH 7 phosphate buffer 30:70 (The buffer was 1.36 g potassium dihydrogen phosphate and 1.42 g disodium hydrogen phosphate in 1 L water.) Flow rate: 1.5 Injection volume: 100 Detector: F ex 230 em 295 CHROMATOGRAM Retention time: 11.3 Internal standard: CGP 47 645 (1-[bis(4-cyanophenyl)fluoromethyl]-1,2,4-triazole) (16.7) Limit of quantitation: 1.40 nM (plasma), 2.80 nM (urine) OTHER SUBSTANCES Extracted: metabolite CGP 44 645 (12.3) KEY WORDS plasma; SPE REFERENCE Marfil, F.; Pineau, V.; Sioufi, A.; Godbillon, J. High-performance liquid chromatography of the aromatase inhibitor, letrozole, and its metabolite in biological fluids with automated liquid-solid extraction and fluorescence detection, J.Chromatogr.B, 1996, 683, 251–258. 346 Levetiracetam Levetiracetam Molecular formula: C8 H14 N2 O2 Molecular weight: 170.21 CAS Registry No: 102767-28-2 Merck Index: 13, 5482 CH3 O NH2 N O SAMPLE Matrix: blood Sample preparation: Condition a 100 mg C18 SPE cartridge (Baker) with 2 mL MeOH and 2 mL water. Add 200 µL serum and 100 µL 20 µg/mL IS in MeOH:water 2:98 to the SPE cartridge, wash with 750 µL water, dry under vacuum for 3 min, elute with 1 mL MeOH:water 1:5, inject a 50 µL aliquot of the eluate. HPLC VARIABLES Column: 150 × 4.6 Spherisorb 3ODS2 Mobile phase: Gradient. MeCN:water from 6:94 to 20:80 over 5 min, to 40:60 over 1 min, maintain at 40:60 for 4 min, return to initial conditions over 1 min, re-equilibrate for 4 min. Flow rate: 1 Injection volume: 150 Detector: UV 205 CHROMATOGRAM Retention time: 6.4 Internal standard: G025 (α-methyl-5,5-dimethyl-2-oxo-1-pyrrolidine acetamide) (7.8) Limit of quantitation: 360 ng/mL OTHER SUBSTANCES Noninterfering: carbamazepine, carbamazepine dihydrodiol, carbamazepine epoxide, N-desmethylsuximide, ethosuximide, lamotrigine, loreclezole, monohydroxycarbamazepine, phenobarbital, phenytoin, primidone, valproic acid, vigabatrin KEY WORDS comparison with GC; pharmacokinetics; serum; SPE REFERENCE Vermeij, T.A.C.; Edelbroek, P.M. High-performance liquid chromatographic and megabore gas-liquid chromatographic determination of levetiracetam (ucb L059) in human serum after solid-phase extraction, J.Chromatogr.B, 1994, 662, 134–139. SAMPLE Matrix: blood, saliva Sample preparation: Vortex 100 µL serum or saliva with 100 µL IS solution and 25 µL 5 M NaOH for 10 s, add 1 mL dichloromethane, vortex for 1 min, centrifuge at 3000 rpm for 5 min. Evaporate the organic layer to dryness, reconstitute the residue with 200 µL mobile phase, inject a 50 µL aliquot. HPLC VARIABLES Guard column: PRP-1 (Burdick & Jackson) Column: 100 × 8 4 µm Nova-pak C18 Radial-Pak Mobile phase: Gradient. A was MeCN:buffer 12:88. B was MeCN:buffer 45:55. A:B 100:0 for 7 min, to A:B 0:100 (step gradient), maintain at 0:100 for 5 min, return to initial conditions (step gradient), re-equilibrate for 5 min. (Prepare A by dissolving Levetiracetam 347 2.28 g dipotassium hydrogen phosphate trihydrate and 5.44 g potassium dihydrogen phosphate in 880 mL water and then adding 120 mL MeCN. Prepare B by dissolving 2.28 g dipotassium hydrogen phosphate trihydrate and 5.44 g potassium dihydrogen phosphate in 550 mL water and then adding 450 mL MeCN.) Flow rate: 1 Injection volume: 50 Detector: UV 208 CHROMATOGRAM Internal standard: ucb 17025 Limit of quantitation: ≤1.3 µg/mL KEY WORDS serum REFERENCE Grim, S.A.; Ryan, M.; Miles, M.V.; Tang, P.H.; Strawsburg, R.H.; deGrauw, T.J.; Fakhoury, T.A.; Baumann, R.J. Correlation of levetiracetam concentrations between serum and saliva, Ther.Drug Monit., 2003, 25, 61–66. ANNOTATED BIBLIOGRAPHY Ratnaraj, N.; Doheny, H.C.; Patsalos, P.N. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb L059) in serum or plasma by high performance liquid chromatography, Ther.Drug Monit., 1996, 18, 154–157. [LOQ 5 µM] 348 Levonordefrin Levonordefrin Molecular formula: C9 H13 NO3 Molecular weight: 183.20 CAS Registry No: 829-74-3 Merck Index: 13, 6725 OH HO HO CH3 NH2 SAMPLE Matrix: blood Sample preparation: Prepare an SPE column by packing 50–100 mesh Bio-Rex 70 (Na+ ) cation exchange resin (Bio-Rad) into a 40 × 10 polypropylene column and washing three times with 1 M HCl, three times with 1 M NaOH, once with 1 M pH 6.5 sodium acetate, and once with 0.01% disodium EDTA. Mix 2 mL plasma with 5 mL 0.1% disodium EDTA, 500 µL 1 M pH 6.5 sodium acetate, and 4 ng IS, add to the SPE column, wash with 10 mL water, elute with 1 mL 700 mM sulfuric acid and 3.5 mL 2 M ammonium sulfate containing 0.1% disodium EDTA. Adjust the pH of the eluate to 8.6 with 3 mL 1 M pH 8.6 Tris-HCl buffer containing 2% disodium EDTA, add 100 mg activated alumina, shake for 3 min. Centrifuge, discard the liquid, wash the alumina three times with 10 mL distilled water. Centrifuge to remove excess water, elute with 200 µL 300 mM perchloric acid, inject a 50–100 µL aliquot of the eluate. HPLC VARIABLES Column: 150 × 4.6 5 µm Spherisorb ODS2 Mobile phase: 100 mM pH 5.0 sodium dihydrogen phosphate containing 2 mM sodium heptanesulfonate and 0.001% disodium EDTA Flow rate: 1.5 Injection volume: 50–100 Detector: E, Bioanalytical Systems LC-4A, glassy carbon electrode +0.50 V, Ag/AgCl reference electrode CHROMATOGRAM Retention time: 12 Internal standard: 3,4-dihydroxybenzylamine (20) Limit of detection: 50 pg/mL OTHER SUBSTANCES Extracted: epinephrine (14), norepinephrine (6) KEY WORDS human; plasma; rabbit; SPE REFERENCE Jackman, G.P.; Oddie, C.J.; Skews, H.; Bobik, A. High-performance liquid chromatographic determination of plasma catecholamines during α-methyldopa therapy, J.Chromatogr., 1984, 308, 301–305. 349 Levosimendan Levosimendan H NC N NC Molecular formula: C14 H12 N6 O Molecular weight: 280.28 CAS Registry No: 141505-33-1 Merck Index: 13, 5491 N N N O H H3C SAMPLE Matrix: blood Sample preparation: Mix 500 µL plasma with 25 µL 1.5 µg/mL IS in 50 mM pH 7.2 phosphate buffer. Using a Cuprophan cellulose membrane (cut-off 15 kDa) dialyze a 370 µL aliquot against 18 mL 40 mM pH 4.0 ammonium acetate buffer. Pump the buffer through a 650 µL recipient channel over 18 min and allow it to flow through column A. At the end of this time, backflush the contents of column A onto column B with the mobile phase, monitor the effluent from column B. (ASTED system. After use, flush the donor side with 10 mL 0.05% Triton X-100 in 0.86% NaCl solution. Flush the recipient side with 4 mL 40 mM pH 4.0 ammonium acetate buffer. Regenerate column A with 1 mL 40 mM pH 4.0 ammonium acetate buffer.) HPLC VARIABLES Column: A 5.8 × 4.6 10 µm Hypersil ODS; B 250 × 4 10 µm LiChrosorb RP-18 Mobile phase: MeOH:THF:32 mM sodium dihydrogen phosphate 65:1:45, adjusted to apparent pH 3.5 with phosphoric acid Flow rate: 1 Detector: UV 380 CHROMATOGRAM Retention time: 6.4 Internal standard: OR-1097 ([[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile) (5.4) Limit of detection: 5 ng/mL (S/N = 3) OTHER SUBSTANCES Interfering: carbamazepine KEY WORDS ASTED; dialysate; plasma REFERENCE Karlsson, M.; Korkolainen, T.; Wikberg, T. Automated analysis of levosimendan in human plasma by on-line dialysis and liquid chromatography, Biomed.Chromatogr., 1997, 11, 54–58. SAMPLE Matrix: blood Sample preparation: Mix 200 (rat) or 500 (dog) µL plasma with 200 µL 50 mM pH 9 phosphate buffer, add 200 µL 1 M HCl, add 4 mL ethyl acetate:n-hexane 50:50, vortex for 2 min, centrifuge at 3500 g for 5 min. Evaporate 3 mL of the organic layer to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL 0.5% pH 9 triethylammonium acetate buffer, inject a 60 µL aliquot. Prepare human plasma samples in the same fashion, but use 1 mL plasma and twice the volumes of reagents. Alternatively filter (Ultrafree-MC 10000) 400 µL plasma while centrifuging at 1200 g for 30 min, inject a 40 µL aliquot of the ultrafiltrate. 350 Levosimendan HPLC VARIABLES Guard column: Guard-Pak CN Column: 250 × 4.6 5 µm Cyclobond I Column temperature: 30 Mobile phase: MeOH:buffer 30:70-33:67 (Prepare the buffer by dissolving 10 mL triethylamine in 2 L and adjusting pH to 6.0 with acetic acid.) Flow rate: 1 Injection volume: 40–60 Detector: UV 380 CHROMATOGRAM Retention time: 19 (+), 21 (−) Limit of quantitation: 10 ng/mL KEY WORDS chiral; dog; human; plasma; rat; ultrafiltrate REFERENCE Wikberg, T.; Korkolainen, T.; Karlsson, M. Enantiomeric bioanalysis of simendan and levosimendan by chiral high-performance liquid chromatography, Chirality, 1996, 8, 511–517. 351 Lidamidine Lidamidine CH3 H H H N N N CH3 Molecular formula: C11 H16 N4 O Molecular weight: 220.27 CAS Registry No: 66871-56-5, 65009-35-0 (HCl) Merck Index: 13, 5502 O CH3 NH SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4 ODS Mobile phase: MeOH:water:ammonium carbonate 60:40:0.02 Detector: UV 254 REFERENCE Zalipsky, J.J.; Won, C.M.; Patel, D.M. Analytical-physical profile of lidamidine hydrochloride (WHR1142A), a novel antidiarrheal agent, Arzneimittelforschung, 1978, 28, 1441–1447. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 2.1 Zorbax Sil Mobile phase: MeOH:dichloromethane:ammonium hydroxide 50:50:0.1 Detector: UV 254 REFERENCE Zalipsky, J.J.; Won, C.M.; Patel, D.M. Analytical-physical profile of lidamidine hydrochloride (WHR1142A), a novel antidiarrheal agent, Arzneimittelforschung, 1978, 28, 1441–1447. 352 Lincomycin Lincomycin CH3 H3C CH3 N HO Molecular formula: C18 H34 N2 O6 S Molecular weight: 406.54 CAS Registry No: 154-21-2, 7179-49-9 (HCl monohydrate) Merck Index: 13, 5522 NH O OH O OH S OH CH3 SAMPLE Matrix: blood Sample preparation: Mix 500 µL serum with 500 µL MeCN, let stand for 20 min, centrifuge at 10 000 g for 5 min, inject a 10 µL aliquot of the supernatant. HPLC VARIABLES Guard column: LichroCart 4-4 RP-18 Column: 125 × 4 5 µm Supersphere RP-18 Column temperature: 35 Mobile phase: MeCN:0.02% trifluoroacetic acid 40:60 Flow rate: 0.75 Injection volume: 10 Detector: MS, ThermoQuest Finnigan LCQ ion trap, APCI positive mode, vaporizer 450◦ , capillary 200◦ , capillary 9 V, discharge current 5 µA, sheath gas 0.6 L/min, auxiliary gas 3 L/min, m/z 405 CHROMATOGRAM Retention time: 2.2 OTHER SUBSTANCES Extracted: clindamycin (m/z 425) (3.7) KEY WORDS lincomycin is IS in original paper; serum REFERENCE Martens-Lobenhoffer, J.; Banditt, P. Sensitive and specific determination of clindamycin in human serum and bone tissue applying liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry, J.Chromatogr.B, 2001, 755, 143–149. SAMPLE Matrix: blood Sample preparation: Vortex 250 µL plasma with 50 µL water for 15 s, add 50 µL 20% trichloroacetic acid in water, vortex for 15 s, centrifuge at 6800 g for 10 min, inject a 20 µL aliquot of the supernatant. HPLC VARIABLES Guard column: 25 × 3 5 µm Hypersil RP-18 Column: 100 × 3 5 µm Hypersil RP-18 Mobile phase: Gradient. MeCN:10 mM ammonium acetate from 30:70 to 70:30 over 0.5 min, maintain at 70:30 for 7.5 min, return to initial conditions over 0.5 min, reequilibrate for 9.5 min. Injection volume: 20 Detector: MS, ThermoQuest Finnigan MAT, ESI, first 3 min and last 8 min of run diverted to waste, spray 3.5 kV, capillary 5 V, octapole 1 offset – 2 V, lens – 16 V, Lincomycin 353 octapole 2 offset – 5 V, RF amplitude 400 V, collision energy 1.2 V, m/z 407.3–389.1– 359.2–126.3 CHROMATOGRAM Retention time: 4.0 Limit of detection: 1.3 ng/mL (for clindamycin) Limit of quantitation: 50 ng/mL (for clindamycin) OTHER SUBSTANCES Extracted: clindamycin (m/z 425.3–389.2–377.2–126.3) (7.4) KEY WORDS dog; lincomycin is IS in original; plasma REFERENCE Cherlet, M.; Croubels, S.; De Backer, P. Determination of clindamycin in animal plasma by highperformance liquid chromatography combined with electrospray ionization mass spectrometry, J.Mass Spectrom., 2002, 37, 848–853. 354 Lindane Lindane Cl Cl Cl Cl Molecular formula: C6 H6 Cl6 Molecular weight: 290.83 CAS Registry No: 58-89-9 Merck Index: 13, 5523 Cl Cl SAMPLE Matrix: solutions HPLC VARIABLES Column: 300 × 3.9 10 µm µBondapak C18 Mobile phase: MeCN:water 60:40 Flow rate: 2.5 Detector: UV 254 OTHER SUBSTANCES Simultaneous: hexachlorobenzene REFERENCE Gopalaswamy, U.V.; Aiyar, A.S. Biotransformation of lindane in the rat, Bull.Environ.Contam.Toxicol., 1984, 32, 148–156. SAMPLE Matrix: solutions HPLC VARIABLES Column: 600 × 0.2 5 µm ODS (Phenomenex) Mobile phase: Carbon dioxide Detector: UV 280 CHROMATOGRAM Retention time: 13 OTHER SUBSTANCES Simultaneous: carbofuran (8), chlorpyrifos (9.9), naphthol (10.1) KEY WORDS SFC; UV restrictor at 100◦ ; pressure from 100 to 300 atm at 4 atm/min REFERENCE Pyo, D.; Kim, H.; Li, W.; Lee, M.L. Supercritical fluid chromatographic detection by use of a parallel flow restrictor, J.Liq.Chromatogr.Rel.Technol., 1997, 20, 3389–3399. 355 Linezolid Linezolid O N O Molecular formula: C16 H20 FN3 O4 Molecular weight: 337.35 CAS Registry No: 165800-03-3 Merck Index: 13, 5526 F N O H N H CH3 O SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg C2 SPE cartridge (Varian) with two 1 mL portions of MeCN and two 1 mL portions of water. Mix 50 µL plasma with 25 µL water and 1 mL 100 ng/mL IS in water, add to the SPE cartridge, wash with 1 mL MeCN:water 5:95, elute with 500 µL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL mobile phase, inject a 100 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Zorbax RXC8 Mobile phase: MeCN:water 20:80 Flow rate: 1 Injection volume: 100 Detector: UV 251 CHROMATOGRAM Retention time: 11 Internal standard: PNU-101145 ((S)-N-[[3-[3-fluoro-4-[4-[(1-hydroxycyclopropyl)carbonyl]-1-piperazinyl]phenyl]- 2-oxo-5-oxazolidinyl]methyl]-acetamide) (9) Limit of detection: 10 ng/mL KEY WORDS dog; mouse; plasma; rabbit; rat; SPE REFERENCE Peng, G.W.; Stryd, R.P.; Murata, S.; Igarashi, M.; Chiba, K.; Aoyama, H.; Aoyama, M.; Zenki, T.; Ozawa, N. Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography, J.Pharm.Biomed.Anal., 1999, 20, 65–73. SAMPLE Matrix: blood Sample preparation: Condition a Sep-Pak C18 with 1 mL MeCN and 1 mL water. Mix 500 µL plasma with 50 µL 10 µg/mL IS in MeCN, add to the SPE cartridge, wash with 1 mL water, elute with 300 µL MeCN. Evaporate the eluate to dryness under a stream of nitrogen at 50◦ , reconstitute the residue with 100 µL MeCN, inject a 10 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Shim-Pack CLC-CN C18 Mobile phase: MeCN:20 mM ammonium acetate 80:20 Flow rate: 1 Injection volume: 10 Detector: MS, Finnigan LCQ, APCI, corona discharge 4.5 kV, vaporization 430◦ , capillary 150◦ 32 V, positive mode, m/z 296.2 356 Linezolid CHROMATOGRAM Retention time: 3.44 Internal standard: N-carbobenzoxy-3-fluoro-4-morpholinylaniline (m/z 223.2) (2.91) Limit of detection: 50 ng/mL Limit of quantitation: 100 ng/mL KEY WORDS plasma; SPE REFERENCE Phillips, O.A.; Abdel-Hamid, M.E.; Al-Hassawi, N.A. Determination of linezolid in human plasma by LC-MS-MS, Analyst, 2001, 126, 609–614. ANNOTATED BIBLIOGRAPHY Ehrlich, M.; Trittler, R.; Daschner, F.D.; Kümmerer, K. A new and rapid method for monitoring the new oxazolidinone antibiotic linezolid in serum and urine by high performance liquid chromatographyintegrated sample preparation, J.Chromatogr.B, 2001, 755, 373–377. [column-switching] Gentry-Nielsen, M.J.; Olsen, K.M.; Preheim, L.C. Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia, Antimicrob.Agents Chemother., 2002, 46, 1345–1351. [linezolid; rat; ceftriaxone; cephalexin is internal standard] Gross, M.; Bürli, R.; Jones, P.; Garcia, M.; Batiste, B.; Kaizerman, J.; Moser, H.; Jiang, V.; Hoch, U.; Duan, J.-X.; Tanaka, R.; Johnson, K.W. Pharmacology of novel heteroaromatic polycycle antibacterials, Antimicrob.Agents Chemother., 2003, 47, 3448–3457. [LC-MS; linezolid; vancomycin] Johnson, R.A.; Haan, D.E.; James, C.A.; Hopkins, N.K. Determination of linezolid, PNU-100766, in human plasma and urine using high-performance liquid chromatography with ultraviolet detection (Abstract 2487), Pharm.Res., 1997, 14, S374. Sisson, T.L.; Jungbluth, G.L.; Hopkins, N.K. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam, J.Clin.Pharmacol., 1999, 39, 1277–1282. [SPE] Welshman, I.R.; Sisson, T.A.; Jungbluth, G.L.; Stalker, D.J.; Hopkins, N.K. Linezolid absolute bioavailability and the effect of food on oral bioavailability, Biopharm.Drug Dispos., 2001, 22, 91–97. 357 Liothyronine Liothyronine Molecular formula: C15 H12 I3 NO4 Molecular weight: 650.97 CAS Registry No: 6893-02-3 Merck Index: 13, 5532 O HO I I OH NH2 O I SAMPLE Matrix: blood, urine Sample preparation: Condition a diol SPE cartridge with 3 mL MeOH and 3 mL water. Serum. Vortex 40 µL serum with 50 µL MeCN, dilute with 200 µL water, centrifuge at 3500 rpm for 15 min, remove organic solvents under a stream of nitrogen at 45◦ , add to the SPE cartridge, elute with 3 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 45◦ , reconstitute the residue with 200 µL 1 µg/mL IS in water, inject a 20 µL aliquot. Urine. Add 100 µL urine to the SPE cartridge, elute with 3 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 45◦ , reconstitute the residue with 200 µL 1 µg/mL IS in water, inject a 20 µL aliquot. HPLC VARIABLES Column: 150 × 4.0 5 µm Inertsil ODS-3 Mobile phase: MeOH:2% acetic acid 65:35 Flow rate: 1 Injection volume: 20 Detector: UV 240 CHROMATOGRAM Retention time: 3 Internal standard: anthraquinone (10.4) Limit of detection: 1 ng OTHER SUBSTANCES Extracted: levothyroxine (LOD 2 ng) (4.7) KEY WORDS serum; SPE REFERENCE Samanidou, V.F.; Gika, H.G.; Papadoyannis, I.N. Rapid HPLC analysis of thyroid gland hormones tri-iodothyronine (T3) and thyroxine (T4) in human biological fluids after SPE, J.Liq.Chromatogr.Rel.Technol., 2000, 23, 681–692. 358 Lomerizine Lomerizine F Molecular formula: C27 H30 F2 N2 O3 Molecular weight: 468.53 CAS Registry No: 101477-55-8, 101477-54-7 (di HCl) Merck Index: 13, 5584 OCH3 H3CO N F OCH3 N SAMPLE Matrix: blood, tissue Sample preparation: Plasma. Mix 100 µL plasma with 10 µL 1 µg/mL IS in MeOH and 90 µL MeOH, add 200 µL 2 M NaOH, shake for 5 min, vortex with 750 µL n-hexane, centrifuge at 1500 g for 5 min, repeat the extraction of the aqueous layer. Evaporate the combined extracts to dryness under a stream of nitrogen, reconstitute the residue with 2 mL MeOH:1 M HCl 90:10, add to a 5 × 5 44–88 µm SP-Toyopearl SPE column, wash with 1 mL MeOH:water 90:10, elute with 1 mL MeOH:1 M ammonia solution 90:10. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with 50 µL MeCN:20 mM pH 5.5 phosphate buffer 70:30, inject a 5–20 µL aliquot. Tissue. Homogenize brain tissue with 320 mM sucrose, centrifuge at 1300 g for 3 min. remove the supernatant and centrifuge it at 17 000 g for 10 min to give the P2 fraction. Mix 400 µL of the P2 fraction with 20 µL 1 µg/mL IS in MeOH, add 800 µL 2 M NaOH, shake for 5 min, vortex with 3 mL n-hexane, centrifuge at 1500 g for 5 min, repeat the extraction of the aqueous layer. Evaporate the combined extracts to dryness under a stream of nitrogen, reconstitute the residue with 2 mL MeOH:1 M HCl 90:10, add to a 5 × 5 44–88 µm SP-Toyopearl SPE column, wash with 1 mL MeOH:water 90:10, elute with 1 mL MeOH:1 M ammonia solution 90:10. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with 50 µL MeCN:20 mM pH 5.5 phosphate buffer 70:30, inject a 5–20 µL aliquot. HPLC VARIABLES Column: 200 × 2.1 5 µm Inertsil C8 Mobile phase: MeCN:20 mM pH 5.5 potassium phosphate buffer 69:31 Flow rate: 0.2 Injection volume: 5–20 Detector: UV 210 CHROMATOGRAM Retention time: 7.7 Internal standard: cinnarizine (8.6) Limit of detection: 100 pg OTHER SUBSTANCES Extracted: flunarizine (9.5) KEY WORDS brain; plasma; rat; SPE REFERENCE Waki, H.; Ando, S. Column liquid chromatography of calcium channel blockers, J.Chromatogr., 1989, 494, 408–412. 359 Lopinavir Lopinavir H3C CH3 H Molecular formula: C37 H48 N4 O5 Molecular weight: 628.80 CAS Registry No: 192725-17-0 Merck Index: 13, 5594 N N O N O O N OH H CH3 O H3C H SAMPLE Matrix: blood Sample preparation: Mix 250 µL plasma with 50 µL MeOH, add 100 µL 2 µg/mL IS in MeOH, add 250 µL 1 M NaOH, add 3 mL hexane:ethyl acetate 50:50, shake at high speed for 25 min, centrifuge at 3000 g for 15 min. Evaporate the organic layer to dryness under a stream of air, reconstitute the residue with 1 mL initial mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Guard column: 10 × 2.1 Symmetry Shield Column: 30 × 2.1 3.5 µm Symmetry C18 Mobile phase: Gradient. MeCN:5 mM pH 3.25 acetate buffer from 25:75 to 80:20 over 4 min using a nonlinear gradient (not specified). Flow rate: 0.35 Injection volume: 20 Detector: MS, PE Sciex API 3000, turbo ionspray source, column effluent split 1:1 before entering source CHROMATOGRAM Retention time: 3.1 Internal standard: Abbott A-86093 (3.2) Limit of detection: 750 pg/mL Limit of quantitation: 16.3 ng/mL OTHER SUBSTANCES Extracted: amprenavir (2.7, LOQ 16.3 ng/mL, LOD 380 pg/mL), indinavir (2.0, LOQ 16.3 ng/mL, LOD 1.5 ng/mL), nelfinavir (2.5, LOQ 16.3 ng/mL, LOD 330 pg/mL), ritonavir (2.9, LOQ 51.2 ng/mL, LOD 650 pg/mL), saquinavir (2.4, LOQ 16.3 ng/mL, LOD 780 pg/mL) KEY WORDS plasma REFERENCE Frerichs, V.A.; DiFrancesco, R.; Morse, G.D. Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry, J.Chromatogr.B, 2003, 787, 393–403. SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 200 µL 10 µg/mL IS in water, add 200 µL 100 mM NaOH, mix, add 4 mL diethyl ether, shake for 5 min, centrifuge at 2500 rpm for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 200 µL initial mobile phase, inject a 100 µL aliquot. 360 Lopinavir HPLC VARIABLES Column: 250 × 4.6 Stability RP18 (CIL, France) Mobile phase: Gradient. MeCN:50 mM pH 5.65 phosphate buffer from 36:64 to 64:36 over 25 min, to 80:20 (step gradient), maintain at 80:20 for 10 min, re-equilibrate at initial conditions for 5 min. Flow rate: 1.5 Injection volume: 100 Detector: UV 240 for 5 min, UV 215 for 22 min, UV 260 for rest of run CHROMATOGRAM Retention time: 18.9 Internal standard: JR051012 (Janssen Cilag) (28.2) Limit of quantitation: 50 ng/mL OTHER SUBSTANCES Extracted: amprenavir (11.2), efavirenz (19.9), indinavir (8.5), nelfinavir (24.1), nevirapine (3.3), ritonavir (17.6), saquinavir (16.7) Noninterfering: acetaminophen, amineptine, amphotericin B, aspirin, bromazepam, buspirone, citalopram, clobazam, diazepam, didanosine, fluconazole, flunitrazepam, fluvoxamine, hydroxyitraconazole, isoniazid, itraconazole, lamivudine, loprazolam, lorazepam, metronidazole, minalcipram, nordiazepam, omeprazole, paroxetine, pyrimethamine, rifampin, sertraline, stavudine, sulfadiazine, trimethoprim, venlafaxine, zalcitabine, zidovudine, zolpidem, zopiclone KEY WORDS plasma REFERENCE Titier, K.; Lagrange, F.; Péhourcq, F.; Edno-Mcheik, L.; Moore, N.; Molimard, M. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma, Ther.Drug Monit., 2002, 24, 417–424. ANNOTATED BIBLIOGRAPHY Droste, J.A.H.; Verweij-van Wissen, C.P.W.G.M.; Burger, D.M. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography, Ther.Drug Monit., 2003, 25, 393–399. [indinavir; amprenavir; saquinavir; ritonavir; lopinavir; nelfinavir; nevirapine] Faux, J.; Venisse, N.; Olivier, J.C.; Bouquet, S. Rapid high-performance liquid chromatography determination of lopinavir, a novel HIV-1 protease inhibitor, in human plasma, Chromatographia, 2001, 54, 469–473. [SPE; LOQ 187 ng/mL] Faux, J.; Venisse, N.; Le Moal, G.; Dupuis, A.; Bouquet, S. Simultaneous determination of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography after solid-phase extraction, Chromatographia, 2003, 58, 421–426. [SPE; amprenavir; indinavir; lopinavir; nelfinavir; ritonavir; saquinavir; efavirenz; nevirapine; prazepam is internal standard] Justesen, U.S.; Pedersen, C.; Klitgaard, N.A. Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography, J.Chromatogr.B, 2003, 783, 491–500. [indinavir; amprenavir; ritonavir; lopinavir; saquinavir; nelfinavir; LOQ 25 ng/mL] Keil, K.; Frerichs, V.A.; DiFrancesco, R.; Morse, G. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma, Ther.Drug Monit., 2003, 25, 340–346. [LOQ 100 ng/mL] Leibenguth, P.; Le Guellec, C.; Besnier, J.-M.; Bastides, F.; Macé, M.; Gaudet, M.-L.; Autret-Leca, E.; Paintaud, G. Therapeutic drug monitoring of HIV protease inhibitors using high-performance liquid Lopinavir 361 chromatography with ultraviolet or photodiode array detection, Ther.Drug Monit., 2001, 23, 679–688. [indinavir; saquinavir; lopinavir; ritonavir; nelfinavir; amprenavir; carbamazepine is internal standard; LOQ 50-100 ng/mL] Marzolini, C.; Béguin, A.; Telenti, A.; Schreyer, A.; Buclin, T.; Biollaz, J.; Decosterd, L.A. Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery, J.Chromatogr.B, 2002, 774, 127–140. [LOQ 100 ng/mL; clozapine is internal standard] Poirier, J.-M.; Robidou, P.; Jaillon, P. Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography, Ther.Drug Monit., 2002, 24, 302–309. [LOQ 25 ng/mL] Ray, J.; Pang, E.; Carey, D. Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography, J.Chromatogr.B, 2002, 775, 225–230. [100 ng/mL] Rentsch, K.M. Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry, J.Chromatogr.B, 2003, 788, 339–350. [SPE; amprenavir; efavirenz; indinavir; lopinavir; nelfinavir; nevirapine; ritonavir; saquinavir; LOQ 1–250 ng/mL] Tribut, O.; Arvieux, C.; Michelet, C.; Chapplain, J.-M.; Allain, H.; Bentué-Ferrer, D. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography, Ther.Drug Monit., 2002, 24, 554–562. [nevirapine; efavirenz; indinavir; amprenavir; nelfinavir; ritonavir; lopinavir; saquinavir; LOQ 25 ng/mL] Turner, M.L.; Reed-Walker, K.; King, J.R.; Acosta, E.P. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography, J.Chromatogr.B, 2003, 784, 331–341. [indinavir; nelfinavir; saquinavir; ritonavir; amprenavir; delavirdine; efavirenz; lopinavir; metabolites; LOQ 50 ng/mL] Usami, Y.; Oki, T.; Nakai, M.; Sagisaka, M.; Kaneda, T. A simple HPLC method for simultaneous determination of lopinavir, ritonavir and efavirenz, Chem.Pharm.Bull., 2003, 26, 715–718. [LOQ 21–60 ng/mL] 362 Loteprednol etabonate Loteprednol etabonate Molecular formula: C24 H31 ClO7 Molecular weight: 466.96 CAS Registry No: 82034-46-6 Merck Index: 13, 5605 O CH3 HO CH3 H H O Cl O O CH3 O H O SAMPLE Matrix: bile, blood, urine Sample preparation: Vortex 100 µL blood with 200 µL MeCN:DMSO 95:5, cool at 0◦ for several min, centrifuge at 3000 rpm for 10 min, inject an aliquot of the supernatant. (A similar procedure can also be used for bile and urine, see Bodor,N.; Wu,W.-M.; Murakami,T.; Engel,S. Soft drugs 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats. Pharm.Res. 1995, 12, 875–879.) HPLC VARIABLES Column: 75 × 3.9 4 µm Nova-Pak phenyl Mobile phase: MeCN:water:acetic acid 45:54:1 Flow rate: 1 Injection volume: 20 Detector: UV 254 CHROMATOGRAM Retention time: 5.12 Limit of detection: <100 ng/mL KEY WORDS rat; whole blood REFERENCE Bodor, N.; Murakami, T.; Wu, W.-M. Soft drugs 18. Oral and rectal delivery of loteprednol etabonate, a novel soft corticosteroid, in rats – for safer treatment of gastrointestinal inflammation, Pharm.Res., 1995, 12, 869–874. SAMPLE Matrix: solutions HPLC VARIABLES Column: 75 × 3.9 4 µm Nova-Pak phenyl Mobile phase: MeCN:water:acetic acid 50:50:1 Flow rate: 1.5 Detector: UV 254 CHROMATOGRAM Retention time: 2.2 Loteprednol etabonate 363 OTHER SUBSTANCES Simultaneous: metabolites REFERENCE Bodor, N.; Drustrup, J.; Wu, W. Effect of cyclodextrins on the solubility and stability of a novel soft corticosteroid, loteprednol etabonate, Pharmazie, 2000, 55, 206–209. Marbofloxacin H3C N O N N CH3 N Molecular formula: C17 H19 FN4 O4 Molecular weight: 362.35 CAS Registry No: 115550-35-1 Merck Index: 13, 5774 F COOH O SAMPLE Matrix: blood Sample preparation: Mix 200 µL plasma with 800 µL 1.5 µg/mL IS in 100 mM pH 7.4 phosphate buffer, add 6 mL chloroform (Caution! Chloroform is a carcinogen!), shake at 200 oscillations/min for 30 min, centrifuge at 13 000 g for 6 min. Evaporate the organic layer to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL phosphate-buffered saline, inject a 10–80 µL aliquot. HPLC VARIABLES Guard column: Novapak C18 Guard-Pak Column: 150 × 3.9 5 µm Novapak C18 Mobile phase: MeCN:buffer 20:80 (The buffer was 20 mM potassium dihydrogen phosphate, 6 mM phosphoric acid, and 12 mM tetraethylammonium bromide, adjusted to pH 3.0 with 2 M NaOH.) Flow rate: 1 Injection volume: 10–80 Detector: F ex 338 em 425 CHROMATOGRAM Retention time: 2.20 Internal standard: enrofloxacin (3.30) Limit of detection: 15 ng/mL OTHER SUBSTANCES Simultaneous: danofloxacin (2.80), difloxacin (4.52), orbifloxacin (3.09), sarafloxacin (4.40) Interfering: ciprofloxacin (2.28), norfloxacin (2.16) KEY WORDS plasma REFERENCE Garcia, M.A.; Solans, C.; Aramayona, J.J.; Rueda, S.; Bregante, M.A. Determination of marbofloxacin in plasma samples by high-performance liquid chromatography using fluorescence detection, J.Chromatogr. B, 1999, 729, 157–161. SAMPLE Matrix: tissue Sample preparation: Condition a 6 mL 10 mm SDB-PRS or MPC-SD (mixed C8 and cation-exchange) SPE disc (3M) with two 1 mL portions of MeCN:96% acetic acid 95:5. Mix 1 g minced kidney with 150 ng IS, 10 mL MeCN, and 2.5 g sodium sulfate, homogenize (turrax) for 2 min, centrifuge at 3000 g for 5 min, filter the supernatant through 2.5 g sodium sulfate and Whatman paper. Acidify the filtrate with 2.5 mL 96% acetic acid and add to the SPE disc, dry under vacuum for 5 min, elute with four 1 mL portions of MeOH:1 M ammonia 75:25. Evaporate the eluate to dryness under a stream 364 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 Marbofloxacin 365 of nitrogen at 35◦ , reconstitute the residue with 300 µL dilute formic acid (pH 2.5), filter (0.45 µm), inject a 50 µL aliquot. HPLC VARIABLES Column: 70 × 4 5 µm Nucleosil 100-5 C18 Column temperature: 25 Mobile phase: Gradient. MeCN:dilute formic acid (pH 2.5) from 2:98 to 70:30 over 5 min, maintain at 70:30 for 1 min. Flow rate: 1 Injection volume: 50 Detector: MS, Micromass Quattro triple-stage quadrupole, ESI, 100 µL/min of column effluent entered the detector, capillary 3.2 kV, source 130◦ , desolvation 400◦ , desolvation gas nitrogen 650 L/h, nebulizer gas nitrogen 75 L/h, collision gas argon, cone 30 V, collision energy 15 eV m/z 363–320 CHROMATOGRAM Retention time: 2.97 Internal standard: quinine (m/z 325–160) (2.74) Limit of detection: <20 ng/g OTHER SUBSTANCES Extracted: cinoxacin (m/z 263–217) (3.91), ciprofloxacin (m/z 332–245) (3.06), danofloxacin (m/z 358–96) (3.10), enoxacin (m/z 321–206) (2.97), enrofloxacin (m/z 360–245) (3.19), flumequine (m/z 262–202) (4.88), nalidixic acid (m/z 233–215) (4.78), norfloxacin (m/z 320–233) (3.01), ofloxacin (m/z 362–261) (3.01), oxolinic acid (m/z 262–216) (4.18) KEY WORDS kidney; pig; SPE REFERENCE Van Vyncht, G.; Jànosi, A.; Bordin, G.; Toussaint, B.; Maghuin-Rogister, G.; De Pauw, E.; Rodriguez, A.R. Multiresidue determination of (fluoro)quinolone antibiotics in swine kidney using liquid chromatography-tandem mass spectrometry, J.Chromatogr.A, 2002, 952, 121–129. ANNOTATED BIBLIOGRAPHY Ballesteros, O.; Toro, I.; Sanz-Nebot, V.; Navalóan, A.; Vı́lchez, J.L.; Barbosa, J. Optimization of the composition and pH of the mobile phase used for separation and determination of a series of quinolone antibacterials regulated by the European Union, Chromatographia, 2002, 56, 413–421. [ciprofloxacin; enrofloxacin; norfloxacin; marbofloxacin; danofloxacin; pipemidic acid; difloxacin; sarafloxacin; flumequine; oxolinic acid; LOD 10 ng/mL; fluorescence detection] Garcia, M.A.; Solans, C.; Calvo, A.; Royo, M.; Hernandez, E.; Rey, R.; Bregante, M.A. HPLC separation and quantification of ofloxacin enantiomers in rabbit plasma. Application to pharmacokinetic studies, Chromatographia, 2002, 56, 39–42. [marbofloxacin is internal standard; fluorescence detection] Gigosos, P.G.; Revesado, P.R.; Cadahı́a, O.; Fente, C.A.; Vazquez, B.I.; Franco, C.M.; Cepeda, A. Determination of quinolones in animal tissues and eggs by high-performance liquid chromatography with photodiode-array detection, J.Chromatogr.A, 2000, 871, 31–36. [enrofloxacin; ciprofloxacin; difloxacin; norfloxacin; marbofloxacin; SPE; LOD 4 ng; UV 280] Hernández-Arteseros, J.A.; Boronat, I.; Compaño, R.; Prat, M.D. Liquid chromatographic separation of fluoroquinolone antibacterials used as veterinary drugs, Chromatographia, 2000, 52, 295–300. [danofloxacin; sarafloxacin; difloxacin; marbofloxacin; enrofloxacin; ciprofloxacin; fluorescence detection] Johnson, G.; Westwood, S.; Houghton, R. A generic approach for the HPLC separation of quinolone antibiotics, Chromatographia, 2002, 55, S127–S131. [nalidixic acid; oxolinic acid; sarafloxacin; difloxacin; pipemidic acid; flumequine; ofloxacin; marbofloxacin; enrofloxacin; ciprofloxacin; danofloxacin] 366 Marbofloxacin Schneider, M.; Thomas, V.; Boisrame, B.; Deleforge, J. Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administration, J.Vet.Pharmacol.Ther., 1996, 19, 56–61. [ofloxacin is internal standard] Toussaint, B.; Bordin, G.; Janosi, A.; Rodriguez, A.R. Validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of 11 (fluoro)quinolone antibiotics in swine kidney, J.Chromatogr.A, 2002, 976, 195–206. [danofloxacin; cinoxacin; ciprofloxacin; enoxacin; enrofloxacin; flumequine; marbofloxacin; nalidixic acid; norfloxacin; ofloxacin; oxolinic acid; SPE] Yorke, J.C.; Froc, P. Quantitation of nine quinolones in chicken tissues by high-performance liquid chromatography with fluorescence detection, J.Chromatogr.A, 2000, 882, 63–77. [ciprofloxacin; danofloxacin; enrofloxacin; nalidixic acid; oxolinic acid; sarafloxacin; difloxacin; flumequine; marbofloxacin; LOQ 7.5–150 ng/g] Masoprocol Masoprocol CH3 HO Molecular formula: C18 H22 O4 Molecular weight: 302.36 CAS Registry No: 500-38-9, 27686-84-6 (meso) Merck Index: 13, 6726 HO 367 OH OH CH3 SAMPLE Matrix: blood Sample preparation: Condition a Bond Elut C18 SPE cartridge with three 3 mL portions of MeOH and three 3 mL portions of water. Mix 500 µL serum with 2.5 µg IS, add to the SPE cartridge, wash with 3 mL water, elute with 300 µL 100 mM HCl in MeOH, inject a 100 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Adsorbosphere C18 Mobile phase: Gradient MeCN:water:trifluoroacetic acid from 30:70:0.1 to 70:30:0.1 over 15 min, maintain at 70:30:0.1 for 15 min. Flow rate: 1.5 Injection volume: 100 Detector: UV (wavelength not specified) CHROMATOGRAM Retention time: 8 Internal standard: tetra-O-methylnordihydroguaiaretic acid (Prepare IS by dissolving 1 equiv masoprocol and 6 equiv potassium carbonate in acetone, add 4 equiv dimethyl sulfate (Caution! Dimethyl sulfate is highly toxic, particularly upon inhalation, and a carcinogen! Perform the reaction in a chemical fume hood!), reflux for 8 h, add 6 equiv 1 M HCl, evaporate the acetone under reduced pressure, extract three times with 100 mL portions of ethyl acetate. Combine the organic layers, wash three times with 100 mL portions of 100 mM HCl, wash three times with 100 mL portions of 1 M NaCl, evaporate the organic layer to dryness, recrystallize the product from dichloromethane.) (20) Limit of detection: 500 ng/mL KEY WORDS mouse; pharmacokinetics; plasma; SPE REFERENCE Lambert, J.D.; Meyers, R.O.; Timmermann, B.N.; Dorr, R.T. Pharmacokinetic analysis by highperformance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse, J.Chromatogr.B, 2001, 754, 85–90. 368 Maxacalcitol Maxacalcitol H3C CH3 O H CH3 OH CH3 Molecular formula: C29 H42 O4 Molecular weight: 418.61 CAS Registry No: 103909-75-7 Merck Index: 13, 5783 H CH2 HO OH SAMPLE Matrix: blood Sample preparation: Condition a 3 mL 200 mg Bond Elut C18 SPE cartridge with 3 mL MeOH:water 80:20, 2 mL water, and 2 mL 1 M HCl. Condition a 1 mL 100 mg Bond Elut NH2 SPE cartridge with 1 mL hexane:isopropanol 70:30 and 1 mL hexane:isopropanol 90:10. Mix 20 µL 16 ng/mL IS in EtOH with 1 mL serum, add 200 µL 1 M HCl, mix, add to the C18 SPE cartridge, wash with 2 mL water, wash with 3 mL MeOH:water 50:50, elute with 4 mL MeOH:water 80:20. Evaporate the eluate to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 100 µL hexane:isopropanol 90:10, add to the NH2 SPE cartridge, wash with 1 mL hexane:isopropanol 90:10, elute with 2 mL hexane:isopropanol 70:30. Evaporate the eluate to dryness, reconstitute the residue with 50 µL mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Column: 250 × 2 5 µm Capcell Pak C18 UG120 Mobile phase: MeOH:10 mM ammonium acetate 90:10 Flow rate: 0.2 Injection volume: 20 Detector: MS, Finnigan TSQ-700 triple quadrupole, electrospray 4.5 kV, positive ion, tube lens 120 V, collision gas argon 2.0 mtorr, collision energy -20 eV, (m/z 436–297) CHROMATOGRAM Retention time: 4.5 Internal standard: ED-94 ((5Z,7E,20S)-20α-(2-hydroxy-2-methylpropoxy)-9,10-secopregna-5,7,10(19)-trien-1α,3β-diol) (m/z 422–297) (4.5) Limit of quantitation: 20 pg/mL KEY WORDS1 serum; SPE REFERENCE Ishigai, M.; Asoh, Y.; Kumaki, K. Determination of 22-oxacalcitriol, a new analog of 1α,25dihydroxyvitamin D3 , in human serum by liquid chromatography-mass spectrometry, J.Chromatogr.B, 1998, 706, 261–267. 369 Medetomidine Medetomidine Molecular formula: C13 H16 N2 Molecular weight: 200.28 CAS Registry No: 86347-14-0 Merck Index: 13, 5811 CH3 H3C CH3 N N H SAMPLE Matrix: blood Sample preparation: Condition a Sep-Pak C18 SPE cartridge with water, MeOH, and 100 mM ammonium acetate. Add 5 mL plasma to the SPE cartridge, wash with 100 mM ammonium acetate, elute with MeOH:100 mM ammonium acetate 75:25. Evaporate the eluate to dryness under reduced pressure, reconstitute the residue in 200 µL mobile phase, inject a 50 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Hitachi gel #3056 Mobile phase: MeOH:100 mM ammonium acetate 65:35 Flow rate: 1 Injection volume: 50 Detector: MS, Hitachi M-1000, APCI interface, drift voltage 21 V, nebulizer 260◦ , vaporizer 399◦ , multiplier voltage 1500 VF, m/z 201 CHROMATOGRAM Retention time: 7.5 Internal standard: detomidine (m/z 187) (6.5) Limit of quantitation: 1–2 ng/mL OTHER SUBSTANCES Extracted: atipamazole (m/z 213) (8.5), midazolam (m/z 326) (10.5) KEY WORDS pharmacokinetics; pig; plasma; SPE REFERENCE Kanazawa, H.; Nishimura, R.; Sasaki, N.; Takeuchi, A.; Takai, N.; Nagata, Y.; Matsushima, Y. Determination of medetomidine, atipamazole and midazolam by liquid chromatography-mass spectrometry, Biomed.Chromatogr., 1995, 9, 188–191. SAMPLE Matrix: blood Sample preparation: Mix 200 µL 250 mM NaOH with 500 µL plasma, add 6 mL dichloromethane, mix gently for 10 min, centrifuge at 1700 g for 10 min. Evaporate 4 mL of the lower organic layer to dryness under a stream of nitrogen, reconstitute the residue with 100 µL 50 mM pH 3.2 phosphate buffer, vortex for 1.5 min, centrifuge at 1700 g for 10 min, inject a 50 µL aliquot. HPLC VARIABLES Guard column: 20 × 4.6 5 µm Supelguard LC-DP Column: 250 × 4.6 5 µm Supelcosil LC-DP Mobile phase: MeCN:50 mM phosphate buffer:triethylamine 27:73:0.05, adjusted to pH 3.2 Flow rate: 1 Injection volume: 50 370 Medetomidine Detector: UV 215 CHROMATOGRAM Retention time: 14.6 Limit of detection: 5 ng/mL OTHER SUBSTANCES Extracted: atipamezole (16.2) KEY WORDS pharmacokinetics; plasma; reindeer REFERENCE Ranheim, B.; Horsberg, T.E.; Nymoen, U.; Soli, N.E.; Tyler, N.J.; Arnemo, J.M. Reversal of medetomidine-induced sedation in reindeer (Rangifer tarandus tarandus) with atipamezole increases the medetomidine concentration in plasma, J.Vet.Pharmacol.Ther., 1997, 20, 350–354. ANNOTATED BIBLIOGRAPHY Kanazawa, H.; Nagata, Y.; Matsushima, Y.; Takai, N.; Uchiyama, H.; Nishimura, R.; Takeuchi, A. Liquid chromatography-mass spectrometry for the determination of medetomidine and other anaesthetics in plasma, J.Chromatogr., 1993, 631, 215–220. [SPE; flumazenil; butorphanol; atropine; ketamine; xylazine; medetomidine; atipamezole; midazolam; dog; LOD 0.5–2.5 ng/mL] Meglutol 371 Meglutol Molecular formula: C6 H10 O5 HO HOOC CH3 COOH Molecular weight: 162.14 CAS Registry No: 503-49-1 Merck Index: 13, 5831 SAMPLE Matrix: blood Sample preparation: Condition a 30 × 10 column of DEAE-cellulose (Serva) with 10 vol of 100 mM pH 7.0 sodium perchlorate and 15 vol of water. Mix 6 mL plasma with 6 mL MeCN, centrifuge at 4000 g for 10 min, suspend the pellet in 6 mL MeCN:water 50:50, centrifuge at 4000 g for 10 min. Combine the supernatants, adjust the pH of a 10 mL aliquot to 7.0 with 100 mM NaOH, add to the DEAE-cellulose column, wash with 10 mL water, elute with 10 mL 100 mM perchloric acid. Freeze-dry the eluate overnight at 0◦ , reconstitute the residue with 500 µL mobile phase, centrifuge at 12 000 g for 2 min, inject a 100 µL aliquot. HPLC VARIABLES Guard column: 50 × 4 micro-Guard-NH2 Column: 300 × 7.8 Aminex HPX-87 cation-exchange (Bio-Rad) Mobile phase: 6.5 mM sulfuric acid Flow rate: 0.5 Injection volume: 100 Detector: UV 210 CHROMATOGRAM Retention time: 8 OTHER SUBSTANCES Extracted: adipic acid (12), citric acid (5), 2-oxoglutaric acid (6.4) KEY WORDS plasma; SPE REFERENCE Lippe, G.; Trevisan, R.; Nosadini, R.; Fabris, R.; Deana, R. 3-Hydroxy-3-methylglutaric, adipic, and 2-oxoglutaric acids measured by HPLC in the plasma from diabetic patients, Clin.Biochem., 1987, 20, 275–279. 372 Melatonin Melatonin Molecular formula: C13 H16 N2 O2 Molecular weight: 232.28 CAS Registry No: 73-31-4 Merck Index: 13, 5838 H N O H3CO N CH3 H SAMPLE Matrix: blood, CSF Sample preparation: For total melatonin, mix 300 µL 60 mM trichloroacetic acid with 1 mL plasma or CSF, let stand at 0◦ for 10 min, centrifuge at 5000 g for 10 min, adjust the pH of the supernatant to 7.4 with 20 µL 1 M NaOH, add to a 1 mL Chem-Elut 1001 SPE cartridge (without preconditioning), let stand for 3–5 min, elute with two 4 mL portions of dichloromethane. Evaporate the eluate to dryness at 37◦ , reconstitute the residue with 60 µL mobile phase, inject a 40 µL aliquot. For free melatonin add 1 mL plasma or CSF directly to the SPE cartridge. HPLC VARIABLES Column: 150 × 4.6 3 µm Extrasil ODS-2 (EsseCi, Italy) Mobile phase: MeCN:75 mM sodium acetate 28:72 (pH 5.0) Flow rate: 1 Injection volume: 40 Detector: F ex 275 em 345; E, Chromsystem EC 41000, 0.9 V CHROMATOGRAM Retention time: 5 Limit of quantitation: 0.5 pg/mL (F) KEY WORDS plasma; SPE REFERENCE Rizzo, V.; Porta, C.; Moroni, M.; Scoglio, E.; Moratti, R. Determination of free and total (free plus proteinbound) melatonin in plasma and cerebrospinal fluid by high-performance liquid chromatography with fluorescence detection, J.Chromatogr.B, 2002, 774, 17–24. SAMPLE Matrix: formulations Sample preparation: Powder tablets and weigh out an amount equivalent to 100 mg melatonin, add 100 mL 50 mM pH 3.0 phosphate buffer, sonicate for 10 min, centrifuge at 3000 rpm for 10 min, filter (0.20 µm), inject an aliquot. HPLC VARIABLES Guard column: 50 × 4.6 5 µm Hypersil ODS Column: 250 × 4.6 5 µm Hypersil ODS Mobile phase: MeCN:MeOH:15 mM pH 2.43 phosphate buffer 14:19:67 containing 0.25% triethylamine (pH 3.0) Flow rate: 1 Injection volume: 20 Detector: UV 223 CHROMATOGRAM Retention time: 6.0 Internal standard: adenosine (2.2) Melatonin 373 Limit of detection: 65 ng/mL Limit of quantitation: 125 ng/mL KEY WORDS tablets REFERENCE Raggi, M.A.; Bugamelli, F.; Pucci, V. Determination of melatonin in galenic preparations by LC and voltammetry, J.Pharm.Biomed.Anal., 2002, 29, 283–289. ANNOTATED BIBLIOGRAPHY Andrisano, V.; Bertucci, C.; Battaglia, A.; Cavrini, V. Photostability of drugs: photodegradation of melatonin and its determination in commercial formulations, J.Pharm.Biomed.Anal., 2000, 23, 15–23. [post-column photochemical derivatization] Azekawa, T.; Sano, A.; Aoi, K.; Sei, H.; Morita, Y. Concurrent on-line sampling of melatonin in pineal microdialysates from conscious rat and its analysis by high-performance liquid chromatography with electrochemical detection, J.Chromatogr., 1990, 530, 47–55. Bechgaard, E.; Lindhardt, K.; Martinsen, L. High-performance liquid chromatographic analysis of melatonin in human plasma and rabbit serum with on-line column enrichment, J.Chromatogr.B, 1998, 712, 177–181. [column-switching; LOD <1 ng/mL] Chanut, E.; Nguyen-Legros, J.; Versaux-Botteri, C.; Trouvin, J.H.; Launay, J.M. Determination of melatonin in rat pineal, plasma and retina by high- performance liquid chromatography with electrochemical detection, J.Chromatogr.B, 1998, 709, 11–18. [LOD 15 pg/mL] Chin, J.R. Determination of six indolic compounds, including melatonin, in rat pineal using highperformance liquid chromatography with serial fluorimetric-electrochemical detection, J.Chromatogr., 1990, 528, 111–121. Dubbels, R.; Reiter, R.J.; Klenke, E.; Goebel, A.; Schnakenberg, E.; Ehlers, C.; Schiwara, H.W.; Schloot, W. Melatonin in edible plants identified by radioimmunoassay and by high performance liquid chromatography-mass spectrometry, J.Pineal Res., 1995, 18, 28–31. Eriksson, K.; Ostin, A.; Levin, J.-O. Quantification of melatonin in human saliva by liquid chromatography-tandem mass spectrometry using stable isotope dilution, J.Chromatogr.B, 2003, 794, 115–123. [SPE; LOD 1 pg/mL] Goldman, M.E.; Hamm, H.; Erickson, C.K. Determination of melatonin by high-performance liquid chromatography with electrochemical detection, J.Chromatogr., 1980, 190, 217–220. Hall, F.; Tengerdy, C.; Morita, M.; Pautler, E. Determination of bovine retinal melatonin with HPLC-EC, Curr.Eye Res., 1985, 4, 847–850. Hamase, K.; Tomita, T.; Kiyomizu, A.; Zaitsu, K. Determination of pineal melatonin by precolumn derivatization reversed-phase high-performance liquid chromatography and its application to the study of circadian rhythm in rats and mice, Anal.Biochem., 2000, 279, 106–110. Harumi, T.; Akutsu, H.; Matsushima, S. Simultaneous determination of serotonin, N-acetylserotonin and melatonin in the pineal gland of the juvenile golden hamster by high-performance liquid chromatography with electrochemical detection, J.Chromatogr.B, 1996, 675, 152–156. Härtter, S.; Morita, S.; Bodin, K.; Ursing, C.; Tybring, G.; Bertilsson, L. Determination of exogenous melatonin and its 6-hydroxy metabolite in human plasma by liquid chromatography-mass spectrometry, Ther.Drug Monit., 2001, 23, 282–286. [LC-MS; LOD <2 ng/mL] Hernandez, G.; Abreu, P.; Alonso, R.; Calzadilla, C.H. Determination of pineal melatonin by highperformance liquid chromatography with electrochemical detection: application for rhythm studies and tissue explants, J.Pineal Res., 1990, 8, 11–19. Iinuma, F.; Hamase, K.; Matsubayashi, S.; Takahashi, M.; Watanabe, M.; Zaitsu, K. Sensitive determination of melatonin by precolumn derivatization and reversed-phase high-performance liquid chromatography, J.Chromatogr.A, 1999, 835, 67–72. [derivatization; LOD 500 amole; rat pineal gland] Itoh, M.T.; Hattori, A.; Sumi, Y. Hydroxyindole-O-methyltransferase activity assay using highperformance liquid chromatography with fluorometric detection: determination of melatonin enzymatically formed from N-acetylserotonin and S-adenosyl-L-methionine, J.Chromatogr.B, 1997, 692, 217–221. 374 Melatonin Kulczykowska, E.; Iuvone, P.M. Highly sensitive and specific assay of plasma melatonin using highperformance liquid chromatography with fluorescence detection preceded by solid-phase extraction, J.Chromatogr.Sci., 1998, 36, 175–178. [fish; LOD 3 pg/mL] Mills, M.H.; King, M.G.; Keats, N.G.; McDonald, R.A. Melatonin determination in human urine by highperformance liquid chromatography with fluorescence detection, J.Chromatogr., 1986, 377, 350–355. Naylor, S.; Johnson, K.L.; Williamson, B.L.; Klarskov, K.; Gleich, G.J. Structural characterization of contaminants in commercial preparations of melatonin by on-line HPLC-electrospray ionizationtandem mass spectrometry, Adv.Exp.Med.Biol., 1999, 467, 769–777. Peniston-Bird, J.F.; Di, W.L.; Street, C.A.; Kadva, A.; Stalteri, M.A.; Silman, R.E. HPLC assay of melatonin in plasma with fluorescence detection, Clin.Chem., 1993, 39, 2242–2247. Presits, P.; Molnár-Perl, I. HPLC of tryptophan and its metabolites using simultaneously UV, native fluorescence and pre-column fluorescence derivatization, Chromatographia, 2003, 57, S87–S92. [UV detection; fluorescence detection; niacin; niacinamide; melatonin] Sagara, Y.; Okatani, Y.; Yamanaka, S.; Kiriyama, T. Determination of plasma 5-hydroxytryptophan, 5hydroxytryptamine, 5-hydroxyindoleacetic acid, tryptophan and melatonin by high-performance liquid chromatography with electrochemical detection, J.Chromatogr., 1988, 431, 170–176. Torano, J.S.; van Rijn-Bikker, P.; Merkus, P.; Guchelaar, H.-J. Quantitative determination of melatonin in human plasma and cerebrospinal fluid with high-performance liquid chromatography and fluorescence detection, Biomed.Chromatogr., 2000, 14, 306–310. [fluorescence detection; 5-fluorotryptamine is internal standard; LOD 8 pg/mL] Vitale, A.A.; Ferrari, C.C.; Aldana, H.; Affanni, J.M. Highly sensitive method for the determination of melatonin by normal-phase high-performance liquid chromatography with fluorometric detection, J.Chromatogr.B, 1996, 681, 381–384. Wakabayashi, H.; Shimada, K.; Aizawa, Y. Determination of serotonin and melatonin in rat pineal gland by high-performance liquid chromatography with ultraviolet and fluorometric dual detection, Chem.Pharm.Bull., 1985, 33, 3875–3880. Wakabayashi, H.; Shimada, K.; Aizawa, Y. Variation of melatonin and serotonin content in rat pineal gland with sex and oestrous phase difference determined by high-performance liquid chromatography with fluorimetric detection, J.Chromatogr., 1986, 381, 21–28. Yamada, K.; Sakamoto, Y.; Satoh, T. A simple method for the measurement of pineal melatonin with a high performance liquid chromatography-UV detection, Res.Commun.Chem.Pathol.Pharmacol., 1984, 46, 283–287. Melengestrol acetate Melengestrol acetate O CH3 Molecular formula: C25 H32 O4 Molecular weight: 396.52 CAS Registry No: 2919-66-6, 5633-18-1 (melengestrol only) Merck Index: 13, 5840 CH3 CH3 OCOCH3 CH2 H H 375 H O CH3 SAMPLE Matrix: tissue Sample preparation: Condition a 3 mL 500 mg CN SPE cartridge with 3 mL ethyl acetate and 5 mL hexane. Cut about 10 g partially thawed fat into small pieces, place in a glass funnel with the outlet covered by glass wool, heat the fat in a microwave oven at high power for 2 or 3 min, collect the rendered fat in a beaker. Add 5 mL MeCN to 2 g liquid fat, heat at 60◦ , shake for 5 min on a reciprocating shaker at high speed, cool in an ice bath for 5 min, centrifuge at 3000 g for 5 min, decant the acetonitrile extract, repeat the extraction procedure, combine the extracts. Add 3 mL hexane to the combined extracts, vortex for 30 s, centrifuge at 1800 g for 5 min, discard the hexane, repeat the hexane wash. Dry the MeCN layer under a stream of nitrogen at 60◦ , dissolve the residue in 4 mL hexane, add 1 mL 100 mM NaOH, add 500 µL 1 M magnesium chloride, shake for 30 s, heat at 60◦ for 15 min, centrifuge at 1800 g for 5 min. Remove the hexane, add 4 mL hexane to the residue, shake for 30 s, centrifuge at 1800 g for 5 min. Combine the hexane extracts and evaporate to dryness under a stream of nitrogen at 60◦ (to remove any water), reconstitute with 1 mL hexane. Add the sample to the SPE cartridge, wash with 5 mL hexane, wash with 6 mL ethyl acetate:hexane 5:95, elute with three 1 mL and one 500 µL portions of ethyl acetate:hexane 20:80. Evaporate the eluate to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 1 mL MeCN:water 70:30, add 10 µL 10% HCl, shake, filter (0.22 µm), inject a 40 µL aliquot. HPLC VARIABLES Guard column: 20 × 4.6 5 µm C18 end-capped with 20% carbon load Column: 250 × 4.6 5 µm C18 end-capped with 20% carbon load Mobile phase: MeCN:water 70:30 Flow rate: 1 Injection volume: 40 Detector: UV 291 CHROMATOGRAM Retention time: 9.32 Limit of detection: 3 ppb Limit of quantitation: 10 ppb OTHER SUBSTANCES Extracted: chlormadinone (8.57), megestrol (8.92) KEY WORDS cow; fat; pig; SPE REFERENCE Andresen, M.T.; Fesser, A.C.E. Liquid chromatographic determination of progestogens in animal fat, J.AOAC Int., 1996, 79, 1037–1042. SAMPLE Matrix: tissue 376 Melengestrol acetate Sample preparation: Condition a 100 mg C18 SPE cartridge (Varian) with MeOH and 10 mM pH 8.5 Tris buffer. Fill a 22 mL vessel (from bottom to top) with 5 g alumina (dried at 120◦ for 48 h before use), 6 g anhydrous sodium sulfate, and 2 g melted (microwave) kidney fat. There is filter paper between the alumina and sodium sulfate. Pass hexane down through the layers at 60◦ at 1500 psi followed by MeCN at 50◦ at 1500 psi. Store the MeCN at −20◦ for 30 min to precipitate fat, filter through a plug of glass wool, evaporate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 2 mL MeOH, mix with 5 mL water, add to the SPE cartridge, wash with 2 mL 20 mM pH 8.5 Tris buffer, wash with 2 mL MeOH:water 40:60, elute with 2 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 75 µL MeCN, add 75 µL 0.5% formic acid, mix, inject a 75 µL aliquot. (The extraction is done in a Dionex ASE system (advanced solvent extraction).) HPLC VARIABLES Column: 150 × 3 5 µm Symmetry (Waters) Column temperature: 40 Mobile phase: Gradient. A:B from 45:55 to 100:0 over 12 min. A was MeCN:water:formic acid 10:90:0.5. B was MeCN:water:formic acid 90:10:0.5. Flow rate: 0.4 Injection volume: 75 Detector: MS, Micromass Quattro Ultima, positive electrospray, capillary 2.5 kV, cone 40 V, source 120◦ , cone gas 189 L/h, desolvation gas 652 L/h, m/z 397.2–279.3–279.3 CHROMATOGRAM Retention time: 8.8 Limit of detection: <2 ng/g OTHER SUBSTANCES Extracted: chloromadinone acetate (m/z 405.2–309.2–345.3) (8.6), chlorotestosterone acetate (m/z 365.2–305.2–323.3) (12.2), delmadinone acetate (m/z 403.2–205.1–181.1) (7.8), flurogestone acetate (m/z 407.2–267.4–225.4) (4.5), medroxyprogesterone acetate (m/z 387.2–327.3–285.3) (8.8), megestrol acetate (m/z 385.2–267.3–325.3) (8.4) KEY WORDS fat; kidney; SPE REFERENCE Hooijerink, H.; van Bennekom, E.O.; Nielen, M.W.F. Screening for gestagens in kidney fat using accelerated solvent extraction and liquid chromatography electrospray tandem mass spectrometry, Anal.Chim.Acta, 2003, 483, 51–59. ANNOTATED BIBLIOGRAPHY Campbell, H.M.; Sauvé, F. Liquid chromatographic determination of melengestrol acetate in feeds, J.AOAC Int., 1993, 76, 1163–1167. Chichila, T.M.; Edlund, P.O.; Henion, J.D.; Epstein, R.L. Determination of melengestrol acetate in bovine tissues by automated coupled-column normal-phase high-performance liquid chromatography, J.Chromatogr., 1989, 488, 389–406. [column-switching] Huopalahti, R.P.; Henion, J.D. Application of supercritical fluid extraction and high performance liquid chromatography/mass spectrometry for the determination of some anabolic agents directly from bovine tissue samples, J.Liq.Chromatogr.Rel.Technol., 1996, 19, 69–87. [UV detection; LC-MS; cow; muscle; liver; LOD 100 ppb; SFE; dexamethasone; trenbolone; triamcinolone acetonide; zeranol; diethylstilbestrol; medroxyprogesterone; melengestrol acetate] Joos, P.E.; Van Ryckeghem, M. Liquid chromatography-tandem mass spectrometry of some anabolic steroids, Anal.Chem., 1999, 71, 4701–4710. [taleranol; estriol; trenbolone; boldenone; fluoxymesterone; nortestosterone; nandrolone; methylboldenone; zeranol; estrone; ethinyl estradiol; diethylstilbestrol; Melengestrol acetate 377 hexestrol; estradiol; dienestrol; testosterone; estranediol; acetoxyprogesterone; delmadinone; norgestrel; methyltestosterone; methandriol; medroxyprogesterone; progesterone; megestrol; chlormadinone; melengestrol; norethandrolone; chlortestosterone; stanozolol; hydroxyprogesterone; caproxyprogesterone] Parks, O.W.; Shadwell, R.J.; Lightfield, A.R.; Maxwell, R.J. Determination of melengestrol acetate in supercritical fluid-solid phase extracts of bovine fat tissue by HPLC-UV and GC-MS, J.Chromatogr.Sci., 1996, 34, 353–357. Roybal, J.E. High pressure liquid chromatographic determination of melengestrol acetate in dry feed supplements, J.Assoc.Off.Anal.Chem., 1981, 64, 661–664. Weigand, J.L.; Dille, D.S. Determination of melengestrol acetate in feedstuffs with liquid chromatographic preparatory column cleanup and quantitative analysis, J.Assoc.Off.Anal.Chem., 1988, 71, 707–709. 378 Memantine Memantine Molecular formula: C12 H21 N Molecular weight: 179.30 CAS Registry No: 19982-08-2 Merck Index: 13, 5851 NH2 H3C CH3 SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 50 µL 1 µg/mL IS in 10 mM HCl, 1 mL 1 M NaOH, and 4 mL n-heptane:isoamyl alcohol 98.5:1.5 on a rocking platform at low speed for 10 min, centrifuge at 1500 g for 10 min. Add the organic supernatant to 150 µL 100 mM HCl, mix at moderate speed for 10 min, centrifuge at 1500 g for 10 min. Evaporate the aqueous layer to dryness under reduced pressure at 45◦ for 1 h, reconstitute the residue with 50 µL 1 M pH 10.3 carbonate buffer, add 25 µL 1% dansyl chloride in MeCN, vortex, let stand at room temperature for 45 min. Evaporate to dryness under reduced pressure at 45◦ for 30 min, reconstitute the residue with 125 µL MeCN:water 75:25, vortex briefly, centrifuge for 3–5 min, inject a 40 µL aliquot of the supernatant. HPLC VARIABLES Column: 250 × 4.6 5 µm Supelcosil LC-18 Mobile phase: MeCN:buffer 73:27 (Prepare mobile phase by mixing 730 mL MeCN, 270 mL 25 mM potassium dihydrogen phosphate, 500 µL orthophosphoric acid, and 600 µL n-butylamine.) Flow rate: 1.8 Injection volume: 40 Detector: F ex 235 em 470 CHROMATOGRAM Retention time: 12.1 Internal standard: amantadine (7.6) Limit of quantitation: 3 ng/mL (S/N 20) OTHER SUBSTANCES Extracted: amoxapine (13.72), m-chlorophenylpiperazine (8.21), clovoxamine (8.45), desipramine (14.54), desmethylcitalopram (6.68), desmethylclomipramine (20.05), desmethyldoxepin (10.55), desmethylmaprotiline (9.56), desmethylmianserin (12.87), desmethylsertraline (15.41), desmethyltrimipramine (19.06), fenfluramine (10.02), fluoxetine (12.94), fluvoxamine (8.36), trans-10-hydroxynortriptyline (5.48), cis-10hydroxynortriptyline (6.18), maprotiline (15.67), norclozapine (8.35), norfenfluramine (5.32), norfluoxetine (8.50), nortriptyline (17.45), paroxetine (10.15), propranolol (7.11), protriptyline (14.59), rimantadine (13.48), sertraline (31.70) Noninterfering: amitriptyline, bupropion, citalopram, clomipramine, clozapine, doxepin, haloperidol, 2-hydroxydesipramine, 2-hydroxyimipramine, imipramine, loxapine, moclobemide, olanzapine, risperidone KEY WORDS derivatization; plasma REFERENCE Suckow, R.F.; Zhang, M.F.; Collins, E.D.; Fischman, M.W.; Cooper, T.B. Sensitive and selective liquid chromatographic assay of memantine in plasma with fluorescence detection after pre-column derivatization, J.Chromatogr.B, 1999, 729, 217–224. Memantine 379 SAMPLE Matrix: solutions HPLC VARIABLES Column: 100 × 4.6 5 µm Prodigy ODS(3) (Phenomenex) Mobile phase: Gradient. MeOH:water:formic acid from 50:50:0.1 to 70:30:0.1 over 3 min, maintain at 70:30:0.1 for 2 min, return to initial conditions over 0.5 min, re-equilibrate for 3.5 min. Flow rate: 0.8 Injection volume: 100 Detector: MS, Agilent HP-1100 MSD, drying gas 30 L/min at 300◦ , nebulizer pressure 30 psi, capillary entrance 3500 V, capillary exit 70 V, m/z 180 CHROMATOGRAM Retention time: 3.6 Limit of quantitation: 100 pM (water), 500 pM (PBS) KEY WORDS use silanized glassware REFERENCE Koeberle, M.J.; Hughes, P.M.; Wilson, C.G.; Skellern, G.G. Development of a liquid chromatographymass spectrometric method for measuring the binding of memantine to different melanins, J.Chromatogr.B, 2003, 787, 313–322. ANNOTATED BIBLIOGRAPHY Duh, T.-H.; Wu, H.-L.; Kou, H.-S.; Lu, C.-Y. (2-Naphthoxy)acetyl chloride, a simple fluorescent reagent, J.Chromatogr.A, 2003, 987, 205–209. [derivatization; amantadine; memantine] 380 Menthol Menthol CH3 Molecular formula: C10 H20 O Molecular weight: 156.26 CAS Registry No: 89-78-1 Merck Index: 13, 5861 OH H3C CH3 SAMPLE Matrix: blood Sample preparation: Heat 5 µL serum, 45 µL water, and 200 mM NaOH in EtOH:water 95:5 at 100◦ for 15 min, cool, add 1 mL water, add 3 mL hexane, vortex for 2 min, centrifuge at 3000 rpm for 5 min. Remove the organic layer and evaporate it to dryness under a stream of nitrogen, reconstitute the residue in 20 µL acetone, add 50 µL 5 mM 4-dimethylaminopyridine in acetone, mix well, add 100 µL 20 mM 3-(2-phthalimidyl)benzoyl azide in acetone, mix well, heat at 125◦ in a stoppered vial for 30 min, cool in a water bath, inject a 10 µL aliquot. (Omit 4-dimethylaminopyridine for cholesterol determinations. Synthesis of 3-(2-phthalimidyl)benzoyl azide is as follows. Mix 680 mg m-aminobenzoic acid in 50 mL diethyl ether with 670 mg o-phthalaldehyde in 100 mL diethyl ether, mix, stir at room temperature for 2 days, filter to obtain 3-(2phthalimidyl)benzoic acid as a white solid. Dissolve 500 mg 3-(2-phthalimidyl)benzoic acid in 15 mL DMF, add 560 mg diphenylphosphoryl azide in 4 mL DMF, add 200 mg triethylamine, stir at 0◦ for 2 h, add 60 mL 5% sodium bicarbonate in water, add 100 mL diethyl ether, shake. Wash the organic layer twice with 100 mL portions of cold water. Collect the solid at the interface and combine it with the residue obtained when the organic layer is evaporated under reduced pressure. Take up the crude product in acetone, add water to precipitate pure product, repeat this procedure twice to obtain 3-(2-phthalimidyl)benzoyl azide as white needles (mp 123–126◦ ).) HPLC VARIABLES Column: 100 × 6 ERC-ODS-1161 (Erma, Tokyo) Mobile phase: MeCN:water 70:30 Flow rate: 1 Injection volume: 10 Detector: F ex 302 em 440 CHROMATOGRAM Retention time: 12 Limit of detection: 100–400 fmol OTHER SUBSTANCES Extracted: decanol (21), nonanol (14), octanol (10), KEY WORDS derivatization; serum; serum extraction only validated for cholesterol REFERENCE Tsuruta, Y.; Date, Y.; Kohashi, K. (2-Phthalimidyl)benzoylazides as fluorescence labeling reagents for alcohols in high-performance liquid chromatography, Anal.Sci., 1991, 7, 411–414. 381 Mepenzolate bromide Mepenzolate bromide H3C CH3 N+ O Br− Molecular formula: C21 H26 BrNO3 Molecular weight: 420.35 CAS Registry No: 76-90-4 Merck Index: 13, 5873 O OH SAMPLE Matrix: blood Sample preparation: Condition a 3 mL diol SPE cartridge (Baker) with 2 mL MeOH and 2 mL water. Add 1 mL plasma to the SPE cartridge, wash with 2 mL water, wash with 2 mL MeOH, elute with 3 mL 60 mM KBr in MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 200 µL mobile phase, inject an aliquot. (Prepare 60 mM KBr in MeOH by sonicating for 45 min.) HPLC VARIABLES Column: 250 × 4 LiChrosorb RP18 Mobile phase: MeOH:water 55:45 containing 4.325 g/L sodium octanesulfonate and 2 mL/L N,N-dimethyloctylamine, adjusted to pH 3.0 with phosphoric acid Flow rate: 1 Detector: UV 220 CHROMATOGRAM Retention time: 8 OTHER SUBSTANCES Extracted: clidinium bromide (9.5), isopropamide iodide (5) KEY WORDS plasma; SPE REFERENCE Russ-Kirschenbaum, R.; Koziol, T.; Woolf, E. Solid phase extraction of quaternary ammonium compounds on diol columns: Application to the HPLC determination of CK-1649 in plasma, J.Liq.Chromatogr., 1989, 12, 3051–3059. SAMPLE Matrix: solutions HPLC VARIABLES Column: 150 × 4.1 5 µm PRP-1 (Hamilton) Mobile phase: Gradient. MeCN:50 mM ammonium acetate from 10:90 to 50:50 over 30 min. Flow rate: 0.5 Injection volume: 20 Detector: MS, Finnigan MAT TSQ-70, thermospray, vaporizer 90◦ , ion-source 250◦ , repeller 50–100 V, make up flow 1 mL/min of MeCN:50 mM ammonium acetate 10:90, collision gas pressure 0.5 Pa, 35 eV, m/z 340 CHROMATOGRAM Retention time: 14 Limit of detection: 50 pg 382 Mepenzolate bromide OTHER SUBSTANCES Simultaneous: antrenyl (m/z 348), clidinium (m/z 352) (15), isopropamide (m/z 353), pipenzolate (m/z 354) (15), propantheline (m/z 368) (22), valethanate (m/z 306) REFERENCE van der Hoeven, R.A.M.; Reeuwijk, H.J.E.M.; Tjaden, U.R.; van der Greef, J. Analysis of quaternary ammonium drugs by thermospray liquid chromatography-mass spectrometry using a resin-based stationary phase, J.Chromatogr.A, 1996, 741, 75–84. 383 Mepixanox Mepixanox Molecular formula: C20 H21 NO3 Molecular weight: 323.38 CAS Registry No: 17854-59-0 Merck Index: 13, 5885 O O OCH3 N SAMPLE Matrix: blood Sample preparation: Add 1 mL plasma or serum and 4 mL 900 ng/mL IS in water to a previously mixed Toxi Tube A (Analytical Systems), rotate for 5 min, centrifuge at 3000 g for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 200 µL MeCN:diethylamine 100:0.004, inject an aliquot. (Toxi Tube A contains 3.5% sodium carbonate, 3.5% sodium bicarbonate, 18% dichloromethane, and 17% dichloroethane, buffered at pH 9.0.) HPLC VARIABLES Column: 250 × 4 5 µm Si 60 (Merck) Mobile phase: MeCN:isopropanol:diethylamine 50:50:0.004 Flow rate: 1 Injection volume: 50 Detector: UV 237 CHROMATOGRAM Retention time: 6.1 Internal standard: chlorpromazine (8.6) Limit of detection: 1 ng/mL Limit of quantitation: 5 ng/mL OTHER SUBSTANCES Simultaneous: amitriptyline (12.2), chlordiazepoxide (5.4), dimefline (6.4), dipyrone (9.1), doxapram (4.0), fluphenazine (2.7), imipramine (15.4), levomepromazine (4.0), nikethamide (5.5), promazine (12.7), promethazine (8.1), thioridazine (12.0) KEY WORDS normal phase; pharmacokinetics; plasma; serum REFERENCE Grossi, G.; Lippi, A.; Battistoni, R.; Martelli, E.; Sturani, C. High-performance liquid chromatographic determination of mepixanthone in serum, J.Chromatogr., 1984, 309, 214–218. 384 Mequinol Mequinol OH CH3 Molecular formula: C7 H8 O2 O Molecular weight: 124.14 CAS Registry No: 150-76-5 SAMPLE Matrix: blood Sample preparation: Mix 100 µL serum with 1 mL 20 µg/mL IS in mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Guard column: present but not specified Column: 150 × 4.6 5 µm Pinkerton ISRP (Regis) Mobile phase: MeOH:100 mM pH 6.8 potassium phosphate buffer 2.5:97.5 Flow rate: 1.2 Injection volume: 20 Detector: UV 280 CHROMATOGRAM Retention time: 5 Internal standard: 4-ethoxyphenol (8) Limit of detection: 2 µg/mL OTHER SUBSTANCES Extracted: acetaminophen (2.9), caffeine (3.8), metoclopramide (3.8), salicylic acid (3.2), theophylline (4) KEY WORDS serum REFERENCE Dawson, C.M.; Belcher, H.J.C.R.; Rainbow, S.J.; Tickner, T.R. Measurement of 4-hydroxyanisole in serum by direct injection high-performance liquid chromatography, J.Chromatogr., 1990, 534, 267–270. 385 Methenamine Methenamine Molecular formula: C6 H12 N4 N N N N Molecular weight: 140.19 CAS Registry No: 100-97-0 Merck Index: 13, 5994 SAMPLE Matrix: air Sample preparation: Pull air through a coated filter at 150 mL/min for 20 min, shake filter with 3 mL MeCN for 1 min, filter (Millex SR) the solution, inject a 10 µL aliquot. (Prepare filter as follows. Mix 300 mg 2,4-dinitrophenylhydrazine hydrochloride, 500 µL 85% phosphoric acid, 1.5 mL glycerol:EtOH 20:80, and 9 mL MeCN. Dip glass fiber filter in this solution for a few seconds, let dry on glass surface at room temperature for 2 h, store in a desiccator over saturated NaCl. Before use, recrystallize 2,4-dinitrophenylhydrazine hydrochloride twice from 4 M HCl. Methenamine is converted to formaldehyde on the filter and the formaldehyde 2,4-dinitrophenylhydrazone is detected by HPLC.) HPLC VARIABLES Column: 100 × 5 10 µm Waters Radial Pak A C18 Mobile phase: MeOH:water 40:60 Flow rate: 0.8 Injection volume: 10 Detector: UV 365 CHROMATOGRAM Retention time: k′ 2.2 Limit of quantitation: 500 ng/mL KEY WORDS derivatization REFERENCE Levin, J.-O.; Fängmark, I. High-performance liquid chromatographic determination of hexamethylenetetramine in air, Analyst, 1988, 113, 511–513. 386 Methoprene Methoprene Molecular formula: C19 H34 O3 Molecular weight: 310.47 CAS Registry No: 40596-69-8 Merck Index: 13, 6013 CH3 H3CO H3C CH3 CH3 O CH3 O CH3 SAMPLE Matrix: blood, urine Sample preparation: Condition a 3 mL 500 mg Sep-Pak C18 SPE cartridge with 3 mL MeCN and 3 mL water. Vortex 500 µL plasma or urine with 100 µL 1 M pH 5.0 acetic acid for 30 s, centrifuge at 1000 g for 5 min, add the supernatant to the SPE cartridge, wash with 3 mL water, elute with 2 mL MeOH, elute with 2 mL MeCN. Evaporate the combined eluates to 500 µL under a stream of nitrogen, inject a 10 µL aliquot. HPLC VARIABLES Guard column: 20 × 4 5 µm Supelco Column: 3000 × 3.9 10 µm µBondapak C18 Mobile phase: Gradient. MeCN:water adjusted to pH 4.0 with 1 M acetic acid 55:45 to 60:40 over 10 min, to 80:20 over 3 min, return to initial conditions over 5 min, re-equilibrate for 2 min. Flow rate: 0.6 for 9 min, to 1 over 1 min, maintain at 1 for 8 min Injection volume: 10 Detector: UV 254 CHROMATOGRAM Retention time: 18.4 Limit of detection: 100 ng/mL (S/N 3) Limit of quantitation: 150 ng/mL OTHER SUBSTANCES Extracted: methoprene acid (12.3), permethrin (UV 210) (17.6), m-phenoxybenzoic acid (UV 210) (7.9), m-phenoxybenzyl alcohol (UV 210) (7.3) KEY WORDS plasma; rat; SPE REFERENCE Abu-Qare, A.W.; Abou-Donia, M.B. A solid phase extraction reversed-phase HPLC method for the simultaneous determination of methoprene, permethrin and selected metabolites in rat plasma and urine, Biomed.Chromatogr., 2001, 15, 464–470. Methoxychlor Methoxychlor Molecular formula: C16 H15 Cl3 O2 Molecular weight: 345.65 CAS Registry No: 72-43-5 Merck Index: 13, 6020 H3CO 387 OCH3 CCl3 SAMPLE Matrix: blood, urine Sample preparation: Add 1 mL urine or whole blood and 3 mL water to a Toxi-Tube A, mix by gentle inversion for 5 min, centrifuge at 1500 g for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 50 µL MeCN:water 50:50, vortex, inject a 10 (urine) or 30 (blood) µL aliquot. HPLC VARIABLES Guard column: 20 mm long Symmetry C18 (Waters) Column: 250 × 4.6 5 µm Symmetry C8 (Waters) Column temperature: 30 Mobile phase: Gradient. MeCN:buffer 15:85 for 6.5 min, 35:65 for 18.5 min (step gradient), 80:20 for 3 min (step gradient), re-equilibrate at initial conditions for 7 min. (The buffer was 6 g sodium dihydrogen phosphate in 1 L water, adjusted to pH 3.8 with 10% phosphoric acid.) Flow rate: 1 for 6.5 min, to 1.5 over 18.5 min, maintain at 1.5 until re-equilibration is complete Injection volume: 10–30 Detector: UV 200 CHROMATOGRAM Retention time: 27.368 OTHER SUBSTANCES Extracted: acamprosate (abs 200.5) (2.97), acebutolol (abs 233.4) (10.233), acefylline heptaminol (abs 207.5) (3.628), acenocoumarol (abs 204) (20.052), acepromazine (abs 249.9) (10.763), aceprometazine (abs 240.5) (14.225), acetaminophen (abs 200.5) (5.592), acetazolamide (abs 265.3) (6.927), acetiamin (abs 200.5) (11.78), acetorphan (abs 200.5) (22.495), acetylleucine (abs 200.5) (9.825), acetylmethionine (abs 200.5) (5.03), 6acetylmorphine (abs 208.7) (7.32), actinoquinol (abs 202.8) (4.637), acyclovir (abs 200.5) (3.073), adenosine (abs 206.4) (2.697), adrafinil (abs 200.5) (13.833), albendazole (abs 218.1) (17.777), aldicarb (abs 200.5) (15.143), alfuzosin (abs 244) (10.37), alimemazine (abs 253.5) (15.257), alminoprofen (abs 201.7) (18.695), almitrine (abs 200.5) (25.905), alprazolam (abs 220.5) (16.972), altazide (abs 226.3) (16.368), altretamine (abs 229.9) (17.833), ambemonium (abs 200.5) (10.543), amfepramone (abs 200.5) (8.688), amiloride (abs 214.6) (3.608), amineptine (abs 200.5) (14.032), amiodarone (abs 204) (21.915), amisulpride (abs 225.2) (8.923), amitriptyline (abs 206.4) (15.878), amlodipine (abs 200.5) (15.093), amobarbital (abs 200.5) (16.617), amoxapine (abs 211.l) (14.187), amoxicillin (abs 200.5) (3.067), amphetamine (abs 200.5) (3.71), amphotericin B (abs 346.2) (15.718), ampicillin (abs 200.5) (3.827), anethole (abs 205.2) (23.902), apomorphine (abs 206.4) (8.962), aprindine (abs 200.5) (16.967), arecoline (abs 207.5) (3.1), aspartame (abs 200.5) (9.8), astemizole (abs 200.5) (13.16), atenolol (abs 200.5) (3.637), atrazine (abs 221.6) (18.177), atropine (abs 200.5) (10.388), bacampicillin (abs 200.5) (14.687), bamethan (abs 200.5) (5.91), bamifylline (abs 207.5) (10.288), barbital (abs 200.5) (10.445), benazepril (abs 205.2) (17.003), bendroflumethiazide (abs 208.7) (18.632), benfluorex (abs 200.5) (16.378), bentazone (abs 224) (13.615), benzbromarone (abs 204) (26.075), benzene (abs 209.9) (19.465), benzophenone (abs 200.5) (16.967), benzoylecgonine (abs 200.5) (9.678), benzydamine (abs 215.8) (14.955), bepridil (abs 202.8) (19.503), 388 Methoxychlor betahistine (abs 200.5) (3.155), betamethasone (abs 200.5) (13.277), betaxolol (abs 200.5) (13.405), bezafibrate (abs 200.5) (18.268), BHT (abs 200.5) (22.015), bidesethylchloroquine (abs 219.3) (3.867), biperiden (abs 200.5) (14.847), biscoumacetate (abs 208.7) (19.172), bisoprolol (abs 200.5) (12.283), boldine (abs 218.1) (8.068), bromadiolone (abs 202.8) (25.363), bromazepam (abs 232.2) (14.732), bromocriptine (abs 200.5) (16.652), brompheniramine (abs 200.5) (13.935), buclizide (abs 200.5) (22.752), buflomedil (abs 201.7) (11.3), bumetanide (abs 200.5) (19.055), buprenorphine (abs 212.2) (14.035), buspirone (abs 236.9) (12.523), butobarbital (abs 200.5) (14.858), N-butylscopolammonium bromide (abs 200.5) (12.232), butylparaben (abs 200.5) (20.332), cafedrine (abs 206.4) (10.235), caffeic acid (abs 321.2) (8.963), caffeine (abs 205.2) (6.647), canrenoate (abs 287.8) (16.52), captodiamine (abs 200.5) (20.15), captopril (abs 200.5) (9.652), carbamazepine (abs 213.4) (15.763), carbaryl (abs 220.5) (17.968), carbimazole (abs 200.5) (11.138), carbinoxamine (abs 200.5) (12.81), carbutamide (abs 200.5) (14.547), carbutamine (abs 200.5) (14.475), carnitine (abs 287.8) (16.058), carpipramine (abs 200.5) (16.18), carteolol (abs 214.6) (5,935), cefadroxil (abs 200.5) (3.188), cefatrizine (abs 200.5) (3.808), cefazolin (abs 200.5) (8.423), cefixime (abs 287.8) (4.823), cefpodoxime (abs 200.5) (18.945), ceftriaxone (abs 245.2) (5.34), cefuroxine (abs 278.3) (16.293, 16.552), celiprolol (abs 232.2) (11.493), cephalexin (abs 200.5) (3.875, 4.792), cetirizine (abs 200.5) (15.683), chlorambucil (abs 201.7) (22.387), chloramphenicol (abs 200.5) (14.105), chlordiazepoxide (abs 244) (15.223), chlorhexidine (abs 200.5) (13.532), chloridazone (abs 227.5) (12.293), chlormadinone (abs 283.1) (24.11), chlormezanone (abs 200.5) (15.493), chlorobenzoic acid (abs 200.5) (16.143), chlorophacinone (abs 200.5) (20.978), 4-chlorophenylbiguanide (abs 200.5) (10.068), chloropicrin (abs 202.8) (19.433), chloroquine (abs 221.6) (5.442), chlorpheniramine (abs 200.5) (12.925), chlorpromazine (abs 254.7) (16.035), chlorpropamide (abs 200.5) (17.657), chlortoluron (abs 209.9) (17.573), cibenzoline (abs 200.5) (13.143), cicletanine (abs 200.5) (13.808), cilazapril (abs 200.5) (14.367), cimetidine (abs 200.5) (3.602), cinchonine (abs 202.8) (10.198), cinnarizine (abs 200.5) (19.258), ciprofibrate (abs 200.5) (21.22), ciprofloxacin (abs 278.3) (9.102), cisapride (abs 214.6) (14.627), clenbuterol (abs 211.1) (10.802), clidinium (abs 200.5) (13.27), clindamycin (abs 200.5) (11.962), clobazam (abs 229.9) (19.19), clobenzorex (abs 200.5) (13.912), clocinizine (abs 200.5) (20.432), clofibrate (abs 200.5) (18.267), clofibride (abs 200.5) (21.067), clomethiazole (abs 249.9) (15.958), clomipramine (abs 200.5) (16.442), clonazepam (abs 200.5) (17.417), clonidine (abs 200.5) (6.128), clorazepate (abs 227.5) (18.44), clotiazepam (abs 211.1) (21.652), cloxacillin (abs 200.5) (15.702), cocaine (abs 200.5) (11.92), codeine (abs 212.2) (4.975), codethyline (abs 211.1) (8.735), colchicine (abs 244) (13.118), colchicoside (abs 244) (5.32), colchicosine (abs 200.5) (5.078), cortivazol (abs 207.5) (12.002), cotinine (abs 200.5) (4.7), coumachlor (abs 204) (22.153), coumafen (abs 205.2) (20.355), coumatetralyl (abs 264.1) (4.993), crimidine (abs 251.1) (3.703), cyamemazine (abs 270) (14.993), cyclandelate (abs 200.5) (26.383), cycloguanil (abs 200.5) (10,793), cyproheptadine (abs 224) (15.015), cyromazine (abs 214.6) (3.283), dacarbazine (abs 323.5) (3.6), dapsone (abs 200.5) (12.583), desethylatrazine (abs 213.4) (12.583), desipramine (abs 200.5) (14.87), desoxy-2-phenobarbital (abs 200.5) (11.047), dexamethasone (abs 241.7) (13.127), dextromethorphan (abs 200.5) (13.312), dextromoramide (abs 200.5) (15.835), dextropropoxyphene (abs 200.5) (15.82), di-syston (abs 200.5) (26.795), diamorphine (abs 206.4) (11.152), diaveridine (abs 200.5) (7.022), diazepam (abs 200.5) (20.327), diazinon (abs 200.5) (25.763), dibekacin (abs 200.5) (14.053), dichlorprop (abs 200.5) (16.947), diclofenac (abs 200.5) (22.115), diethylstilbestrol (abs 200.5) (20.882), difemerine (abs 200.5) (13.222), digitoxin (abs 219.3) (18.725), digoxin (abs 220.5) (13.852), dihydralazine (abs 219.3) (2.81), dihydrocodeine (abs 208.7) (4.7), diltiazem (abs 200.5) (13.992), dimerazole (abs 200.5) (8.007), dimethyl phthalate (abs 200.5) (17.04), dimetridazole (abs 320) (9.955, 10.118), dinoseb (abs 213.4) (23.652), diphacinone (abs 200.5) (19.63), dipheniramine (abs 200.5) (14.092), diprophylline (abs 206.4) (3.625), dipropyline (abs 207.5) (16.305), dipyridamole (abs 285.5) (13.197), disopyramide (abs 200.5) (11.445), disulfiram (abs 216.9) (25.13), diuron (abs 211.1) (18.503), domperidone (abs 207.5) (12.355), dosulepin (abs 200.5) (14.943), doxepin (abs 206.4) (14.095), doxorubicin (abs 232.2) (12.057), doxylamine (abs 200.5) (11.147), droperidol (abs 202.8) (21.18), dropropizine (abs 200.5) (7.243), econazole (abs 200.5) (20.137), EDDP (abs 200.5) (14.655), embutramide (abs 200.5) (17.365), emetine (abs 202.8) (9.385), enalapril (abs 211.1) (3.432), enoxacin (abs 268.9) (7.672), ephedrine Methoxychlor 389 (abs 206.4) (5.655), epinephrine (abs 200.5) (2.87), esculin (abs 202.8) (5.277), eserine (abs 204) (8.253), estazolam (abs 221.6) (16.495), β-estradiol (abs 200.5) (18.202), estriol (abs 200.5) (13.142), ethosuximide (abs 200.5) (10.485), ethyl paraben (abs 200.5) (16.19), etodolac (abs 225.2) (21.503), famotidine (abs 202.8) (3.487), felodipine (abs 200.5) (24.423), fenbufen (abs 200.5) (19.292), fenfluramine (abs 207.5) (13.055), fenofibrate (abs 200.5) (18.262), fenoprofen (abs 200.5) (21.16), fenoverine (abs 200.5) (15.57), fenozolone (abs 220.5) (12.913), fenproporex (abs 200.5) (19.263), fentanyl (abs 255.8) (14.202), flavone (abs 201.7) (20.768), flecaine (abs 204) (14.417), floctafenine (abs 209.9) (17.177), flubendazole (abs 211.1) (16.745), fluconazole (abs 200.5) (11.398), flucytosine (abs 200.5) (3.052), flunarizine (abs 200.5) (19.317), flunindione (abs 222.8) (17.892), flunitrazepam (abs 200.5) (18.558), fluorouracil (abs 204) (3.433), fluoxetine (abs 200.5) (16.185), flupenthixol (abs 228.7) (17.358), fluphenazine (abs 259.4) (17.357), flurbiprofen (abs 200.5) (21.337), flutamide (abs 200.5) (22.248), fluvoxamine (abs 200.5) (15.347), folic acid (abs 200.5) (3.583), fumaric acid (abs 206.4) (2.985), furaltadone (abs 347.4) (8,927), furazolidone (abs 347.4) (12.24), furosemide (abs 234.6) (15.17), fusidic acid (abs 200.5) (24.86), gentamicin (abs 200.5) (14.037), glibenclamide (abs 200.5) (21.953), gliclazide (abs 200.5) (20.5), glipizide (abs 200.5) (17.603), glutathione (abs 200.5) (2.835), griseofulvin (abs 292.6) (18.392), guaiacol (abs 200.5) (13.787), guaifenesin (abs 200.5) (11.435), guanfacine (abs 200.5) (11.387), halofantrine (abs 258.2) (22.993), haloperidol (abs 200.5) (14.415), harpagoside (abs 279.5) (13.48), hematoporphyrin (abs 347.4) (18.66), histidine (abs 211.1) (2.613), hydrochlorothiazide (abs 226.3) (9.397), hydrocortisone (abs 242.9) (17.735), 4-hydroxybutyrate (abs 207.5) (2.772), 3-hydroxytyramine (abs 200.5) (3.002), hydroxyzine (abs 200.5) (15.267), hyoscyamine (abs 200.5) (9.657), ibuprofen (abs 200.5) (23.815), imidazole (abs 205.2) (2.74), imipramine (abs 200.5) (15.113), inchonidine (abs 202.8) (10.480), indomethacin (abs 201.7) (21.748), indoramine (abs 200.5) (12.533), iodoform (abs 200.5) (22.05), isoquercitrin (abs 205.2) (10.582), isosorbide (abs 200.5) (18.48), isothipendyl (abs 248.8) (13.467), isradipine (abs 200.5) (22.352), josamycine (abs 231.1) (16.763), ketamine (abs 202.8) (9.637), ketoconazole (abs 202.8) (15.738), ketoprofen (abs 200.5) (19.628), lacidipine (abs 239.3) (27.235), lactic acid (abs 200.5) (3.227), lanzoprazole (abs 200.5) (16.613), levamisole (abs 213.4) (6.97), levodopa (abs 200.5) (3.575), levomepromazine (abs 251.1) (15.842), levopenbutolol (abs 200.5) (15.928), lidocaine (abs 200.5) (9.922), linuron (abs 209.9) (21.253), lisuride (abs 209.9) (4.53), lobeline (abs 200.5) (14.625), loflazepate (abs 228.7) (21.027), lomustine (abs 229.9) (22.982), loprazolam (abs 200.5) (13.387), loratadine (abs 200.5) (22.943), lorazepam (abs 228.7) (17.175), loxapine (abs 209.9) (14.553), LSD (abs 200.5) (12.003), lufenuron (abs 209.9) (27.658), maprotiline (abs 200.5) (15.508), MCPA (abs 200.5) (15.877), MDA (abs 200.5) (8.058), MDMA (abs 200.5) (9.058), MDPA (abs 200.5) (11.185), mebendazole (abs 209.9) (16.077), mebezonium (abs 225.2) (3.4), meclozine (abs 200.5) (19.955), mecoprop (abs 200.5) (17.705), medazepam (abs 200.5) (15.83), medifoxamine (abs 200.5) (13.833), medroxyprogesterone (abs 241.7) (24.203), mefenorex (abs 207.5) (11.897), mefloquine (abs 222.8) (16.597), megestrol (abs 290.2) (23.815), melatonin (abs 200.5) (12.923), melphalan (abs 201.7) (12.93), meperidine (abs 200.5) (11.77), mesalamine (abs 205.2) (4.737), metamitron (abs 200.5) (11.853), metaproterenol (abs 200.5) (4.15), metformin (abs 233.4) (2.803), methacycline (abs 242.9) (11.493), methadone (abs 200.5) (15.753), methamphetamine (abs 206.4) (8.433), methionine (abs 200.5) (2.988), methyclothiazide (abs 226.3) (15.36), methyldopa (abs 200.5) (2.96), 3-methyldopamine (abs 200.5) (3.23), 4-methyldopamine (abs 200.5) (4.185), methylhydroxyprogesterone (abs 242.9) (21.852), methylparaben (abs 200.5) (14.04), methylprednisolone (abs 245.2) (18.887), metoclopramide (abs 213.4) (9.915), metoprolol (abs 200.5) (10.722), metronidazole (abs 320) (6.778), mexiletine (abs 200.5) (11.468), mianserin (abs 200.5) (13.787), miconazole (abs 202.8) (21.53), midazolam (abs 200.5) (14.873), minaprin (abs 204) (11.225), minocycline (abs 200.5) (22.637), minoxidil (abs 231.1) (9.76), moclobemide (abs 200.5) (10.218), molsidomine (abs 312.8) (10.007), monodesbutylhalofantrine (abs 258.2) (20.45), monodesethylchloroquine (abs 219.3) (4.675), moroxydine (abs 236.9) (2.873), morphine (abs 211.1) (3.315), N-acetyl-l-tyrosine ethyl ester (abs 200.5) (11.997), nadolol (abs 200.5) (6.77), nadoxolol (abs 211.1) (12.445), naftidrofuryl (abs 225.2) (15.832), nalidixic acid (abs 258.2) (16.008), nalorphine (abs 211.1) (4.76), naloxone (abs 200.5) (14.028), naltrexone (abs 205.2) (6.087), nefopam (abs 200.5) (12.653), nemonapride (abs 212.2) (14.985), neopynamine (abs 209.9) (3.233), neostigmine (abs 200.5) (4.782), netilmicin (abs 206.4) (12.082), niacin (abs 209.9) (3.163), niacinamide (abs 214.6) (3.61), niaprazine 390 Methoxychlor (abs 200.5) (11.092), nicardipine (abs 205.2) (15.528), nicergoline (abs 202.8) (15.452), niclosamide (abs 205.2) (23.92), nifedipine (abs 236.9) (19.485), niflumic acid (abs 200.5) (21.968), nifuroxazide (abs 200.5) (13.43), nikethamide (abs 200.5) (10.623), nitrazepam (abs 200.5) (16.927), nitrendipine (abs 236.9) (22.087), nitrofural (abs 260.6) (10.323), nizatidine (abs 316.4) (3.302), noramidopyrine (abs 200.5) (9.157), norclomipramine (abs 200.5) (16.617), norephedrine (abs 205.2) (5.015), norepinephrine (abs 200.5) (2.8), norethisterone (abs 240.5) (24.038), norgestrel (abs 241.7) (21.565), norpropoxyphene (abs 200.5) (15.478), nortriptyline (abs 206.4) (15.603), noscapine (abs 213.4) (12.827), ofloxacin (abs 295) (8.648), omeprazole (abs 200.5) (14.065), opiclone (abs 200.5) (10.372), opipramol (abs 255.8) (14.163), oxacillin (abs 200.5) (14.76), oxatomide (abs 205.2) (15.797), oxazepam (abs 228.7) (16.745), oxprenolol (abs 200.5) (12.017), pancuronium (abs 200.5) (3.027), papaverine (abs 251.1) (12.12), paraminosalicylic acid (abs 207.5) (5.875), parbendazole (abs 207.5) (18.15), parconazole (abs 202.8) (15.5), paroxetine (abs 200.5) (15.275), pefloxacin (abs 278.3) (8.942), penfluridol (abs 200.5) (20.183), pentaerythritol (abs 200.5) (23.082), pentazocine (abs 200.5) (12.522), pentobarbital (abs 200.5) (16.437), pentoxifylline (abs 206.4) (11.477), pentoxyverine (abs 200.5) (15.582), perindopril (abs 206.4) (13.698), perphenazine (abs 255.8) (15.96), phenindione (abs 226.3) (18.062), phenobarbital (abs 200.5) (13.993), phenol (abs 200.5) (13.422), phenoxyethanol (abs 200.5) (13.375), phenylbutazone (abs 200.5) (24.098), phenytoin (abs 200.5) (16.288), phloroglucinol (abs 202.8) (4.172), pholcodine (abs 211.1) (2.687), phorate (abs 200.5) (26.477), phosdrin (abs 215.8) (13.615), phthalic acid (abs 201.7) (6.59), pilocarpine (abs 214.6) (4.622), pimaricin (abs 303.3) (13.637), pimozide (abs 205.2) (17.192), pinaverium (abs 213.4) (21.337), pindolol (abs 215.8) (8.568), pipamperone (abs 200.5) (10.918), piperacillin (abs 200.5) (12.758), piperine (abs 341.5) (20.373), piperonyl butoxide (abs 202.8) (27.627), pipothiazine (abs 262.9) (14.695), piracetam (abs 200.5) (3.295), piretanide (abs 200.5) (17.8), pirisudanol (abs 209.9) (3.462), piroxicam (abs 200.5) (16.57), pivampicillin (abs 200.5) (15.813), pizotifene (abs 200.5) (15.197), pralidoxime (abs 295) (2.863), prazepam (abs 200.5) (23.36), prazosin (abs 246.4) (10.608), prednisolone (abs 246.4) (14.113), prednisone (abs 241.7) (14.178), prifinium (abs 200.5) (15.622), primidone (abs 200.5) (11.13), pristinamycin (abs 227.5) (17.235), procaine (abs 292.6) (5.218), progesterone (abs 242.9) (23.835), proguanil (abs 200.5) (13.61), promethazine (abs 251.1) (14.482), prometrine (abs 221.6) (21.89), propafenone (abs 211.1) (15.128), propazine (abs 221.6) (20.433), propericyazine (abs 270) (14.168), propoxur (abs 200.5) (17.293), propranolol (abs 213.4) (13.06), propylparaben (abs 200.5) (18.34), proscillaridine a (abs 200.5) (15.585), protopine (abs 205.2) (11.707), psilocybin (abs 220.5) (3.343), pyrazinamide (abs 208.7) (3.823), pyridostigmine (abs 200.5) (3.228), pyrimethamine (abs 208.7) (12.497), pyroglutamic acid (abs 200.5) (3.008), quercetin (abs 202.8) (14.168), quinapril (abs 200.5) (16.782), quinidine (abs 208.7) (11.025), quinine (abs 208) (11.253), quinupramine (abs 200.5) (15.168), ramipril (abs 206.4) (15.678), ranitidine (abs 228.7) (3.74), reserpine (abs 218.1) (16.433), resorcinol (abs 200) (8.027), rifabutin (abs 208.7) (17.583), rifampin (abs 236.9) (16.167), rifamycin (abs 225.2) (20.85), rilmenidine (abs 200.5) (9.8), ronidazole (abs 308) (8.265), rosmarinic acid (abs 200.5) (10.637), rosoxacin (abs 271.2) (13.467), roxithromycin (abs 200.5) (15.833), rutine (abs 204) (10.1), saccharin (abs 200.5) (5.907), salicylic acid (abs 202.8) (12.12), scopolamine (abs 200.5) (7.39), secnidazole (abs 318.8) (9.668), secobarbital (abs 200.5) (17.42), selegiline (abs 207.5) (10.712), simazine (abs 220.5) (15.752), sisomicin (abs 200.5) (14.032), sotalol (abs 200.5) (3.842), spironolactone (abs 239.3) (20.68), strychnine (abs 207.5) (9.202), sulbutiamine (abs 200.5) (12.97), sulfachloropyrazine (abs 271.2) (14.763), sulfadiazine (abs 200.5) (8.375), sulfadimethoxine (abs 200.5) (14.735), sulfadoxine (abs 200.5) (13.345), sulfaguanidine (abs 200.5) (3.795), sulfamethoxazole (abs 200.5) (13.445), sulfamethoxypyridazine (abs 200.5) (11.217), sulfanilamide (abs 200.5) (5.047), sulfathiazole (abs 200.5) (9.022), sulindac (abs 200.5) (16.627), sulpiride (abs 212.2) (3.858), sultopride (abs 212.2) (13.012), synephrine (abs 200.5) (3.02), tamoxifen (abs 200.5) (20.652), temazepam (abs 200.5) (18.562), tenoxicam (abs 200.5) (12.733), terbutaline (abs 200.5) (3.683), terfenadine (abs 200.5) (19.118), terpine (abs 312.8) (13.868), tetracaine (abs 312.8) (13.69), tetracycline (abs 274.8) (9.888), tetramisole (abs 214.6) (6.97), tetrazepam (abs 226.3) (22.378), theobromine (abs 204) (3.79), theodrenaline (abs 201.7) (3.682), theophylline (abs 202.8) (4.877), thiamphenicol (abs 200.5) (7), thiopental (abs 285.5) (19.202), thioproperazine (abs 265.3) (15.212), thioridazine (abs 262.9) (17.168), tianeptine (abs 206.4) (14.877), tiapride (abs 213.4) (5.468), Methoxychlor 391 tiaprofenic acid (abs 200.5) (17.653), ticlopidine (abs 200.5) (13.813), tiemonium (abs 200.5) (11.795), timolol (abs 296.1) (10.295), tinidazole (abs 317.6) (10.563), tioclomarol (abs 200.5) (22.525), tobramycin (abs 200.5) (13.393), tofisopam (abs 204) (18.508), toloxatone (abs 204) (14.107), toluene (abs 215.8) (21.88), trandolapril (abs 206.4) (16.993), trazodone (abs 211.1) (12.683), triamterene (abs 215.8) (8.705), triazolam (abs 220.5) (17.353), trichlorocarbanilide (abs 264.1) (25.573), trichloromethiazide (abs 225.2) (14.907), trifluoperazine (abs 258.2) (17.747), trifluperidol (abs 200.5) (21.638), trihexyphenidyl (abs 200.5) (15.298), trimebutine (abs 213.4) (14.588), trimetazidine (abs 206.4) (6.06), trimethoprim (abs 205.2) (8.282), trimipramine (abs 200.5) (15.943), triprolidine (abs 200.5) (13.133), tritoqualine (abs 214.6) (20.968), tropatepine (abs 200.5) (15.425), vanillin (abs 231.1) (11.687), verapamil (abs 201.7) (15.365), veratrine (abs 220.5) (13.647), veratrole (abs 201.7) (16.377), viloxazine (abs 200.5) (10.993), vinblastine (abs 200.5) (8.37), vincamine (abs 221.6) (12.08), vincristine (abs 220.5) (13.765), vinylbital (abs 200.5) (16.583), virginiamycin (abs 227.5) (17.21), vitamin B1 (abs 200.5) (2.597), vitamin B2 (abs 267.7) (7.182), vitamin B5 (abs 200.5) (3.772), vitamin B6 (abs 200.5) (2.895), vitamin B12 (abs 207.5) (3.777), vitamin C (abs 249.9) (2.928), vitamin H (abs 200.5) (8.89), warfarin (abs 205.2) (20.358), xanthydrol (abs 209.9) (18.857), xipamide (abs 218.1) (18.823), xylene (abs 218.1) (23.985), yohimbine (abs 220.5) (11.51), zipeprol (abs 205.2) (13.45), zolpidem (abs 208.7) (11.882), zuclopenthixol (abs 206.4) (16.325) [abs = wavelength of maximum absorbance] KEY WORDS whole blood REFERENCE Gaillard, Y.; Pépin, G. Use of high-performance liquid chromatography with photodiode-array UV detection for the creation of a 600-compound library. Application to forensic toxicology, J.Chromatogr.A, 1997, 763, 149–163. SAMPLE Matrix: cell cultures Sample preparation: Add 20% MeCN to cell culture, let stand at room temperature for 15 min, centrifuge at 600 g for 5 min, inject a 400 µL aliquot of the supernatant. HPLC VARIABLES Column: 150 × 4.6 5 µm Zorbax SB-C8 Mobile phase: Gradient. MeCN:water:acetic acid 40:60:1 for 2 min, to 90:10:1 over 8 min, maintain at 90:10:1 for 15 min Injection volume: 400 Detector: UV 254 CHROMATOGRAM Retention time: 12 OTHER SUBSTANCES Extracted: metabolites REFERENCE Charles, G.D.; Bartels, M.J.; Gennings, C.; Zacharewski, T.R.; Freshour, N.L.; Gollapudi, B.B.; Carney, E.W. Incorporation of S-9 activation into an ER-α transactivation assay, Repro.Toxicol., 2000, 14, 207–216. 392 Methyltestosterone Methyltestosterone CH3 OH CH3 CH3 H Molecular formula: C20 H30 O2 Molecular weight: 302.45 CAS Registry No: 58-18-4 Merck Index: 13, 6148 H H O SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg Bond Elut C1 SPE cartridge with 2 column vol of MeCN and 2 column vol of water. Mix 500 µL serum with 25 µL 1 µg/mL IS in MeCN, add 500 µL water, vortex for 5 s, add to the SPE cartridge, wash with 3 column vol of water, wash with 1 column vol of MeCN:water 20:80, air dry at high vacuum for 10 min. Elute with 1 mL hexane:chloroform 50:50 (Caution! Chloroform is a carcinogen!), evaporate the eluate to dryness under a stream of nitrogen at 45◦ , reconstitute with 50 µL MeCN, vortex while adding 200 µL water, inject a 50 µL aliquot. HPLC VARIABLES Guard column: 15 × 4.6 7 µm silica (Brownlee) Column: 220 × 4.6 5 µm silica (Brownlee) Column temperature: 50 Mobile phase: MeCN:50 mM pH 2.5 sodium phosphate buffer 21:79 Flow rate: 1 Injection volume: 50 Detector: UV 247 CHROMATOGRAM Retention time: 5.8 Internal standard: testosterone propionate (9.1) Limit of detection: 2 ng/mL KEY WORDS serum: SPE REFERENCE Lampert, B.L.; Stewart, J.T. Determination of anabolic steroids and zeranol in human serum by isocratic reverse phase HPLC on silica, J.Liq.Chromatogr., 1989, 12, 3231–3249. 393 Metrizamide Metrizamide HO O H OH Molecular formula: C18 H22 I3 N3 O8 OH OH Molecular weight: 789.10 CAS Registry No: 31112-62-6 Merck Index: 13, 6176 N O H O H3C I I N CH3 N I O CH3 H SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 50 µL 1.5 mg/mL IS and 200 µL 20% zinc sulfate in water, add 200 µL saturated aqueous barium hydroxide, mix, heat on a steam bath for 2 min, cool, centrifuge, inject a 25 µL aliquot. HPLC VARIABLES Guard column: 60 × 4 Corasil C18 Column: 250 × 4.6 Partisil 10 ODS Mobile phase: MeOH:water:acetic acid 5:94.5:0.5 Flow rate: 2 Injection volume: 25 Detector: UV 244 CHROMATOGRAM Retention time: 3.9 Internal standard: 3-dimethylaminomethyleneimino-2,4,6-triiodobenzoic acid (11.2) Limit of detection: 720 ng/mL Limit of quantitation: 2.5 µg/mL KEY WORDS pharmacokinetics; plasma REFERENCE Kullberg, M.P.; Biddlecome, C.E.; Ross, R.W.; Edelson, J. High-performance liquid chromatographic determination of metrizamide in plasma, J.Chromatogr., 1979, 168, 533–537. 394 Metyrosine Metyrosine Molecular formula: C10 H13 NO3 Molecular weight: 195.21 CAS Registry No: 672-87-7 Merck Index: 13, 6183 O H2N OH CH3 HO SAMPLE Matrix: blood Sample preparation: Condition a 1 mL Bond Elut SCX SPE cartridge with 2 mL MeOH and 2 mL 100 mM HCl. Vortex 1 mL serum with 20 µL 100 µg/mL IS in MeOH and 1 mL water for 2 min, add to the SPE cartridge, wash with 2 mL water, air dry for 3 min, elute with four 250 µL portions of buffer, inject a 100 µL aliquot. (The buffer was 1 M dipotassium hydrogen phosphate adjusted to pH 5.0 with 1 M phosphoric acid.) HPLC VARIABLES Column: 250 × 4.6 5 µm Spherisorb ODS2 Mobile phase: MeCN:MeOH:buffer 5:2.5:92.5 (Prepare mobile phase by dissolving 30 mg sodium 1-heptanesulfonate hydrate, 1.379 g sodium dihydrogen phosphate monohydrate, 2.5 mL MeOH, and 5 mL MeCN in 100 mL water. Adjust pH to 3.0 with 100 mM phosphoric acid.) Flow rate: 1 Injection volume: 100 Detector: F ex 282 em 370 CHROMATOGRAM Retention time: 10.4 Internal standard: dopamine hydrochloride (8.9) Limit of detection: 1 µg/mL OTHER SUBSTANCES Extracted: methyldopa (LOD 100 ng/mL) (6.2) KEY WORDS cow; serum; SPE REFERENCE Hefnawy, M.M.; Stewart, J.T. Determination of metyrosine and its metabolite in serum by reversed phase high performance liquid chromatography using solid phase extraction and fluorescence detection, J.Liq.Chromatogr.Rel.Technol., 1997, 20, 3009–3016. SAMPLE Matrix: solutions Sample preparation: Prepare metyrosine methyl esters by treatment of racemic metyrosine with absolute MeOH and concentrated sulfuric acid (J.Am.Chem.Soc. 1978, 100, 6536). Dissolve 5 mg of the racemic metyrosine methyl esters in 5 mL MeCN:water 50:50 containing 0.5% v/v triethylamine. Heat a 50 µL aliquot of this solution at 45◦ for 15 min, add 10 µL 0.5% w/v 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl isothiocyanate in MeCN, heat at 45◦ for 2 h, add 10 µL 0.5% v/v hydrazine in MeCN (Caution! Hydrazine is carcinogenic and toxic!), heat at 45◦ for 15 min. Evaporate the mixture under a stream of nitrogen, reconstitute the residue with 250 µL mobile phase, inject a 100 µL aliquot. (Prepare 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl isothiocyanate solution and hydrazine solution fresh each day.) Metyrosine 395 HPLC VARIABLES Column: 250 × 4.6 5 µm Spherisorb ODS Mobile phase: MeCN:water 35:65 containing 0.1% triethylamine, adjusted to pH 4.0 with trifluoroacetic acid Flow rate: 1 Injection volume: 100 Detector: UV 250 CHROMATOGRAM Retention time: 7.32 (L), 8.73 (D) KEY WORDS chiral; derivatization REFERENCE Hefnawy, M.M.; Stewart, J.T. HPLC separation of metyrosine enantiomers as methyl esters derivatized with 2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl isothiocyanate, J.Liq.Chromatogr.Rel.Technol., 1998, 21, 381–389. 396 Micafungin Micafungin HO HO Molecular formula: C56 H71 N9 O23 S OH O O N N H H3C H2N Molecular weight: 1270.29 CAS Registry No: 235114-32-6, 208538-73-2 (Na salt) Merck Index: 13, 6199 O OH O S O O H N N O HOH O H N HO H H CH3 O H N N O HO O N OH H O O HO OH H3C SAMPLE Matrix: blood Sample preparation: Acidify plasma, add MeCN, centrifuge, dilute the supernatant with phosphate buffer, inject a 75 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm TSK-GEL ODS80TM Column temperature: 50 Mobile phase: MeCN:20 mM potassium dihydrogen phosphate 41:59 Flow rate: 1 Injection volume: 75 Detector: F ex 273 em 464 CHROMATOGRAM Retention time: 12 Limit of detection: 10 ng/mL Limit of quantitation: 100 ng/mL KEY WORDS pharmacokinetics; plasma; rabbit REFERENCE Groll, A.H.; Mickiene, D.; Petraitis, V.; Petraitiene, R.; Ibrahim, K.H.; Piscitelli, S.C.; Bekersky, I.; Walsh, T.J. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits, Antimicrob.Agents Chemother., 2001, 45, 3322–3327. SAMPLE Matrix: tissue Sample preparation: Homogenize (Ultra-Turrax 10N head) tissue with 4 vol of ice-cold pH 7.4 phosphate-buffered saline at 0◦ twice for 30 s each time, let stand at 4◦ C for 30 min, centrifuge at 2000 g for 10 min, add to a C8 SPE cartridge (Varian), wash and elute using MeCN/50 mM pH 4.0 ammonium acetate mixtures (unspecified). Evaporate the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with MeOH:50 mM pH 4.0 ammonium acetate 50:50, inject a 75 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Alltech Inertsil C8 Mobile phase: MeCN:20 mM pH 4.0 ammonium acetate 45:55 Flow rate: 0.75 Micafungin 397 Injection volume: 75 Detector: UV 273 CHROMATOGRAM Retention time: 8 Limit of detection: 10 ng/mL Limit of quantitation: 50 ng/mL KEY WORDS brain; kidney; liver; lung; plasma; SPE; spleen REFERENCE Groll, A.H.; Mickiene, D.; Petraitis, V.; Petraitiene, R.; Ibrahim, K.H.; Piscitelli, S.C.; Bekersky, I.; Walsh, T.J. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits, Antimicrob.Agents Chemother., 2001, 45, 3322–3327. 398 Milnacipran Milnacipran Molecular formula: C15 H22 N2 O H2N Molecular weight: 246.35 CAS Registry No: 92623-85-3 Merck Index: 13, 6216 CH3 N O CH3 SAMPLE Matrix: blood Sample preparation: Vortex 1 mL whole blood with 3 mL water and 20 µL 100 µg/mL IS in MeOH for 1 min, add to a Toxi Tube A, shake gently for 5 min, centrifuge at 2800 rpm for 10 min. Evaporate the organic layer to dryness, reconstitute the residue with 100 µL MeOH, inject a 20 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Symmetry (Waters) Column temperature: 30 Mobile phase: MeCN:MeOH:100 mM ammonium acetate 30:30:40 Flow rate: 1 Injection volume: 20 Detector: UV 220 CHROMATOGRAM Retention time: 4.64 Internal standard: tetrazepam (21.7) Limit of quantitation: 10 ng/mL OTHER SUBSTANCES Extracted: bromazepam (5.7), nordiazepam (10.4) KEY WORDS whole blood REFERENCE Rop, P.P.; Sournac, M.H.; Burle, J.; Fornaris, M.; Coiffait, P.E. Blood concentration of milnacipran in a case of a fatal automobile accident, J.Anal.Toxicol., 2002, 26, 123–126. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 5 µm Satisfaction RP 18 AB (CIL, France) Column temperature: 45 Mobile phase: MeCN:buffer 35:65 (The buffer was 25 mM potassium dihydrogen phosphate and 10 mM triethylamine adjusted to pH 4.80 with phosphoric acid.) Flow rate: 1 Injection volume: 20 Detector: UV 225 CHROMATOGRAM Retention time: 4.26 Milnacipran 399 OTHER SUBSTANCES Simultaneous: citalopram (7.66), desmethylcitalopram (6.98), desmethylmirtazapine (3.63), desmethylvenlafaxine (3.16), fluoxetine (17.94), fluvoxamine (12.44), mirtazapine (5.14), norfluoxetine (15.22), paroxetine (10.24), sertraline (20.00), venlafaxine (4.74) REFERENCE Dallet, P.; Labat, L.; Richard, M.; Langlois, M.H.; Dubost, J.P. A reversed-phase HPLC method development for the separation of new antidepressants, J.Liq.Chromatogr.Rel.Technol., 2002, 25, 101–111. ANNOTATED BIBLIOGRAPHY Duverneuil, C.; de la Grandmaison, G.L.; De Mazancourt, P.; Alvarez, J.-C. A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs, Ther.Drug Monit., 2003, 25, 565–573. [LOD 2.5–10 ng/mL; plasma; fluoxetine; norfluoxetine; sertraline; paroxetine; citalopram; fluvoxamine; moclobemide; mirtazapine; milnacipran; toloxatone; venlafaxine; viloxazine] Titier, K.; Castaing, N.; Scotto-Gomez, E.; Pehourcq, F.; Moore, N.; Molimard, M. High-performance liquid chromatographic method with diode array detection for identification and quantification of the eight new antidepressants and five of their active metabolites in plasma after overdose, Ther.Drug Monit., 2003, 25, 581–587. [LOQ 25–100 ng/mL; fluvoxamine; paroxetine; sertraline; fluoxetine; citalopram; mirtazapine; milnacipran; venlafaxine; norfluoxetine] 400 Mirtazapine Mirtazapine Molecular formula: C17 H19 N3 Molecular weight: 265.35 CAS Registry No: 61337-67-5 Merck Index: 13, 6230 N N N CH3 SAMPLE Matrix: blood Sample preparation: Mix 1 mL whole blood with 20 µL 1 µg/mL dibenzepin in MeOH:water 50:50, add 300 µL pH 11 Tris buffer, mix, add 500 µL butyl acetate, vortex for 2 min, centrifuge. Preserve the aqueous layer (A). Remove the organic layer and add it to 75 µL 10 mM ammonium acetate buffer containing 0.1% formic acid (pH 3.2), evaporate (?). Add 75 µL MeCN, sonicate for 5 min, centrifuge at 5000 rpm for 5 min, keep the extract as B. Add 20 µL 1 µg/mL enalapril in MeOH:water 50:50 and 120 mg NaCl to the aqueous layer (A), mix, add 500 µL pH 3 phosphate buffer, add 600 µL 8.5% phosphoric acid, add 5 mL dichloromethane:isopropanol 95:5, shake at 250 cycles/min in a bench-top shaker for 30 min, centrifuge at 5000 rpm for 5 min. Remove the lower organic layer and evaporate it to dryness under a stream of air at 45◦ . Reconstitute the residue with 150 µL initial mobile phase, sonicate, centrifuge, combine with extract B, inject a 30 µL aliquot. (Sample preparation from Gergov,M.; Robson,J.N.; Ojanperä,I.; Heinonen,O.P.; Vuori,E. Simultaneous screening and quantitation of 18 antihistamine drugs in blood by liquid chromatography ionspray tandem mass spectrometry. Forensic Sci.Inter. 2001, 121, 108–115.) HPLC VARIABLES Guard column: 40 mm long 4 µm Purospher RP-18 LiChro Cart 4-4 Column: 100 × 2.1 4 µm Genesis C18 (Jones Chromatography) Column temperature: 35 Mobile phase: Gradient. MeCN:buffer from 20:80 to 100:0 over 10 min, maintain at 0:100 for 3 min, re-equilibrate at initial conditions for 5 min. (The buffer was 10 mM ammonium acetate containing 0.1% formic acid (pH 3.2).) Flow rate: 0.2 Injection volume: 30 Detector: MS, PE Sciex API 365 triple-stage quadrupole LC-MS-MS, PE Sciex Turbo Ion Spray interface, positive ion mode, needle voltage 5.2 kV, nebulizer gas air at 60 psi, curtain gas nitrogen at 40 psi, collision cell gas nitrogen at 40 psi, turbo ionspray heater 375◦ , heater gas flow 7 L/min CHROMATOGRAM Retention time: 4.4 Internal standard: dibenzepin, enalapril Limit of detection: <20 ng/mL OTHER SUBSTANCES Extracted: acebutolol (3.8, LOD 0.1 µg/mL), acrivastine (5.7, LOD <0.02 µg/mL), alprazolam (6.1, LOD <0.02 µg/mL), alprenolol (5.4, LOD 0.01 µg/mL), amantadine (3.4, LOD 0.1 µg/mL), amiloride (2.0, LOD 0.1 µg/mL), aminophenazone (2.8, LOD <5 µg/mL), amiodarone (10.2, LOD 0.05 µg/mL), amitriptyline (6.6, LOD <0.02 µg/mL), astemizole (5.8, LOD <0.02 µg/mL), atenolol (1.7, LOD 0.30 µg/mL), azacyclonol (5.1, LOD 0.02 µg/mL), benzhexol (6.6, LOD <0.02 µg/mL), benzoylecgonine (3.3, LOD 0.01 µg/mL), betaxolol (5.5, LOD 0.01 µg/mL), biperidine (6.2, LOD <0.02 µg/mL), bisoprolol (5.0, LOD <0.02 µg/mL), brompheniramine (5.3, LOD 0.002 µg/mL), bupivacaine (5.1, LOD <0.02 µg/mL), buprenorphine (5.9, LOD 0.01 µg/mL), buspirone (5.1, LOD 0.002 µg/mL), caffeine (2.8, LOD 1 µg/mL), carbamazepine Mirtazapine 401 (6.1, LOD <0.02 µg/mL), carbinoxamine (5.1, LOD 0.002 µg/mL), carisoprodol (6.7, LOD <5 µg/mL), carvedilol (6.2, LOD <0.02 µg/mL), celiprolol (4.3, LOD 0.05 µg/mL), cetirizine (6.3, LOD 0.05 µg/mL), chlorcyclizine (6.6, LOD <0.02 µg/mL), chlordiazepoxide (5.7, LOD <0.02 µg/mL), chlormezanone (5.8, LOD <5 µg/mL), chloroquine (2.7, LOD 0.02 µg/mL), chlorpheniramine (5.1, LOD 0.002 µg/mL), chlorpromazine (7.0, LOD 0.02 µg/mL), chlorpropamide (6.7, LOD <5 µg/mL), chlorprothixene (7.0, LOD <0.02 µg/mL), cinnarizine (7.9, LOD <0.02 µg/mL), citalopram (5.7, LOD <0.02 µg/mL), clemastine (7.7, LOD 0.02 µg/mL), clobazam (7.3, LOD <0.02 µg/mL), clobutinol (5.3, LOD 0.02 µg/mL), clomethiazole (6.2, LOD 0.5 µg/mL), clomipramine (7.1, LOD <0.02 µg/mL), clonazepam (6.6, LOD <0.02 µg/mL), clonidine (2.8, LOD 0.1 µg/mL), clozapine (5.6, LOD <0.02 µg/mL), cocaine (4.6, LOD <0.02 µg/mL), codeine (2.5, LOD 0.1 µg/mL), coumatetralyl (8.4, LOD 0.05 µg/mL), cyclizine (5.8, LOD <0.02 µg/mL), dextropropoxyphene (6.6, LOD 0.05 µg/mL), demoxepam (5.8, LOD 0.02 µg/mL), dextromethorphan (5.5, LOD <0.02 µg/mL), diazepam (8.1, LOD 0.02 µg/mL), diltiazem (5.8, LOD <0.02 µg/mL), diphenhydramine (5.7, LOD <0.02 µg/mL), dipyridamole (5.4, LOD 0.005 µg/mL), disopyramine (4.4, LOD <0.02 µg/mL), dixyrazine (6.8, LOD 0.005 µg/mL), doxapram (4.8, LOD <0.02 µg/mL), doxepin (5.9, LOD <0.02 µg/mL), ebastine (9.6, LOD 0.005 µg/mL), embutramide (6.7, LOD 0.005 µg/mL), ergotamine (5.5, LOD 0.005 µg/mL), ethenzamide (5.0, LOD 0.05 µg/mL), ethylmorphine (3.2, LOD 0.05 µg/mL), ethylparathion (9.7, LOD <5 µg/mL), etodroxizine (6.4, LOD <0.02 µg/mL), felodipine (9.6, LOD 0.02 µg/mL), fenazepam (7.5, LOD <0.02 µg/mL), fenfluramine (5.3, LOD <0.02 µg/mL), fenkamfamine (5.1, LOD <0.02 µg/mL), fentanyl (5.5, LOD <0.02 µg/mL), fexofenadine (6.3, LOD <0.02 µg/mL), flecainide (5.9, LOD <0.02 µg/mL), fluconazole (4.0, LOD 0.1 µg/mL), flumazenil (5.2, LOD <0.02 µg/mL), flunitrazepam (7.1, LOD 0.002 µg/mL), fluoxetine (6.8, LOD 0.1 µg/mL), flupentixol (7.5, LOD 0.18 µg/mL), fluvoxamine (6.3, LOD 0.02 µg/mL), glibenclamide (8.5, LOD <0.02 µg/mL), glipizide (6.8, LOD <0.05 µg/mL), haloperidol (6.1, LOD <0.02 µg/mL), histapyrrodine (6.3, LOD 0.02 µg/mL), hydrocodone (3.0, LOD 0.05 µg/mL), hydroxychloroquine (2.4, LOD <0.3 µg/mL), hydroxyzine (6.3, LOD <0.02 µg/mL), imipramine (6.4, LOD 0.05 µg/mL), indomethacin (8.6, LOD 0.05 µg/mL), isoniazid (2.2, LOD 3 µg/mL), isradipine (8.6, LOD 0.05 µg/mL), ketamine (3.6, LOD <0.05 µg/mL), ketobemidone (3.3, LOD <0.05 µg/mL), ketoprofen (7.3, LOD 0.1 µg/mL), ketorolac (6.2, LOD 0.05 µg/mL), labetalol (4.9, LOD 0.05 µg/mL), lamotrigine (4.0, LOD 0.1 µg/mL), levocabastine (5.8, LOD 0.01 µg/mL), levomepromazine (6.5, LOD 0.02 µg/mL), lidocaine (3.7, LOD <0.05 µg/mL), loratadine (9.3, LOD 0.002 µg/mL), lorazepam (6.6, LOD 0.02 µg/mL), lormetazepam (7.4, LOD <0.02 µg/mL), LSD (4.7, LOD <0.02 µg/mL), malathion (8.9, LOD 10 µg/mL), maprotiline (6.4, LOD <0.02 µg/mL), MDMA (3.3, LOD 0.02 µg/mL), meclozine (8.5, LOD <0.02 µg/mL), medazepam (6.3, LOD <0.02 µg/mL), meloxicam (7.1, LOD 0.01 µg/mL), melperone (5.0, LOD <0.02 µg/mL), meperidine (4.7, LOD <0.02 µg/mL), mepivacaine (3.7, LOD <0.02 µg/mL), meprobamate (4.9, LOD 0.1 µg/mL), mesoridazine (5.4, LOD <0.02 µg/mL), methamphetamine (3.3, LOD 0.05 µg/mL), methadone (6.7, LOD <0.02 µg/mL), methylparathion (8.6, LOD 10 µg/mL), methylphenidate (4.2, LOD <0.02 µg/mL), metoclopramide (3.8, LOD <0.02 µg/mL), metoprolol (4.1, LOD 0.02 µg/mL), metronidazole (2.6, LOD 1 µg/mL), mexiletine (4.4, LOD 0.05 µg/mL), mianserin (5.7, LOD <0.02 µg/mL), midazolam (5.9, LOD <0.02 µg/mL), mizolastine (5.5, LOD 0.01 µg/mL), moclobemide (3.7, LOD 0.05 µg/mL), molindone (4.0, LOD <0.02 µg/mL), monoacetylmorphine (2.7, LOD 0.1 µg/mL), morphine (2.0, LOD 0.1 µg/mL), nicotine (2.2, LOD 0.05 µg/mL), nifedipine (7.5, LOD 0.02 µg/mL), nikethamide (3.6, LOD <0.02 µg/mL), nitrazepam (6.5, LOD <0.02 µg/mL), nizatidine (1.7, LOD 1 µg/mL), nomifensine (4.6, LOD <0.02 µg/mL), nortriptyline (6.4, LOD <0.02 µg/mL), norverapamil (6.2, LOD 1 µg/mL), noscapine (5.0, LOD <0.02 µg/mL), olanzapine (3.0, LOD 0.05 µg/mL), ondansetron (4.6, LOD <0.02 µg/mL), orphenadrine (6.1, LOD <0.02 µg/mL), oxazepam (6.3, LOD <0.02 µg/mL), oxcarbazepine (5.3, LOD 0.02 µg/mL), oxprenolol (4.7, LOD 0.02 µg/mL), oxycodone (2.8, LOD 0.05 µg/mL), papaverine (4.8, LOD <0.02 µg/mL), acetaminophen (2.5, LOD <5 µg/mL), paroxetine (6.2, LOD 0.02 µg/mL), pemoline (3.3, LOD 0.05 µg/mL), pentazocine (5.0, LOD <0.02 µg/mL), pentifylline (7.3, LOD <5 µg/mL), pentoxyverine (6.6, LOD <0.02 µg/mL), perphenazine (6.9, LOD 0.002 µg/mL), phenazone (3.9, LOD 0.05 µg/mL), phencyclidine (5.3, LOD 0.05 µg/mL), pheniramine 402 Mirtazapine (4.1, LOD 0.02 µg/mL), phenylbutazone (9.0, LOD <5 µg/mL), phenylpropanolamine (2.5, LOD 0.3 µg/mL), phenytoin (6.1, LOD 0.05 µg/mL), pindolol (3.3, LOD 0.05 µg/mL), piroxicam (6.6, LOD 0.02 µg/mL), pitofenone (5.4, LOD <0.02 µg/mL), pizotifen (6.5, LOD <0.02 µg/mL), practolol (1.8, LOD 0.1 µg/mL), prazosin (4.1, LOD 0.05 µg/mL), prilocaine (3.8, LOD <0.02 µg/mL), primidone (4.0, LOD <5 µg/mL), procainamide (2.2, LOD 0.05 µg/mL), prochlorperazine (7.5, LOD 0.02 µg/mL), promazine (6.2, LOD <0.02 µg/mL), promethazine (6.0, LOD 0.05 µg/mL), propafenone (6.3, LOD <0.02 µg/mL), propranolol (5.4, LOD 0.02 µg/mL), propyphenazone (6.6, LOD 0.50 µg/mL), pseudoephedrine (2.6, LOD 1 µg/mL), quinine (4.2, LOD 0.02 µg/mL), ranitidine (1.8, LOD 0.1 µg/mL), risperidone (4.9, LOD <0.02 µg/mL), rocurone (3.8, LOD 0.1 µg/mL), ropivacaine (4.6, LOD <0.02 µg/mL), salicylamide (4.2, LOD <5 µg/mL), selegiline (4.1, LOD 0.05 µg/mL), sertindole (7.2, LOD <0.02 µg/mL), sertraline (6.8, LOD 0.02 µg/mL), sulindac (6.5, LOD 0.02 µg/mL), simazine (6.0, LOD 0.1 µg/mL), sincocaine (6.5, LOD <0.02 µg/mL), sisapride (5.9, LOD <0.02 µg/mL), sotalol (2.1, LOD 0.1 µg/mL), strychnine (5.3, LOD 0.05 µg/mL), sulpiride (1.9, LOD 0.1 µg/mL), sulthiame (4.1, LOD 0.05 µg/mL), temazepam (7.2, LOD <0.02 µg/mL), terbutaline (2.3, LOD 0.1 µg/mL), terfenadine (8.1, LOD 0.002 µg/mL), terodiline (6.7, LOD <0.02 µg/mL), tetracaine (5.7, LOD <0.02 µg/mL), dronabinol (12.3, LOD 0.05 µg/mL), tetrahydrozoline (3.6, LOD 0.1 µg/mL), theobromine (2.3, LOD <5 µg/mL), theophylline (2.4, LOD <5 µg/mL), thioridazine (7.5, LOD 0.02 µg/mL), timolol (3.8, LOD 0.05 µg/mL), thiothixene (6.7, LOD 0.02 µg/mL), tolbutamide (7.1, LOD <5 µg/mL), toremifene (8.7, LOD 0.02 µg/mL), tramadol (4.2, LOD 0.02 µg/mL), trazodone (5.2, LOD <0.02 µg/mL), triamterene (3.2, LOD 0.1 µg/mL), triazolam (6.7, LOD 0.002 µg/mL), trimeprazine (6.4, LOD <0.02 µg/mL), trimethoprim (3.1, LOD 0.05 µg/mL), trimipramine (6.7, LOD <0.02 µg/mL), venlafaxine (4.9, LOD 0.02 µg/mL), verapamil (6.5, LOD <0.02 µg/mL), warfarin (7.9, LOD <0.02 µg/mL), yohimbine (4.5, LOD <0.02 µg/mL), zolpidem (4.7, LOD <0.02 µg/mL), zopiclone (4.0, LOD 0.1 µg/mL) KEY WORDS whole blood REFERENCE Gergov, M.; Ojanperä, I.; Vuori, E. Simultaneous screening for 238 drugs in blood by liquid chromatography-ionspray tandem mass spectrometry with multiple-reaction monitoring, J.Chromatogr.B, 2003, 795, 41–53. SAMPLE Matrix: blood Sample preparation: Condition a 3 mL 130 mg Bond Elut Certify SPE cartridge with 3 mL MeOH, 3 mL water, and 1 mL 100 mM pH 6.0 potassium phosphate buffer. Vortex 1 mL plasma, 2 mL 100 mM pH 6.0 potassium phosphate buffer, and 100 µL 1 µg/mL IS in EtOH, add to the SPE cartridge, wash with 3 mL water, wash with 1 mL 1 M acetic acid, wash with 3 mL MeOH, draw air through the column for 5 min, elute with 3 mL dichloromethane:isopropanol:ammonium hydroxide 78:20:2. Evaporate the eluate to dryness under a stream of air at 55◦ , reconstitute the residue with 120 µL mobile phase, inject a 80 µL aliquot. HPLC VARIABLES Guard column: 25 × 4.6 10 µm Chiralpak AD Column: 50 × 4.6 10 µm Chiralpak AD Mobile phase: Hexane:EtOH:isopropanol 98:1:1 Flow rate: 1.5 Injection volume: 80 Detector: UV 290 CHROMATOGRAM Retention time: 12.5 (+), 15.0 (−) Mirtazapine 403 Internal standard: imipramine (3.8) Limit of quantitation: 10 ng/mL KEY WORDS chiral; plasma; SPE REFERENCE Dodd, S.; Burrows, G.D.; Norman, T.R. Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography, J.Chromatogr.B, 2000, 748, 439–443. SAMPLE Matrix: formulations Sample preparation: Extract a 300 mg amount powdered tablets with 100 mL MeCN:water 50:50, inject a 10 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Hypersil ODS Column temperature: 40 Mobile phase: MeCN:MeOH:THF:buffer 14.875:12.67:7.455:65 (The buffer was 18 g/L tetramethylammonium hydroxide pentahydrate in water adjusted to pH 7.4 with 85% phosphoric acid.) Flow rate: 1.5 Injection volume: 10 Detector: UV 210 CHROMATOGRAM Limit of detection: 0.01–0.04% Limit of quantitation: 0.02–0.12% OTHER SUBSTANCES Simultaneous: impurities KEY WORDS comparison with capillary electrophoresis; tablets REFERENCE Wynia, G.S.; Windhorst, G.; Post, P.C.; Maris, F.A. Development and validation of a capillary electrophoresis method within a pharmaceutical quality control environment and comparison with high-performance liquid chromatography, J.Chromatogr.A, 1997, 773, 339–350. ANNOTATED BIBLIOGRAPHY Dallet, P.; Labat, L.; Richard, M.; Langlois, M.H.; Dubost, J.P. A reversed-phase HPLC method development for the separation of new antidepressants, J.Liq.Chromatogr.Rel.Technol., 2002, 25, 101–111. [fluvoxamine; fluoxetine; sertraline; paroxetine; citalopram; venlafaxine; milnacipran; mirtazapine] Duverneuil, C.; de la Grandmaison, G.L.; De Mazancourt, P.; Alvarez, J.-C. A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs, Ther.Drug Monit., 2003, 25, 565–573. [LOD 2.5–10 ng/mL; plasma; fluoxetine; norfluoxetine; sertraline; paroxetine; citalopram; fluvoxamine; moclobemide; mirtazapine; milnacipran; toloxatone; venlafaxine; viloxazine] Frahnert, C.; Rao, M.L.; Grasmäder, K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring, J.Chromatogr.B, 2003, 794, 35–47. [SPE; sulpiride; moclobemide; amisulpride; venlafaxine; normirtazapine; melperone; reboxetine; zolpidem; nordoxepin; diazepam; risperidone; benperidol; normaprotiline; dibenzepine; opipramol; fluvoxamine; quetiapine; desipramine; citalopram; norfluoxetine; norclozapine; nortriptyline; haloperidol; paroxetine; maprotiline; mirtazapine; fluoxetine; doxepin; norclomipramine; imipramine; trifluperidol; olanzapine; trimipramine; amitriptyline; 404 Mirtazapine ziprasidone; promethazine; mianserin; clomipramine; clozapine; fluphenazine; nefazodone; sertraline; chlorprothixene; thioridazine; pimozide; LOQ 5–10 ng/mL] Labat, L.; Dallet, P.; Kummer, E.; Dubost, J.P. Spectrophotometric, spectrofluorimetric, HPLC and CZE determination of mirtazapine in pharmaceutical tablets, J.Pharm.Biomed.Anal., 2002, 28, 365–371. [pirenzepine is internal standard] Maris, F.A.; Dingler, E.; Niehues, S. High-performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its demethyl metabolite in human plasma, J.Chromatogr.B, 1999, 721, 309–316. [LOQ 0.5 ng/mL] Moody, J.D.; Freeman, J.P.; Fu, P.P.; Cerniglia, C.E. Biotransformation of mirtazapine by Cunninghamella elegans, Drug Metab.Dispos., 2002, 30, 1274–1279. Morgan, P.E.; Tapper, J.; Spencer, E.P. Measurement of total mirtazapine and normirtazapine in plasma/serum by liquid chromatography with fluorescence detection, J.Chromatogr.B, 2003, 798, 211–215. [LOQ 1 ng/mL; imipramine is internal standard] Ptácek, P.; Klı́ma, J.; Macek, J. Determination of mirtazapine in human plasma by liquid chromatography, J.Chromatogr.B, 2003, 794, 323–328. [fluorescence detection; LOQ 1.5 ng/mL; zolpidem is internal standard] Romiguieres, T.; Pehourcq, F.; Matoga, M.; Begaud, B.; Jarry, C. Determination of mirtazapine and its demethyl metabolite in plasma by high-performance liquid chromatography with ultraviolet detection; Application to management of acute intoxication, J.Chromatogr.B, 2002, 775, 163–168. [LOQ 20 ng/mL; opipramol is internal standard] Thieme, D.; Sachs, H. Improved screening capabilities in forensic toxicology by application of liquid chromatography-tandem mass spectrometry, Anal.Chim.Acta, 2003, 492, 171–186. [alprazolam; dothiepin; piritramide; cocaine; lorazepam; lormetazepam; clonazepam; flunitrazepam; bromazepam; midazolam; flurazepam; nitrazepam; temazepam; medazepam; nordazepam; diazepam; methylclonazepam; triazolam; oxazepam; haloperidol; benperidol; sulpiride; amisulpride; mirtazapine; citalopram; olanzapine; paroxetine; fluoxetine; sertraline; zopiclone; zolpidem; risperidone; quetiapine; fentanyl; pipamperone; meperidine; buprenorphine; propoxyphene; pentazocine; phenazocine; EDDP; tilidine; methadone; morphine; codeine; dihydrocodeine; acetylmorphine; amphetamine; ephedrine; norephedrine; pseudoephedrine; methylephedrine; amphetaminil; benzphetamine; methylphenidate; nikethamide; amfeparone; clobenzorex; atropine; scopolamine; ajmaline; aconitine; colchicine; strychnine; metoprolol; acebutolol; propranolol; sotalol; atenolol; bisoprolol; amiloride; triamterene; warfarin; brodifacoum; coumatetralyl; phenprocoumon; methaqualone; clomethiazole; acetaminophen; methoxamine; vecuronium; neostigmine; LSD] Titier, K.; Castaing, N.; Scotto-Gomez, E.; Pehourcq, F.; Moore, N.; Molimard, M. High-performance liquid chromatographic method with diode array detection for identification and quantification of the eight new antidepressants and five of their active metabolites in plasma after overdose, Ther.Drug Monit., 2003, 25, 581–587. [LOQ 25–100 ng/mL; fluvoxamine; paroxetine; sertraline; fluoxetine; citalopram; mirtazapine; milnacipran; venlafaxine; norfluoxetine] 405 Misoprostol Misoprostol H3C Molecular formula: C22 H38 O5 Molecular weight: 382.53 CAS Registry No: 59122-46-2 Merck Index: 13, 6232 O O OH OCH3 CH3 HO SAMPLE Matrix: blood Sample preparation: Mix 200 µL plasma with 200 µL 100 ppm 2-naphthoic acid and 300 µL MeCN, shake well, centrifuge for 10 min, inject a 20 µL aliquot of the supernatant. HPLC VARIABLES Column: 250 × 4.6 5 µm Zorbax C8 Mobile phase: MeCN:MeOH:20 mM pH 3.0 potassium phosphate buffer 30:24:46 Flow rate: 1.7 Injection volume: 20 Detector: UV 210; Radioactivity (3 H) CHROMATOGRAM Retention time: 18.5 (diastereomers not resolved) Internal standard: 2-naphthoic acid (6) Limit of quantitation: LOQ 1 µg (UV), 12 pg (radioactivity detector) OTHER SUBSTANCES Extracted: iloprost (LOQ 500 ng (UV), 42 pg (radioactivity detector)) (14.7, 15.9 (diastereomers)) KEY WORDS plasma; rat REFERENCE Womack, I.M.; Lee, A.S.; Kamath, B.; Agrawal, K.C.; Kishore, V. A high performance liquid radiochromatographic assay for the simultaneous analysis of iloprost and misoprostol, Prostaglandins, 1996, 52, 249–259. 406 Mizolastine Mizolastine F O Molecular formula: C24 H25 FN6 O Molecular weight: 432.49 CAS Registry No: 108612-45-9 Merck Index: 13, 6242 H N N N N N N CH3 SAMPLE Matrix: blood Sample preparation: Mix 1 mL whole blood with 20 µL 1 µg/mL dibenzepin in MeOH:water 50:50, add 300 µL pH 11 Tris buffer, mix, add 500 µL butyl acetate, vortex for 2 min, centrifuge. Preserve the aqueous layer (A). Remove the organic layer and add it to 75 µL 10 mM ammonium acetate buffer containing 0.1% formic acid (pH 3.2), evaporate (?). Add 75 µL MeCN, sonicate for 5 min, centrifuge at 5000 rpm for 5 min, keep the extract as B. Add 20 µL 1 µg/mL enalapril in MeOH:water 50:50 and 120 mg NaCl to the aqueous layer (A), mix, add 500 µL pH 3 phosphate buffer, add 600 µL 8.5% phosphoric acid, add 5 mL dichloromethane:isopropanol 95:5, shake at 250 cycles/min in a bench-top shaker for 30 min, centrifuge at 5000 rpm for 5 min. Remove the lower organic layer and evaporate it to dryness under a stream of air at 45◦ . Reconstitute the residue with 150 µL initial mobile phase, sonicate, centrifuge, combine with extract B, inject a 30 µL aliquot. (Sample preparation from Gergov,M.; Robson,J.N.; Ojanperä,I.; Heinonen,O.P.; Vuori,E. Simultaneous screening and quantitation of 18 antihistamine drugs in blood by liquid chromatography ionspray tandem mass spectrometry. Forensic Sci.Inter. 2001, 121, 108–115.) HPLC VARIABLES Guard column: 40 mm long 4 µm Purospher RP-18 LiChro Cart 4-4 Column: 100 × 2.1 4 µm Genesis C18 (Jones Chromatography) Column temperature: 35 Mobile phase: Gradient. MeCN:buffer from 20:80 to 100:0 over 10 min, maintain at 0:100 for 3 min, re-equilibrate at initial conditions for 5 min. (The buffer was 10 mM ammonium acetate containing 0.1% formic acid (pH 3.2).) Flow rate: 0.2 Injection volume: 30 Detector: MS, PE Sciex API 365 triple-stage quadrupole LC-MS-MS, PE Sciex Turbo Ion Spray interface, positive ion mode, needle voltage 5.2 kV, nebulizer gas air at 60 psi, curtain gas nitrogen at 40 psi, collision cell gas nitrogen at 40 psi, turbo ionspray heater 375◦ , heater gas flow 7 L/min CHROMATOGRAM Retention time: 5.5 Internal standard: dibenzepin, enalapril Limit of detection: 10 ng/mL OTHER SUBSTANCES Extracted: acebutolol (3.8, LOD 0.1 µg/mL), acrivastine (5.7, LOD <0.02 µg/mL), alprazolam (6.1, LOD <0.02 µg/mL), alprenolol (5.4, LOD 0.01 µg/mL), amantadine (3.4, LOD 0.1 µg/mL), amiloride (2.0, LOD 0.1 µg/mL), aminophenazone (2.8, LOD <5 µg/mL), amiodarone (10.2, LOD 0.05 µg/mL), amitriptyline (6.6, LOD <0.02 µg/mL), astemizole (5.8, LOD <0.02 µg/mL), atenolol (1.7, LOD 0.30 µg/mL), azacyclonol (5.1, LOD 0.02 µg/mL), benzhexol (6.6, LOD <0.02 µg/mL), benzoylecgonine (3.3, LOD 0.01 µg/mL), betaxolol (5.5, LOD 0.01 µg/mL), biperidine (6.2, LOD <0.02 µg/mL), bisoprolol (5.0, LOD <0.02 µg/mL), brompheniramine (5.3, LOD 0.002 µg/mL), bupivacaine (5.1, LOD <0.02 µg/mL), buprenorphine (5.9, LOD 0.01 µg/mL), buspirone (5.1, LOD 0.002 µg/mL), caffeine (2.8, LOD 1 µg/mL), carbamazepine Mizolastine 407 (6.1, LOD <0.02 µg/mL), carbinoxamine (5.1, LOD 0.002 µg/mL), carisoprodol (6.7, LOD <5 µg/mL), carvedilol (6.2, LOD <0.02 µg/mL), celiprolol (4.3, LOD 0.05 µg/mL), cetirizine (6.3, LOD 0.05 µg/mL), chlorcyclizine (6.6, LOD <0.02 µg/mL), chlordiazepoxide (5.7, LOD <0.02 µg/mL), chlormezanone (5.8, LOD <5 µg/mL), chloroquine (2.7, LOD 0.02 µg/mL), chlorpheniramine (5.1, LOD 0.002 µg/mL), chlorpromazine (7.0, LOD 0.02 µg/mL), chlorpropamide (6.7, LOD <5 µg/mL), chlorprothixene (7.0, LOD <0.02 µg/mL), cinnarizine (7.9, LOD <0.02 µg/mL), citalopram (5.7, LOD <0.02 µg/mL), clemastine (7.7, LOD 0.02 µg/mL), clobazam (7.3, LOD <0.02 µg/mL), clobutinol (5.3, LOD 0.02 µg/mL), clomethiazole (6.2, LOD 0.5 µg/mL), clomipramine (7.1, LOD <0.02 µg/mL), clonazepam (6.6, LOD <0.02 µg/mL), clonidine (2.8, LOD 0.1 µg/mL), clozapine (5.6, LOD <0.02 µg/mL), cocaine (4.6, LOD <0.02 µg/mL), codeine (2.5, LOD 0.1 µg/mL), coumatetralyl (8.4, LOD 0.05 µg/mL), cyclizine (5.8, LOD <0.02 µg/mL), dextropropoxyphene (6.6, LOD 0.05 µg/mL), demoxepam (5.8, LOD 0.02 µg/mL), dextromethorphan (5.5, LOD <0.02 µg/mL), diazepam (8.1, LOD 0.02 µg/mL), diltiazem (5.8, LOD <0.02 µg/mL), diphenhydramine (5.7, LOD <0.02 µg/mL), dipyridamole (5.4, LOD 0.005 µg/mL), disopyramine (4.4, LOD <0.02 µg/mL), dixyrazine (6.8, LOD 0.005 µg/mL), doxapram (4.8, LOD <0.02 µg/mL), doxepin (5.9, LOD <0.02 µg/mL), ebastine (9.6, LOD 0.005 µg/mL), embutramide (6.7, LOD 0.005 µg/mL), ergotamine (5.5, LOD 0.005 µg/mL), ethenzamide (5.0, LOD 0.05 µg/mL), ethylmorphine (3.2, LOD 0.05 µg/mL), ethylparathion (9.7, LOD <5 µg/mL), etodroxizine (6.4, LOD <0.02 µg/mL), felodipine (9.6, LOD 0.02 µg/mL), fenazepam (7.5, LOD <0.02 µg/mL), fenfluramine (5.3, LOD <0.02 µg/mL), fenkamfamine (5.1, LOD <0.02 µg/mL), fentanyl (5.5, LOD <0.02 µg/mL), fexofenadine (6.3, LOD <0.02 µg/mL), flecainide (5.9, LOD <0.02 µg/mL), fluconazole (4.0, LOD 0.1 µg/mL), flumazenil (5.2, LOD <0.02 µg/mL), flunitrazepam (7.1, LOD 0.002 µg/mL), fluoxetine (6.8, LOD 0.1 µg/mL), flupentixol (7.5, LOD 0.18 µg/mL), fluvoxamine (6.3, LOD 0.02 µg/mL), glibenclamide (8.5, LOD <0.02 µg/mL), glipizide (6.8, LOD <0.05 µg/mL), haloperidol (6.1, LOD <0.02 µg/mL), histapyrrodine (6.3, LOD 0.02 µg/mL), hydrocodone (3.0, LOD 0.05 µg/mL), hydroxychloroquine (2.4, LOD <0.3 µg/mL), hydroxyzine (6.3, LOD <0.02 µg/mL), imipramine (6.4, LOD 0.05 µg/mL), indomethacin (8.6, LOD 0.05 µg/mL), isoniazid (2.2, LOD 3 µg/mL), isradipine (8.6, LOD 0.05 µg/mL), ketamine (3.6, LOD <0.05 µg/mL), ketobemidone (3.3, LOD <0.05 µg/mL), ketoprofen (7.3, LOD 0.1 µg/mL), ketorolac (6.2, LOD 0.05 µg/mL), labetalol (4.9, LOD 0.05 µg/mL), lamotrigine (4.0, LOD 0.1 µg/mL), levocabastine (5.8, LOD 0.01 µg/mL), levomepromazine (6.5, LOD 0.02 µg/mL), lidocaine (3.7, LOD <0.05 µg/mL), loratadine (9.3, LOD 0.002 µg/mL), lorazepam (6.6, LOD 0.02 µg/mL), lormetazepam (7.4, LOD <0.02 µg/mL), LSD (4.7, LOD <0.02 µg/mL), malathion (8.9, LOD 10 µg/mL), maprotiline (6.4, LOD <0.02 µg/mL), MDMA (3.3, LOD 0.02 µg/mL), meclozine (8.5, LOD <0.02 µg/mL), medazepam (6.3, LOD <0.02 µg/mL), meloxicam (7.1, LOD 0.01 µg/mL), melperone (5.0, LOD <0.02 µg/mL), meperidine (4.7, LOD <0.02 µg/mL), mepivacaine (3.7, LOD <0.02 µg/mL), meprobamate (4.9, LOD 0.1 µg/mL), mesoridazine (5.4, LOD <0.02 µg/mL), methamphetamine (3.3, LOD 0.05 µg/mL), methadone (6.7, LOD <0.02 µg/mL), methylparathion (8.6, LOD 10 µg/mL), methylphenidate (4.2, LOD <0.02 µg/mL), metoclopramide (3.8, LOD <0.02 µg/mL), metoprolol (4.1, LOD 0.02 µg/mL), metronidazole (2.6, LOD 1 µg/mL), mexiletine (4.4, LOD 0.05 µg/mL), mianserin (5.7, LOD <0.02 µg/mL), midazolam (5.9, LOD <0.02 µg/mL), mirtazapine (4.4, LOD <0.02 µg/mL), moclobemide (3.7, LOD 0.05 µg/mL), molindone (4.0, LOD <0.02 µg/mL), monoacetylmorphine (2.7, LOD 0.1 µg/mL), morphine (2.0, LOD 0.1 µg/mL), nicotine (2.2, LOD 0.05 µg/mL), nifedipine (7.5, LOD 0.02 µg/mL), nikethamide (3.6, LOD <0.02 µg/mL), nitrazepam (6.5, LOD <0.02 µg/mL), nizatidine (1.7, LOD 1 µg/mL), nomifensine (4.6, LOD <0.02 µg/mL), nortriptyline (6.4, LOD <0.02 µg/mL), norverapamil (6.2, LOD 1 µg/mL), noscapine (5.0, LOD <0.02 µg/mL), olanzapine (3.0, LOD 0.05 µg/mL), ondansetron (4.6, LOD <0.02 µg/mL), orphenadrine (6.1, LOD <0.02 µg/mL), oxazepam (6.3, LOD <0.02 µg/mL), oxcarbazepine (5.3, LOD 0.02 µg/mL), oxprenolol (4.7, LOD 0.02 µg/mL), oxycodone (2.8, LOD 0.05 µg/mL), papaverine (4.8, LOD <0.02 µg/mL), acetaminophen (2.5, LOD <5 µg/mL), paroxetine (6.2, LOD 0.02 µg/mL), pemoline (3.3, LOD 0.05 µg/mL), pentazocine (5.0, LOD <0.02 µg/mL), pentifylline (7.3, LOD <5 µg/mL), pentoxyverine (6.6, LOD <0.02 µg/mL), perphenazine (6.9, LOD 0.002 µg/mL), phenazone (3.9, LOD 0.05 µg/mL), phencyclidine (5.3, LOD 0.05 µg/mL), pheniramine 408 Mizolastine (4.1, LOD 0.02 µg/mL), phenylbutazone (9.0, LOD <5 µg/mL), phenylpropanolamine (2.5, LOD 0.3 µg/mL), phenytoin (6.1, LOD 0.05 µg/mL), pindolol (3.3, LOD 0.05 µg/mL), piroxicam (6.6, LOD 0.02 µg/mL), pitofenone (5.4, LOD <0.02 µg/mL), pizotifen (6.5, LOD <0.02 µg/mL), practolol (1.8, LOD 0.1 µg/mL), prazosin (4.1, LOD 0.05 µg/mL), prilocaine (3.8, LOD <0.02 µg/mL), primidone (4.0, LOD <5 µg/mL), procainamide (2.2, LOD 0.05 µg/mL), prochlorperazine (7.5, LOD 0.02 µg/mL), promazine (6.2, LOD <0.02 µg/mL), promethazine (6.0, LOD 0.05 µg/mL), propafenone (6.3, LOD <0.02 µg/mL), propranolol (5.4, LOD 0.02 µg/mL), propyphenazone (6.6, LOD 0.50 µg/mL), pseudoephedrine (2.6, LOD 1 µg/mL), quinine (4.2, LOD 0.02 µg/mL), ranitidine (1.8, LOD 0.1 µg/mL), risperidone (4.9, LOD <0.02 µg/mL), rocurone (3.8, LOD 0.1 µg/mL), ropivacaine (4.6, LOD <0.02 µg/mL), salicylamide (4.2, LOD <5 µg/mL), selegiline (4.1, LOD 0.05 µg/mL), sertindole (7.2, LOD <0.02 µg/mL), sertraline (6.8, LOD 0.02 µg/mL), sulindac (6.5, LOD 0.02 µg/mL), simazine (6.0, LOD 0.1 µg/mL), sincocaine (6.5, LOD <0.02 µg/mL), sisapride (5.9, LOD <0.02 µg/mL), sotalol (2.1, LOD 0.1 µg/mL), strychnine (5.3, LOD 0.05 µg/mL), sulpiride (1.9, LOD 0.1 µg/mL), sulthiame (4.1, LOD 0.05 µg/mL), temazepam (7.2, LOD <0.02 µg/mL), terbutaline (2.3, LOD 0.1 µg/mL), terfenadine (8.1, LOD 0.002 µg/mL), terodiline (6.7, LOD <0.02 µg/mL), tetracaine (5.7, LOD <0.02 µg/mL), dronabinol (12.3, LOD 0.05 µg/mL), tetrahydrozoline (3.6, LOD 0.1 µg/mL), theobromine (2.3, LOD <5 µg/mL), theophylline (2.4, LOD <5 µg/mL), thioridazine (7.5, LOD 0.02 µg/mL), timolol (3.8, LOD 0.05 µg/mL), thiothixene (6.7, LOD 0.02 µg/mL), tolbutamide (7.1, LOD <5 µg/mL), toremifene (8.7, LOD 0.02 µg/mL), tramadol (4.2, LOD 0.02 µg/mL), trazodone (5.2, LOD <0.02 µg/mL), triamterene (3.2, LOD 0.1 µg/mL), triazolam (6.7, LOD 0.002 µg/mL), trimeprazine (6.4, LOD <0.02 µg/mL), trimethoprim (3.1, LOD 0.05 µg/mL), trimipramine (6.7, LOD <0.02 µg/mL), venlafaxine (4.9, LOD 0.02 µg/mL), verapamil (6.5, LOD <0.02 µg/mL), warfarin (7.9, LOD <0.02 µg/mL), yohimbine (4.5, LOD <0.02 µg/mL), zolpidem (4.7, LOD <0.02 µg/mL), zopiclone (4.0, LOD 0.1 µg/mL) KEY WORDS whole blood REFERENCE Gergov, M.; Ojanperä, I.; Vuori, E. Simultaneous screening for 238 drugs in blood by liquid chromatography-ionspray tandem mass spectrometry with multiple-reaction monitoring, J.Chromatogr.B, 2003, 795, 41–53. SAMPLE Matrix: blood Sample preparation: Mix 1 g plasma with 20 µL 15 µg/mL IS in MeOH, add 200 µL MeCN, vortex, centrifuge at 11 000 g for 4 min, inject a 200 µL aliquot onto column A and elute to waste with mobile phase A; after 2 min, backflush the contents of column A onto column B with mobile phase B; after 1.5 min, remove column A from the circuit, elute column B with mobile phase B, monitor the effluent from column B. Backflush column A with MeCN:water 50:50, MeCN, MeOH:water 50:50, re-equilibrate with mobile phase A. HPLC VARIABLES Column: A 75 × 2.1 30–40 µm Perisorb C18; B 20 × 4.6 40 µm Pelliguard C18 (Supelchem) + 150 × 4.6 5 µm Hypersil BDS C8 Mobile phase: A MeCN:water 10:90; B MeCN:25 mM pH 4.5 phosphate buffer 40:60 Flow rate: 1 Injection volume: 200 Detector: UV 285 CHROMATOGRAM Retention time: 6.6 Internal standard: SL 86.0116 (chloro analogue of mizolastine) (8.2) Limit of quantitation: 2.5 ng/mL Mizolastine 409 KEY WORDS column-switching; comparison with liquid–liquid extraction and SPE; plasma REFERENCE Ascalone, V.; Guinebault, P.; Rouchouse, A. Determination of mizolastine, a new antihistaminic drug, in human plasma by liquid-liquid extraction and column-switching techniques in combination with high-performance liquid chromatography, J.Chromatogr., 1993, 619, 275–284. SAMPLE Matrix: blood Sample preparation: Mix 1 g plasma with 20 µL 15 µg/mL IS in MeOH, add 500 µL 700 mM pH 9 borate buffer, add 7 mL diethyl ether, shake on a tumble extractor at 40 rpm for 10 min, centrifuge at 2000 g at 5◦ for 5 min. Remove the organic layer and add it to 25 mM pH 2.6 phosphate buffer, shake on a tumble extractor at 20 rpm for 10 min. Discard the organic layer, remove traces of ether from the aqueous layer with a stream of nitrogen at 40◦ , inject a 150 µL aliquot. (Prepare 700 mM pH 9 borate buffer by dissolving 6.18 g boric acid and 7.46 g KCl in 100 mL water and adjusting to pH 9 with ca. 50 mL 1 M NaOH.) HPLC VARIABLES Guard column: 20 × 4.6 40 µm Pelliguard C18 (Supelchem) Column: 150 × 4.6 5 µm Hypersil BDS C8 Mobile phase: MeCN:25 mM pH 2.5 phosphate buffer:triethylamine 35:65:0.1 Flow rate: 1 Injection volume: 150 Detector: UV 285 CHROMATOGRAM Retention time: 3.6 Internal standard: SL 86.0116 (chloro analogue of mizolastine) (4.6) Limit of quantitation: 0.5 ng/mL KEY WORDS comparison with column-switching and SPE; liquid–liquid extraction; plasma REFERENCE Ascalone, V.; Guinebault, P.; Rouchouse, A. Determination of mizolastine, a new antihistaminic drug, in human plasma by liquid-liquid extraction and column-switching techniques in combination with high-performance liquid chromatography, J.Chromatogr., 1993, 619, 275–284. SAMPLE Matrix: blood Sample preparation: Condition a 100 mg 40 µm Bakerbond CN SPE cartridge with 1 mL MeOH saturated with ammonium dihydrogen phosphate and 2 mL water. Mix 1 mL plasma with 500 µL 200 ng/mL IS in MeCN:water, mix, add a 1.4 mL aliquot to the SPE cartridge, wash twice with 2 mL portions of water, wash twice with 1 mL portions of MeOH:water 30:70, dry, elute with 600 µL MeOH saturated with ammonium dihydrogen phosphate, mix the eluate (ca. 300 µL) with 400 µL 50 mM pH 4.6 phosphate buffer, inject a 650 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Ultrabase C8 Mobile phase: MeCN:50 mM pH 4.6 phosphate buffer:triethylamine 45:55:0.1 Flow rate: 1 Injection volume: 650 Detector: UV 285 410 Mizolastine CHROMATOGRAM Retention time: 8 Internal standard: SL 86.0116 (chloro analogue of mizolastine) (10) Limit of quantitation: 1 ng/mL KEY WORDS comparison with column-switching and liquid–liquid extraction; plasma; SPE REFERENCE Ascalone, V.; Guinebault, P.; Rouchouse, A. Determination of mizolastine, a new antihistaminic drug, in human plasma by liquid-liquid extraction and column-switching techniques in combination with high-performance liquid chromatography, J.Chromatogr., 1993, 619, 275–284. Moexipril Moexipril H3C O O Molecular formula: C27 H34 N2 O7 N Molecular weight: 498.57 CAS Registry No: 103775-10-6, 82586-52-5 (HCl) Merck Index: 13, 6250 H HOOC CH3 411 OCH3 N OCH3 O SAMPLE Matrix: formulations Sample preparation: Inject an aliquot of a 50 µg/mL solution in water. HPLC VARIABLES Column: 5 µm Ultrasphere-ODS Mobile phase: MeCN:THF:50 mM pH 2 ammonium phosphate 35:10:55 Flow rate: 1 Detector: UV 220 OTHER SUBSTANCES Simultaneous: degradants KEY WORDS lyophilized powder REFERENCE Strickley, R.G.; Visor, G.C.; Lin, L.H.; Gu, L. An unexpected pH effect on the stability of moexipril lyophilized powder, Pharm.Res., 1989, 6, 971–975. 412 Mofezolac Mofezolac O N COOH Molecular formula: C19 H17 NO5 Molecular weight: 339.34 CAS Registry No: 78967-07-4 Merck Index: 13, 6254 H3CO OCH3 SAMPLE Matrix: blood, urine Sample preparation: Condition a Sep-Pak C18 SPE cartridge with 5 mL MeOH and 5 mL water. Plasma. Add 4 mL ice-cold MeCN to 500 µL plasma, vortex for 30 s, place on ice for 30 min, centrifuge refrigerated at 2000 g for 15 min. Evaporate the supernatant to dryness under a stream of nitrogen, reconstitute the residue with 2 mL water, add to the SPE cartridge, wash with 3 mL water, elute with 4 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with 100 µL MeOH, inject a 20 µL aliquot. Urine. Mix 1 mL urine with 1 mL 10 mM pH 7.0 phosphate buffer, add to the SPE cartridge, wash with 3 mL water, elute with 4 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with 200 µL MeOH:water 40:60, inject a 20 µL aliquot. (10 mM pH 7.0 Phosphate buffer was 35.81 g disodium hydrogen phosphate dodecahydrate and 13.61 g potassium dihydrogen phosphate in 1 L water, pH adjusted to 7.0 with NaOH or phosphoric acid.) HPLC VARIABLES Column: 150 × 6 5 µm Shimadzu Shim-pack CLC ODS Column temperature: 35 Mobile phase: Gradient. MeOH:20 mM pH 6.4 potassium dihydrogen phosphate buffer from 0:100 to 100:0 over 33 min. Flow rate: 1.5 Injection volume: 20 Detector: UV 254 CHROMATOGRAM Retention time: 23.9 Limit of detection: 10 ng/mL (plasma), 100 ng/mL (urine) OTHER SUBSTANCES Extracted: metabolites KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Marunaka, T.; Maniwa, M. High-performance of liquid chromatographic determination of [3,4-di(4-methoxyphenyl)-5-isoxazolyl]acetic acid and its metabolites in human plasma and urine, J.Chromatogr., 1987, 422, 227–233. 413 Mometasone furoate Mometasone furoate Cl HO Molecular formula: C27 H30 Cl2 O6 Molecular weight: 521.44 CAS Registry No: 83919-23-7 Merck Index: 13, 6264 O O CH3 O O CH3 Cl H CH3 H O SAMPLE Matrix: blood Sample preparation: Mix 400 µL plasma with IS, extract with 8 mL nchlorobutane:ethyl acetate 95:5. Evaporate the organic layer to dryness, reconstitute the residue with 35 µL MeOH, inject an 8 µL aliquot. HPLC VARIABLES Column: 33 × 4.6 3 µm LC-18-DB Mobile phase: MeOH:25 mM ammonium acetate 80:20 Flow rate: 1 Injection volume: 8 Detector: MS, PE Sciex API-III, positive ion daughter, m/z 355.0 CHROMATOGRAM Retention time: 24 Internal standard: betamethasone 17,21-dipropionate (m/z 279.3) Limit of quantitation: 49.7 pg/mL OTHER SUBSTANCES Extracted: mometasone (15), metabolites KEY WORDS pharmacokinetics; plasma REFERENCE Affrime, M.B.; Cuss, F.; Padhi, D.; Wirth, M.; Pai, S.; Clement, R.P.; Lim, J.; Kantesaria, B.; Alton, K.; Cayen, M.N. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers, J.Clin.Pharmacol., 2000, 40, 1227–1236. SAMPLE Matrix: blood, simulated gastric fluid, simulated intestinal fluid, simulated lung fluid Sample preparation: Mix 500 µL plasma, simulated gastric fluid, simulated intestinal fluid, or simulated lung fluid with 500 µL 10 µg/mL IS in EtOH, add 4 mL dichloromethane, mix on a roller mixer for 30 min, centrifuge at 2500 rpm for 15 min. Evaporate the organic layer to dryness under a stream of nitrogen at 37◦ , reconstitute the residue with 250 µL mobile phase, centrifuge at 15 000 rpm for 3 min, inject a 50 µL aliquot of the supernatant. HPLC VARIABLES Column: 150 × 4.6 5 µm Ultrasphere C8 Mobile phase: MeOH:water 59:41 Flow rate: 1.5 Injection volume: 50 Detector: UV 248 414 Mometasone furoate CHROMATOGRAM Retention time: 17 Internal standard: dexamethasone 21-acetate (7) Limit of detection: 50 ng/mL Limit of quantitation: 200 ng/mL OTHER SUBSTANCES Extracted: degradants Simultaneous: beclomethasone dipropionate (33.9), budesonide (12.3), fluticasone propionate (16.3), hydrocortisone (3.2), prednisone (2.7) KEY WORDS plasma REFERENCE Teng, X.W.; Foe, K.; Brown, K.F.; Cutler, D.J.; Davies, N.M. High-performance liquid chromatographic analysis of mometasone furoate and its degradation products. Application to in vitro degradation studies, J.Pharm.Biomed.Anal., 2001, 26, 313–319. ANNOTATED BIBLIOGRAPHY Teng, X.W.; Cutler, D.J.; Davies, N.M. Mometasone furoate degradation and metabolism in human biological fluids and tissues, Biopharm.Drug Dispos., 2003, 24, 321–333. [plasma; urine; microsomal incubations; lung tissue] 415 Monensin Monensin Molecular formula: C36 H62 O11 Molecular weight: 670.87 CAS Registry No: 17090-79-8 Merck Index: 13, 6270 H3C HO CH3 H3C H3CO H3C O H CH3 COOH O H H O H O CH3 H CH3 O CH3 HO OH SAMPLE Matrix: blood Sample preparation: Vortex 100 µL MeOH:water 80:20 and 400 µL trichloroacetic acid solution with 500 µL plasma, centrifuge at 4000 rpm for 4 min, filter (Spin-X) the supernatant, inject a 30 µL aliquot of the filtrate. (Prepare trichloroacetic acid solution as follows. Dissolve 85 g trichloroacetic acid in 15 mL water. Store this solution in the refrigerator. Dilute 150 µL of this solution with 100 mL acetone.) HPLC VARIABLES Guard column: C18 Column: 250 × 4.6 5 µm Supelco Discovery C18 Mobile phase: MeOH:10 mM ammonium acetate 85:15 Flow rate: 0.8 for 15 min, 1 for 10 min Injection volume: 30 Detector: MS, PE Sciex API 100 single quadrupole, turbo ionspray, turbo probe 150◦ , air 6 L/min, 50 µL/min flowed into detector, m/z 693.7 CHROMATOGRAM Retention time: 15 Limit of detection: 4 ng/mL Limit of quantitation: 8 ng/mL OTHER SUBSTANCES Extracted: lasalocid (10), narasin (23), salinomycin (20) KEY WORDS chicken; plasma REFERENCE Hormazábal, V.; Yndestad, M. Determination of amprolium, ethopabate, lasalocid, monensin, narasin, and salinomycin in chicken tissues, plasma, and egg using liquid chromatography-mass spectrometry, J.Liq.Chromatogr.Rel.Technol., 2000, 23, 1585–1598. 416 Morantel Morantel H3C N S Molecular formula: C12 H16 N2 S Molecular weight: 220.34 CAS Registry No: 20574-50-9, 26155-31-7 (tartrate) Merck Index: 13, 6289 N CH3 SAMPLE Matrix: abomasal fluid, blood, feces, intestinal fluid, ruminal fluid Sample preparation: Add 100 µL 50 µg/mL IS to 5 mL plasma, abomasal fluid, intestinal fluid, ruminal fluid or 5 g feces, mix, add 10 mL 200 mM ammonium hydroxide, add 30 mL chloroform (Caution! Chloroform is a carcinogen!), shake mechanically for 30 min, centrifuge at 2000 g for 15 min, filter (Whatman 1 PS) the chloroform layer. Add 3 mL 1 M sulfuric acid to the filtrate, shake for 15 min, centrifuge at 2000 g for 5 min. Remove a 1 mL aliquot, neutralize with 2 drops concentrated ammonium hydroxide, inject a 50 µL aliquot. HPLC VARIABLES Column: 10 µm Bondex C18 (Phenomenex) Mobile phase: MeCN:pH 3.5 ammonium acetate buffer 28:72 Flow rate: 1.3 Injection volume: 50 Detector: UV 318 CHROMATOGRAM Retention time: 5.64 Internal standard: pyrantel tartrate (3.97) Limit of detection: 25 ng/mL (plasma, ruminal fluid), 20 ng/mL (abomasal fluid, intestinal fluid), 50 ng/g (feces) KEY WORDS cow; plasma REFERENCE Lanusse, C.E.; Gascon, L.H.; Ranjan, S.; Prichard, R.K. Morantel tartrate release from a longacting intraruminal device in cattle: pharmacokinetics and gastrointestinal distribution, J.Vet.Pharmacol.Ther., 1992, 15, 117–123. Mosapride Mosapride 417 H3C O F Molecular formula: C21 H25 ClFN3 O3 Molecular weight: 421.90 CAS Registry No: 112885-41-3, 112885-42-4 (citrate) Merck Index: 13, 6306 O N H N NH2 Cl O SAMPLE Matrix: blood Sample preparation: Condition a Sep-Pak C18 SPE cartridge with two 3 mL portions of MeOH, two 3 mL portions of water, and two 2 mL portions of 20 mM pH 7.0 phosphate buffer. Mix 50 µL 100 µg/mL IS in water, 2 mL pH 7.0 sodium phosphate buffer, and 1 mL plasma, add to the SPE cartridge, wash with two 3 mL portions of water, elute with 2 mL MeOH, evaporate the eluate to dryness under reduced pressure at 50◦ , dissolve the residue in 400 µL MeOH:0.05% acetic acid 45:55, centrifuge at 5000 rpm for 10 min, inject a 180 µL aliquot. HPLC VARIABLES Guard column: 20 × 9 µBondapak C18 Column: 150 × 4 5 µm Shim-pack CLC-ODS (Shimadzu) Mobile phase: MeOH:0.05% acetic acid from 20:80 to 38.7:61.3 over 7 min, to 90:10 in 2 min, maintain at 90:10 for 4 min, from 90:10 to 20:80 in 0.5 min, maintain at 20:80 for 4.5 min. Flow rate: 1.3 Injection volume: 180 Detector: F ex 314 em 354 CHROMATOGRAM Retention time: 13 Internal standard: AD-9675 ((+)-4-amino-5-chloro-2-ethoxy-N-[[4-propyl-2-morpholinyl]methyl]benzamide citrate) (10.5) OTHER SUBSTANCES Extracted: metabolites KEY WORDS plasma; rat; SPE REFERENCE Yokoyama, I.; Mizuki, Y.; Yamaguchi, T.; Fujii, T. Simultaneous enantiomeric determination of a gastroprokinetic agent mosapride citrate and its metabolite in plasma using α1 -acid glycoprotein HPLC column, J.Pharm.Biomed.Anal., 1997, 15, 1527–1535. SAMPLE Matrix: formulations Sample preparation: Let powdered 50 mg tablet stand in 25 mL MeOH for 6 h with occasional sonication, filter (0.45 µm). Dilute the filtrate to 10 µg/mL with mobile phase. HPLC VARIABLES Guard column: 20 mm long Pelliguard LC-18 (Supelco) Column: 150 × 4.6 5 µm RP C-18 418 Mosapride Column temperature: 40 Mobile phase: MeOH:20 mM pH 4.0 potassium phosphate buffer 70:30 Flow rate: 1.1 Injection volume: 20 Detector: UV 274 CHROMATOGRAM Retention time: 6.1 Internal standard: risperidone (4.1) KEY WORDS tablets REFERENCE Krishnaiah, Y.S.R.; Murthy, T.K.; Sankar, D.G.; Satyanarayana, V. The determination of mosapride citrate in bulk drug samples and pharmaceutical dosage forms using HPLC, Anal.Sci., 2002, 18, 1269–1271. SAMPLE Matrix: solutions Sample preparation: Inject a 100 µL aliquot of a solution in 200 µL 20 mM disodium hydrogen phosphate:20 mM citric acid 65:35. HPLC VARIABLES Guard column: 10 × 3 Chiral AGP Column: 100 × 4 10 µm Chiral AGP (Chrom Tech) Mobile phase: Gradient. A was MeOH. B was 20 mM disodium hydrogen phosphate. C was 20 mM citric acid. A:B:C for 0:65:35 for 4 min, to 5:60:35 over 6 min, maintain at 5:60:35 for 3 min, to 15:48:37 over 1 min, to 25:40:35 over 11 min, to 0:65:35 over 1 min, maintain at 0:65:35 for 4 min. (The pH of the mobile phase was 4.4 between 4 and 6 min and 5.0 between 20 and 22 min.) Flow rate: 1 Injection volume: 100 Detector: F ex 314 em 354 CHROMATOGRAM Retention time: 20.8 (R), 21.8 (S) Internal standard: AD-9675 ((+)-4-amino-5-chloro-2-ethoxy-N-[[4-propyl-2-morpholinyl]methyl]benzamide citrate) (9.5) KEY WORDS chiral REFERENCE Yokoyama, I.; Mizuki, Y.; Yamaguchi, T.; Fujii, T. Simultaneous enantiomeric determination of a gastroprokinetic agent mosapride citrate and its metabolite in plasma using α1 -acid glycoprotein HPLC column, J.Pharm.Biomed.Anal., 1997, 15, 1527–1535. ANNOTATED BIBLIOGRAPHY Itoh, H.; Nagano, T.; Takeyama, M. Effects of mosapride citrate on human plasma levels of motilin, gastrin, somatostatin, and secretin, Biol.Pharm.Bull., 2001, 24, 1072–1075. [LOQ 10 ng/mL] Karlsson, A.; Aspegren, A. The use of mobile phase pH and column temperature to reverse the retention order of enantiomers on Chiral-AGP, Chromatographia, 1998, 47, 189–196. Mosapride 419 Krishnaiah, Y.S.R.; Murthy, T.K.; Sankar, D.C.; Satyanarayana, V. A validated RP-HPLC method for the determination of mosapride citrate in bulk drug samples and pharmaceutical formulations, Pharmazie, 2002, 57, 814–816. Kumar, Y.R.; Babu, J.M.; Sarma, M.S.P.; Seshidhar, B.; Reddy, S.S.; Reddy, G.S.; Vyas, K. Application of LC-MS/MS for the identification of a polar impurity in mosapride, a gastroprokinetic drug, J.Pharm.Biomed.Anal., 2003, 32, 361–368. 420 Moxifloxacin Moxifloxacin Molecular formula: C21 H24 FN3 O4 Molecular weight: 401.43 CAS Registry No: 151096-09-2 Merck Index: 13, 6316 H OCH3 N H N N H F COOH O SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 30 mg OASIS HLB SPE cartridge with 1 mL MeOH and 1 mL water. Mix 1 mL plasma with 100 µL 500 ng/mL IS in water, add to the SPE cartridge, wash with two 1 mL portions of water, elute with 1 mL MeOH:trifluoroacetic acid 99.9:0.1. Evaporate the eluate to dryness under reduced pressure, reconstitute the residue with 100 µL mobile phase, inject a 10 µL aliquot. HPLC VARIABLES Column: 100 × 4.6 5 µm Hypersil C18 Mobile phase: MeCN:0.1% formic acid 40:60 Flow rate: 1 Injection volume: 10 Detector: MS, PE Sciex API 3000, TurboIonSpray, positive ion mode, source 400◦ , ionspray 3500 V, declustering 65 V, focusing 300 V, collision energy 20 eV, collision gas nitrogen, column effluent split 1:5 before entering the detector, m/z 402–384 CHROMATOGRAM Retention time: 2.75 Internal standard: lomefloxacin (m/z 352–308) (2.32) Limit of detection: 50 pg/mL Limit of quantitation: 1 ng/mL KEY WORDS plasma; SPE REFERENCE Vishwanathan, K.; Bartlett, M.G.; Stewart, J.T. Determination of moxifloxacin in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry, J.Pharm.Biomed.Anal., 2002, 30, 961–968. SAMPLE Matrix: blood, tissue Sample preparation: Condition a 1 mL 30 mg OASIS HLB SPE cartridge with 1 mL MeOH and 1 mL water. Homogenize (Ultra Turrax) 250 mg lung tissue with 2.5 mL PBS, centrifuge at 3080 g for 15 min. Mix 1.2 mL plasma or lung homogenate with 300 µL 10 µg/mL IS in water, add a 1.5 mL aliquot to the SPE cartridge, wash with 1 mL water, dry with air, elute with 1 mL MeOH:trifluoroacetic acid 99.9:0.1. Evaporate the eluate to dryness under a stream of nitrogen at 50◦ , reconstitute the residue with 500 µL mobile phase, inject a 50 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Supelcosil ABZ+ Mobile phase: MeCN:buffer 18:82 (The buffer was 10 mM potassium dihydrogen phosphate adjusted to pH 4 with orthophosphoric acid.) Flow rate: 1.25 Moxifloxacin 421 Injection volume: 50 Detector: UV 296 CHROMATOGRAM Retention time: 6.2 Internal standard: enrofloxacin (3.5) Limit of detection: 6.5 ng/mL (plasma), 50 ng/g (lung) Limit of quantitation: 30 ng/mL (plasma), 400 ng/g (lung) KEY WORDS lung; plasma; SPE REFERENCE Lemoine, T.; Breilh, D.; Ducint, D.; Dubrez, J.; Jougon, J.; Velly, J.F.; Saux, M.C. Determination of moxifloxacin (BAY 12–8039) in plasma and lung tissue by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method with a new polymeric cartridge, J.Chromatogr.B, 2000, 742, 247–254. SAMPLE Matrix: blood, vitreous humor Sample preparation: Serum. Rotate 400 µL serum with 3.2 mL dichloromethane at 20 rpm for 10 min, shake for 1 min. Shake the organic layer with 200 µL 20 mM pH 2.0 orthophosphoric acid for 1 min, centrifuge at 2000 g at 10◦ for 10 min, inject a 20 µL aliquot of the aqueous layer. Vitreous humor. Centrifuge vitreous humor briefly, inject a 20 µL aliquot. HPLC VARIABLES Column: 75 × 4.6 3 µm Ultrasphere C18 Mobile phase: MeCN:buffer 12:88 (serum) or 10:90 (vitreous humor) (The buffer was 5 mM tetrabutylammonium bromide adjusted to pH 1.8 with phosphoric acid.) Flow rate: 1.5 Injection volume: 20 Detector: UV 296 CHROMATOGRAM Limit of detection: 10 ng/mL KEY WORDS rabbit; serum REFERENCE Bronner, S.; Jehl, F.; Peter, J.-D.; Ploy, M.-C.; Renault, C.; Arvis, P.; Monteil, H.; Prevost, G. Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors, Antimicrob.Agents Chemother., 2003, 47, 1621–1629. ANNOTATED BIBLIOGRAPHY Ba, B.B.; Etienne, R.; Ducint, D.; Quentin, C.; Saux, M.-C. Determination of moxifloxacin in growth media by high-performance liquid chromatography, J.Chromatogr.B, 2001, 754, 107–112. [fluorescence detection; LOQ 50 ng/mL] Djabarouti, S.; Boselli, E.; Allaouchiche, B.; Ba, B.; Nguyen, A.T.; Gordien, J.B.; Bernadou, J.M.; Saux, M.C.; Breilh, D. Determination of levofloxacin in plasma, bronchoalveolar lavage and bone tissues by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method, J.Chromatogr.B, 2004, 799, 165–172. [SPE; moxifloxacin is internal standard] 422 Moxifloxacin Liang, H.; Kays, M.B.; Sowinski, K.M. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma, J.Chromatogr.B, 2002, 772, 53–63. Paillard, D.; Grellet, J.; Dubois, V.; Saux, M.-C.; Quentin, C. Discrepancy between uptake and intracellular activity of moxifloxacin in a Staphylococcus aureus-human THP-1 monocytic cell model, Antimicrob.Agents Chemother., 2002, 46, 288–293. [column-switching; fluorescence detection; LOD 1 ng/mL] Stass, H.; Dalhoff, A. Determination of BAY 12–8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing, J.Chromatogr.B, 1997, 702, 163–174. Tobin, C.M.; Sunderland, J.; White, L.O.; MacGowan, A.P.; Reeves, D.S. An isocratic high performance liquid chromatography (HPLC) assay for moxifloxacin, a new 8-methoxyquinolone, J.Antimicrob.Chemother., 1998, 42, 278–279. Wallace, A.W.; Victory, J.M.; Amsden, G.W. Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers, J.Clin.Pharmacol., 2003, 43, 92–96. [moxifloxacin is internal standard] Xuan, D.; Zhong, M.; Mattoes, H.; Bui, K.Q.; McNabb, J.; Nicolau, D.P.; Quintiliani, R.; Nightingale, C.H. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model, Antimicrob.Agents Chemother., 2001, 45, 794–799. [serum; fluorescence detection; LOQ 100 ng/mL; ciprofloxacin is IS] 423 Moxonidine Moxonidine OCH3 H Molecular formula: C9 H12 ClN5 O Molecular weight: 241.68 CAS Registry No: 75438-57-2 Merck Index: 13, 6318 H3C N N N N Cl N H SAMPLE Matrix: blood, urine Sample preparation: Plasma. Condition a 10 mm 6 mL SPE disk (3M Empore) with MeOH and water. Mix 1 mL plasma with 1 mL water at 0◦ , add 10 ng IS, add to the SPE disk, wash with MeOH:water 15:85, elute with MeOH:water:trifluoroacetic acid 95:5:3. Evaporate the eluate to dryness under reduced pressure at 45◦ , reconstitute the residue with 150 µL 100 mM ammonium acetate, inject a 125 µL aliquot. Urine. Condition a 1 mL Bakerbond carboxylic acid SPE cartridge with MeOH and water. Mix 1 mL urine with 1 mL water, add 100 ng IS, vortex, add to the SPE cartridge, wash with 1 mL water, wash with 1 mL MeOH:water 50:50, elute with MeOH:water:trifluoroacetic acid 95:5:3. Evaporate the eluate to dryness under reduced pressure at 45◦ , reconstitute the residue with 150 µL 100 mM ammonium acetate, inject a 60 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Supelcosil C18 LC-ABZ Mobile phase: Gradient. MeCN:25 mM pH 5 ammonium acetate 0:100 for 2 min, to 4:96 over 20 min, maintain at 4:96 for 4 min, return to initial conditions over 1 min. Flow rate: 1 Injection volume: 60–125 Detector: MS, PE Sciex API-III Plus, APCI, heated nebulizer, 25% of column effluent entered the detector, m/z 242–44 CHROMATOGRAM Retention time: 27 Internal standard: clonidine (m/z 230–213) Limit of quantitation: 50 pg/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS plasma; SPE REFERENCE He, M.M.; Abraham, T.L.; Lindsay, T.J.; Schaefer, H.C.; Pouliquen, I.J.; Payne, C.; Czeskis, B.; Shipley, L.A.; Oliver, S.D.; Mitchell, M.I. Metabolism and disposition of the antihypertensive agent moxonidine in humans, Drug Metab.Dispos., 2003, 31, 334–342. Nadifloxacin HO CH3 N N Molecular formula: C19 H21 FN2 O4 Molecular weight: 360.38 CAS Registry No: 124858-35-1 Merck Index: 13, 6371 F COOH O SAMPLE Matrix: blood Sample preparation: Shake 1 mL plasma, 10 µL 100 ng/mL IS in MeOH, 1 mL 25 mM pH 6.86 phosphate buffer, and 5 mL chloroform for 10 min (Caution! Chloroform is a carcinogen!), centrifuge at 1800 g for 10 min. Remove a 3.5 mL aliquot of the lower chloroform layer and evaporate it to dryness under a stream of air at 40◦ , reconstitute the residue with 120 µL MeOH, inject a 40 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm TSK-gel ODS-80TM Mobile phase: MeCN:THF:25 mM pH 5.5 ammonium phosphate buffer 35:3:65 Flow rate: 1 Injection volume: 40 Detector: UV 295 CHROMATOGRAM Retention time: 6.8 Internal standard: OPC-7258 (9-fluoro-6,7-dihydro-5-methyl-8-morpholinyl-1-oxo-1H, 5H-benzo[i,j]quinolizine-2-carboxylic acid) (11.3) Limit of detection: 1 ng/mL Limit of quantitation: 5 ng/mL KEY WORDS human; pharmacokinetics; plasma; rat REFERENCE Koike, M.; Akiyama, H.; Shimizu, T. High-performance liquid chromatographic procedure for the determination of rat plasma concentrations of a new antibacterial agent, (±)-9-fluoro-6,7-dihydro-8(4-hydroxy-1-piperidyl)-5-methyl-1-oxo-1H,5H- benzo[i, j]quinolizine-2-carboxylic acid, for topical use, J.Chromatogr., 1990, 526, 235–239. 424 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 425 Naftopidil Naftopidil O N OH N Molecular formula: C24 H28 N2 O3 Molecular weight: 392.49 CAS Registry No: 57149-07-2 Merck Index: 13, 6382 H3CO SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma, 10 µL 5 µg/mL IS in MeOH, 500 µL 1 M pH 9.2 dipotassium hydrogen phosphate buffer, and 8 mL diethyl ether, rotate for 10 min. Add 5 mL of the organic layer to 300 µL 50 mM sulfuric acid, rotate for 10 min, centrifuge at 1000 g, discard the organic layer, remove traces of ether from the aqueous layer with a stream of nitrogen for 30 s. Remove a 250 µL aliquot of the aqueous layer and add it to 50 µL 1 M pH 9.2 dipotassium hydrogen phosphate buffer, mix, inject a 100 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm RP-LiChrosorb Select B (Hibar) Mobile phase: MeCN:MeOH:buffer 22.5:22.5:55 (The buffer was 20 mM potassium dihydrogen phosphate adjusted to pH 1.8 with phosphoric acid.) Flow rate: 0.8 Injection volume: 100 Detector: F ex 215 em 320 CHROMATOGRAM Retention time: 9.3 Internal standard: carvedilol (7.7) Limit of detection: 1 ng/mL Limit of quantitation: 2 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS pharmacokinetics; plasma REFERENCE Niebch, G.; Borbe, H.O.; Besenfelder, E. High-performance liquid chromatography of naftopidil, a novel antihypertensive drug, and two metabolites in human plasma, J.Chromatogr., 1990, 534, 247–252. SAMPLE Matrix: tissue Sample preparation: Mix 200 mg frozen (−80◦ ) tissue with 100 µL 1.16 µg/mL IS in MeOH:water 50:50 and 200 µL water in a PTFE tube precooled in liquid nitrogen, homogenize (Braun microdismembrator), pour the contents into a centrifuge tube, wash in with 500 µL water, wash in with 500 µL acetone, vortex for 2 min, centrifuge at 4000 rpm at 4◦ for 20 min. Evaporate the supernatant to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 1 mL 500 mM pH 3.5 potassium acetate buffer, centrifuge, add the supernatant dropwise to a 1 mL 100 mg 40 µm Bond-Elut cyano SPE cartridge, wash twice with 1 mL portions of water, elute with two 250 µL aliquots of MeCN:100 mM pH 5 potassium acetate buffer 80:20, inject a 100 µL aliquot. 426 Naftopidil HPLC VARIABLES Guard column: 17 × 4 5 µm Spherisorb C6 Column: 150 × 4.6 5 µm Spherisorb C6 Mobile phase: MeCN:250 mM pH 4 potassium acetate buffer 65:35 Flow rate: 1 Injection volume: 100 Detector: F ex 285 em 360 CHROMATOGRAM Retention time: 5.4 Internal standard: naftopidil (5.4) Limit of quantitation: 10 pg/mg (S/N 10) (for carvedilol) OTHER SUBSTANCES Extracted: carvedilol (4.7) KEY WORDS heart; naftopidil is IS in original; SPE REFERENCE Behn, F.; Läer, S.; Scholz, H. Determination of carvedilol in human cardiac tissue by high-performance liquid chromatography, J.Chromatogr.Sci., 2001, 39, 121–124. 427 Nandrolone Nandrolone CH3 OH H H Molecular formula: C18 H26 O2 Molecular weight: 274.40 CAS Registry No: 434-22-0 Merck Index: 13, 6391 H H O SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg Bond Elut C1 SPE cartridge with 2 column vol of MeCN and 2 column vol of water. Mix 500 µL serum with 25 µL 5 µg/mL IS in MeCN, add 500 µL water, vortex for 5 s, add to the SPE cartridge, wash with 2 column vol of water, wash with 1 column vol of MeCN:water 10:90, elute with 1 mL MeCN:water 45:55, concentrate the eluate to 250 µL under a stream of nitrogen at 45◦ , inject a 50 µL aliquot. HPLC VARIABLES Guard column: 15 × 4.6 7 µm silica (Brownlee) Column: 220 × 4.6 5 µm silica (Brownlee) Column temperature: 60 Mobile phase: MeCN:100 mM pH 2.5 sodium phosphate buffer 15:85 Flow rate: 1 Injection volume: 50 Detector: UV 247 CHROMATOGRAM Retention time: 8.2 Internal standard: spironolactone (7.8) Limit of detection: 3 ng/mL OTHER SUBSTANCES Extracted: fluoxymesterone (5.4), methandrostenolone (9.3), methyltestosterone (9.6), stanozolol (UV 230; LOD 7 ng/mL) (12.7), testosterone (8.6), zeranol (UV 263) (3.6) KEY WORDS serum: SPE REFERENCE Lampert, B.L.; Stewart, J.T. Determination of anabolic steroids and zeranol in human serum by isocratic reverse phase HPLC on silica, J.Liq.Chromatogr., 1989, 12, 3231–3249. SAMPLE Matrix: blood, urine Sample preparation: Condition a 3 mL 500 mg Baker C18 SPE cartridge with 2.5 mL MeOH and 5 mL water. Serum. Mix 2 mL serum with 4 ng IS and 15 mL 150 mM pH 5 acetate buffer, sonicate for 5 min, add to the SPE cartridge, wash with 5 mL 150 mM pH 5 acetate buffer, wash with 10 mL water, wash with 2.5 mL MeOH:water 40:60, elute with 4 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with 100 µL MeOH, inject a 5 µL aliquot. Urine. Heat 2 mL urine, 10 ng IS, and 20 µL β-glucuronidase/aryl sulfatase (Helix pomatia) (Boehringer Mannheim) at 37◦ for 12 h, cool, add 15 mL 150 mM pH 5 acetate buffer, add to the SPE cartridge, wash with 5 mL 150 mM pH 5 acetate buffer, wash with 10 mL water, wash with 2.5 mL MeOH:water 40:60, elute with 4 mL MeOH. Evaporate the eluate to 428 Nandrolone dryness under a stream of nitrogen, reconstitute the residue with 100 µL MeOH, inject a 5 µL aliquot. HPLC VARIABLES Column: 250 × 2 5 µm Kingsorb C18 (Phenomenex) Mobile phase: MeCN:water 70:30 containing 2 mM ammonium acetate Flow rate: 0.15 Injection volume: 5 Detector: MS, PE Sciex API-III Plus triple quadrupole, APCI, positive ion mode, nebulizer gas air at 400 kPa, curtain gas nitrogen at 0.6 L/min, auxiliary gas air 1.5 L/min, collision gas argon, nebulizer 350◦ , discharge current 4 µA, orifice 90 V, m/z 275–83, 275–109 CHROMATOGRAM Retention time: 5.6 Internal standard: d2 -17β-testosterone (m/z 291–99) (6.1) Limit of quantitation: 100 pg/mL OTHER SUBSTANCES Extracted: 17α-nortestosterone (m/z 275–83, 275–109) (6.4), progesterone (m/z 315–97) (11.4), 17α-testosterone (m/z 289–107, 289–109) (7.2), 17β-testosterone (m/z 289–107, 289–109) (6.1) KEY WORDS cow; serum; SPE REFERENCE Draisci, R.; Palleschi, L.; Ferretti, E.; Lucentini, L.; Cammarata, P. Quantitation of anabolic hormones and their metabolites in bovine serum and urine by liquid chromatography-tandem mass spectrometry, J.Chromatogr.A, 2000, 870, 511–522. 429 Narasin Narasin Molecular formula: C43 H72 O11 CH3 H3C HOOC Molecular weight: 765.02 CAS Registry No: 55134-13-9 Merck Index: 13, 6445 H O CH3 H CH3 CH3 H3C O OH CH3 OH OH CH3 H O O O CH3 H O CH3 CH3 SAMPLE Matrix: blood Sample preparation: Vortex 100 µL MeOH:water 80:20 and 400 µL trichloroacetic acid solution with 500 µL plasma, centrifuge at 4000 rpm for 4 min, filter (Spin-X) the supernatant, inject a 30 µL aliquot of the filtrate. (Prepare trichloroacetic acid solution as follows. Dissolve 85 g trichloroacetic acid in 15 mL water. Store this solution in the refrigerator. Dilute 150 µL of this solution with 100 mL acetone.) HPLC VARIABLES Guard column: C18 Column: 250 × 4.6 5 µm Supelco Discovery C18 Mobile phase: MeOH:10 mM ammonium acetate 85:15 Flow rate: 0.8 for 15 min, 1 for 10 min Injection volume: 30 Detector: MS, PE Sciex API 100 single quadrupole, turbo ionspray, turbo probe 150◦ , air 6 L/min, 50 µL/min flowed into detector, m/z 693.7 CHROMATOGRAM Retention time: 23 Limit of detection: 5 ng/mL Limit of quantitation: 10 ng/mL OTHER SUBSTANCES Extracted: lasalocid (10), monensin (15), salinomycin (20) KEY WORDS chicken; plasma REFERENCE Hormazábal, V.; Yndestad, M. Determination of amprolium, ethopabate, lasalocid, monensin, narasin, and salinomycin in chicken tissues, plasma, and egg using liquid chromatography-mass spectrometry, J.Liq.Chromatogr.Rel.Technol., 2000, 23, 1585–1598. 430 Nartograstim Nartograstim Molecular formula: C850 H1344 N226 O245 S8 Molecular weight: 18905.67 CAS Registry No: 134088-74-7 Merck Index: 13, 4552 SAMPLE Matrix: solutions HPLC VARIABLES Column: TSK gel ODS-120T (Tosoh) Mobile phase: Gradient. MeCN:0.1% trifluoroacetic acid from 40:60 to 90:10 over 80 (?) min. Flow rate: 1 CHROMATOGRAM Retention time: 39 (oxidized form), 42 (reduced form) REFERENCE Yamasaki, M.; Konishi, N.; Yamaguchi, K.; Itoh, S.; Yokoo, Y. Purification and characterization of recombinant human granulocyte colony-stimulating factor (rhG-CSF) derivatives: KW-2228 and other derivatives, Biosci.Biotechnol.Biochem., 1998, 62, 1528–1534. Nateglinide Nateglinide Molecular formula: C19 H27 NO3 Molecular weight: 317.42 CAS Registry No: 105816-04-4 Merck Index: 13, 6454 431 COOH O N H CH3 CH3 SAMPLE Matrix: blood Sample preparation: Mix 50 µL plasma with 10 µL 5 µg/mL IS in MeOH and 100 µL MeCN for 10 min, centrifuge at 3000 g for 10 min. Evaporate the supernatant to dryness under a stream of nitrogen at 50◦ , reconstitute the residue with 30 µL mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Guard column: present but not specified Column: 250 × 3 5 µm ProntoSIL 120-5-C18 AQ (Bischoff) Column temperature: 50 Mobile phase: MeCN:MeOH:buffer 30:8:70 (The buffer was 100 mM potassium hydrogen phosphate (sic) adjusted to pH 4.0 with 30% KOH.) Flow rate: 1 Injection volume: 20 Detector: UV 210 CHROMATOGRAM Retention time: 14.1 Internal standard: carbamazepine (6.7) Limit of quantitation: 100 pg/mL KEY WORDS pharmacokinetics; plasma REFERENCE Bauer, S.; Störmer, E.; Kirchheiner, J.; Michael, C.; Brockmöller, J.; Roots, I. Rapid and simple method for the analysis of nateglinide in human plasma using HPLC analysis with UV detection, J.Pharm.Biomed.Anal., 2003, 31, 551–555. SAMPLE Matrix: blood Sample preparation: Mix 500 µL plasma with IS and 2 mL 50 mM pH 6.6 phosphate buffer, add to a conditioned (unspecified) Sep-Pak SPE cartridge, wash with two 3 mL portions of water, elute with 5 mL MeOH. Evaporate the eluate to dryness, reconstitute the residue with 250 µL mobile phase, mix, centrifuge, inject a 150 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Supelcosil LC-ABZ Mobile phase: MeCN:50 mM pH 6.27 phosphate buffer 35:65 Injection volume: 150 Detector: UV 210 CHROMATOGRAM Internal standard: N-(trans-4-t-butylcyclohexylcarbonyl)-D-phenylalanine Limit of quantitation: 50 ng/mL 432 Nateglinide KEY WORDS pharmacokinetics; plasma REFERENCE Weaver, M.L.; Orwig, B.A.; Rodriguez, L.C.; Graham, E.D.; Chin, J.A.; Shapiro, M.J.; McLeod, J.F.; Mangold, J.B. Pharmacokinetics and metabolism of nateglinide in humans, Drug Metab.Dispos., 2001, 29, 415–421. ANNOTATED BIBLIOGRAPHY Anderson, D.M.; Shelley, S.; Crick, N.; Buraglio, M. No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers, J.Clin.Pharmacol., 2002, 42, 1358–1365. [LOQ 50 ng/mL; SPE; column-switching] Choudhury, S.; Hirschberg, Y.; Filipek, R.; Lasseter, K.; McLeod, J.F. Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis, J.Clin.Pharmacol., 2000, 40, 634–640. [SPE; LOQ 25.8 ng/mL] Ono, I.; Matsuda, K.; Kanno, S. Determination of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine in human plasma by solid-phase extraction and column-switching high-performance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 1996, 678, 384–387. [LOQ 50 ng/mL] Ono, I.; Matsuda, K.; Kanno, S. Determination of N-(trans-4-isopropylcyclohexanecarbonyl)-D-phenylalanine and its metabolites in human plasma and urine by column-switching high-performance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 1997, 692, 397–404. Qi, M.; Wang, P.; Sun, Y.; Li, Y. Determination of the L-enantiomer of nateglinide in a bulk drug substance by chiral reversed-phase liquid chromatography, J.Liq.Chromatogr.Rel.Technol., 2003, 26, 1839–1845. [LOD (L) 300 ng/mL (D) 400 ng/mL; LOQ (L) 800 ng/mL (D) 1000 ng/mL] Nebivolol Nebivolol OH O H N 433 OH O Molecular formula: C22 H25 F2 NO4 Molecular weight: 405.43 CAS Registry No: 99200-09-6 Merck Index: 13, 6459 F F SAMPLE Matrix: solutions Sample preparation: Inject a 20 µL aliquot of a 100 µg/mL solution in EtOH. HPLC VARIABLES Column: 150 × 4.6 5 µm Chiralpak AD-RH Column temperature: 23 ± 1 Mobile phase: Isopropanol Flow rate: 0.5 Injection volume: 20 Detector: UV 220 CHROMATOGRAM Retention time: 13.17 (+), 17.45 (−) KEY WORDS chiral REFERENCE Aboul-Enein, H.Y.; Ali, I. HPLC enantiomeric resolution of nebivolol on normal and reversed amylose based chiral phases, Pharmazie, 2001, 56, 214–216. SAMPLE Matrix: urine Sample preparation: Mix 5 mL urine with 50 µL 10 µg/mL IS, add 500 µL 1 M pH 5.2 sodium acetate buffer, add 50 µL β-glucuronidase/aryl sulfatase (Helix pomatia) (Boehringer Mannheim), heat at 50◦ for 1 h, cool, add 500 mg sodium hydrogen carbonate:potassium carbonate 2:1, add 1 mL t-butanol, add 5 mL MTBE, add 1 g sodium sulfate, shake for 15 min, centrifuge for 10 min. Evaporate the organic layer to dryness under reduced pressure at 50◦ , reconstitute the residue with 50 µL MeCN, inject a 5 µL aliquot. HPLC VARIABLES Column: 55 × 4 3 µm Purospher STAR RP-18e (Merck) Column temperature: 25 Mobile phase: Gradient. A MeCN. B was pH 3.5 ammonium acetate buffer (4 mM ammonium acetate and 1% acetic acid). A:B from 0:100 to 80:20 over 4 min, re-equilibrate at initial conditions for 3 min. Flow rate: 1 Injection volume: 5 Detector: MS, PE Sciex API 2000 triple quadrupole, APCI, 10% of column effluent entered the detector, positive ionization, interface 400◦ , ionization 5.9 kV, m/z 151.0 CHROMATOGRAM Retention time: 3.82 Internal standard: bupranolol (216.1) Limit of detection: 10 ng/mL 434 Nebivolol OTHER SUBSTANCES Extracted: acebutolol (m/z 116.2), alprenolol (m/z 116.3), atenolol (m/z 145.1), betaxolol (m/z 116.1), befunolol(m/z 56.0), bisoprolol (m/z 116.3), bunitrolol (m/z 193.2) (2.97), butofilolol (m/z 256.4), carazolol (m/z 116.3), carteolol (m/z 237.3), carvedilol (m/z 100.2) (3.69), celiprolol (m/z 251.1), cloranolol (m/z 236.1), esmolol (m/z 145.1), indenolol (m/z 171.1), labetalol (m/z 91.1), levobunolol (m/z 236.3), mepindolol (m/z 116.2), metipranolol (m/z 116.2), metoprolol (m/z 116.2), moprolol (m/z 116.2), nadolol (m/z 254.4), nifenalol (m/z 165.2), oxprenolol (m/z 72.0), penbutolol (m/z 236.4), pindolol (m/z 116.2), propranolol (m/z 116.1), sotalol (m/z 133.2), talinolol (m/z 308.3) (3.83), timolol (m/z 261.2), toliprolol (m/z 147.2) REFERENCE Thevis, M.; Opfermann, G.; Schänzer, W. High speed determination of beta-receptor blocking agents in human urine by liquid chromatography/tandem mass spectrometry, Biomed.Chromatogr., 2001, 15, 393–402. ANNOTATED BIBLIOGRAPHY Ali, I.; Aboul-Enein, H.Y. Enantioseparation of some clinically used drugs by HPLC using cellulose Tris (3,5-dichlorophenylcarbamate) chiral stationary phase, Biomed.Chromatogr., 2003, 17, 113–117. [metoprolol; teratolol; tolamolol; nebivolol; econazole; miconazole; cromakalim; etodolac] Woestenborghs, R.; Embrechts, L.; Heykants, J. HPLC-fluorescence method for the determination of the new β1 -adrenoreceptor blocking agent nebivolol in human plasma, Methodol.Surv.Biochem.Anal., 1988, 18, 215–216. 435 Nelfinavir Nelfinavir H Molecular formula: C32 H45 N3 O4 S Molecular weight: 567.79 CAS Registry No: 159989-64-7, 159989-65-8 (mesylate) Merck Index: 13, 6471 CH3 O S O CH3 CH3 CH3 N HO N H N OH H H SAMPLE Matrix: blood Sample preparation: Condition an Extrasep C18 SPE cartridge (Lida) with 2 mL MeOH and 2 mL water. Dilute 500 µL serum with 500 µL water, add to the SPE cartridge, wash with 500 µL water, elute with 1 mL MeOH. Evaporate the eluate to dryness with vortexing under reduced pressure at 40◦ and reconstitute the residue with 300 µL MeOH, inject a 10 µL aliquot. HPLC VARIABLES Column: two 150 × 4.6 3 µm Luna C18 columns in series Column temperature: 60 Mobile phase: Gradient. MeCN:4 mM sulfuric acid from 8:92 to 63:37 over 45 min, maintain at 63:37 for 5 min. Flow rate: 0.85 Injection volume: 10 Detector: UV 265 for 31 min then UV 240 CHROMATOGRAM Retention time: 33.5 Limit of detection: 400 ng/mL OTHER SUBSTANCES Extracted: delavirdine (25.5, LOD 110 ng/mL), efavirenz (51, LOD 62 ng/mL), indinavir (24.5, LOD 210 ng/mL), nelfinavir (33.5, LOD 400 ng/mL), nevirapine (23.5, LOD 84 ng/mL), ritonavir (50.5, LOD 510 ng/mL), saquinavir (35, LOD 100 ng/mL) KEY WORDS SPE; serum REFERENCE Simon, V.A.; Thiam, M.D.; Lipford, L.C. Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography, J.Chromatogr.A, 2001, 913, 447–453. SAMPLE Matrix: blood Sample preparation: Mix 250 µL plasma with 50 µL MeOH, add 100 µL 2 µg/mL IS in MeOH, add 250 µL 1 M NaOH, add 3 mL hexane:ethyl acetate 50:50, shake at high speed for 25 min, centrifuge at 3000 g for 15 min. Evaporate the organic layer to dryness under a stream of air, reconstitute the residue with 1 mL initial mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Guard column: 10 × 2.1 Symmetry Shield 436 Nelfinavir Column: 30 × 2.1 3.5 µm Symmetry C18 Mobile phase: Gradient. MeCN:5 mM pH 3.25 acetate buffer from 25:75 to 80:20 over 4 min using a nonlinear gradient (not specified). Flow rate: 0.35 Injection volume: 20 Detector: MS, PE Sciex API 3000, turbo ionspray source, column effluent split 1:1 before entering source CHROMATOGRAM Retention time: 2.5 Internal standard: Abbott A-86093 (3.2) Limit of detection: 330 pg/mL Limit of quantitation: 16.3 ng/mL OTHER SUBSTANCES Extracted: amprenavir (2.7, LOQ 16.3 ng/mL, LOD 380 pg/mL), indinavir (2.0, LOQ 16.3 ng/mL, LOD 1.5 ng/mL), lopinavir (3.1, LOQ 16.3 ng/mL, LOD 750 pg/mL), ritonavir (2.9, LOQ 51.2 ng/mL, LOD 650 pg/mL), saquinavir (2.4, LOQ 16.3 ng/mL, LOD 780 pg/mL) KEY WORDS plasma REFERENCE Frerichs, V.A.; DiFrancesco, R.; Morse, G.D. Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry, J.Chromatogr.B, 2003, 787, 393–403. SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 200 µL 10 µg/mL IS in water, add 200 µL 100 mM NaOH, mix, add 4 mL diethyl ether, shake for 5 min, centrifuge at 2500 rpm for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 200 µL initial mobile phase, inject a 100 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 Stability RP18 (CIL, France) Mobile phase: Gradient. MeCN:50 mM pH 5.65 phosphate buffer from 36:64 to 64:36 over 25 min, to 80:20 (step gradient), maintain at 80:20 for 10 min, re-equilibrate at initial conditions for 5 min. Flow rate: 1.5 Injection volume: 100 Detector: UV 240 for 5 min, UV 215 for 22 min, UV 260 for rest of run CHROMATOGRAM Retention time: 24.1 Internal standard: JR051012 (Janssen Cilag) (28.2) Limit of quantitation: 50 ng/mL OTHER SUBSTANCES Extracted: amprenavir (11.2), efavirenz (19.9), indinavir (8.5), lopinavir (18.9), nevirapine (3.3), ritonavir (17.6), saquinavir (16.7) Noninterfering: acetaminophen, amineptine, amphotericin B, aspirin, bromazepam, buspirone, citalopram, clobazam, diazepam, didanosine, fluconazole, flunitrazepam, fluvoxamine, hydroxyitraconazole, isoniazid, itraconazole, lamivudine, loprazolam, lorazepam, metronidazole, minalcipram, nordiazepam, omeprazole, paroxetine, pyrimethamine, rifampin, sertraline, stavudine, sulfadiazine, trimethoprim, venlafaxine, zalcitabine, zidovudine, zolpidem, zopiclone Nelfinavir 437 KEY WORDS plasma REFERENCE Titier, K.; Lagrange, F.; Péhourcq, F.; Edno-Mcheik, L.; Moore, N.; Molimard, M. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma, Ther.Drug Monit., 2002, 24, 417–424. SAMPLE Matrix: blood Sample preparation: Briefly vortex 250 µL 1 µg/mL IS in MeOH with 250 µL plasma, add 500 µL 100 mM pH 10.5 ammonium hydroxide, vortex, add 2 mL MeCN:ethyl acetate 10:90, vortex for 4 min, centrifuge at 2060 g, evaporate the organic layer to dryness under a stream of nitrogen at 50◦ , reconstitute with 150 µL mobile phase, vortex for 2 min, inject a 100 µL aliquot. HPLC VARIABLES Guard column: Nova-Pak C18 Column: 250 × 4.6 5 µm Symmetry C18 (Waters) Mobile phase: MeCN:25 mM sodium dihydrogen phosphate adjusted to pH 3.4 with phosphoric acid 42:58 Flow rate: 1.3 Injection volume: 100 Detector: UV 220 CHROMATOGRAM Retention time: 8.2 Internal standard: 6,7-dimethyl-2,3-di(2-pyridyl)quinoxaline (9.9) Limit of quantitation: 50 ng/mL KEY WORDS plasma REFERENCE Wu, E.Y.; Wilkinson, J.M.I.I.; Naret, D.G.; Daniels, V.L.; Williams, L.J.; Khalil, D.A.; Shetty, B.V. Highperformance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma, J.Chromatogr.B, 1997, 695, 373–380. ANNOTATED BIBLIOGRAPHY Aymard, G.; Legrand, M.; Trichereau, N.; Diquet, B. Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography, J.Chromatogr.B, 2000, 744, 227–240. [amprenavir; efavirenz; indinavir; nelfinavir; ritonavir; saquinavir; abacavir; didanosine; lamivudine; stavudine; nevirapine; zidovudine; column-switching; SPE; LOQ 5–100 ng/mL] Bouley, M.; Briere, C.; Padoin, C.; Petitjean, O.; Tod, M. Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography, Ther.Drug Monit., 2001, 23, 56–60. [LOQ 25–250 ng/mL] Chi, J.; Jayewardene, A.L.; Stone, J.A.; Motoya, T.; Aweeka, F.T. Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS, J.Pharm.Biomed.Anal., 2002, 30, 675–684. [LOQ 5 ng/mL] Cociglio, M.; Hillaire-Buys, D.; Peyrière, H.; Alric, R. Performance analysis of a rapid HPLC determination with the solvent demixing extraction of HIV antiproteases and efavirenz in plasma, J.Chromatogr.Sci., 2003, 41, 80–86. [LOD 1–175 ng/mL] Dailly, E.; Thomas, L.; Kergueris, M.F.; Jolliet, P.; Bourin, M. High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, 438 Nelfinavir ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction, J.Chromatogr.B, 2001, 758, 129–135. [LOQ 50–400 ng/mL] Droste, J.A.H.; Verweij-van Wissen, C.P.W.G.M.; Burger, D.M. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography, Ther.Drug Monit., 2003, 25, 393–399. [LOQ 50–70 ng/mL] Faux, J.; Venisse, N.; Le Moal, G.; Dupuis, A.; Bouquet, S. Simultaneous determination of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography after solid-phase extraction, Chromatographia, 2003, 58, 421–426. [LOQ 50 – 120 ng/mL; amprenavir; indinavir; lopinavir; nelfinavir; ritonavir; saquinavir; efavirenz; nevirapine; prazepam is internal standard] Hugen, P.W.H.; Verweij-van Wissen, C.P.W.G.M.; Burger, D.M.; Wuis, E.W.; Koopmans, P.P.; Hekster, Y.A. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography, J. Chromatogr.B, 1999, 727, 139–149. [LOQ 45 ng/mL] Janoly, A.; Bleyzac, N.; Favetta, P.; Gagneu, M.C.; Bourhis, Y.; Coudray, S.; Oger, I.; Aulagner, G. Simple and rapid high-performance liquid chromatographic method for nelfinavir, M8 nelfinavir metabolite, ritonavir and saquinavir assay in plasma, J.Chromatogr.B, 2002, 780, 155–160. [LOD 200 ng/mL] Justesen, U.S.; Pedersen, C.; Klitgaard, N.A. Simultaneous quantitative determination of the HIV protease inhibitors indinavir, amprenavir, ritonavir, lopinavir, saquinavir, nelfinavir and the nelfinavir active metabolite M8 in plasma by liquid chromatography, J.Chromatogr.B, 2003, 783, 491–500. [LOQ 25 ng/mL] Keil, K.; Frerichs, V.A.; DiFrancesco, R.; Morse, G. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma, Ther.Drug Monit., 2003, 25, 340–346. [LOQ 100–200 ng/mL] Lamotte, C.; Peytavin, G.; Farinotti, R. Determination of nelfinavir, a potent HIV protease inhibitor, and its active metabolite M8 in human plasma by high-performance liquid chromatography with photodiode-array detection, J.Chromatogr.B, 1999, 735, 159–170. [LOQ 25 ng/mL] Poirier, J.-M.; Radembino, N.; Robidou, P.; Jaillon, P. Simultaneous determination of the five HIVprotease inhibitors: Amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by solid-phase extraction and column liquid chromatography, Ther.Drug Monit., 2000, 22, 465–473. [LOQ 25 ng/mL] Poirier, J.-M.; Robidou, P.; Jaillon, P. Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography, Ther.Drug Monit., 2002, 24, 302–309. [LOQ 25 ng/mL] Proust, V.; Toth, K.; Hulin, A.; Taburet, A.-M.; Gimenez, F.; Singlas, E. Simultaneous high-performance liquid chromatographic determination of the antiretroviral agents amprenavir, nelfinavir, ritonavir, saquinavir, delavirdine and efavirenz in human plasma, J.Chromatogr.B, 2000, 742, 453–458. [LOQ 50–150 ng/mL] Remmel, R.P.; Kawle, S.P.; Weller, D.; Fletcher, C.V. Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma, Clin.Chem., 2000, 46, 73–81. [LOQ 20–50 ng/mL] Rentsch, K.M. Sensitive and specific determination of eight antiretroviral agents in plasma by highperformance liquid chromatography-mass spectrometry, J.Chromatogr.B, 2003, 788, 339–350. [SPE; LOQ 1–250 ng/mL; amprenavir; efavirenz; indinavir; lopinavir; nelfinavir; nevirapine; ritonavir; saquinavir] Sarasa-Nacenta, M.; López-Púa, Y.; Mallolas, J.; Blanco, J.L.; Gatell, J.M.; Carné, X. Simultaneous determination of the HIV-protease inhibitors indinavir, amprenavir, ritonavir, saquinavir and nelfinavir in human plasma by reversed-phase high-performance liquid chromatography, J.Chromatogr.B, 2001, 757, 325–332. [SPE; LOQ 10–85 ng/mL] Simon, V.A.; Thiam, M.D.; Lipford, L.C. Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography, J.Chromatogr.A, 2001, 913, 447–453. [SPE; LOD 30–440 ng/mL; zalcitabine; lamivudine; stavudine; didanosine; zidovudine; nevirapine; abacavir; indinavir; delavirdine; nelfinavir; saquinavir; ritonavir; efavirenz] Tribut, O.; Arvieux, C.; Michelet, C.; Chapplain, J.-M.; Allain, H.; Bentué-Ferrer, D. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography, Ther.Drug Nelfinavir 439 Monit., 2002, 24, 554–562. [LOQ 25 ng/mL; nevirapine; efavirenz; indinavir; amprenavir; nelfinavir; ritonavir; lopinavir; saquinavir] Turner, M.L.; Reed-Walker, K.; King, J.R.; Acosta, E.P. Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography, J.Chromatogr.B, 2003, 784, 331–341. [LOQ 50 ng/mL; indinavir; nelfinavir; saquinavir; ritonavir; amprenavir; delavirdine; efavirenz; lopinavir] van Heeswijk, R.P.G.; Hoetelmans, R.M.W.; Harms, R.; Meenhorst, P.L.; Mulder, J.W.; Lange, J.M.A.; Beijnen, J.H. Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 1998, 719, 159–168. [SPE; LOQ 25–50 ng/mL] Villani, P.; Feroggio, M.; Gianelli, L.; Bartoli, A.; Montagna, M.; Maserati, R.; Regazzi, M.B. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography-mass spectrometry assay, Ther.Drug Monit., 2001, 23, 380–388. [LOD 10–25 ng/mL; LOQ 20–40 ng/mL; saquinavir; indinavir; ritonavir; nelfinavir; amprenavir; nevirapine; delavirdine; efavirenz] Yamada, H.; Kotaki, H.; Nakamura, T.; Iwamoto, A. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir and nelfinavir in human plasma by highperformance liquid chromatography, J.Chromatogr.B, 2001, 755, 85–89. [LOQ 50 ng/mL] Zhang, K.E.; Wu, E.; Patick, A.K.; Kerr, B.; Zorbas, M.; Lankford, A.; Kobayashi, T.; Maeda, Y.; Shetty, B.; Webber, S. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: Structural identification, levels in plasma, and antiviral activities, Antimicrob.Agents Chemother., 2001, 45, 1086–1093. [LC-MS; reserpine is internal standard; LOQ 20 ng/mL] 440 Nequinate Nequinate Molecular formula: C22 H23 NO4 Molecular weight: 365.42 CAS Registry No: 13997-19-8 Merck Index: 13, 6498 H O N H3C OCH3 O O SAMPLE Matrix: feed Sample preparation: Slurry 100 g 100–200 mesh Dowex 50 W-X8 (H+ ) cation-exchange resin with 500 mL 10% HCl, heat to boiling with continuous stirring, cool, discard liquid, wash resin twice with 500 mL portions of water, wash with 250 mL MeOH, filter (Whatman No. 541 paper), rinse with 200 mL MeOH, air dry. Slurry 5 g resin with 50 mL 10% HCl, pour into a chromatography column, wash with water until the effluent is neutral to litmus, wash with 50 mL MeOH. Do not allow to go dry at any stage. Shake 20 g finely ground feed with 100 mL 2% methanesulfonic acid in MeOH for 30 min, filter (Whatman No. 541 paper). Add 25 mL filtrate to 100 mL 10% HCl and 100 mL dichloromethane, shake for 1 min, extract the aqueous phase twice with 40 mL portions of dichloromethane. Combine the organic layers and evaporate to dryness under reduced pressure at 40◦ , reconstitute the residue with 20–25 mL MeOH, add to the ion-exchange column, rinse flask with 10 mL MeOH, add the rinse to the column, wash the column with 50 mL MeOH, elute the column with 150 mL 2% methanesulfonic acid in MeOH. Mix the eluate with 300 mL 10% HCl and 130 mL dichloromethane, shake for 1 min, extract the aqueous layer twice with 70 mL portions of dichloromethane. Combine the organic layers and evaporate to dryness under reduced pressure at 40◦ , reconstitute the residue with 10 mL MeOH, inject a 20 µL aliquot. HPLC VARIABLES Column: 300 × 3.9 µBondapak C18 Mobile phase: MeOH:water 75:25 Flow rate: 1.5 Injection volume: 20 Detector: UV 265 CHROMATOGRAM Retention time: 8 Limit of quantitation: 1 µg/g OTHER SUBSTANCES Noninterfering: clopidol KEY WORDS SPE REFERENCE Merson, G.H.J.; Hill, L.A.; Johnson, S.F. Determination of methyl benzoquate in poultry feeding stuffs using high-performance liquid chromatography, Analyst, 1985, 110, 761–764. 441 Neridronic acid Neridronic acid Molecular formula: C6 H17 NO7 P2 O OH HO H2N Molecular weight: 277.15 CAS Registry No: 79778-41-9 P P OH OH OH O SAMPLE Matrix: formulations Sample preparation: Dilute injections 100-fold, inject a 20 µL aliquot. Disintegrate a 5 mg tablet in 100 mL water, sonicate for 5 min, centrifuge an aliquot at 3600 g for 4 min, inject a 20 µL aliquot of the supernatant. HPLC VARIABLES Column: 150 × 4.6 10 µm IC-PAK Anion HC (Waters) Column temperature: 30 Mobile phase: 1.5 mM nitric acid containing 0.5 mM copper(II) nitrate (Prepare column by pumping ILC Regenerant A (Waters) and 100 mM nitric acid for 30 min.) Flow rate: 1 Injection volume: 20 Detector: UV 245 CHROMATOGRAM Retention time: 1.5 OTHER SUBSTANCES Simultaneous: alendronate (k′ 0.48), clodronate (k′ 26.4), etidronate (5.8 min), olpadronate (k′ 0.82), pamidronate (2 min) KEY WORDS complexation; injections; tablets REFERENCE Sparidans, R.W.; Den Hartigh, J.; Vermeij, P. High-performance ion-exchange chromatography with in-line complexation of bisphosphonates and their quality control in pharmaceutical preparations, J.Pharm.Biomed.Anal., 1995, 13, 1545–1550. SAMPLE Matrix: solutions Sample preparation: Vortex 100 µL of an 80–500 µg/mL solution in water with 50 µL EtOH, 40 µL pyridine, 10 µL triethylamine, and 2 µL phenylisothiocyanate, heat at 80◦ for 5 min, evaporate under nitrogen at 80◦ , reconstitute with 1 mL water, wash twice with 2 mL portions of chloroform:1-pentanol 90:10 (Caution! Chloroform is a carcinogen!), inject a 20 µL aliquot of the aqueous layer. HPLC VARIABLES Column: 100 × 3 5 µm Chromspher C18 Mobile phase: MeCN:20 mM pH 7–8 phosphate buffer containing 5 mM tetraethylammonium hydroxide and 0.5 mM etidronate (adsorption suppressor) 3:97 Flow rate: 0.4 Injection volume: 20 Detector: UV 240 OTHER SUBSTANCES Simultaneous: alendronate, pamidronate 442 Neridronic acid KEY WORDS derivatization REFERENCE Sparidans, R.W.; Den Hartigh, J.; Beijnen, J.H.; Vermeij, P. Derivatization of pamidronate and other amino(bis)phosphonates with different isothiocyanates prior to ion-pair liquid chromatography, J.Chromatogr.A, 1997, 782, 211–217. 443 Nevirapine Nevirapine H H3C O N Molecular formula: C15 H14 N4 O Molecular weight: 266.30 CAS Registry No: 129618-40-2 Merck Index: 13, 6514 N N N SAMPLE Matrix: blood Sample preparation: Condition an Extrasep C18 SPE cartridge (Lida) with 2 mL MeOH and 2 mL water. Dilute 500 µL serum with 500 µL water, add to the SPE cartridge, wash with 500 µL water, elute with 1 mL MeOH. Evaporate the eluate to dryness with vortexing under reduced pressure at 40◦ and reconstitute the residue with 300 µL MeOH, inject a 10 µL aliquot. HPLC VARIABLES Column: two 150 × 4.6 3 µm Luna C18 columns in series Column temperature: 60 Mobile phase: Gradient. MeCN:4 mM sulfuric acid from 8:92 to 63:37 over 45 min, maintain at 63:37 for 5 min. Flow rate: 0.85 Injection volume: 10 Detector: UV 265 for 31 min then UV 240 CHROMATOGRAM Retention time: 23.5 Limit of detection: 84 ng/mL OTHER SUBSTANCES Extracted: delavirdine (25.5, LOD 110 ng/mL), efavirenz (51, LOD 62 ng/mL), indinavir (24.5, LOD 210 ng/mL), nelfinavir (33.5, LOD 400 ng/mL), ritonavir (50.5, LOD 510 ng/mL), saquinavir (35, LOD 100 ng/mL) KEY WORDS SPE; serum REFERENCE Simon, V.A.; Thiam, M.D.; Lipford, L.C. Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography, J.Chromatogr.A, 2001, 913, 447–453. SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 200 µL 10 µg/mL IS in water, add 200 µL 100 mM NaOH, mix, add 4 mL diethyl ether, shake for 5 min, centrifuge at 2500 rpm for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 200 µL initial mobile phase, inject a 100 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 Stability RP18 (CIL, France) Mobile phase: Gradient. MeCN:50 mM pH 5.65 phosphate buffer from 36:64 to 64:36 over 25 min, to 80:20 (step gradient), maintain at 80:20 for 10 min, re-equilibrate at initial conditions for 5 min. Flow rate: 1.5 444 Nevirapine Injection volume: 100 Detector: UV 240 for 5 min, UV 215 for 22 min, UV 260 for rest of run CHROMATOGRAM Retention time: 3.3 Internal standard: JR051012 (Janssen Cilag) (28.2) Limit of quantitation: 100 ng/mL OTHER SUBSTANCES Extracted: amprenavir (11.2), efavirenz (19.9), indinavir (8.5), lopinavir (18.9), nelfinavir (24.1), ritonavir (17.6), saquinavir (16.7) Noninterfering: acetaminophen, amineptine, amphotericin B, aspirin, bromazepam, buspirone, citalopram, clobazam, diazepam, didanosine, fluconazole, flunitrazepam, fluvoxamine, hydroxyitraconazole, isoniazid, itraconazole, lamivudine, loprazolam, lorazepam, metronidazole, minalcipram, nordiazepam, omeprazole, paroxetine, pyrimethamine, rifampin, sertraline, stavudine, sulfadiazine, trimethoprim, venlafaxine, zalcitabine, zidovudine, zolpidem, zopiclone KEY WORDS plasma REFERENCE Titier, K.; Lagrange, F.; Péhourcq, F.; Edno-Mcheik, L.; Moore, N.; Molimard, M. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma, Ther.Drug Monit., 2002, 24, 417–424. SAMPLE Matrix: bulk Sample preparation: Mix 24 mg drug substance with 4 mL MeCN and 80 mL mobile phase, sonicate until all solid dissolves, cool, make up to 100 mL with mobile phase, inject a 50 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Supelcosil LC-ABZ Column temperature: 35 Mobile phase: MeCN:25 mM pH 5.0 ammonium dihydrogen phosphate buffer 20:80 Flow rate: 1 Injection volume: 50 Detector: UV 220 CHROMATOGRAM Retention time: 7.44 Limit of detection: 0.001% (S/N 3) Limit of quantitation: 0.003% (S/N 10) OTHER SUBSTANCES Simultaneous: impurities KEY WORDS robust; stability-indicating REFERENCE Li, Q.C.; Tougas, T.; Cohen, K.; Lee, R.; Meagan, P.; Corson, M.; Muchnick, T. Validation of a highperformance liquid chromatography method for the assay of and determination of related organic impurities in nevirapine drug substance, J.Chromatogr.Sci., 2000, 38, 246–254. Nevirapine 445 ANNOTATED BIBLIOGRAPHY Aymard, G.; Legrand, M.; Trichereau, N.; Diquet, B. Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography, J.Chromatogr.B, 2000, 744, 227–240. [amprenavir; efavirenz; indinavir; nelfinavir; ritonavir; saquinavir; abacavir; didanosine; lamivudine; stavudine; nevirapine; zidovudine; column-switching; SPE; LOQ 5–100 ng/mL] Chi, J.; Jayewardene, A.L.; Stone, J.A.; Aweeka, F.T. An LC-MS-MS method for the determination of nevirapine, a non-nucleoside reverse transcriptase inhibitor, in human plasma, J.Pharm.Biomed.Anal., 2003, 31, 953–959. [LOQ 25 ng/mL] Dailly, E.; Thomas, L.; Kergueris, M.F.; Jolliet, P.; Bourin, M. High-performance liquid chromatographic assay to determine the plasma levels of HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction, J.Chromatogr.B, 2001, 758, 129–135. [LOQ 50–400 ng/mL] Droste, J.A.H.; Verweij-van Wissen, C.P.W.G.M.; Burger, D.M. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography, Ther.Drug Monit., 2003, 25, 393–399. [LOQ 50–70 ng/mL] Erickson, D.A.; Mather, G.; Trager, W.F.; Levy, R.H.; Keirns, J.J. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450, Drug Metab.Dispos., 1999, 27, 1488–1495. Fan, B.; Stewart, J.T. Determination of zidovudine/zalcitabine/nevirapine in human plasma by ion-pair HPLC, J.Liq.Chromatogr.Rel.Technol., 2001, 24, 3017–3026. [SPE; LOQ 20–58 ng/mL; aprobarbital is internal standard] Fan, B.; Stewart, J.T. Determination of zidovudine/lamivudine/nevirapine in human plasma using ionpair HPLC, J.Pharm.Biomed.Anal., 2002, 28, 903–908. [SPE; LOQ 53–59 ng/mL] Faux, J.; Venisse, N.; Le Moal, G.; Dupuis, A.; Bouquet, S. Simultaneous determination of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography after solid-phase extraction, Chromatographia, 2003, 58, 421–426. [LOQ 50 – 120 ng/mL; amprenavir; indinavir; lopinavir; nelfinavir; ritonavir; saquinavir; efavirenz; nevirapine; prazepam is internal standard] Hollanders, R.M.F.; van Ewijk-Beneken Kolmer, E.W.J.; Burger, D.M.; Wuis, E.W.; Koopmans, P.P.; Hekster, Y.A. Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography, J.Chromatogr.B, 2000, 744, 65–71. [LOD 50 ng/mL; LOQ 100 ng/mL] Kishimoto, W.; Takano, J.; Senda, C.; Ishiguro, N.; Sakai, K.; Igarashi, T. Quantitative prediction of in vivo drug interactions between nevirapine and antifungal agents from in vitro data in rats, Biol.Pharm.Bull., 2000, 23, 1027–1032. Lips, A.G.A.M.; Lameijer, W.; Fokkens, R.H.; Nibbering, N.M.M. Methodology for the development of a drug library based upon collision-induced fragmentation for the identification of toxicologically relevant drugs in plasma samples, J.Chromatogr.B, 2001, 759, 191–207. [plasma; LC-MS; morphine; sotalol; acetaminophen; codeine; olanzapine; caffeine; amphetamine; lamotrigine; phenytoin; nevirapine; phenobarbital; clozapine; midazolam; flurazepam; paroxetine; promethazine; flecainide; haloperidol; oxazepam; phenprocoumon; lorazepam; naproxen; amitriptyline; zopiclone; sertraline; zuclopenthixol; triazolam; flunitrazepam; saquinavir; pimozide; clomipramine; clobazam; valproic acid; chlordiazepoxide; diazepam; ritonavir; ibuprofen; promazine is internal standard] Lopez, R.M.; Pou, L.; Gomez, M.R.; Ruiz, I.; Monterde, J. Simple and rapid determination of nevirapine in human serum by reversed-phase high-performance liquid chromatography, J.Chromatogr.B, 2001, 751, 371–376. [LOQ 100 ng/mL] Marchei, E.; Valvo, L.; Pacifici, R.; Pellegrini, M.; Tossini, G.; Zuccaro, P. Simultaneous determination of zidovudine and nevirapine in human plasma by RP-LC, J.Pharm.Biomed.Anal., 2002, 29, 1081–1088. [SPE; LOD 25–50 ng/mL; LOQ 50–150 ng/mL] Marzolini, C.; Béguin, A.; Telenti, A.; Schreyer, A.; Buclin, T.; Biollaz, J.; Decosterd, L.A. Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery, J.Chromatogr.B, 2002, 774, 127–140. [SPE; LOD 15–50 ng/mL; LOQ 60–100 ng/mL; clozapine is internal standard] Moyer, T.P.; Temesgen, Z.; Enger, R.; Estes, L.; Charlson, J.; Oliver, L.; Wight, A. Drug monitoring of antiretroviral therapy for HIV-1 infection: Method validation and results of a pilot study, Clin.Chem., 1999, 45, 1465–1476. [serum; LOD 10–100 ng/mL; didanosine; lamivudine; stavudine; zalcitabine; zidovudine; delavirdine; nevirapine; indinavir; nelfinavir; ritonavir; saquinavir] 446 Nevirapine Palladino, D.E.; Hopkins, J.L.; Ingraham, R.H.; Warren, T.C.; Kapadia, S.R.; Van Moffaert, G.J.; Grob, P.M.; Stevenson, J.M.; Cohen, K.A. High-performance liquid chromatography and photoaffinity crosslinking to explore the binding environment of nevirapine to reverse transcriptase of human immunodeficiency virus, J.Chromatogr.A, 1994, 676, 99–112. Pav, J.W.; Rowland, L.S.; Korpalski, D.J.; Elvin, A.T. HPLC-UV method for the quantitation of nevirapine (ViramuneTM ) in human plasma, serum, and milk following solid phase extraction (Abstract 4214), Pharm.Res., 1997, 14, S697. Pav, J.W.; Rowland, L.S.; Korpalski, D.J. HPLC-UV method for the quantitation of nevirapine in biological matrices following solid phase extraction, J.Pharm.Biomed.Anal., 1999, 20, 91–98. [SPE; LOQ 25 ng/mL; plasma; serum; milk; CSF] Rabin, L.; Hincenbergs, M.; Moreno, M.B.; Warren, S.; Linquist, V.; Datema, R.; Charpiot, B.; Seifert, J.; Kaneshima, H.; McCune, J.M. Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing if anti-human immunodeficiency virus type I compounds, Antimicrob.Agents Chemother., 1996, 40, 755–762. [plasma; LOD 8 ng/mL] Rentsch, K.M. Sensitive and specific determination of eight antiretroviral agents in plasma by highperformance liquid chromatography-mass spectrometry, J.Chromatogr.B, 2003, 788, 339–350. [SPE; LOQ 1–250 ng/mL; amprenavir; efavirenz; indinavir; lopinavir; nelfinavir; nevirapine; ritonavir; saquinavir] Rezk, N.L.; Tidwell, R.R.; Kashuba, A.D.M. Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using highperformance liquid chromatography with ultraviolet absorbance detection, J.Chromatogr.B, 2002, 774, 79–88. [LOQ 10–25 ng/mL; SPE; hexobarbital is internal standard] Rezk, N.L.; Tidwell, R.R.; Kashuba, A.D.M. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection, J.Chromatogr.B, 2003, 791, 137–147. [SPE; LOQ 10 ng/mL; zalcitabine; lamivudine; didanosine; stavudine; zidovudine; abacavir; hexobarbital is internal standard] Riska, P.; Lamson, M.; Macgregor, T.; Sabo, J.; Hattox, S.; Pav, J.; Keirns, J. Disposition and biotransformation of the antiretroviral drug nevirapine in humans, Drug Metab.Dispos., 1999, 27, 895–901. Riska, P.S.; Joseph, D.P.; Dinallo, R.M.; Davidson, W.C.; Keirns, J.J.; Hattox, S.E. Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees, Drug Metab.Dispos., 1999, 27, 1434–1447. [SPE] Simon, V.A.; Thiam, M.D.; Lipford, L.C. Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography, J.Chromatogr.A, 2001, 913, 447–453. [SPE; LOD 30–440 ng/mL; zalcitabine; lamivudine; stavudine; didanosine; zidovudine; nevirapine; abacavir; indinavir; delavirdine; nelfinavir; saquinavir; ritonavir; efavirenz] Störmer, E.; von Moltke, L.L.; Perloff, M.D.; Greenblatt, D.J. Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture, Pharm.Res., 2002, 19, 1038–1045. [verapamil; efavirenz; nevirapine; delavirdine] Tribut, O.; Arvieux, C.; Michelet, C.; Chapplain, J.-M.; Allain, H.; Bentué-Ferrer, D. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography, Ther.Drug Monit., 2002, 24, 554–562. [LOQ 25 ng/mL; nevirapine; efavirenz; indinavir; amprenavir; nelfinavir; ritonavir; lopinavir; saquinavir] van Heeswijk, R.P.; Hoetelmans, R.M.; Meenhorst, P.L.; Mulder, J.W.; Beijnen, J.H. Rapid determination of nevirapine in human plasma by ion-pair reversed- phase high-performance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 1998, 713, 395–399. [LOQ 52 ng/mL] Villani, P.; Feroggio, M.; Gianelli, L.; Bartoli, A.; Montagna, M.; Maserati, R.; Regazzi, M.B. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography-mass spectrometry assay, Ther.Drug Monit., 2001, 23, 380–388. [LOD 10–25 ng/mL; LOQ 20–40 ng/mL; saquinavir; indinavir; ritonavir; nelfinavir; amprenavir; nevirapine; delavirdine; efavirenz] 447 Nicarbazin Nicarbazin NO2 O2N O Molecular formula: C19 H18 N6 O6 N N Molecular weight: 426.38 CAS Registry No: 330-95-0 Merck Index: 13, 6519 H H H3C N CH3 N CH3 SAMPLE Matrix: blood Sample preparation: Vortex 100 µL plasma with 200 µL MeCN, centrifuge for 5 min, inject a 60 µL aliquot of the supernatant. HPLC VARIABLES Guard column: 15 × 4.6 C18 Column: 250 × 4.6 5 µm Keystone ODS/H Column temperature: 35 Mobile phase: MeCN:water 60:40 Flow rate: 1 Injection volume: 60 Detector: UV 347 CHROMATOGRAM Retention time: 8.5 (dinitrocarbanilide) Limit of detection: 27–35 ng/mL KEY WORDS chicken; duck; goose; plasma REFERENCE Primus, T.M.; Kohler, D.J.; Goodall, M.A.; Yoder, C.; Griffin, D.; Miller, L.; Johnston, J.J. Determination of 4,4′ -dinitrocarbanilide (DNC), the active component of the antifertility agent nicarbazin, in chicken, duck, and goose plasma, J.Agric.Food Chem., 2001, 49, 3589–3593. 448 Nilutamide Nilutamide H3C Molecular formula: C12 H10 F3 N3 O4 H3C Molecular weight: 317.22 CAS Registry No: 63612-50-0 Merck Index: 13, 6572 H N O N CF3 O NO2 SAMPLE Matrix: blood, urine Sample preparation: Extract 1 mL plasma or urine with 2 mL chloroform (Caution! Chloroform is a carcinogen!). Evaporate an aliquot of the organic layer to dryness, reconstitute the residue with 1 mL mobile phase, inject a 10–20 µL aliquot. HPLC VARIABLES Column: 250 mm long 5 µm C18 Mobile phase: MeOH Flow rate: 1.2 Injection volume: 10–20 Detector: UV 254 CHROMATOGRAM Retention time: 4.5 Limit of detection: 50 ng/mL KEY WORDS plasma REFERENCE Pendyala, L.; Creaven, P.J.; Huben, R.; Tremblay, D.; Bertagna, C. Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate, Cancer Chemother.Pharmacol., 1988, 22, 69–76. 449 Nipradilol Nipradilol Molecular formula: C15 H22 N2 O6 Molecular weight: 326.34 CAS Registry No: 81486-22-8 Merck Index: 13, 6590 CH3 H3C N H O OH O ONO2 SAMPLE Matrix: solutions Sample preparation: Add 50 µL L-menthoxyacetyl chloride to a solution of 5–10 mg nipradilol in 500 µL dry pyridine, let stand at room temperature for 30 min, add 50 µL water, evaporate to dryness under reduced pressure, reconstitute with 5 mL chloroform (Caution! Chloroform is a carcinogen!), wash twice with 3 mL portions of 1 M HCl, wash with 3 mL saturated sodium bicarbonate solution, dry over anhydrous sodium sulfate, inject an aliquot. HPLC VARIABLES Column: 200 × 4 10 µm Partisil-10 Mobile phase: Hexane:ethyl acetate 100:20 Flow rate: 1.5 Detector: UV 275 CHROMATOGRAM Retention time: 14 (2′ R,3S), 15 (2′ S,3R), 17 (2′ S,3S), 20 (2′ R,3R) [ 2′ hydroxy, 3 nitroxy] KEY WORDS chiral; derivatization; normal phase REFERENCE Yoneda, M.; Shiratsuchi, M.; Yoshimura, M.; Ohkawa, Y.; Muramatsu, T. Optical resolution and determination of absolute configuration of nipradilol, Chem.Pharm.Bull., 1985, 33, 2735–2742. 450 Nitazoxanide Nitazoxanide O O2N Molecular formula: C12 H9 N3 O5 S Molecular weight: 307.29 CAS Registry No: 55981-09-4 Merck Index: 13, 6595 S N O O CH3 N H SAMPLE Matrix: blood, urine Sample preparation: Plasma. Vortex 500 µL plasma and IS with 1 mL MeCN, centrifuge, inject a 20 µL aliquot of the supernatant. Urine. Mix 500 µL urine with 500 µL 1% Helix Pomatia juice (type H2, Sigma) in 100 mM pH 5 acetate buffer, heat at 37◦ overnight, inject an aliquot. HPLC VARIABLES Column: 100 × 4.6 5 µm Nucleosil C18 Mobile phase: Gradient. MeCN:20 mM pH 2.5 phosphate buffer from10:90 to 35:65 over 8 min. Injection volume: 20 Detector: UV 360 CHROMATOGRAM Internal standard: nifuroxazide Limit of quantitation: 20 ng/mL (plasma), 200 ng/mL (urine) KEY WORDS only desacetylnitazoxanide is detected in plasma and urine; plasma REFERENCE Stockis, A.; Deroubaix, X.; Lins, R.; Jeanbaptiste, B.; Calderon, P.; Rossignol, J.F. Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers, Int.J.Clin.Pharmacol.Ther., 1996, 34, 349–351. SAMPLE Matrix: microsomal incubations, urine Sample preparation: Urine. Mix 2 mL urine with 10 µL 100 U/mL β-glucuronidase, 5 µL arylsulfatase (Helix pomatia) (Boehringer Mannheim), and 200 µL 1 M pH 5.5 acetate buffer, heat at 37◦ for 3 h, add 200 µL 1 M formic acid, centrifuge, inject a 100 µL aliquot. Microsomal incubations. Mix 1 mL microsomal incubation with 100 µL 2 M formic acid, add 550 µL MeCN, mix, centrifuge, inject an aliquot. (This method is also said to work for plasma and feces, but there are no details.) (Only the deacylated compound tizanoxide is detected in biological fluids.) HPLC VARIABLES Column: Nucleosil 5C18 Mobile phase: Gradient. MeCN:10 mM formic acid from 10:90 to 90:10 over (?) Injection volume: 100 Detector: MS, VG Quattro II Nitazoxanide 451 KEY WORDS dog; human; liver; monkey; rat REFERENCE Broekhuysen, J.; Stockis, A.; Lins, R.L.; De Graeve, J.; Rossignol, J.F. Nitazoxanide: pharmacokinetics and metabolism in man, Int.J.Clin.Pharmacol.Ther., 2000, 38, 387–394. 452 Nitenpyram Nitenpyram Cl N H3C N Molecular formula: C11 H15 ClN4 O2 Molecular weight: 270.72 CAS Registry No: 150824-47-8 Merck Index: 13, 6596 NO2 N H CH3 SAMPLE Matrix: fruit, vegetables Sample preparation: Condition a 3 mL 500 mg Bond Elut PSA (weak anion-exchange) SPE cartridge with 10 mL acetone and 10 mL acetone:hexane 50:50. Condition a 6 mL 1 g Mega Bond Elut silica SPE cartridge with 10 mL acetone and 10 mL acetone:hexane 30:70. Blend (Polytron) 20 g sample with 100 mL MeCN for 2 min, filter (paper). Add 5 g NaCl to the filtrate and shake mechanically for 1 min. Evaporate 50 mL of the MeCN layer to near dryness, take up in 2 mL acetone, wash out flask with 2 mL acetone. Combine the acetone solutions with 4 mL hexane, add to the PSA SPE cartridge, elute with 5 mL acetone:hexane 50:50. Evaporate the eluates and dissolve in 2 mL acetone:hexane 30:70, add to the silica SPE cartridge, wash with 10 mL acetone:hexane 30:70. Discard all effluent from the silica SPE cartridge. Elute with 10 mL acetone:hexane 40:60 (for acetamiprid and imidacloprid) and 20 mL acetone (for nitenpyram). Evaporate each eluate to dryness, reconstitute the residue with 2 mL MeOH, inject a 10 µL aliquot. HPLC VARIABLES Column: 75 × 4.6 3 µm Cadenza CD-C18 (Imtakt, Kyoto) Column temperature: 50 Mobile phase: Gradient. MeCN:50 mM potassium dihydrogen phosphate 3:97 for 3 min, to 40:60 over 7 min, maintain at 40:60 for 5 min, to 100:0 over 5 min, maintain at 100:0 for 5 min, to 5:95 over 5 min, maintain at 5:95 for 5 min. Flow rate: 0.8 Injection volume: 10 Detector: UV 270 CHROMATOGRAM Retention time: 11 Limit of detection: 20 ng/g OTHER SUBSTANCES Extracted: acetamiprid (UV 245; LOD 10 ng/g) (15), imidacloprid (LOD 10 ng/g) (14) KEY WORDS cucumber; eggplant; grape; Japanese radish; potato; SPE; tomato REFERENCE Obana, H.; Okihashi, M.; Akutsu, K.; Kitagawa, Y.; Hori, S. Determination of acetamiprid, imidacloprid, and nitenpyram residues in vegetables and fruits by high-performance liquid chromatography with diode-array detection, J.Agric.Food Chem., 2002, 50, 4464–4467. 453 Nomegestrol Nomegestrol H3C CH3 O OH Molecular formula: C21 H28 O3 H Molecular weight: 328.45 CAS Registry No: 58691-88-6 H H H O CH3 SAMPLE Matrix: blood Sample preparation: Condition a Sep Pak C18 SPE cartridge with MeOH and water. Add 1 mL plasma to the SPE cartridge, wash with 5 mL water, wash with 2 mL MeOH:water 70:30, elute with 2 mL MeOH. Evaporate the eluate to dryness, reconstitute the residue with 150 µL EtOH, inject a 20 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Ultrasphere Mobile phase: MeOH:water 70:30 Flow rate: 1.2 Injection volume: 20 Detector: UV 280 CHROMATOGRAM Retention time: 13 KEY WORDS plasma; SPE; for nomegestrol acetate REFERENCE Ezan, E.; Benech, H.; Bucourt, R.; Ardouin, T.; Tchernatinsky, C.; Thomas, J.L.; Paris, J.; Grognet, J.M. Enzyme immunoassay for nomegestrol acetate in human plasma, J.Steroid Biochem.Mol.Biol., 1993, 46, 507–514. 454 Nonoxynol-9 Nonoxynol-9 CAS Registry No: 26027-38-3 Merck Index: 13, 6711 (OCH2CH2)nOH n=9 H3C SAMPLE Matrix: blood Sample preparation: Mix 1 mL whole blood with 1 g solid NaCl, grind (sic) for 5 min, extract twice with 4 mL portions of benzene (Caution! Benzene is a carcinogen!), centrifuge at 8000 rpm for 30 min. Combine the extracts and evaporate them to dryness under a stream of nitrogen, dry under vacuum at 50◦ for 1 h, reconstitute the residue with 100 µL MeOH, centrifuge, inject a 20 µL aliquot of the supernatant. HPLC VARIABLES Column: 250 × 4.6 TSK-Gel C18 Mobile phase: MeOH:water (ratio not given) Injection volume: 20 Detector: UV 221 CHROMATOGRAM Retention time: 7.3 Limit of quantitation: 50 ng/mL KEY WORDS whole blood; also, using normal phase with a silica column and n-hexane at UV 276 gives numerous peaks for oligomers. REFERENCE Yang, J.; Zhao, Z. Quantitative analysis of nonoxynol-9 in the blood, Contraception, 1991, 43, 161–166. 455 Nystatin Nystatin Molecular formula: C47 H75 NO17 (A1 ) Molecular weight: 926.09 (A1 ) CAS Registry No: 1400-61-9, 34786-70-4 (A1 ) Merck Index: 13, 6770 OH H3C HO O O CH3 OH OH OH OH OH OH O COOH H3C O O OH CH3 NH2 OH SAMPLE Matrix: blood, tissue Sample preparation: Plasma. Mix 800 µL MeOH with 400 µL plasma, let stand at 4◦ for 30 min, centrifuge at 2000 g for 10 min, centrifuge the supernatant in a separate tube at 10 000 g for 4 min. Filter (Durapore 0.22 µm) 400 µL of the supernatant while centrifuging at 4000 g for 4 min, inject a 200 µL aliquot of the filtrate. Tissue. Homogenize (Tissuemizer 10 N head) tissue with 2 vol of ice-cold MeOH at 0◦ , let stand at 4◦ for 30 min, centrifuge at 2000 g for 10 min, centrifuge the supernatant in a separate tube at 10 000 g for 4 min. Filter (Durapore 0.22 µm) 400 µL of the supernatant while centrifuging at 4000 g for 4 min, inject a 200 µL aliquot of the filtrate. HPLC VARIABLES Guard column: 15 × 3.2 5 µm NewGuard RP-18 Column: 300 × 3.9 10 µm µBondapak C18 Column temperature: 30 Mobile phase: MeCN:MeOH:10 mM sodium phosphate buffer containing 1 mM EDTA 30:30:40, adjusted to pH 6.0 with 85% phosphoric acid Flow rate: 2 Injection volume: 200 Detector: UV 305 CHROMATOGRAM Retention time: 8.1, 10.0 Limit of quantitation: 50 ng/mL OTHER SUBSTANCES Noninterfering: acetaminophen, amikacin, amitriptyline, carbamazepine, ceftazidime, cyclosporine, digoxin, disopyramide, ethosuximide, gentamicin, lidocaine, lithium, methotrexate, phenobarbital, phenytoin, primidone, procainamide, propranolol, quinidine, salicylic acid, theophylline, tobramycin, valproic acid, vancomycin KEY WORDS human; pharmacokinetics; plasma; rabbit REFERENCE Groll, A.H.; Mickiene, D.; Werner, K.; Piscitelli, S.C.; Walsh, T.J. High-performance liquid chromatographic determination of liposomal nystatin in plasma and tissues for pharmacokinetic and tissue distribution studies, J.Chromatogr.B, 1999, 735, 51–62. Octocrylene Molecular formula: C24 H27 NO2 Molecular weight: 361.48 CH3 CN O CH3 O CAS Registry No: 6197-30-4 SAMPLE Matrix: sunscreen Sample preparation: Heat 2 g sunscreen in 40 mL MeOH and 250 µL 2 M sulfuric acid at 60◦ for 5 min until a homogeneous solution develops, cool, make up to 50 mL with MeOH, dilute a 1 mL aliquot to 5 mL with initial mobile phase, inject a 5–50 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm PLRP-S (Polymer Labs) Column temperature: 25 Mobile phase: Gradient. MeCN:THF:buffer 10:10:80 for 2.5 min, to 45:45:10 over 22.5 min, maintain at 45:45:10 for 10 min, return to initial conditions over 5 min, reequilibrate for 5 min. (The buffer was 1.4 g/L citric acid monohydrate containing 6.8 g/L tetrabutylammonium hydroxide, adjusted to pH 9.0 with concentrated ammonia.) Flow rate: 0.8 for 2.5 min, to 0.6 over 2.5 min, maintain at 0.6 for 10 min, return to 0.8 over 5 min, maintain at 0.8 for 5 min Injection volume: 5–50 Detector: UV 302 CHROMATOGRAM Retention time: 29.13 Limit of detection: 50–500 ppm OTHER SUBSTANCES Simultaneous: benzophenone-3 (25.93 min, UV 288), benzophenone-4 (12.47 min, UV 241), 3-benzylidene-d,l-camphor (26.47 min, UV 293), benzylidene camphor sulfonic acid (15.77 min, UV 297), butyl methoxydibenzoylmethane (29.71 min, UV 359), camphor benzalkonium methosulfate (6.178 min, UV 288), 3-(4′ -ethylbenzylidene)-d,l-camphor (27.30 min, UV 297), homosalate (30.32 min, UV 241), isoamyl p-methoxycinnamate (26.93 min, UV 307), isopropyl dibenzoylmethane (29.86 min, UV 350), megasol (29.17 min, UV 241), octyl dimethyl PABA (28.83 min, UV 312), octyl methoxycinnamate (29.43 min, UV 307), octyl salicylate (30.03 min, UV 241), octyl triazone (33.72 min, UV 312), PEG−25 p-aminobenzoic acid (10.79 min, UV 307), phenylbenzimidazole sulfonic acid (8.898 min, UV 302), terephthalydiene dicamphor sulfonic acid (13.18 min, UV 340), urocanic acid (2.468 min, UV 278) REFERENCE Rastogi, S.C.; Jensen, G.H. Identification of UV filters in sunscreen products by high-performance liquid chromatography-diode-array detection, J.Chromatogr.A, 1998, 828, 311–316. 456 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 Oleic acid 457 Oleic acid Molecular formula: C18 H34 O2 Molecular weight: 282.46 H3C(CH2)6 (CH2)6COOH CAS Registry No: 112-80-1 Merck Index: 13, 6898 SAMPLE Matrix: blood Sample preparation: Mix 10 µL plasma with 200 µL 40 µg/mL IS in EtOH and 90 µL EtOH, add 100 µL 2 M KOH in EtOH:water 50:50, heat at 80◦ for 20 min, cool to room temperature. Add 200 µL 20 mM 2-nitrophenylhydrazine in 300 mM HCl:EtOH 50:50, add 200 µL 250 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in EtOH:pyridine 97:3, heat at 80◦ for 5 min. Cool the solution to room temperature, add 10% KOH in MeOH:water 50:50, heat again at 80◦ for 5 min, cool to room temperature. Add 4 mL 33 mM pH 4.6 potassium phosphate buffer:500 mM HCl 70:10, extract with 4 mL hexane by shaking vigorously for 2 min. Centrifuge at 20 000 rpm for 10 min, evaporate the upper layer under a stream of nitrogen, resuspend the residue in 400 µL MeOH, inject a 50 µL aliquot. HPLC VARIABLES Guard column: 20 × 2 20–40 µm LiChroprep C18 Column: 250 × 6 YMC FA C8 (Hichrom) + Apex 3 µm ODS (Jones Chromatography) in series Column temperature: 45 Mobile phase: Gradient. A was MeCN. B was MeCN:MeOH:water 75:11:14. A:B 0:100 for 20 min, from 0:100 to 100:0 over 5 min, maintain at 100:0 for 10 min, return to initial conditions over for 2 min, re-equilibrate. Flow rate: 1.5 Injection volume: 50 Detector: UV 400 CHROMATOGRAM Retention time: 20 Internal standard: margaric acid OTHER SUBSTANCES Extracted: arachidonic acid (14.5), docosanoic acid (38), eicosanoic acid (34), eicosatrienoic acid (17), eicosapentanoic acid (12), lauric acid (10), linoleic acid (15.5), linolenic acid (12.5), gamma-linolenic acid (13), myristic acid (13), palmitic acid (18.5), palmitoleic acid (15), stearic acid (27), tetracosanoic acid (42) KEY WORDS derivatization; plasma REFERENCE Bailey, A.L.; Southon, S. Determination of total long-chain fatty acids in human plasma and lipoproteins, before and during copper-stimulated oxidation, by high-performance liquid chromatography, Anal.Chem., 1998, 70, 415–419. SAMPLE Matrix: blood Sample preparation: Vortex 5 µL serum, 5 µL EtOH, and 50 µL 4% pyridine in EtOH containing 20 mM HCl for 10 s, add 25 µL 50 mM reagent in DMF, add 15 µL 458 Oleic acid 2 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide in water, heat at 37◦ for 10 min, centrifuge at 1000 g for 5 min, inject a 10 µL aliquot of the supernatant. (The reagent was 6,7-dimethoxy-1-methyl-2(1H)-quinoxalinone-3-propionylcarboxylic acid hydrazide. Synthesis is as follows. Stir 483 g veratrole in 1.45 L acetic acid at 15◦ , add 683 g concentrated nitric acid (s.g. 1.05) over 1 h keeping the temperature below 40◦ (cool if necessary), add 2.127 L fuming nitric acid (s.g. 1.50) over 1 h keeping the temperature below 30◦ , allow to stand for 2 h, pour into a large volume of cold water, filter, wash the solid until it is free from acid, recrystallize from EtOH to give 4,5-dinitroveratrole (mp 129.5–130.5◦ ) (J.Am.Chem.Soc. 1946, 68, 1536). Reflux 5 g 4,5-dinitroveratrole in 200 mL benzene (Caution! Benzene is a carcinogen!), add 100 g 60 mesh iron powder and 20 mL concentrated HCl in small portions over 1 h, reflux for 4 h, add 10 mL water, reflux for 2 h, cool, make alkaline with 2.5 M NaOH, extract several times with 200 mL portions of benzene. Combine the extracts and evaporate to dryness, add 10 mL concentrated HCl, recrystallize from EtOH to give 1,2-diamino-4,5-dimethoxybenzene hydrochloride as slightly pink needles (mp 240◦ d) (Anal.Chim.Acta 1982, 134, 39). Dissolve 2.5 mmol 1,2-diamino-4,5-dimethoxybenzene monohydrochloride and 2.4 mmol α-ketoglutaric acid in 30 mL 500 mM HCl, heat in a boiling water bath for 2 h, cool in ice, filter, wash the precipitate with water, dry under vacuum, recrystallize from MeOH:water 90:10 to give 6,7-dimethoxy-2(1H)-quinoxalinone-3-propionylcarboxylic acid as yellow needles (mp 240◦ ) (Chem.Pharm.Bull. 1985, 33, 3493). Treat 1.5 g 6,7-dimethoxy-2(1H)-quinoxalinone-3-propionylcarboxylic acid in 100 mL MeOH with ethereal diazomethane, evaporate to dryness under reduced pressure, dissolve the residue in 30 mL chloroform (Caution! Chloroform is a carcinogen!), chromatograph on a 250 × 35 column of 70–230 mesh silica gel 60 (Merck) with hexane:ethyl acetate 50:50 to give methyl 6,7-dimethoxy-1-methyl-2(1H)-quinoxalinone-3-propionylcarboxylate as colorless needles (mp 178–179◦ ). Dissolve 900 mg methyl 6,7-dimethoxy-1-methyl2(1H)-quinoxalinone-3-propionylcarboxylate in 100 mL 45% hydrazine hydrate in water, heat at 100◦ for 1 h, recrystallize the precipitate from EtOH to give 6,7-dimethoxy-1methyl-2(1H)-quinoxalinone-3-propionylcarboxylic acid hydrazide as colorless needles (mp 205–206◦ ) (Analyst 1990, 115, 1363).) HPLC VARIABLES Column: 250 × 4.6 10 µm YMC-Pack C8 (Yamamura, Kyoto) Column temperature: 30 ± 0.2 Mobile phase: Gradient. MeCN:water 55:45 for 56 min, to 95:5 over 16 min, maintain at 95:5 for 4 min, re-equilibrate at initial conditions for 4 min. Flow rate: 1 Injection volume: 100 Detector: F ex 360 em 435 CHROMATOGRAM Retention time: 62.5 Limit of detection: 2–7 fmol OTHER SUBSTANCES Extracted: arachidonic acid (41), dihomo-gamma-linolenic acid (51), docosahexaenoic acid (41), eicosapentaenoic acid (20.5), lauric acid (12), linoleic acid (39), linolenic acid (27), margaric acid (66), myristic acid (24), myristoleic acid (16), palmitic acid (49), palmitoleic acid (30), stearic acid (72) Noninterfering: adipic acid, alcohols, aldehydes, amines, amino acids, benzoic acid, cinnamic acid, α-keto acids, lactic acid, malic acid, malonic acid, oxalic acid, phenols, salicylic acid, succinic acid, sugars KEY WORDS derivatization; serum Oleic acid 459 REFERENCE Iwata, T.; Inoue, K.; Nakamura, M.; Yamaguchi, M. Simple and highly sensitive determination of free fatty acids in human serum by high performance liquid chromatography with fluorescence detection, Biomed.Chromatogr., 1992, 6, 120–123. SAMPLE Matrix: blood Sample preparation: Mix 100 µL serum with 20 µL 5 mM IS in isopropanol, add 500 µL isopropanol:n-heptane:2 M phosphoric acid 40:10:1, mix, let stand at room temperature for 5–10 min, add 200 µL n-heptane, add 300 µL water, vortex thoroughly, centrifuge at 1000 g for 5 min. Remove a 200 µL aliquot of the upper organic layer and evaporate it to dryness under a stream of nitrogen, reconstitute the residue in 6 µL reagent, 500 µL MeCN, and ca. 1 mg potassium bicarbonate, flush the tube with nitrogen, close the PTFE-lined cap tightly, heat at 85◦ with vigorous stirring for 45 min (weigh vial before and after heating to check for leakage), cool, remove stir bar, centrifuge, inject a 10–25 µL aliquot of the supernatant. (The reagent was 50 mM p-bromophenacyl bromide in MeCN containing 5 mM 18-crown-6, store protected from light.) HPLC VARIABLES Guard column: 4 × 4 5 µm CN Column: 25 × 4 3 µm Spherisorb C6 Column temperature: 30 Mobile phase: MeCN:water 77:23 Flow rate: 1.3 Injection volume: 10–25 Detector: UV 254 CHROMATOGRAM Retention time: 13 Internal standard: heptadecanoic acid (margaric acid) (15) Limit of detection: 800 nM OTHER SUBSTANCES Extracted: arachidonic acid (9.8), docosahexaenoic acid (9), eicosapentaenoic acid (8), elaidic acid (14), lauric acid (6), linoleic acid (10.5), linolenic acid (8.5), myristic acid (8.8), myristoleic acid (7), palmitic acid (12), palmitoleic acid (9.5), stearic acid (18) KEY WORDS derivatization; serum REFERENCE Puttmann, M.; Krug, H.; von Ochsenstein, E.; Kattermann, R. Fast HPLC determination of serum free fatty acids in the picomole range, Clin.Chem., 1993, 39, 825–832. SAMPLE Matrix: blood Sample preparation: Sonicate 10 µL serum, 44 µL MeOH, and 1 µL pyridine for 5 min, add 25 µL 100 mM reagent in DMF, add 20 µL 400 mM 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide in MeOH, let stand at 25◦ for 2 h, centrifuge, inject an aliquot. (The reagent was 2-(5-hydrazinocarbonyl-2-furyl)-5,6-dimethoxybenzothiazole, which is synthesized as follows. Pass dry hydrogen chloride into a mixture of 12.6 g methyl 2-furoate, 4.5 g paraformaldehyde, and 3.4 g anhydrous zinc chloride in 50 mL dry chloroform for 3 h while holding the reaction temperature at 30◦ (Caution! Chloroform is a carcinogen!). After cooling, pour the contents of the flask into 100 mL 460 Oleic acid cold water, remove the chloroform layer, extract the aqueous layer with chloroform (cf Coll.Czech.Chem.Commun. 1960, 25, 1058). Combine the chloroform layers, neutralize, dry over anhydrous calcium chloride, evaporate, distil to give 5-chloromethyl furyl-2-carboxylic acid methyl ester (bp 108◦ /4 mm Hg). Reflux 10 g 5-chloromethyl furyl-2-carboxylic acid methyl ester and 25 g silver carbonate in 100 mL THF:water 70:30 for 5 h, filter through Celite, concentrate the filtrate under reduced pressure, chromatograph the product on silica gel with chloroform to give 5-hydroxymethyl furyl-2-carboxylic acid methyl ester as a light yellow oil. Add a solution of 2.9 g 5-hydroxymethyl furyl-2-carboxylic acid methyl ester in 30 mL dichloromethane to 12 g pyridinium chlorochromate in 100 mL dichloromethane, stir at room temperature for 4 h, evaporate to dryness under reduced pressure, chromatograph on silica with dichloromethane to give 5-formyl furyl-2-carboxylic acid methyl ester as a light yellow powder. Add 10 mL concentrated nitric acid dropwise to 20 g 4-bromoveratrole in 60 mL acetic acid while keeping the temperature at 10–30◦ with occasional cooling; when the addition is complete, pour the reaction mixture into ice water. Collect the precipitate and dissolve it in 500 mL hot EtOH, add activated charcoal, filter, add 40 mL water to the filtrate to give 4,5-dimethoxy-2-nitrobromobenzene as a light yellow crystalline solid (mp 121–122◦ ). Prepare sodium sulfide by melting together 5 g sodium sulfide nonahydrate and 700 mg sulfur, add this mixture to 5 g 4,5-dimethoxy-2-nitrobromobenzene in 50 mL EtOH:water 95:5, reflux for 30 min, pour into ice water, collect the solid, recrystallize from dichloromethane to give di(4,5-dimethoxy-2-nitrophenyl)sulfide as yellow needles (mp 231–232◦ ). Add 15 mL concentrated HCl dropwise to 1.5 g di(4,5-dimethoxy-2-nitrophenyl)sulfide and 4.5 g tin powder stirred at 40–50◦ in 150 mL EtOH, reflux for 1 h, cool to room temperature, filter, add 1.17 g 5-formyl furyl-2-carboxylic acid methyl ester to the filtrate, reflux for 1 h, cool, filter, chromatograph the solid on silica gel with dichloromethane, recrystallize from EtOH to give 5-(5′ ,6′ -dimethoxybenzothiazolyl)-N-furan-2-carboxylic acid methyl ester as a yellow powder (mp 192–202◦ ). Add 2 mL hydrazine hydrate (Caution! Hydrazine hydrate is a carcinogen!) to 800 mg 5-(5′ ,6′ -dimethoxybenzothiazolyl)N-furan-2-carboxylic acid methyl ester in 20 mL EtOH, reflux for 30 min, collect the solid, wash with MeOH, dry under vacuum over phosphorus pentoxide to give 2-(5-hydrazinocarbonyl-2-furyl)-5,6-dimethoxybenzothiazole as a light yellow solid (mp 226–228◦ ).) HPLC VARIABLES Column: 250 × 4.6 5 µm Wakosil-II 5C18 HG Column temperature: 40 Mobile phase: Gradient. MeCN:water from 70:30 to 75:25 over 25 min, to 100:0 over 15 min, maintain at 100:0. Flow rate: 1 Injection volume: 10 Detector: F ex 363 em 452 CHROMATOGRAM Retention time: 35 Limit of detection: 50 fmol OTHER SUBSTANCES Extracted: alprostadil (51), arachidonic acid (24), dinoprost (41), dinoprostone (50), lauric acid (10), linoleic acid (25), linolenic acid (18), margaric acid (38), myristic acid (19), myristoleic acid (12), palmitic acid (32), palmitoleic acid (21), stearic acid (42) KEY WORDS derivatization; serum REFERENCE Saito, M.; Ushijima, T.; Sasamoto, K.; Ohkura, Y.; Ueno, K. 2-(5-Hydrazinocarbonyl-2-furyl)-5,6-dimethoxybenzothiazole as a precolumn fluorescence derivatization reagent for carboxylic acids in Oleic acid 461 high-performance liquid chromatography and its application to the assay of fatty acids in human serum, Anal.Sci., 1995, 11, 103–107. SAMPLE Matrix: blood Sample preparation: Vortex 10 µL plasma, 200 µL 500 mM pH 6.5 phosphate buffer, 50 µL 20 µM IS in MeOH, and 2 mL n-heptane:chloroform 50:50 for 2 min (Caution! Chloroform is a carcinogen!), centrifuge at 1000 g for 10 min. Remove the lower organic layer and evaporate it to dryness, reconstitute the residue in two 100 µL aliquots of acetone. Evaporate the acetone solution to dryness, add 2–3 mg finely powdered potassium bicarbonate:sodium sulfate 50:50, add 50 µL 800 µM dibenzo-18-crown-6 in acetone, add 50 µL 2 mM 7-acetoxy-4-bromomethylcoumarin in acetone, heat at 50◦ in the dark for 30 min, inject a 50 µL aliquot. (7-Acetoxy-4-bromomethylcoumarin is available from TCI America or Tokyo Kasei, or it may be prepared as follows. Reflux 50 g 7-hydroxy-4-methylcoumarin (β-methylumbelliferone) and 100 mL acetic anhydride for 1 h, cool, pour into 500 mL cold water, filter, dry the solid, recrystallize from EtOH to give 4-methyl-7-acetoxycoumarin. Reflux 10 g 4-methyl-7-acetoxycoumarin, 9 g N-bromosuccinimide, a little 2,2′ -(azobis(2methylpropionitrile) (α,α ′ -azobisisobutyronitrile, Eastman), and 100 mL carbon tetrachloride for 20 h, cool, evaporate under reduced pressure to remove the solvent, wash the residue with water, filter, dry, recrystallize from ethyl acetate/cyclohexane to give 7-acetoxy-4-bromomethyl-coumarin (mp 184–185◦ ) (J.Chromatogr. 1982, 234, 121).) HPLC VARIABLES Column: 250 × 4 5 µm LiChrosorb RP-18 Column temperature: 40 Mobile phase: Gradient. MeCN:MeOH:water from 35:35:30 to 0:90:10 over 70 min (convex gradient). Flow rate: 1.2 Injection volume: 50 Detector: F ex 365 em 460 following post-column reaction. The column effluent mixed with 200 mM NaOH in MeOH:water 80:20 pumped at 0.4 mL/min and the mixture flowed through a 3.5 m ×0.5 mm ID stainless steel coil at 50◦ to the detector. CHROMATOGRAM Retention time: 51 Internal standard: margaric acid (57) Limit of detection: 5 pmol OTHER SUBSTANCES Extracted: arachidonic acid (37), capric acid (17), caproic acid (6), caprylic acid (11), heptanoic acid (9), lauric acid (26), linoleic acid (42), linolenic acid (35), myristic acid (36), myristoleic acid (28), nonanoic acid (15), palmitic acid (50), palmitoleic acid (39), stearic acid (66), tridecanoic acid (30), undecanoic acid (21) KEY WORDS derivatization; plasma; post-column reaction REFERENCE Tsuchiya, H.; Hayashi, T.; Sato, M.; Tatsumi, M.; Takagi, N. Simultaneous separation and sensitive determination of free fatty acids in blood plasma by high-performance liquid chromatography, J.Chromatogr., 1984, 309, 43–52. SAMPLE Matrix: blood Sample preparation: Vortex 50 µL plasma, 10 µL IS solution, and 450 µL micelle solution for 10 s, add 25 µL 28 mg/mL 9-bromomethylacridine in acetone, mix. Remove a 50 µL aliquot and heat it to 60◦ for 6 min, inject the whole amount through a 2 µm 462 Oleic acid stainless steel filter of 8 sq mm area onto column A, wash to waste with 400 µL mobile phase A, backflush the contents of column A onto column B with the mobile phase B, monitor the effluent from column B. After each injection, backflush the stainless steel filter with 1 mL buffer. (The micelle solution was 25 mM Arkopal N-130 (a polyoxyethylene(13)nonylphenol, Hoechst Holland, Amsterdam) in 10 mM pH 7.0 phosphate buffer containing 6 mM tetrakis(decyl)ammonium bromide. 9-Bromomethylacridine is available from TCI America or Tokyo Kasei, or it may be prepared as follows. Heat 10 g diphenylamine, 10 mL glacial acetic acid, and 40 g anhydrous zinc chloride to 220◦ , evaporate excess acetic acid with stirring, heat at 220–230◦ for 6 h, digest with hot 10% sulfuric acid, make strongly alkaline with 25% ammonia to dissolve the zinc chloride. Extract the insoluble residue with toluene. Extract the organic layer with 10% sulfuric acid, make the aqueous layer alkaline with aqueous ammonia. Collect the yellow precipitate that separates and recrystallize it twice from petroleum ether to give 9-methyl acridine as pale yellow needles (Chromatographia 1989, 28, 267). Reflux 560 mg 9-methylacridine, 445 mg N-bromosuccinimide, and 10 mg benzoyl peroxide in 30 mL carbon tetrachloride for more than 2 h, cool, chromatograph on silica gel with benzene:ethyl acetate 30:1 (Caution! Benzene is a carcinogen!) to obtain 9-bromomethylacridine as yellow crystals (mp 147–151◦ ) (Anal.Lett. 1987, 20, 1581).) HPLC VARIABLES Column: A 10 × 2.1 40 µm Chromsep C18 (Chrompack); B 100 × 3 5 µm Chromspher C18 (Chrompack) Mobile phase: A 10 mM pH 7.0 phosphate buffer; B Gradient. MeOH:water 75:25 for 3 min, to 100:0 over 12 min (concave gradient). Injection volume: 50 Detector: UV 254; F ex 362 em 418 CHROMATOGRAM Retention time: 10 Internal standard: heptadecanoic acid (13) Limit of detection: 300 nM OTHER SUBSTANCES Extracted: arachidonic acid (7), linoleic acid (9), linolenic acid (6), myristic acid (8), palmitic acid (10.5), palmitoleic acid (7.5), stearic acid (13.5) KEY WORDS column-switching; derivatization; plasma REFERENCE van der Horst, F.A.L.; Post, M.H.; Holthuis, J.J.M.; Brinkman, U.A.T. Automated high-performance liquid chromatographic determination of plasma free fatty acids using on-line derivatization with 9bromomethylacridine based on micellar phase-transfer catalysis, J.Chromatogr., 1990, 500, 443–452. SAMPLE Matrix: solutions Sample preparation: Mix 100 µL of a solution in EtOH, EtOH/water, or water with 400 µL reagent solution and 200 µL 20 mM 2-nitrophenylhydrazine hydrochloride in water, heat at 60◦ for 20 min, add 100 µL 15% KOH in MeOH:water 80:20, heat at 60◦ for 15 min, cool, inject a 1–2 µL aliquot. (Prepare the reagent by mixing equal volumes of 3% pyridine in EtOH and 250 mM 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride in EtOH.) HPLC VARIABLES Column: 250 × 4.6 5 µm YMC-C8 (Yamamuta Chemical Research, Kyoto) Column temperature: 50 Oleic acid 463 Mobile phase: MeOH:water 86:14 adjusted to pH 4.5 with 100 mM HCl Flow rate: 1.2 Injection volume: 1–2 Detector: UV 230; UV 400 CHROMATOGRAM Retention time: 10.7 Limit of detection: 2.5–5 pmol (UV 230), 10–15 pmol (UV 400) OTHER SUBSTANCES Simultaneous: capric acid (3), lauric acid (5), linoleic acid (8.5), linolenic acid (7), myristic acid (6.5), palmitic acid (10), palmitoleic acid (7.5), stearic acid (14) KEY WORDS derivatization REFERENCE Miwa, H.; Hiyama, C.; Yamamoto, M. High-performance liquid chromatography of short- and long-chain fatty acids as 2-nitrophenylhydrazides, J.Chromatogr., 1985, 321, 165–174. ANNOTATED BIBLIOGRAPHY Abushufa, R.; Reed, P.; Weinkove, C. Fatty acids in erythrocytes measured by isocratic HPLC, Clin.Chem., 1994, 40, 1707–1712. [oleic acid; arachidonic acid; palmitoleic acid; linoleic acid; eicosatrienoic acid; palmitic acid; stearic acid] Akasaka, K.; Suzuki, T.; Ohrui, H.; Meguro, H.; Shindo, Y.; Takahashi, H. 9-Bromomethylacridine a novel fluorescent labeling reagent of carboxylic group for HPLC, Anal.Lett., 1987, 20, 1581–1594. [caprylic acid; capric acid; lauric acid; linolenic acid; arachidonic acid; palmitoleic acid; myristic acid; linoleic acid; oleic acid; palmitic acid; stearic acid] Akasaka, K.; Ohrui, H.; Meguro, H. Determination of carboxylic acids by high-performance liquid chromatography with 2-(2,3-anthracenedicarboximido)ethyl trifluoromethanesulfonate as highly sensitive fluorescent labelling reagent, Analyst, 1993, 118, 765–768. [LOD 1.4–3.8 pmol; caprylic acid; caproic acid; lauric acid; myristoleic acid; eicosapentaenoic acid; linolenic acid; myristic acid; docosahexaenoic acid; palmitoleic acid; arachidonic acid; linoleic acid; eicosatrienoic acid; palmitic acid; oleic acid; eicosadienoic acid; margaric acid; stearic acid; gondoic acid] Baty, J.D.; Pazouki, S.; Dolphin, J. Analysis of fatty acids as their anthrylmethyl esters by highperformance liquid chromatography with fluorescence detection, J.Chromatogr., 1987, 395, 403–411. [plasma; LOD 50 ng; lauric acid; linolenic acid; arachidonic acid; myristic acid; palmitoleic acid; linoleic acid; palmitic acid; oleic acid; stearic acid; arachidic acid; behenic acid; lignoceric acid; margaric acid] Borch, R.F. Separation of long chain fatty acids as phenacyl esters by high pressure liquid chromatography, Anal.Chem., 1975, 47, 2437–2439. [LOD 100 ng; lauric acid; myristoleic acid; linolenic acid; myristic acid; palmitoleic acid; arachidonic acid; linoleic acid; pentadecanoic acid; linolelaidic acid; eicosatrienoic acid; palmitic acid; oleic acid; vaccenic acid; petroselinic acid; elaidic acid; eicosadienoic acid; heptadecanoic acid; stearic acid; eicosaenoic acid; nonadecanoic acid; arachidic acid; erucic acid; heneicosanoic acid; behenic acid; nervonic acid; lignoceric acid] Carrier, A.; Parent, J. Liquid chromatography-mass spectrometry determination of free fatty acids in phospholipid-based formulations, J.Liq.Chromatogr.Rel.Technol., 2001, 24, 97–107. [stearic acid; linoleic acid; linolenic acid; palmitic acid; oleic acid] Cooper, M.J.; Anders, M.W. Determination of long chain fatty acids as 2-naphthacyl esters by high pressure liquid chromatography and mass spectrometry, Anal.Chem., 1974, 46, 1849–1852. [oleic acid; linolenic acid; linoleic acid; dihomolinolenic acid; arachidonic acid] Czauderna, M.; Kowalczyk, J. Separation of some mono-, di- and tri-unsaturated fatty acids containing 18 carbon atoms by high-performance liquid chromatography and photodiode array detection, J.Chromatogr.B, 2001, 760, 165–178. [derivatization; linoleic acid; linolenic acid; oleic acid; ricinoleic acid; myristic acid; palmitic acid; vaccenic acid; stearic acid] Eguchi, Y. Analysis of lipoprotein lipase activity using high-performance liquid chromatography, Biomed.Chromatogr., 2002, 16, 500–503. [oleic acid; derivatization] Ergan, F.; Andre, G. Simple high performance liquid chromatography methods for monitoring lipase reactions, Lipids, 1989, 24, 76–78. [oleic; acid; linolenic acid; linoleic acid; palmitic acid; stearic acid] 464 Oleic acid Fuse, T.; Kusu, F.; Takamura, K. Determination of higher fatty acids in oils by high-performance liquid chromatography with electrochemical detection, J.Chromatogr.A, 1997, 764, 177–182. [linoleic acid; oleic acid; palmitic acid; stearic acid; post-column reaction; derivatization; camellia oil; olive oil; rapeseed oil; corn oil; soybean oil; LOD 20 pmol] Ghiggeri, G.M.; Candiano, G.; Delfino, G.; Queirolo, C.; Ginevri, F.; Perfamo, F.; Gusmano, R. Separation of the 9-anthryldiazomethane derivates of fatty acids by high-performance liquid chromatography on a fatty acid analysis column. Application to albumin-bound fatty acid analysis, J.Chromatogr., 1986, 381, 411–418. [derivatization; caproic acid; caprylic acid; capric acid; lauric acid; myristoleic acid; myristic acid; linolenic acid; linoleic acid; palmitic acid; arachidonic acid; oleic acid; stearic acid; eicosanoic acid; arachidic acid; erucic acid; behenic acid; neuronic acid] Golden, K.D.; Williams, O.J. Amino acid, fatty acid, and carbohydrate content of Artocarpus altilis (breadfruit), J.Chromatogr.Sci., 2001, 39, 243–250. [derivatization; oleic acid; linoleic acid] Hamilton, J.G.; Comai, K. Separation of neutral lipid free fatty acid and phospholipid classes by normal phase HPLC, Lipids, 1988, 23, 1150–1153. [oleic acid; phosphatidylcholine; phosphatidylethanolamine; phosphatidylinositol] Hanis, T.; Smrz, M.; Klir, P.; Macek, K.; Klima, J.; Base, J.; Deyl, Z. Determination of fatty acids as phenacyl esters in rat adipose tissue and blood vessel walls by high-performance liquid chromatography, J.Chromatogr., 1988, 452, 443–457. [derivatization; LOD 0.8–1.2 ng; column temp 40; caproic acid; caprylic acid; capric acid; lauric acid; myristic acid; myristoleic acid; pentadecanoic acid; palmitic acid; palmitoleic acid; heptadecanoic acid; stearic acid; oleic acid; elaidic acid; linoleic acid; linoelaidic acid; eicosenoic acid; eicosadienoic acid; eicosatrienoic acid; arachidonic acid; erucic acid; docosahexaenoic acid] Hoffman, N.E.; Liao, J.C. High pressure liquid chromatography of p-methoxyanilides of fatty acids, Anal.Chem., 1976, 48, 1104–1106. [gradient; stearic acid; palmitoleic acid; oleic acid; linoleic acid; linolenic acid; arachidonic acid; erucic acid; docoshexaenoic acid; nervonic acid; tetradecanoic acid; pentadecanoic acid; hexadecanoic acid; octadecanoic acid; eicosanoic acid; docosanoic acid; tetracosanoic acid; palmitic acid; myristic acid] Holcapek, M.; Jandera, P.; Fischer, J.; Prokes, B. Analytical monitoring of the production of biodiesel by high-performance liquid chromatography with various detection methods, J.Chromatogr.A, 1999, 858, 13–31. Hu, M.; Niculescu, M.; Zhang, X.M.; Hui, A. High-performance liquid chromatographic determination of polysorbate 80 in pharmaceutical suspensions, J.Chromatogr.A, 2003, 984, 233–236. [derivatization; oleic acid] Ikeda, M.; Shimada, K.; Sakaguchi, T. High-performance liquid chromatographic determination of free fatty acids with 1-naphthylamine, J.Chromatogr., 1983, 272, 251–259. [derivatization; serum; column temp 40; LOD 4 ng; margaric acid; myristic acid; palmitoleic acid; linoleic acid; palmitic acid; oleic acid; stearic acid] Ikeda, M.; Shimada, K.; Sakaguchi, T.; Matsumoto, U. Fluorometric high-performance liquid chromatography of 9-aminophenanthrene-derivatized free fatty acids, J.Chromatogr., 1984, 305, 261–270. [derivatization; column temp 40; LOD 10–15 pmol; myristic acid; palmitic acid; palmitoleic acid; stearic acid; linoleic acid; arachidonic acid; oleic acid; margaric acid] Ikenoya, S.; Hiroshima, O.; Ohmae, M.; Kawabe, K. Electrochemical detector for high-performance liquid chromatography. IV. Analysis of fatty acids, bile acids and prostaglandins by derivatization to an electrochemically active form, Chem.Pharm.Bull., 1980, 28, 2941–2947. [derivatization; dinoprost; dinoprostone; guinea pig; plasma; column temp 25; LOD 0.5–2 ng/mL; palmitic acid; palmitoleic acid; stearic acid; oleic acid; linoleic acid; linolenic acid; cholic acid; chenodiol; deoxycholic acid; lithocholic acid] Iwata, T.; Hirose, T.; Nakamura, M.; Yamaguchi, M. 4-(1-Methylphenanthro[9,10-d]imidazol-2-yl) benzohydrazide as derivatization reagent for carboxylic acids in high-performance liquid chromatography with conventional and laser-induced fluorescence detection, Analyst, 1994, 119, 1747–1751. [LOD 0.4–2.3 fmol; arachidic acid; margaric acid; palmitic acid; stearic acid; arachidonic acid; docosahexaenoic acid; linoleic acid; oleic acid; prostaglandin D2 ; dinoprostone; prostaglandin E2α ; thromboxane A2 ; androsterone glucuronide; dehydroisoandrosterone glucuronide; etiocholanolone glucuronide; testosterone glucuronide] Jones, P.J.; Pencharz, P.B.; Clandinin, M.T. Absorption of 13 C-labeled stearic, oleic, and linoleic acids in humans: application to breath tests, J.Lab.Clin.Med., 1985, 105, 647–652. [oleic acid; linoleic acid] Jordi, H.C. Separation of long and short chain fatty acids as naphthacyl and substituted phenacyl esters by high performance liquid chromatography, J.Liq.Chromatogr., 1978, 1, 215–230. [acetic acid; Oleic acid 465 propionic acid; butyric acid; caproic acid; caprylic acid; capric acid; lauric acid; myristic acid; palmitic acid; stearic acid; arachidic acid; behenic acid; lignoceric acid; palmitoleic acid; oleic acid; elaidic acid; vaccenic acid; linoleic acid; linolenic acid; nervonic acid; arachidonic acid; lactic acid; valeric acid; heptanoic acid; nonanoic acid; undecanoic acid; tridecanoic acid; pentadecanoic acid; heptadecanoic acid; nonadecanoic acid; heneicosanoic acid; tricosanoic acid; myristoleic acid; palmitelaidic acid; linolelaidic acid; eicosenoic acid; erucic acid; eicosatrienoic acid; brassidic acid; docosahexenoic acid; eicosapentaenoic acid] Juanéda, P. Utilisation of reversed-phase high-performance liquid chromatography as an alternative to silver-ion chromatography for the separation of cis- and trans-C18:1 fatty acid isomers, J.Chromatogr.A, 2002, 954, 285–289. [derivatization; oleic acid] Kaneda, H.; Kano, Y.; Kamimura, M.; Osawa, T.; Kawakishi, S. Analysis of long-chain fatty acids in beer by HPLC-fluorescence detection method, J.Agric.Food Chem., 1990, 38, 1363–1367. [column temp 40; derivatization; gradient; LOD 0.2 ng/mL; LOQ 0.4 ng/mL; lauric acid; linolenic acid; myristic acid; palmitoleic acid; linoleic acid; palmitic acid; oleic acid; heptadecanoic acid; stearic acid] Kelly, R.A.; O’Hara, D.S.; Kelley, V. High-performance liquid chromatographic separation of femtomolar quantities of endogenous carboxylic acids, including arachidonic acid metabolites, as 4-bromomethyl7-acetoxycoumarin derivatives, J.Chromatogr., 1987, 416, 247–254. [arachidonic acid; fluorescence detection; gradient; post-column reaction; rat; plasma; SPE; LOD 10 fmol; lauric acid; myristoleic acid; linoleic acid; myristic acid; palmitoleic acid; eicosatrienoic acid; palmitic acid; oleic acid; margaric acid; stearic acid] Korte, W.D. 9-(Chloromethyl)anthracene: a useful derivatizing reagent for enhanced ultraviolet and fluorescence detection of carboxylic acids with liquid chromatography, J.Chromatogr., 1982, 243, 153–157. [chenodiol; cholic acid; deoxycholic acid; lauric acid; myristic acid; linoleic acid; palmitic acid; oleic acid; stearic acid; glycocholic acid; glycochenodeoxycholic acid; glycodeoxycholic acid] Kotani, A.; Fuse, T.; Kusu, F. Determination of plasma free fatty acids by high-performance liquid chromatography with electrochemical detection, Anal.Biochem., 2000, 284, 65–69. [linoleic acid; oleic; acid] Lawrence, J.F.; Charbonneau, C.F. Direct, sensitive and selective detection of free fatty acids by highperformance liquid chromatography with post-column ion-pair extraction and absorbance detection, J.Chromatogr., 1988, 445, 189–197. [gradient; post-column extraction; butter; margarine; orange juice; LOD 26–83 ng; caprylic acid; capric acid; lauric acid; linolenic acid; myristic acid; palmitoleic acid; linoleic acid; linolelaidic acid; oleic acid; palmitic acid; elaidic acid; stearic acid] Lee, Y.M.; Nakamura, H.; Nakajima, T. Rapid determination by high-performance liquid chromatography of free fatty acids released from rat platelets after derivatization with monodansylcadaverine, J.Chromatogr., 1990, 515, 467–473. [gradient; platelets; fluorescence; fluorescence detection; column temp 40; LOD 0.1 pmol; lauric acid; myristoleic acid; linolenic acid; myristic acid; palmitoleic acid; linoleic acid; palmitic acid; oleic acid; stearic acid] Li, Z.; Gu, T.; Kelder, B.; Kopchick, J.J. Analysis of fatty acids in mouse cells using reversed-phase high-performance liquid chromatography, Chromatographia, 2001, 54, 463–467. [oleic acid; linoleic acid; alprostadil; dinoprostone; prostaglandin E3 ; prostaglandin F1α ] Lu, C.Y.; Wu, H.L.; Chen, S.H.; Kou, H.S. Highly sensitive determination of long-chain free fatty acids by fluorogenic derivatization and liquid chromatography, Chromatographia, 2001, 53, S250–S253. [lauric acid; myristic acid; palmitic acid; stearic acid; palmitoleic acid; oleic acid; linoleic acid; margaric acid] Mehta, A.; Oeser, A.M.; Carlson, M.G. Rapid quantitation of free fatty acids in human plasma by highperformance liquid chromatography, J.Chromatogr.B, 1998, 719, 9–23. [linoleic acid; derivatization; oleic acid] Miwa, H.; Yamamoto, M. Improved method of determination of biologically important C10:0 -C22:6 fatty acids as their 2-nitrophenylhydrazides by reversed-phase high-performance liquid chromatography, J.Chromatogr., 1986, 351, 275–282. [column temp 30; LOQ 2.5 pmol; capric acid; lauric acid; myristoleic acid; eicosapentenoic acid; linolenic acid; myristic acid; docosahexenoic acid; palmitoleic acid; arachidonic acid; linoleic acid; eicosatrienoic acid; palmitic acid; oleic acid; margaric acid is internal standard; stearic acid] Miwa, H.; Yamamoto, M.; Nishida, T.; Nunoi, K.; Kikuchi, M. High-performance liquid chromatographic analysis of serum long-chain fatty acids by direct derivatization method, J.Chromatogr., 1987, 416, 237–245. [LOD 100–200 fmol; column temp 30; capric acid; lauric acid; myristoleic acid; eicosapentaenoic acid; linolenic acid; myristic acid; docosahexaenoic acid; palmitoleic acid; arachidonic acid; linoleic acid; dihomolinolenic acid; palmitic acid; oleic acid; margaric acid is internal standard; stearic acid] 466 Oleic acid Miwa, H.; Yamamoto, M. Liquid chromatographic determination of free and total fatty acids in milk and milk products as their 2-nitrophenylhydrazides, J.Chromatogr., 1990, 523, 235–246. [milk; butter; cheese; condensed milk; ice cream; gradient; column temp 35; LOD 0.5–2 pmol; lactic acid; acetic acid; propionic acid; isobutyric acid; butyric acid; isovaleric acid; valeric acid; 2-ethylbutyric acid; isocaproic acid; caproic acid; caprylic acid; capric acid; lauric acid; myristoleic acid; eicosapentaenoic acid; linolenic acid; myristic acid; docosahexaenoic acid; palmitoleic acid; arachidonic acid; linoleic acid; linoelaidic acid; eicosatrienoic acid; palmitic acid; docosatetraenoic acid; oleic acid; elaidic acid; eicosadienoic acid; margaric acid; docosatrienoic acid; stearic acid; eicosaenoic acid; docosadienoic acid; arachidic acid; erucic acid] Miwa, H.; Yamamoto, M. Rapid liquid chromatographic determination of fatty acids as 2-nitrophenylhydrazine derivatives, J.AOAC Int., 1996, 79, 493–497. [column temp 50; derivatization; caprylic acid; capric acid; lauric acid; myristoleic acid; octadecatetraenoic acid; eicosapentaenoic acid; linolenic acid; myristic acid; docosahexaenoic acid; palmitoleic acid; arachidonic acid; linoleic acid; linoelaidic acid; eicosatrienoic acid; dihomolinolenic acid; palmitic acid; docosatetraenoic acid; oleic acid; elaidic acid; eicosadienoic acid; margaric acid is internal standard; docosatrienoic acid; stearic acid; eicosenoic acid; docosadienoic acid; arachidic acid; erucic acid] Morita, H.; Konishi, M. Electrogenerated chemiluminescence derivatization reagents for carboxylic acids and amines in high-performance liquid chromatography using tris(2,2′ -bipyridine)ruthenium(II), Anal.Chem., 2002, 74, 1584–1589. [histamine; post-column reaction; linoleic acid; oleic acid] Morita, H.; Konishi, M. Electrogenerated chemiluminescence derivatization reagent, 3-isobutyl-9,10dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ylamine, for carboxylic acid in highperformance liquid chromatography using tris(2,2′ -bipyridine)ruthenium(II), Anal.Chem., 2003, 74, 940–946. [lauric acid; myristoleic acid; myristic acid; linolenic acid; palmitoleic acid; arachidonic acid; linoleic acid; oleic acid; stearic acid] Nakashima, K.; Taguchi, Y.; Kuroda, N.; Akiyama, S.; Duan, G. 2-(4-Hydrazinocarbonylphenyl)-4,5diphenylimidazole as a versatile fluorescent derivatization reagent for the high-performance liquid chromatographic analysis of free fatty acids, J.Chromatogr., 1993, 619, 1–8. [lauric acid; myristic acid; linolenic acid; palmitoleic acid; linoleic acid; arachidonic acid; palmitic acid; oleic acid; stearic acid; margaric acid; LOD 7–57 fmol; serum; gradient; fluorescence detection] Netting, A.G.; Duffield, A.M. Pentafluorobenzyl esters as derivatives for the semi-preparative highperformance liquid chromatography of fatty acids, J.Chromatogr., 1983, 257, 174–179. [derivatization; SPE; normal phase; stearic acid; oleic acid; linoleic acid; linolenic acid] Nimura, N.; Kinoshita, T. Fluorescent labeling of fatty acids with 9-anthryldiazomethane (ADAM) for high performance liquid chromatography, Anal.Lett., 1980, 13, 191–202. [derivatization; propionic acid; butyric acid; valeric acid; caproic acid; heptanoic acid; caprylic acid; capric acid; lauric acid; myristic acid; linolenic acid; linoleic acid; palmitic acid; stearic acid; oleic acid] Nimura, N.; Kinoshita, T.; Yoshida, T.; Uetake, A.; Nakai, C. 1-Pyrenyldiazomethane as a fluorescent labeling reagent for liquid chromatographic determination of carboxylic acids, Anal.Chem., 1988, 60, 2067–2070. [derivatization; gradient; isocratic; fluorescence detection; LOD 20–30 fmol; lactic acid; formic acid; propionic acid; dinoprostone; dinoprost; alprostadil; linolenic acid; palmitoleic acid; myristic acid; linoleic acid; palmitic acid; oleic acid; stearic acid; arachidic acid] Pei, P.T.-S.; Kossa, W.C.; Ramachandran, S.; Henly, R.S. High pressure reverse phase liquid chromatography of fatty acid p-bromophenacyl esters, Lipids, 1976, 11, 814–816. [linoleic acid; derivatization; linolenic acid; linoleaidic acid; oleic acid; elaidic acid; stearic acid; palmitoleic acid; palmitelaidic acid; petroselinic acid] Ryan, P.J.; Honeyman, T.W. Determination of fatty acids by high-performance liquid chromatography of Dns-ethanolamine derivatives, J.Chromatogr., 1984, 312, 461–466. [derivatization; fluorescence detection; bulk; linolenic acid; palmitoleic acid; linoleic acid; eicosadienoic acid; palmitic acid; oleic acid; elaidic acid; margaric acid; arachidonic acid] Saito, M.; Ushijima, T.; Sasamoto, K.; Ohkura, Y.; Ueno, K. 2-(5-Hydrazinocarbonyl-2-oxazolyl)-5,6-dimethoxybenzothiazole as a precolumn fluorescence derivatization reagent for carboxylic acids in high-performance liquid chromatography and its application to the assay of fatty acids in human serum, J.Chromatogr.B, 1995, 674, 167–175. [column temp 40; fluorescence detection; lauric acid; myristic acid; gradient; palmitic acid; stearic acid; margaric acid; nonadecanoic acid; myristoleic acid; palmitoleic acid; linoleic acid; oleic acid; arachidonic acid; dinoprost; dinoprostone; alprostadil; prostaglandin F1α ] Sasamoto, K.; Ushijima, T.; Saito, M.; Ohkura, Y. Precolumn fluorescence derivatization of carboxylic acids using 4-aminomethyl-6,7-dimethoxycoumarin in a two-phase medium, Anal.Sci., 1996, 12, 189–193. [serum; column temp 40; LOD 20–50 fmol; linoleic acid; palmitic acid; oleic acid; lauric acid; Oleic acid 467 myristoleic acid; linolenic acid; myristic acid; palmitoleic acid; arachidonic acid; margaric acid; stearic acid; nonadecanoic acid] Tojo, H.; Ono, T.; Okamoto, M. Reverse-phase high-performance liquid chromatographic assay of phospholipases: application of spectrophotometric detection to rat phospholipase A2 isozymes, J.Lipid Res., 1993, 34, 837–844. [derivatization; enzyme incubations; column temp 20; palmitic acid; margaric acid; stearic acid; oleic acid; linoleic acid; linolenic acid; arachidonic acid] Vioque, E.; Maza, M.P.; Millán, F. High-performance liquid chromatography of fatty acids as their p-phenylazophenacyl esters, J.Chromatogr., 1985, 331, 187–192. [derivatization; bulk; formic acid; acetic acid; propionic acid; butyric acid; valeric acid; caproic acid; heptanoic acid; caprylic acid; nonanoic acid; capric acid; undecanoic acid; lauric acid; tridecanoic acid; myristic acid; pentadecanoic acid; palmitic acid; margaric acid; stearic acid; arachidic acid; linolenic acid; linoleic acid; oleic acid] Wolf, J.H.; Korf, J. Improved automated precolumn derivatization reaction of fatty acids with bromomethylmethoxycoumarin as label, J.Chromatogr., 1990, 502, 423–430. [derivatization; whole blood; gradient; fluorescence detection; rat; palmitoleic acid; myristic acid; oleic acid; palmitic acid; stearic acid; arachidonic acid] Wood, R.; Lee, T. High-performance liquid chromatography of fatty acids: quantitative analysis of saturated, monoenoic, polyenoic and geometrical isomers, J.Chromatogr., 1983, 254, 237–246. [bulk; derivatization; gradient; LOQ 10 ng; lauric acid; myristoleic acid; tridecanoic acid; linolenic acid; myristic acid; arachidonic acid; linoleic acid; pentadecanoic acid; palmitic acid; oleic acid; elaidic acid; stearic acid; heptadecanoic acid] Yamaguchi, M.; Hara, S.; Matsunaga, R.; Nakamura, M.; Ohkura, Y. 3-Bromomethyl-6,7-dimethoxy-1methyl-2(1H)-quinoxalinone as a new fluorescence derivatization reagent for carboxylic acids in high-performance liquid chromatography, J.Chromatogr., 1985, 346, 227–236. [gradient; fluorescence detection; LOD 0.3–1 fmol; propionic acid; butyric acid; valeric acid; caproic acid; caprylic acid; capric acid; lauric acid; myristic acid; palmitic acid; margaric acid; stearic acid; arachidic acid; myristoleic acid; palmitoleic acid; linolenic acid; arachidonic acid; linoleic acid; oleic acid; benzoic acid; salicylic acid; p-aminobenzoic acid; aminobenzoic acid; uridine; deoxyuridine; thymidine; imidazoleacetic acid; methylimidazoleacetic acid; glucuronic acid] Yanagisawa, I.; Yamane, M.; Urayama, T. Simultaneous separation and sensitive determination of free fatty acids in blood plasma by high-performance liquid chromatography, J.Chromatogr., 1985, 345, 229–240. [fluorescence detection; serum; SPE; gradient; acetic acid; propionic acid; pyruvic acid; lactic acid; butyric acid; isobutyric acid; hydroxybutyric acid; valeric acid; isovaleric acid; pentenoic acid; caproic acid; isocaproic acid; hexenoic acid; heptanoic acid; heptenoic acid; caprylic acid; octenoic acid; nonanoic acid; capric acid; undecanoic acid; lauric acid; tridecanoic acid; myristic acid; myristoleic acid; pentadecanoic acid; palmitic acid; palmitoleic acid; palmitelaidic acid; heptadecanoic acid; stearic acid; petroselinic acid; oleic acid; elaidic acid; vaccenic acid; linoleic acid; linoelaidic acid; linolenic acid; nonadecanoic acid; arachidic acid; eicosenoic acid; eicosadienoic acid; homolinolenic acid; eicosatrienoic acid; arachidonic acid; eicospentaenoic acid; heneicosanoic acid; behenic acid; erucic acid; brassidic acid; docosahexaenoic acid; tricosanoic acid; lignoceric acid; nervonic acid] Yasaka, Y.; Tanaka, M.; Matsumoto, T.; Katakawa, J.; Tetsumi, T.; Shono, T. 2-(Phthalimino)ethyl trifluoromethanesulfonate as a highly reactive ultraviolet-labeling agent for carboxylic acids in highperformance liquid chromatography, Anal.Sci., 1990, 6, 49–52. [mouse; brain; LOD 200 fmol; palmitic acid; oleic acid; margaric acid; stearic acid] Yasaka, Y.; Tanaka, M.; Shono, T.; Tetsumi, T.; Katakawa, J. 2-(2,3-Naphthalimino)ethyl trifluoromethanesulfonate as a highly reactive ultraviolet and fluorescent labelling agent for the liquid chromatographic determination of carboxylic acids, J.Chromatogr., 1990, 508, 133–140. [fluorescence detection; UV detection; mouse; brain; LOD 4 fmol; docosahexaenoic acid; arachidonic acid; palmitic acid; oleic acid; margaric acid; stearic acid] Yoshida, T.; Uetake, A.; Yamaguchi, H.; Nimura, N.; Kinoshita, T. New preparation method for 9-anthryldiazomethane (ADAM) as a fluorescent labeling reagent for fatty acids and derivatives, Anal.Biochem., 1988, 173, 70–74. [derivatization; LOQ 125 pmol; gradient; isocratic; fluorescence; fluorescence detection; column temp 50; linolenic acid; palmitoleic acid; arachidic acid; stearic acid; myristic acid; linoleic acid; palmitic acid; oleic acid; lactic acid; acetic acid; propionic acid; pyruvic acid; levulinic acid; ketobutyric acid; ketovaleric acid; ketocaproic acid; glycolic acid; hydroxyisobutyric acid; hydroxyisocaproic acid; hydroxycaprylic acid; hydroxynaphthoic acid; hydroxymyristic acid; hydroxystearic acid] You, J.; Zhang, W.; Jia, X.; Zhang, Y. An improved derivatization method for sensitive determination of fatty acids by high-performance liquid chromatography using 9-(2-hydroxylethyl)-carbazole as derivatization reagent with fluorescence detection, Chromatographia, 2001, 54, 316–322. [derivatization; fluorescence detection; linoleic acid; oleic acid; stearic acid] 468 Oleic acid You, J.; Zhang, W.; Zhang, Y. Simple derivatization method for sensitive determination of fatty acids with fluorescence detection by high-performance liquid chromatography using 9-(2-hydroxyethyl)-carbazole as derivatization reagent, Anal.Chim.Acta, 2001, 436, 163–172. [derivatization; linoleic acid; oleic acid] Zaitseva, I.; Ajmal, M.; Cersosimo, E. Application of high-performance liquid chromatography of plasma fatty acids as their phenacyl esters to evaluate splanchnic and renal fatty acid balance in vivo, J.Chromatogr.B, 1999, 727, 15–22. [derivatization; linoleic acid; oleic acid] Olmesartan Olmesartan Molecular formula: C29 H30 N6 O6 Molecular weight: 558.58 H3C CH3 HO O O O N O N H3C CAS Registry No: 144689-63-4 Merck Index: 13, 6909 469 O H CH3 N N N N SAMPLE Matrix: microsomal incubations Sample preparation: Mix 100 µL microsomal incubation with 100 µL MeCN, centrifuge at 10 000 g for 3 min, inject a 10 µL aliquot. HPLC VARIABLES Column: 150 × 6.9 YMC-Pack ODS-A-312 C18 Mobile phase: MeCN:water:PIC A 45:55:2.2 Flow rate: 1 Injection volume: 10 Detector: UV 254 CHROMATOGRAM Retention time: 6 KEY WORDS human; intestine; liver; rat REFERENCE Kobayashi, N.; Fujimori, I.; Watanabe, M.; Ikeda, T. Real-time monitoring of metabolic reactions by microdialysis in combination with tandem mass spectrometry: hydrolysis of CS-866 in vitro in human and rat plasma, livers, and small intestines, Anal.Biochem., 2000, 287, 272–278. 470 Olopatadine Olopatadine O COOH Molecular formula: C21 H23 NO3 Molecular weight: 337.41 CAS Registry No: 113806-05-6, 140462-76-6 (HCl) Merck Index: 13, 6910 N CH3 CH3 SAMPLE Matrix: blood Sample preparation: Condition a Bond Elut C18 SPE cartridge with 1 mL MeOH, 2 mL water, 2 mL 1% bovine serum albumin in water, and 5 mL water. Vortex 250 µL plasma, 50 µL 200 ng/mL IS in water, and 250 µL water, add to the SPE cartridge, wash with 2 mL water, elute with 1 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with 50 µL mobile phase, filter (0.2 µm PTFE), inject a 10 µL aliquot. HPLC VARIABLES Column: 50 × 2 5 µm Develosil ODS HG-5 Mobile phase: MeOH:10 mM acetic acid 45:55 Flow rate: 0.1 Injection volume: 10 Detector: MS, Micromass Quattro, electrospray, ion source 120◦ , capillary 4.0 kV, counter current electrode 1.2 kV, cone 20 V, positive mode, collision gas argon 0.2 Pa, collision energy 20 eV, m/z 338–165 CHROMATOGRAM Retention time: 2.5 Internal standard: KF11796 ((11Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-propionic acid) (m/z 352–247–179) (4) Limit of quantitation: 1 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Fujita, K.; Magara, H.; Kobayashi, H. Determination of olopatadine, a new antiallergic agent, and its metabolites in human plasma by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry, J.Chromatogr.B, 1999, 731, 345–352. SAMPLE Matrix: microsomal incubations Sample preparation: Mix 100 µL microsomal incubation with 100 µL ice-cold MeCN, centrifuge at 14 020 g for 10 min, filter the supernatant, inject an aliquot of the filtrate. HPLC VARIABLES Column: 150 × 6 5 µm YMC-Pack AM312 Mobile phase: MeCN:0.1% trifluoroacetic acid 20:80 Flow rate: 1 Detector: Radioactivity (14 C) Olopatadine 471 OTHER SUBSTANCES Extracted: metabolites KEY WORDS human; liver REFERENCE Kajita, J.; Inano, K.; Fuse, E.; Kuwabara, T.; Kobayashi, H. Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities, Drug Metab.Dispos., 2002, 30, 1504–1511. 472 Orbifloxacin Orbifloxacin Molecular formula: C19 H20 F3 N3 O3 Molecular weight: 395.38 CAS Registry No: 113617-63-3 CH3 H N H3C F N N F COOH F O SAMPLE Matrix: blood Sample preparation: Mix 200 µL plasma with 800 µL 1.5 µg/mL IS in 100 mM pH 7.4 phosphate buffer, add 6 mL chloroform (Caution! Chloroform is a carcinogen!), shake at 200 oscillations/min for 30 min, centrifuge at 13 000 g for 6 min. Evaporate the organic layer to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL phosphate-buffered saline, inject an aliquot. HPLC VARIABLES Guard column: Novapack C18 Guard-Pak Column: 150 × 3.9 5 µm Novapack C18 Mobile phase: MeCN:buffer 20:80 (The buffer was 20 mM potassium dihydrogen phosphate containing 6 mM phosphoric acid and 12 mM tetraethylammonium bromide, pH adjusted to 3.0 with 2 M NaOH.) Flow rate: 1 Detector: F ex 338 em 425 CHROMATOGRAM Retention time: 3.09 Internal standard: norfloxacin (2.16) Limit of detection: 9 ng/mL (sic) Limit of quantitation: 4 ng/mL OTHER SUBSTANCES Simultaneous: ciprofloxacin (2.28), danofloxacin (2.80), difloxacin (4.52), enrofloxacin (3.30), marbofloxacin (2.20), sarafloxacin (4.40) KEY WORDS plasma; rabbit REFERENCE Garcı́a, M.A.; Solans, C.; Aramayona, J.J.; Rueda, S.; Bregante, M.A. Determination of orbifloxacin in rabbit plasma by high-performance liquid chromatography with fluorescence detection, J.Chromatogr. Sci., 1999, 37, 199–202. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4 Develosil ODS-7 Mobile phase: MeOH:dioxane:100 mM pH 3.5 citrate buffer 12:5:84 (Caution! Dioxane is a carcinogen!) Flow rate: 1.2 Detector: UV 290 Orbifloxacin 473 CHROMATOGRAM Retention time: 6 OTHER SUBSTANCES Simultaneous: degradation products KEY WORDS photodegradation REFERENCE Morimura, T.; Kohno, K.; Nobuhara, Y.; Matsukura, H. Photoreaction and active oxygen generation by photosensitization of a new antibacterial fluoroquinolone derivative, orbifloxacin, in the presence of chloride ion, Chem.Pharm.Bull., 1997, 45, 1828–1832. SAMPLE Matrix: tissue Sample preparation: Condition a 3 mL 250 mg Supelclean ENVI C18 SPE cartridge with 2 mL MeOH and 2 mL MeCN. Pack 250 mg 200–400 mesh AG MP-1 resin (BioRad) between frits in an empty 3 mL tube, condition with MeOH, water, and 5 mL 8 mM NaOH. Add 5 mL MeCN to 1.5 g pureed fish, sonicate (Sonifier 450, 30% duty cycle, 40% power) for 3 min, rotate for 10 min, centrifuge at 3000 rpm for 5 min, repeat extraction with 5 mL MeCN. Combine the extracts and evaporate them to ca. 4 mL under a stream of nitrogen at 45◦ , add to the C18 SPE cartridge, elute with another 1 mL MeCN. Dilute all the eluates to 40 mL with 8 mM NaOH. Add this solution to the AG MP-1 cartridge, wash with 2 mL water, wash with 2 mL MeOH, dry with a stream of nitrogen, elute with 3 mL MeCN:2% formic acid 20:80, add 90 µL IS solution to the eluate, inject a 10 µL aliquot. (IS solution contained 500 ng/mL clenbuterol and 50 ng/mL penbutolol in MeCN:water 20:80.) HPLC VARIABLES Column: 150 × 2.1 5 µm Zorbax Extend C18 Column temperature: 30 Mobile phase: Gradient. MeCN:2% formic acid:water 20:10:70 for 3 min, to 55:10:35 over 0.1 min, maintain at 55:10:35 for 6.9 min, return to initial conditions over 0.1 min, re-equilibrate for 6.9 min. Flow rate: 0.2 Injection volume: 10 Detector: MS, Micromass Quattro LC triple quadrupole, positive ion mode, nebulizer gas nitrogen 100 L/h, drying gas nitrogen 700 L/h, collision gas argon at 1 µbar, source block 110◦ , desolvation 350◦ , cone 32 V, collision energy 16 eV, m/z 396.36–352.11 CHROMATOGRAM Retention time: 2.57 Internal standard: clenbuterol (m/z 277.00–203.00, cone 20 V, collision 15 eV) (3.13), penbutolol (m/z 292.27–236.13, cone 28 V, collision 16 eV) (8.53) Limit of detection: 5 ng/g OTHER SUBSTANCES Extracted: ciprofloxacin (m/z 332.15–288.07, cone 40 V, collision 16 eV; LOD 10 ng/g) (2.17), danofloxacin (m/z 358.08–95.91, cone 38 V, collision 22 eV) (2.23), enrofloxacin (m/z 360.24–316.14, cone 40 V, collision 16 eV) (2.41), flumequine (m/z 262.14–202.03, cone 28 V, collision 34 eV) (9.31), nalidixic acid (m/z 233.09–187.05, cone 28 V, collision 28 eV) (9.14), oxolinic acid (m/z 262.12–160.02, cone 28 V, collision 40 eV) (8.11), piromidic acid (m/z 289.17–243.06, cone 34 V, collision 28 eV) (10.05), sarafloxacin (m/z 386.20–299.06, cone 40 V, collision 28 eV) (3.04) 474 Orbifloxacin KEY WORDS abalone; fish; SPE; trout REFERENCE Johnston, L.; Mackay, L.; Croft, M. Determination of quinolones and fluoroquinolones in fish tissue and seafood by high-performance liquid chromatography with electrospray ionisation tandem mass spectrometric detection, J.Chromatogr.A, 2002, 982, 97–109. ANNOTATED BIBLIOGRAPHY Morimura, T.; Ohno, T.; Matsukura, H.; Nobuhara, Y. Photodegradation kinetics of the new antibacterial fluoroquinolone derivative, orbifloxacin, in aqueous solution, Chem.Pharm.Bull., 1995, 43, 1000–1004. Morimura, T.; Ohno, T.; Matsukura, H.; Nobuhara, Y. Degradation kinetics of the new antibacterial fluoroquinolone derivative, orbifloxacin, in aqueous solution, Chem.Pharm.Bull., 1995, 43, 1052–1054. Morimura, T.; Nobuhara, Y.; Matsukura, H. Photodegradation products of a new antibacterial fluoroquinolone derivative, orbifloxacin, in aqueous solution, Biol.Pharm.Bull., 1997, 45, 373–377. Schneider, M.J.; Donoghue, D.J. Multiresidue analysis of fluoroquinolone antibiotics in chicken tissue using liquid chromatography-fluorescence-multiple mass spectrometry, J.Chromatogr.B, 2002, 780, 83–92. [ciprofloxacin; norfloxacin; danofloxacin; enrofloxacin; orbifloxacin; sarafloxacin; difloxacin; LOQ 10 ng/g] Schneider, M.J.; Donoghue, D.J. Multiresidue determination of fluoroquinolone antibiotics in eggs using liquid chromatography-fluorescence-mass spectrometry, Anal.Chim.Acta, 2003, 483, 39–49. [norfloxacin; ciprofloxacin; danofloxacin; enrofloxacin; orbifloxacin; sarafloxacin; difloxacin; LOQ 10 ng/g] Orlistat Orlistat Molecular formula: C29 H53 NO5 Molecular weight: 495.73 475 O H CH3 O N O H3C CAS Registry No: 96829-58-2 Merck Index: 13, 6935 O O CH3 (CH2)10CH3 SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 50 µL 100 ng/mL IS in MeOH, add 1 mL MeCN, vortex, centrifuge at RCF 834 for 5 min. Remove the upper layer and add it to 5 mL hexane, rotate for 20 min, centrifuge at RCF 834 for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen at 25◦ , reconstitute the residue with 30 µL MeCN:2 mM ammonium acetate 70:30, inject a 10 µL aliquot. HPLC VARIABLES Column: 50 × 2 5 µm Deltabond phenyl (Keystone) Mobile phase: MeCN:2 mM ammonium acetate 90:10 Flow rate: 0.2 Injection volume: 10 Detector: MS, PE Sciex API-III, APCI, tandem triple quadrupole, positive ion mode, declustering potential 38 V, sprayer 4600 V, multiplier −4200 V, nebulizer gas nitrogen at 60 psi, curtain gas nitrogen at 1.2 L/min, collision gas argon, m/z 496–160 CHROMATOGRAM Retention time: 1.2 Internal standard: d5 -orlistat (m/z 501–160) Limit of detection: 0.1 ng/mL Limit of quantitation: 0.2 ng/mL KEY WORDS plasma REFERENCE Bennett, P.K.; Li, Y.T.; Edom, R.; Henion, J. Quantitative determination of Orlistat (tetrahydrolipostatin, Ro 18–0647) in human plasma by high-performance liquid chromatography coupled with ion spray tandem mass spectrometry, J.Mass Spectrom., 1997, 32, 739–749. SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma, IS, and 1 mL MeCN, centrifuge. Mix the supernatant with 5 mL hexane, shake, centrifuge. Remove the upper hexane layer and evaporate it to dryness, reconstitute the residue with 50 µL MeCN:10 mM ammonium acetate 70:30, inject a 20 µL aliquot. HPLC VARIABLES Guard column: 2 mm long Column: 100 × 2 Spherisorb C6 Mobile phase: A MeCN:0.1% formic acid 95:5; or B MeOH:water 85:15 for 2.4 min, to 100:0 (step gradient), maintain at 100:0 for 3 min, re-equilibrate at 85:15 for 3 min. Flow rate: A 0.15; B 0.15 for 2.4 min then 0.3 Injection volume: 20 476 Orlistat Detector: MS Finnigan LCQ, quadrupolar ion trap, capillary electrospray, needle voltage 4 kV; nebulizer gas flow at 60% of maximum; capillary temperature 250◦ ; capillary potential 20 V; lens potential 10 V, positive ion MS-MS mode, m/z 140–350 CHROMATOGRAM Retention time: 1.1 (A), 2.4 (B) Internal standard: d5 -orlistat Limit of quantitation: 0.3 ng/mL KEY WORDS plasma REFERENCE Wieboldt, R.; Campbell, D.A.; Henion, J. Quantitative liquid chromatographic-tandem mass spectrometric determination of orlistat in plasma with a quadrupole ion trap, J.Chromatogr.B, 1998, 708, 121–129. 477 Oseltamivir Oseltamivir H3C H3C Molecular formula: C16 H28 N2 O4 Molecular weight: 312.40 CAS Registry No: 196618-13-0, 204255-11-8 (phosphate) Merck Index: 13, 6958 H O O N H3C H2N CH3 O O SAMPLE Matrix: blood Sample preparation: Condition a 100 mg C18 SPE cartridge (Varian) with 1 mL MeCN:water 75:25 and 1 mL 10 mM HCl in MeCN:water 5:95. Mix 100 µL plasma with 25 µL 1 M citric acid and 100 µL 1 µg/mL IS in 50 mM sodium dihydrogen phosphate, add to the SPE cartridge, wash with 1 mL 10 mM HCl in MeCN:water 5:95, elute with 400 µL MeCN:water 75:25, add 50 µL 20 mM KCN in 200 mM pH 6.5 phosphate buffer to the eluate, add 50 µL 20 mM naphthalene-2,3-dialdehyde in MeCN, vortex, heat at 40◦ for 45 min. Evaporate to dryness under reduced pressure at room temperature, reconstitute the residue with 100 µL 50 mM sodium dihydrogen phosphate, centrifuge, inject a 40 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Prodigy (ODS-2) (Phenomenex) Column temperature: 40 Mobile phase: MeCN:water 27:73 containing 50 mM sodium acetate Flow rate: 2 Injection volume: 40 Detector: F ex 420 em 472 CHROMATOGRAM Retention time: 5.2 (for GS4071 the free acid active metabolite) Internal standard: GS4057 ((3R, 4R, 5S)-4-acetamido- 5 -amino-3-(1-cyclopentanoxy)1-cyclohexene-1-carboxylic acid) (4.3) Limit of detection: 20 ng/mL (S/N 3) Limit of quantitation: 50 ng/mL KEY WORDS derivatization; plasma; rat; SPE REFERENCE Eisenberg, E.J.; Cundy, K.C. High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde, J.Chromatogr.B, 1998, 716, 267–273. SAMPLE Matrix: blood, tissue, urine Sample preparation: Homogenize (Ultraturrax) 1 g lung or liver, centrifuge at 1300 g at 4◦ for 10 min, filter (0.2 µm Gelman Z-spin) while centrifuging at 15 000 g for 15 min, inject an aliquot of the filtrate. Filter (Millipore 10 000 MW cut-off) plasma or urine while centrifuging at 15 000 g for 15 min, inject an aliquot of the ultrafiltrate. HPLC VARIABLES Column: 125 × 4 5 µm Inertsil C-18 Mobile phase: Gradient. A was 50 mM ammonium acetate. B was MeCN:50 mM ammonium acetate 60:40. A:B from 90:10 to 0:100 over 20 min. 478 Oseltamivir Flow rate: 1 Detector: UV 220; Radioactivity (14 C) CHROMATOGRAM Retention time: 14.5 OTHER SUBSTANCES Extracted: GS4071 (free acid active metabolite) (7), other metabolites KEY WORDS liver; lung; plasma; rat; ultrafiltrate REFERENCE Sweeny, D.J.; Lynch, G.; Bidgood, A.M.; Lew, W.; Wang, K.-Y.; Cundy, K.C. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat, Drug Metab.Dispos., 2000, 28, 737–741. SAMPLE Matrix: blood, urine Sample preparation: Condition a 3 mL 7 mm Empore Mixed Phase Cation-MPC SPE disc with 1 mL MeOH, three 3 mL portions of MeOH:50 mM ammonium acetate 90:10, and 1 mL 5 mM pH 3.5 ammonium acetate. Mix 100 µL plasma or urine with 50 µL IS solution and 1 mL 5 mM pH 3.5 ammonium acetate buffer, add to the SPE disc, wash with 1 mL water, wash with 1 mL MeOH, wash with 1 mL MeOH:water 90:10, dry under vacuum, elute with 1 mL MeOH:50 mM ammonium acetate 90:10. Evaporate the eluate to dryness under a stream of nitrogen at ca. 50◦ , reconstitute the residue with 150 µL water, centrifuge at >500 rpm, inject a 100 µL aliquot. (IS solution contained 50 ng/ml of d3 -oseltamivir and 2 µg/ml of d3 -GS4071 in water). HPLC VARIABLES Column: 100 × 5 4 µm Nova-Pak CN HP radial compression Mobile phase: MeOH:80 mM pH 3 formic acid 50:50 Flow rate: 0.5 Injection volume: 100 Detector: MS, Finnigan TSQ 7000 tandem quadrupole, electrospray, collision gas argon, m/z 313–224 CHROMATOGRAM Retention time: 5 Internal standard: d3 -oseltamivir (m/z 316–227); d3 -GS4071 (m/z 288–201) Limit of quantitation: 1 ng/mL (plasma), 5 ng/mL (urine) OTHER SUBSTANCES Extracted: GS4071 (de-ethylated active metabolite) (LOQ 10 ng/mL (plasma), 30 ng/mL (urine); m/z 285–198) (3.5) KEY WORDS ferret; human; marmoset; mouse; plasma; rabbit; rat; SPE REFERENCE Wiltshire, H.; Wiltshire, B.; Citron, A.; Clarke, T.; Serpe, C.; Gray, D.; Herron, W. Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64–0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine, J.Chromatogr.B, 2000, 745, 373–388. 479 Oxaliplatin Oxaliplatin Molecular formula: C8 H14 N2 O4 Pt Molecular weight: 397.29 CAS Registry No: 61825-94-3 Merck Index: 13, 6981 H H N O O O O Pt N H H SAMPLE Matrix: blood Sample preparation: Filter (Sartorius Centrisart I 10 000 MW cut-off) while centrifuging at 4000 g at 4◦ for 1 h, inject an aliquot of the ultrafiltrate. HPLC VARIABLES Column: 250 × 4 5 µm Hypercarb Mobile phase: MeOH:250 mM pH 7.0 succinic acid buffer 90:10 Flow rate: 0.5 Injection volume: 25 Detector: UV 344 following post-column reaction. The column effluent mixed with 2.7 mM sodium N, N-diethyldithiocarbamate in MeOH pumped at 0.17 mL/min and the mixture flowed through a 2.3 m long 0.51 mm ID length of PTFE tubing to the detector. A 2 m length of the tubing was heated in a microwave field (ca. 130 W, Smithcreator, Personal Chemistry, Sweden) at about 110◦ . CHROMATOGRAM Retention time: 12 Limit of quantitation: 40 ng/mL (S/N 10) KEY WORDS pharmacokinetics; post-column reaction; ultrafiltrate; whole blood REFERENCE Ehrsson, H.; Wallin, I. Liquid chromatographic determination of oxaliplatin in blood using post-column derivatization in a microwave field followed by photometric detection, J.Chromatogr.B, 2003, 795, 291–294. SAMPLE Matrix: blood, urine Sample preparation: Plasma. Filter (Amicon MPS-1 with a YMT membrane) while centrifuging at 4◦ at 3000 g for 15 min, inject an aliquot of the ultrafiltrate. Urine. Directly inject an aliquot of urine. (Protect from light.) HPLC VARIABLES Column: 250 × 4.6 Inertsil ODS-2 Column temperature: 40 Mobile phase: MeCN:10 mM pH 5.5 acetate buffer 5:95 Flow rate: 1 Injection volume: 100 Detector: UV 290 following post-column reaction. The column effluent mixed with the reagent (maintained at 0◦ ) pumped at 0.3 mL/min and the mixture flowed through a 10 m ×0.5 mm ID PTFE coil at 60◦ to the detector. (The reagent was 10 mM pH 5.5 acetate buffer containing 40 mM sodium bisulfite.) CHROMATOGRAM Retention time: 11 480 Oxaliplatin Limit of detection: 60 nM OTHER SUBSTANCES Extracted: carboplatin (6.5), tetraplatin (8) KEY WORDS plasma; post-column reaction; rabbit REFERENCE Kizu, R.; Yamamoto, T.; Yokoyama, T.; Tanaka, M.; Miyazaki, M. A sensitive postcolumn derivatization/UV detection system for HPLC determination of antitumor divalent and quadrivalent platinum complexes, Chem.Pharm.Bull., 1995, 43, 108–114. SAMPLE Matrix: solutions Sample preparation: Inject an aliquot of a 700 µg/mL solution of oxaliplatin in MeOH containing 800 µg/mL IS. HPLC VARIABLES Column: 250 × 4.6 10 µm Vydac C18 Column temperature: 24 Mobile phase: MeCN:water 80:20 Flow rate: 0.8 Detector: UV 255 CHROMATOGRAM Retention time: 3.4 Internal standard: flavone (4.6) KEY WORDS robust; validated REFERENCE Ficarra, R.; Calabrò, M.L.; Cutroneo, P.; Tommasini, S.; Melardi, S.; Semreen, M.; Furlanetto, S.; Ficarra, P.; Altavilla, G. Validation of a LC method for the analysis of oxaliplatin in a pharmaceutical formulation using an experimental design, J.Pharm.Biomed.Anal., 2002, 29, 1097–1103. ANNOTATED BIBLIOGRAPHY Heudi, O.; Mercier-Jobard, S.; Cailleux, A.; Allain, P. Mechanisms of reaction of L-methionine with carboplatin and oxaliplatin in different media: a comparison with cisplatin, Biopharm.Drug Dispos., 1999, 20, 107–116. Luo, F.R.; Yen, T.-Y.; Wyrick, S.D.; Chaney, S.G. High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin, J.Chromatogr.B, 1999, 724, 345–356. 481 Oxiconazole Oxiconazole N Molecular formula: C18 H13 Cl4 N3 O Molecular weight: 492.14 CAS Registry No: 64211-45-6, 64211-46-7 (nitrate) Merck Index: 13, 7006 Cl N Cl O N Cl Cl SAMPLE Matrix: formulations Sample preparation: Dissolve lotion containing 50 mg oxiconazole in 50 mL MeOH, dilute a 5 mL aliquot to 50 mL with mobile phase, inject an aliquot. Shake cream containing 50 mg oxiconazole with 50 mL chloroform:MeOH 50:50 for 30 min (Caution! Chloroform is a carcinogen!), make up to 100 mL with MeOH, centrifuge at 4000 rpm at 4◦ for 15 min, filter, dilute fivefold with MeOH. HPLC VARIABLES Guard column: LiChrocart 4-4 Column: 125 × 4 5 µm LiChrocart C8 Mobile phase: MeOH:20 mM ammonium acetate buffer 85:15 Flow rate: 1 Injection volume: 20 Detector: UV 254 CHROMATOGRAM Retention time: 2.7 Limit of detection: 1.2 µg/mL Limit of quantitation: 3.75 µg/mL OTHER SUBSTANCES Noninterfering: benzyl alcohol KEY WORDS cream; lotion; stability-indicating REFERENCE Milano, J.; Morsch, L.M.; Gonalves Cardoso, S. LC method for the analysis of Oxiconazole in pharmaceutical formulations, J.Pharm.Biomed.Anal., 2002, 30, 175–180. SAMPLE Matrix: solutions Sample preparation: Inject an aliquot of a 100 µg/mL solution in MeOH. HPLC VARIABLES Column: 125 × 4 5 µm LiChrospher 100 RP8 Mobile phase: MeCN:20 mM ammonium acetate buffer 75:25 Flow rate: 1 Detector: UV 254 CHROMATOGRAM Retention time: 4.93 482 Oxiconazole OTHER SUBSTANCES Simultaneous: bifonazole, photodegradation products REFERENCE Thoma, K.; Kübler, N. Untersuchung der Photostabilität von Antimykotika. 1. Mitt.: Photostabilität von Azolantimykotika [Photodegradation of antimycotic drugs. Part 1: Photodegradation of azole antimycotics], Pharmazie, 1996, 51, 885–892. Panipenem Molecular formula: C15 H21 N3 O4 S Molecular weight: 339.42 CAS Registry No: 87726-17-8 Merck Index: 13, 7079 NH OH H H H3C N N CH3 S O COOH SAMPLE Matrix: blood Sample preparation: Vortex 10 µL plasma with 10 µL of 200 mM MOPS (3-(Nmorpholino)propanesulfonic acid) solution, add 100 µL MeOH, mix, centrifuge at 12 000 rpm for 5 min, inject a 25 µL aliquot of the supernatant. HPLC VARIABLES Column: 150 × 4.6 5 µm Inertsil ODS-2 Mobile phase: MeOH:buffer 35:65 (The buffer was 5 mM pH 5.8 sodium dihydrogen phosphate containing 5 mM sodium n-dodecylsulfate.) Flow rate: 0.8 Injection volume: 25 Detector: UV 300 CHROMATOGRAM Retention time: 6 Limit of quantitation: 500 ng/mL KEY WORDS plasma REFERENCE Kokubun, H.; Kimura, T.; Murase, S.; Shimada, S.; Kubo, H.; Matsumoto, M.; Nowatari, M.; Matsuura, N. Determination of panipenem in neonatal plasma by HPLC, Anal.Sci., 2000, 16, 1077–1078. HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 483 484 Parecoxib Parecoxib H3C N H Molecular formula: C19 H18 N2 O4 S Molecular weight: 370.42 CAS Registry No: 198470-84-7, 197502-82-2 (Na salt) O N H3C O O S O SAMPLE Matrix: formulations Sample preparation: Inject a 10 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm YMC ODS-AQ Column temperature: 40 Mobile phase: MeCN:10 mM pH 3.0 phosphate buffer 40:60 Flow rate: 2 Injection volume: 10 Detector: UV 215 CHROMATOGRAM Retention time: 9.5 OTHER SUBSTANCES Simultaneous: valdecoxib (5) KEY WORDS injections; stability-indicating REFERENCE Crane, I.M.; Mulhern, M.G.; Nema, S. Stability of reconstituted parecoxib for injection with commonly used diluents, J.Clin.Pharm.Ther., 2003, 28, 363–369. 485 Paricalcitol Paricalcitol CH3 H3C CH3 CH3 OH Molecular formula: C27 H44 O3 CH3 Molecular weight: 416.63 CAS Registry No: 131918-61-1 Merck Index: 13, 7111 H HO OH SAMPLE Matrix: blood Sample preparation: Extract plasma with ether, inject an aliquot onto column A and column B in series and elute with mobile phase. After 1.5 min, remove column A from the circuit. Continue to elute column B with mobile phase and collect fractions. Regenerate column A by backflushing with a stronger mobile phase HPLC VARIABLES Column: A 23 × 4 PVA-Sil; B 250 × 4.6 PVA-Sil Mobile phase: MTBE:isopropanol 97.5:2.5 Detector: Radio receptor assay (after evaporation of fractions) KEY WORDS column-switching; normal phase; plasma REFERENCE Chang, M.; Qasawa, B.; Chu, S. Determination of 19-nor-1α,25 dihydroxy-vitamin D2 (ABT-358) in plasma using a combination of HPLC and radio-receptor assay techniques (Abstract 2648), Pharm.Res., 1997, 14, S427. SAMPLE Matrix: solutions Sample preparation: Inject an aliquot of a solution in mobile phase. HPLC VARIABLES Column: 80 × 6.2 3 µm Zorbax SIL Mobile phase: Hexane:isopropanol:MeOH 91:7:2 Flow rate: 1 Detector: UV 251 CHROMATOGRAM Retention time: 11.9 OTHER SUBSTANCES Simultaneous: metabolites KEY WORDS normal phase 486 Paricalcitol REFERENCE Shankar, V.N.; Propp, A.E.; Schroeder, N.; Surber, B.W.; Makin, H.L.J.; Jones, G. In vitro metabolism of 19-nor-1α,25-(OH)2 D2 in cultured cell lines: inducible synthesis of lipid- and water-soluble metabolites, Arch.Biochem.Biophys., 2001, 387, 297–306. SAMPLE Matrix: solutions Sample preparation: Inject an aliquot of a solution in mobile phase. HPLC VARIABLES Column: 250 × 4.6 6 µm Zorbax CN Mobile phase: Hexane:isopropanol:MeOH 88:10:2 Flow rate: 1 Detector: UV 251 CHROMATOGRAM Retention time: 8.57 OTHER SUBSTANCES Simultaneous: metabolites REFERENCE Shankar, V.N.; Propp, A.E.; Schroeder, N.; Surber, B.W.; Makin, H.L.J.; Jones, G. In vitro metabolism of 19-nor-1α,25-(OH)2 D2 in cultured cell lines: inducible synthesis of lipid- and water-soluble metabolites, Arch.Biochem.Biophys., 2001, 387, 297–306. 487 Pazufloxacin Pazufloxacin Molecular formula: C16 H15 FN2 O4 Molecular weight: 318.30 CAS Registry No: 127045-41-4 Merck Index: 13, 7128 CH3 O N H2N F COOH O SAMPLE Matrix: blood Sample preparation: Vortex 50 µL plasma with 350 µL 1 µg/mL IS in MeOH, cen- trifuge. Evaporate the supernatant to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with mobile phase, inject an aliquot. HPLC VARIABLES Column: 150 × 4.6 Cosmosil 5C18 Column temperature: 40 Mobile phase: MeCN:1 M ammonium acetate:50 mM citric acid 15:1:84 Flow rate: 1 Detector: F ex 335 em 450 CHROMATOGRAM Internal standard: lomefloxacin Limit of quantitation: 100 ng/mL KEY WORDS plasma; rat REFERENCE Hasegawa, T.; Nadai, M.; Haghgoo, S.; Yamaki, K.; Takagi, K.; Nabeshima, T. Influence of a newly developed quinolone, T-3761, on pharmacokinetics of theophylline in rats, Antimicrob.Agents Chemother., 1995, 39, 2138–2140. SAMPLE Matrix: blood, urine Sample preparation: Dilute plasma with an equal volume of MeOH, centrifuge, inject an aliquot. Dilute urine with mobile phase, inject an aliquot. HPLC VARIABLES Column: 150 × 4 Develosil ODS-HG-5 Mobile phase: MeCN:200 mM pH 7.0 phosphate buffer:water 9:5:86 containing 0.68% tetra-n-butylammonium hydrogen sulfate Detector: UV 330 KEY WORDS plasma; rat REFERENCE Hayakawa, H.; Takagi, K.; Takano, Y.F.; Kawamura, Y.; Tsuji, A. Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats, J.Pharm.Pharmacol., 2002, 54, 1229–1236. 488 Penciclovir Penciclovir Molecular formula: C10 H15 N5 O3 Molecular weight: 253.26 CAS Registry No: 39809-25-1 Merck Index: 13, 7154 O H N N H2N N N OH OH SAMPLE Matrix: blood Sample preparation: Mix 200 µL blood with 600 µL 16% trichloroacetic acid, centrifuge, inject an aliquot of the supernatant. HPLC VARIABLES Guard column: C18 Guard-Pak (Waters) Column: 100 × 8 Nova-Pak C18 (in a Z module) Mobile phase: Gradient. A was 50 mM sodium hydrogen phosphate. B was MeOH:water 80:20 containing 5 mM sodium dihydrogen phosphate. A:B 99:1 for 1.5 min, to 5:95 over 18.5 min, re-equilibrate at initial conditions for 10 min. Flow rate: 1.6 Detector: UV 254 CHROMATOGRAM Retention time: 13.5 Limit of detection: 200 ng/mL OTHER SUBSTANCES Extracted: acyclovir (LOD 250 ng/mL) (11.6) KEY WORDS mouse; pharmacokinetics; whole blood REFERENCE Boyd, M.R.; Bacon, T.H.; Sutton, D. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) in animals, Antimicrob.Agents Chemother., 1988, 32, 358–363. SAMPLE Matrix: blood Sample preparation: Condition a 1 mL Bond Elut SCX SPE cartridge with 1 mL MeOH, 1 mL water, and 1 mL 1 mM pH 7 sodium dihydrogen phosphate buffer. Mix 500 µL plasma with 50 µL 100 µg/mL IS in water, add 500 µL 16% trichloroacetic acid, mix, centrifuge (12 cm rotor arm) at 3000 rpm for 5 min. Add the supernatant to 500 µL 1 mM pH 7 sodium dihydrogen phosphate buffer, add to the SPE cartridge, wash with 1 mL 1 mM pH 7 sodium dihydrogen phosphate buffer, elute with 500 µL MeOH:250 mM pH 11 potassium dihydrogen phosphate 20:80, inject a 25–50 µL aliquot of the eluate. HPLC VARIABLES Guard column: 15 × 3.2 7 µm Newguard RP-18 Column: 250 × 4.6 5 µm Spherisorb ODS2 Mobile phase: MeOH:10 mM pH 7 sodium dihydrogen phosphate buffer 10:90 Flow rate: 1 Injection volume: 25–50 Detector: UV 254 Penciclovir 489 CHROMATOGRAM Retention time: 9 Internal standard: BRL 42377 (9-(4-hydroxy-2-hydroxymethylbut-1-yl)guanine) (10.5) Limit of quantitation: 100 ng/mL KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Fowles, S.E.; Pierce, D.M. High-performance liquid chromatographic method for the determination of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL-39123) in human plasma and urine, Analyst, 1989, 114, 1373–1375. SAMPLE Matrix: blood, urine Sample preparation: Condition a Bond Elut SCX strong cation exchange SPE cartridge with 1 mL MeOH, 1 mL water, and 1 mL 1 mM pH 7.0 disodium hydrogen phosphate buffer. Mix 500 µL plasma or 100 µL urine with 100 µL 20–50 µg/mL IS in water and 100–500 µL 16% trichloroacetic acid, add the supernatant to the SPE cartridge, wash with 1 mL MeOH:1 mM pH 7.0 disodium hydrogen phosphate buffer 20:80, elute with 1 mL MeOH:100 mM pH 11.0 dipotassium hydrogen phosphate buffer 25:75, inject an aliquot. HPLC VARIABLES Column: 3 µm Apex 1 ODS Mobile phase: Gradient. A was MeOH:10 mM pH 7.0 disodium hydrogen phosphate buffer 7:93. B was MeOH:10 mM pH 7.0 disodium hydrogen phosphate buffer 35:65. A:B from 100:0 to 0:100 over 4 min, maintain at 0:100 for 1.5 min, return to 0:100 over 1 min. Flow rate: 2 Detector: UV 254 CHROMATOGRAM Retention time: 1.5 Internal standard: 6-deoxy-9-(4-hydroxy-2-hydroxymethylbut-1-yl)guanine (BRL 44056) (UV 305) (2.8) Limit of detection: 500 ng/mL (plasma); 50 µg/mL (urine) OTHER SUBSTANCES Extracted: famciclovir (UV 305) (6); metabolites KEY WORDS dog; human; plasma; rat; SPE REFERENCE Winton, C.F.; Fowles, S.E.; Pierce, D.M.; Hodge, A.V. Gradient high-performance liquid chromatographic method for the analysis of the pro-drug famciclovir and its metabolites, including the active anti-viral agent penciclovir, in plasma and urine, Anal.Proc., 1990, 27, 181–182. 490 Pentaerythritol tetranitrate Pentaerythritol tetranitrate Molecular formula: C5 H8 N4 O12 ONO2 ONO2 O2NO ONO2 Molecular weight: 316.14 CAS Registry No: 78-11-5 Merck Index: 13, 7186 SAMPLE Matrix: blood Sample preparation: Vigorously shake 5 mL plasma with 8 mL ethyl acetate for 1 min, sonicate for 5 min, centrifuge at 3000 rpm for 3 min, repeat extraction with 8 mL ethyl acetate, repeat extraction with 6 mL ethyl acetate. Pass the extracts through a C18 SPE cartridge, filter (0.5 µm) the eluate. Evaporate the eluate to 200 µL under a stream of nitrogen at 35◦ , inject a 25 µL aliquot. HPLC VARIABLES Column: 300 × 3.9 10 µm µBondapak CN Mobile phase: Iso-octane:dichloromethane:MeOH 75:20:5 Flow rate: 1.5 Injection volume: 25 Detector: TEA (Thermal Energy Analyzer; nitrosyl specific), Thermo Electron Corpo- ration Model 502, pyrolyzer 500◦ , carrier gas nitrogen at 5 mL/min, reaction chamber 0.6 torr, cryogenic trap -78◦ CHROMATOGRAM Retention time: 7 Limit of quantitation: 1 ng/mL OTHER SUBSTANCES Extracted: isosorbide dinitrate (4), nitroglycerin (5), metabolites KEY WORDS plasma REFERENCE Yu, W.C.; Goff, E.U. Measurement of plasma concentrations of vasodilators and metabolites by the TEA Analyzer, Biopharm.Drug Dispos., 1983, 4, 311–319. 491 Pentosan polysulfate Pentosan polysulfate Molecular weight: 1500–5000 CAS Registry No: 37300-21-3, 37319-17-8 (sodium salt) Merck Index: 13, 7212 O HSO3O O OSO3H n n = 6−12 SAMPLE Matrix: solutions HPLC VARIABLES Column: LiChrospher Si 100 diol Column temperature: 25 Mobile phase: 200 mM NaCl Flow rate: 1 Detector: Refractive Index CHROMATOGRAM Retention time: 2 REFERENCE Muller, D.; Ndoume-Nze, M.; Jozefonvicz, J. High-pressure size-exclusion chromatography of anticoagulant materials, J.Chromatogr., 1984, 297, 351–358. 492 Perflubron Perflubron Molecular formula: C8 BrF17 F F F F F F F F F F F F F F F F F Br Molecular weight: 498.96 CAS Registry No: 423-55-2 Merck Index: 13, 7235 SAMPLE Matrix: solutions HPLC VARIABLES Column: Dynamax Microsorb silica (Rainin) Mobile phase: Hexane:isopropanol 50:1 Flow rate: 2 Injection volume: 20 Detector: UV 254 CHROMATOGRAM Retention time: 1.6 OTHER SUBSTANCES Simultaneous: phenol (3.8) Interfering: 1-(4-perfluorobutylphenyl)-1-hexanone KEY WORDS normal phase REFERENCE Williams, T.D.; Jay, M.; Lehmler, H.-J.; Clark, M.E.; Stalker, D.J.; Bummer, P.M. Solubility enhancement of phenol and phenol derivatives in perfluorooctyl bromide, J.Pharm.Sci., 1998, 87, 1585–1589. 493 Perospirone Perospirone Molecular formula: C23 H30 N4 O2 S Molecular weight: 426.58 CAS Registry No: 150915-41-6, 129273-38-7 (HCl) Merck Index: 13, 7259 H O N H N O N N S SAMPLE Matrix: blood Sample preparation: Vortex 2 mL plasma, 500 µL water, 500 µL 1 mM NaOH, and 100 µL 250 ng/mL IS in water for 10 s, add 5 mL n-hexane:chloroform 70:30 (Caution! Chloroform is a carcinogen!), shake for 10 min, centrifuge at 1700 g at 4◦ for 10 min. Evaporate the organic layer to dryness under reduced pressure at 45◦ , reconstitute the residue with 750 µL mobile phase A, inject a 500 µL aliquot onto column A and elute to waste with mobile phase A; after 13.5 min, elute the contents of column A onto column B with mobile phase B; after another 3.5, min remove column A from the circuit, elute column B with mobile phase B, monitor the effluent from column B. (Re-equilibrate column A with mobile phase A for 18 min.) HPLC VARIABLES Column: A 35 × 4.6 10 µm TSK gel PW (methacrylate polymer) (Tosoh); B 150 × 4.6 5 µm C18 STR ODS II (Shinwa, Kyoto) Column temperature: 30 (column B only) Mobile phase: A MeCN:50 mM pH 4.6 phosphate buffer:6 M perchloric acid 4.6:94.9:0.5; B MeCN:50 mM pH 4.6 phosphate buffer:6 M perchloric acid 41.5:58.0:0.5 Flow rate: A 1.2; B 0.6 Injection volume: 500 Detector: F ex 315 em 405 CHROMATOGRAM Retention time: 25 Internal standard: tiospirone (29.5) Limit of detection: 60 pg/mL Limit of quantitation: 100 pg/mL OTHER SUBSTANCES Extracted: metabolite (ID-15036) (21.5) Noninterfering: alprazolam, bromperidol, chlorpromazine, diazepam, haloperidol, levomepromazine, nitrazepam, risperidone KEY WORDS column-switching; pharmacokinetics; plasma REFERENCE Yasui-Furukori, N.; Inoue, Y.; Tateishi, T. Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography, J.Chromatogr.B, 2003, 789, 239–245. 494 Phenazopyridine hydrochloride Phenazopyridine hydrochloride Molecular formula: C11 H12 ClN5 Molecular weight: 249.71 CAS Registry No: 136-40-3 Merck Index: 13, 7296 NH2 N H2N N N HCl SAMPLE Matrix: blood Sample preparation: Vigorously mix 1 mL plasma, 50 µL 40 µg/mL IS, 200 µL 100 mM NaOH, and 4 mL MTBE, centrifuge at 3000 rpm for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 1 mL 20 mM phosphoric acid, inject an 80 µL aliquot. HPLC VARIABLES Guard column: BDS C8 Column: 100 × 4.6 5 µm LiChrospher 60 RP-Select B Mobile phase: MeCN:20 mM pH 2.7 potassium dihydrogen phosphate buffer 30:70 Flow rate: 1.5 Injection volume: 80 Detector: UV 405 CHROMATOGRAM Retention time: 2.5 Internal standard: diltiazem (UV 238) (3.9) Limit of detection: 10 ng/mL Limit of quantitation: 50 ng/mL KEY WORDS plasma REFERENCE Farin, D.; Piva, G.; Kitzes-Cohen, R. Determination of phenazopyridine in human plasma by high performance liquid chromatography, Chromatographia, 2000, 52, 179–180. SAMPLE Matrix: blood, urine Sample preparation: Condition a 3 mL 130 mg Bond Elut Certify SPE cartridge with 3 mL MeOH and 3 mL 200 mM pH 6.0 phosphate buffer. Vortex 3 mL serum or urine with 3 mL 400 mM pH 6.0 phosphate buffer for 1 min, add to the SPE cartridge at 1 mL/min, wash with 3 mL MeOH:200 mM pH 6.0 phosphate buffer 5:95, pass air through the SPE cartridge for 10 s, elute with 750 µL MeOH:10% ammonia 100:20 at 0.5 mL/min. Add a few drops of 1 M HCl to the eluate and evaporate to dryness under a stream of nitrogen, reconstitute the residue with 150 µL mobile phase, inject an aliquot. HPLC VARIABLES Guard column: 10 × 2.1 5 µm Hypersil C18 Column: 150 × 4.6 5 µm Hypersil C18 Column temperature: 45 Mobile phase: Gradient. A was MeCN:buffer 5:95. B was MeCN:buffer 50:50. A:B from 85:15 to 10:90 over 20 min, maintain at 10:90 for 5 min, return to initial conditions over 3 min, re-equilibrate for 6 min. (The buffer was 50 mM pH 3.0 phosphate buffer containing 375 mg/L sodium octyl sulfate and 3 mL/L triethylamine.) Phenazopyridine hydrochloride 495 Flow rate: 1 Detector: UV 240 CHROMATOGRAM Retention time: 17.1 OTHER SUBSTANCES Extracted: acebutolol (UV 326,235) (12.8), acetaminophen (UV 247) (2.7), N-acetylprocainamide (UV 268) (4.9), amineptine (UV 268) (19.3), amitriptyline (UV 240,211) (22.3), amobarbital (UV 211) (15.3), amoxapine (UV 296,211.5) (19.1), amphetamine (UV 254) (11.2), aprobarbital (14.7), atenolol (UV 275,230) (4.3), atropine (UV 260) (11.3), barbital (UV 212) (5.5), benzhexol (UV 260) (22.5), benztropine (UV 257,223) (22.9), benzoylecgonine (UV 278,235) (6.7), bromazepam (UV 235) (13.3), buprenorphine (UV 284,213) (19.4), buspirone (UV 302,239,211) (16.2), butabarbital (UV 211) (10.1), caffeine (UV 270) (3.5), carbamazepine (UV 283,215) (15.1), chloramphenicol (UV 277) (10.6), chlordiazepoxide (UV 303,245) (15.1), chlormethiazole (UV 252,211) (12.4), chlorpromazine (UV 310,255) (23.9), cimetidine (UV 219) (3.5), citalopram (UV 239) (19.0), clobazam (UV 292,231) (20.5), clomipramine (UV 250,211) (23.6), clonazepam (UV 310,240,211) (18.5), clonidine (UV 265) (6.9), cloperastine (UV 238) (26.2), cloxazolam (UV 340,265,239.5) (18.4), cocaine (UV 278,235) (14.7), codeine (UV 280,211) (5.0), desipramine (UV 250) (20.5), diazepam (UV 313,229) (22.6), dihydrocodeine (UV 282,211) (4.8), diltiazem (UV 242,211.5) (19.2), diphenhydramine (UV 258) (19.4), disopyramide (UV 260) (14.9), dothiepin (UV 303,263,231,211) (21.5), doxepin (UV 291) (19.1), ephedrine (UV 257) (6.2), erythromycin (UV 211) (23.3), fentanyl (UV 262) (18.4), flecainide (UV 299) (19.5), flumazenil (UV 250) (11.0), fluoxetine (UV 262,228) (22.6), fluphenazine (UV 310,257) (23.7), flupenthixol (UV 268,231) (27.2), flurazepam (UV 315,231) (20.6), fluvoxamine (UV 251) (20.8), furosemide (UV 344,275,235) (13.2), glutethimide (15.8), guaifenesin (UV 275,224) (6.7), haloperidol (UV 245,220) (19.6), hydralazine (UV 304,260,211) (3.5), hydroxyzine (UV 231) (21.2), ibuprofen (UV 263,219.5) (28.0), imipramine (UV 250,211) (21.6), indomethacin (UV 299,240) (27.9), ketamine (UV 270) (12.7), ketoconazole (UV 295,240) (20.8), labetalol (UV 303) (15.7), lidocaine (UV 266) (13.7), lorazepam (UV 318,231.5) (18.4), lormetazepam (UV 315,231) (20.5), loxapine (UV 295,250) (19.8), maprotiline (UV 272) (22.0), MDMA (UV 287,235) (13.0), methadone (23.0), methamphetamine (UV 254) (12.0), methaqualone (UV 308,267,227) (18.1), methylephedrine (UV 254) (7.7), methylphenidate (UV 260) (15.0), metoclopramide (UV 311,275,215) (13.0), metoprolol (UV 275,223) (13.8), mianserin (UV 280) (19.3), midazolam (UV 221) (19.3), moclobemide (UV 238) (14.1), molindone (UV 301,256,211) (13.6), morphine (UV 286,212) (2.7), nadolol (UV 272,219) (6.6), naloxone (UV 282,209) (5.0), naproxen (UV 270,231.5) (20.2), nifedipine (UV 335,235) (20.8), nitrazepam (UV 310,260,219) (16.3), nordiazepam (UV 310,231) (19.7), norfluoxetine (UV 262,228) (21.4), nortriptyline (UV 240) (21.0), ofloxacin (UV 327,295.5,230) (9.5), oxycodone (UV 280) (9.9), oxymorphone (UV 280) (6.7), paroxetine (UV 295,235) (19.8), pentobarbital (UV 211) (14.9), pericyazine (UV 269,232) (19.6), perphenazine (UV 320,255,210) (22.2), pethidine (15.5), phenazopyridine (UV 240) (17.1), phencyclidine (UV 265) (17.8), pheniramine (UV 260) (13.0), phenobarbital (9.9), phentermine (UV 254) (12.5), phenylephrine (UV 302,259,219) (9.2), phenylpropanolamine (UV 258) (4.9), phenyltoloxamine (UV 272) (20.6), phenytoin (15.3), pholcodine (UV 284,211.5) (4.0), pimozide (UV 280) (25.3), pinazepam (UV 310,227.5) (25.5), piroxicam (UV 248) (15.9), prazepam (UV 311,231.5) (25.1), primidone (6.2), procainamide (UV 280,210) (3.6), promethazine (UV 297,250) (21.7), propoxyphene (UV 259) (21.8), protriptyline (UV 290,211) (21.4), pseudoephedrine (UV 257) (6.2), quinidine (UV 330,240,212) (13.8), ranitidine (UV 315,227) (4.6), salicylic acid (UV 300,234) (6.5), secobarbital (UV 211) (16.0), sertraline (UV 273) (23.2), spironolactone (UV 240) (24.5), sulfamethoxazole (UV 269.5,211.5) (8.0), sulpiride (UV 293,213) (4.0), temazepam (UV 231.5,312) (19.5), terfenadine (UV 260,219) (27.4), theophylline (UV 270) (2.5), thiopentone (UV 288,238) (18.7), thioridazine (UV 314,265) (24.5), thiothixene (UV 308,259,231) (22.0), tocainide (UV 276) (8.8), tolbutamide (UV 228) (18.9), trazodone (UV 250) (14.9), triazolam (UV 223) (19.3), triflupromazine (UV 496 Phenazopyridine hydrochloride 308,257) (25.8), trimeprazine (UV 250) (26.9), trimethoprim (UV 272) (10.9), trimipramine (UV 250,211) (23.9), verapamil (UV 280,230) (21.6), zopiclone (UV 305,218) (12.3), zuclopenthixol (UV 325,267,227) (22.0) Interfering: alprazolam (UV 225) (17.5), brompheniramine (UV 227, UV 263) (17.2), chlorpheniramine (UV 263, UV 223) (17.3), clozapine (UV 211, UV 290) (17.0), fenfluramine (UV 263) (17.2), flunitrazepam (UV 220, UV 253, UV 313) (17.5), mesoridazine (UV 220, UV 273) (17.2), oxazepam (UV 229, UV 310) (17.5), oxazolam (UV 234) (17.0), pentazocine (UV 280) (16.7), phenolphthalein (UV 231, UV 278) (16.8), propranolol (UV215, UV 230, UV 290) (17.2), propyphenazone (UV 249, UV 274) (17.0), risperidone (UV 236, UV 276) (16.7) KEY WORDS serum; SPE REFERENCE Lai, C.-K.; Lee, T.; Au, K.-M.; Chan, A.Y.-W. Uniform solid-phase extraction procedure for toxicological drug screening in serum and urine by HPLC with photodiode-array detection, Clin.Chem., 1997, 43, 312–325. Phentermine Phentermine 497 NH2 H3C CH3 Molecular formula: C10 H15 N Molecular weight: 149.23 CAS Registry No: 122-09-8, 1197-21-3 (HCl) Merck Index: 13, 7346 SAMPLE Matrix: blood Sample preparation: Condition a 200 mg Bond Elut C18 SPE cartridge with 1 mL MeOH, 1 mL water, and 2 mL 10 mM pH 9.3 ammonium carbonate buffer. Centrifuge serum, whole blood, or urine at 14 000 g for 5 min. Vortex 0.2–1 mL aliquots of the supernatant with 2 mL 10 mM pH 9.3 ammonium carbonate buffer and IS, centrifuge at 5000 g for 10 min, add 2 mL of the supernatant to the SPE cartridge, wash with 2 mL 10 mM pH 9.3 ammonium carbonate buffer, dry SPE cartridge under vacuum for 5 min, elute with 500 µL MeOH:500 mM acetic acid 90:10. Add 10 µL 1 mM HCl to the eluate, evaporate to dryness under a stream of nitrogen, reconstitute the residue with 100 µL mobile phase, centrifuge at 14 000 g for 4 min, inject a 5–20 µL aliquot. HPLC VARIABLES Column: 125 × 3 Superspher RP 18 Mobile phase: MeCN:50 mM pH 3.0 ammonium formate buffer 25:75 Flow rate: 0.3 Injection volume: 5–20 Detector: MS, Finnigan MAT SSQ 7000, APCI, positive ion mode, sheath gas nitrogen 70 psi, auxiliary gas nitrogen 20 mL/min, capillary 190◦ , vaporizer 450◦ , corona current 5 µA CHROMATOGRAM Retention time: 4.3 Internal standard: d10 -methamphetamine Limit of detection: 1 ng/mL OTHER SUBSTANCES Extracted: amphetamine (3.4), cathinone (2.6), ephedrine (3.1), fenfluramine (7.0), MDA (3.5), MDEA (5.2), MDMA (4.2), methamphetamine (4.1), norfenfluramine (4.2), phenylpropanolamine (2.5) KEY WORDS serum; SPE; urine; whole blood REFERENCE Bogusz, M.J. Liquid chromatography-mass spectrometry as a routine method in forensic sciences: a proof of maturity, J.Chromatogr.B, 2000, 748, 3–19. SAMPLE Matrix: blood Sample preparation: Mix 100 µL plasma with 10 µL 2 µM IS in water, add 200 µL 100 mM pH 10.6 borate buffer, add 750 µL ethyl acetate, vortex for 1 min, centrifuge at 1700 g at 4◦ for 10 min. Add 10 µL acetic acid to the organic layer, evaporate to dryness under reduced pressure at 45◦ over 15 min. Vortex the residue with 75 µL 4.7 mM dansyl chloride in MeCN and 25 µL 20 mM pH 9.0 carbonate buffer, heat at 45◦ for 30 min, add 3 µL MeCN:methylamine 80:20, let stand for 10 min, add 4 µL 3 M HCl, inject a 20 µL aliquot. 498 Phentermine HPLC VARIABLES Column: 250 × 4.6 5 µm Diasopak SP-120-5-ODS (Daiso, Osaka) Mobile phase: Gradient. A was MeOH:100 mM acetic acid 60:40. B was MeCN. A:B 80:20 for 20 min, to 45:55 over 2 min, maintain at 45:55 for 17 min, return to initial conditions. Flow rate: 1 Injection volume: 20 Detector: F ex 325 em 530 CHROMATOGRAM Retention time: 31 Internal standard: fluoxetine (45) Limit of quantitation: 5 nM OTHER SUBSTANCES Extracted: 4-bromo-2,5-dimethoxyphenylethylamine (30), epinephrine (21), fenfluramine (39), norepinephrine (16), 2-phenylethylamine (25) KEY WORDS derivatization; human; pharmacokinetics; plasma; rat REFERENCE Kaddoumi, A.; Nakashima, M.N.; Wada, M.; Kuroda, N.; Nakahara, Y.; Nakashima, K. HPLC of (±)fenfluramine and phentermine in plasma after derivatization with dansyl chloride, J.Liq.Chromatogr. Rel.Technol., 2001, 24, 57–67. SAMPLE Matrix: blood, urine Sample preparation: Condition a 3 mL 130 mg Bond Elut Certify SPE cartridge with 3 mL MeOH and 3 mL 200 mM pH 6.0 phosphate buffer. Vortex 3 mL serum or urine with 3 mL 400 mM pH 6.0 phosphate buffer for 1 min, add to the SPE cartridge at 1 mL/min, wash with 3 mL MeOH:200 mM pH 6.0 phosphate buffer 5:95, pass air through the SPE cartridge for 10 s, elute with 750 µL MeOH:10% ammonia 100:20 at 0.5 mL/min. Add a few drops of 1 M HCl to the eluate and evaporate to dryness under a stream of nitrogen, reconstitute the residue with 150 µL mobile phase, inject an aliquot. HPLC VARIABLES Guard column: 10 × 2.1 5 µm Hypersil C18 Column: 150 × 4.6 5 µm Hypersil C18 Column temperature: 45 Mobile phase: Gradient. A was MeCN:buffer 5:95. B was MeCN:buffer 50:50. A:B from 85:15 to 10:90 over 20 min, maintain at 10:90 for 5 min, return to initial conditions over 3 min, re-equilibrate for 6 min. (The buffer was 50 mM pH 3.0 phosphate buffer containing 375 mg/L sodium octyl sulfate and 3 mL/L triethylamine.) Flow rate: 1 Detector: UV 254 CHROMATOGRAM Retention time: 12.5 OTHER SUBSTANCES Extracted: acetaminophen (UV 247) (2.7), N-acetylprocainamide (UV 268) (4.9), alprazolam (UV 225) (17.5), amineptine (UV 268) (19.3), amitriptyline (UV 240,211) (22.3), amobarbital (UV 211) (15.3), amoxapine (UV 296,211.5) (19.1), amphetamine (UV 254) (11.2), aprobarbital (14.7), atenolol (UV 275,230) (4.3), atropine (UV 260) (11.3), Phentermine 499 barbital (UV 212) (5.5), benzhexol (UV 260) (22.5), benztropine (UV 257,223) (22.9), benzoylecgonine (UV 278,235) (6.7), bromazepam (UV 235) (13.3), brompheniramine (UV 263,227) (17.2), buprenorphine (UV 284,213) (19.4), buspirone (UV 302,239,211) (16.2), butabarbital (UV 211) (10.1), caffeine (UV 270) (3.5), carbamazepine (UV 283,215) (15.1), chloramphenicol (UV 277) (10.6), chlordiazepoxide (UV 303,245) (15.1), chlorpheniramine (UV 263,223) (17.3), chlorpromazine (UV 310,255) (23.9), cimetidine (UV 219) (3.5), citalopram (UV 239) (19.0), clobazam (UV 292,231) (20.5), clomipramine (UV 250,211) (23.6), clonazepam (UV 310,240,211) (18.5), clonidine (UV 265) (6.9), cloperastine (UV 238) (26.2), cloxazolam (UV 340,265,239.5) (18.4), clozapine (UV 290,211) (17.0), cocaine (UV 278,235) (14.7), codeine (UV 280,211) (5.0), desipramine (UV 250) (20.5), diazepam (UV 313,229) (22.6), dihydrocodeine (UV 282,211) (4.8), diltiazem (UV 242,211.5) (19.2), diphenhydramine (UV 258) (19.4), disopyramide (UV 260) (14.9), dothiepin (UV 303,263,231,211) (21.5), doxepin (UV 291) (19.1), ephedrine (UV 257) (6.2), erythromycin (UV 211) (23.3), fenfluramine (UV 263) (17.2), fentanyl (UV 262) (18.4), flecainide (UV 299) (19.5), flumazenil (UV 250) (11.0), flunitrazepam (UV 313,253,220) (17.5), fluoxetine (UV 262,228) (22.6), fluphenazine (UV 310,257) (23.7), flupenthixol (UV 268,231) (27.2), flurazepam (UV 315,231) (20.6), fluvoxamine (UV 251) (20.8), furosemide (UV 344,275,235) (13.2), glutethimide (15.8), guaifenesin (UV 275,224) (6.7), haloperidol (UV 245,220) (19.6), hydralazine (UV 304,260,211) (3.5), hydroxyzine (UV 231) (21.2), ibuprofen (UV 263,219.5) (28.0), imipramine (UV 250,211) (21.6), indomethacin (UV 299,240) (27.9), ketoconazole (UV 295,240) (20.8), labetalol (UV 303) (15.7), lidocaine (UV 266) (13.7), lorazepam (UV 318,231.5) (18.4), lormetazepam (UV 315,231) (20.5), loxapine (UV 295,250) (19.8), maprotiline (UV 272) (22.0), mesoridazine (UV 273,220) (17.2), methadone (23.0), methaqualone (UV 308,267,227) (18.1), methylephedrine (UV 254) (7.7), methylphenidate (UV 260) (15.0), metoprolol (UV 275,223) (13.8), mianserin (UV 280) (19.3), midazolam (UV 221) (19.3), moclobemide (UV 238) (14.1), molindone (UV 301,256,211) (13.6), morphine (UV 286,212) (2.7), nadolol (UV 272,219) (6.6), naloxone (UV 282,209) (5.0), naproxen (UV 270,231.5) (20.2), nifedipine (UV 335,235) (20.8), nitrazepam (UV 310,260,219) (16.3), nordiazepam (UV 310,231) (19.7), norfluoxetine (UV 262,228) (21.4), nortriptyline (UV 240) (21.0), ofloxacin (UV 327,295.5,230) (9.5), oxazepam (UV 310,229) (17.6), oxazolam (UV 234) (17.0), oxycodone (UV 280) (9.9), oxymorphone (UV 280) (6.7), paroxetine (UV 295,235) (19.8), pentazocine (UV 280) (16.7), pentobarbital (UV 211) (14.9), pericyazine (UV 269,232) (19.6), perphenazine (UV 320,255,210) (22.2), pethidine (15.5), phenazopyridine (UV 240) (17.1), phencyclidine (UV 265) (17.8), phenobarbital (9.9), phenolphthalein (UV 278,231) (16.8), phentermine (UV 254) (12.5), phenylephrine (UV 302,259,219) (9.2), phenylpropanolamine (UV 258) (4.9), phenyltoloxamine (UV 272) (20.6), phenytoin (15.3), pholcodine (UV 284,211.5) (4.0), pimozide (UV 280) (25.3), pinazepam (UV 310,227.5) (25.5), piroxicam (UV 248) (15.9), prazepam (UV 311,231.5) (25.1), primidone (6.2), procainamide (UV 280,210) (3.6), promethazine (UV 297,250) (21.7), propoxyphene (UV 259) (21.8), propranolol (UV 290,230,215) (17.2), propyphenazone (UV 274,249) (17.0), protriptyline (UV 290,211) (21.4), pseudoephedrine (UV 257) (6.2), quinidine (UV 330,240,212) (13.8), ranitidine (UV 315,227) (4.6), risperidone (UV 276,236) (16.7), salicylic acid (UV 300,234) (6.5), secobarbital (UV 211) (16.0), sertraline (UV 273) (23.2), spironolactone (UV 240) (24.5), sulfamethoxazole (UV 269.5,211.5) (8.0), sulpiride (UV 293,213) (4.0), temazepam (UV 231.5,312) (19.5), terfenadine (UV 260,219) (27.4), theophylline (UV 270) (2.5), thiopentone (UV 288,238) (18.7), thioridazine (UV 314,265) (24.5), thiothixene (UV 308,259,231) (22.0), tocainide (UV 276) (8.8), tolbutamide (UV 228) (18.9), trazodone (UV 250) (14.9), triazolam (UV 223) (19.3), triflupromazine (UV 308,257) (25.8), trimeprazine (UV 250) (26.9), trimethoprim (UV 272) (10.9), trimipramine (UV 250,211) (23.9), verapamil (UV 280,230) (21.6), zuclopenthixol (UV 325,267,227) (22.0) Interfering: acebutolol (UV 235, UV 326) (12.8), chlormethiazole (UV 211, UV 252) (12.4), ketamine (UV 270) (12.7), MDA (UV 235, UV 287) (12.4), MDMA (UV 235, UV 287) (13.0), methamphetamine (12.0), metoclopramide (UV 215, UV 275, UV 311) (13.0), pheniramine (UV 260) (13.0), zopiclone (UV 218, UV 305) (12.3), KEY WORDS serum; SPE 500 Phentermine REFERENCE Lai, C.-K.; Lee, T.; Au, K.-M.; Chan, A.Y.-W. Uniform solid-phase extraction procedure for toxicological drug screening in serum and urine by HPLC with photodiode-array detection, Clin.Chem., 1997, 43, 312–325. ANNOTATED BIBLIOGRAPHY Bogusz, M.J.; Krüger, K.-D.; Maier, R.-D. Analysis of underivatized amphetamines and related phenethylamines with high-performance liquid chromatography-atmospheric pressure chemical ionization mass spectrometry, J.Anal.Toxicol., 2000, 24, 77–84. [SPE; LOD 1–5 ng/mL; amphetamine; fenfluramine; methamphetamine; phentermine; cathinone; propylhexedrine; ephedrine; phenylpropanolamine; norfenfluramine; phenylethylamine] Kaddoumi, A.; Kubota, A.; Nakashima, M.N.; Takahashi, M.; Nakashima, K. High performance liquid chromatography with UV detection for the simultaneous determination of sympathomimetic amines using 4-(4,5-diphenyl-1H-imidazole-2-yl)benzoyl chloride as a label, Biomed.Chromatogr., 2001, 15, 379–388. [human; rat; plasma; derivatization; LOD 50–100 nM; ephedrine; norephedrine; 2-phenylethylamine; fenfluramine; phentermine; cyclohexylamine; fluoxetine is internal standard; pharmacokinetics] Kaddoumi, A.; Nakashima, M.N.; Nakashima, K. Fluorometric determination of DL-fenfluramine, DLnorfenfluramine and phentermine in plasma by achiral and chiral high-performance liquid chromatography, J.Chromatogr.B, 2001, 763, 79–90. [fluorescence detection; derivatization; human; rat; LOD 10 nM; ephedrine; norephedrine] Kaddoumi, A.; Nakashima, M.N.; Maki, T.; Matsumura, Y.; Nakamura, J.; Nakashima, K. Liquid chromatography studies on the pharmacokinetics of phentermine and fenfluramine in brain and blood microdialysates after intraperitoneal administration to rats, J.Chromatogr.B, 2003, 791, 291–303. [fluorescence detection; derivatization; LOQ 5 nM; fluoxetine is internal standard] Unterhalt, B.; Wenning, C. Zur Trennung von Oxetacain und seinen Metaboliten [Separation of oxetacaine and its metabolites], Pharmazie, 2001, 56, 58–60. [oxetacaine; mephentermine; phentermine] Phosphatidylcholine Phosphatidylcholine CAS Registry No: 8002-43-5 Merck Index: 13, 5447 501 O O R O R O O O− O P N+(CH3)3 O R = fatty acid SAMPLE Matrix: blood Sample preparation: Shake 2 mL blood, 4 mL chloroform (Caution! Chloroform is a carcinogen!), and 2 mL MeOH vigorously for 2 min, cool in ice, centrifuge at 800 g. Evaporate the lower chloroform layer to dryness under a stream of nitrogen, reconstitute the residue with chloroform:MeOH 2:1, inject an aliquot. HPLC VARIABLES Guard column: 60 × 4.6 5 µm SI 60 (Merck) Column: 250 × 4.6 5 µm Lichrosorb Diol Column temperature: 55 Mobile phase: Gradient. A was MeCN. B was MeCN:water 80:20. A:B 88:12 for 5 min, to 77:23 over 3 min, to 30:70 over 4 min, to 25:75 over 1 min, maintain at 25:75 for 5 min, return to initial conditions over 1 min. Flow rate: 2.5 Detector: UV 201 CHROMATOGRAM Retention time: 14 OTHER SUBSTANCES Extracted: phosphatidylethanolamine (13), sphingomyelin (16) KEY WORDS whole blood REFERENCE Heinze, T.; Kynast, G.; Dudenhausen, J.W.; Saling, E. Effect of blood and meconium on the determination of phospholipids in amniotic fluid using high pressure liquid chromatography, J.Perinat.Med., 1988, 16, 53–60. SAMPLE Matrix: blood Sample preparation: Sonicate 300 µL whole blood, 600 µL water, and 5 mL MeOH containing 0.01% BHT for 1 min, add 10 mL chloroform (Caution! Chloroform is a carcinogen!), sonicate for 1 min, vortex for 30 s, let stand at room temperature for 1 h, add 5 mL water, mix for 5 s, centrifuge at 2600 g for 10 min. Evaporate the lower organic layer to dryness under a stream of nitrogen, reconstitute the residue with 300 µL chloroform:MeOH 95:5, inject a 10 µL aliquot. HPLC VARIABLES Guard column: 10 × 2 5 µm LiChrospher 100 diol Column: 250 × 2 5 µm LiChrospher 100 diol Column temperature: 30 Mobile phase: Gradient. A was chloroform. B was MeOH:formic acid 99.9:0.1 with ammonia added to pH 5.3 (ca. 0.05% ammonia) and 0.05% triethylamine. A:B from 95:5 502 Phosphatidylcholine to 70:30 over 11 min, to 20:80 over 3 min, maintain at 20:80 for 4 min, return to initial conditions over 2 min, re-equilibrate for 10 min. Flow rate: 0.3 Injection volume: 10 Detector: MS, Finnigan LCQ, electrospray, ionization needle 4.5 kV, capillary 230◦ , sheath gas flow 90 units CHROMATOGRAM Retention time: 7.07 (m/z 878.5; C18:0, C22:6), 7.28 (m/z 826.5; C16:0, C20:4), 7.84 (m/z 778.5; C16:0, C16:0) Limit of detection: 0.1–5 ng OTHER SUBSTANCES Extracted: phosphatidylethanolamine (10), phosphatidylglycerol (6), phosphatidylinositol (13), phosphatidylserine (17) KEY WORDS whole blood REFERENCE Uran, S.; Larsen, A.; Jacobsen, P.B.; Skotland, T. Analysis of phospholipid species in human blood using normal-phase liquid chromatography coupled with electrospray ionization ion-trap tandem mass spectrometry, J.Chromatogr.B, 2001, 758, 265–275. SAMPLE Matrix: lung lavage fluid Sample preparation: Centrifuge lung lavage fluid at 4◦ at 450 g for 10 min. Shake 10 mL supernatant and 40 mL chloroform:MeOH 2:1 at 4◦ for 3 min (Caution! Chloroform is a carcinogen!). Remove the lower organic phase and wash it with 2 mL 50 mM NaCl, centrifuge, dry under a stream of nitrogen at 45◦ , reconstitute with 500 µL mobile phase, vortex at 4◦ for 1 min, inject a 100 µL aliquot. HPLC VARIABLES Guard column: 20 × 2.1 5 µm Encapharm 100 spherical silica gel (Molnar, Berlin) Column: 120 × 4.6 5 µm Encapharm 100 spherical silica gel (Molnar, Berlin) Column temperature: 30 Mobile phase: Gradient. A was chloroform:MeOH:ammonium hydroxide 80:19.5:0.5. B was chloroform:MeOH:water:ammonium hydroxide 60:34:5.5:0.5. A:B from 100:0 to 0:100 over 14 min, return to initial conditions over 7 min, re-equilibrate for 10 min. Flow rate: 1 Injection volume: 100 Detector: Evaporative Light-Scattering Detector, SEDERE Sedex-45, evaporation temperature 50◦ , nebulization gas nitrogen, pressure 200 kPa, flow 6 L/min, response is nonlinear but proportional to the power 1.7 of the mass and must be calibrated for each compound CHROMATOGRAM Retention time: 13.11 Limit of detection: 100 ng OTHER SUBSTANCES Extracted: diarachidoylphosphatidylcholine (12.75), dilinoleylphosphatidylcholine (12.69), diphosphatidylglycerol (6.30), lysophosphatidylcholine (18.46, 18.81), phosphatidic acid (13.78), phosphatidylethanolamine (9.00), phosphatidylglycerol (5.37), phosphatidylinositol (10.75), phosphatidylserine (11.81), sphingomyelin (15.24, 15.72) Phosphatidylcholine 503 REFERENCE Bünger, H.; Pison, U. Quantitative analysis of pulmonary surfactant phospholipids by high-performance liquid chromatography and light-scattering detection, J.Chromatogr.B, 1995, 672, 25–31. ANNOTATED BIBLIOGRAPHY Wada, M.; Nakashima, K.; Kuroda, N.; Akiyama, S.; Imai, K. Sensitive flow-injection method with peroxylate chemiluminescence detection combined with preparative high-performance liquid chromatography for determination of choline-containing phospholipids in human serum, J.Chromatogr.B, 1996, 678, 129–136. 504 Phosphatidylglycerol Phosphatidylglycerol Merck Index: 13, 8030 SAMPLE Matrix: blood Sample preparation: Sonicate 300 µL whole blood, 600 µL water, and 5 mL MeOH containing 0.01% BHT for 1 min, add 10 mL chloroform (Caution! Chloroform is a carcinogen!), sonicate for 1 min, vortex for 30 s, let stand at room temperature for 1 h, add 5 mL water, mix for 5 s, centrifuge at 2600 g for 10 min. Evaporate the lower organic layer to dryness under a stream of nitrogen, reconstitute the residue with 300 µL chloroform:MeOH 95:5, inject a 10 µL aliquot. HPLC VARIABLES Guard column: 10 × 2 5 µm LiChrospher 100 diol Column: 250 × 2 5 µm LiChrospher 100 diol Column temperature: 30 Mobile phase: Gradient. A was chloroform (Caution! Chloroform is a carcinogen!). B was MeOH:formic acid 99.9:0.1 with ammonia added to pH 5.3 (ca. 0.05% ammonia) and 0.05% triethylamine. A:B from 95:5 to 70:30 over 11 min, to 20:80 over 3 min, maintain at 20:80 for 4 min, return to initial conditions over 2 min, re-equilibrate for 10 min. Flow rate: 0.3 Injection volume: 10 Detector: MS, Finnigan LCQ, electrospray, ionization needle 4.5 kV, capillary 230◦ , sheath gas flow 90 units CHROMATOGRAM Retention time: 6 (m/z 721.5; C16:0, C16:0), 7.28 (m/z 749.5; C16:0, C18:0), 7.84 (m/z 777.5; C18:0, C18:0) Limit of detection: 0.1–5 ng OTHER SUBSTANCES Extracted: phosphatidylcholine (7.5), phosphatidylethanolamine (10), phosphatidylinositol (13), phosphatidylserine (17) KEY WORDS whole blood REFERENCE Uran, S.; Larsen, A.; Jacobsen, P.B.; Skotland, T. Analysis of phospholipid species in human blood using normal-phase liquid chromatography coupled with electrospray ionization ion-trap tandem mass spectrometry, J.Chromatogr.B, 2001, 758, 265–275. SAMPLE Matrix: formulations Sample preparation: Dilute liposome dispersions 10-fold with chloroform:MeOH 60:40, centrifuge at 2700 g for 15 min, inject an aliquot of the supernatant. (Caution! Chloroform is a carcinogen!) HPLC VARIABLES Column: 250 × 4.6 5 µm Zorbax amino Mobile phase: MeCN:MeOH:buffer 64:28:8 (The buffer was 10 mM phosphoric acid adjusted to pH 4.8 with dilute ammonium hydroxide solution. To prepare mobile phase, mix MeCN and MeOH and then add buffer.) Flow rate: 1.5 Phosphatidylglycerol 505 Injection volume: 5–20 Detector: Refractive Index CHROMATOGRAM Retention time: 6 Limit of detection: 29 µg/mL OTHER SUBSTANCES Simultaneous: acyl lysophosphatidylcholine, acyl lysophosphatidylglycerol, phosphatidylcholine (5) KEY WORDS liposome dispersions REFERENCE Grit, M.; Crommelin, D.J.A.; Lang, J. Determination of phosphatidylcholine, phosphatidylglycerol and their lyso forms from liposome dispersions by high-performance liquid chromatography using highsensitivity refractive index detection, J.Chromatogr., 1991, 585, 239–246. SAMPLE Matrix: lung lavage fluid Sample preparation: Centrifuge lung lavage fluid at 4◦ at 450 g for 10 min. Shake 10 mL supernatant and 40 mL chloroform:MeOH 2:1 at 4◦ for 3 min (Caution! Chloroform is a carcinogen!). Remove the lower organic phase and wash it with 2 mL 50 mM NaCl, centrifuge, dry under a stream of nitrogen at 45◦ , reconstitute with 500 µL mobile phase, vortex at 4◦ for 1 min, inject a 100 µL aliquot. HPLC VARIABLES Guard column: 20 × 2.1 5 µm Encapharm 100 spherical silica gel (Molnar, Berlin) Column: 120 × 4.6 5 µm Encapharm 100 spherical silica gel (Molnar, Berlin) Column temperature: 30 Mobile phase: Gradient. A was chloroform:MeOH:ammonium hydroxide 80:19.5:0.5. B was chloroform:MeOH:water:ammonium hydroxide 60:34:5.5:0.5. A:B from 100:0 to 0:100 over 14 min, return to initial conditions over 7 min, re-equilibrate for 10 min. Flow rate: 1 Injection volume: 100 Detector: Evaporative Light-Scattering Detector, SEDERE Sedex-45, evaporation temperature 50◦ , nebulization gas nitrogen, pressure 200 kPa, flow 6 L/min, response is nonlinear but proportional to the power 1.7 of the mass and must be calibrated for each compound CHROMATOGRAM Retention time: 5.37 Limit of detection: 100 ng OTHER SUBSTANCES Extracted: diarachidoylphosphatidylcholine (12.75), dilinoleylphosphatidylcholine (12.69), diphosphatidylglycerol (6.30), lysophosphatidylcholine (18.46, 18.81), phosphatidic acid (13.78), phosphatidylcholine (13.11), phosphatidylethanolamine (9.00), phosphatidylinositol (10.75), phosphatidylserine (11.81), sphingomyelin (15.24, 15.72) REFERENCE Bünger, H.; Pison, U. Quantitative analysis of pulmonary surfactant phospholipids by high-performance liquid chromatography and light-scattering detection, J.Chromatogr.B, 1995, 672, 25–31. 506 Phosphatidylglycerol SAMPLE Matrix: tissue Sample preparation: Homogenize (Potter-Elvehjem) liver or lung with 20 volumes chloroform:MeOH 2:1, filter (paper), wash with a volume of 50 mM NaCl equal to onefifth the volume of extract, centrifuge (J.Biol.Chem. 1957, 226, 497). Remove the lower organic layer and evaporate it to dryness under a stream of nitrogen, reconstitute with chloroform:MeOH 25:75, inject an aliquot. (Caution! Chloroform is a carcinogen!) HPLC VARIABLES Guard column: 10 × 4.6 5 µm Nucleosil 5 NH2 Column: 50 × 4.6 5 µm Nucleosil 5 NH2 + 175 × 4.6 5 µm Nucleosil 5 NH2 Column temperature: 50 Mobile phase: MeCN:MeOH:water:50% methylphosphonic acid in water 73:25:1.5:0.03, adjusted to pH 3 with 25% ammonium hydroxide in water Flow rate: 1 Detector: F ex 340 em 460 following post-column derivatization. The column effluent mixed with the reagent pumped at 4.5 mL/min and the mixture flowed through a 2 m ×0.8 mm ID coil of PTFE tubing at 50◦ to the detector. (The reagent was 1 L water to which was added 250 µL Brij 35 (30% w/v), 50 mg sodium azide, and 150 µL 3 mM diphenylhexatriene in MeCN.) CHROMATOGRAM Retention time: 22 OTHER SUBSTANCES Extracted: dipalmitolyphosphatidylcholine KEY WORDS gastric mucosa; liver; lung; pig; post-column reaction REFERENCE Bernhard, W.; Linck, M.; Creutzburg, H.; Postle, A.D.; Arning, A.; Martin-Carrera, I.; Sewing, K.-F. High-performance liquid chromatographic analysis of phospholipids from different sources with combined fluorescence and ultraviolet detection, Anal.Biochem., 1994, 220, 172–180. ANNOTATED BIBLIOGRAPHY Alvarez, J.G.; Touchstone, J.C. Separation of acidic and neutral lipids by aminopropyl-bonded silica gel column chromatography, J.Chromatogr., 1992, 577, 142–145. Bonanno, L.M.; Denizot, B.A.; Tchoreloff, P.C.; Puisieux, F.; Cardot, P.J. Determination of phospholipids from pulmonary surfactant using an on-line coupled silica/reversed-phase high-performance liquid chromatography system, Anal.Chem., 1992, 64, 371–379. Dethloff, L.A.; Gilmore, L.B.; Hook, G.E. Separation of pulmonary surfactant phospholipids by highperformance liquid chromatography, J.Chromatogr., 1986, 382, 79–87. Ishizuka, T.; Ishikawa, K.; Maseki, M.; Tomoda, Y.; Tsuda, T. Determination of phosphatidylglycerol in amniotic fluid for prediction of foetal lung maturity by microbore-column liquid chromatography, J.Chromatogr., 1986, 380, 43–53. Jaaskelainen, I.; Urtti, A. Liquid chromatography determination of liposome components using a lightscattering evaporative detector, J.Pharm.Biomed.Anal., 1994, 12, 977–982. Jungalwala, F.B.; Evans, J.E.; McCluer, R.H. Compositional and molecular species analysis of phospholipids by high performance liquid chromatography coupled with chemical ionization mass spectrometry, J.Lipid Res., 1984, 25, 738–749. Kynast, G.; Schmitz, C. Simplified quantitative determination of phospholipids in amniotic fluid, alveolar lavages and milk using high performance liquid chromatography (HPLC), J.Perinat.Med., 1989, 17, 203–212. Nissen, H.P.; Kreysel, H.W. Analysis of phospholipids in human semen by high-performance liquid chromatography, J.Chromatogr., 1983, 276, 29–35. Phosphatidylglycerol 507 Pison, U.; Gono, E.; Joka, T.; Obertacke, U.; Obladen, M. High-performance liquid chromatography of adult human bronchoalveolar lavage: assay for phospholipid lung profile, J.Chromatogr., 1986, 377, 79–89. Sas, B.; Peys, E.; Helsen, M. Efficient method for (lyso)phospholipid class separation by high-performance liquid chromatography using an evaporative light-scattering detector, J.Chromatogr.A, 1999, 864, 179–182. Scarim, J.; Ghanbari, H.; Taylor, V.; Menon, G. Determination of phosphatidylcholine and disaturated phosphatidylcholine content in lung surfactant by high performance liquid chromatography, J.Lipid Res., 1989, 30, 607–611. Smith, L.A.; Norman, H.A.; Cho, S.H.; Thompson, G.A. Jr. Isolation and quantitative analysis of phosphatidylglycerol and glycolipid molecular species using reversed-phase high-performance liquid chromatography with flame ionization detection, J.Chromatogr., 1985, 346, 291–299. 508 Piketoprofen Piketoprofen O Molecular formula: C22 H20 N2 O2 Molecular weight: 344.41 CAS Registry No: 60576-13-8 Merck Index: 13, 7503 CH3 H N N O CH3 SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 (S,S)-Whelk-O (Regis) Mobile phase: Hexane:isopropanol:acetic acid 70:30:0.5 Flow rate: 1 Injection volume: 5 Detector: UV 270 CHROMATOGRAM Retention time: k′ 2.97 (α 1.17) KEY WORDS chiral REFERENCE Baeyens, W.R.G.; Van Der Weken, G.; Aboul-Enein, H.Y.; Reygaerts, S.; Smet, E. Comparison of the enantiomeric separation of some 2-arylpropionic acids on a novel Pirkle-concept stationary packing by narrow-bore and conventional liquid chromatography, Biomed.Chromatogr., 2000, 14, 58–60. SAMPLE Matrix: bulk Sample preparation: Prepare a 1.0 mg/mL solution. Inject an aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Chiralcel OJ-R Mobile phase: MeCN:buffer 35:65 (A) or MeCN:MeOH:buffer 35:35:30 (B) (Prepare the buffer by dissolving 70.25 g sodium perchlorate in water, adjust to pH 2.0 with concentrated perchloric acid, make up to 1 L with water.) Flow rate: 0.5 Detector: UV 230; UV 254 CHROMATOGRAM Retention time: k′ 3.53 (mobile phase A, α = 1.29), k′ 0.61 (mobile phase B, α = 1.17) KEY WORDS chiral REFERENCE Van Overbeke, A.; Baeyens, W.; Oda, H.; Aboul-Enein, H.Y. Direct enantiomeric HPLC separation of several 2-arylpropionic acids, barbituric acids and benzodiazepines on Chiralcel OJ-R chiral stationary phase, Chromatographia, 1996, 43, 599–606. 509 Pilsicainide Pilsicainide Molecular formula: C17 H24 N2 O Molecular weight: 272.38 CAS Registry No: 88069-67-4, 88069-49-2 (HCl hemihydrate) Merck Index: 13, 7508 H CH3 N N O H3C SAMPLE Matrix: blood Sample preparation: Mix 500 µL serum with 1 mL 100 mM NaOH, add 100 µL 10 µg/mL IS, add 5 mL chloroform (Caution! Chloroform is a carcinogen!), shake for 10 min, centrifuge at 2270 g for 5 min. Evaporate 4 mL of the organic layer to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 50 µL MeCN, inject a 40 µL aliquot. HPLC VARIABLES Column: 100 × 5 10 µm Radial-pak 5CN Mobile phase: MeCN:10 mM ammonium acetate 70:30 Flow rate: 2.5 Injection volume: 40 Detector: UV 210 CHROMATOGRAM Internal standard: mexiletine Limit of quantitation: 250 ng/mL KEY WORDS comparison with ELISA; rabbit; serum REFERENCE Saita, T.; Fujito, H.; Mori, M. ELISA for the quantification of pilsicainide, Biol.Pharm.Bull., 2001, 24, 1113–1116. SAMPLE Matrix: blood, urine Sample preparation: Plasma. Shake 500 µL plasma, 200 µL 500 mM NaOH, and 2 mL diethyl ether for 5 min, centrifuge at 3000 g for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL mobile phase, inject a 50 µL aliquot. Urine. Condition a Bond Elut CN SPE cartridge with two 1 mL portions of water, 1 mL MeCN:200 mM sodium perchlorate 1:2, and three 1 mL portions of water. Heat 10 mL urine with 40 µL β-glucuronidase (8 units) at 37◦ for 16 h, add 1 mL to the SPE cartridge, centrifuge the SPE cartridge at 1000 g for 5 min, wash with 1 mL MeCN:water 1:2, centrifuge at 2000 g for 5 min, elute with 1 mL MeCN:water 1:2, centrifuge at 2000 g for 5 min, inject a 100 µL aliquot of the eluate. HPLC VARIABLES Column: 150 × 4.6 STR ODS-II (Shimadzu) Column temperature: 40 Mobile phase: MeCN:MeOH:25 mM pH 4.7 phosphate buffer 10:3:87 Flow rate: 1.5 Injection volume: 50–100 Detector: UV 210 510 Pilsicainide CHROMATOGRAM Limit of detection: 10 ng/mL Limit of quantitation: 50 ng/mL (plasma), 1 µg/mL (urine) OTHER SUBSTANCES Noninterfering: cimetidine, probenecid KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Shiga, T.; Hashiguchi, M.; Urae, A.; Kasanuki, H.; Rikihisa, T. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans, Clin.Pharmacol.Ther., 2000, 67, 222–228. 511 Pioglitazone Pioglitazone Molecular formula: C19 H20 N2 O3 S N O O S N H3C Molecular weight: 356.45 CAS Registry No: 111025-46-8 Merck Index: 13, 7533 H O SAMPLE Matrix: blood Sample preparation: Mix 200 µL plasma with 100 µL 50 ng/mL IS in MeCN and 1 mL 100 mM pH 4 ammonium acetate buffer, add 4 mL MTBE:1-chlorobutane 50:50, shake at high speed for 20 min, centrifuge at 4000 rpm for 20 min. Evaporate the organic layer to dryness under a stream of nitrogen at 45◦ , reconstitute the residue with 100 µL mobile phase, vortex for 1 min, centrifuge at 4000 rpm for 5 min, inject a 10 µL aliquot of the supernatant. HPLC VARIABLES Column: 50 × 2 3 µm MetaChem Polaris C18-A Mobile phase: MeCN:water 60:40 containing 10 mM ammonium acetate and 0.02% trifluoroacetic acid Flow rate: 0.2 Injection volume: 10 Detector: MS, Micromass Quattro LC, triple quadrupole, electrospray atmospheric pressure ionization, positive ion mode, capillary 3.5 kV, cone 35 V, extractor 3 V, desolvation 400◦ , ion source 80◦ , collision energy 35 eV, argon 1.9 mtorr, m/z 257–134 CHROMATOGRAM Retention time: 1.37 Internal standard: (5-(4-(2-(5-(2-methyl-1,3-dioxolan-2-yl)-2-pyridyl)ethoxy)benzylidene)-2,4-thiazolidinedione (m/z 413–178) (1.26) Limit of quantitation: 0.5 ng/mL (S/N 30) OTHER SUBSTANCES Extracted: metabolites KEY WORDS plasma REFERENCE Lin, Z.J.; Ji, W.; Desai-Krieger, D.; Shum, L. Simultaneous determination of pioglitazone and its two active metabolites in human plasma by LC-MS/MS, J.Pharm.Biomed.Anal., 2003, 33, 101–108. SAMPLE Matrix: formulations Sample preparation: Sonicate powdered tablet containing 500 mg metformin and 30 mg pioglitazone with 100 mL 100 mM HCl for 10 min with intermittent shaking, add 40 mL MeCN, sonicate for 25 min with intermittent shaking, cool to room temperature, add 10 mL MeCN, make up to 200 mL with 100 mM HCl, mix well, centrifuge at 10 000 rpm for 10 min. Mix a 2 mL aliquot with 1 mL 250 µg/mL IS in MeCN:100 mM HCl 25:75, make up to 50 mL with diluent, inject an aliquot. (The diluent was MeCN:5 mM disodium hydrogen phosphate 30:70, adjusted to pH 2.3 with HCl.) HPLC VARIABLES Column: 150 × 4.6 5 µm Zorbax XDB C18 512 Pioglitazone Column temperature: 40 Mobile phase: MeCN:10 mM disodium hydrogen phosphate containing 5 mM sodium dodecyl sulfate 34:66, adjusted to pH 7.1 with orthophosphoric acid Flow rate: 1 Injection volume: 25 Detector: UV 226 CHROMATOGRAM Retention time: 7.82 Internal standard: methylparaben (3.30) Limit of detection: 3 ng/mL Limit of quantitation: 10 ng/mL OTHER SUBSTANCES Extracted: metformin (LOD 22 ng/mL, LOQ 70 ng/mL) (5.06) KEY WORDS tablets; validation details REFERENCE Kolte, B.L.; Raut, B.B.; Deo, A.A.; Bagool, B.A.; Shinde, D.B. Simultaneous high-performance liquid chromatographic determination of pioglitazone and metformin in pharmaceutical-dosage form, J.Chromatogr.Sci., 2004, 42, 27–31. SAMPLE Matrix: solutions Sample preparation: Inject a 1 µL aliquot of a solution in MeOH:water 10:90. HPLC VARIABLES Column: 20 × 2 5 µm DASH BetaBasic C8 (ThermoHypersil Keystone) Mobile phase: Gradient. A was MeCN:water:formic acid 5:95:0.1. B was MeCN:water: formic acid 95:5:0.1. A:B 100:0 for 0.2 min, to 0:100 over 1.5 min. Flow rate: 1.5 Injection volume: 1 Detector: MS, PE Sciex API-3000, TurboIonspray, electrospray 4500 V, ring 290 V, orifice 60 V, drying gas 400◦ , 20% of column effluent entered the detector, m/z 357.2–134 CHROMATOGRAM Retention time: 0.87 OTHER SUBSTANCES Simultaneous: amitriptyline (m/z 278.3–233) (1.1), aprepitant (MK-869) (m/z 535.3–277) (1.4), diclofenac (m/z 296.1–215) (1.35), enoxacin (m/z 321.2–234) (0.7), fenofibrate (m/z 360.9–233) (1.6), finasteride (m/z 373.2–317) (1.2), indinavir (m/z 614.4–421) (0.93), raloxifene (m/z 474.1–112) (0.97) REFERENCE Romanyshyn, L.A.; Tiller, P.R. Ultra-short columns and ballistic gradients: considerations for ultra-fast chromatographic liquid chromatographic-tandem mass spectrometric analysis, J.Chromatogr.A, 2001, 928, 41–51. ANNOTATED BIBLIOGRAPHY Kiyota, Y.; Kondo, T.; Maeshiba, Y.; Hashimoto, A.; Yamashita, K.; Yoshimura, Y.; Motohashi, M.; Tanayama, S. Studies on the metabolism of the new antidiabetic agent pioglitazone. Identification of metabolites in rats and dogs, Arzneimittelforschung, 1997, 47, 22–28. [LC-MS] Pioglitazone 513 Kolte, B.L.; Raut, B.B.; Deo, A.A.; Bagool, M.A.; Shinde, D.B. Liquid chromatographic method for the determination of rosiglitazone in human plasma, J.Chromatogr.B, 2003, 788, 37–44. [pioglitazone is internal standard] Radhakrishna, T.; Rao, D.S.; Reddy, G.O. Determination of pioglitazone hydrochloride in bulk and pharmaceutical formulations by HPLC and MEKC methods, J.Pharm.Biomed.Anal., 2002, 29, 593–607. [impurities] Shen, Z.; Reed, J.R.; Creighton, M.; Liu, D.Q.; Tang, Y.S.; Hora, D.F.; Feeney, W.; Szewczyk, J.; Bakhtiar, R.; Franklin, R.B.; Vincent, S.H. Identification of novel metabolites of pioglitazone in rat and dog, Xenobiotica, 2003, 33, 499–509. [LC-MS; dog; rat; bile; plasma; urine] Xue, Y.-J.; Turner, K.C.; Meeker, J.B.; Pursley, J.; Arnold, M.; Unger, S. Quantitative determination of pioglitazone in human serum by direct-injection high-performance liquid chromatography mass spectrometry and its application to a bioequivalence study, J.Chromatogr.B, 2003, 795, 215–226. [LC-MS; column-switching; LOQ 9 ng/mL] Yamashita, K.; Murakami, H.; Okuda, T.; Motohashi, M. High-performance liquid chromatographic determination of pioglitazone and its metabolites in human serum and urine, J.Chromatogr.B, 1996, 677, 141–146. [SPE; LOD 10 ng/mL] Zhong, W.Z.; Lakings, D.B. Determination of pioglitazone in dog serum using solid-phase extraction and high-performance liquid chromatography with ultraviolet (229 nm) detection, J.Chromatogr., 1989, 490, 377–385. Zhong, W.Z.; Williams, M.G. Simultaneous quantitation of pioglitazone and its metabolites in human serum by liquid chromatography and solid phase extraction, J.Pharm.Biomed.Anal., 1996, 14, 465–473. [LOQ 20 ng/mL] 514 Pipercuronium bromide Pipercuronium bromide Molecular formula: C35 H62 Br2 N4 O4 Molecular weight: 762.71 CAS Registry No: 52212-02-9 Merck Index: 13, 7540 O H3C CH3 O CH3 CH3 N CH3 + CH3 N H O O H N H 2Br− N+ CH3 H CH3 SAMPLE Matrix: blood Sample preparation: Condition a 1 mL Bond-Elut C18 SPE cartridge with 1 mL MeOH:MeCN 2:1 and 1 mL water. Acidify 1 mL plasma with 150 µL 1 M sodium dihydrogen phosphate. Add 20–200 ng IS to 1 mL acidified plasma, add to the SPE cartridge, wash with 1 mL water, wash with 1 mL 100 mM pH 3 sodium dihydrogen phosphate, elute with 400 µL mobile phase, discard first 100 µL eluate, inject a 200 µL aliquot of the remaining eluate. (Although the original method was only validated for vecuronium, it can also be used to determine pipecuronium; see: D’Honneur,G.; Khalil,M.; Dominique,C.; Haberer,J.P.; Kleef,U.W.; Duvaldestin,P. Pharmacokinetics and pharmacodynamics of pipecuronium in patients with cirrhosis. Anesth.Analg. 1993, 77, 1203–1206.) HPLC VARIABLES Column: 150 × 3.9 4 µm Nova-Pak C18 Mobile phase: Dioxane:water 20:80 containing 100 mM sodium dihydrogen phosphate and 0.44 mM 9,10-dimethoxyanthracene-2-sulfonate, pH adjusted to 3 with phosphoric acid. (Caution! Dioxane is a carcinogen!) (After each series of analyses, flush column with 200 mL MeOH and then re-equilibrate with 120 mL mobile phase.) Flow rate: 1 Injection volume: 200 Detector: F ex 380 em 452 following post-column extraction. The column effluent mixed with dichloroethane pumped at 1.6 mL/min and the mixture flowed through a 1 m ×0.25 mm ID stainless steel coil to a phase separator (Anal.Chim.Acta 1987, 192, 267) and then the organic phase flowed through the detector. CHROMATOGRAM Internal standard: 1-(3α,17β-diacetoxy-2β-piperidino-5α-androstan-16β,5α-yl)piperidine (16) Limit of detection: 20 ng/mL OTHER SUBSTANCES Extracted: vecuronium (LOD 5 ng/mL) (13) KEY WORDS pharmacokinetics; SPE REFERENCE Paanakker, J.E.; Thio, J.M.S.L.; Van den Wildenberg, H.M.; Kaspersen, F.M. Assay of vecuronium in plasma using solid-phase extraction, high-performance liquid chromatography and post-column ionpair extraction with fluorimetric detection, J.Chromatogr., 1987, 421, 327–335. 515 Pirlimycin Pirlimycin Molecular formula: C17 H31 ClN2 O5 S Molecular weight: 410.96 CAS Registry No: 79548-73-5, 78822-40-9 (HCl) Merck Index: 13, 7583 H N O CH3 Cl N H OH O OH CH3 S OH CH3 SAMPLE Matrix: milk Sample preparation: Shake 3 mL extracting solution and 1 mL milk for 30 s, centrifuge at 1000 g for 4 min. Remove the supernatant and add 2 mL extracting solution to the pellet. Shake for 30 s and centrifuge at 1000 g for 4 min. Combine the supernatants, add 6 mL 1-chlorobutane, add 500 µL water, shake for 30 s, centrifuge at 1000 g for 4 min. Remove the lower aqueous phase and add 2 mL water to the organic layer. Shake for 30 s and centrifuge at 1000 g for 4 min. Combine the aqueous layers, evaporate to 2 mL under nitrogen at 55–60◦ , add 1 mL 15% ammonia, mix. Within 30 s, add 15 mL dichloromethane and shake for 30 s. (Caution! Wear gloves and eye protection, ammonia may escape under pressure!) Centrifuge at 1000 g for 4 min. Remove the water layer and evaporate the organic layer to dryness under nitrogen at 60◦ . Add 500 µL 250 µM NaOH, vortex for 10 s, add 500 µL 100 µg/mL 9-fluorenylmethyl chloroformate in MeCN, vortex for 10 s, let stand for 1 h, vortex for 10 s, let stand at room temperature for at least another 2 h. Inject a 50 µL aliquot. (The extracting solution was 125 µL concentrated HCl in 100 mL MeCN.) HPLC VARIABLES Column: 100 × 2.1 5 µm Hypersil ODS Column temperature: 35 Mobile phase: MeOH:MeCN:1% acetic acid 30:30:40 Flow rate: 0.6 Injection volume: 50 Detector: UV 264 CHROMATOGRAM Retention time: 8.8 Limit of quantitation: 100 ppb KEY WORDS cow; derivatization REFERENCE Heller, D.N. Determination of pirlimycin residue in milk by liquid chromatographic analysis of the 9-fluorenylmethyl chloroformate derivative, J.AOAC Int., 1997, 80, 975–981. SAMPLE Matrix: solutions Sample preparation: Prepare a solution in mobile phase, inject a 25 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 Zorbax C8 Mobile phase: MeCN:water 12:88 containing 0.25 g/L tetrabutylammonium perchlorate and 2 mL/L 70% perchloric acid, apparent pH adjusted to 2.5 with 50% NaOH Flow rate: 1.5 516 Pirlimycin Injection volume: 25 Detector: UV 214 CHROMATOGRAM Retention time: 15 OTHER SUBSTANCES Simultaneous: benzyl alcohol, clindamycin (22.5), lincomycin (k′ 0.9) REFERENCE Theis, D.L. Ion-pairing liquid chromatographic method for the determination of pirlimycin hydrochloride, J.Chromatogr., 1987, 402, 335–343. SAMPLE Matrix: tissue Sample preparation: Mix 2 mL ground liver with 100 µL 10 µg/mL IS in water, add 10 mL MeCN:trifluoroacetic acid 99.75:0.25, homogenize (Polytron) at medium–high speed for 30 s, filter, wash tube and filter cake twice with 5 mL portions of MeCN:water:trifluoroacetic acid 84.75:15:0.25, filter the washes. Combine the filtrates and shake with 25 mL n-butyl chloride for 10 s, centrifuge at 500 g for 1 min, remove the aqueous layer, add 4 mL water to the organic layer, shake for 5–10 s, centrifuge at 500 g for 1 min. Combine the aqueous layers, evaporate to 1.5–2.0 mL under a stream of nitrogen at 80◦ , cool to room temperature, add 1 mL 15% ammonium hydroxide, extract with 15 mL dichloromethane. Evaporate the organic layer to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 2 mL MeCN:100 mM pH 6.8 ammonium acetate buffer 20:80, inject a 100 µL aliquot. (Sample preparation from Hornish,R.E.; Cazers,A.R.; Chester,S.T.,Jr.; Roof,R.D. Identification and determination of pirlimycin residue in bovine milk and liver by high-performance liquid chromatography-thermospray mass spectrometry. J.Chromatogr.B 1995, 674, 219–235.) HPLC VARIABLES Column: 150 × 2.1 Zorbax C18 Mobile phase: MeCN:100 mM ammonium formate 30:70 Flow rate: 0.18 Injection volume: 100 Detector: MS, Finnigan TSQ 7000, APCI, single quad mode, Q3 as analyzer, corona 4 kV, corona current 4.5 kV, capillary 180–200◦ , m/z 411–413 CHROMATOGRAM Retention time: 14 Internal standard: iso-pirlimycin (10.5) Limit of quantitation: 25 ng/g OTHER SUBSTANCES Extracted: pirlimycin sulfone (m/z 443), pirlimycin sulfoxide (m/z 427–429) KEY WORDS cow; liver REFERENCE Hornish, R.E.; Roof, R.D.; Wiest, J.R. Pirlimycin residue in bovine liver-a case of reverse metabolism, Analyst, 1998, 123, 2463–2467. Pirlimycin 517 ANNOTATED BIBLIOGRAPHY Heller, D.N. Determination and confirmation of pirlimycin residue in bovine milk and liver by liquid chromatography/thermospray mass spectrometry: Interlaboratory study, J.AOAC Int., 1996, 79, 1054–1061. Hornish, R.E.; Cazers, A.R.; Chester, S.T. Jr.; Roof, R.D. Identification and determination of pirlimycin residue in bovine milk and liver by high-performance liquid chromatography-thermospray mass spectrometry, J.Chromatogr.B, 1995, 674, 219–235. [SPE; LOQ 50 ng/mL; LOQ 25 ng/g] Shah, J.A.; Weber, D.J. High-performance liquid chromatographic assay of pirlimycin in human serum and urine using 9-fluorenylmethylchloroformate, J.Chromatogr., 1984, 309, 95–105. [derivatization] 518 Poloxalene Poloxalene Molecular weight: ca. 3000 CAS Registry No: 9003-11-6 Merck Index: 13, 7644 SAMPLE Matrix: solutions Sample preparation: Inject a 20 µL aliquot of a 3% solution in mobile phase HPLC VARIABLES Column: 300 × 7.5 10 µm HP Plgel 500A Mobile phase: THF Flow rate: 1 Injection volume: 20 Detector: Refractive Index CHROMATOGRAM Retention time: 9 REFERENCE Wigman, L.S.; Abdel-Kader, H.; Menon, G.K. Size exclusion chromatography of poloxalene poloxamers: polyethylene glycol-polypropylene glycol co-polymers used to control cattle bloat, J.Pharm.Biomed.Anal., 1994, 12, 719–722. SAMPLE Matrix: solutions Sample preparation: Inject a 20 µL aliquot of a 3% solution in mobile phase HPLC VARIABLES Column: 300 × 7.5 10 µm Spherogel TSK2000SW 250A Mobile phase: MeOH:water 30:70 Flow rate: 1 Injection volume: 20 Detector: Refractive Index CHROMATOGRAM Retention time: 6 REFERENCE Wigman, L.S.; Abdel-Kader, H.; Menon, G.K. Size exclusion chromatography of poloxalene poloxamers: polyethylene glycol-polypropylene glycol co-polymers used to control cattle bloat, J.Pharm.Biomed.Anal., 1994, 12, 719–722. 519 Pramipexole Pramipexole Molecular formula: C10 H17 N3 S Molecular weight: 211.33 CAS Registry No: 104632-26-0 Merck Index: 13, 7790 H H3C N S NH2 N SAMPLE Matrix: blood Sample preparation: Vortex 1 mL plasma, 50 µL 180 ng/mL IS in 1% acetic acid, 100 µL 1 M NaOH, and 6 mL MTBE for 5 min, centrifuge at 630 g for 5 min, freeze in dry ice acetone. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 100 µL MeOH:water 95:5, inject a 70 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Zorbax SB CN Mobile phase: MeOH:water:100 mM ammonium acetate 80:15:5 Flow rate: 1.2 Injection volume: 70 Detector: MS, PE Sciex API-III, triple quadrupole, orifice 45 V, nebulizer probe 470◦ , nebulizer gas at 550 kPa, auxiliary flow 1.5 L/min, corona discharge needle 3 µA, m/z 212–153 CHROMATOGRAM Retention time: 3.4 Internal standard: BHT-920 (m/z 210–141) (2.2) Limit of quantitation: 50 pg/mL KEY WORDS plasma; use polypropylene containers REFERENCE Lau, Y.Y.; Selenka, J.M.; Hanson, G.D.; Talaat, R.; Ichhpurani, N. Determination of pramipexole (U-98,528) in human plasma by high-performance liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry, J.Chromatogr.B, 1996, 683, 209–216. SAMPLE Matrix: blood, urine Sample preparation: Vortex 1 mL plasma or urine, 50 µL 30 ng/mL (plasma) or 15 µg/mL (urine) IS in 1% acetic acid, 100 µL 1 M NaOH, and 6 mL diethyl ether for 5 min, centrifuge at 2500 g for 5 min, freeze in dry ice/acetone. Extract the organic layer with 100 (plasma) or 200 (urine) µL buffer. Freeze in dry ice/acetone, discard organic layer, remove all traces of ether with a stream of nitrogen, thaw, inject a 50 µL aliquot. (The buffer was 1.7 g potassium dihydrogen phosphate, 1.7 g sodium acetate, and 0.5 g sodium heptanesulfonate in 500 mL water, adjusted to pH 3.5 with acetic acid.) HPLC VARIABLES Guard column: 15 × 3.2 7 µm Brownlee RP-8 Column: 250 × 4.6 5 µm Zorbax Rx C8 Mobile phase: MeCN:buffer 45:55 (The buffer was 10.2 g potassium dihydrogen phosphate, 10.2 g sodium acetate, and 4.5 g sodium heptanesulfonate in 3 L water, adjusted to pH 3.5 with acetic acid.) Flow rate: 1.2 Injection volume: 50 520 Pramipexole Detector: E, ESA 5100A, 5011 analytical cell, 5020 guard cell, electrode 2 0.6 V (detection), electrode 1 0.2 V (impurity screening), guard cell 0.65 V (mobile-phase conditioning) (plasma); UV 286 (urine) CHROMATOGRAM Retention time: 14.4 Internal standard: BHT-920 (10.7) Limit of quantitation: 50 pg/mL (plasma), 10 ng/mL (urine) KEY WORDS plasma REFERENCE Lau, Y.Y.; Hanson, G.D.; Ichhpurani, N. Determination of pramipexole (U-98,528) in human plasma and urine by high-performance liquid chromatography with electrochemical and ultraviolet detection, J.Chromatogr.B, 1996, 683, 217–223. 521 Pranlukast Pranlukast Molecular formula: C27 H23 N5 O4 Molecular weight: 481.50 CAS Registry No: 103177-37-3 Merck Index: 13, 7795 O H H N O O N N N N O SAMPLE Matrix: blood Sample preparation: Add IS to 200 µL plasma, wash with hexane:isopropanol 95:5, add MeCN to the aqueous layer, centrifuge. Evaporate the supernatant to dryness, reconstitute the residue with mobile phase, inject an aliquot. HPLC VARIABLES Column: 300 × 4.6 C18 Mobile phase: MeCN:70 mM ammonium formate buffer 45:55 Flow rate: 1 Detector: UV 262 CHROMATOGRAM Internal standard: ONO-RS-425 (4-oxo-6-methyl-8-(4-phenylbutoxy)benzoylamino)-2(tetrazol-5-yl)-4H-1-benzopyran) Limit of quantitation: 10 ng/mL KEY WORDS pharmacokinetics; plasma REFERENCE Brocks, D.R.; Upward, J.; Hust, R.; Köester, F.E.; Collie, H.; Qian, Y.; Dennis, M.J. The pharmacokinetics of pranlukast in healthy young and elderly subjects, Int.J.Clin.Pharmacol.Ther., 1996, 34, 375–379. SAMPLE Matrix: blood Sample preparation: Mix 100 µL plasma with 100 µL 250 ng/mL IS in 1 M citric acid solution, inject a 30–50 µL aliquot onto column A and elute to waste with water at 1 mL/min; after 25 s, elute to waste with water at 7 mL/min; after another 15 s, elute to waste with water at 1 mL/min; after 70 s, backflush column A with water for 70 s, elute the contents of column A onto column B with the mobile phase. HPLC VARIABLES Column: A 10 × 2 40 µm Ph-EC-IST SPE cartridge (Jones Chromatography); B 20 × 2 unspecified guard column + 30 × 2 3 µm Hypersil BDS C-18 Mobile phase: Gradient. MeOH:20 mM ammonium acetate 25:75 for 0.3 min, to 70:30 over 0.1 min, maintain at 70:30 for 2 min, to 90:10 over 0.1 min, maintain at 90:10 over 0.8 min, return to initial conditions over 0.1 min. Flow rate: 0.3 Injection volume: 30–50 Detector: MS, PE Sciex API-III Plus triple quadrupole, turbo ionspray, negative ion mode, ionspray -3200 V, interface -650 V, orifice -68 V, collision energy 23 V, nebulizer gas air at 42 psi and 0.6 L/min, curtain gas nitrogen at 1.0 L/min, auxiliary gas air at 5.0 L/min, turbo-ionspray probe 350◦ , collision gas argon, ca. 60 µL/mL of column effluent entered the detector, m/z 480.0–291.0 522 Pranlukast CHROMATOGRAM Internal standard: SK&F 108566 (m/z 423.0–244.0) (1.9) Limit of quantitation: 10 ng/mL KEY WORDS column-switching; plasma REFERENCE Marchese, A.; McHugh, C.; Kehler, J.; Bi, H. Determination of pranlukast and its metabolites in human plasma by LC/MS/MS with PROSPEKTTM on-line solid-phase extraction, J.Mass.Spectrom., 1998, 33, 1071–1079. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 10 µm Cosmosil 5C18-MS Column temperature: 50 Mobile phase: Gradient. MeCN:10 mM pH 4.2 potassium phosphate buffer 0:100 for 2 min, to 75:25 over 7.5 min, maintain at 75:25 for 5.5 min. Isocratic. MeCN:buffer 50:50 Flow rate: 1.5 Detector: UV (wavelength not specified) CHROMATOGRAM Retention time: 13.4 (gradient) or 6.7 (isocratic) OTHER SUBSTANCES Simultaneous: acetazolamide (7.9), acyclovir (7.0), allopurinol (7.3), aniracetam (8.6), benazepril (11.5), betamethasone (10.8), camostat mesylate (8.8), carbamazepine (10.8), cilazapril (10.7), cimetidine (7.5), clofibrate (15.0), clonazepam (11.3), cyclophosphamide (9.9), delapril (11.9), dexamethasone (10.9), diazepam (12.5), digoxin (9.0), dilazep (10.6), diltiazem (10.2), docarpamine (11.4), eperisone (8.7), ethosuximide (9.0), fenbufen (11.8), fluconazole (9.2), flutamide (12.7), fominoben (12.6), hydrocortisone acetate (12.1), imidapril (10.1), indomethacin (12.6), irinotecan (9.2), maprotiline (10.5), methotrexate (8.0), nefiracetam (9.7), nifedipine (11.9), nitrazepam (11.2), pentobarbital (10.9), phenobarbital (10.0), phenytoin (10.8), pindolol (8.3), pranoprofen (10.4), prednisolone (10.3), primidone (8.9), quinapril (10.5), spironolactone (12.4), sulpiride (7.6), sulthiame (9.3), tolbutamide (11.6), tranilast (10.5), triamcinolone (11.2), warfarin (12.0), zonisamide (9.5) (gradient retention times; isocratic conditions may differ) REFERENCE Sugiyama, T.; Matsuyama, R.; Usui, S.; Katagiri, Y.; Hirano, K. Selection of mobile phases in highperformance liquid chromatographic determination for medicines, Biol.Pharm.Bull., 2000, 23, 274–278. 523 Prednicarbate Prednicarbate O H3C Molecular formula: C27 H36 O8 O CH3 HO Molecular weight: 488.57 CAS Registry No: 73771-04-7 Merck Index: 13, 7805 O O CH3 O H O H H O SAMPLE Matrix: cell incubations Sample preparation: Sonicate cells, extract twice with 3 mL portions of ethyl acetate by vortexing for 1 min, centrifuge at 1000 rpm for 5 min. Evaporate the combined organic layers to dryness under a stream of nitrogen, reconstitute the residue with 1 mL MeOH, vortex for 1 min, evaporate to dryness, reconstitute the residue with 100 µL MeOH, centrifuge, inject a 20 µL aliquot. HPLC VARIABLES Column: 125 × 4 5 µm LiChrospher 100 RP-18 Mobile phase: Gradient. MeCN:water from 20:80 to 100:0 over 20 min. Flow rate: 1 Injection volume: 20 Detector: UV 254 CHROMATOGRAM Retention time: 15.1 Internal standard: betamethasone (9.4) Limit of detection: 10 ng/mL Limit of quantitation: 100 ng/mL OTHER SUBSTANCES Extracted: prednisolone (7.8), prednisolone 17-ethylcarbonate (11.1), prednisolone 21ethylcarbonate (12.5) REFERENCE Gysler, A.; Lange, K.; Korting, H.C.; Schäfer-Korting, M. Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts, Pharm.Res., 1997, 14, 793–797. 524 Propionylpromazine Propionylpromazine Molecular formula: C20 H24 N2 OS CH3 N O H3C Molecular weight: 340.49 CAS Registry No: 3568-24-9 Merck Index: 13, 7921 N CH3 S SAMPLE Matrix: formulations Sample preparation: Vortex 100 mg formulation with 10 mL hexane, sonicate for 5 min, add 10 mL 50 mM HCl, vortex, centrifuge at 835 g for 2 min. Repeat the extraction of the hexane layer with 10 mL 50 mM HCl. Combine the aqueous layers and make up to 50 mL with 50 mM HCl. Dilute a 2 mL aliquot to 10 mL with MeCN:mobile-phase buffer 70:30, filter (0.45 µm PTFE), inject a 1 µL aliquot. (Protect from light. Use of hexane may not be necessary, depending on the nature of the formulation.) HPLC VARIABLES Column: 150 × 2 5 µm ODS/H C18 (Keystone) Column temperature: 40 Mobile phase: MeCN:buffer 85:15 (Prepare the buffer by diluting 25 mL of a 200 mM heptanesulfonic acid premixed solution (Alltech) to 1 L with water.) Flow rate: 0.3 Injection volume: 1 Detector: UV 280 CHROMATOGRAM Retention time: 3 Limit of detection: 0.09% REFERENCE Hurlbut, D.B.; Primus, T.M.; Goodall, M.J.; Volz, S.A.; Johnston, J.J. Determination of propionylpromazine hydrochloride in formulation matrices using reversed-phase ion-pair small bore liquid chromatography, J.AOAC Int., 1999, 82, 1321–1328. SAMPLE Matrix: tissue Sample preparation: Condition a Sep-Pak C18 SPE cartridge with 5 mL MeOH and 5 mL water. Homogenize kidney with a kitchen grinder. Weigh out a 5 g sample and add 20 mL MeCN with continuous gentle mixing, mix vigorously on a vibromixer at 1500 rpm for 30 s, sonicate for 2 min, centrifuge at 4000 g for 5 min. Mix 7.5 mL sample extract and 40 mL 10% NaCl and add to SPE cartridge, wash with 1 mL 10 mM sulfuric acid, wash with 2 mL air, elute with 2 mL acidic MeCN. Place eluate in a washed tube and evaporate to 300 µL at 70◦ under a stream of nitrogen, mix gently, add 1 mL n-hexane, mix on a vibromixer for 30 s, centrifuge at 2000 g, inject a 50 µL aliquot of the aqueous phase. (Acidic MeCN was 1 mL 50 mM sulfuric acid and 100 mL MeCN. The washed tube was prepared by rinsing with concentrated ammonia, water, and acetone and drying under a stream of nitrogen.) HPLC VARIABLES Guard column: 10 × 2.1 37–50 µm Bondapak C18 Column: 300 × 3.9 Bondapak C18 Mobile phase: MeCN:water 55:45 containing 2.46 g/L anhydrous sodium acetate, pH adjusted to 6.5 with acetic acid Flow rate: 1.2 Propionylpromazine 525 Injection volume: 50 Detector: UV 240 CHROMATOGRAM Retention time: 18 Limit of detection: 4 ng/g OTHER SUBSTANCES Extracted: acepromazine (13), azaperol (Fex 246 em 351) (5), azaperone (8), carazolol (5), haloperidol (8.5), chlorpromazine (25), xylazine (7) KEY WORDS kidney; pig; SPE REFERENCE Keukens, H.J.; Aerts, M.M.L. Determination of residues of carazolol and a number of tranquilizers in swine kidney by high-performance liquid chromatography with ultraviolet and fluorescence detection, J.Chromatogr., 1989, 464, 149–161. SAMPLE Matrix: tissue Sample preparation: Condition a Bond-Elut C18 SPE cartridge with 5 mL MeOH and 5 mL water. Cut pig kidney or liver into small pieces and homogenize. 5 g Homogenate + 10 mL MeCN, shake, vortex for 30 s, sonicate for 3 min, vortex for 30 s, sonicate for 3 min, centrifuge at 10000 g for 20 min. Add 7.5 mL supernatant and 40 mL 10% NaCl to the SPE cartridge at about 1 mL/min, do not allow cartridge to dry out, wash with 850 µL 10 mM sulfuric acid, dry with air, elute with 3.5 mL acidic MeCN. Evaporate the eluate to dryness under a stream of nitrogen at 50◦ , reconstitute the residue in 300 µL 10 mM sulfuric acid, vortex briefly, add 1 mL hexane, vortex for 30 s, centrifuge at 2000 g for 5 min, inject an aliquot of the aqueous layer. (Acidic MeCN was 1 mL 50 mM sulfuric acid in 100 mL MeCN.) HPLC VARIABLES Guard column: Hypersil 5 µm SAS C1 Column: 250 mm long 5 µm Hypersil SAS C1 Mobile phase: MeCN:water 50:50 containing 0.77 g/L ammonium acetate Flow rate: 2 Detector: E, ESA Model 5100A Coulochem, first electrode +0.4 V, second electrode (which was monitored) +0.7 V, Model 5020 guard cell after pump but before injector at +0.75 V CHROMATOGRAM Retention time: 25 Limit of detection: 2 ng/g OTHER SUBSTANCES Extracted: acepromazine (18), azaperol (5), azaperone (6.5), carazolol (9), chlorpromazine (32), haloperidol (12.5), xylazine (10) KEY WORDS kidney; liver; pig; SPE REFERENCE Rose, M.D.; Shearer, G. Determination of tranquilisers and carazolol residues in animal tissue using high-performance liquid chromatography with electrochemical detection, J.Chromatogr., 1992, 624, 471–477. 526 Propionylpromazine ANNOTATED BIBLIOGRAPHY Delahaut, P.; Levaux, C.; Eloy, P.; Dubois, M. Validation of a method for detecting and quantifying tranquillisers and a β-blocker in pig tissues by liquid chromatography-tandem mass spectrometry, Anal.Chim.Acta, 2003, 483, 335–340. [SPE; LOD 1–10 ng/g; propionylpromazine; acepromazine; chlorpromazine; xylazine; carazolol; azaperone; azaperol; haloperidol; isobutcar; levamisole is internal standard] Quintana, M.C.; Blanco, M.H.; Lacal, J.; Hernández, L. Analysis of pharmaceutical residues in bovine liver by HPLC, J.Liq.Chromatogr.Rel.Technol., 2001, 24, 735–745. [LOD 21–298 ng/mL; dexamethasone; betamethasone; betamethasone acetate; xylazine; haloperidol; acepromazine; propionylpromazine; chlorpromazine] Propoxycaine hydrochloride 527 Propoxycaine hydrochloride Molecular formula: C16 H27 ClN2 O3 Molecular weight: 330.86 CAS Registry No: 550-83-4 Merck Index: 13, 7930 CH3 O O N O CH3 CH3 HCl NH2 SAMPLE Matrix: formulations Sample preparation: Dilute with mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Column: 300 × 3.9 µBondapak phenyl Mobile phase: MeCN:buffer 30:70 (The buffer was 25 mM pH 3.0 potassium dihydrogen phosphate containing 50 mM sodium heptanesulfonate.) Flow rate: 1 Injection volume: 20 Detector: UV 254 CHROMATOGRAM Retention time: 18.9 OTHER SUBSTANCES Simultaneous: levonordefrin (3.6), norepinephrine (3.9), procaine (9.8) KEY WORDS injections; stability-indicating REFERENCE Storms, M.L.; Stewart, J.T. Stability-indicating HPLC assays for the determination of prilocaine and procaine drug combinations, J.Pharm.Biomed.Anal., 2002, 30, 49–58. 528 Propylene glycol Propylene glycol HO OH Molecular formula: C3 H8 O2 Molecular weight: 76.09 CAS Registry No: 57-55-6 Merck Index: 13, 7947 SAMPLE Matrix: blood, tissue Sample preparation: Plasma. Mix 50 µL plasma with 10 µL 50 µg/mL IS and 50 µL 4 M NaOH, add 1 mL benzoyl chloride solution, vortex for 30 min, add 25 µL 1% glycine, vortex for 15 min, let stand at room temperature for 45 min, centrifuge at 4000 rpm for 5 min. Remove a 100 µL aliquot of the pentane layer and evaporate it to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 1 mL MeOH, inject a 10 µL aliquot. Tissue. Homogenize rat lung tissue with 4 vol of water. Mix 100 µL homogenate with 10 µL 100 µg/mL IS, let stand at room temperature for 30 min, vortex thoroughly, centrifuge at 4000 rpm for 10 min. Mix 50 µL of the supernatant with 50 µL 4 M NaOH, add 1 mL benzoyl chloride solution, vortex for 30 min, add 25 µL 1% glycine, vortex for 15 min, let stand at room temperature for 45 min, centrifuge at 4000 rpm for 5 min. Remove a 100 µL aliquot of the pentane layer and evaporate it to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL MeOH, inject a 10 µL aliquot. (Prepare benzoyl chloride solution by mixing 125 µL benzoyl chloride with 10 mL pentane.) HPLC VARIABLES Column: 100 × 2.1 3.5 µm Symmetry Shield RP-18 (Waters) Mobile phase: MeOH:water:formic acid 78:22:0.1 Flow rate: 0.25 Injection volume: 10 Detector: MS, Applied Biosystems API365, APCI, ionspray 4500 V, declustering potential 1 V, focusing potential 120 V, entrance potential -2.5 V, collision entrance potential 8.57 V, collision energy 13 V, collision exit potential 16 V, probe 450◦ , turbo gas flow 7 L/min, m/z 285.1–163.2 CHROMATOGRAM Retention time: 3.5 Internal standard: 1,4-butanediol (m/z 299.0–177.2) (4.4) Limit of detection: 269 ng/mL (plasma), 1.12 µg/g (lung) Limit of quantitation: 448 ng/mL (plasma), 1.62 µg/g (lung) KEY WORDS derivatization; lung; plasma; rat REFERENCE Gao, S.; Wilson, D.M.; Edinboro, L.E.; McGuire, G.M.; Williams, S.G.P.; Karnes, H.T. Improvement of sensitivity for the determination of propylene glycol in rat plasma and lung tissue using HPLC/tandem MS and derivatization with benzoyl chloride, J.Liq.Chromatogr.Rel.Technol., 2003, 26, 3413–3431. 529 Propylhexedrine Propylhexedrine Molecular formula: C10 H21 N H N CH3 CH3 Molecular weight: 155.28 CAS Registry No: 101-40-6 Merck Index: 13, 7952 SAMPLE Matrix: blood Sample preparation: Condition a 200 mg Bond-Elut C18 SPE cartridge with 1 mL MeOH, 1 mL water, and 2 mL 10 mM pH 9.3 ammonium carbonate buffer. Centrifuge whole blood or serum at 14 000 g for 5 min. Vortex 0.2–1 mL of the supernatant with IS and 2 mL 10 mM pH 9.3 ammonium carbonate buffer, centrifuge at 5000 g for 10 min, add 2 mL of the supernatant to the SPE cartridge and allow to pass through over 5 min, wash with 2 mL 10 mM pH 9.3 ammonium carbonate buffer, dry with vacuum for 5 min, elute with 500 µL MeOH:500 mM acetic acid 90:10. Add 10 µL 1 mM HCl to the eluate and evaporate to dryness under a stream of nitrogen, reconstitute the residue with 100 µL mobile phase, centrifuge at 14 000 g for 4 min, inject a 5–20 µL aliquot of the supernatant. HPLC VARIABLES Column: 125 × 3 4 µm Superspher 100 RP 18 Mobile phase: MeCN:50 mM pH 3.0 ammonium formate buffer 25:75 Flow rate: 0.8 Injection volume: 5–20 Detector: MS, Finnigan MAT SSQ 7000, APCI, positive ion mode, sheath gas nitrogen 70 psi, auxiliary gas nitrogen 20 mL/min, capillary 190◦ , vaporizer 450◦ , corona current 5 µA, m/z 204–156–157 CHROMATOGRAM Retention time: 3.9 Internal standard: norfenfluramine (m/z 212–204–187–159 (4.4) Limit of detection: 2 ng/mL OTHER SUBSTANCES Extracted: amphetamine (m/z 147–136–119–91) (3.7), cathinone (m/z 150–147–132) (3), ephedrine (m/z 160-166–148) (3.1), fenfluramine (m/z 232–212–159) (7), MDA (m/z 180–163–147) (3.8), MDEA (m/z 215–208–163) (5.3), MDMA (m/z 199–194–163–133) (4.3), methamphetamine (m/z 160–150–119–91) (4.2), norfenfluramine (m/z 212–204–187–159) (4.4), phentermine (m/z 160–150–133–91) (4.4), phenylethylamine (m/z 147–122–105) (3.1), phenylpropanolamine (m/z 152–147–134) (2.8) KEY WORDS serum; SPE; whole blood REFERENCE Bogusz, M.J.; Krüger, K.-D.; Maier, R.-D. Analysis of underivatized amphetamines and related phenethylamines with high-performance liquid chromatography-atmospheric pressure chemical ionization mass spectrometry, J.Anal.Toxicol., 2000, 24, 77–84. 530 Protirelin Protirelin H N O H O Molecular formula: C16 H22 N6 O4 N Molecular weight: 362.38 CAS Registry No: 24305-27-9 Merck Index: 13, 9663 H H O O NH2 H N N H N SAMPLE Matrix: blood Sample preparation: Mix 1 mL serum with 2 mL water and 7.5 mL cold EtOH/HCl, let stand at 4◦ for 12 h, centrifuge at 2800 rpm at 4◦ for 30 min, adjust the pH of the supernatant to 8.3 with concentrated ammonium hydroxide, let stand at 4◦ for 15 min, centrifuge at 2800 rpm at 4◦ for 20 min, adjust the pH of the supernatant to 5.3 with 4 M HCl. For each 1 mL of extract, add 25 µL 2 M ammonium acetate, adjust pH to 5.3; to each 10 mL of extract, slowly add 15 mL cold EtOH and 25 mL diethyl ether, let stand at 4◦ for 12 h, centrifuge at 2800 rpm at 4◦ for 30 min. Collect the precipitate and dry it under nitrogen, reconstitute with 100 mM pH 3.10 sodium dihydrogen phosphate, inject an aliquot containing 1.1–3.3 nmol. (Prepare EtOH/HCl by adding 7.5 mL concentrated HCl to 375 mL 95% EtOH. Sample preparation from Oyama,H.; Tenku,A.; Kakita,K.; Matsumura,S.; Nishida,S.; Horino,M. Recovery of human C-peptide by acid-ethanol extraction. Endocrinol.Japon. 1978, 25, 493–498.) HPLC VARIABLES Column: 250 × 4.5 Spherisorb S5 ODS2 Column temperature: 37 Mobile phase: Gradient. MeCN: 100 mM pH 3.10 sodium dihydrogen phosphate from 0:100 to 28:72 over 14 min, to 31.2:68.8 over 8 min, to 32.8:67.2 over 8 min, to 42.8 over 5 min, to 60:40 over 3.5 min, maintain at 60:40. Flow rate: 1 Injection volume: 200 Detector: UV 220 CHROMATOGRAM Retention time: 7.5 OTHER SUBSTANCES Extracted: porcine C-peptide (21), porcine glucagon (24), porcine monocomponent insulin (25), porcine pancreatic polypeptide (36), porcine proinsulin (30), somatostatin (24), vasoactive intestinal polypeptide (19) KEY WORDS cord; plasma REFERENCE Knip, M. Analysis of pancreatic peptide hormones by reversed-phase high-performance liquid chromatography, Horm.Metab.Res., 1984, 16, 487–491. SAMPLE Matrix: blood Sample preparation: Mix whole blood with ice-cold EtOH, centrifuge (?), evaporate to dryness under reduced pressure or a stream of nitrogen at 35◦ , reconstitute with 0.1% trifluoroacetic acid, centrifuge briefly, inject an aliquot of the supernatant. Protirelin 531 HPLC VARIABLES Column: 250 × 4.6 Ultrasphere ODS Mobile phase: Gradient. MeCN:water:trifluoroacetic acid from 0:100:0.1 to 100:0:0.1 over 50 min Flow rate: 1 Injection volume: 1000 Detector: RIA (of fractions) CHROMATOGRAM Retention time: 16 KEY WORDS rat REFERENCE Sheward, W.J.; Harmar, A.J.; Fraser, H.M.; Fink, G. Thyrotropin-releasing hormone in rat pituitary stalk blood and hypothalamus: studies with high performance liquid chromatography, Endocrinology, 1983, 113, 1865–1869. 532 Prulifloxacin Prulifloxacin Molecular formula: C21 H20 FN3 O6 S Molecular weight: 461.46 CAS Registry No: 123447-62-1 O O O H N CH3 N N F CH3 S COOH O SAMPLE Matrix: blood, urine Sample preparation: Inject urine directly. Condition a 200 mg Sep-Pak Vac PS-1 SPE cartridge with 3 mL MeOH and 3 mL 1% acetic acid. Mix 500 µL plasma with 1 mL 1% acetic acid, add to the SPE cartridge, wash with 1 mL 1% acetic acid, elute with 4 mL MeCN:1% acetic acid 90:10. Evaporate the eluate to dryness under reduced pressure, reconstitute the residue with MeOH, inject an aliquot. HPLC VARIABLES Column: 250 × 4.6 Capcell Pak C18 SG120 (Shiseido) Column temperature: 40 Mobile phase: MeCN:MeOH:50 mM pH 2 sodium phosphate buffer 10:20:60 Flow rate: 1.0–1.7 Detector: UV 275; Radioactivity (14 C) CHROMATOGRAM Retention time: 15 OTHER SUBSTANCES Extracted: metabolites KEY WORDS dog; monkey; plasma; rat REFERENCE Okuyama, Y.; Morino, A. Pharmacokinetics of prulifloxacin. 3rd communication: metabolism in rats, dogs and monkeys, Arzneimittelforschung, 1997, 47, 293–298. Pyrethrins Pyrethrins Molecular formula: C21 H28 O3 (pyrethrin I), C22 H28 O5 (pyrethrin II) Molecular weight: 328.44 (pyrethrin I), 372.45 (pyrethrin II) CAS Registry No: 121-21-1 (pyrethrin I), 121-29-9 (pyrethrin II) Merck Index: 13, 8054 533 O H3C R CH3 CH3 O CH2 O CH3 R = CH3 (I) or COOCH3 (II) SAMPLE Matrix: formulations Sample preparation: Dissolve 5 g formulation in 100 mL isopropanol that contains 5 mL IS, dilute with isopropanol, filter (0.45 µm PTFE), inject a 10 µL aliquot. HPLC VARIABLES Column: 200 × 4.6 3 µm Pinnacle C8 (Restek) Column temperature: 50 Mobile phase: Gradient. MeCN:MeOH:water 40:15:45 for 10 min, to 45:15:40 over 5 min, maintain at 45:15:40 for 10 min, to 50:15:35 over 10 min, to 55:15:30 over 10 min. (For MS, all components contained 0.1% trifluoroacetic acid.) Flow rate: 0.8 Injection volume: 10 Detector: UV 240; MS Finnigan TSQ 7000, electrospray, triple-stage quadrupole, positive ion mode, capillary 5.0 kV, electrospray vaporizer 400◦ , capillary 210◦ , collision gas argon 1.5 mtorr CHROMATOGRAM Retention time: 21 (pyrethrin II), 37 (pyrethrin I) Internal standard: 2,2-dimethylpropiophenone (9) Limit of detection: 160 ng/mL (pyrethrin I, UV), 60 ng/mL (pyrethrin II, UV) Limit of quantitation: 430 ng/mL (pyrethrin I, UV), 120 ng/mL (pyrethrin II, UV) OTHER SUBSTANCES Simultaneous: cinerin I (35), cinerin II (20), jasmolin I (42), jasmolin II (26), (S)methoprene (45), piperonyl butoxide (24) KEY WORDS validation details REFERENCE Wang, I.-H.; Subramanian, V.; Moorman, R.; Ko, J.; Johnson, D. A validated reversed-phase HPLC method for analyzing pyrethrins, piperonyl butoxide, and (S)-methoprene in pesticide formulations, LC.GC, 1999, 17, 260–275. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4 5 µm Polygosil C18 (MetaChem) Mobile phase: MeOH:isopropanol:EtOH 35:15:50 Flow rate: 0.5 Detector: UV 225 534 Pyrethrins CHROMATOGRAM Retention time: 15 (pyrethrin II), 31 (pyrethrin I) MetaChem Catalog; 1995; page 46. SAMPLE Matrix: solutions HPLC VARIABLES Column: 150 × 8 Nucleosil 5 NO2 Mobile phase: n-Hexane:THF 96:4 Flow rate: 2 Detector: UV 220 CHROMATOGRAM Retention time: 18 (pyrethrin I) OTHER SUBSTANCES Simultaneous: bioallethrin (15, 16), cinerin (14), jasmolin (12.5) KEY WORDS normal phase REFERENCE Ando, T.; Kurotsu, Y.; Uchiyama, M. High performance liquid chromatographic separation of the stereoisomers of natural pyrethrins and related compounds, Agric.Biol.Chem., 1986, 50, 491–493. SAMPLE Matrix: solutions HPLC VARIABLES Column: two 300 × 4 10 µm µPorasil columns in series Mobile phase: Dichloromethane:water-saturated dichloromethane 50:50 Flow rate: 0.6 Injection volume: 10 Detector: UV 254; Refractive Index CHROMATOGRAM Retention time: 18–57 (numerous isomers) KEY WORDS normal phase REFERENCE Otieno, D.A.; Jondiko, I.J.; McDowell, P.G.; Kezdy, F.J. Quantitative analysis of the pyrethrins by HPLC, J.Chromatogr.Sci., 1982, 20, 566–570. SAMPLE Matrix: urine Sample preparation: Add 4 g solid NaCl, 3.5 mL MeCN, and 5 mL saturated NaCl solution to 5 mL MeCN, shake for 1 min. Remove the MeCN layer and extract the aqueous layer with 1 mL MeCN. Combine the MeCN layers and adjust to a known volume (0.5–1 mL), mix, filter (0.45 µm), inject a 40 µL aliquot. Pyrethrins 535 HPLC VARIABLES Column: 150 × 3 3 µm Luna C18(2) (Phenomenex) Column temperature: 30 Mobile phase: Gradient. MeCN:water 10:90 for 1 min, to 90:10 over 30 min, maintain at 90:10 for 4 min, to 100:0 over 1 min, maintain at 100:0 for 10 min, return to initial conditions over 1 min. Flow rate: 0.5 Injection volume: 40 Detector: UV 235 CHROMATOGRAM Retention time: 29.6 (pyrethrin I), 33.7 (pyrethrin II) Limit of detection: 4 ng/mL (pyrethrin I), 40 ng/mL (pyrethrin II) OTHER SUBSTANCES Extracted: allethrin (31.8, LOD 5 ng/mL), bifenthrin (37, LOD 5 ng/mL), cyfluthrin (34.3, LOD 5 ng/mL), fenvalerate (35.3, LOD 2 ng/mL), cis-permethrin (35.7, LO 5 ng/mL), trans-permethrin (36.3, LOD 5 ng/mL), phenothrin (36.4, LOD 5 ng/mL), m-phenoxybenzyl alcohol (21, LOD 5 ng/mL), resmethrin (35.2, LOD 5 ng/mL), tetramethrin (31.4, LOD 5 ng/mL) REFERENCE Loper, B.L.; Anderson, K.A. Determination of pyrethrin and pyrethroid pesticides in urine and water matrices by liquid chromatography with diode array detection, J.AOAC Int., 2003, 86, 1236–1240. ANNOTATED BIBLIOGRAPHY Essig, K.; Zhao, Z. Method development and validation of a high-performance liquid chromatographic method for pyrethrum extract, J.Chromatogr.Sci., 2001, 39, 473–480. [pyrethrins; cinerin; jasmolin; normal phase] Wang, I.-H.; Moorman, R.; Burleson, J. Simultaneous determination of dipropyl pyridine-2,5-dicarboxylate, N-octyl bicycloheptene dicarboximide, piperonyl butoxide, and pyrethrins in pet shampoo by reversed phase high-performance liquid chromatography, J.Liq.Chromatogr.Rel.Technol., 1996, 19, 3293–3304. Quetiapine N O OH N Molecular formula: C21 H25 N3 O2 S Molecular weight: 383.52 N CAS Registry No: 111974-69-7, 111974-72-2 (hemifumarate) Merck Index: 13, 8127 S SAMPLE Matrix: blood Sample preparation: Mix 400 µL plasma and 10 µL 2.5 µg/mL IS in MeCN:MeOH 50:50, add 25 µL 15% ammonium hydroxide, add 3 mL ethyl acetate, vortex for 30 s, centrifuge for 5 min. Add the upper organic layer to 1 mL 200 mM HCl, vortex for 30 s, centrifuge for 5 min, discard the organic layer. Basify the aqueous layer with 500 µL 15% ammonium hydroxide, add 3 mL ethyl acetate, vortex for 30 s, centrifuge for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen at 35◦ , reconstitute the residue with 30 µL MeCN:MeOH:20 mM pH 7.4 phosphate buffer containing 30 mM KCl 10:30:60, inject a 25 µL aliquot. HPLC VARIABLES Column: 150 × 2.1 5 µm Zorbax Stablebond phenyl SB-Ph Mobile phase: MeCN:MeOH:20 mM pH 7.4 phosphate buffer containing 30 mM KCl 10:50:40 Flow rate: 0.25 Injection volume: 25 Detector: UV 225; E, Bioanalytical Systems LC-44, precell 0.25 V, analytical cell 0.55 V, Ag/AgCl reference cell CHROMATOGRAM Retention time: 9 (UV 225) Internal standard: M 214,652 (2-(2-[4-(8-chlorodibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl]ethoxy)ethanol) (UV 225) (16) Limit of quantitation: 2.5 ng/mL OTHER SUBSTANCES Extracted: metabolite ICI 214,227 (7-hydroxylated) (E) (5), metabolite M 236,303 (7hydroxylated, N-dealkylated) (E) (14) KEY WORDS pharmacokinetics; plasma REFERENCE Davis, P.C.; Wong, J.; Gefvert, O. Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection, J.Pharm.Biomed.Anal., 1999, 20, 271–282. SAMPLE Matrix: blood Sample preparation: Condition a 3 mL 3M-Empore mixed-phase SPE extraction disc with 1 mL MeOH and 1 mL water. Mix 900 µL serum with 100 µL 3 µg/mL IS in serum and 2 mL 100 mM pH 6.0 potassium dihydrogen phosphate buffer, add to the SPE disc, wash with 1 mL water, wash with 1 mL 1 M acetic acid, wash with 1 mL n-hexane, wash with 2 mL n-hexane:ethyl acetate 50:50, wash with 1 mL MeOH, elute with 1 mL 536 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 Quetiapine 537 isopropanol:25% ammonia:dichloromethane 20:2:78. Evaporate the eluate to dryness, reconstitute the residue with 250 µL MeCN:water 30:70, inject a 100 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Nucleosil 100-5-Protect 1 (endcapped) Column temperature: 25 Mobile phase: MeCN:25 mM pH 7.0 potassium dihydrogen phosphate 40:60 Flow rate: 1 Injection volume: 100 Detector: UV 230 CHROMATOGRAM Retention time: 11.7 Internal standard: melperone (8.8) Limit of quantitation: 5 ng/mL OTHER SUBSTANCES Extracted: amisulpride (6.1), amitriptyline (23.4), m-chlorophenylpiperazine (8.0), citalopram (13.3), clomipramine (30.8), clozapine (30.9), desipramine (12.8), O-desmethylvenlafaxine (4.8), diazepam (11.0), doxepin (18.3), fluoxetine (17.8), 9-hydroxyrisperidone (6.6), imipramine (20.6), maprotiline (15.3), melperone (8.8), mianserin (29.0), mirtazapine (16.6), moclobemide (5.6), nefazodone (32.5), norclomipramine (19.2), norclozapine (14.4), nordoxepin (10.9), norfluoxetine (13.4), nortriptyline (14.5), paroxetine (15.3), quetiapine (11.7), reboxetine (10.2), risperidone (11.1), sertraline (33.6), sulpiride (4.1), trimipramine (21.5), venlafaxine (7.3), ziprasidone (26.4) Simultaneous: benperidol (11.5), chlorprothixene (36.4), fluphenazine (31.0), haloperidol (15.3), normirtazapine (8.3), olanzapine (21.0), pimozide (44.1), promethazine (28.1), thioridazine (43.2), trifluperidol (20.8), zolpidem (10.2) Noninterfering: biperiden, buspirone, carbamazepine, lorazepam, perazine, valproic acid, zopiclone, zotepine Interfering: dibenzepin (11.5), fluvoxamine (11.6), normaprotiline (11.5), opipramol (11.6) KEY WORDS serum; SPE REFERENCE Frahnert, C.; Rao, M.L.; Grasmäder, K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring, J.Chromatogr.B, 2003, 794, 35–47. ANNOTATED BIBLIOGRAPHY Hasselstrom, J.; Linnet, K. Fully automated on-line quantification of quetiapine in human serum by solid phase extraction and liquid chromatography, J.Chromatogr.B, 2003, 798, 9–16. [LOD 10.3 nM; trifluoperazine is internal standard] Mandrioli, R.; Fanali, S.; Ferranti, A.; Raggi, M.A. HPLC analysis of the novel antipsychotic drug quetiapine in human plasma, J.Pharm.Biomed.Anal., 2002, 30, 969–977. [triprolidine is internal standard; SPE; LOQ 4 ng/mL] Thieme, D.; Sachs, H. Improved screening capabilities in forensic toxicology by application of liquid chromatography-tandem mass spectrometry, Anal.Chim.Acta, 2003, 492, 171–186. [hair; LC-MS; alprazolam; dothiepin; piritramide; cocaine; lorazepam; lormetazepam; clonazepam; flunitrazepam; bromazepam; midazolam; flurazepam; nitrazepam; temazepam; medazepam; nordazepam; diazepam; methylclonazepam; triazolam; oxazepam; haloperidol; benperidol; sulpiride; amisulpride; mirtazapine; citalopram; olanzapine; paroxetine; fluoxetine; sertraline; zopiclone; zolpidem; risperidone; quetiapine; fentanyl; pipamperone; meperidine; buprenorphine; propoxyphene; pentazocine; phenazocine; EDDP; 538 Quetiapine tilidine; methadone; morphine; codeine; dihydrocodeine; acetylmorphine; amphetamine; ephedrine; norephedrine; pseudoephedrine; methylephedrine; amphetaminil; benzphetamine; methylphenidate; nikethamide; amfeparone; clobenzorex; atropine; scopolamine; ajmaline; aconitine; colchicine; strychnine; metoprolol; acebutolol; propranolol; sotalol; atenolol; bisoprolol; amiloride; triamterene; warfarin; brodifacoum; coumatetralyl; phenprocoumon; methaqualone; clomethiazole; acetaminophen; methoxamine; vecuronium; neostigmine; LSD] 539 Quinfamide Quinfamide Molecular formula: C16 H13 Cl2 NO4 Molecular weight: 354.19 O O O CAS Registry No: 62265-68-3 Merck Index: 13, 8147 N Cl O Cl SAMPLE Matrix: blood, feces, urine Sample preparation: Condition a Sep-Pak C18 SPE cartridge with 2 mL MeOH, 1 mL 5 µg/mL diazepam in MeOH (sic), and 2 mL water. Dissolve 10 mg lyophilized feces in 10 mL MeCN. Add 1 mL plasma, urine, or feces solution to the SPE cartridge, wash with 12 mL water, elute with 1 mL MeCN, vortex the eluate, inject a 20 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Zorbax SB-CN Mobile phase: MeCN:MeOH:water 10:50:40 Flow rate: 0.7 Injection volume: 20 Detector: UV 269 CHROMATOGRAM Retention time: 9.7 Internal standard: diazepam (8.5) Limit of quantitation: 80 ng/mL OTHER SUBSTANCES Extracted: 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolol (metabolite) (6.5) KEY WORDS plasma; SPE REFERENCE Morales, J.M.; Jung, C.H.; Alarcón, A.; Barreda, A. Solid-phase extraction and liquid chromatographic quantitation of quinfamide in biological samples, J.Chromatogr.B, 2000, 746, 133–139. 540 Quinupristin Quinupristin H3C N CH3 Molecular formula: C53 H67 N9 O10 S Molecular weight: 1022.24 CAS Registry No: 120138-50-3 Merck Index: 13, 8176 CH3 N N N O CH3 N H S N O O O NH H O O CH3 H O O N O H N OH SAMPLE Matrix: blood Sample preparation: Condition a CN SPE cartridge (Lida-Interchim) with 1 mL MeOH, 1 mL water, and 1 mL buffer. Add 1 mL 3.8% sodium citrate and 2.5 mL 250 mM HCl to 10 mL whole blood. Shake gently by hand and centrifuge at 2000 g at 4◦ for 15 min. Add 1 mL buffer and 50 µL 100 µg/mL IS in MeOH to 1.35 mL acidified plasma. Vortex for a few seconds, centrifuge at 4000 g at 4◦ for 5 min. Add either supernatant to the SPE cartridge and dry the SPE cartridge with 3 mL air. Elute with 500 µL MeOH:water 70:30 containing 3.5 mM pentane sulfonic acid, inject an aliquot. (The buffer was a mixture of 85 mM pH 3.0 citric acid monohydrate containing 81 mM NaOH and 60 mM HCl.) HPLC VARIABLES Guard column: 10 µm µBondapak C18 Column: 125 × 4.6 5 µm Kromasil C18 (Higgins Analytical) Mobile phase: Gradient. MeCN:buffer 30:70 for 11 min, then 32:68 for 4 min (step gradient), to 40:60 over 0.6 min, maintain at 40:60 for 0.4 min, at 38:62 for 18 min (step gradient), at 80:20 for 2 min (step gradient), re-equilibrate at 30:70 for 9 min. (Prepare buffer by adding 800 µL 70% perchloric acid to 1 L water.) Flow rate: 0.5 for 11 min, 1 for 25 min, 0.5 for 9 min Injection volume: 500 Detector: UV 235 CHROMATOGRAM Retention time: 22.1 Internal standard: dimethylamino-3-propyl thiomethylene-5 virginiamycin S (31.0) Limit of quantitation: 25 pg/mL OTHER SUBSTANCES Extracted: metabolites, dalfopristin (12.7), pristinamycin II A (24.1) KEY WORDS plasma; SPE; whole blood REFERENCE Le Liboux, A.; Pasquier, O.; Montay, G. Simultaneous high-performance liquid chromatographic determination of quinupristin, dalfopristin and their main metabolites in human plasma, J.Chromatogr.B, 1998, 708, 161–168. Quinupristin 541 SAMPLE Matrix: formulations Sample preparation: Inject a 5–10 µL aliquot of the infusion solution. HPLC VARIABLES Column: 125 × 4 5 µm LiChrospher-100 RP18 Column Temperature: 40 ± 1 Mobile phase: Gradient. A:B from 0:100 to 66:34 over 42.5 min, return to initial conditions over 1.5 min, re-equilibrate for 5 min. A was MeCN:buffer 65:35. B was MeCN:buffer 20:80. The buffer was 30 mM potassium dihydrogen phosphate adjusted to pH 2.9 with phosphoric acid. Flow rate: 1.1 Injection volume: 5–10 Detector: UV 254 CHROMATOGRAM Retention time: 23.9, 23.1, 27.0 Limit of quantitation: 0.12% OTHER SUBSTANCES Simultaneous: impurities, dalfopristin (LOQ 0.05%) (8.5) KEY WORDS infusion; injection; stability-indicating REFERENCE Vasselle, B.; Gousset, G.; Bounine, J.-P. Development and validation of a high-performance liquid chromatographic stability-indicating method for the analysis of Synercid in quality control, stability and compatibility studies, J.Pharm.Biomed.Anal., 1999, 19, 641–657. ANNOTATED BIBLIOGRAPHY Abdel-Hamid, M.E.; Phillips, O.A. LC-MS/MS determination of Synercid injections, J.Pharm.Biomed. Anal., 2003, 32, 1167–1174. [pristinamycin; quinupristin; dalfopristin] Rabeprazole H N O N S Molecular formula: C18 H21 N3 O3 S O N Molecular weight: 359.45 CAS Registry No: 117976-89-3, 117976-90-6 (Na salt) Merck Index: 13, 8181 OCH3 CH3 SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 100 µL 1% diethylamine in water, add 100 µL 0.1% diethylamine in MeOH, add 1 mL pH 10.38 Britton–Robinson buffer, add 4 mL ethyl acetate, shake for 10 min, centrifuge at 1500 g for 5 min, repeat extraction twice. Combine the organic layers and evaporate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 100 µL 0.1% diethylamine in MeOH, inject a 30 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Inertsil C8 Column temperature: 40 Mobile phase: MeCN:100 mM pH 7.00 phosphate buffer 28:72, adjusted to pH 7.00 with phosphoric acid Flow rate: 1.4 Injection volume: 30 Detector: UV 288 CHROMATOGRAM Retention time: 6.5 Internal standard: IS735 (5-methyl-2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl} methylsulfinyl]-1H-benzimidazole sodium salt) (10.1) Limit of quantitation: 5 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS pharmacokinetics; plasma REFERENCE Nakai, H.; Shimamura, Y.; Kanazawa, T.; Yasuda, S.; Kayano, M. Determination of a new H+ -K+ ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance liquid chromatography, J.Chromatogr.B, 1994, 660, 211–220. SAMPLE Matrix: formulations Sample preparation: Weigh out powdered tablet containing 15 mg rabeprazole, dissolve in 100 mL water, filter, inject a 20 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 4.6 µm VP-ODS Shim-pack Mobile phase: MeOH:water 70:30 Flow rate: 2 Injection volume: 20 Detector: UV 284 542 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 Rabeprazole 543 CHROMATOGRAM Retention time: 5.2 Limit of detection: 25 ng/mL Limit of quantitation: 76 ng/mL OTHER SUBSTANCES Simultaneous: degradants KEY WORDS comparison with HPTLC; validation data REFERENCE el-Gindy, A.; El-Yazby, F.; Maher, M.M. Spectrophotometric and chromatographic determination of rabeprazole in presence of its degradation products, J.Pharm.Biomed.Anal., 2003, 31, 229–242. ANNOTATED BIBLIOGRAPHY Mano, N.; Oda, Y.; Takakuwa, S.; Chiku, S.; Nakata, H.; Asakawa, N. Plasma direct injection highperformance liquid chromatographic method for simultaneously determining E3810 enantiomers and their metabolites by using flavoprotein-conjugated column, J.Pharm.Sci., 1996, 85, 903–907. [chiral; dog; column-switching] Takakuwa, S.; Chiku, S.; Nakata, H.; Yuzuriha, T.; Mano, N.; Asakawa, N. Enantioselective high-performance liquid chromatographic assay for determination of the enantiomers of a new anti-ulcer agent, E3810, in Beagle dog plasma and rat plasma, J.Chromatogr.B, 1995, 673, 113–122. [chiral; LOQ 30 ng/mL] 544 Ractopamine Ractopamine OH N Molecular formula: C18 H23 NO3 Molecular weight: 301.38 CAS Registry No: 97825-25-7, 90274-24-1 (HCl) Merck Index: 13, 8184 OH H HO CH3 SAMPLE Matrix: tissue, urine Sample preparation: Condition a ChromP SPE cartridge (Supelco) with 6 mL ethyl acetate, 6 mL MeOH, and 6 mL water. Condition a Screen DAU SPE cartridge (Supelco) with 2 mL MeOH, 2 mL water, and 2 mL 100 mM pH 6 phosphate buffer. Freeze-dry and grind 15 g tissue or 200–500 mg retina, add 12 mL MeOH, add 15 mL 2 M pH 5.2 acetate buffer, stir for 30 min, centrifuge at 2000 g for 15 min. Remove the supernatant and evaporate the MeOH. Mix 10 mL urine with 2 mL 2 M pH 5.2 acetate buffer. Add the tissue or urine preparations to 400 µL Helix pomatia preparation containing 25 U/µL (Sigma), heat at 60◦ for 15 h, centrifuge, add the supernatant to the ChromP SPE cartridge, wash with 5 mL hexane, wash with 12 mL hexane:diethyl ether 70:30, elute with 24 mL diethyl ether. Evaporate the eluate to dryness, reconstitute with 6 mL 100 mM pH 6 phosphate buffer, add to the DAU SPE cartridge, wash with 1 mL 1 M acetic acid, wash with 6 mL MeOH, elute with 6 mL ethyl acetate:32% ammonium hydroxide 97:3. Evaporate the eluate to dryness, reconstitute the residue with 50 µL MeOH:water:acetic acid 5:95:0.5, inject a 10 µL aliquot. HPLC VARIABLES Guard column: 10 × 2 5 µm Nucleosil C18AB Column: 50 × 2 5 µm Nucleosil C18AB Mobile phase: Gradient. MeOH:0.5% acetic acid from 95:5 to 50:50 over 10 min, to 10:90 over 10 min, maintain at 10:90 for 10 min (?), re-equilibrate at initial conditions for 10 min. (sic). Flow rate: 0.22 Injection volume: 10 Detector: MS, Micromass QuattroLC, triple quadrupole, nebulizing gas nitrogen 90 L/h, desolvation gas nitrogen 600 L/h, source 120◦ , desolvation 350◦ , capillary 3.5 kV, sampling cone 25 V, collision gas argon 0.4 µbar, collision energy 15–25 V, m/z 302–284–150 CHROMATOGRAM Retention time: 8.58 Internal standard: isoxsuprine (m/z 302–284–164–136–121–107–91) (10.35) Limit of detection: 10 ng/kg Limit of quantitation: 30 ng/kg KEY WORDS kidney; liver; lung; meat; pig; retina; SPE REFERENCE Antignac, J.-P.; Marchand, P.; Le Bizec, B.; Andre, F. Identification of ractopamine residues in tissue and urine samples at ultra-trace level using liquid chromatography-positive electrospray tandem mass spectrometry, J.Chromatogr.B, 2002, 774, 59–66. SAMPLE Matrix: tissue Sample preparation: Condition a Sep-Pak Alumina A SPE cartridge with ethyl acetate. Add IS to tissue, extract 10 g homogenized tissue three times with 20 mL portions of MeOH, and combine the extracts. Evaporate an 8 mL aliquot to dryness, reconstitute Ractopamine 545 with 1 mL 25 mM pH 5.0 sodium acetate buffer, add 20 µL β-glucuronidase (Helix pomatia) (Sigma), heat at 65◦ for 2 h, mix with 2 mL 25 mM pH 10.3 sodium borate buffer, extract three times with 7 mL portions of ethyl acetate, add the combined extracts to the alumina SPE cartridge, wash with ethyl acetate, dry under vacuum, elute with 10 mL MeOH. Evaporate the eluate to dryness, reconstitute the residue with 4 mL 1 M acetic acid, add to a 6 mL 500 mg Oasis MCX SPE cartridge, elute with 4 mL 2% ammonia in MeOH. Evaporate the eluate to dryness, reconstitute the residue with 500 µL 2% acetic acid, inject a 100 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Supelcosil LC-18-DB Mobile phase: MeCN:water:glacial acetic acid 32:68:2 containing 0.87 g/L 1-pentanesulfonic acid Flow rate: 1 Injection volume: 100 Detector: F ex 226 em 306 CHROMATOGRAM Retention time: 5.4 Internal standard: ritodrine (4.7) Limit of quantitation: 1 ng/g KEY WORDS cow; pig; muscle; SPE REFERENCE Shishani, E.; Chai, S.C.; Jamokha, S.; Aznar, G.; Hoffman, M.K. Determination of ractopamine in animal tissues by liquid chromatography-fluorescence and liquid chromatography/tandem mass spectrometry, Anal.Chim.Acta, 2003, 483, 137–145. SAMPLE Matrix: tissue Sample preparation: Condition a Sep-Pak Alumina A SPE cartridge with ethyl acetate. Add IS to tissue, extract 10 g homogenized tissue three times with 20 mL portions of MeOH, and combine the extracts. Evaporate an 8 mL aliquot to dryness, reconstitute with 1 mL 25 mM pH 5.0 sodium acetate buffer, add 20 µL β-glucuronidase (Helix pomatia) (Sigma), heat at 65◦ for 2 h, mix with 2 mL 25 mM pH 10.3 sodium borate buffer, extract three times with 7 mL portions of ethyl acetate, add the combined extracts to the alumina SPE cartridge, wash with ethyl acetate, dry under vacuum, elute with 10 mL MeOH. Evaporate the eluate to dryness, reconstitute the residue with 4 mL 1 M acetic acid, add to a 6 mL 500 mg Oasis MCX SPE cartridge, elute with 4 mL 2% ammonia in MeOH. Evaporate the eluate to dryness, reconstitute the residue with 200 µL MeOH for MS detection, inject an aliquot. HPLC VARIABLES Column: 50 × 2.1 5 µm Discovery RP-Amide C-16 (Supelco) Mobile phase: Gradient. MeCN:pH 4.5 ammonium acetate buffer from 5:95 to 100:0 over 2 min. Flow rate: 0.5 Detector: MS, PE Sciex API-III, positive mode, nebulizer 500◦ , interface 55◦ , nebulizer gas 0.6 L/min, auxiliary flow 2.8 L/min, collision gas argon, m/z 302–164, 302–107, 302–121 CHROMATOGRAM Internal standard: ritodrine (m/z 288–150) Limit of quantitation: 1 ng/g 546 Ractopamine KEY WORDS cow; pig; muscle; SPE REFERENCE Shishani, E.; Chai, S.C.; Jamokha, S.; Aznar, G.; Hoffman, M.K. Determination of ractopamine in animal tissues by liquid chromatography-fluorescence and liquid chromatography/tandem mass spectrometry, Anal.Chim.Acta, 2003, 483, 137–145. ANNOTATED BIBLIOGRAPHY Turberg, M.P.; Macy, T.D.; Lewis, J.J.; Coleman, M.R. Determination of ractopamine hydrochloride in swine, cattle, and turkey feeds by liquid chromatography with coulometric detection, J.AOAC Int., 1994, 77, 840–847. [SPE; LOQ 1.25 ppm] Turberg, M.P.; Macy, T.D.; Lewis, J.J.; Coleman, M.R. Determination of ractopamine hydrochloride in swine and turkey tissues by liquid chromatography with coulometric detection, J.AOAC Int., 1995, 78, 1394–1402. [liver; kidney; muscle; fat; SPE; LOD 0.5 ppb] Turberg, M.P.; Rodewald, J.M.; Coleman, M.R. Determination of ractopamine in monkey plasma and swine serum by high-performance liquid chromatography with electrochemical detection, J.Chromatogr.B, 1996, 675, 279–285. [SPE; LOQ 2 ng/mL] 547 Raloxifene Raloxifene HO S OH Molecular formula: C28 H27 NO4 S Molecular weight: 473.59 CAS Registry No: 84449-90-1, 82640-04-8 (HCl) Merck Index: 13, 8190 O O N SAMPLE Matrix: blood Sample preparation: Mix 100 ng IS with 300 µL plasma, add 600 µL acetone, mix, let stand on ice for 10 min, centrifuge. Evaporate the supernatant to dryness under reduced pressure, reconstitute the residue with 100 µL 500 mM pH 9.0 sodium carbonate and 100 µL dichloromethane, mix thoroughly, centrifuge, inject a 40 µL aliquot of the organic layer. HPLC VARIABLES Column: 10 µm Zorbax C8 or LiChrosorb C8 Mobile phase: MeCN:100 mM pH 4.0 sodium acetate 50:50 Flow rate: 2 Injection volume: 40 Detector: E, BAS LC-3, glassy carbon electrode +0.65 V CHROMATOGRAM Retention time: 5.8 Internal standard: (4-(2-(dimethylamino)ethoxy)phenyl)(6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl)methanone (3.9) KEY WORDS dog; monkey; plasma; rat REFERENCE Lindstrom, T.D.; Whitaker, N.G.; Whitaker, G.W. Disposition and metabolism of a new benzothiophene antiestrogen in rats, dogs and monkeys, Xenobiotica, 1984, 14, 841–847. SAMPLE Matrix: solutions Sample preparation: Inject a 1 µL aliquot of a solution in MeOH:water 10:90. HPLC VARIABLES Column: 20 × 2 5 µm DASH BetaBasic C8 (ThermoHypersil Keystone) Mobile phase: Gradient. A was MeCN:water:formic acid 5:95:0.1. B was MeCN:water: formic acid 95:5:0.1. A:B 100:0 for 0.2 min, to 0:100 over 1.5 min. Flow rate: 1.5 Injection volume: 1 Detector: MS, PE Sciex API-3000, TurboIonspray, electrospray 4500 V, ring 290 V, orifice 60 V, drying gas 400◦ , 20% of column effluent entered the detector, m/z 474.1–112 CHROMATOGRAM Retention time: 0.97 OTHER SUBSTANCES Simultaneous: amitriptyline (m/z 278.3–233) (1.1), aprepitant (MK-869) (m/z 535.3–277) (1.4), diclofenac (m/z 296.1–215) (1.35), enoxacin (m/z 321.2–234) (0.7), 548 Raloxifene fenofibrate (m/z 360.9–233) (1.6), finasteride (m/z 373.2–317) (1.2), indinavir (m/z 614.4–421) (0.93), pioglitazone (357.2–134) (0.87) REFERENCE Romanyshyn, L.A.; Tiller, P.R. Ultra-short columns and ballistic gradients: considerations for ultra-fast chromatographic liquid chromatographic-tandem mass spectrometric analysis, J.Chromatogr.A, 2001, 928, 41–51. Ramosetron Ramosetron CH3 N H N Molecular formula: C17 H17 N3 O Molecular weight: 279.34 CAS Registry No: 132036-88-5 Merck Index: 13, 8195 549 O N SAMPLE Matrix: blood, urine Sample preparation: Shake 1 (animal) or 2 (human) mL plasma or 1 mL urine with 200 µL 100 µg/mL IS in water, 1 mL saturated sodium bicarbonate, and 5 mL ethyl acetate for 15 min, centrifuge at 1200 g for 10 min. Remove the organic layer and add it to 2.5 mL 400 mM HCl, shake for 15 min, centrifuge at 800 g for 5 min. Remove the aqueous layer, add 2 mL saturated sodium bicarbonate solution to the aqueous layer, stir, let stand at room temperature for 20 min, add 4.5 mL ethyl acetate, shake for 15 min, centrifuge at 800 g for 5 min. Evaporate the organic layer to dryness under reduced pressure, reconstitute the residue with 100 µL mobile phase, inject a 60 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 TSK-gel ODS-80-Tm (Tosoh) (plasma) or 250 × 4.6 Cosmosil 5C18AR (Nacalai Tesque) (urine) Mobile phase: MeCN:100 mM potassium dihydrogen phosphate:100 mM phosphoric acid 25:37.5:37.5 (plasma) or MeCN:100 mM potassium dihydrogen phosphate:100 mM phosphoric acid 33:33:33 containing 400 µM sodium dodecyl sulfate (urine) Flow rate: 1 Injection volume: 60 Detector: UV 311 CHROMATOGRAM Retention time: 10 Internal standard: GSA 110 (9-methyl-3-[(5-methylimidazole-4-yl)methyl]-2,3,4,9tetrahydrothiopyrano[2,3-b]indole-4-one fumarate) (14) Limit of detection: 200 pg/mL (S/N 3, human plasma), 500 pg/mL (rat, dog plasma), 1 ng/mL (human urine) KEY WORDS dog; human; plasma; rat REFERENCE Miura, H.; Takeshige, T.; Kobayashi, S.-i.; Higuchi, S. A simple method for the determination of YM060 in plasma and urine by high performance liquid chromatography, Biomed.Chromatogr., 1994, 8, 103–104. SAMPLE Matrix: solutions HPLC VARIABLES Column: 150 × 4 Crestpak C18S-10 Mobile phase: MeCN:buffer 15:85 (The buffer was 3% triethylamine adjusted to pH 2.0 with phosphoric acid.) Flow rate: 2 Detector: Radioactivity (11 C) 550 Ramosetron CHROMATOGRAM Retention time: 7.3 REFERENCE Ishiwata, K.; Ishii, K.; Ishii, S.-I.; Senda, M. Synthesis of 5-HT3 receptor antagonists, [11 C]Y-25130 and [11 C]YM060, Appl.Radiat.Isot., 1995, 46, 907–910. 551 Rapacuronium bromide Rapacuronium bromide Br− O Molecular formula: C37 H61 BrN2 O4 Molecular weight: 677.81 CAS Registry No: 156137-99-4 Merck Index: 13, 8201 CH3 O CH3 N H O O N+ H H H CH3 SAMPLE Matrix: bile, blood, stoma fluid, tissue, urine Sample preparation: Caution! The method as described is applied to and validated for rocuronium. However, Wierda et al. (Wierda,J.M.K.H.; Beaufort,A.M.; Kleef,U.W.; Smeulers,N.J.; Agoston,S. Preliminary investigations of the clinical pharmacology of three short-acting non-depolarizing neuromuscular blocking agents, Org 9453, Org 9489 and Org 9487. Can.J.Anaesth. 1994, 41, 213–220.) state that ‘‘the compounds were determined by means of the HPLC method described for rocuronium bromide, which was modified and validated for . . . Org 9487’’ [rapacuronium]. Homogenize (Ultra-Turrax) 1 g tissue with 9 mL 1 M sodium dihydrogen phosphate for 10 min. Acidify 1 mL plasma, urine, or bile with 200 µL 1 M sodium dihydrogen phosphate. Homogenize 1 mL stoma fluid with 200 µL 1 M sodium dihydrogen phosphate. Make up 50–1000 µL plasma, 200–1000 µL urine, 5–200 µL bile, 1000 µL stoma fluid, or 100–1000 µL tissue homogenate to 2 mL with water, add 1 mL buffer, add 150 ng IS, add 7 mL dichloromethane, vortex for 15 s, centrifuge at 740 g for 5 min. Remove the lower organic layer and evaporate it to dryness under a stream of air at 37◦ , reconstitute the residue in 200 µL mobile phase, inject a 100 µL aliquot (or less). (The buffer was prepared by mixing 6 mL of an aqueous solution containing 7.505 mg/mL glycine and 5.85 mg/mL NaCl, with 4 mL 100 mM NaOH and 6.2 g KI.) HPLC VARIABLES Guard column: 4 × 6 µBondapak C18 Column: 150 × 3.9 5 µm Lichrospher 100-RP18 Mobile phase: Dioxane:buffer 16:84 (Caution! Dioxane is a carcinogen!) (The buffer was 100 mM sodium dihydrogen phosphate containing 0.11 mM 9,10-dimethoxyanthracene2-sulfonate and 0.11 mM 1-heptanesulfonic acid, pH adjusted to 3.0 with orthophosphoric acid. After each series of analyses, flush column with 15 mL water and 75 mL MeOH.) Flow rate: 1 Injection volume: 100 Detector: F ex 385 em 452 following post-column extraction. The column effluent mixed with dichloroethane pumped at 1 mL/min and the mixture flowed through a 1 m × 0.25 mm ID stainless steel coil to a phase separator (Organon International) and then the organic phase flowed through the detector (J.Chromatogr. 1987, 421, 327; Anal.Chim.Acta 1987, 192, 267). CHROMATOGRAM Retention time: 9 (for rocuronium) Internal standard: 1-(3α,17β-dihydroxy-2β-morpholino-5α-androstan-16β-yl)-1-methylpiperidinium bromide (Org 7402, Organon) (21) Limit of detection: 3 ng (plasma), 4 ng (urine, bile), 5 ng (tissue) Limit of quantitation: 10 ng/mL (plasma), 25 ng/mL (urine), 100 ng/mL (bile), 20 ng/mL (stoma fluid) 552 Rapacuronium bromide OTHER SUBSTANCES Simultaneous: cefotaxime, ceftazidime, ceftriaxone, cefuroxime, cefamandole, cephradine, dixyrazine, meperidine, metocurine, metoprolol, sulfamethoxazole, trimethoprim Interfering: alizapride, atracurium, ketamine, ketogan, lidocaine, metoclopramide, nimodipine, prochlorperazine, tubocurarine aprotinin, atropine, bupivacaine, chlorpromazine, dalteparin, dexamethasone, diazepam, dopamine, droperidol, etomidate, fentanyl, furosemide, gallamine, haloperidol, midazolam, morphine, neostigmine, nitroglycerin, nitroprusside, oxytocin, pancuronium, pentobarbital, phenylephrine, phenytoin, pipecuronium, piperacillin, promethazine, propofol, ranitidine, succinylcholine, sufentanil, terbutaline, thiopental, vecuronium, verapamil Noninterfering: alfentanil, KEY WORDS human; dog; plasma; liver; lung REFERENCE Kleef, U.W.; Proost, J.H.; Roggeveld, J.; Wierda, J.M.K.H. Determination of rocuronium and its putative metabolites in body fluids and tissue homogenates, J.Chromatogr., 1993, 621, 65–76. 553 Remifentanil Remifentanil Molecular formula: C20 H28 N2 O5 Molecular weight: 376.45 CAS Registry No: 132875-61-7 Merck Index: 13, 8216 O N OCH3 N H3C O OCH3 O SAMPLE Matrix: blood Sample preparation: Mix 500 µL whole blood with 10 µL 50% citric acid and 25 µL 500 ng/mL IS in 1 mM HCl, add 500 µL 100 mM pH 7.4 phosphate buffer, vortex until homogeneous, add 2 mL dichloromethane, shake mechanically for 10 min, centrifuge at 13 000 rpm for 10 min. Evaporate the lower dichloromethane layer to dryness under a stream of nitrogen at room temperature, reconstitute the residue with 125 µL mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Column: 33 × 4.6 Pecosphere C18 (Perkin-Elmer) Mobile phase: MeCN:chloroform 50:50 containing 2 mM ammonium acetate (Caution! Chloroform is a carcinogen!) Flow rate: 0.3 Injection volume: 20 Detector: MS, PE Sciex API-III Plus triple quadrupole, turbo ionspray, positive ion mode, turbo 200◦ , orifice 60 V, auxiliary gas nitrogen at 4 L/min, curtain gas at 1.2 L/min, m/z 377–228 CHROMATOGRAM Retention time: 1.3 Internal standard: d4 -remifentanil (381–232) Limit of quantitation: 0.1 ng/mL KEY WORDS whole blood REFERENCE Bender, J.; van den Elshout, J.; Selinger, K.; Broeders, G.; Dankers, J.; van der Heiden, C. Determination of remifentanil in human heparinised whole blood by tandem mass spectrometry with short-column separation, J.Pharm.Biomed.Anal., 1999, 21, 559–567. SAMPLE Matrix: blood Sample preparation: Condition a Bond Elut phenyl SPE cartridge with 1 mL MeOH and 1 mL 50 mM pH 3 potassium phosphate buffer. Add 500 µL plasma and 750 µL 800 ng/mL IS in 50 mM pH 3 potassium phosphate buffer to the SPE cartridge, wash with 1 mL 50 mM pH 3 potassium phosphate buffer, wash with 1 mL MeCN, elute with 1 mL MeOH. Evaporate the eluate to dryness under reduced pressure, reconstitute the residue with 200 µL mobile phase, inject a 50–100 µL aliquot. HPLC VARIABLES Guard column: 4 × 3 C1 Column: 150 × 4.6 5 µm Spherisorb C1 Mobile phase: MeCN:MeOH:50 mM pH 3 potassium phosphate buffer:water 18:12:4. 8:65.2 Flow rate: 1.5 554 Remifentanil Injection volume: 50–100 Detector: UV 210 CHROMATOGRAM Retention time: 9 Internal standard: GI97559 (ethyl 3-{4-methoxycarbonyl-4-[(1-oxopropyl)-phenylamino]-1-piperidine}propanoate) (10.5) Limit of detection: 0.5 ng/mL Limit of quantitation: 8 ng/mL OTHER SUBSTANCES Extracted: demethoxyremifentanil (metabolite) (4) KEY WORDS dog; pharmacokinetics; plasma; SPE REFERENCE Kabbaj, M.; Varin, F. Simultaneous solid-phase extraction combined with liquid chromatography with ultraviolet absorbance detection for the determination of remifentanil and its metabolite in dog plasma, J.Chromatogr.B, 2003, 783, 103–111. ANNOTATED BIBLIOGRAPHY Haidar, S.H.; Liang, Z.; Selinger, K.; Hamlett, L.; Eddington, N.D. Determination of remifentanil, an ultra-short-acting opioid anesthetic, in rat blood by high-performance liquid chromatography with ultraviolet detection, J.Pharm.Biomed.Anal., 1996, 14, 1727–1732. [LOQ 2.5 ng/mL] Selinger, K.; Lanzo, C.; Sekut, A. Determination of remifentanil in human and dog blood by HPLC with UV detection, J.Pharm.Biomed.Anal., 1994, 12, 243–248. [LOQ 1 ng/mL] Vishwanathan, K.; Stewart, J.T. HPLC determination of a propofol and remifentanil mixture, J.Liq.Chromatogr.Rel.Technol., 1999, 22, 923–931. [LOD 200 ng/mL] 555 Repaglinide Repaglinide CH3 H3C O Molecular formula: C27 H36 N2 O4 Molecular weight: 452.58 CAS Registry No: 135062-02-1 Merck Index: 13, 8220 NH COOH O CH3 N SAMPLE Matrix: blood Sample preparation: Centrifuge plasma at 13 000 g for 2 min and dilute with 2 vol of 200 mM HCl, inject a 160 µL aliquot onto column A and elute to waste with water; after 3 min, backflush the contents of column A onto column B with mobile phase, monitor the effluent from column B. At the end of the separation, wash column A with MeCN:MeOH:dioxane 24:68:8. (Caution! Dioxane is a carcinogen!) HPLC VARIABLES Column: A 17 × 2.9 30–40 µm Perisorb RP-2 (Merck); B 17 × 4.6 5 µm ODS-Hypersil + 125 × 4 5 µm LiChrospher 100 RP-18 Mobile phase: MeCN:MeOH:dioxane:buffer 18.24:51.68:6.08:24 (Caution! Dioxane is a carcinogen!) (The buffer was 3 g potassium dihydrogen phosphate and 0.5 g lithium perchlorate in 1 L water, adjusted to pH 2.7 with orthophosphoric acid.) Flow rate: 1 Injection volume: 160 Detector: E, Waters 460, 1.04 V (to prevent contamination, column effluent passes through the detector only from 7.5–13.8 min) CHROMATOGRAM Retention time: 9 Limit of detection: 5 ng/mL KEY WORDS column-switching; plasma REFERENCE Greischel, A.; Beschke, K.; Rapp, H.; Roth, W. Quantitation of the new hypoglycaemic agent AG-EE 388 ZW in human plasma by automated high-performance liquid chromatography with electrochemical detection, J.Chromatogr., 1991, 568, 246–252. SAMPLE Matrix: formulations Sample preparation: Dissolve powdered tablet containing 25 mg repaglinide and 25 mg nimesulide in 25 mL MeOH, shake well, filter (0.45 µm), dilute filtrate with mobile phase to a concentration of 1 µg/mL, inject a 20 µL aliquot. HPLC VARIABLES Guard column: 20 mm long Shim-pack ODS (Shimadzu) Column: 150 × 4.6 5 µm Shim-pack RP-C18 Column temperature: 30 Mobile phase: MeOH:buffer 50:50 (The buffer was 0.1% triethylamine adjusted to pH 7 with 1% orthophosphoric acid.) Flow rate: 1 Injection volume: 20 Detector: UV 235 556 Repaglinide CHROMATOGRAM Retention time: 3.4 Internal standard: nimesulide (2.04) Limit of quantitation: 100 ng/mL KEY WORDS tablets REFERENCE Gandhimathi, M.; Ravi, T.K.; Renu, S.K. Determination of repaglinide in pharmaceutical formulations by HPLC with UV detection, Anal.Sci., 2003, 19, 1675–1677. ANNOTATED BIBLIOGRAPHY Niemi, M.; Neuvonen, P.J.; Kivistö, K.T. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide, Clin.Pharmacol.Ther., 2001, 70, 58–65. [LC-MS; LOQ 50 pg/mL; indomethacin is internal standard] Reddy, K.V.S.R.K.; Babu, J.M.; Mathad, V.T.; Eswaraiah, S.; Reddy, M.S.; Dubey, P.K.; Vyas, K. Impurity profile study of repaglinide, J.Pharm.Biomed.Anal., 2003, 32, 461–467. Thomsen, M.S.; Chassard, D.; Evène, E.; Nielsen, K.K.; Jorgensen, M. Pharmacokinetics of repaglinide in healthy Caucasian and Japanese subjects, J.Clin.Pharmacol., 2003, 43, 23–28. [LC-MS; LOQ 200 pg/mL; SPE] Ricinoleic acid Ricinoleic acid Molecular formula: C18 H34 O3 557 CH3(CH2)5 (CH2)6COOH HO Molecular weight: 289.46 CAS Registry No: 141-22-0 Merck Index: 13, 8295 SAMPLE Matrix: blood Sample preparation: Vortex 20 µL plasma, 10 µL 2 mg/mL margaric acid in MeOH, and 200 µL 500 mM KOH in EtOH for 30 s, centrifuge at 2500 g for 10 min. Remove the supernatant and heat it at 100◦ for 30 min, cool, add 200 µL 1 M HCl, add 2 mL chloroform (Caution! Chloroform is a carcinogen!), mix vigorously for 5 min, centrifuge at 460 g for 5 min. Remove the organic layer and evaporate it to dryness under reduced pressure at 43◦ , reconstitute the residue in 500 µL benzene (Caution! Benzene is a carcinogen!), sonicate for 1 min, add 500 µL 2% oxalyl chloride in benzene, heat at 70◦ for 30 min, evaporate to dryness under reduced pressure, reconstitute with 100 µL benzene, add 100 µL 40 mM 1-naphthylamine (Caution! 1-Naphthylamine is a carcinogen!) in benzene, vortex for 30 s, heat at 37◦ for 30 min, evaporate to dryness, reconstitute with MeOH:MeCN:water 72:13:15, vortex for 20 s, inject a 20 µL aliquot. (This method was developed for Cremophor EL, which is saponified to ricinoleic acid and then derivatized with 1-naphthylamine. However, the method should work for ricinoleic acid in plasma.) HPLC VARIABLES Column: two 100 × 3 5 µm Spherisorb ODS-I glass columns in series Mobile phase: MeCN:MeOH:10 mM pH 7.0 potassium phosphate buffer 13:72:15 Flow rate: 0.4 Injection volume: 20 Detector: UV 280 CHROMATOGRAM Retention time: 10.0 Internal standard: margaric acid (27.8) Limit of detection: 0.005% Limit of quantitation: 0.01% OTHER SUBSTANCES Simultaneous: arachidonic acid, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitic acid, palmitoleic acid, stearic acid KEY WORDS derivatization; human; mouse; plasma REFERENCE Sparreboom, A.; van Tellingen, O.; Huizing, M.T.; Nooijen, W.J.; Beijnen, J.H. Determination of polyoxyethyleneglycerol triricinolate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography, J.Chromatogr.B, 1996, 681, 355–362. 558 Rifaximin Rifaximin Molecular formula: C43 H51 N3 O11 Molecular weight: 785.88 CAS Registry No: 80621-81-4 Merck Index: 13, 8304 CH3 O CH3 HO CH3 OH O OH OH CH3 O H3C CH3O CH3 N H CH3 N O N O CH3 O CH3 SAMPLE Matrix: blood, urine Sample preparation: Mix 1 mL plasma or 2 mL urine with 100 µL 1 µg/mL IS solution, add 6 mL ethyl acetate, shake horizontally for 10 min, centrifuge. Remove the organic layer and, for urine samples only, wash with 1 mL 200 mM NaOH. Evaporate a 5 mL aliquot of the organic layer to dryness under reduced pressure, reconstitute the residue with 200 µL MeCN:mobile phase 20:80, vortex, sonicate for 10 min, inject a 40 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Kromasil C18 Mobile phase: MeCN:water:500 mM pH 7.2 phosphate buffer 47:48:5 containing 1 g/L tetrabutylammonium phosphate Injection volume: 40 Detector: E, ESA Coulochem Model 5100A, guard cell Model 5020 + 0.7 V, analytical cell Model 5010, channel 1 + 0.28 V, channel 2 + 0.6 V CHROMATOGRAM Retention time: 7.5 Internal standard: 17α-estradiol (6.0) Limit of quantitation: 2 ng/mL KEY WORDS plasma REFERENCE Descombe, J.J.; Dubourg, D.; Picard, M.; Palazzini, E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers, Int.J.Clin.Pharmacol.Res., 1994, 14, 51–56. 559 Rilmazafone Rilmazafone CH3 O N CH3 Molecular formula: C21 H20 Cl2 N6 O3 N Molecular weight: 475.34 CAS Registry No: 99593-25-6 Merck Index: 13, 8305 N N N O Cl H NH2 O Cl SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 100 µL 1 M pH 5.0 acetate buffer and 5 mL EtOH, centrifuge at 1000 rpm for 15 min. Evaporate 5 mL of the supernatant to dryness, reconstitute the residue with 5 mL 100 mM pH 5.0 acetate buffer, add 4 mL of this solution to a Sep-Pak C18 SPE cartridge, elute with 5 mL MeOH, evaporate the eluate to dryness, reconstitute the residue with 200 µL 100 mM pH 11.6 sodium carbonate buffer, inject a 5–10 µL aliquot. HPLC VARIABLES Guard column: 50 × 4 Nucleosil 10C18 Column: 150 × 4.6 Nucleosil 5C18 Mobile phase: MeCN:buffer 35:65 (Prepare the buffer by dissolving one vial of Waters PIC reagent A in 650 mL water.) Flow rate: 1.5 Injection volume: 5–10 Detector: UV 254 CHROMATOGRAM Retention time: 7 OTHER SUBSTANCES Extracted: metabolites KEY WORDS plasma; rat REFERENCE Matsubara, T.; Touchi, A.; Yamada, N.; Sugeno, K. Induction of rat liver microsomal drug-metabolizing enzymes by a new sleep inducer 450191-S and plasma levels of 450191-S-metabolites, J.Pharmacobiodyn., 1986, 9, 249–256. 560 Risedronate sodium Risedronate sodium O N HO Molecular formula: C7 H10 NNaO7 P2 Molecular weight: 305.09 CAS Registry No: 115436-72-1, 105462-24-6 (free acid) Merck Index: 13, 8315 OH P P O OH OH ONa SAMPLE Matrix: urine Sample preparation: Condition a 1 mL 30 mg HLB SPE cartridge (Waters) with 2 mL MeOH, 1 mL water, and 1 mL 10 mM mM 1-octyltriethylammonium phosphate. Immediately upon collection, add 25 µL 6 M HCl to each 1 mL urine, freeze at – 20◦ until ready to analyze. Mix 5 mL urine with 25 µL 125 µg/mL IS in water, add 50 µL 1.25 M calcium chloride solution, add 65 µL 30% NaOH, vortex; if no precipitate is observed, add 10 µL aliquots of 30% NaOH until a visible precipitate forms, centrifuge at 5020 g for 10 min, discard the supernatant, dissolve the precipitate in 50 µL 1 M HCl; if necessary, add 25 µL aliquots of 1 M HCl until the precipitate is completely dissolved, dilute with 5 mL water, add 50 µL NaOH to produce a second precipitate, centrifuge, discard the aqueous layer. Repeat the process. Dissolve the third precipitate in 500 µL 50 mM ethylene glycol-bis(β-aminoethyl ether)-N, N, N ′ ,N ′ -tetraacetic acid (EGTA), sonicate for 5 min, vortex, add 4.5 mL water, add 100 µL 500 mM 1-octyltriethylammonium phosphate, vortex for 10 s, add to the SPE cartridge at 0.3–0.5 mL/min, wash with 1 mL water, wash with 1 mL MeOH:water 5:95, elute with 1 mL MeOH by centrifuging at 70 g for 5 min. Evaporate the eluate to dryness under a stream of nitrogen at 50◦ , reconstitute the residue with 500 µL 10 mM pH 6.25 sodium phosphate containing 1 mM etidronate, inject a 100 µL aliquot onto column A and elute to waste with mobile phase A; after 3.5 min, divert the effluent from column A onto column B and continue to elute with mobile phase A; after another 3 min, remove column A from the circuit, elute column B with mobile phase B, monitor the effluent from column B. HPLC VARIABLES Column: A 50 × 4.6 3.5 µm X-Terra RP 18 (Waters); B 150 × 4.6 4 µm Synergi Polar RP (Phenomenex) Column temperature: 30 (A and B) Mobile phase: A MeCN:10 mM sodium phosphate containing 5 mM 1-octyltriethylammonium phosphate and 1 mM etidronate 8:92, apparent pH 6.25; B MeCN:11 mM sodium phosphate containing 5 mM 1-octyltriethylammonium phosphate and 1.1 mM etidronate 13:87, apparent pH 6.25 Flow rate: 1 Injection volume: 100 Detector: UV 262 CHROMATOGRAM Retention time: 18.5 Internal standard: 2-(3-pyridinyl)oxy-1-hydroxymethane diphosphonic acid tetraammonium salt (23) Limit of quantitation: 7.5 ng/mL KEY WORDS column-switching; SPE REFERENCE Vallano, P.T.; Shugarts, S.B.; Kline, W.F.; Woolf, E.J.; Matuszewski, B.K. Determination of risedronate in human urine by column-switching ion-pair high-performance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 2003, 794, 23–33. 561 Rizatriptan Rizatriptan Molecular formula: C15 H19 N5 Molecular weight: 269.34 CAS Registry No: 144034-80-0, 145202-66-0 (benzoate) Merck Index: 13, 8324 H N N N N N CH3 CH3 SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg Bond Elut C2 SPE cartridge with two 1 mL portions of MeOH and two 1 mL portions of water. Mix 1 mL plasma with 100 µL 100 ng/mL IS in water, add to the SPE cartridge, wash with 1 mL water, wash with two 1 mL portions of MeOH:water 30:70, elute with 1 mL MeOH:10 mM pH 5.0 ammonium acetate 60:40. Evaporate the eluate to dryness at 50◦ , reconstitute the residue with 200 µL mobile phase, sonicate for 10 min, vortex, inject a 25 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Spherisorb CN Mobile phase: MeCN:MeOH:water:trifluoroacetic acid 54:4:42:0.1 Flow rate: 1 Injection volume: 25 Detector: MS, PE Sciex API-III triple quadrupole, nebulizer probe 500◦ , positive ionization, nebulizer gas at 80 psi, auxiliary gas at 2 L/min, corona discharge +3 µA, 0.1143 mm orifice, orifice 45 V, collision gas argon, m/z 270–201 CHROMATOGRAM Retention time: 5 Internal standard: L-743,214 (N, N-diethyl analogue) (m/z 298–229) (5.5) Limit of quantitation: 0.5 ng/mL KEY WORDS pharmacokinetics; plasma; SPE REFERENCE McLoughlin, D.A.; Olah, T.V.; Ellis, J.D.; Gilbert, J.D.; Halpin, R.A. Quantitation of the 5HT1D agonists MK-462 and sumatriptan in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry, J.Chromatogr.A, 1996, 726, 115–124. 562 Rofecoxib Rofecoxib O O Molecular formula: C17 H14 O4 S Molecular weight: 314.36 CAS Registry No: 162011-90-7 Merck Index: 13, 8330 H3C S O O SAMPLE Matrix: blood Sample preparation: Add 50 µL 100 mM NaOH to 100 µL serum dropwise while gently vortexing, mix thoroughly, add 1 mL 600 ng/mL IS in ethyl acetate, vortex for 30 s, centrifuge at 1200 g for 10 min. Evaporate the organic layer to dryness under a stream of nitrogen at 37◦ , reconstitute the residue with 100 µL mobile phase, inject a 40 µL aliquot. HPLC VARIABLES Column: 150 × 3.9 5 µm Novapak C18 Mobile phase: MeCN:50 mM sodium acetate 40:60, pH 6.4 Flow rate: 1 Injection volume: 40 Detector: UV 273 CHROMATOGRAM Retention time: 3.23 Internal standard: 5-ethyl-5-tolyl barbituric acid (2.17) Limit of quantitation: 20 ng/mL OTHER SUBSTANCES Noninterfering: EDTA, heparin, ibuprofen, indomethacin, naproxen KEY WORDS plasma REFERENCE Aravind, M.K.; Prescilla, R.; Ofenstein, J.P. A rapid and sensitive high-performance liquid chromatography assay for rofecoxib in human serum, J.Chromatogr.Sci., 2002, 40, 26–28. SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 100 µL 10 µg/mL IS in MeCN and 1 mL pH 9.8 carbonate buffer, add 8 mL MTBE, rotate for 15 min. Evaporate the organic layer to dryness, reconstitute the residue with 500 µL MeCN, vortex for 1 min, add 50 µL water, vortex and sonicate for 15 min, inject a 25 µL aliquot. HPLC VARIABLES Guard column: 20 × 3 YMC ODS AQ Column: 100 × 3 3 µm YMC ODS AQ Mobile phase: MeCN:water 50:50 Flow rate: 0.4 Injection volume: 25 Detector: MS, PE Sciex API-III Plus triple quadrupole, ionspray, negative ionization, orifice – 40 V, corona – 40 µA, nebulizer gas air at 80 psi, collision gas argon, m/z 313–257 Rofecoxib 563 CHROMATOGRAM Retention time: 5 Internal standard: 4-(4-methanesulfonylphenyl)-3-(4-methylphenyl)-5H-furan-2-one (m/z 327–271) (6.5) Limit of quantitation: 100 pg/mL KEY WORDS pharmacokinetics; plasma REFERENCE Chavez-Eng, C.M.; Constanzer, M.L.; Matuszewski, B.K. Determination of Rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection, J.Chromatogr.B, 2000, 748, 31–39. SAMPLE Matrix: blood Sample preparation: Vortex 1 mL plasma with 50 µL MeCN and 25 µL 400 ng/mL IS in MeCN, add 1 mL 100 mM pH 5 acetate buffer, vortex, add 8 mL hexane:dichloromethane 50:50, mix on a flat-bed shaker for 5 min, centrifuge at 1500 g for 5 min, freeze in dry ice/acetone. Evaporate the organic layer to dryness under a stream of nitrogen at 50◦ , reconstitute the residue with 1 mL mobile phase, inject a 150 µL aliquot. HPLC VARIABLES Guard column: 20 × 4 5 µm BDS-Hypersil C18 Column: 100 × 4.6 5 µm BDS-Hypersil C18 Mobile phase: MeCN:water 35:65 Flow rate: 1.2 Injection volume: 150 Detector: F ex 250 em 375 following post-column reaction. The column effluent flowed through a 10 m ×0.3 mm ID reaction coil irradiated at 254 nm (Astec Beam Boost) to the detector. CHROMATOGRAM Retention time: 6 Internal standard: 4-(4-methanesulfonylphenyl)-3-(4-methylphenyl)-5H-furan-2one (9) Limit of quantitation: 0.5 ng/mL KEY WORDS plasma; post-column photochemical derivatization REFERENCE Woolf, E.; Fu, I.; Matuszewski, B. Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection, J.Chromatogr.B, 1999, 730, 221–227. ANNOTATED BIBLIOGRAPHY Abdel-Hamid, M.E. LC-MS analysis of selected sulfur-containing non-steroid antiinflammatory agents: applications to pharmaceutical products, J.Liq.Chromatogr.Rel.Technol., 2000, 23, 3095–3107. [LCMS; LOQ 100 ng/mL; rofecoxib; sulindac; celecoxib; piroxicam; tenoxicam] Chavez-Eng, C.M.; Constanzer, M.L.; Matuszewski, B.K. High-performance liquid chromatographictandem mass spectrometric evaluation and determination of stable isotope labeled analogs of rofecoxib in human plasma samples from oral bioavailability studies, J.Chromatogr.B, 2002, 767, 117–129. [LOQ 100 pg/mL] 564 Rofecoxib Ehrich, E.W.; Dallob, A.; De Lepeleire, I.; Van Hecken, A.; Riendeau, D.; Yuan, W.; Porras, A.; Wittreich, J.; Seibold, J.R.; De Schepper, P.; Mehlisch, D.R.; Gertz, B.J. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model, Clin.Pharmacol.Ther., 1999, 65, 336–347. [fluorescence detection] Halpin, R.A.; Geer, L.A.; Zhang, K.E.; Marks, T.M.; Dean, D.C.; Jones, A.N.; Melillo, D.; Doss, G.; Vyas, K.P. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs, Drug Metab.Dispos., 2000, 28, 1244–1254. [LOQ 1 ng/mL; plasma; post-column photochemical derivatization; fluorescence detection] Halpin, R.A.; Porras, A.G.; Geer, L.A.; Davis, M.R.; Cui, D.; Doss, G.A.; Woolf, E.; Musson, D.; Matthews, C.; Mazenko, R.; Schwartz, J.I.; Lasseter, K.C.; Vyas, K.P.; Baillie, T.A. The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects, Drug Metab.Dispos., 2002, 30, 684–693. [plasma; urine; bile; feces; LOQ 0.5 ng/mL; post-column photochemical derivatization; fluorescence detection] Hsieh, J.Y.-K.; Lin, L.; Matuszewski, B.K. High-throughput liquid chromatographic determination of rofecoxib in human plasma using a fully automated on-line solid-phase extraction system, J.Liq.Chromatogr.Rel.Technol., 2001, 24, 799–812. [LOQ 0.5 ng/mL; plasma; post-column photochemical derivatization; fluorescence detection; SPE] Krishna Reddy, K.V.S.R.; Babu, J.M.; Dubey, P.K.; Chandra Sekhar, B.; Om Reddy, G.; Vyas, K. Isolation and characterisation of process-related impurities in rofecoxib, J.Pharm.Biomed.Anal., 2002, 29, 355–360. Mao, B.; Abrahim, A.; Ge, Z.; Ellison, D.K.; Hartman, R.; Prabhu, S.V.; Reamer, R.A.; Wyvratt, J. Examination of rofecoxib solution decomposition under alkaline and photolytic stress conditions, J.Pharm.Biomed.Anal., 2002, 28, 1101–1113. [stability-indicating] Matthews, C.Z.; Woolf, E.J.; Matuszewski, B.K. Improved procedure for the determination of rofecoxib in human plasma involving 96-well solid-phase extraction and fluorescence detection, J.Chromatogr.A, 2002, 949, 83–89. [LOQ 0.5 ng/mL; plasma; post-column photochemical derivatization; fluorescence detection; SPE] Niederberger, E.; Tegeder, I.; Schäfer, C.; Seegel, M.; Grösch, S.; Geisslinger, G. Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation, J.Pharmacol.Exp.Ther., 2003, 304, 1153–1160. [plasma; post-column photochemical derivatization; fluorescence detection] Radhakrishna, T.; Rao, D.S.; Reddy, G.O. LC determination of rofecoxib in bulk and pharmaceutical formulations, J.Pharm.Biomed.Anal., 2001, 26, 617–628. Slaughter, D.; Takenaga, N.; Lu, P.; Assang, C.; Walsh, D.J.; Arison, B.H.; Cui, D.; Halpin, R.A.; Geer, L.A.; Vyas, K.P.; Baillie, T.A. Metabolism of rofecoxib in vitro using human liver subcellular fractions, Drug Metab.Dispos., 2003, 31, 1398–1408. [LC-MS] Vallano, P.T.; Mazenko, R.S.; Woolf, E.J.; Matuszewski, B.K. Monolithic silica liquid chromatography columns for the determination of cyclooxygenase II inhibitors in human plasma, J.Chromatogr.B, 2002, 779, 249–257. [LOQ 0.5 ng/mL; plasma; post-column photochemical derivatization; fluorescence detection; SPE] Werner, U.; Werner, D.; Mundkowski, R.; Gillich, M.; Brune, K. Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans, J.Chromatogr.B, 2001, 760, 83–90. [LC-MS; plasma; LOQ 1 ng/mL; celecoxib is internal standard] Werner, U.; Werner, D.; Pahl, A.; Mundkowski, R.; Gillich, M.; Brune, K. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry, Biomed.Chromatogr., 2002, 16, 56–60. [LC-MS; rofecoxib is internal standard] 565 Ropinirole Ropinirole Molecular formula: C16 H24 N2 O Molecular weight: 260.37 CAS Registry No: 91374-21-9, 91374-20-8 (HCl) Merck Index: 13, 8338 H N O H3C H3C N SAMPLE Matrix: blood Sample preparation: Condition a 3 mL low displacement C18 SPE cartridge (Baker) with 3 column vol of MeOH and 3 column vol of water. Mix 1 mL plasma with 50 µL 2 µg/mL IS in water, add to the SPE cartridge, wash with 10 mL water, wash with 10 mL MeCN, elute with 3.5 mL MeCN:water:ammonium hydroxide 100:2:0.5. Evaporate the eluate to dryness under a stream of nitrogen at 35◦ , immediately reconstitute the residue with 300 µL mobile phase, mix vigorously, inject a 10–100 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Ultrasphere ODS Mobile phase: MeCN:70 mM pH 3.8 ammonium formate buffer 25:75 containing 0.3% EDTA and 0.005% sodium octyl sulfate Flow rate: 1 Injection volume: 10–100 Detector: UV 250 CHROMATOGRAM Retention time: 9.4 Internal standard: 4-(2-di-N,N-propylaminoethyl)-7-methoxy-2-(3H)-indoline HCl (11.5) Limit of detection: 5 ng/mL Limit of quantitation: 10 ng/mL KEY WORDS dog; human; pharmacokinetics; plasma; rat; SPE REFERENCE Swagzdis, J.E.; Mico, B.A. Liquid chromatographic determination of 4-(2-di-N,N-propylaminoethyl)-2(3H)-indolone in rat, dog, and human plasma with ultraviolet detection, J.Pharm.Sci., 1986, 75, 90–91. 566 Rosiglitazone Rosiglitazone Molecular formula: C18 H19 N3 O3 S S CH3 N N O O O N H Molecular weight: 357.43 CAS Registry No: 122320-73-4, 155141-29-0 (maleate) Merck Index: 13, 8346 SAMPLE Matrix: blood Sample preparation: Vortex 1 mL plasma with 50 µL 10 µg/mL IS in pH 2.3 buffer for 1 min, add 200 µL 20 mM pH 9.3 disodium tetraborate solution, vortex for 1 min, add 5 mL dichloromethane, shake horizontally for 10 min, centrifuge at 735 g for 10 min. Evaporate the organic layer to dryness under a stream of nitrogen at room temperature, reconstitute the residue with 5 mL n-hexane:dichloromethane 80:20, vortex for 30 s, add 350 µL pH 2.3 buffer, vortex for 2 min, centrifuge at 735 g for 10 min, inject a 100 µL aliquot. (Prepare pH 2.3 buffer by dissolving 0.136 g of potassium dihydrogen phosphate in 800 ml of water, adjusting to pH 2.3 with 10% HCl, and diluting to 1 L with water.) HPLC VARIABLES Column: 150 × 4.6 5 µm Zorbax SB C18 Column temperature: 30 Mobile phase: MeOH:buffer 30:70 (Prepare the buffer by dissolving 1.41 g of disodium hydrogen phosphate and 1.56 g of sodium dihydrogen phosphate in 800 ml water, adjusting to pH 2.6 with orthophosphoric acid and diluting to 1 L with water.) Flow rate: 1.2 Injection volume: 100 Detector: UV 245 CHROMATOGRAM Retention time: 8.3 Internal standard: pioglitazone (18.0) Limit of quantitation: 5 ng/mL KEY WORDS plasma REFERENCE Kolte, B.L.; Raut, B.B.; Deo, A.A.; Bagool, M.A.; Shinde, D.B. Liquid chromatographic method for the determination of rosiglitazone in human plasma, J.Chromatogr.B, 2003, 788, 37–44. SAMPLE Matrix: blood Sample preparation: Mix 250 µL plasma with 10 µg IS for 15 s, add 3 mL ethyl acetate, vortex for 1 min, centrifuge at 2000 rpm for 10 min. Evaporate the organic layer to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 750 µL mobile phase, inject a 50 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Hichrom KR100-5C18-250A Mobile phase: MeCN:MeOH:10 mM potassium dihydrogen phosphate 50:10:40, adjusted to pH 6.5 with triethylamine Rosiglitazone 567 Flow rate: 1 Injection volume: 50 Detector: F ex 247 em 367 CHROMATOGRAM Retention time: 8 Internal standard: celecoxib (16) Limit of quantitation: 5 ng/mL KEY WORDS plasma REFERENCE Mamidi, R.N.V.S.; Benjamin, B.; Ramesh, M.; Srinivas, N.R. Simple method for the determination of rosiglitazone in human plasma using a commercially available internal standard, Biomed.Chromatogr., 2003, 17, 417–420. ANNOTATED BIBLIOGRAPHY Cox, P.J.; Ryan, D.A.; Hollis, F.J.; Harris, A.-M.; Miller, A.K.; Vousden, M.; Cowley, H. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans, Drug Metab.Dispos., 2000, 28, 772–780. [plasma; urine; feces; UV detection; LC-MS; SPE] Di Cicco, R.A.; Allen, A.; Carr, A.; Fowles, S.; Jorkasky, D.K.; Freed, M.I. Rosiglitazone does not alter the pharmacokinetics of metformin, J.Clin.Pharmacol., 2000, 40, 1280–1285. [dialysis; fluorescence detection; LOQ 2.5 ng/mL] Mamidi, R.N.V.S.; Chaluvadi, M.R.; Benjamin, B.; Ramesh, M.; Katneni, K.; Babu, A.P.; Bhanduri, J.; Rao, N.M.U.; Rajagopalan, R. HPLC method for the determination of rosiglitazone in human plasma and its application in a clinical pharmacokinetic study, Arzneimittelforschung, 2002, 52, 560–564. [fluorescence detection; LOQ 5 ng/mL] Muxlow, A.-M.; Fowles, S.; Russell, P. Automated high-performance liquid chromatography method for the determination of rosiglitazone in human plasma, J.Chromatogr.B, 2001, 752, 77–84. [dialysis; fluorescence detection; LOQ 3 ng/mL] Radhakrishna, T.; Satyanarayana, J.; Satyanarayana, A. LC determination of rosiglitazone in bulk and pharmaceutical formulation, J.Pharm.Biomed.Anal., 2002, 29, 873–880. Rao, M.N.V.S.; Mullangi, R.; Katneni, K.; Ravikanth, B.; Babu, A.P.; Rani, U.P.; Naidu, M.U.R.; Srinivas, N.R.; Rajagopalan, R. Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone, J.Clin.Pharmacol., 2002, 42, 670–675. [fluorescence detection; LOQ 5 ng/mL] 568 Rosuvastatin calcium Rosuvastatin calcium F Molecular formula: 2C22 H27 FN3 O6 S.Ca Molecular weight: 1001.14 CAS Registry No: 147098-20-2 H OH O O OH N H S H3C N CH3 CO2− Ca++ N CH3 CH3 2 SAMPLE Matrix: blood Sample preparation: Condition a 30 mg Oasis HLB SPE cartridge (in 96 well plate) with 1 mL MeOH and 1 mL 0.5% acetic acid. Mix 500 µL plasma with 500 µL 100 mM pH 4 acetate buffer, 50 µL 150 ng/mL IS in MeOH:1 M acetic acid 50:50, and 750 µL 1 M acetic acid, vortex for 2 s, centrifuge at 738 g for 7 min, add 1.7 mL of the supernatant to the SPE cartridge, wash with 1 mL MeOH:0.5% acetic acid 30:70, elute with 1 mL 0.5% acetic acid in MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 130 µL 0.5% acetic acid, centrifuge at 1700 or 9500 g for 10 min, inject a 100 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Luna C18(2) Mobile phase: MeOH:0.2% formic acid 70:30 (divert first 2 min of run to waste) Flow rate: 1 Injection volume: 100 Detector: MS, PE Sciex API 365, TurboIonspray 450◦ , 0.2 mL/min entered detector, positive ion mode, ionspray 3000 V, ring 160 V, orifice 44 V, nebulizer gas nitrogen at 14 units, TurboIonspray gas nitrogen at 7 L/min, collision gas nitrogen 4 units, curtain gas nitrogen 8 units, deflector −250 V, electron multiplier 2900 V, collision energy −47.5 V, m/z 482.2–258.2 CHROMATOGRAM Retention time: 3.6 Internal standard: d6 -rosuvastatin (m/z 488.2–264.2) Limit of quantitation: 100 pg/mL KEY WORDS plasma; SPE REFERENCE Hull, C.K.; Penman, A.D.; Smith, C.K.; Martin, P.D. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection, J.Chromatogr.B, 2002, 772, 219–228. Sarafloxacin Molecular formula: C20 H17 F2 N3 O3 Molecular weight: 385.36 CAS Registry No: 98105-99-8, 91296-87-6 (HCl) Merck Index: 13, 8447 F H N N N F COOH O SAMPLE Matrix: blood Sample preparation: Mix 200 µL plasma with 800 µL 750 ng/mL IS in 100 mM pH 7.4 phosphate buffer, add 6 mL chloroform (Caution! Chloroform is a carcinogen!), shake at 200 oscillations/min for 30 min, centrifuge at 13 000 g for 6 min. Evaporate the organic layer to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL phosphate-buffered saline, inject a 10–80 µL aliquot. HPLC VARIABLES Guard column: Guard-Pak Novapak C18 Column: 150 × 3.9 5 µm Novapak C18 Mobile phase: MeCN:buffer 18:82 (The buffer was 20 mM potassium dihydrogen phosphate containing 6 mM phosphoric acid and 12 mM tetraethylammonium bromide adjusted to pH 3.0 with 2 M NaOH.) Flow rate: 1 Injection volume: 10–80 Detector: F ex 338 em 425 CHROMATOGRAM Retention time: 5.6 Internal standard: norfloxacin (2.2) Limit of detection: 6 ng/mL Limit of quantitation: 12 ng/mL OTHER SUBSTANCES Extracted: difloxacin (6.2) KEY WORDS plasma; rabbit REFERENCE Garcia, M.A.; Solans, C.; Aramayona, J.J.; Rueda, S.; Bregante, M.A. Simultaneous determination of difloxacin and its primary metabolite sarafloxacin in rabbit plasma, Chromatographia, 2000, 51, 487–490. SAMPLE Matrix: blood Sample preparation: Condition a 1 mL Bond Elut C2 SPE cartridge with two 1 mL portions of MeOH and three 1 mL portions of 2 mM phosphoric acid. Add 300 µL 500 mM phosphoric acid to the SPE cartridge, add 250 µL serum, add 50 µL 500 ng/mL IS in mobile phase, add 250 µL water, wash with 100 µL water, wash with 100 µL 100 mM phosphoric acid, elute with five 100 µL aliquots of MeOH:500 mM phosphoric acid 70:30, dilute the eluate with 500 µL water, inject a 20 µL aliquot. 569 570 Sarafloxacin HPLC VARIABLES Guard column: 10 × 3 5 µm PLRP-S (Polymer Laboratories) Column: 150 × 4.6 5 µm PLRP-S (Polymer Laboratories) Mobile phase: MeCN:MeOH:2 mM phosphoric acid 20:8:72 Flow rate: 0.9 Injection volume: 20 Detector: F ex 278 em 440 CHROMATOGRAM Retention time: 5 Internal standard: enrofloxacin (3.5) Limit of detection: 5 ng/g KEY WORDS fish; serum; SPE REFERENCE Steffenak, I.; Hormazabal, V.; Yndestad, M. A rapid assay for the determination of sarafloxacin (A-55620) in fish serum by high performance liquid chromatography, J.Liq.Chromatogr., 1991, 14, 1983–1988. ANNOTATED BIBLIOGRAPHY Holtzapple, C.K.; Pishko, E.J.; Stanker, L.H. Separation and quantification of two fluoroquinolones in serum by on-line high-performance immunoaffinity chromatography, Anal.Chem., 2000, 72, 4148–4153. [LOD 1.7 ng/mL; fluorescence detection] Holtzapple, C.K.; Buckley, S.A.; Stanker, L.H. Determination of fluoroquinolones in serum using an on-line clean-up column coupled to high-performance immunoaffinity-reversed-phase liquid chromatography, J.Chromatogr.B, 2001, 754, 1–9. [LOD 1.7 ng/mL; fluorescence detection] Selamectin Selamectin Molecular formula: C43 H63 NO11 Molecular weight: 769.96 CAS Registry No: 220119-17-5 Merck Index: 13, 8500 571 OCH3 HO H3C CH3 O H O CH3 O H O H3C O O OH H O H CH3 N HO SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg Isolute C18 SPE cartridge (Jones Chromatography) with 1 mL MeOH and 1 mL water. Vortex 0.2 (cat) or 1 (dog) mL plasma with 10 µL 1 µg/mL IS in MeOH and 1 mL MeCN:water 30:70, add to the SPE cartridge, wash with 1 mL water, dry under vacuum, elute with two 500 µL portions of MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 37◦ , make sure sample is completely dry, reconstitute the residue with 100 µL triethylamine:MeCN 50:50, mix thoroughly, add 150 µL trifluoroacetic acid:MeCN 33:67, mix thoroughly. Evaporate the sample to 75 µL under a stream of nitrogen at 40◦ (ca. 20 min), add 250 µL 2.0 M ammonia in MeOH, mix gently. Evaporate the sample to 75 µL under a stream of nitrogen at 40◦ (ca. 10 min), add 200 µL MeCN, mix thoroughly, inject a 100 µL aliquot. HPLC VARIABLES Column: 250 × 3.2 Spherisorb RPB Mobile phase: MeCN:THF:water 68:15:17 Flow rate: 0.5 Injection volume: 100 Detector: F ex 360 em 450 CHROMATOGRAM Retention time: 14 Internal standard: UK-127,053 (methoxyselamectin) (11.5) Limit of quantitation: 0.2 ng/mL (dog), 1 ng/mL (cat) KEY WORDS cat; derivatization; dog; plasma; SPE REFERENCE Walker, D.K.; Fenner, K.S. A sensitive method for the measurement of the novel pet endectocide, selamectin (UK-124,114), in dog and cat plasma by chemical derivatisation and high-performance liquid chromatography with fluorescence detection, J.Pharm.Biomed.Anal., 2000, 24, 105–111. 572 Sermorelin Sermorelin Molecular formula: C149 H246 N44 O42 S Molecular weight: 3357.94 CAS Registry No: 86168-78-7 Merck Index: 13, 8535 SAMPLE Matrix: blood Sample preparation: Condition a Sep-Pak C18 SPE cartridge with MeOH, 0.01% trifluoroacetic acid in MeCN, and 0.01% trifluoroacetic acid in water. Mix 200 µL serum with 800 µL cold 50 mM pH 0.8 (sic) phosphate buffer, add to the SPE cartridge, elute with 2 mL MeCN:water:trifluoroacetic acid 40:60:0.01, lyophilize the eluate, reconstitute with initial mobile phase, inject an aliquot. HPLC VARIABLES Column: 150 × 3.9 10 µm µBondapak C18 Mobile phase: Gradient. MeCN:water:trifluoroacetic acid from 20:80:0.01 to 36:64:0.01 over 40 min, wash at 40:60:0.01 for 10 min. Flow rate: 1.5 Detector: UV 214 CHROMATOGRAM Retention time: 33 OTHER SUBSTANCES Extracted: metabolites KEY WORDS rat; serum; SPE REFERENCE Boulanger, L.; Roughly, P.; Gaudreau, P. Catabolism of rat growth hormone-releasing factor(1–29) amide in rat serum and liver, Peptides, 1992, 13, 681–689. SAMPLE Matrix: blood Sample preparation: Condition a Sep-Pak C18 SPE cartridge with 2 mL 80% acetic acid and 4 mL 10 mM trifluoroacetic acid. Mix 1 mL plasma with 200 µL 1 M trifluoroacetic acid, place on ice, add to the SPE cartridge, wash with 3 mL 100 mM trifluoroacetic acid, pass 20 mL air through the cartridge, elute with 3 mL 80% acetic acid, inject an aliquot. HPLC VARIABLES Column: 150 × 3.9 5 µm Delta-Pak C18 (Waters) Mobile phase: Gradient. A was MeCN:water:trifluoroacetic acid 95:5:0.1. B was 0.1% trifluoroacetic acid. A:B from 34:66 to 50:50 over 60 min. Flow rate: 1 Detector: UV 215 CHROMATOGRAM Retention time: 20 Sermorelin 573 OTHER SUBSTANCES Extracted: metabolites KEY WORDS pig; plasma; SPE REFERENCE Su, C.M.; Jensen, L.R.; Heimer, E.P.; Felix, A.M.; Pan, Y.C.; Mowles, T.F. In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma, Horm.Metab.Res., 1991, 23, 15–21. ANNOTATED BIBLIOGRAPHY Zarandi, M.; Serfozo, P.; Zsigo, J.; Deutch, A.H.; Janaky, T.; Olsen, D.B.; Bajusz, S.; Schally, A.V. Potent agonists of growth hormone-releasing hormone. II, Pept.Res., 1992, 5, 190–193. 574 Sibutramine Sibutramine Molecular formula: C17 H26 ClN Molecular weight: 279.86 CH3 Cl CH3 N H3C CH3 CAS Registry No: 106650-56-0, 125494-59-9 (HCl monohydrate) Merck Index: 13, 8559 SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma, 50 µL 80 µg/mL IS in MeOH, 1 mL saturated sodium bicarbonate, and 5 mL cyclohexane, centrifuge. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 100 µL mobile phase, inject a 50 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Hypersil ODS-2 C18 Column temperature: 25 Mobile phase: MeOH:10 mM pH 3.5 ammonium acetate buffer 75:25 (divert first 3 min to waste) Flow rate: 1 Injection volume: 50 Detector: MS, quadrupole, electrospray, drying gas nitrogen 10.5 L/min, nebulizer 45 psi, drying gas 350◦ , capillary 4 kV, positive ion mode, fragmenter 70 V, m/z 280 CHROMATOGRAM Retention time: 5 Internal standard: phenoprolamine HCl (N-(2-(3,4-dimethoxyphenyl)ethyl)-N-(2-(2,6dimethylphenoxy)-1-methylethyl)amine) (m/z 344) (3.5) Limit of quantitation: 50 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS plasma REFERENCE Ding, L.; Hao, X.; Huang, X.; Zhang, S. Simultaneous determination of sibutramine and its N-desmethyl metabolites in human plasma by liquid chromatography-electrospray ionization-mass spectrometry: method and clinical applications, Anal.Chim.Acta, 2003, 492, 241–248. SAMPLE Matrix: solutions Sample preparation: Inject a 10 µL aliquot of a 1 mg/mL solution. HPLC VARIABLES Guard column: 50 mm long Chiralcel OD Column: 250 × 4.6 10 µm Chiralcel OD Column temperature: 30 Mobile phase: Hexane:EtOH:trifluoroacetic acid 93:7:0.05 Flow rate: 1 Injection volume: 10 Detector: UV 225 Sibutramine 575 CHROMATOGRAM Retention time: 10 (–), 14 (+) KEY WORDS chiral REFERENCE Radhakrishna, T.; Narayana, C.L.; Rao, D.S.; Vyas, K.; Reddy, G.O. LC method for the determination of assay and purity of sibutramine hydrochloride and its enantiomers by chiral chromatography, J.Pharm.Biomed.Anal., 2000, 22, 627–639. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 5 µm Microsorb-MV (Varian) Mobile phase: MeOH:water:triethylamine 80:20:0.3, pH adjusted to 4.5 with 85% phosphoric acid Flow rate: 1.1 Injection volume: 20 Detector: UV 225 CHROMATOGRAM Retention time: 4 KEY WORDS stability-indicating REFERENCE Segall, A.I.; Collado, E.A.; Ricci, R.A.; Pizzorno, M.T. Reversed-phase HPLC determination of sibutramine hydrochloride in the presence of its oxidatively-induced degradation products, J.Liq.Chromatogr.Rel.Technol., 2003, 26, 977–986. 576 Sildenafil Sildenafil O H CAS Registry No: 139755-83-2, 171599-83-0 (citrate) Merck Index: 13, 8563 O O Molecular formula: C22 H30 N6 O4 S Molecular weight: 474.59 N N S N H3C CH3 N N N O CH3 CH3 SAMPLE Matrix: blood Sample preparation: Condition a 25 mg Certify mixed-mode SPE cartridge in a 96 well plate (Varian) with 500 µL MeOH and 500 µL 5% acetic acid. Mix 350 µL plasma with 20 µL 500 ng/mL IS in MeOH:water 50:50 and 350 µL 5% acetic acid, add to the SPE cartridge, wash with 500 µL 5% acetic acid, wash with 500 µL MeOH, dry for 3 min, elute with two 350 µL portions of MeCN:ammonium hydroxide 98:2. Evaporate the eluate to dryness, reconstitute the residue with 200 µL 0.05% trifluoroacetic acid in MeCN, inject a 10 µL aliquot. HPLC VARIABLES Column: 50 × 3 5 µm Betasil silica (Keystone) Mobile phase: Unspecified. However, in similar analyses, the authors have reported MeCN:water:trifluoroacetic acid 90:10:0.1 (J.Pharm.Biomed.Anal. 2003, 32, 609), MeCN: water:formic acid 90:10:0.1 (J.Chromatogr.B 1999, 735, 255), and MeCN:water:trifluoroacetic acid 95:5:0.05 (J.Chromatogr.B 2001, 754, 387) Flow rate: 0.4 Injection volume: 10 Detector: MS, PE Sciex API 3000, electrospray, positive ion mode, ionspray needle 5000 V, turbo gas 400◦ , auxiliary gas 8 L/min, nebulizer gas 12 units, curtain gas 8 units, collision gas 4 units, declustering 46 V, focusing 200 V, collision energy 77 V, m/z 475–283 CHROMATOGRAM Retention time: 1.7 Internal standard: 1-[[3-(7-methoxy-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine (m/z 489–297) (1.6) Limit of quantitation: 1 ng/mL OTHER SUBSTANCES Extracted: desmethylsildenafil (metabolite) (m/z 461–283) (1.6) KEY WORDS plasma; SPE REFERENCE Eerkes, A.; Addison, T.; Naidong, W. Simultaneous assay of sildenafil and desmethylsildenafil in human plasma using liquid chromatography-tandem mass spectrometry on silica column with aqueous-organic mobile phase, J.Chromatogr.B, 2002, 768, 277–284. SAMPLE Matrix: blood Sample preparation: Vortex 1 mL plasma with 100 µL 20 µg/mL IS in MeOH and 100 µL 1 M NaOH for 5 s, add 3 mL ethyl acetate, vortex for 5 min, centrifuge at 2950 g Sildenafil 577 for 10 min. Evaporate the organic layer to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 200 µL mobile phase, inject a 100 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Inertsil 5 ODS-2 Mobile phase: MeCN:buffer 55:45 (The buffer was 30 mM potassium dihydrogen phosphate adjusted to pH 6.0 with 1 M NaOH.) Flow rate: 0.5 Injection volume: 100 Detector: UV 230 CHROMATOGRAM Retention time: 7.5 Internal standard: butylparaben (12) Limit of quantitation: 10 ng/mL KEY WORDS pharmacokinetics; plasma REFERENCE Sheu, M.-T.; Wu, A.-B.; Yeh, G.-C.; Hsia, A.; Ho, H.-O. Development of a liquid chromatographic method for bioanalytical applications with sildenafil, J.Chromatogr.B, 2003, 791, 255–262. SAMPLE Matrix: formulations Sample preparation: Weigh out powdered tablets containing 100 mg of active, dissolve in 100 mL MeCN:water 50:50, add IS, dilute with mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm LiChrospher C18 Mobile phase: MeCN:water 52:48 Flow rate: 1 Injection volume: 20 Detector: UV 245 CHROMATOGRAM Retention time: 7.2 Internal standard: piroxicam (2.2) Limit of detection: 15 ng/mL Limit of quantitation: 50 ng/mL KEY WORDS stability-indicating; tablets REFERENCE Dinesh, N.D.; Vishukumar, B.K.; Nagaraja, P.; Gowda, N.M.M.; Rangappa, K.S. Stability indicating RP-LC determination of sildenafil citrate (Viagra) in pure form and in pharmaceutical samples, J.Pharm.Biomed.Anal., 2002, 29, 743–748. ANNOTATED BIBLIOGRAPHY Aboul-Enein, H.Y.; Hefnawy, M.M. Rapid determination of sildenafil citrate in pharmaceutical preparations using monolithic silica HPLC column, J.Liq.Chromatogr.Rel.Technol., 2003, 26, 2897–2908. [LOD 25 ng/mL] Cooper, J.D.H.; Muirhead, D.C.; Taylor, J.E.; Baker, P.R. Development of an assay for the simultaneous determination of sildenafil (Viagra) and its metabolite (UK-103,320) using automated sequential trace 578 Sildenafil enrichment of dialysates and high-performance liquid chromatography, J.Chromatogr.B, 1997, 701, 87–95. Daraghmeh, N.; Al-Omari, M.; Badwan, A.A.; Jaber, A.M.Y. Determination of sildenafil citrate and related substances in the commercial products and tablet dosage form using HPLC, J.Pharm.Biomed.Anal., 2001, 25, 483–492. Jeong, C.K.; Lee, H.-Y.; Jang, M.-S.; Kim, W.B.; Lee, H.S. Narrowbore high-performance liquid chromatography for the simultaneous determination of sildenafil and its metabolite UK-103,320 in human plasma using column switching, J.Chromatogr.B, 2001, 752, 141–147. [LOQ 10 ng/mL] Kim, J.; Ji, H.Y.; Kim, S.J.; Lee, H.W.; Lee, S.-S.; Kim, D.S.; Yoo, M.; Kim, W.B.; Lee, H.S. Simultaneous determination of sildenafil and its active metabolite UK-103,320 in human plasma using liquid chromatography-tandem mass spectrometry, J.Pharm.Biomed.Anal., 2003, 32, 317–322. [LOQ 2 ng/mL] Lee, M.; Min, D.I. Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate, Ther.Drug Monit., 2001, 23, 21–26. [LOD 10 ng/mL] Liaw, J.; Chang, T.-W. Determination of transdermal sildenafil in nude mouse skin by reversed-phase high-performance liquid chromatography, J.Chromatogr.B, 2001, 765, 161–166. [LOQ 5 ng/mL] Nagaraju, V.; Sreenath, D.; Rao, J.T.; Rao, R.N. Separation and determination of synthetic impurities of sildenafil (Viagra) by reversed-phase high-performance liquid chromatography, Anal.Sci., 2003, 19, 1007–1011. Segall, A.I.; Vitale, M.F.; Perez, V.L.; Palacios, M.L.; Pizzorno, M.T. Reversed-phase HPLC determination of sildenafil citrate in the presence of its oxidative-induced degradation products, J.Liq.Chromatogr.Rel.Technol., 2000, 23, 1377–1386. [stability-indicating] Tracqui, A.; Ludes, B. HPLC-MS for the determination of sildenafil citrate (Viagra) in biological fluids. Application to the salivary excretion of sildenafil after oral intake, J.Anal.Toxicol., 2003, 27, 88–94. [saliva; plasma; LOD 0.2 ng/mL; LOQ 0.5 ng/mL] Walker, D.K.; Ackland, M.J.; James, G.C.; Muirhead, G.J.; Rance, D.J.; Wastall, P.; Wright, P.A. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man, Xenobiotica, 1999, 29, 297–310. [SPE; LOQ 1 ng/mL] Warrington, J.S.; Shader, R.I.; von Moltke, L.L.; Greenblatt, D.J. In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions, Drug Metab.Dispos., 2000, 28, 392–397. [buspirone is internal standard] Warrington, J.S.; von Moltke, L.L.; Harmatz, J.S.; Shader, R.I.; Greenblatt, D.J. The effect of age on sildenafil biotransformation in rat and mouse liver microsomes, Drug Metab.Dispos., 2003, 31, 1306–1309. Simethicone 579 Simethicone CAS Registry No: 8050-81-5 Merck Index: 13, 3241 SAMPLE Matrix: formulations Sample preparation: Add formulation (oral liquid or crushed tablet) to 25 mL dichloromethane and 25 mL diluted HCl (2:1), shake vigorously for 5 min, let stand for 1 h. Dry 5 mL of the lower organic layer over 500 mg anhydrous sodium sulfate, filter (0.45 µm nylon), inject an aliquot of the filtrate. HPLC VARIABLES Column: 250 × 4.6 5 µm Alltima C8 Mobile phase: Gradient. MeCN:chloroform from 45:55 to 15:85 over 5 min, return to initial conditions over 5 min, re-equilibrate for 5 min. (Caution! Chloroform is a carcinogen!) Flow rate: 1 Detector: Evaporative Light Scattering Detector, Alltech model 500, drift tube 95◦ , nebulizer 2 L/min CHROMATOGRAM Retention time: 9.2 KEY WORDS crushed tablet; oral liquid REFERENCE Moore, D.E.; Liu, T.X.; Miao, W.G.; Edwards, A.; Elliss, R. A RP-LC method with evaporative light scattering detection for the assay of simethicone in pharmaceutical formulations, J.Pharm.Biomed.Anal., 2002, 30, 273–278. 580 Sivelestat Sivelestat Molecular formula: C20 H22 N2 O7 S Molecular weight: 434.47 CAS Registry No: 127373-66-4, 201677-61-4 (Na salt tetrahydrate) Merck Index: 13, 8629 O O S O H3C H3C O CH3 N H O N COOH H SAMPLE Matrix: blood, urine Sample preparation: Mix plasma or urine with IS, filter (0.22 µm), inject a 40 (plasma) or 10 (urine) µL aliquot onto column A and elute to waste with mobile phase A; after 7 min, backflush the contents of column A onto column B with mobile phase B; after 3 min, remove column A from the circuit and backflush the contents of column B onto column C with mobile phase C; after 3 min, remove column B from the circuit, continue to elute column C with mobile phase C, monitor the effluent from column C. HPLC VARIABLES Column: A 10 × 4.6 5 µm SPS-C18 + 150 × 4.6 5 µm SPS-C18 Semipermeable-Surface (Regis); B 150 × 4.6 5 µm YMC-A602; C 150 × 4.6 5 µm Capcell Pak C18 (Shiseido) Mobile phase: A MeCN:50 mM pH 7 phosphate buffer 10:90; B MeCN:water 10:90; C Gradient. MeCN:20 mM pH 3.8 potassium dihydrogen phosphate buffer 20:80 for 10 min, to 40:50 over 20 min, maintain at 40:50 for 15 min. Flow rate: 1 Injection volume: 40 (plasma), 10 (urine) Detector: UV 240 CHROMATOGRAM Retention time: 32 Internal standard: ONO-EI-547 (N-[2′ -[4-(2,2-dimethylpropionyloxy)-3-methylphenylsulfonylamino]-5′ -methylbenzoyl]aminoacetic acid) (38), ONO-EI-537 (N-[2′ -[4-hydroxy-3-methylphenylsulfonylamino]benzoyl]aminoacetic acid) (20) Limit of quantitation: 156 ng/mL (plasma), 1.56 µg/mL (urine) KEY WORDS column-switching; plasma REFERENCE Shintani, T.; Takamoto, M.; Sawada, M.; Aishita, H.; Nakagawa, T. Simultaneous determination of human neutrophil elastase inhibitor (ONO-5046) and its metabolite in plasma and urine by direct injection column-switching HPLC, J.Pharm.Biomed.Anal., 1994, 12, 397–405. SAMPLE Matrix: blood, urine Sample preparation: Mix plasma or urine with IS, dilute 500 µL plasma or 100 µL urine with water and 1 M HCl, add to a Sep-Pak C18 SPE cartridge, elute with MeOH. Add the eluate to a Bond Elut SAX SPE cartridge, elute with MeOH:100 mM HCl 60:40, extract the eluate with ethyl acetate. Evaporate the organic layer to dryness, reconstitute the residue with 150 µL mobile phase, inject a 50 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 3 µm Chemcosorb 3Dph Mobile phase: Gradient. MeCN:20 mM pH 3.8 potassium dihydrogen phosphate buffer from 20:80 to 40:50 over 40 min, maintain at 40:50 for 15 min. Sivelestat 581 Flow rate: 1 Injection volume: 50 Detector: UV 240 CHROMATOGRAM Internal standard: ONO-EI-547 (N-[2′ -[4-(2,2-dimethylpropionyloxy)-3-methylphenylsulfonylamino]-5′ -methylbenzoyl]aminoacetic acid), ONO-EI-537 (N-[2′ -[4-hydroxy-3methylphenylsulfonylamino]benzoyl]aminoacetic acid) Limit of quantitation: 125 ng/mL (plasma), 1.25 µg/mL (urine) KEY WORDS comparison with column-switching (above); plasma; SPE REFERENCE Shintani, T.; Takamoto, M.; Sawada, M.; Aishita, H.; Nakagawa, T. Simultaneous determination of human neutrophil elastase inhibitor (ONO-5046) and its metabolite in plasma and urine by direct injection column-switching HPLC, J.Pharm.Biomed.Anal., 1994, 12, 397–405. 582 Sodium oxybate Sodium oxybate Molecular formula: C4 H7 NaO3 Molecular weight: 126.09 HO COONa CAS Registry No: 502-85-2, 591-81-1 (free acid) Merck Index: 13, 4840 SAMPLE Matrix: solutions Sample preparation: Mix 200 µL of a solution in MeOH:water 10:90 with 150 µL 20 mM 0.5 mM tetrakis(decyl)ammonium bromide in 5 mM pH 7.0 phosphate buffer and 100 µL 4.2 mg/mL 2-bromoacetyl-6-methoxynaphthalene in acetone, stir at 70◦ for 65 min, add 150 µL 80 µg/mL IS in MeCN, sonicate for 1 min, inject a 50 µL aliquot. (Preparation of 2-bromoacetyl-6-methoxynaphthalene is given in Organic Syntheses, Collective Volume 6, page 175; available free of cost at www.orgsyn.org.) HPLC VARIABLES Column: 250 × 4.5 Hypersil 5 ODS Column temperature: 35 Mobile phase: MeCN:MeOH:25 mM pH 4.5 phosphate buffer 18.7:15.3:66 Flow rate: 1.7 Injection volume: 50 Detector: F ex 300 em 460 CHROMATOGRAM Retention time: 35 Internal standard: 4-(6-methoxy-2-naphthyl)-4-oxobutanoic acid (Synthesis of 4-(6methoxy-2-naphthyl)-4-oxobutanoic acid is as follows. Dissolve 5 g 2-acetyl-6-methoxynaphthalene (6′ -methoxy-2′ -acetonaphthone) in the minimum amount of warm glacial acetic acid, add 2.5 g glyoxylic acid, reflux for 24 h, evaporate to dryness under reduced pressure, dissolve the residue in chloroform, extract three times with 5% sodium carbonate solution (Caution! Chloroform is a carcinogen!). Combine the extracts and acidify them with concentrated HCl, filter to recover the product, recrystallize from MeOH/water to obtain 4-(6-methoxy-2-naphthyl)-4-oxo-2-butenoic acid (mp 165–168◦ ). Dissolve 4 g 4-(6-methoxy-2-naphthyl)-4-oxo-2-butenoic acid in the minimum amount of THF, add palladium on charcoal, hydrogenate until 450 mL hydrogen are absorbed, filter, evaporate to dryness under reduced pressure, recrystallize from acetic acid to obtain 4-(6-methoxy-2-naphthyl)-4-oxobutanoic acid as a white solid (mp 148◦ ) (Farmaco Ed.Sci. 1982, 37, 171).) (25) KEY WORDS derivatization REFERENCE Gatti, R.; Bousquet, E.; Bonazzi, D.; Cavrini, V. Determination of carboxylic acid salts in pharmaceuticals by high-performance liquid chromatography after pre-column fluorogenic labelling, Biomed.Chromatogr., 1996, 10, 19–24. Somatropin 583 Somatropin Molecular formula: C990 H1529 N263 O299 S7 Molecular weight: 22124.12 CAS Registry No: 9002-72-6, 12629-01-5 (human) Merck Index: 13, 8789 SAMPLE Matrix: blood Sample preparation: Prepare an immunoaffinity chromatography column by circulating 5 mL 500 µg/mL polyclonal antibodies raised against porcine somatotropin in 200 mM pH 8.3 sodium bicarbonate containing 500 mM NaCl through a 1 mL Hitrap NHS-activated immunoaffinity chromatography column (Amersham Pharmacia) for 12 h. Wash and deactivate the column by passing in sequence three times 6 mL 500 mM pH 8.3 ethanolamine containing 500 mM NaCl and 6 mL 100 mM pH 4 sodium acetate containing 500 mM NaCl. Slowly pass 10 mL serum (0.5 drop/s) through the column, wash with 5 mL 200 mM pH 8.3 sodium bicarbonate containing 500 mM NaCl, elute with 5 mL EtOH:water 70:30, concentrate with a diafiltration device (MW cut-off 10 000 Da, Vivasciences) while centrifuging at 6000 g for 30 min, inject a 25 µL aliquot of the residue. Alternatively, dissolve 1 g urea in 10 mL plasma, filter with a diafiltration device (MW cut-off 30 000 Da, Vivasciences) while centrifuging at 6000 g for 30 min, pass 5 mL through a Hiload 26/60 Superdex 75 pg GPC column (Amersham Pharmacia), concentrate the appropriate fraction with a diafiltration device (MW cut-off 10 000 Da, Vivasciences) while centrifuging at 6000 g for 30 min, inject a 25 µL aliquot of the residue. HPLC VARIABLES Column: 50 × 1 3.5 µm Zorbax Extend-C18 Mobile phase: Gradient. MeCN:1% acetic acid from 10:90 to 90:10 over 5 min Flow rate: 0.06 Injection volume: 25 Detector: MS, Agilent 1100 MSD, electrospray, positive ion, nebulizer 20 psi, cap- illary 5000 V, drying gas 7 L/min at 350◦ , voltage applied to capillary 190 V, m/z 1279.2–1359.1 (natural porcine), m/z 1270.5–1349.5 (recombinant porcine) CHROMATOGRAM Limit of detection: 10 ng/mL KEY WORDS immunoaffinity; pig; plasma; serum; ultrafiltrate REFERENCE Blokland, M.H.; Sterk, S.S.; van Ginkel, L.A.; Stephany, R.W.; Heck, A.J.R. Analysis for endogenous and recombinant porcine somatotropine in serum, Anal.Chim.Acta, 2003, 483, 201–206. 584 Squalane Squalane Molecular formula: C30 H62 Molecular weight: 422.81 CAS Registry No: 111-01-3 Merck Index: 13, 8846 SAMPLE Matrix: cell cultures Sample preparation: Centrifuge cell culture at 2772 g at 4◦ for 20 min, extract the supernatant with diethyl ether. Evaporate the extracts to dryness, reconstitute the residue with n-propanol, inject an aliquot. HPLC VARIABLES Column: Nucleosil-100 C18 Mobile phase: n-Propanol Flow rate: 0.5 Detector: Refractive Index REFERENCE Berekaa, M.M.; Steinbüchel, A. Microbial degradation of the multiply branched alkane 2,6,10,15,19,23hexamethyltetracosane (squalane) by Mycobacterium fortuitum and Mycobacterium ratisbonense, Appl.Environ.Microbiol., 2000, 66, 4462–4467. Squalene 585 Squalene Molecular formula: C30 H50 Molecular weight: 410.72 CAS Registry No: 111-02-4 Merck Index: 13, 8847 SAMPLE Matrix: cell cultures Sample preparation: Centrifuge cell culture at 2772 g at 4◦ for 20 min, extract the supernatant with diethyl ether. Evaporate the extracts to dryness, reconstitute the residue with n-propanol, inject an aliquot. HPLC VARIABLES Column: Nucleosil-100 C18 Mobile phase: n-Propanol Flow rate: 0.5 Detector: UV (wavelength not specified) REFERENCE Berekaa, M.M.; Steinbüchel, A. Microbial degradation of the multiply branched alkane 2,6,10,15,19,23hexamethyltetracosane (squalane) by Mycobacterium fortuitum and Mycobacterium ratisbonense, Appl.Environ.Microbiol., 2000, 66, 4462–4467. SAMPLE Matrix: food Sample preparation: Mix 500 mg solid food or milk powder, 5 g liquid milk, or 100–200 mg oil or fat with 10 mL EtOH, add 2 mL 50% KOH solution, heat at 70◦ for 8 min with periodic agitation, cool, add 20 mL hexane:diisopropyl ether 75:25, shake mechanically for 5 min, add 30 mL water, invert 10 times, centrifuge at 180 g for 10 min. Evaporate 10 mL of the organic layer to dryness at <45◦ , reconstitute the residue with 1 mL EtOH or hexane, inject a 20–50 µL aliquot. HPLC VARIABLES Guard column: Guard-Pak C18 Column: 5 µm Rad-Pak C18 Mobile phase: MeOH Flow rate: 1 Injection volume: 20–50 Detector: UV 212 CHROMATOGRAM Retention time: 32 OTHER SUBSTANCES Simultaneous: campesterol (28), cholesterol (24), β-sitosterol (30), α-tocopherol (15), δ-tocopherol (12), γ -tocopherol (14) REFERENCE Indyk, H.E. Simultaneous liquid chromatographic determination of cholesterol, phytosterols and tocopherols in foods, Analyst, 1990, 115, 1525–1530. 586 Squalene ANNOTATED BIBLIOGRAPHY Domnas, A.; Biswas, S.S.; Gallagher, P.A. Squalene metabolism in two species of Lagenidium, Can.J. Microbiol., 1994, 40, 523–531. Piretti, M.V.; Pagliuca, G.; Tarozzi, G. Simultaneous reversed-phase high-performance liquid chromatographic separation of non-polar isoprenoid lipids and their determination, J.Chromatogr.B, 1995, 674, 177–185. Sulpice, J.C.; Ferezou, J. Squalene isolation by HPLC and quantitative comparison by HPLC and GLC, Lipids, 1984, 19, 631–635. 587 Stanozolol Stanozolol CH3 OH CH3 CH3 Molecular formula: C21 H32 N2 O Molecular weight: 328.49 N CAS Registry No: 10418-03-8 Merck Index: 13, 8873 H H H H N H SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg Bond Elut C1 SPE cartridge with 2 column vol of MeCN and 2 column vol of water. Mix 500 µL serum with 25 µL 5 µg/mL IS in MeCN, add 500 µL water, vortex for 5 s, add to the SPE cartridge, wash with 2 column vol of water, wash with 1 column vol of MeCN:water 10:90, elute with 1 mL MeCN:water 45:55, concentrate the eluate to 250 µL under a stream of nitrogen at 45◦ , inject a 50 µL aliquot. HPLC VARIABLES Guard column: 15 × 4.6 7 µm silica (Brownlee) Column: 220 × 4.6 5 µm silica (Brownlee) Column temperature: 60 Mobile phase: MeCN:100 mM pH 2.5 sodium phosphate buffer 15:85 Flow rate: 1 Injection volume: 50 Detector: UV 230 CHROMATOGRAM Retention time: 12.7 Internal standard: spironolactone (7.8) Limit of detection: 7 ng/mL OTHER SUBSTANCES Extracted: fluoxymesterone (UV 247) (5.4), methandrostenolone (UV 247) (9.3), methyltestosterone (UV 247) (9.6), nandrolone (UV 247) (8.2), testosterone (UV 247) (8.6), zeranol (UV 263) (3.6) KEY WORDS serum: SPE REFERENCE Lampert, B.L.; Stewart, J.T. Determination of anabolic steroids and zeranol in human serum by isocratic reverse phase HPLC on silica, J.Liq.Chromatogr., 1989, 12, 3231–3249. 588 Succimer Succimer Molecular formula: C4 H6 O4 S2 Molecular weight: 182.22 HOOC SH HOOC SH CAS Registry No: 304-55-2 Merck Index: 13, 8949 SAMPLE Matrix: blood Sample preparation: Mix 100–250 µL whole blood or plasma with 50 µL 50–125 mM dithiothreitol and 100 mM pH 8.3 ammonium bicarbonate buffer containing IS to a final volume of 2 mL, purge headspace with nitrogen, mix vigorously for 1 min, let stand in the dark at room temperature for 30 min, filter (2 mL Centricon 30) while centrifuging at 6000 rpm for 1 h. Add 200 µL 80 mM monobromobimane in 100 mM ammonium bicarbonate buffer to the ultrafiltrate, purge with nitrogen, mix vigorously for 1 min, let stand in the dark at room temperature for 10 min, wash with 2 vol of dichloromethane, shake for 15 s, centrifuge at 2500 rpm for 2 min, repeat the wash. Add 17 µL 6 M HCl to the aqueous layer, inject an aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Spherisorb ODS-2 Mobile phase: Gradient. A was 10 mM tetrabutylammonium bromide in MeOH containing 10 mM sodium acetate. B was 10 mM tetrabutylammonium bromide in 10 mM pH 4.1 acetate buffer. A:B 52.5:47.5 for 10 min, to 90:10 over 2 min, maintain at 90:10 for 5 min, return to initial conditions over 2 min, re-equilibrate at initial conditions for 11 min. Flow rate: 1 Injection volume: 10 Detector: F ex 356 em 450 (see also Maiorino,R.M.; Barry,T.J.; Aposhian,H.V. Determination and metabolism of dithiol chelating agents: Electrolytic and chemical reduction of oxidized dithiols in urine. Anal.Biochem. 1987, 160, 217–226.) CHROMATOGRAM Retention time: 7.1 Internal standard: 2,3-dimercaptopropane-1-sulfonic acid (10.2) Limit of quantitation: 5 µM OTHER SUBSTANCES Extracted: dithiothreitol (5.5) KEY WORDS derivatization; plasma; whole blood REFERENCE Maiorino, R.M.; Akins, J.M.; Blaha, K.; Carter, D.E.; Aposhian, H.V. Determination and metabolism of dithiol chelating agents: X. In humans, meso-2,3-dimercaptosuccinic acid is bound to plasma proteins via mixed disulfide formation, J.Pharmacol.Exp.Ther., 1990, 254, 570–577. Succinylcholine chloride 589 Succinylcholine chloride Molecular formula: C14 H30 Cl2 N2 O4 Molecular weight: 361.31 CAS Registry No: 71-27-2, 55-94-7 (bromide), 541-19-5 (iodide) Merck Index: 13, 8959 (chloride), 8958 (bromide), 8960 (iodide) O (H3C)3N+ O O N+(CH3)3 2Cl− O SAMPLE Matrix: blood Sample preparation: Condition a Bond Elut C2 SPE cartridge with 3 mL TMAH buffer and 3 mL water. Mix 1 mL plasma with 1 mL water and 100 µL 100 ng/mL IS in 100 mM pH 5.0 phosphate buffer, add to the SPE cartridge, wash with 3 mL water, wash with 3 mL MeCN, wash with 3 mL MeOH, elute with two 250 µL portions of TMAH buffer, inject a 150 µL aliquot of the eluate. (Prepare TMAH buffer by dissolving 275.6 mg tetramethylammonium chloride in 1 mL water and adding 240 mL MeOH, adjust to apparent pH 3.0 with 100 mM HCl, make up to 250 mL with MeOH.) HPLC VARIABLES Column: 125 × 4.6 5 µm Spherisorb CN Column temperature: 35 Mobile phase: MeCN:MeOH:30 mM phosphoric acid 35:25:45, adjusted to apparent pH 5.00 with concentrated ammonium hydroxide Flow rate: 2 Injection volume: 150 Detector: E, ESA Coulochem II, 5010 analytical cell, detector 1 450 mV (screen), detector 2 750 mV (monitored) CHROMATOGRAM Retention time: 9.2 Internal standard: pipecuronium (19.8) Limit of quantitation: 250 ng/mL OTHER SUBSTANCES Simultaneous: mivacurium (21), rocuronium (18), vecuronium (21) KEY WORDS plasma; SPE REFERENCE Gao, H.; Roy, S.; Donati, F.; Varin, F. Determination of succinylcholine in human plasma by highperformance liquid chromatography with electrochemical detection, J.Chromatogr.B, 1998, 718, 129–134. SAMPLE Matrix: blood Sample preparation: Vortex thoroughly 400 µL plasma with 40 µL 500 mg/mL trichloroacetic acid, centrifuge at 12 500 g for 5 min, inject a 100 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 8 µm Cp-tm-Spher C8 (Chrompack) Mobile phase: MeCN:MeOH:50 mM pH 5.0 potassium phosphate buffer 35:5:60 Flow rate: 1.2 590 Succinylcholine chloride Injection volume: 100 Detector: F ex 257 em 282 CHROMATOGRAM Retention time: 6.3 Limit of quantitation: 100 ng/mL KEY WORDS pharmacokinetics; plasma REFERENCE Lagerwerf, A.J.; Vanlinthout, L.E.; Vree, T.B. Rapid determination of succinylcholine in human plasma by high-performance liquid chromatography with fluorescence detection, J.Chromatogr., 1991, 570, 390–395. 591 Sulfabromomethazine Sulfabromomethazine CH3 Molecular formula: C12 H13 BrN4 O2 S Molecular weight: 357.23 CAS Registry No: 116-45-0 Merck Index: 13, 8983 S H2N Br O N O N N CH3 H SAMPLE Matrix: tissue Sample preparation: Cut 20 g tissue into small pieces and add to 25 mL dichloromethane, let stand for 20–30 min with frequent stirring with a glass rod, filter through glass wool, repeat extraction twice more. Combine the dichloromethane layers and shake with 10 mL 1.5 M sulfuric acid for 15 min. Remove the aqueous phase and add it to 10 mL dichloromethane, shake for 10 min, discard the organic phase, repeat the wash, add 1 mL 10% dipotassium hydrogen phosphate to the aqueous phase, add 3 mL 40% NaOH, mix well, allow to cool, adjust pH to 5–6 with 1.5 M sulfuric acid or 40% NaOH, add 5 mL dichloromethane, extract for 15 min, repeat the extraction. Pass the organic layers through anhydrous sodium sulfate, evaporate to 1 g on a hot plate at 60–70◦ (in a hood!), inject a 10 µL aliquot. For confirmation of sulfabromomethazine, add 1 mL MeOH to the extract, add 2 drops acetic anhydride, heat at 80–90◦ on a hot plate until acetic acid fumes are no longer seen, reconstitute with 1 g dichloromethane, inject a 10 µL aliquot. (Note: Extraction from the sample matrix is only demonstrated for sulfamethazine, but it should work for sulfabromomethazine.) HPLC VARIABLES Column: 250 mm long MicroPak CN-10 Mobile phase: Isooctane:chloroform:MeOH:acetic acid 30.5:65:4:0.5 (Caution! Chloroform is a carcinogen!) Flow rate: 0.33 Injection volume: 10 Detector: UV 254 CHROMATOGRAM Retention time: 3.56 (4.16 for acetyl sulfabromomethazine) Limit of detection: 20 ppb (for sulfamethazine) OTHER SUBSTANCES Extracted: acetylsulfachlorpyridazine (6.68), acetylsulfadiazine (6.78), acetylsulfadimethoxine (4.70), acetylsulfaethoxypyridazine (5.23), acetylsulfamethazine (5.34), sulfachlorpyridazine (5.60), sulfadiazine (5.55), sulfadimethoxine (3.99), sulfaethoxypyridazine (4.60), sulfamethazine (4.34) Noninterfering: sulfamerazine, sulfathiazole, sulfanilamide, sulfapyridine, sulfaquinoline KEY WORDS cow; liver; fat; kidney; muscle REFERENCE Seymour, D.; Rupe, B.D. High-pressure liquid chromatographic determination of sulfamethazine residues in beef tissues, J.Pharm.Sci., 1980, 69, 701–703. 592 Sulfachlorpyridazine Sulfachlorpyridazine Molecular formula: C10 H9 ClN4 O2 S Molecular weight: 284.73 O N O S H2N N Cl N H CAS Registry No: 80-32-0, 23282-55-5 (Na salt) Merck Index: 13, 8985 SAMPLE Matrix: honey Sample preparation: Condition a 200 mg Oasis HLB SPE cartridge with 3 mL MeCN and two 2 mL portions of water. Dissolve 7.5 g honey in 15 mL 2 M HCl, let stand at room temperature for 30 min, add 30 mL 300 mM citric acid, mix, filter. Adjust the pH of a 20 mL aliquot of the filtrate to 3.5–4.5 with 25% ammonia, immediately add to the SPE cartridge and pass through within 10–15 min, wash with three 3 mL portions of water, let dry for 4 min, elute with 3 mL MeCN. Evaporate the eluate to a small volume under reduced pressure at 40◦ , add 500 µL mobile phase, vortex, inject a 10 µL aliquot. HPLC VARIABLES Guard column: 2 mm long 5 µm Nucleosil 100 C18 HD Column: 50 × 2 5 µm Nucleosil 100-5 C18 HD Mobile phase: Gradient. A was MeCN:water:formic acid 5:94.7:0.3. B was MeCN:formic acid 99.7:0.3. A:B from 100:0 to 70:30 over 10 min, maintain at 70:30 for 2 min, return to initial conditions over 0.1 min, re-equilibrate for 6.9 min. Flow rate: 0.2 Injection volume: 10 Detector: MS, Micromass Quattro LCZ, triple quadrupole, electrospray, capillary 3.25 kV, cone 25 V, extractor 3 V, RF lens 0.3 V, source 90◦ , desolvation 250◦ , cone gas flow 50 L/h, desolvation gas nitrogen 560 L/h, nebulizer gas flow is factory preset, LM 1 resolution 12, HM 1 resolution 12, ion energy 1 V, entrance voltage −5 V, exit voltage 0 V, collision cell pressure 2 µbar argon, LM 2 resolution 12, HM 2 resolution 12, ion energy 2 V, multiplier voltage 650 V, m/z 285–156 CHROMATOGRAM Retention time: 12.9 Limit of detection: 1 ppb OTHER SUBSTANCES Extracted: chlortetracycline (m/z 479–444) (LOD 1 ppb) (13.1), flumequine (m/z 262–244) (LOD 1 ppb) (17.9), oxytetracycline (m/z 461–426) (LOD 4 ppb) (11.1), sulfacetamide (m/z 215–156) (LOD 4 ppb) (5.6), sulfachloropyrazine (m/z 285–156) (LOD 1 ppb) (15.8), sulfadiazine (m/z 251–156) (LOD 2 ppb) (6.5), sulfadimethoxine (m/z 311–156) (LOD 1 ppb) (16.0), sulfadoxine (m/z 311–156) (LOD 0.4 ppb) (13.5), sulfaguanidine (m/z 215–156) (LOD 2 ppb) (2.0), sulfamerazine (m/z 265–156) (LOD 1 ppb) (8.9), sulfamethazine (m/z 279–186) (LOD 1 ppb) (10.4), sulfamethizole (m/z 271–156) (LOD 0.5 ppb) (11.5), sulfamethoxazole (m/z 254–156) (LOD 1 ppb) (14.0), sulfamethoxypyridazine (m/z 281–156) (LOD 0.4 ppb) (11.5), sulfanilamide (m/z 173–156) (LOD 4 ppb) (2.4), sulfapyridine (m/z 250–156) (LOD 11 ppb) (8.3), sulfathiazole (m/z 256>) (LOD 156 ppb) (1 8.6), sulfisoxazole (m/z 268–156) (LOD 1 ppb) (14.9), tetracycline (m/z 445–410) (LOD 4 ppb) (10.5) KEY WORDS SPE REFERENCE Kaufmann, A.; Roth, S.; Ryser, B.; Widmer, M.; Guggisberg, D. Quantitative LC/MS-MS determination of sulfonamides and some other antibiotics in honey, J.AOAC Int., 2002, 85, 853–860. Sulfachlorpyridazine 593 SAMPLE Matrix: solutions Sample preparation: Inject an aliquot of a solution in MeOH. HPLC VARIABLES Column: 300 × 3.9 µBondapak C18 Mobile phase: MeCN:water:acetic acid 12.5:86.5:1 Flow rate: 1.6 Injection volume: 10 Detector: UV 254 CHROMATOGRAM Retention time: 13 OTHER SUBSTANCES Simultaneous: sulfabenzamide (25), sulfacetamide (4), sulfadiazine (5), sulfadimethoxine (40), sulfamerazine (7), sulfamethazine (8), sulfamethizole (9), sulfamethoxazole (16), sulfanilamide (2.5), sulfapyridine (6), sulfisoxazole (20) REFERENCE Roos, R.W. High pressure liquid chromatographic determination of sulfisoxazole in pharmaceuticals and separation patterns of other sulfonamides, J.Assoc.Off.Anal.Chem., 1981, 64, 851–854. SAMPLE Matrix: tissue Sample preparation: Condition a 500 mg Chromabond SA cation-exchange SPE cartridge (Macherey-Nagel) with 6 mL hexane, dry under vacuum for 10 min, condition with 6 mL dichloromethane:acetone:acetic acid 50:50:2, do not allow to go dry. Homogenize (Polytron) 10 g sample with 60 mL dichloromethane:acetone 50:50 for 30 s, rinse the apparatus with 2–3 mL dichloromethane:acetone 50:50, centrifuge the mixture at 2500 rpm for 10 min. Filter (cotton wool) the supernatant and wash it through with a little dichloromethane:acetone 50:50, add 5 mL acetic acid to the filtrate, mix, remove one-tenth of this mixture and add it to the SPE cartridge at 2 mL/min, do not allow the SPE cartridge to run dry, wash with 5 mL water, wash with 5 mL MeOH, dry under vacuum for 10 min, pass gaseous ammonia through the SPE cartridge until the acid is neutralized (when air is passed through the cartridge, moist pH paper should turn blue), elute with 3 mL MeOH at 1–2 mL/min, carefully evaporate to dryness under reduced pressure (100 mbar) at 40◦ , reconstitute with 500 µL initial mobile phase, centrifuge, inject a 50 µL aliquot of the supernatant. HPLC VARIABLES Column: 125 × 4 5 µm LiChrospher 100 RP-18 Mobile phase: Gradient. A was MeCN:20 mM pH 5 sodium acetate buffer 5.5:94.5. B was MeCN:EtOH:20 mM pH 5 sodium acetate buffer 50:10:40. A:B from 100:0 to 0:100 over 32 min (concave gradient), return to initial conditions over 4 min, re-equilibrate at initial conditions for 10 min. Flow rate: 0.8 Injection volume: 50 Detector: UV 270; F ex 395 em 495 following post-column reaction. The column effluent mixed with ice-cold reagent pumped at 0.3 mL/min and this mixture flowed through a 2.3 m × 0.5 mm ID coil in a cooled ultrasonic bath to the detector. (Prepare reagent by dissolving 25 mg fluorescamine in 25 mL MeCN and adding 75 mL buffer and 200 µL mercaptoethanol. The buffer was 20 mM sodium dihydrogen phosphate adjusted to pH 3 with 1 M phosphoric acid.) 594 Sulfachlorpyridazine CHROMATOGRAM Retention time: 22 Limit of detection: 0.5–5 ppb OTHER SUBSTANCES Extracted: sulfadiazine (10), sulfadimethoxine (28), sulfadoxine (24), sulfaguanidine (3), sulfamerazine (16.5), sulfamethazine (20), sulfamethizole (18), sulfamethoxypyridazine (21), sulfanilamide (3.7), sulfapyridine (15.7), sulfathiazole (15) KEY WORDS kidney; muscle; post-column reaction; SPE REFERENCE Pacciarelli, B.; Reber, S.; Douglas, C.; Dietrich, S.; Etter, R. Bestimmung von 12 Sulfonamiden in Fleisch und Nieren mittels HPLC und Nachsäulenderivatisierung [Determination of 12 sulfonamides in meat and kidney by HPLC and post column derivatization], Mitt.geb.Lebensmittelunters.Hyg., 1991, 82, 45–55. SAMPLE Matrix: tissue Sample preparation: Cut 20 g tissue into small pieces and add to 25 mL dichloromethane, let stand for 20–30 min with frequent stirring with a glass rod, filter through glass wool, repeat extraction twice more. Combine the dichloromethane layers and shake with 10 mL 1.5 M sulfuric acid for 15 min. Remove the aqueous phase and add it to 10 mL dichloromethane, shake for 10 min, discard the organic phase, repeat the wash, add 1 mL 10% dipotassium hydrogen phosphate to the aqueous phase, add 3 mL 40% NaOH, mix well, allow to cool, adjust pH to 5–6 with 1.5 M sulfuric acid or 40% NaOH, add 5 mL dichloromethane, extract for 15 min, repeat the extraction. Pass the organic layers through anhydrous sodium sulfate, evaporate to 1 g on a hot plate at 60–70◦ (in a hood!), inject a 10 µL aliquot. For confirmation of sulfachlorpyridazine, add 1 mL MeOH to the extract, add 2 drops acetic anhydride, heat at 80–90◦ on a hot plate until acetic acid fumes are no longer seen, reconstitute with 1 g dichloromethane, inject a 10 µL aliquot. (Note: Extraction from the sample matrix is only demonstrated for sulfamethazine, but it should work for sulfachlorpyridazine.) HPLC VARIABLES Column: 250 mm long MicroPak CN-10 Mobile phase: Isooctane:chloroform:MeOH:acetic acid 30.5:65:4:0.5 (Caution! Chloroform is a carcinogen!) Flow rate: 0.33 Injection volume: 10 Detector: UV 254 CHROMATOGRAM Retention time: 5.60 (6.68 for acetylsulfachlorpyridazine) Limit of detection: 20 ppb (for sulfamethazine) OTHER SUBSTANCES Extracted: acetylsulfabromomethazine (4.16), acetylsulfadiazine (6.78), acetylsulfadimethoxine (4.70), acetylsulfaethoxypyridazine (5.23), acetylsulfamethazine (5.34), sulfabromomethazine (3.56), sulfadiazine (5.55), sulfadimethoxine (3.99), sulfaethoxypyridazine (4.60), sulfamethazine (4.34) Noninterfering: sulfamerazine, sulfathiazole, sulfanilamide, sulfapyridine, sulfaquinoline Sulfachlorpyridazine 595 KEY WORDS cow; liver; fat; kidney; muscle REFERENCE Seymour, D.; Rupe, B.D. High-pressure liquid chromatographic determination of sulfamethazine residues in beef tissues, J.Pharm.Sci., 1980, 69, 701–703. ANNOTATED BIBLIOGRAPHY Combs, M.T.; Ashraf-Khorassani, M.; Taylor, L.T. Method development for the separation of sulfonamides by supercritical fluid chromatography, J.Chromatogr.Sci., 1997, 35, 176–180. [sulfamethazine; sulfamerazine; sulfapyridine; sulfadimethoxine; sulfadiazine; sulfaquinoxaline; sulfachlorpyridazine; sulfathiazole] Combs, M.T.; Ashraf-Khorassani, M.; Taylor, L.T. HPLC/atmospheric pressure chemical ionization-mass spectroscopy of eight regulated sulfonamides, J.Pharm.Biomed.Anal., 1999, 19, 301–308. [LOD 0.05–6 ng; sulfathiazole; sulfamethazine; sulfamerazine; sulfapyridine; sulfadimethoxine; sulfadiazine; sulfaquinoxaline; sulfachlorpyridazine] McGrane, M.; O’Keeffe, M.; Smyth, M.R. The analysis of sulphonamide drug residues in pork muscle using automated dialysis, Anal.Lett., 1999, 32, 481–495. [LOD 40 ng/g; sulfadiazine; sulfathiazole; sulfapyridine; sulfamerazine; sulfamethizole; sulfamethazine; sulfamethoxypyridazine; sulfachlorpyridazine; sulfisoxazole] Thomas, G.K.; Millar, R.G.; Anstis, P.W. Stability of sulfonamide antibiotics in spiked pig liver tissue during frozen storage, J.AOAC Int., 1997, 80, 988–995. [sulfamethazine; sulfadimethoxine; sulfachlorpyridazine; sulfathiazole; sulfaquinoxaline] 596 Sulfaethoxypyridazine Sulfaethoxypyridazine Molecular formula: C12 H14 N4 O3 S Molecular weight: 294.32 O N O S H2N N O CH3 N H CAS Registry No: 963-14-4 SAMPLE Matrix: tissue Sample preparation: Condition a 3 mL 500 mg Sep-Pak C18 SPE cartridge with 20 mL MeOH and 20 mL water. Shake 5 g homogenized tissue and 25 mL chloroform mechanically for 2 min (Caution! Chloroform is a carcinogen!), centrifuge at 3000 g for 5 min, repeat the extraction. Combine the lower organic layers, add 10 mL 10% NaCl in 100 mM NaOH, shake vigorously for 1 min. Remove the upper aqueous layer and centrifuge it at 1500 g for 10 min. Remove 8 mL of the upper aqueous layer and add it to 10 mL 1 M pH 6 sodium dihydrogen phosphate, vortex for 20 s, add to the SPE cartridge, wash with 20 mL water, elute with 1 mL MeOH. Add 2 mL 50 mM sodium dihydrogen phosphate to the eluate, filter (0.45 µm), inject a 20–50 µL aliquot. (SPE cartridge must have a carbon loading of 14%.) HPLC VARIABLES Column: 250 × 4.6 5 µm Spherisorb C18 ODS Mobile phase: MeOH:50 mM sodium dihydrogen phosphate 30:70 Flow rate: 0.8 Injection volume: 20–50 Detector: UV 265 CHROMATOGRAM Retention time: 24.5 Limit of detection: 2 ng/g (for sulfamethazine) OTHER SUBSTANCES Extracted: sulfamethazine (10.5) Simultaneous: sulfachlorpyridazine (12.1), sulfadiazine (3.8), sulfadimethoxine (45), sulfadoxine (17.2), sulfamerazine (6.4), sulfamethoxazole (14), sulfamethoxypyridazine (11.7), sulfanilamide (8.0), sulfathiazole (4.2) KEY WORDS kidney; liver; muscle; pig; SPE; the method is validated for sulfamethazine and sulfaethoxypyridazine is the internal standard REFERENCE Boison, J.O.K.; Keng, L.J.-Y. Determination of sulfamethazine in bovine and porcine tissues by reversedphase liquid chromatography, J.AOAC Int., 1994, 77, 558–564. SAMPLE Matrix: tissue Sample preparation: Cut 20 g tissue into small pieces and add to 25 mL dichloromethane, let stand for 20–30 min with frequent stirring with a glass rod, filter through glass wool, repeat extraction twice more. Combine the dichloromethane layers and shake with 10 mL 1.5 M sulfuric acid for 15 min. Remove the aqueous phase and add it to 10 mL dichloromethane, shake for 10 min, discard the organic phase, repeat the wash, add 1 mL 10% dipotassium hydrogen phosphate to the aqueous phase, add 3 mL 40% NaOH, mix well, allow to cool, adjust pH to 5–6 with 1.5 M sulfuric acid or 40% NaOH, add 5 mL dichloromethane, extract for 15 min, repeat the extraction. Pass the Sulfaethoxypyridazine 597 organic layers through anhydrous sodium sulfate, evaporate to 1 g on a hot plate at 60–70◦ (in a hood!), inject a 10 µL aliquot. For confirmation of sulfaethoxypyridazine, add 1 mL MeOH to the extract, add 2 drops acetic anhydride, heat at 80–90◦ on a hot plate until acetic acid fumes are no longer seen, reconstitute with 1 g dichloromethane, inject a 10 µL aliquot. (Note: Extraction from the sample matrix is only demonstrated for sulfamethazine, but it should work for sulfaethoxypyridazine.) HPLC VARIABLES Column: 250 mm long MicroPak CN-10 Mobile phase: Isooctane:chloroform:MeOH:acetic acid 30.5:65:4:0.5 (Caution! Chloroform is a carcinogen!) Flow rate: 0.33 Injection volume: 10 Detector: UV 254 CHROMATOGRAM Retention time: 4.60 (5.23 for acetylsulfaethoxypyridazine) Limit of detection: 20 ppb (for sulfamethazine) OTHER SUBSTANCES Extracted: acetylsulfabromomethazine (4.16), acetylsulfachlorpyridazine (6.68), acetylsulfadiazine (6.78), acetylsulfadimethoxine (4.70), acetylsulfamethazine (5.34), sulfabromomethazine (3.56), sulfachlorpyridazine (5.60), sulfadiazine (5.55), sulfadimethoxine (3.99), sulfamethazine (4.34) Noninterfering: sulfamerazine, sulfathiazole, sulfanilamide, sulfapyridine, sulfaquinoline KEY WORDS cow; liver; fat; kidney; muscle REFERENCE Seymour, D.; Rupe, B.D. High-pressure liquid chromatographic determination of sulfamethazine residues in beef tissues, J.Pharm.Sci., 1980, 69, 701–703. 598 Sulfamerazine Sulfamerazine Molecular formula: C11 H12 N4 O2 S Molecular weight: 264.31 O N O S H2N N N CH3 H CAS Registry No: 127-79-7, 127-58-2 (Na salt) Merck Index: 13, 8998 SAMPLE Matrix: blood Sample preparation: Vortex 1 mL plasma with 5–20 µg IS, 1 mL 10 mM pH 6.8 dipotassium hydrogen phosphate buffer, and 10 mL ethyl acetate:isopropanol 98:2 for 10 s, centrifuge at 1000 g for 10 min. Evaporate the organic layer to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 100 µL MeOH, inject a 5–50 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Spherisorb ODS1 Mobile phase: MeCN:MeOH:20 mM sodium dihydrogen phosphate 5:4:91 Flow rate: 1.5 Injection volume: 5–50 Detector: E, EDT Research LCA 15, +1.0 V CHROMATOGRAM Retention time: 21.5 Internal standard: sulfamethazine (36) Limit of quantitation: 1 µg/mL OTHER SUBSTANCES Extracted: sulfadiazine (13.0), sulfapyridine (18.5) KEY WORDS pharmacokinetics; plasma; sheep REFERENCE Mallett, D.N.; Gulaid, A.A.; Dennis, M.J. High-performance liquid chromatographic method with electrochemical detection for the concomitant assay of sulphadiazine, sulphamerazine and sulphapyridine in plasma, J.Chromatogr., 1988, 428, 190–195. SAMPLE Matrix: blood Sample preparation: Mix 1 mL plasma with 1 mL MeOH, centrifuge at 2000 g for 10 min, inject a 20 µL aliquot. HPLC VARIABLES Guard column: Corasil/C18 Column: µBondapak C18 Mobile phase: MeOH:water 40:60 Flow rate: 0.8 Injection volume: 20 Detector: UV 254 CHROMATOGRAM Retention time: 5.40 Limit of quantitation: 10 ng/mL Sulfamerazine 599 OTHER SUBSTANCES Extracted: acetylsulfisoxazole (4.40), sulfaguanidine (3.90), sulfisoxazole (4.20), sulfamethazine (6.10), sulfanilamide (3.05), sulfapyridine (5.00), sulfathiazole (3.30) KEY WORDS plasma REFERENCE Suber, R.L.; Edds, G.T. High performance liquid chromatographic determinations of sulfonamides by ionic suppression, J.Liq.Chromatogr., 1980, 3, 257–268. ANNOTATED BIBLIOGRAPHY Goehl, T.J.; Mathur, L.K.; Strum, J.D.; Jaffe, J.M.; Pitlick, W.H.; Shah, V.P.; Poust, R.I.; Colaizzi, J.L. Simple high-pressure liquid chromatographic determination of trisulfapyrimidines in human serum, J.Pharm.Sci., 1978, 67, 404–406. [sulfamerazine; sulfadiazine; sulfamethazine] 600 Sulfanitran Sulfanitran Molecular formula: C14 H13 N3 O5 S Molecular weight: 335.34 CAS Registry No: 122-16-7 Merck Index: 13, 9019 NO2 O O S O H3C N N H H SAMPLE Matrix: feed, premix Sample preparation: Shake ground feed containing 1.5 mg sulfanitran with 80 mL MeOH at 60◦ for 20 min, cool, let stand for 2 h, make up to 100 mL with MeOH, mix well, filter (Whatman No. 2 paper), filter (0.50 µm), inject a 20 µL aliquot. Shake premix containing 150 mg sulfanitran with 100 mL DMF on a rotary shaker for 1 h, filter (Whatman No. 2 paper), filter (0.50 µm), dilute 1 mL filtrate to 50 mL with DMF, inject a 20 µL aliquot. HPLC VARIABLES Guard column: 100 × 3 (OD) Bondapak C18/Corasil Column: 300 × 4 µBondapak C18 Mobile phase: MeCN:water 45:55 Flow rate: 1 Injection volume: 20 Detector: UV 254 CHROMATOGRAM Retention time: 6 OTHER SUBSTANCES Extracted: dinsed (9) REFERENCE Eaves, K.L.; Colvin, B.M.; Hanks, A.R.; Bushway, R.J. High pressure liquid chromatographic determination of sulfanitran and dinsed in medicated feeds and premixes, J.Assoc.Off.Anal.Chem., 1977, 60, 1064–1066. SAMPLE Matrix: tissue Sample preparation: Prepare a 30 × 6 column of 80–200 mesh neutral alumina (Brockman Activity I) and wash with two 2 mL portions of chloroform:ethyl acetate 50:50 (Caution! Chloroform is a carcinogen!). Blend (Polytron) 2.5 g partially frozen tissue with 20 mL chloroform:ethyl acetate:DMSO 50:50:0.8 at medium speed for 45 s, centrifuge at 3500 rpm for 5 min (10 min for liver), pass the organic layer through a plug of glass wool. Pass 15 mL filtrate through the alumina column, wash with three 1 mL portions of chloroform, wash with 3 mL chloroform, force remaining chloroform out with air pressure until dry, pass air through the column for an additional 5 min, elute with MeOH:50 mM pH 6.0 potassium phosphate buffer 50:50, collect first 2 mL eluate, inject a 50 µL aliquot. (Protect from light.) HPLC VARIABLES Column: 250 × 4.6 5 µm Supelcosil LC-18 Mobile phase: MeOH:buffer 42.5:57.5 (The buffer was 50 mM potassium dihydrogen phosphate containing 1 mM EDTA, adjusted to pH 6.0 with 1 M NaOH.) Flow rate: 1 Injection volume: 50 Sulfanitran 601 Detector: E, Bioanalytical Systems BAS Model LC-4B, glassy carbon electrode −0.8V, Ag/AgCl reference electrode CHROMATOGRAM Retention time: 13.2 Limit of detection: <6 ng/g OTHER SUBSTANCES Extracted: aklomide (5.3), furazolidone (4.0), nitrofurazone (4.1), nitromide (6.7), zoalene (6.2) KEY WORDS chicken; liver; muscle; SPE REFERENCE Parks, O.W. Liquid chromatographic-electrochemical detection screening procedure for six nitro-containing drugs in chicken tissues at low ppb level, J.Assoc.Off.Anal.Chem., 1989, 72, 567–569. 602 Sultamicillin Sultamicillin Molecular formula: C25 H30 N4 O9 S2 Molecular weight: 594.66 O S N NH2 H O H H N CH3 H3C O CH3H3C N O CAS Registry No: 76497-13-7, 83105-70-8 (tosylate) Merck Index: 13, 9083 H S O O O O O SAMPLE Matrix: bulk Sample preparation: Inject a 20 µL aliquot of a solution in MeCN:25 mM pH 7.0 phosphate buffer 70:30. HPLC VARIABLES Column: 150 × 4.6 5 µm Kromasil C18 Column temperature: 20 Mobile phase: MeCN:25 mM pH 7.0 phosphate buffer 48:52 Flow rate: 1 Injection volume: 20 Detector: UV 215 CHROMATOGRAM Retention time: 4.92 Limit of detection: 200 ng/mL OTHER SUBSTANCES Extracted: degradants, impurities REFERENCE Laviana, L.; Fernández-Marı́, F.; Bayod, M.; Blanco, D. HPLC for in-process control in the production of sultamicillin, J.Pharm.Biomed.Anal., 2003, 26, 321–328. SAMPLE Matrix: formulations Sample preparation: Sonicate a finely powdered tablet with 50 mL MeCN for 10 min, make up to 100 mL with MeCN, filter (Whatman No. 42 paper), dilute a 1 mL aliquot to 100 mL with MeCN, inject a 20 µL aliquot. HPLC VARIABLES Column: 250 × 3.9 5 µm Shodex C18 Mobile phase: MeCN:20 mM sodium dihydrogen phosphate 20:60, pH adjusted to 3.0 with dilute phosphoric acid Injection volume: 20 Detector: UV 215 CHROMATOGRAM Retention time: 7.8 Limit of detection: 10 µg/mL Limit of quantitation: 40 µg/mL OTHER SUBSTANCES Extracted: p-toluenesulfonic acid (3.7) Sultamicillin 603 KEY WORDS tablets REFERENCE Argekar, A.P.; Kunjir, S.S. Quantitative estimation of sultamicillin p-toluenesulfonate in pharmaceutical preparations by reverse-phase high performance liquid chromatography, J.Pharm.Biomed.Anal., 1996, 15, 423–427. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 10 µm Cosmosil 5C18-MS Column temperature: 50 Mobile phase: Gradient. MeCN:10 mM pH 2.5 potassium phosphate buffer 0:100 for 2 min, to 75:25 over 7.5 min, maintain at 75:25 for 5.5 min. Isocratic. MeCN:buffer 15:85. Flow rate: 1.5 Detector: UV (wavelength not specified) CHROMATOGRAM Retention time: 8.3 (gradient) or 4.3 (isocratic) OTHER SUBSTANCES Simultaneous: acetaminophen (7.9), alacepril (10.9), ampicillin (7.9), aspirin (10.0), caffeine (8.5), carbenicillin (9.5), cefotiam (7.2), chlorpromazine (10.8), cromolyn (8.9), enalapril (9.9), loperamide (11.6), ofloxacin (8.3), procainamide (7.4), procaine (7.9), propranolol (9.6), tegafur (8.4), temocapril (12.3), theophylline (8.0), tulobuterol (8.9) (gradient retention times; isocratic conditions may differ) REFERENCE Sugiyama, T.; Matsuyama, R.; Usui, S.; Katagiri, Y.; Hirano, K. Selection of mobile phases in highperformance liquid chromatographic determination for medicines, Biol.Pharm.Bull., 2000, 23, 274–278. Tacalcitol OH H 3C CH3 Molecular formula: C27 H44 O3 Molecular weight: 416.63 CAS Registry No: 57333-96-7 Merck Index: 13, 9114 CH3 H CH3 H CH2 HO OH SAMPLE Matrix: solutions HPLC VARIABLES Column: 25 × 6.2 Zorbax SIL Mobile phase: n-Hexane:isopropanol 90:10 Flow rate: 1.5 Detector: Radioreceptor assay CHROMATOGRAM Retention time: 20 REFERENCE Shigeno, C.; Yamamoto, I.; Dokoh, S.; Hino, M.; Aoki, J.; Yamada, K.; Morita, R.; Kameyama, M.; Torizuka, K. Identification of 1,24(R)-dihydroxyvitamin D3 -like bone-resorbing lipid in a patient with cancer-associated hypercalcemia, J.Clin.Endocrinol.Metab., 1985, 61, 761–768. SAMPLE Matrix: solutions HPLC VARIABLES Column: 25 × 4.6 Zorbax ODS Mobile phase: MeOH:water 80:20 Flow rate: 1 Detector: Radioreceptor assay CHROMATOGRAM Retention time: 19 REFERENCE Shigeno, C.; Yamamoto, I.; Dokoh, S.; Hino, M.; Aoki, J.; Yamada, K.; Morita, R.; Kameyama, M.; Torizuka, K. Identification of 1,24(R)-dihydroxyvitamin D3 -like bone-resorbing lipid in a patient with cancer-associated hypercalcemia, J.Clin.Endocrinol.Metab., 1985, 61, 761–768. 604 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 605 Talipexole Talipexole Molecular formula: C10 H15 N3 S S H2C N NH2 N Molecular weight: 209.32 CAS Registry No: 101626-70-4, 36085-73-1 (di HCl) Merck Index: 13, 9129 SAMPLE Matrix: blood, urine Sample preparation: Vortex 1 mL urine or plasma with 50 µL 1% acetic acid, 100 µL 1 M NaOH, and 6 mL diethyl ether for 5 min, centrifuge at 2500 g for 5 min, freeze in dry ice/acetone. Add the organic layer to 100 (plasma) or 200 (urine) µL buffer, mix, freeze in dry ice/acetone, discard the organic layer, remove traces of organic solvent with a stream of nitrogen, thaw, inject a 50 µL aliquot. (Prepare the buffer by dissolving 1.7 g potassium dihydrogen phosphate, 1.7 g sodium acetate, and 0.5 g sodium heptanesulfonate in 500 mL water, adjust pH to 3.5 with acetic acid. Use only polypropylene containers.) HPLC VARIABLES Guard column: 15 × 3.2 7 µm Brownlee RP-8 Column: 250 × 4.6 5 µm Zorbax Rx C8 Mobile phase: MeCN:buffer 13:87 (Prepare mobile phase by dissolving 10.2 g potassium dihydrogen phosphate, 10.2 g sodium acetate, and 4.5 g sodium heptanesulfonate in 3 L water, adjust pH to 3.5 with acetic acid, add 450 mL MeCN.) Flow rate: 1.2 Injection volume: 50 Detector: E, ESA 5100A detector, 5020 guard cell 0.65 V, 5011 analytical cell, electrode 1 0.2 V (impurity screening), electrode 2 0.6 V (monitored); UV 286 CHROMATOGRAM Retention time: 10 Limit of quantitation: 50 pg/mL (plasma, E), 10 ng/mL (urine, UV) (for pramipexole) OTHER SUBSTANCES Extracted: pramipexole (15) KEY WORDS plasma; method is validated for pramipexole and talipexole is IS; recovery of talipexole from plasma is 98.2% and from urine is 95.1% REFERENCE Lau, Y.Y.; Hanson, G.D.; Ichhpurani, N. Determination of pramipexole (U-98,528) in human plasma and urine by high-performance liquid chromatography with electrochemical and ultraviolet detection. J.Chromatogr.B, 1996, 683, 217–223. SAMPLE Matrix: blood Sample preparation: Vortex 1 mL plasma with 50 µL 1% acetic acid, 100 µL 1 M NaOH, and 6 mL MTBE for 5 min, centrifuge at 630 g for 5 min, freeze in dry ice/acetone. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 100 µL MeOH:water 95:5, inject a 70 µL aliquot. (Use only polypropylene containers.) 606 Talipexole HPLC VARIABLES Column: 150 × 4.6 5 µm Zorbax SB CN Mobile phase: MeOH:water:100 mM ammonium acetate 80:15:5 Flow rate: 1.2 Injection volume: 70 Detector: MS, PE Sciex API-III triple quadrupole, nebulizer 470◦ , gas-phase chemical ionization, positive ion mode, Corona discharge 3 µA, nebulizer gas at 550 kPa, auxiliary gas 1.5 L/min, orifice 45 V, m/z 210–141 CHROMATOGRAM Retention time: 2.2 Limit of quantitation: 50 pg/mL (for pramipexole) OTHER SUBSTANCES Extracted: pramipexole (m/z 212–153) (3.4) KEY WORDS plasma; method is validated for pramipexole, and talipexole is IS; recovery of talipexole is 85.4% REFERENCE Lau, Y.Y.; Hanson, G.D.; Ichhpurani, N. Determination of pramipexole (U-98,528) in human plasma and urine by high-performance liquid chromatography with electrochemical and ultraviolet detection, J.Chromatogr.B, 1996, 683, 217–223. 607 Taltirelin Taltirelin Molecular formula: C17 H23 N7 O5 Molecular weight: 405.41 CAS Registry No: 103300-74-9, 201677-75-0 (tetrahydrate) Merck Index: 13, 9135 N H O N N NH O H H3C N N O O NH2 O SAMPLE Matrix: blood Sample preparation: Condition a 3 mL 60 mg Oasis HLB divinylbenzene-N-vinylpyrrolidone SPE cartridge with 1 mL MeOH, 1 mL water, and 1 mL 200 mM sodium carbonate. Mix 500 µL plasma with 50 µL mobile phase A and 1 mL 200 mM sodium carbonate, add to the SPE cartridge, wash with 2 mL water, elute with 1 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 250 µL 50 ng/mL IS in mobile phase A, inject a 25 µL aliquot. HPLC VARIABLES Column: 150 × 2 5 µm Daisopak SP-120-30DS-BP (Daiso, Osaka) Column temperature: 40 Mobile phase: Gradient. A was MeOH:0.1% formic acid 7.5:92.5. B was MeOH:0.1% formic acid 90:10. A:B 100:0 for 3 min, to 0:100 over 1 min, maintain at 0:100 for 3 min, return to initial conditions over 0.1 min, re-equilibrate for 12.9 min. Flow rate: 0.2 Injection volume: 25 Detector: MS, PE Sciex API 3000, TurboIonSpray, positive ionization, source 475◦ , source flow rate 7 L/min, ionspray 5000 V, nebulizer gas air at 14 units, curtain gas nitrogen at 12 units, collision gas nitrogen at 4 units, collision energy – 80 eV, m/z 406–264 CHROMATOGRAM Retention time: 3.1 Internal standard: N-[(S)-hexahydro-1-methyl-2,6-dioxo-4-pyrimidinylcarbonyl]-L-histidine (m/z 310–264) (2.7) Limit of quantitation: 17 pg/mL OTHER SUBSTANCES Extracted: taltirelin acid-type (4.9) KEY WORDS plasma; SPE REFERENCE Horimoto, S.; Mayumi, T.; Tagawa, K.; Yamakita, H.; Yoshikawa, M. Determination of taltirelin, a new stable thyrotropin-releasing hormone analogue, in human plasma by high-performance liquid chromatography turbo-ionspray ionization tandem mass spectrometry, J.Pharm.Biomed.Anal., 2002, 30, 1361–1369. 608 Technetium Tc 99m bicisate Technetium Tc 99m bicisate Molecular formula: C12 H21 N2 O5 S99m 2 Tc Molecular weight: 436.44 CAS Registry No: 121281-41-2 Merck Index: 13, 9181 O H3C O H O N O N 99m Tc S O CH3 S SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 Dynamax C8 (Rainin) Mobile phase: Gradient. MeCN:50 mM ammonium acetate (unspecified) Flow rate: 1 Detector: UV 254; Radioactivity (99 Tc) CHROMATOGRAM Retention time: 7.1 REFERENCE Walovitch, R.C.; Franceschi, M.; Picard, M.; Cheesman, E.H.; Hall, K.M.; Makuch, J.; Watson, M.W.; Zimmerman, R.E.; Watson, A.D.; Ganey, M.V.; Williams, S.J.; Holman, B.L. Metabolism of 99m Tc-L,Lethyl cysteinate dimer in healthy volunteers, Neuropharmacology, 1991, 30, 283–292. Tegaserod Tegaserod NH H Molecular formula: C16 H23 N5 O Molecular weight: 301.39 CAS Registry No: 145158-71-0, 189188-57-6 (maleate) Merck Index: 13, 9194 609 N N N H CH3 H3CO N H SAMPLE Matrix: microsomal incubations Sample preparation: Add an equal volume of cold MeOH, 70% perchloric acid, or 10% trichloroacetic acid, cool on dry ice, centrifuge at 100 000 g for 10 min, inject an aliquot of the supernatant. HPLC VARIABLES Guard column: 20 × 4.6 5 µm Supelco LC-18 Column: 150 × 4.6 5 µm Supelco LC-18 Column temperature: 40 Mobile phase: Gradient. MeCN:10 mM pH 5.4 ammonium acetate 0:100 for 10 min, to 10:90 over 20 min, to 90:10 over 41 min, to 100:0 over 19 min. Flow rate: 1 Detector: Radioactivity (14 C) (scintillator flow 3 mL/min); MS, Finnigan MAT TSQ 700 triple-stage quadrupole, electrospray, 0.25 mL/min of column effluent mixed with 0.1 mL/min MeCN and entered the detector, sheath liquid methanol at 0.1 mL/min, sheath gas nitrogen 45 psi, auxiliary gas nitrogen 5 units, spray 4.5 kV, transfer capillary 240◦ , collision offset 30 V CHROMATOGRAM Retention time: 67 OTHER SUBSTANCES Extracted: metabolites KEY WORDS human; liver REFERENCE Vickers, A.E.M.; Zollinger, M.; Dannecker, R.; Tynes, R.; Heitz, F.; Fischer, V. In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions, Drug Metab.Dispos., 2001, 29, 1269–1276. 610 Telithromycin Telithromycin N Molecular formula: C43 H65 N5 O10 N N Molecular weight: 812.00 CAS Registry No: 191114-48-4 Merck Index: 13, 9199 O H3C H3C O CH3 N O OCH3 CH3 H3C O CH3 O O H 3C N CH3 HO O CH3 O CH3 SAMPLE Matrix: blood Sample preparation: Mix plasma with MeCN, centrifuge. Evaporate the supernatant to dryness under a stream of nitrogen, reconstitute the residue with MeCN:MeOH:50 mM ammonium acetate 18.1:21.9:60 containing IS, inject an aliquot. HPLC VARIABLES Column: 125 × 4 5 µm Purospher RP-18e Mobile phase: MeCN:MeOH:50 mM ammonium acetate 24:29:52 Flow rate: 1 Detector: F ex 263 em 460 CHROMATOGRAM Internal standard: RU 66260 Limit of quantitation: 5 ng/mL KEY WORDS guinea pig; pharmacokinetics; plasma REFERENCE Edelstein, P.H.; Edelstein, M.A. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia, Antimicrob.Agents Chemother., 1999, 43, 90–95. 611 Telmesteine Telmesteine O O N Molecular formula: C7 H11 NO4 S Molecular weight: 205.23 CAS Registry No: 122946-43-4 S CH3 COOH H SAMPLE Matrix: bile, blood, urine Sample preparation: Plasma. Mix 300 µL plasma with 600 µL MeCN, centrifuge at 1000 g for 10 min. Evaporate the supernatant to dryness under a stream of nitrogen, reconstitute the residue with 50 µL initial mobile phase, inject a 30 µL aliquot. Urine, bile. Add 1 mL urine or bile to an activated Sep-Pak C18 SPE cartridge, wash with two 1 mL portions of water, elute with 1 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with 100 µL initial mobile phase, inject a 30 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm YMC-Pak C8 Mobile phase: Gradient. MeCN:0.1% acetic acid from 20:80 to 40:60 over 25 min, maintain at 40:60 for 5 min Flow rate: 1 Injection volume: 30 Detector: Radioactivity (14 C); MS, Agilent LC-MSD Trap, 10% of column effluent entered MS detector CHROMATOGRAM Retention time: 21.1 OTHER SUBSTANCES Extracted: glucuronide conjugate (15.8) KEY WORDS pharmacokinetics; plasma; rat; SPE REFERENCE Lee, J.; Son, J.; Rhee, S.W.; Kim, D.H. Absorption, distribution, metabolism and excretion of telmesteine, a mucolitic agent, in rat, Xenobiotica, 2003, 33, 755–765. 612 Telmisartan Telmisartan Molecular formula: C33 H30 N4 O2 CH3 N N Molecular weight: 514.62 CAS Registry No: 144701-48-4 Merck Index: 13, 9209 CH3 N N CH3 COOH SAMPLE Matrix: blood Sample preparation: Inject a 100 µL aliquot of plasma onto column A and elute to waste with mobile phase A; after 3 min, backflush the contents of column A onto column B using mobile phase B; after 3 min, elute column B with mobile phase B, monitor the effluent from column B. HPLC VARIABLES Column: A 17 × 4.6 unspecified enrichment column; B 125 × 4.6 Nucleosil 100-5 C18 Mobile phase: A 50 mM pH 4.5 ammonium acetate; B MeCN:50 mM pH 4.5 ammonium acetate 10:90; C Gradient. MeCN:50 mM pH 4.5 ammonium acetate 30:70 for 3 min, to 60:40 over 12 min Flow rate: 1 Injection volume: 100 Detector: F ex 305 em 365 CHROMATOGRAM Retention time: 18 Limit of quantitation: 2.5 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS column-switching; plasma; rat REFERENCE Ebner, T.; Heinzel, G.; Prox, A.; Beschke, K.; Wachsmuth, H. Disposition and chemical stability of telmisartan 1-O-acylglucuronide, Drug Metab.Dispos., 1999, 27, 1143–1149. SAMPLE Matrix: urine Sample preparation: Condition a 1 mL 100 mg Bond Elut C8 SPE cartridge with 2 mL MeOH and 1 mL 100 mM pH 6 phosphate buffer. Shake 1 mL urine with 500 µL 100 mM pH 6 phosphate buffer, centrifuge at 3500 rpm (16.1 g) at 4◦ for 5 min, add a 1 mL aliquot to the SPE cartridge, wash with 1 mL MeOH:100 mM pH 6 phosphate buffer 30:70, dry under full vacuum for 20 min, elute with 1 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 500 µL mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Guard column: 20 × 3.9 4 µm Novapak C18 Column: 150 × 3.9 4 µm Novapak C18 Mobile phase: MeCN:5 mM pH 6.0 phosphate buffer 45:55 Flow rate: 0.5 Telmisartan 613 Injection volume: 20 Detector: F ex 305 em 365 CHROMATOGRAM Retention time: 2.5 Limit of quantitation: 1 ng/mL KEY WORDS SPE REFERENCE Torrealday, N.; González, L.; Alonso, R.M.; Jiménez, R.M.; Ortiz Lastra, E. Experimental design approach for the optimisation of a HPLC-fluorimetric method for the quantitation of the angiotensin II receptor antagonist telmisartan in urine, J.Pharm.Biomed.Anal., 2003, 32, 847–857. 614 Temocapril Temocapril Molecular formula: C23 H28 N2 O5 S2 Molecular weight: 476.62 CAS Registry No: 111902-57-9 Merck Index: 13, 9215 H3C O O S N H S N O COOH SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 Mightysil RP-18 Mobile phase: MeOH:water:phosphoric acid 50:50:0.05 Flow rate: 1 Detector: UV 220 OTHER SUBSTANCES Simultaneous: enalapril REFERENCE Kitagawa, S.; Takeda, J.; Sato, S. Uptake of enalapril by rabbit small intestinal brush-border membrane vesicles, Biol.Pharm.Bull., 1999, 22, 762–764. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 10 µm Cosmosil 5C18-MS Column temperature: 50 Mobile phase: Gradient. MeCN:10 mM pH 2.5 potassium phosphate buffer 0:100 for 2 min, to 75:25 over 7.5 min, maintain at 75:25 for 5.5 min. Isocratic. MeCN:buffer 50:50. Flow rate: 1.5 Detector: UV (wavelength not specified) CHROMATOGRAM Retention time: 12.3 (gradient) or 5.7 (isocratic) OTHER SUBSTANCES Simultaneous: acetaminophen (7.9), alacepril (10.9), ampicillin (7.9), aspirin (10.0), caffeine (8.5), carbenicillin (9.5), cefotiam (7.2), chlorpromazine (10.8), cromolyn (8.9), enalapril (9.9), loperamide (11.6), ofloxacin (8.3), procainamide (7.4), procaine (7.9), propranolol (9.6), sultamicillin tosylate (8.3), tegafur (8.4), theophylline (8.0), tulobuterol (8.9) (gradient retention times; isocratic conditions may differ) REFERENCE Sugiyama, T.; Matsuyama, R.; Usui, S.; Katagiri, Y.; Hirano, K. Selection of mobile phases in highperformance liquid chromatographic determination for medicines, Biol.Pharm.Bull., 2000, 23, 274–278. 615 Temozolomide Temozolomide Molecular formula: C6 H6 N6 O2 Molecular weight: 194.15 CAS Registry No: 85622-93-1 Merck Index: 13, 9218 NH2 O N N N N N CH3 O SAMPLE Matrix: blood Sample preparation: Vortex 500 µL plasma with 500 µL 1 µg/mL IS in water, 50 µL 1 M HCl, and 5 mL ethyl acetate for 10 min, centrifuge at 4500 g for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen at 45◦ , reconstitute the residue with 300 µL mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 5 µm Ultrasphere ODS Mobile phase: MeCN:0.1% acetic acid 10:90 Flow rate: 1 Injection volume: 20 Detector: UV 316 CHROMATOGRAM Retention time: 2.7 Internal standard: ethazolastone (5.0) Limit of quantitation: 100 ng/mL KEY WORDS pharmacokinetics; plasma REFERENCE Kim, H.; Likhari, P.; Parker, D.; Statkevich, P.; Marco, A.; Lin, C.-C.; Nomeir, A.A. High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma, J.Pharm.Biomed.Anal., 2001, 24, 461–468. SAMPLE Matrix: blood, urine Sample preparation: Condition a 100 mg Chromabond C18 SPE cartridge (MachereyNagel) with two 1 mL portions of MeOH and two 1 mL portions of 0.5% acetic acid. Mix 1 mL plasma with 100 µL 1 M HCl. Mix 10 mL urine with 1 mL 1 M HCl. Mix 235 µL acidified plasma or urine with 115 µL 20 (plasma) or 160 (urine) µg/mL IS in 100 mM HCl. Add a 160 µL aliquot of this solution to the SPE cartridge, pull through under light vacuum, let stand for 1 min (important!), wash with 750 µL 0.5% acetic acid, dry under vacuum for 5 min, elute with 1.25 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at room temperature, reconstitute the residue with 200 µL 0.5% acetic acid, centrifuge, inject a 30 µL aliquot. HPLC VARIABLES Guard column: 20 × 4 5 µm HP ODS-Hypersil Column: 100 × 4.6 5 µm HP ODS-Hypersil Mobile phase: MeOH:0.5% acetic acid 10:90 Flow rate: 1 Injection volume: 30 Detector: UV 330 616 Temozolomide CHROMATOGRAM Retention time: 3.2 Internal standard: ethazolastone (7.4) Limit of quantitation: 200 ng/mL (plasma), 2 µg/mL (urine) KEY WORDS pharmacokinetics; plasma; SPE REFERENCE Shen, F.; Decosterd, L.A.; Gander, M.; Leyvraz, S.; Biollax, J.; Lejeune, F. Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction, J.Chromatogr.B, 1995, 667, 291–300. ANNOTATED BIBLIOGRAPHY Chowdhury, S.K.; Laudicina, D.; Blumenkrantz, N.; Wirth, M.; Alton, K.B. An LC/MS/MS method for the quantitation of MTIC (5-(3-N-methyltriazen-1-yl)-imidazole-4-carboxamide), a bioconversion product of temozolomide, in rat and dog plasma, J.Pharm.Biomed.Anal., 1999, 19, 659–668. Kim, H.K.; Lin, C.-C.; Parker, D.; Veals, J.; Lim, J.; Likhari, P.; Statkevich, P.; Marco, A.; Nomeir, A.A. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma, J.Chromatogr.B, 1997, 703, 225–233. Ma, J.; Li, S.; Reed, K.; Guo, P.; Gallo, J.M. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models, J.Pharmacol.Exp.Ther., 2003, 305, 833–839. [plasma; rat] 617 Tenofovir disoproxil fumarate Tenofovir disoproxil fumarate Molecular formula: C19 H30 N5 O10 P.C4 H4 O4 Molecular weight: 635.51 CAS Registry No: 202138-50-9, 147127-20-6 (tenofovir only) Merck Index: 13, 9223 NH2 N N O N CH3 O N O P O O O CH3 O O O CH3 CH3 HOOC COOH O CH3 SAMPLE Matrix: blood Sample preparation: Mix 200 µL plasma with 20 µL 2.5 µg/mL IS in water, add 600 µL MeOH, vortex for 30 s, centrifuge at 2200 g for 10 min. Evaporate the supernatant to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 200 µL reagent, heat at 80◦ for 40 min, cool at – 20◦ for 10 min, inject a 40–80 µL aliquot. (The reagent was 0.34% chloroacetaldehyde in 100 mM pH 4.5 acetate buffer, prepared just before use.) HPLC VARIABLES Guard column: 15 × 3 (Cluzeau) Column: 250 × 3 5 µm C8 plus satisfaction (Cluzeau, France) Column temperature: 35 Mobile phase: MeCN:5 mM pH 6 phosphate buffer containing 5 mM tetrabutylammonium chloride 15:85 Flow rate: 0.5 Injection volume: 40–80 Detector: F ex 236 em 420 CHROMATOGRAM Retention time: 11.7 (of tenofovir) Internal standard: adefovir (9.5) Limit of quantitation: 5 ng/mL KEY WORDS derivatization; plasma REFERENCE Jullien, V.; Tréluyer, J.-M.; Pons, G.; Rey, E. Determination of tenofovir in human plasma by highperformance liquid chromatography with spectrofluorimetric detection, J.Chromatogr.B, 2003, 785, 377–381. SAMPLE Matrix: blood Sample preparation: Mix 200 µL plasma with 1 µg/mL IS and 400 µL 0.1% trifluoroacetic acid in MeCN, centrifuge. Evaporate the supernatant to dryness under reduced pressure at room temperature, reconstitute the residue with 200 µL 0.34% chloroacetaldehyde in 100 mM pH 4.5 sodium acetate buffer, vortex, centrifuge. Heat the supernatant at 95◦ for 40 min, evaporate to dryness, reconstitute with 200 µL mobile phase A, inject a 20 µL aliquot. 618 Tenofovir disoproxil fumarate HPLC VARIABLES Guard column: 15 × 3.2 Brownlee RP-18 Newguard Column: 150 × 4.6 Zorbax RX-C18 Column temperature: 35 Mobile phase: Gradient. A was MeCN:buffer 5:95. B was MeCN:buffer 65:35. A:B 100:0 for 8 min, to 0:100 for 10 min, return to initial conditions (step gradient), reequilibrate for 8 min. (The buffer was 20 mM pH 6.0 phosphate buffer containing 5 mM tetrabutylammonium hydrogen phosphate.) Flow rate: 1.5 Injection volume: 20 Detector: F ex 236 em 420 CHROMATOGRAM Internal standard: 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) KEY WORDS derivatization; dog; plasma; method validated for tenofovir only REFERENCE Shaw, J.-P.; Sueoka, C.M.; Oliyai, R.; Lee, W.A.; Arimilli, M.N.; Kim, C.U.; Cundy, K.C. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs, Pharm.Res., 1997, 14, 1824–1829. SAMPLE Matrix: blood, microsomal incubations Sample preparation: Mix 50 µL plasma or microsomal incubation with 100 µL 0.1% trifluoroacetic acid in MeCN, centrifuge for 5 min at 14 000 rpm, inject a 50 µL aliquot of the supernatant. HPLC VARIABLES Guard column: 15 × 3.2 Brownlee RP-18 Newguard Column: 250 × 4.6 5 µm Zorbax RX-C18 Column temperature: 35 Mobile phase: Gradient. MeCN:20 mM pH 6.0 phosphate buffer from 0:100 to 65:35 over 15 min, return to initial conditions (step gradient), re-equilibrate for 7 min. Flow rate: 1 Injection volume: 50 Detector: UV 262 KEY WORDS dog; intestine; liver; plasma; method validated for tenofovir and tenofovir disoproxil REFERENCE Shaw, J.-P.; Sueoka, C.M.; Oliyai, R.; Lee, W.A.; Arimilli, M.N.; Kim, C.U.; Cundy, K.C. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs, Pharm.Res., 1997, 14, 1824–1829. ANNOTATED BIBLIOGRAPHY Cundy, K.C.; Sueoka, C.; Lynch, G.R.; Griffin, L.; Lee, W.A.; Shaw, J.-P. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs, Antimicrob.Agents Chemother., 1998, 42, 687–690. [derivatization; adefovir is internal standard; fluorescence detection; LOQ 25 ng/mL; tenofovir only] Sentenac, S.; Fernandez, C.; Thuillier, A.; Lechat, P.; Aymard, G. Sensitive determination of tenofovir in human plasma samples using reversed-phase liquid chromatography, J.Chromatogr.B, 2003, 793, 317–324. [SPE; tenofovir only; LOQ 10 ng/mL] Tenofovir disoproxil fumarate 619 Sparidans, R.W.; Crommentuyn, K.M.L.; Schellens, J.H.M.; Beijnen, J.H. Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde, J.Chromatogr.B, 2003, 791, 227–233. [tenofovir only; derivatization; adefovir is internal standard; LOQ 20 ng/mL; fluorescence detection] Van Gelder, J.; Witvrouw, M.; Pannecouque, C.; Henson, G.; Bridger, G.; Naesens, L.; De Clercq, E.; Annaert, P.; Shafiee, M.; Van den Mooter, G.; Kinget, R.; Augustijns, P. Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA, Int.J.Pharm., 1999, 186, 127–136. [tenofovir only] 620 Teprenone Teprenone Molecular formula: C23 H38 O Molecular weight: 330.55 CAS Registry No: 6809-52-5 Merck Index: 13, 9228 O CH3 SAMPLE Matrix: blood Sample preparation: Condition a 200 mg Bond Elut C18 SPE cartridge with 1 column vol of MeOH and 2 column vol of water. Vortex 1 mL plasma, 100 µL 10 µg/mL IS in MeOH, and 1 mL water, add 1 mL EtOH, add 100 µL 50% KOH solution, heat in a boiling water bath for 10 min, cool, add 3 mL hexane, shake for 10 min, centrifuge at 1670 g for 5 min, repeat extraction twice more. Combine the organic layers, evaporate to dryness under a stream of nitrogen at 45◦ , reconstitute the residue with 200 µL 0.5% HCl in isopropanol, add 200 µL 0.2% dansylhydrazine in isopropanol, heat at 35◦ for 60 min, add 1 mL water, add to the SPE cartridge, wash twice with 3 mL portions of water, wash with 1 mL MeCN, elute with three 500 µL portions of MeOH:chloroform 50:50 (Caution! Chloroform is a carcinogen!). Evaporate the eluate to dryness under a stream of nitrogen at 45◦ , reconstitute the residue with 200 µL EtOH, sonicate, centrifuge at 1670 g for 5 min, inject a 50 µL aliquot. HPLC VARIABLES Column: 150 × 6 5 µm YMC-A312 C18 Column temperature: 30 Mobile phase: MeCN:water:triethylamine 92.5:7.5:0.015 Flow rate: 1.8 Injection volume: 50 Detector: F ex 365 em 515 CHROMATOGRAM Retention time: 9 (cis-5, syn), 10 (trans-5, syn), 13 (cis-5, anti), 14 (trans-5, anti) Internal standard: 7,11,15,19-tetramethyl-6,10,14,18-eicosatetraen-3-one (15, 16 (syn/ anti)) Limit of quantitation: 8 ng/mL (cis), 12 ng/mL (trans) KEY WORDS derivatization; pharmacokinetics; plasma; SPE; teprenone is a cis:trans (39.8:60.2) mixture at the 5-double bond and produces syn and anti derivatives at the ketone REFERENCE Seki, T.; Hashida, N.; Kanazawa, T. Determination of tetraprenylacetone in human plasma by highperformance liquid chromatography with fluorescence derivatization using dansylhydrazine, J. Chromatogr., 1988, 424, 410–415. Teriparatide 621 Teriparatide Molecular formula: C181 H291 N55 O51 S2 Molecular weight: 4117.72 CAS Registry No: 52232-67-4, 99294-94-7 (acetate) Merck Index: 13, 9241 SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 10 Vydac C-18 Mobile phase: Gradient. MeCN:0.1% trifluoroacetic acid from 20:80 to 60:40 over 40 min. Detector: UV (wavelength not specified) REFERENCE Oldenburg, K.R.; D’Orfani, A.L.; Selick, H.E. A method for the high-level expression of a parathyroid hormone analog in Escherichia coli, Protein Expr.Purif., 1994, 5, 278–284. 622 Tetrachlorvinphos Tetrachlorvinphos Molecular formula: C10 H9 Cl4 O4 P Molecular weight: 365.96 CAS Registry No: 22248-79-9 Merck Index: 13, 9267 O H3CO H3CO P Cl Cl O Cl Cl SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 2.2 6–8 µm silica Mobile phase: n-Hexane:EtOH 98.5:1.5 Flow rate: 0.55 Injection volume: 5 Detector: Transport flame ionization CHROMATOGRAM Retention time: 3 (β isomer), 4 (α isomer) KEY WORDS normal phase REFERENCE Szalontai, G. High-performance liquid chromatography of organophosphorus insecticides, J.Chromatogr., 1976, 124, 9–16. Tetrahydrozoline Tetrahydrozoline Molecular formula: C13 H16 N2 623 H N N Molecular weight: 200.28 CAS Registry No: 84-22-0, 522-48-5 (HCl) Merck Index: 13, 9292 SAMPLE Matrix: blood Sample preparation: Mix 1 mL whole blood with 20 µL 1 µg/mL dibenzepin in MeOH:water 50:50, add 300 µL pH 11 Tris buffer, mix, add 500 µL butyl acetate, vortex for 2 min, centrifuge. Preserve the aqueous layer (A). Remove the organic layer and add it to 75 µL 10 mM ammonium acetate buffer containing 0.1% formic acid (pH 3.2), evaporate (?). Add 75 µL MeCN, sonicate for 5 min, centrifuge at 5000 rpm for 5 min, keep the extract as B. Add 20 µL 1 µg/mL enalapril in MeOH:water 50:50 and 120 mg NaCl to the aqueous layer (A), mix, add 500 µL pH 3 phosphate buffer, add 600 µL 8.5% phosphoric acid, add 5 mL dichloromethane:isopropanol 95:5, shake at 250 cycles/min in a bench-top shaker for 30 min, centrifuge at 5000 rpm for 5 min. Remove the lower organic layer and evaporate it to dryness under a stream of air at 45◦ . Reconstitute the residue with 150 µL initial mobile phase, sonicate, centrifuge, combine with extract B, inject a 30 µL aliquot. (Sample preparation from Gergov,M.; Robson,J.N.; Ojanperä,I.; Heinonen,O.P.; Vuori,E. Simultaneous screening and quantitation of 18 antihistamine drugs in blood by liquid chromatography ionspray tandem mass spectrometry. Forensic Sci.Inter. 2001, 121, 108–115.) HPLC VARIABLES Guard column: 40 mm long 4 µm Purospher RP-18 LiChro Cart 4-4 Column: 100 × 2.1 4 µm Genesis C18 (Jones Chromatography) Column temperature: 35 Mobile phase: Gradient. MeCN:buffer from 20:80 to 100:0 over 10 min, maintain at 0:100 for 3 min, re-equilibrate at initial conditions for 5 min. (The buffer was 10 mM ammonium acetate containing 0.1% formic acid (pH 3.2).) Flow rate: 0.2 Injection volume: 30 Detector: MS, PE Sciex API 365 triple-stage quadrupole LC-MS-MS, PE Sciex TurboIonSpray interface, positive ion mode, needle voltage 5.2 kV, nebulizer gas air at 60 psi, curtain gas nitrogen at 40 psi, collision cell gas nitrogen at 40 psi, turbo ionspray heater 375◦ , heater gas flow 7 L/min CHROMATOGRAM Retention time: 3.6 Internal standard: dibenzepin, enalapril Limit of detection: 100 ng/mL OTHER SUBSTANCES Extracted: acebutolol (3.8, LOD 0.1 µg/mL), acetaminophen (2.5, LOD <5 µg/mL), acrivastine (5.7, LOD <0.02 µg/mL), alprazolam (6.1, LOD <0.02 µg/mL), alprenolol (5.4, LOD 0.01 µg/mL), amantadine (3.4, LOD 0.1 µg/mL), amiloride (2.0, LOD 0.1 µg/mL), aminophenazone (2.8, LOD <5 µg/mL), amiodarone (10.2, LOD 0.05 µg/mL), amitriptyline (6.6, LOD <0.02 µg/mL), astemizole (5.8, LOD <0.02 µg/mL), atenolol (1.7, LOD 0.30 µg/mL), azacyclonol (5.1, LOD 0.02 µg/mL), benzhexol (6.6, LOD <0.02 µg/mL), benzoylecgonine (3.3, LOD 0.01 µg/mL), betaxolol (5.5, LOD 0.01 µg/mL), biperidine (6.2, LOD <0.02 µg/mL), bisoprolol (5.0, LOD <0.02 µg/mL), brompheniramine (5.3, LOD 0.002 µg/mL), bupivacaine (5.1, LOD <0.02 µg/mL), buprenorphine (5.9, LOD 0.01 µg/mL), buspirone (5.1, LOD 0.002 µg/mL), caffeine (2.8, LOD 1 µg/mL), carbamazepine 624 Tetrahydrozoline (6.1, LOD <0.02 µg/mL), carbinoxamine (5.1, LOD 0.002 µg/mL), carisoprodol (6.7, LOD <5 µg/mL), carvedilol (6.2, LOD <0.02 µg/mL), celiprolol (4.3, LOD 0.05 µg/mL), cetirizine (6.3, LOD 0.05 µg/mL), chlorcyclizine (6.6, LOD <0.02 µg/mL), chlordiazepoxide (5.7, LOD <0.02 µg/mL), chlormezanone (5.8, LOD <5 µg/mL), chloroquine (2.7, LOD 0.02 µg/mL), chlorpheniramine (5.1, LOD 0.002 µg/mL), chlorpromazine (7.0, LOD 0.02 µg/mL), chlorpropamide (6.7, LOD <5 µg/mL), chlorprothixene (7.0, LOD <0.02 µg/mL), cinnarizine (7.9, LOD <0.02 µg/mL), citalopram (5.7, LOD <0.02 µg/mL), clemastine (7.7, LOD 0.02 µg/mL), clobazam (7.3, LOD <0.02 µg/mL), clobutinol (5.3, LOD 0.02 µg/mL), clomethiazole (6.2, LOD 0.5 µg/mL), clomipramine (7.1, LOD <0.02 µg/mL), clonazepam (6.6, LOD <0.02 µg/mL), clonidine (2.8, LOD 0.1 µg/mL), clozapine (5.6, LOD <0.02 µg/mL), cocaine (4.6, LOD <0.02 µg/mL), codeine (2.5, LOD 0.1 µg/mL), coumatetralyl (8.4, LOD 0.05 µg/mL), cyclizine (5.8, LOD <0.02 µg/mL), dextropropoxyphene (6.6, LOD 0.05 µg/mL), demoxepam (5.8, LOD 0.02 µg/mL), dextromethorphan (5.5, LOD <0.02 µg/mL), diazepam (8.1, LOD 0.02 µg/mL), diltiazem (5.8, LOD <0.02 µg/mL), diphenhydramine (5.7, LOD <0.02 µg/mL), dipyridamole (5.4, LOD 0.005 µg/mL), disopyramine (4.4, LOD <0.02 µg/mL), dixyrazine (6.8, LOD 0.005 µg/mL), doxapram (4.8, LOD <0.02 µg/mL), doxepin (5.9, LOD <0.02 µg/mL), dronabinol (12.3, LOD 0.05 µg/mL), ebastine (9.6, LOD 0.005 µg/mL), embutramide (6.7, LOD 0.005 µg/mL), ergotamine (5.5, LOD 0.005 µg/mL), ethenzamide (5.0, LOD 0.05 µg/mL), ethylmorphine (3.2, LOD 0.05 µg/mL), ethylparathion (9.7, LOD <5 µg/mL), etodroxizine (6.4, LOD <0.02 µg/mL), felodipine (9.6, LOD 0.02 µg/mL), fenazepam (7.5, LOD <0.02 µg/mL), fenfluramine (5.3, LOD <0.02 µg/mL), fenkamfamine (5.1, LOD <0.02 µg/mL), fentanyl (5.5, LOD <0.02 µg/mL), fexofenadine (6.3, LOD <0.02 µg/mL), flecainide (5.9, LOD <0.02 µg/mL), fluconazole (4.0, LOD 0.1 µg/mL), flumazenil (5.2, LOD <0.02 µg/mL), flunitrazepam (7.1, LOD 0.002 µg/mL), fluoxetine (6.8, LOD 0.1 µg/mL), flupentixol (7.5, LOD 0.18 µg/mL), fluvoxamine (6.3, LOD 0.02 µg/mL), glibenclamide (8.5, LOD <0.02 µg/mL), glipizide (6.8, LOD <0.05 µg/mL), haloperidol (6.1, LOD <0.02 µg/mL), histapyrrodine (6.3, LOD 0.02 µg/mL), hydrocodone (3.0, LOD 0.05 µg/mL), hydroxychloroquine (2.4, LOD <0.3 µg/mL), hydroxyzine (6.3, LOD <0.02 µg/mL), imipramine (6.4, LOD 0.05 µg/mL), indomethacin (8.6, LOD 0.05 µg/mL), isoniazid (2.2, LOD 3 µg/mL), isradipine (8.6, LOD 0.05 µg/mL), ketamine (3.6, LOD <0.05 µg/mL), ketobemidone (3.3, LOD <0.05 µg/mL), ketoprofen (7.3, LOD 0.1 µg/mL), ketorolac (6.2, LOD 0.05 µg/mL), labetalol (4.9, LOD 0.05 µg/mL), lamotrigine (4.0, LOD 0.1 µg/mL), levocabastine (5.8, LOD 0.01 µg/mL), levomepromazine (6.5, LOD 0.02 µg/mL), lidocaine (3.7, LOD <0.05 µg/mL), loratadine (9.3, LOD 0.002 µg/mL), lorazepam (6.6, LOD 0.02 µg/mL), lormetazepam (7.4, LOD <0.02 µg/mL), LSD (4.7, LOD <0.02 µg/mL), malathion (8.9, LOD 10 µg/mL), maprotiline (6.4, LOD <0.02 µg/mL), MDMA (3.3, LOD 0.02 µg/mL), meclozine (8.5, LOD <0.02 µg/mL), medazepam (6.3, LOD <0.02 µg/mL), meloxicam (7.1, LOD 0.01 µg/mL), melperone (5.0, LOD <0.02 µg/mL), meperidine (4.7, LOD <0.02 µg/mL), mepivacaine (3.7, LOD <0.02 µg/mL), meprobamate (4.9, LOD 0.1 µg/mL), mesoridazine (5.4, LOD <0.02 µg/mL), methamphetamine (3.3, LOD 0.05 µg/mL), methadone (6.7, LOD <0.02 µg/mL), methylparathion (8.6, LOD 10 µg/mL), methylphenidate (4.2, LOD <0.02 µg/mL), metoclopramide (3.8, LOD <0.02 µg/mL), metoprolol (4.1, LOD 0.02 µg/mL), metronidazole (2.6, LOD 1 µg/mL), mexiletine (4.4, LOD 0.05 µg/mL), mianserin (5.7, LOD <0.02 µg/mL), midazolam (5.9, LOD <0.02 µg/mL), mirtazapine (4.4, LOD <0.02 µg/mL), mizolastine (5.5, LOD 0.01 µg/mL), moclobemide (3.7, LOD 0.05 µg/mL), molindone (4.0, LOD <0.02 µg/mL), monoacetylmorphine (2.7, LOD 0.1 µg/mL), morphine (2.0, LOD 0.1 µg/mL), nicotine (2.2, LOD 0.05 µg/mL), nifedipine (7.5, LOD 0.02 µg/mL), nikethamide (3.6, LOD <0.02 µg/mL), nitrazepam (6.5, LOD <0.02 µg/mL), nizatidine (1.7, LOD 1 µg/mL), nomifensine (4.6, LOD <0.02 µg/mL), nortriptyline (6.4, LOD <0.02 µg/mL), norverapamil (6.2, LOD 1 µg/mL), noscapine (5.0, LOD <0.02 µg/mL), olanzapine (3.0, LOD 0.05 µg/mL), ondansetron (4.6, LOD <0.02 µg/mL), orphenadrine (6.1, LOD <0.02 µg/mL), oxazepam (6.3, LOD <0.02 µg/mL), oxcarbazepine (5.3, LOD 0.02 µg/mL), oxprenolol (4.7, LOD 0.02 µg/mL), oxycodone (2.8, LOD 0.05 µg/mL), papaverine (4.8, LOD <0.02 µg/mL), paroxetine (6.2, LOD 0.02 µg/mL), pemoline (3.3, LOD 0.05 µg/mL), pentazocine (5.0, LOD <0.02 µg/mL), pentifylline (7.3, LOD <5 µg/mL), pentoxyverine (6.6, LOD <0.02 µg/mL), perphenazine (6.9, LOD 0.002 µg/mL), phenazone (3.9, LOD 0.05 µg/mL), phencyclidine (5.3, LOD 0.05 µg/mL), pheniramine (4.1, LOD 0.02 µg/mL), phenylbutazone (9.0, LOD <5 µg/mL), phenylpropanolamine (2.5, LOD 0.3 µg/mL), phenytoin (6.1, Tetrahydrozoline 625 LOD 0.05 µg/mL), pindolol (3.3, LOD 0.05 µg/mL), piroxicam (6.6, LOD 0.02 µg/mL), pitofenone (5.4, LOD <0.02 µg/mL), pizotifen (6.5, LOD <0.02 µg/mL), practolol (1.8, LOD 0.1 µg/mL), prazosin (4.1, LOD 0.05 µg/mL), prilocaine (3.8, LOD <0.02 µg/mL), primidone (4.0, LOD <5 µg/mL), procainamide (2.2, LOD 0.05 µg/mL), prochlorperazine (7.5, LOD 0.02 µg/mL), promazine (6.2, LOD <0.02 µg/mL), promethazine (6.0, LOD 0.05 µg/mL), propafenone (6.3, LOD <0.02 µg/mL), propranolol (5.4, LOD 0.02 µg/mL), propyphenazone (6.6, LOD 0.50 µg/mL), pseudoephedrine (2.6, LOD 1 µg/mL), quinine (4.2, LOD 0.02 µg/mL), ranitidine (1.8, LOD 0.1 µg/mL), risperidone (4.9, LOD <0.02 µg/mL), rocurone (3.8, LOD 0.1 µg/mL), ropivacaine (4.6, LOD <0.02 µg/mL), salicylamide (4.2, LOD <5 µg/mL), selegiline (4.1, LOD 0.05 µg/mL), sertindole (7.2, LOD <0.02 µg/mL), sertraline (6.8, LOD 0.02 µg/mL), sulindac (6.5, LOD 0.02 µg/mL), simazine (6.0, LOD 0.1 µg/mL), sincocaine (6.5, LOD <0.02 µg/mL), sisapride (5.9, LOD <0.02 µg/mL), sotalol (2.1, LOD 0.1 µg/mL), strychnine (5.3, LOD 0.05 µg/mL), sulpiride (1.9, LOD 0.1 µg/mL), sulthiame (4.1, LOD 0.05 µg/mL), temazepam (7.2, LOD <0.02 µg/mL), terbutaline (2.3, LOD 0.1 µg/mL), terfenadine (8.1, LOD 0.002 µg/mL), terodiline (6.7, LOD <0.02 µg/mL), tetracaine (5.7, LOD <0.02 µg/mL), theobromine (2.3, LOD <5 µg/mL), theophylline (2.4, LOD <5 µg/mL), thioridazine (7.5, LOD 0.02 µg/mL), timolol (3.8, LOD 0.05 µg/mL), thiothixene (6.7, LOD 0.02 µg/mL), tolbutamide (7.1, LOD <5 µg/mL), toremifene (8.7, LOD 0.02 µg/mL), tramadol (4.2, LOD 0.02 µg/mL), trazodone (5.2, LOD <0.02 µg/mL), triamterene (3.2, LOD 0.1 µg/mL), triazolam (6.7, LOD 0.002 µg/mL), trimeprazine (6.4, LOD <0.02 µg/mL), trimethoprim (3.1, LOD 0.05 µg/mL), trimipramine (6.7, LOD <0.02 µg/mL), venlafaxine (4.9, LOD 0.02 µg/mL), verapamil (6.5, LOD <0.02 µg/mL), warfarin (7.9, LOD <0.02 µg/mL), yohimbine (4.5, LOD <0.02 µg/mL), zolpidem (4.7, LOD <0.02 µg/mL), zopiclone (4.0, LOD 0.1 µg/mL) KEY WORDS whole blood REFERENCE Gergov, M.; Ojanperä, I.; Vuori, E. Simultaneous screening for 238 drugs in blood by liquid chromatography-ionspray tandem mass spectrometry with multiple-reaction monitoring, J.Chromatogr.B, 2003, 795, 41–53. 626 Thalidomide Thalidomide O N O Molecular formula: C13 H10 N2 O4 Molecular weight: 258.23 CAS Registry No: 50-35-1 Merck Index: 13, 9326 N O O H SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg C18 SPE cartridge (Varian) with 1 column vol of MeOH and one column volume of water. Vortex 1 mL 25 mM pH 2.5 phosphate buffer with 1 mL plasma, add 100 µL 100 µg/mL labetalol in MeOH, vortex, add to the SPE cartridge, wash with 2 column vol of water, dry under vacuum, elute with 1 mL anhydrous diethyl ether, evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with 130 µL mobile phase, inject a 50 µL aliquot. HPLC VARIABLES Guard column: Bioptic AV-1 (Meta Chem Technologies, Torrance CA) Column: 150 × 4.5 Bioptic AV-1 (Meta Chem Technologies, Torrance CA) Mobile phase: Isopropanol:100 mM pH 4 phosphate buffer 2:98 Flow rate: 0.6 Injection volume: 50 Detector: UV 300 CHROMATOGRAM Retention time: 8.4 (S-(−)), 10.5 (R-(+)) Internal standard: labetalol (6.7) Limit of detection: 50 ng/mL Limit of quantitation: 100 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS chiral; plasma; SPE REFERENCE Haque, A.; Stewart, J.T. Determination of racemic thalidomide in human plasma by use of an avidin column and solid phase extraction, J.Liq.Chromatogr.Rel.Technol., 1998, 21, 2151–2163. SAMPLE Matrix: blood Sample preparation: Mix 500 µL serum with 20 µL 250 µg/mL IS in MeOH, add 500 µL 10% trichloroacetic acid solution with constant vortexing for 30 s, centrifuge at 2700 g for 5 min, inject a 20 µL aliquot. HPLC VARIABLES Guard column: 20 × 4.6 Discovery C18 (Supelco) Column: 125 × 4.6 5 µm Discovery C18 (Supelco) Mobile phase: MeOH:buffer 75:25 (The buffer was 10 mM potassium dihydrogen phosphate adjusted to pH 3.0 with 43% phosphoric acid.) Flow rate: 1.5 Injection volume: 20 Detector: UV 220 Thalidomide 627 CHROMATOGRAM Retention time: 7.9 Internal standard: phenacetin (15.0) Limit of quantitation: 222 ng/mL OTHER SUBSTANCES Simultaneous: clofazimine (8.3), dapsone (3.5), indinavir (4.0), isoniazid (2.1), lamivudine (2.2), nevirapine (15.0), rifampin (2.5), saquinavir (2.5), stavudine (2.1), trimethoprim (4.8), ritonavir (2.2), zidovudine (4.0) Noninterfering: cyclosporine, rifabutin, sulfamethoxazole, prednisolone KEY WORDS pharmacokinetics; serum REFERENCE Toraño, J.S.; Verbon, A.; Guchelaar, H.-J. Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection, J.Chromatogr.B, 1999, 734, 203–210. ANNOTATED BIBLIOGRAPHY Boughton, B.J.; Sheehan, T.M.; Wood, J.; O’Brien, D.; Butler, M.; Simpson, A.; Hale, K.A. High-performance liquid chromatographic assay of plasma thalidomide: stabilization of specimens and determination of a tentative therapeutic range for chronic graft-versus-host disease, Ann.Clin.Biochem., 1995, 32, 79–83. Delon, A.; Favreliere, S.; Couet, W.; Courtois, P.; Bouquet, S. Rapid and sensitive determination of thalidomide in human plasma by high- performance liquid chromatography, J.Liq.Chromatogr., 1995, 18, 297–309. [SPE; pharmacokinetics; ciprofloxacin is internal standard; LOQ 62.5 ng/mL; simultaneous acyclovir, flucytosine, metronidazole, azathioprine, ceftazidime, cefotaxime; non-interfering cyclosporine, cyclophosphamide, prednisolone, hydroxyzine, nifedipine, diltiazem, amphotericin, clonazepam, clobazam, diazepam] Eriksson, T.; Bjorkman, S.; Fyge, A.; Ekberg, H. Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation, J.Chromatogr., 1992, 582, 211–216. Eriksson, T.; Bjorkman, S.; Roth, B.; Fyge, A.; Hoglund, P. Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis, Chirality, 1998, 10, 223–228. [chiral] Haque, A.; Stewart, J.T. Determination of racemic thalidomide in human plasma by use of an avidin column and solid phase extraction (Abstract 4163), Pharm.Res., 1997, 14, S684–S685. Huupponen, R.; Pykkö, K. Stability of thalidomide in human plasma, Clin.Chem., 1995, 41, 1199. Teo, S.K.; Chandula, R.S.; Harden, J.L.; Stirling, D.I.; Thomas, S.D. Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry, J.Chromatogr.B, 2002, 767, 145–151. [LOQ 2 ng/mL] 628 Thialbarbital Thialbarbital H O N Molecular formula: C13 H16 N2 O2 S Molecular weight: 264.35 CAS Registry No: 467-36-7 Merck Index: 13, 9363 S N H O H2C SAMPLE Matrix: solutions HPLC VARIABLES Column: 150 × 2 Chiralcel OJ-R Mobile phase: MeCN:water 30:70 Flow rate: 0.2 Injection volume: 8 Detector: UV 235 CHROMATOGRAM Retention time: 21, 27 (enantiomers) KEY WORDS chiral REFERENCE Aboul-Enein, H.Y.; Schmid, M.G.; Tuscher, C.; Gübitz, G.; Laffranchini, M.; Bojarski, J. Chiral separation of several thiobarbiturates on a cellulose tris(4-methylbenzoate) phase under reversed-phase conditions, J.Liq.Chromatogr.Rel.Technol., 2001, 24, 69–77. Thyrotropin 629 Thyrotropin Molecular formula: C1039 H1602 N274 O307 S27 Molecular weight: 23709.28 CAS Registry No: 9002-71-5 Merck Index: 13, 9870 SAMPLE Matrix: solutions HPLC VARIABLES Guard column: Vydac 214 FSK 54 Column: 250 × 4.6 5 µm C4 Vydac 214 TP 54 Column temperature: 25 Mobile phase: Gradient. A was 50 mM pH 7.0 phosphate buffer. B was MeCN:50 mM pH 7.0 phosphate buffer 50:50. A:B from 75:25 to 0:100 over 40 min. (Place a silica column packed with 7.9–12.4 µm LiChrosorb Si-60 silica between pump and injector.) Flow rate: 0.5 Injection volume: 5–200 Detector: UV 280 CHROMATOGRAM Retention time: 33–36 Limit of detection: 200 ng REFERENCE Ezequiel de Oliveira, J.; de Mendonça, F.; Peroni, C.N.; Bartolini, P.; Ribela, M.T.C.P. Determination of Chinese hamster ovary cell-derived recombinant thyrotropin by reversed-phase liquid chromatography, J.Chromatogr.B, 2003, 787, 345–355. SAMPLE Matrix: solutions HPLC VARIABLES Guard column: 75 × 7.5 SW Column: 600 × 7.5 10 µm G2000 SW Mobile phase: 20 mM pH 7.0 phosphate buffer containing 150 mM NaCl Flow rate: 1 Injection volume: 5–50 Detector: UV 280 (?) CHROMATOGRAM Retention time: 17 REFERENCE Ezequiel de Oliveira, J.; de Mendonça, F.; Peroni, C.N.; Bartolini, P.; Ribela, M.T.C.P. Determination of Chinese hamster ovary cell-derived recombinant thyrotropin by reversed-phase liquid chromatography, J.Chromatogr.B, 2003, 787, 345–355. 630 Tiagabine Tiagabine Molecular formula: C20 H25 NO2 S2 Molecular weight: 375.56 CAS Registry No: 115103-54-3, 145821-59-6 (HCl) Merck Index: 13, 9493 H3C S N S COOH CH3 SAMPLE Matrix: blood Sample preparation: Condition a 3 mL Bond Elut C8 SPE cartridge with 5 mL MeOH and 2 mL water. Mix 1 mL plasma with 200 µL water and 200 µL 1 µg/mL IS in MeOH:water 50:50, centrifuge at 1000 g for 15 min, add the supernatant to the SPE cartridge, wash with 2 mL water, wash with 2 mL MeOH:water 5:95, elute with 1 mL MeOH. Evaporate the eluate to dryness under a stream of air at 40◦ , reconstitute the residue with 200 µL mobile phase, inject a 50–60 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Ultrasphere ODS C18 Mobile phase: MeCN:MeOH:water 37:10:53 containing 10 mM sodium dihydrogen phosphate and 5 mM sodium octanesulfonate Flow rate: 1.2 Injection volume: 50–60 Detector: E, Environmental Sciences Coulochem Model 5100A, porous graphite electrode – 0.50 V (screen), porous graphite electrode +0.76 V (monitored), guard cell +0.95 V (before injector) CHROMATOGRAM Retention time: 16 Internal standard: (R)-N-(4-(3-methyl-2-thienyl)-4-(2-thienyl)but-3-enyl)nipecotic acid (12) Limit of quantitation: 2 ng/mL KEY WORDS plasma; SPE REFERENCE Gustavson, L.E.; Chu, S.Y. High-performance liquid chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection, J.Chromatogr., 1992, 574, 313–318. 631 Tiletamine hydrochloride Tiletamine hydrochloride Molecular formula: C12 H17 NOS.HCl Molecular weight: 259.80 CAS Registry No: 14176-50-2 O HCl S N H CH3 SAMPLE Matrix: blood, tissue Sample preparation: Add IS to serum or tissue, make alkaline with pH 9.5 borate buffer, extract with ethyl acetate. Extract the organic layer with 1 mL 100 mM HCl. Basify the aqueous layer with 100 mg sodium borate, extract with ethyl acetate. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with MeCN:water 25:75 (serum) or mobile phase (tissue), inject a 70 µL aliquot. HPLC VARIABLES Column: 250 × 4 5 µm LiChrospher 60 RP-select B C8 Mobile phase: MeCN:50 mM pH 6.8 phosphate buffer 26:74 Flow rate: 1 Injection volume: 70 Detector: UV 233 CHROMATOGRAM Retention time: 18.9 Internal standard: pindolol (9.7) Limit of quantitation: 10 ng/mL OTHER SUBSTANCES Extracted: zolazepam (LOQ 2 ng/mL) (12.5) KEY WORDS bear; muscle; serum REFERENCE Semple, H.A.; Gorecki, D.K.J.; Farley, S.D.; Ramsay, M.A. Pharmacokinetics and tissue residues of Telazol in free-ranging polar bears, J.Wildlife Dis., 2000, 36, 653–662. SAMPLE Matrix: blood, urine Sample preparation: Mix 1 mL pH 7 buffer with 5 mL whole blood or urine, add 1 µg IS1, add 6 µg IS2, add 7 mL hexane:toluene:isoamyl alcohol 90:5:5, vortex, centrifuge, remove the organic layer. Add 1 mL pH 9.5 buffer to the aqueous layer, extract with 6 mL hexane:isoamyl alcohol 99:1. Combine the organic layers, evaporate to dryness under a stream of nitrogen, reconstitute the residue with 250 µL MeCN:water:trifluoroacetic acid 45:55:0.05, evaporate to half volume to remove MeCN, inject a 50 µL aliquot. HPLC VARIABLES Guard column: 5 µm Altima C18 Column: 20 × 2.1 5 µm Altima C18 Column temperature: 40 Mobile phase: Gradient. A was MeCN:water:trifluoroacetic acid 10:90:0.05. B was MeCN:water:trifluoroacetic acid 80:20:0.05. A:B 100:0 for 5 min, to 0:100 over 50 min, re-equilibrate at initial conditions for 15 min. 632 Tiletamine hydrochloride Flow rate: 0.25 Injection volume: 50 Detector: MS, HP 5989B, electron impact; UV 205; UV 290 CHROMATOGRAM Internal standard: SKF-525 A (IS1), 5-ethyl-5-p-tolylbarbituric acid (IS2) OTHER SUBSTANCES Extracted: zolazepam KEY WORDS whole blood REFERENCE Cording, C.J.; Deluca, R.; Camporese, T.; Spratt, E. A fatality related to the veterinary anesthetic Telazol, J.Anal.Toxicol., 1999, 23, 552–555. SAMPLE Matrix: tissue Sample preparation: Homogenize 1.5 g tissue with 300 µL 1 µg/mL IS in water and 6 mL 500 mM pH 9.5 sodium borate buffer, add 10 mL ethyl acetate, vortex for 20 min, repeat the extraction. Combine the organic layers and extract twice with 2 mL portions of 100 mM HCl. Combine the aqueous layers and make basic with 200 mg sodium borate, extract with 12 mL ethyl acetate. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 200 µL MeCN:water 20:80, inject a 70 µL aliquot. HPLC VARIABLES Column: 250 × 4 5 µm LiChrospher 60 RP-select B C8 Mobile phase: MeCN:50 mM pH 5.5 sodium phosphate buffer 16:84 Flow rate: 1 Injection volume: 70 Detector: UV 233 CHROMATOGRAM Retention time: 45 Internal standard: ripazapam (51.5) OTHER SUBSTANCES Extracted: tiletamine metabolite CI-398 (23.5), zolazepam (58), zolazepam metabolites KEY WORDS bear; fat; kidney; muscle REFERENCE Semple, H.A.; Gorecki, D.K.J.; Farley, S.D.; Ramsay, M.A. Pharmacokinetics and tissue residues of Telazol in free-ranging polar bears, J.Wildlife Dis., 2000, 36, 653–662. 633 Tilmicosin Tilmicosin O Molecular formula: C46 H80 N2 O13 Molecular weight: 869.13 CAS Registry No: 108050-54-0 Merck Index: 13, 9516 CH3 CH3 H3C H3C HO CH3 O O OCH3 H3C H3C O OCH3 O OH HO O O N CH3 OH CH3 CH3 SAMPLE Matrix: blood Sample preparation: Condition a 500 mg Bond Elut C18 SPE cartridge with MeOH and water. Add 2 mL serum to the SPE cartridge, wash with water, wash with 5% ammonium hydroxide, wash with water, elute with 2 mL MeOH:acetic acid 5:95. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with 1 mL diluent, inject an aliquot. (The diluent was MeOH:water:1 M dibutylammonium phosphate 50:47.5:2.5.) HPLC VARIABLES Column: 250 × 4.6 5 µm Hi-Chrom Reversible phenyl (Regis) Mobile phase: Gradient. A was MeCN:water 50:50 adjusted to pH 2.5 with orthophosphoric acid. B was water adjusted to pH 2.5 with orthophosphoric acid. C was 168 mL dibutylamine in 700 mL water, adjust to pH 2.5 with orthophosphoric acid, make up to 1 L with water. A:B:C 100:0:0 for 3 min, to 55:30:15 over 1 min, maintain at 55:30:15 for 7 min, return to initial conditions over 1 min, re-equilibrate for 8 min. Flow rate: 1.5 Injection volume: 50 Detector: UV 280 CHROMATOGRAM Retention time: 11 Limit of detection: 2.6 ng/mL Limit of quantitation: 50 mg/mL KEY WORDS cow; pharmacokinetics; serum; sheep REFERENCE Modric, S.; Webb, A.I.; Derendorf, H. Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle, J.vet.Pharmacol.Therap., 1998, 21, 444–452. 634 Tiludronic acid Tiludronic acid Molecular formula: C7 H9 ClO6 P2 S O OH P Cl S Molecular weight: 318.61 CAS Registry No: 89987-06-4, 149845-07-8 (Na salt), 155453-10-4 (Na salt hemihydrate) Merck Index: 13, 9518 P O OH OH OH SAMPLE Matrix: blood, urine Sample preparation: Mix 200 µL plasma or urine with 400 µL 5 µg/mL IS in water, add 100 µL 1 M NaOH, add 100 µL 180 mM calcium chloride, add 1 mL water, vortex, centrifuge at 11 600 g. Discard the liquid phase and dissolve the residue in 100 µL 1 M HCl, add 200 µL 1 M NaOH, add 100 µL 180 mM calcium chloride (only for plasma samples), add 1 mL water, vortex, centrifuge at 11 600 g. Discard the liquid phase and vortex the residue with 200 µL mobile phase containing 100 mM disodium EDTA until dissolution is complete, inject a 20–100 µL aliquot. HPLC VARIABLES Column: 150 × 4.1 5 µm PRP-1 (Hamilton) Column temperature: 22 Mobile phase: MeCN:buffer 13:87 (The buffer was 50 mM pH 11.8 disodium hydrogen phosphate containing 5 mM tetrabutylammonium phosphate.) Flow rate: 1 Injection volume: 20–100 Detector: UV 280 CHROMATOGRAM Retention time: 3 Internal standard: (3-trifluoromethyl)-thiomethylene bisphosphonic acid (4) Limit of quantitation: 50 ng/mL KEY WORDS baboon; human; monkey; mouse; plasma REFERENCE Fels, J.-P.; Guyonnet, J.; Berger, Y.; Cautreels, W. Determination of (4-chlorophenyl)thiomethylene bisphosphonic acid, a new bisphosphonate, in biological fluids by high-performance liquid chromatography, J.Chromatogr., 1988, 430, 73–79. 635 Tirilazad Tirilazad O CH3 N H3C Molecular formula: C38 H52 N6 O2 Molecular weight: 624.86 CAS Registry No: 110101-66-1 Merck Index: 13, 9540 N H N N CH3 N H O N SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg Bond Elut C18 SPE cartridge with 2 mL MeOH and 2 mL water. Vortex 500 µL plasma with 500 µL 5 µg/mL IS in MeCN for 1 min, centrifuge at 1500 g at 4◦ , add 800 µL of the supernatant to the SPE cartridge, wash with two 1 mL portions of MeCN:water 50:50, elute with two 1 mL portions of MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 350 µL MeCN, vortex for 1 min, dilute with 150 µL water, inject an aliquot. HPLC VARIABLES Guard column: 15 × 3.2 7 µm NewGuard RP-8 (Brownlee) Column: 250 × 4.6 5 µm Suplecosil LC-8 Mobile phase: MeCN:buffer 75:25 (The buffer was 22 mM triethylamine adjusted to pH 5.0 with glacial acetic acid.) Flow rate: 1 Injection volume: 100 Detector: UV 254 CHROMATOGRAM Retention time: 10.5 Internal standard: 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-3α-hydroxy-16α-methyl-5α-pregna-20-one (16) Limit of quantitation: 12 ng/mL (S/N 10) KEY WORDS plasma; rat REFERENCE Cox, J.W.; Pullen, R.H. High-performance liquid chromatographic determination of a 21-aminosteroid antioxidant in plasma, J.Chromatogr., 1988, 424, 293–302. SAMPLE Matrix: blood Sample preparation: Add 150 µL water and 300 µL IS in MeCN to 100 µL plasma, centrifuge, add 450 µL of the supernatant to a conditioned (unspecified) Advanced Automated Sample Processor C8 SPE cartridge containing 0.5 mL water (?), wash with 500 µL MeCN:water 25:75, elute the contents directly onto column A in series with column B using mobile phase, remove column A from the circuit, continue to elute column B with mobile phase, monitor the effluent from column B. HPLC VARIABLES Column: A 15 × 3.2 7 µm Brownlee New Guard C18; B 250 × 4.6 Supelco LC8 Mobile phase: MeCN:water:triethylamine:acetic acid 80:20:0.1:0.2 Flow rate: 1.5 Detector: UV 254 636 Tirilazad CHROMATOGRAM Retention time: 8 Internal standard: (16α)-21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16methylpregna-3-ol-20-one (PNU-76824) (15) Limit of quantitation: 5.4 ng/mL KEY WORDS column-switching; pharmacokinetics; plasma; rat REFERENCE Wang, Y.; Mesfin, G.-M.; Rodriguez, C.A.; Slater, J.G.; Schuette, M.R.; Cory, A.L.; Higgins, M.J. Venous irritation, pharmacokinetics, and tissue distribution of tirilazad in rats following intravenous administration of a novel supersaturated submicron lipid emulsion, Pharm.Res., 1999, 16, 930–938. SAMPLE Matrix: microsomal incubations Sample preparation: Vortex 500 µL microsomal incubation with 500 µL MeCN for 20 s, centrifuge at 2100 g at 4◦ for 25 min, inject an aliquot of the supernatant. HPLC VARIABLES Column: 250 × 4.6 5 µm Kromasil C18 Mobile phase: Gradient. MeCN:100 mM ammonium acetate from 10:90 to 100:0 in 60 min, maintain at 100:0 for 40 min Flow rate: 0.5 Detector: MS, Finnigan 4021 quadrupole, thermal pneumatic nebulizer with momentum separator, positive ion CI mode with ammonia as moderating gas, tip 180◦ , expansion region 80◦ , helium 150 psi with a 360 × 75 µm fused silica capillary; Radioactivity (14 C) CHROMATOGRAM Retention time: 80 OTHER SUBSTANCES Extracted: metabolites KEY WORDS human; liver REFERENCE Wienkers, L.C.; Steenwyk, R.C.; Sanders, P.E.; Pearson, P.G. Biotransformation of tirilazad in human: 1. Cytochrome P450 3A-mediated hydroxylation of tirilazad mesylate in human liver microsomes, J.Pharmacol.Exp.Ther., 1996, 277, 982–990. ANNOTATED BIBLIOGRAPHY Cox, J.W.; Pullen, R.H. Irregular retention properties of 21-aminosteroid antioxidants in octylsilane bonded-phase high-performance liquid chromatography, J.Chromatogr., 1988, 424, 285–292. Fleishaker, J.C.; Straw, R.N.; Cross, C.J. Pharmacokinetics of tirilazad and U-89678, an active, reduced metabolite, following acute head trauma in adults, J.Pharm.Sci., 1997, 86, 434–437. [LOQ 5 ng/mL] Hoerle, S.L.; Snider, B.G. Determination of degradation products occurring in acidic solutions of a 21-aminosteroid (tirilazad) using a gradient HPLC method, J.Liq.Chromatogr., 1995, 18, 3269–3282. Wienkers, L.C.; Steenwyk, R.C.; Mizsak, S.A.; Pearson, P.G. In vitro metabolism of tirilazad mesylate in male and female rats. Contribution of cytochrome P4502C11 and 4 -5α-reductase, Drug Metab.Dispos., 1995, 23, 383–392. Tirofiban Tirofiban COOH H Molecular formula: C22 H36 N2 O5 S 637 N O N H Molecular weight: 440.60 CAS Registry No: 144494-65-5, 150915-40-5 (HCl monohydrate) Merck Index: 13, 9541 S O CH3 O SAMPLE Matrix: blood Sample preparation: Vortex 500 µL plasma with 50 µL 100 ng/mL IS and 500 µL 100 mM perchloric acid briefly, add 5 mL 1-chlorobutane, shake for 10 min, centrifuge, extract the aqueous layer twice more with 5 mL portions of ethyl acetate. Combine the organic layers and evaporate them to dryness under a stream of nitrogen at 40◦ , reconstitute the residue with 250 µL EtOH:toluene 50:50, evaporate to dryness under a stream of nitrogen at 40◦ , add 400 µL 10 mM dimethylaminopyridine in MeCN, add 40 µL trifluoroacetic anhydride, heat at 40◦ for 30 min, remove excess reagents with a stream of nitrogen, reconstitute the residue with 150 µL mobile phase, inject a 25 µL aliquot. HPLC VARIABLES Column: 250 × 4.6 5 µm Zorbax RX-C18 Mobile phase: MeCN:1 mM ammonium acetate 41.5:58.5, pH 6.0 Injection volume: 25 Detector: MS, Sciex Model API-III triple-quadrupole, API, negative ion mode, orifice potential – 60 V, electron multiplier +4.4 kV, interface 50◦ , nebulizer 500◦ , nebulizer air 1 L/min, curtain gas 700 mL/min, m/z 535 CHROMATOGRAM Retention time: 5.2 Internal standard: N-phenylsulfonyl-O-[4-(butane-4-piperidinyl]-L-tyrosine (L-702, 128) (5.1) Limit of quantitation: 400 pg/mL KEY WORDS derivatization; pharmacokinetics; plasma REFERENCE Ellis, J.D.; Hand, E.L.; Gilbert, J.D. Use of LC-MS/MS to cross-validate a radioimmunoassay for the fibrinogen receptor antagonist, Aggrastat (tirofiban hydrochloride) in human plasma, J. Pharm. Biomed. Anal., 1997, 15, 561–569. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 5 µm Symmetry C18 (Waters) Column temperature: 40 Mobile phase: MeCN:10 mM pH 2.3 potassium phosphate buffer 22:78 Flow rate: 1.5 Injection volume: 50 Detector: UV 227 638 Tirofiban KEY WORDS stability-indicating REFERENCE Bergquist, P.A.; Manas, D.; Hunke, W.A.; Reed, R.A. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs, Amer.J.Health-Syst.Pharm., 2001, 58, 1218–1223. ANNOTATED BIBLIOGRAPHY Bergquist, P.A.; Zimmerman, J.; Kenney, R.R.; Han, R.Y.-H.; Hunke, W.A. Stability of tirofiban hydrochloride in three commonly used i.v. solutions and polyvinyl chloride administration sets, Am.J.HealthSyst.Pharm., 1999, 56, 1627–1629. [stability-indicating] Garabito, M.J.; Jimenez, L.; Bautista, F.J.; Santos-Rubio, M.D.; Perez-Rodrigo, I. Stability of tirofiban hydrochloride in 0.9% sodium chloride injection for 30 days, Am.J.Health-Syst.Pharm., 2001, 58, 1850–1851. [stability-indicating] Vickers, S.; Theoharides, A.D.; Arison, B.; Balani, S.K.; Cui, D.; Duncan, C.A.; Ellis, J.D.; Gorham, L.M.; Polsky, S.L.; Prueksaritanont, T.; Ramjit, H.G.; Slaughter, D.E.; Vyas, K.P. In vitro and in vivo studies on the metabolism of tirofiban, Drug Metab.Dispos., 1999, 27, 1360–1366. [rat; dog; bile; urine; feces; radiolabeled; metabolites] 639 Tiropramide Tiropramide Molecular formula: C28 H41 N3 O3 Molecular weight: 467.64 CAS Registry No: 55837-29-1, 53567-47-8 (HCl) Merck Index: 13, 9543 O H3C H3C N H N O O N CH3 CH3 SAMPLE Matrix: blood Sample preparation: Filter (0.22 µm PVDF) plasma, inject a 100 µL aliquot onto column A and elute to waste with mobile phase A at 0.5 mL/min; after 4.5 min, direct the effluent from column A onto column B and then to waste (continue to use mobile phase A); after another 3 min, backflush the contents of column B onto column C with mobile phase B at 0.1 mL/min, monitor the effluent from column C for 10.5 min. HPLC VARIABLES Column: A 20 × 4 5 µm Capcell Pak MF Ph-1 polymer-coated mixed function (change after 35 samples); B 35 × 2 5 µm Capcell Pak C18 UG 120; C 250 × 1.5 Capcell Pak C18 UG 120 Column temperature: 30 (columns A and C only) Mobile phase: A MeCN:50 mM pH 7.0 potassium phosphate buffer 12:88; B MeCN:10 mM pH 7.0 potassium phosphate buffer 50:50 Flow rate: A 0.5; B 0.1 Injection volume: 100 Detector: UV 230 CHROMATOGRAM Retention time: 14 Limit of quantitation: 5 ng/mL KEY WORDS column-switching; pharmacokinetics; plasma REFERENCE Baek, S.K.; Lee, S.S.; Park, E.J.; Sohn, D.H.; Lee, H.S. Semi-micro high-performance liquid chromatographic analysis of tiropramide in human plasma using column-switching, J.Pharm.Biomed.Anal., 2003, 31, 185–189. SAMPLE Matrix: blood Sample preparation: Mix 100 µL plasma with 10 µL 50 ng/mL IS in MeOH and 100 µL 50 µM NaOH, add 800 µL MTBE, vortex at high speed for 5 min, centrifuge at 5000 g for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen at 35◦ , reconstitute the residue with 40 µL MeCN:water 50:50, vortex for 2 min, inject a 10 µL aliquot. HPLC VARIABLES Column: 100 × 2 3 µm Luna C8 Column temperature: 30 Mobile phase: MeCN:10 mM pH 4.5 ammonium formate buffer 50:50 Flow rate: 0.2 Injection volume: 10 640 Tiropramide Detector: MS, Micromass Quattro LC, tandem quadrupole, positive ionization electrospray, ion source 120◦ , desolvation 250◦ , cone 42 V, collision energy 24 eV, collision gas argon, m/z 469–367 CHROMATOGRAM Retention time: 2.0 Internal standard: cisapride (cone 45 V, m/z 467–184) (1.9) Limit of quantitation: 2 ng/mL KEY WORDS pharmacokinetics; plasma REFERENCE Lee, H.W.; Ji, H.Y.; Kim, H.H.; Cho, H.-Y.; Lee, Y.-B.; Lee, H.S. Determination of tiropramide in human plasma by liquid chromatography-tandem mass spectrometry, J.Chromatogr.B, 2003, 796, 395–400. 641 Tizanidine Tizanidine N S N Cl Molecular formula: C9 H8 ClN5 S N Molecular weight: 253.72 CAS Registry No: 51322-75-9, 64461-82-1 (HCl) Merck Index: 13, 9561 N H N H SAMPLE Matrix: formulations Sample preparation: Weigh out ground tablets containing 2 mg tizanidine, add 20 mL mobile phase, sonicate for 5 min, make up to 50 mL with mobile phase, filter, discard first 10 mL filtrate. Dilute 2 mL of the subsequent filtrate to 10 mL with mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Column: 150 × 5 5 µm Hypersil CN Mobile phase: MeCN:MeOH:buffer 18:57:50 (Prepare the buffer by dissolving 2.5 mL 50 mM sodium 1-heptanesulfonate in water and 800 µL triethylamine in 800 mL water, adjust pH to 3.3 with glacial acetic acid, make up to 1 L with water.) Flow rate: 1 Injection volume: 20 Detector: UV 227 CHROMATOGRAM Retention time: 7 Limit of quantitation: 51 ng/mL OTHER SUBSTANCES Simultaneous: degradants, impurities KEY WORDS stability-indicating; tablets REFERENCE Qi, M.-L.; Wang, P.; Wang, L. Validated liquid chromatography method for assay of tizanidine in drug substance and formulated products, Anal.Chim.Acta, 2003, 478, 171–177. SAMPLE Matrix: solutions Sample preparation: Inject an aliquot of a 100 µg/mL solution in MeOH. HPLC VARIABLES Column: 150 × 4.6 5 µm JASCO-RP-C18 Column temperature: 50 Mobile phase: Carbon dioxide:MeOH:acetic acid 90.9:8.918:0.182 Flow rate: 1.5 Injection volume: 20 Detector: UV 235 CHROMATOGRAM Retention time: 8.81 Internal standard: guaifenesin (5.40) Limit of detection: 600 ng/mL 642 Tizanidine OTHER SUBSTANCES Simultaneous: baclofen (13.64), chlorzoxazone (3.03), methocarbamol (3.92) KEY WORDS outlet pressure 12.75 Mpa; SFC REFERENCE Bhoir, I.C.; Raman, B.; Sundaresan, M.; Bhagwat, A.M. Development of an isocratic SFC method for four centrally active muscle relaxant drugs, Anal.Lett., 1998, 31, 1533–1542. Tolcapone Tolcapone Molecular formula: C14 H11 NO5 Molecular weight: 273.24 CAS Registry No: 134308-13-7 Merck Index: 13, 9585 643 O HO HO CH3 NO2 SAMPLE Matrix: blood Sample preparation: Mix 200 µL plasma with 25 µL IS in MeCN, add 300 µL MeCN, let stand at 4◦ for 15 min, centrifuge for 5 min. Mix 100 µL of the supernatant with 100 µL 50 mM pH 2 sodium dihydrogen phosphate buffer, inject an 80 µL aliquot. HPLC VARIABLES Guard column: 10 × 4 5 µm Hypersil ODS Column: 125 × 4 5 µm Hypersil ODS Mobile phase: MeOH:THF:buffer 55:45:5 (Prepare the buffer by mixing 550 mL MeOH containing 11.5 g/L N-hexylmethylamine with 450 mL 50 mM sodium dihydrogen phosphate, adjust apparent pH to 2.1 with phosphoric acid, add 50 mL THF.) Flow rate: 1 Injection volume: 80 Detector: UV 270 CHROMATOGRAM Retention time: 7 Internal standard: 3-hydroxy-4-methoxy-4′ -methyl-5-nitrobenzophenone (10.5) Limit of quantitation: 50 ng/mL OTHER SUBSTANCES Extracted: 3-O-methyl metabolite (9) KEY WORDS dog; human; monkey; mouse; plasma; rat REFERENCE Heizmann, P.; Schmitt, M.; Leube, J.; Martin, H.; Saner, A. Determination of the catechol-O-methyltransferase inhibitor tolcapone and three of its metabolites in animal and human plasma and urine by reversed-phase high-performance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 1999, 730, 153–160. SAMPLE Matrix: urine Sample preparation: Mix 25 µL urine with 25 µL IS in MeCN and 200 µL MeCN:10% phosphoric acid 12.5:87.5, vortex, centrifuge, inject a 50 µL aliquot. HPLC VARIABLES Guard column: 10 × 4 3 µm Spherisorb ODS-1 Column: 125 × 4 3 µm Spherisorb ODS-1 Column temperature: 25 Mobile phase: MeCN:THF:50 mM sodium dihydrogen phosphate 17:13:70, adjusted to apparent pH 2.1 with phosphoric acid Flow rate: 1 Injection volume: 50 Detector: UV 270 644 Tolcapone CHROMATOGRAM Retention time: 18 Internal standard: 3-hydroxy-4-methoxy-4′ -methyl-5-nitrobenzophenone (27) Limit of quantitation: 200 ng/mL OTHER SUBSTANCES Extracted: 4′ -carboxylic acid metabolite (8), glucuronide metabolite (5), 3-O-methyl metabolite (22) REFERENCE Heizmann, P.; Schmitt, M.; Leube, J.; Martin, H.; Saner, A. Determination of the catechol-O-methyl transferase inhibitor tolcapone and three of its metabolites in animal and human plasma and urine by reversed-phase high-performance liquid chromatography with ultraviolet detection, J.Chromatogr.B, 1999, 730, 153–160. ANNOTATED BIBLIOGRAPHY Dingemanse, J.; Jorga, K.M.; Schmitt, M.; Gieschke, R.; Fotteler, B.; Zürcher, G.; Da Prada, M.; van Brummelen, P. Integrated pharmacokinetics and pharmacodynamics of the novel-O-methyltransferase inhibitor tolcapone during first administration to humans, Clin.Pharmacol.Ther., 1995, 57, 508–517. [LOQ 50 ng/mL] Lave, T.; Dupin, S.; Schmitt, M.; Kapps, M.; Meyer, J.; Morgenroth, B.; Chou, R.C.; Jaeck, D.; Coassolo, P. Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans, Xenobiotica, 1996, 26, 839–851. 645 Topiramate Topiramate Molecular formula: C12 H21 NO8 S Molecular weight: 339.36 CAS Registry No: 97240-79-4 Merck Index: 13, 9625 O O O S O H 3C H3C O O NH2 CH3 O O CH3 SAMPLE Matrix: blood, CSF Sample preparation: Vortex 200 µL plasma or CSF with 25 µL 20 µg/mL IS in MeCN:water 50:50 and 400 µL MeCN, centrifuge at 10 900 rpm for 5 min. Mix a 250 µL aliquot of the supernatant with 100 µL 0.1% formic acid, inject a 10 µL aliquot. HPLC VARIABLES Column: 50 × 2 3 µm Luna C18(2) Column temperature: 40 Mobile phase: MeOH:200 µM ammonium acetate:formic acid 40:60:0.1 Flow rate: 0.25 Injection volume: 10 Detector: MS, PE Sciex API 3000, nebulizer 375◦ , nebulizer gas nitrogen at 75 psi, corona needle – 3 mA, auxiliary gas nitrogen at 10 units, curtain gas nitrogen at 8 units, negative ion mode, collision gas nitrogen at 5 units, collision energy 60 eV, m/z 338.2–78.1 CHROMATOGRAM Retention time: 2.95 Internal standard: 1,2:3,4-bis-O-(1-methylethylidene-α-D-galactopyranose sulfamate) (collision energy 30 eV, m/z 338.2–96.1) (3.50) Limit of quantitation: 40 ng/mL KEY WORDS comparison with FPIA; plasma REFERENCE Christensen, J.; Hojskov, C.S.; Poulsen, J.H. Liquid chromatography tandem mass spectrometry assay for topiramate analysis in plasma and cerebrospinal fluid: Validation and comparison with fluorescencepolarization immunoassay, Ther.Drug Monit., 2002, 24, 658–664. SAMPLE Matrix: blood, urine Sample preparation: Plasma. Mix 500 µL plasma with 30 µL 100 µg/mL IS in MeOH, extract with 10 mL diethyl ether. Evaporate the organic layer to dryness, reconstitute the residue with 75 µL MeOH:10 mM ammonium acetate 50:50, inject a 10 µL aliquot. Urine. Mix 100 µL urine with 900 µL water and 30 µL 100 µg/mL IS in MeOH, extract with 10 mL diethyl ether. Evaporate the organic layer to dryness, reconstitute the residue with 150 µL MeOH:10 mM ammonium acetate 50:50, inject a 10 µL aliquot. HPLC VARIABLES Column: 100 × 2.1 3.5 µm Symmetry C18 (Waters) Mobile phase: Gradient. MeOH:10 mM ammonium acetate 5:95 for 2 min, to 50:50 over 4 min. Flow rate: 0.25 Injection volume: 10 646 Topiramate Detector: MS, Bruker Esquire-LC, electrospray, positive ion mode, nebulizer 20 psi, capillary 4300 V, drying gas 300◦ and 8 L/min, m/z 357 CHROMATOGRAM Retention time: 14 Internal standard: d12 -topiramate (m/z 369) Limit of quantitation: 625 ng/mL OTHER SUBSTANCES Extracted: metabolites KEY WORDS pharmacokinetics; plasma REFERENCE Britzi, M.; Soback, S.; Isoherranen, N.; Levy, R.H.; Perucca, E.; Doose, D.R.; Maryanoff, B.E.; Bialer, M. Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay, Ther.Drug Monit., 2003, 25, 314–322. ANNOTATED BIBLIOGRAPHY Christensen, J.; Hojskov, C.S.; Dam, M.; Poulsen, J.H. Plasma concentration of topiramate correlates with cerebrospinal fluid concentration, Ther.Drug Monit., 2001, 23, 529–535. Contin, M.; Riva, R.; Albani, F.; Baruzzi, A. Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma, J.Chromatogr.B, 2001, 761, 133–137. [LOQ 250 ng/mL] Duong, H.T.; Guh, H.Y.; Ko, C.Y.; Micheel, A.P.; Thakur, M.S. A HPLC assay for coating integrity of topiramate sprinkle formulation, J.Pharm.Biomed.Anal., 2002, 29, 69–74. [sprinkles; LOD 0.07%; refractive index detector] Langman, L.J.; Kaliciak, H.A.; Boone, S.A. Fatal acute topiramate toxicity, J.Anal.Toxicol., 2003, 27, 323–324. [topiramate; LC-MS; gabapentin; vigabatrin; droperidol is internal standard] 647 Topotecan Topotecan Molecular formula: C23 H23 N3 O5 CH3 N CH3 HO Molecular weight: 421.44 CAS Registry No: 123948-87-8, 119413-54-6 (HCl) Merck Index: 13, 9626 O N N O H3C OH O SAMPLE Matrix: blood Sample preparation: Vortex 200 µL plasma with 800 µL cold (dry ice) MeOH for 10 s, centrifuge at 7000 g for 2 min. Dilute 2 vol of supernatant with 1 vol of water (to measure lactone form) or 1.5% phosphoric acid (to measure total amount), inject a 20 µL aliquot. HPLC VARIABLES Guard column: 10 × 3 ChromGuard RP SS (Varian) Column: 150 × 3 3.5 µm SB-C18 (Agilent) Column temperature: 50 Mobile phase: MeOH:buffer 27:73 (The buffer was 75 mM potassium dihydrogen phosphate containing 0.2% triethylamine, adjusted to pH 6.5 with KOH.) Flow rate: 0.8 Injection volume: 20 Detector: F ex 376 em 530 CHROMATOGRAM Retention time: 13.7 Limit of quantitation: 250 pg/mL OTHER SUBSTANCES Extracted: N-desmethyltopotecan (LOQ 50 pg/mL) (7.6) KEY WORDS plasma REFERENCE Bai, F.; Kirstein, M.N.; Hanna, S.K.; Iacono, L.C.; Johnston, B.; Stewart, C.F. Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection, J.Chromatogr.B, 2003, 784, 225–232. SAMPLE Matrix: blood Sample preparation: Vortex 900 µL plasma with 100 µL buffer for 20 s. Add a 200 µL aliquot to 800 µL cold (–40◦ ) MeOH, vortex for 20 s, centrifuge for 2 min. Mix a 500 µL aliquot of the supernatant with 500 µL buffer, inject a 200 µL aliquot. (The buffer was 8 mM disodium hydrogen phosphate containing 1 mM potassium dihydrogen phosphate, 137 mM NaCl, and 3 mM KCl and was adjusted to pH 2.0 for lactone or pH 11.0 for carboxylate forms.) HPLC VARIABLES Guard column: Guard-Pak C18 NovaPak Column: 150 × 3.9 4 µm NovaPak C18 648 Topotecan Mobile phase: MeCN:buffer 12:88 (The buffer was 3% triethylamine adjusted to pH 5.5 with glacial acetic acid.) Flow rate: 1 Injection volume: 200 Detector: F (tunable) ex 390 em 520, F (filter) ex 350–470 em 510–650 CHROMATOGRAM Retention time: 2.5 (carboxylate), 5.2 (lactone) Limit of detection: 300 pg/mL (lactone, filter F), 260 pg/mL (lactone, tunable F), 150 pg/mL (carboxylate, filter F), 100 pg/mL (carboxylate, tunable F) Limit of quantitation: 750 pg/mL (lactone, filter F), 500 pg/mL (lactone, tunable F), 500 pg/mL (carboxylate, filter F), 250 pg/mL (carboxylate, tunable F) KEY WORDS plasma REFERENCE Warner, D.L.; Burke, T.G. Comparison of filter and tunable fluorescence detection for the HPLC simultaneous quantitation of lactone and carboxylate forms of topotecan in plasma, J.Liq.Chromatogr.Rel. Technol., 1997, 20, 1523–1537. ANNOTATED BIBLIOGRAPHY Beijnen, J.H.; Smith, B.R.; Keijer, W.J.; van Gijn, R.; ten Bokkel Huinink, W.W.; Vlasveld, L.T.; Rodenhuis, S.; Underberg, W.J. High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma, J.Pharm.Biomed.Anal., 1990, 8, 789–794. Boucaud, M.; Pinguet, F.; Poujol, S.; Astre, C.; Bressolle, F. Sensitive high performance liquid chromatographic fluorescence determination of topotecan in human plasma and parotid saliva, J.Liq.Chromatogr.Rel.Technol., 2000, 23, 2373–2390. [LOQ 50 pg/mL] Loos, W.J.; Stoter, G.; Verweij, J.; Schellens, J.H.M. Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine, J.Chromatogr.B, 1996, 678, 309–315. [LOQ 0.1 ng/mL; fluorescence detection] Loos, W.J.; van Zomeren, D.M.; Gelderblom, H.; Verweij, J.; Nooter, K.; Stoter, G.; Sparreboom, A. Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography, J.Chromatogr.B, 2002, 766, 99–105. [LOQ 200 pg/mL; fluorescence detection] Rosing, H.; Doyle, E.; Davies, B.E.; Beijnen, J.H. High-performance liquid chromatographic determination of the novel antitumour drug topotecan as the total of the lactone plus carboxylate forms in human plasma, J.Chromatogr.B, 1995, 668, 107–115. [LOQ 0.05 ng/mL; fluorescence detection] Rosing, H.; Doyle, E.; Beijnen, J.H. The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma, J.Pharm.Biomed.Anal., 1996, 15, 279–286. [LOQ 0.1 ng/mL; fluorescence detection] Rosing, H.; van Zomeren, D.M.; Doyle, E.; ten Bokkel Huinink, W.W.; Schellens, J.H.M.; Bult, A.; Beijnen, J.H. Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods, J.Chromatogr.B, 1999, 727, 191–203. [LOQ 100 pg/mL; fluorescence detection] 649 Tosufloxacin Tosufloxacin Molecular formula: C19 H15 F3 N4 O3 Molecular weight: 404.34 CAS Registry No: 100490-36-6. 104051-69-6 (HCl), 115964-29-9 (tosylate) Merck Index: 13, 9632 F H2N F N N N F COOH O SAMPLE Matrix: bile, blood, urine Sample preparation: Dilute urine 1:20. Dilute bile 1:10. Vortex 500 µL serum, diluted urine, or diluted bile with 3.2 mL dichloromethane, rotate at 20 rpm for 10 min, centrifuge at 1000 g for 10 min. Remove 3 mL of the lower organic phase and add it to 200 µL pH 2.5 acetic acid, rotate at 20 rpm for 10 min, centrifuge at 1000 g for 10 min, inject a 20 µL aliquot of the aqueous layer. HPLC VARIABLES Column: 150 × 4.6 5 µm Ultrasphere C18 Mobile phase: MeCN:buffer 18:82, pH adjusted to 2 with 14.6 M phosphoric acid (The buffer was 10 mM sodium dihydrogen phosphate containing 5 mM tetrabutylammonium bromide.) Flow rate: 2 Injection volume: 20 Detector: F ex 265 em 433 CHROMATOGRAM Retention time: 2 Limit of detection: 20 ng/mL (serum), 500 ng/mL (urine), 250 ng/mL (bile) OTHER SUBSTANCES Noninterfering: amikacin, aztreonam, carbamazepine, cephalosporins, ciprofloxacin, clavulanic acid, difloxacin, digitoxin, digoxin, fleroxacin, fosfomycin, furosemide, gentamicin, imipenem, lidocaine, netilmicin, norfloxacin, ofloxacin, pefloxacin, penicillins, phenobarbital, phenytoin, primidone, procainamide, quinidine, rifampin, salicylic acid, teicoplanin, theophylline, tobramycin, valproic acid, vancomycin KEY WORDS human; pig; serum REFERENCE Koechlin, C.; Jehl, F.; Linger, L.; Monteil, H. High-performance liquid chromatography for the determination of three new fluoroquinolones, fleroxacin, temafloxacin and A-64730, in biological fluids, J.Chromatogr., 1989, 491, 379–387. SAMPLE Matrix: wastewater Sample preparation: Condition a mixed-phase (C8 and benzenesulfonate) cationexchange SPE disc (Varian) with 2 mL MeOH and 2 mL water at pH 3. Adjust pH of wastewater to 3, pass 50–150 mL through the SPE disc at 1 mL/min, dry under vacuum for 5 min, elute with 2.5 mL 5% ammonia in MeOH:water 15:85. Neutralize the eluate with 500 µL 85% phosphoric acid, inject a 200 µL aliquot. 650 Tosufloxacin HPLC VARIABLES Guard column: 20 × 3 5 µm Discovery RP-AmideC16 (Supelco) Column: 250 × 3 5 µm Discovery RP-AmideC16 (Supelco) Column temperature: 50 Mobile phase: Gradient. MeCN:25 mM pH 2.4 orthophosphoric acid from 5:95 to 7:93 over 17 min, maintain at 7:93 for 5 min, to 17:83 over 13 min, to 85:15 (step gradient), maintain at 85:15 for 5 min, return to initial conditions over 2 min, re-equilibrate for 10 min. Flow rate: 0.7 Injection volume: 200 Detector: F ex 278 em 445 CHROMATOGRAM Retention time: 35 OTHER SUBSTANCES Extracted: ciprofloxacin (19.5), danofloxacin (23), difloxacin (28), enrofloxacin (22.5), fleroxacin (14), lomefloxacin (21), norfloxacin (18), ofloxacin (15.5), pipemidic acid (6), KEY WORDS SPE REFERENCE Golet, E.M.; Alder, A.C.; Hartmann, A.; Ternes, T.A.; Giger, W. Trace determination of fluoroquinolone antibacterial agents in urban wastewater by solid-phase extraction and liquid chromatography with fluorescence detection, Anal.Chem., 2001, 73, 3632–3638. ANNOTATED BIBLIOGRAPHY Lyon, D.J.; Cheung, S.W.; Chan, C.Y.; Cheng, A.F. Rapid HPLC assay of clinafloxacin, fleroxacin, levofloxacin, sparfloxacin and tosufloxacin, J.Antimicrob.Chemother., 1994, 34, 446–448. [in conjunction with Chan,C.Y.; Lam,A.W.; French,G.L. Rapid HPLC assay of fluoroquinolones in clinical specimens. J.Antimicrob.Chemother. 1989, 23, 597–604.] 651 Travoprost Travoprost CH3 Molecular formula: C26 H35 F3 O6 Molecular weight: 500.55 CAS Registry No: 157283-68-6 CH3 O H HO H OH O H H O H OH F F F SAMPLE Matrix: blood Sample preparation: Condition a SPEC 3 mL 15 mg MP1 nonpolar reversed-phase/ strong cation-exchange SPE Cartridge (Ansys) with 500 µL MeOH and 500 µL 40 mM formic acid. Mix 1 mL plasma with 50 µL 400 IU/mL rabbit liver esterase (Sigma) in buffered saline, heat at 37◦ for 45 min. (This hydrolyzes travoprost to the free acid.) Mix 1 mL plasma with 15 µL 20 ng/mL IS and 1 mL 100 mM formic acid, add to the SPE cartridge, rinse tube with 0.5–1 mL water, add rinse to the SPE cartridge, wash with 500 µL water, dry under vacuum, wash with two 500 µL portions of toluene:dichloromethane 60:40, dry under vacuum, elute with 600 µL toluene:methylformate 20:80. Evaporate the eluate to dryness under a stream of nitrogen at 30◦ , reconstitute the residue with 125 µL MeOH:water 50:50, inject a 35 µL aliquot. HPLC VARIABLES Column: 150 × 2 5 µm Phenomenex Columbus C18 Mobile phase: MeOH:5 mM pH 6.3 ammonium formate 70:30 Flow rate: 0.2 Injection volume: 35 Detector: MS, Micromass Quattro LC, electrospray, capillary 3.0 kV, sample cone 40 V, extraction cone 2 V, RF lens 0.3 V, source temperature 125◦ , drying gas 250◦ , MS1 parameters LM resolution 14, HM resolution 14, ion energy 1.2 V, entrance and exit set to 0 and 1, collision energy 30 eV, MS2 parameters LM resolution 15.0, HM resolution 15.0, ion energy 1.2 V, multiplier 650 V, nebulizing gas 75 L/h, drying gas 570 L/h, collision gas argon, m/z 457–161 CHROMATOGRAM Retention time: 5.3 (as travoprost free acid) Internal standard: AL-5848X (tetradeutero travoprost free acid) (m/z 461–161) Limit of quantitation: 10 pg/mL KEY WORDS plasma; SPE REFERENCE McCue, B.A.; Cason, M.M.; Curtis, M.A.; Faulkner, R.D.; Dahlin, D.C. Determination of travoprost and travoprost free acid in human plasma by electrospray HPLC/MS/MS, J.Pharm.Biomed.Anal., 2002, 28, 199–208. 652 Trenbolone Trenbolone CH3 OH H Molecular formula: C18 H22 O2 Molecular weight: 270.37 CAS Registry No: 10161-33-8, 10161-34-9 (acetate), 23454-33-3 (cyclohexylmethylcarbonate) Merck Index: 13, 9659 H O SAMPLE Matrix: blood Sample preparation: Serum. Condition a 3 mL Oasis HLB SPE cartridge with 3 mL MeOH and 3 mL water. Add 1 mL serum containing 100 ng IS to the SPE cartridge, wash with 3 mL water, elute with 2 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 45◦ , reconstitute the residue with 100 µL MeOH:water 50:50, inject a 5 µL aliquot. Urine. Condition a 360 mg Sep-Pak C18 SPE cartridge with 5 mL MeOH and 10 mL water. Adjust the pH of 5 mL urine containing 100 ng IS to 5.5 with acetate buffer, add 50 µL β-glucuronidase-aryl sulfatase (Type H-2 Helix Pomatia, Boehringer Mannheim), heat at 37◦ overnight, cool, add to the SPE cartridge, wash with 5 mL water, elute with 3 mL MeOH. Evaporate the eluate to dryness under a stream of nitrogen at 45◦ , reconstitute the residue with 100 µL MeOH:water 50:50, inject a 5 µL aliquot. HPLC VARIABLES Guard column: 4 × 2 Phenomenex C18 Column: 250 × 2.1 5 µm Hypersil C18 Mobile phase: MeOH:2.88 mM ammonium formate 65:35 Flow rate: 0.15 Injection volume: 5 Detector: MS, PE Sciex API 365, turbo ionspray, positive mode, source 4000 V, orifice 30 V, ring 250 V, nebulizer gas nitrogen at 8 units, curtain gas nitrogen at 8 units, collision gas nitrogen at 3 units, collision energy – 42 eV, vaporizer 450◦ , m/z 271.2–253.3–227.2–199.2 CHROMATOGRAM Retention time: 13.8 Internal standard: methyltestosterone (m/z 303.1–109.1–97.0) (22.9) Limit of detection: 350 pg/mL Limit of quantitation: 1 ng/mL KEY WORDS cow; serum; SPE REFERENCE Buiarelli, F.; Cartoni, G.P.; Coccioli, F.; De Rossi, A.; Neri, B. Determination of trenbolone and its metabolite in bovine fluids by liquid chromatography-tandem mass spectrometry, J.Chromatogr.B, 2003, 784, 1–15. Treprostinil Treprostinil Molecular formula: C23 H34 O5 Molecular weight: 390.51 CAS Registry No: 81846-19-7 H O 653 COOH HO H H HO H H CH3 SAMPLE Matrix: blood Sample preparation: Extract 1 mL plasma with hexane:ethyl acetate 70:30. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with MeOH:water:100 mM ammonium formate:formic acid 50:47.5:2.5:0.05, inject a 25 µL aliquot. HPLC VARIABLES Column: 100 × 2 Betasil C18 (Keystone) Mobile phase: MeCN:water:100 mM ammonium formate:formic acid 33.25:61.75:5:0.1 Flow rate: 0.3 Injection volume: 25 Detector: MS, PE Sciex API-III or API 365, ionspray, atmospheric pressure ionization, negative ionization CHROMATOGRAM Retention time: 2.5 Internal standard: LRXA-97 JO2 (a dimethylene homolog) (3.5) Limit of quantitation: 25 pg/mL KEY WORDS pharmacokinetics; plasma REFERENCE Wade, M.; Baker, F.J.; Roscigno, R.; DellaMaestra, W.; Hunt, T.L.; Lai, A.A. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion, J.Clin.Pharmacol., 2004, 44, 83–88. SAMPLE Matrix: formulations Sample preparation: Inject a 20 µL aliquot of a 4–130 µg/mL solution in water, 0.9% NaCl, or 5% dextrose. HPLC VARIABLES Column: 250 × 4.6 5 µm Hypersil ODS Mobile phase: Gradient. MeCN:water:trifluoroacetic acid 40:60:0.1 for 17 min, 78:22:0.1 for 18 min (step gradient (?)), initial conditions for 7 min (step gradient (?)). Flow rate: 2 Injection volume: 20 Detector: UV 217 CHROMATOGRAM Retention time: 15.0 Limit of detection: 0.025% Limit of quantitation: 0.05% 654 Treprostinil OTHER SUBSTANCES Simultaneous: m-cresol (preservative) (3.4), degradants KEY WORDS injections; stability-indicating REFERENCE Phares, K.R.; Weiser, W.E.; Miller, S.P.; Myers, M.A.; Wade, M. Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents, Am.J.Health-Syst.Pharm., 2003, 60, 916–922. 655 Trichlorfon Trichlorfon Molecular formula: C4 H8 Cl3 O4 P O H3CO P H3CO CCl3 OH Molecular weight: 257.44 CAS Registry No: 52-68-6 Merck Index: 13, 9696 SAMPLE Matrix: blood Sample preparation: Vortex 1 mL plasma and 5 mL chloroform for 15 s, centrifuge at 800 g at 0–5◦ for 15 min (Caution! Chloroform is a carcinogen!). Remove a 4.5 mL aliquot of the organic layer and add it to 3.5 mL 5 M HCl, vortex for 15 s, centrifuge at 800 g at 0–5◦ for 15 min. Remove a 4 mL aliquot of the chloroform layer and add it to 200 mg anhydrous calcium sulfate, vortex, centrifuge at 800 g at 0–5◦ for 5 min. Evaporate the chloroform layer to dryness in an acid-washed vial under a stream of nitrogen at room temperature, reconstitute the residue with 120 µL water, vortex, centrifuge at 11 000 g at 0–5◦ for 5 min, inject a 100 µL aliquot. (However, Aden Abdi et al. claim that substantial base-catalyzed conversion of trichlorfon to dichlorvos can occur under these conditions and plasma should be acidified with phosphoric acid before extraction. (Aden Abdi,Y.; Villén,T.; Gustafsson,L.L.; Ericsson,O.; Sjöqvist,F. Methodological commentary on the analysis of metrifonate and dichlorvos in biological samples. J.Chromatogr. 1993, 612, 336–337.) These workers recommend mixing blood with an equal volume of 740 mM phosphoric acid immediately upon collection. Trichlorfon can still be extracted from the acidified sample. (Aden Abdi,Y.; Villén,T. Pharmacokinetics of metrifonate and its rearrangement product dichlorvos in whole blood. Pharmacol.Toxicol. 1991, 68, 137–139.)) HPLC VARIABLES Guard column: 37–50 µm C18/Corasil Column: 300 × 3.9 10 µm C18 Mobile phase: MeOH:THF:1 mM pH 3.0 sodium octanesulfonate 10:0.1:89.9 Flow rate: 2 Injection volume: 200 Detector: UV 210 CHROMATOGRAM Retention time: 10.8 Limit of detection: 1 µg/mL KEY WORDS plasma REFERENCE Unni, L.K.; Hannant, M.E.; Becker, R.E. High-performance liquid chromatographic method using ultraviolet detection for measuring metrifonate and dichlorvos levels in human plasma, J.Chromatogr., 1992, 573, 99–103. 656 Triethanolamine Triethanolamine OH HO N OH Molecular formula: C6 H15 NO3 Molecular weight: 149.19 CAS Registry No: 102-71-6 Merck Index: 13, 9739 SAMPLE Matrix: solutions HPLC VARIABLES Column: 100 × 4 Alltech Universal Cation Mobile phase: 3 mM methanesulfonic acid Flow rate: 1 Injection volume: 100 Detector: Conductivity (nonsuppressed mode, indirect conductivity detection) CHROMATOGRAM Retention time: 6 OTHER SUBSTANCES Simultaneous: ammonium (4), calcium (12), ethanolamine (4.2), lithium (3), magnesium (10), potassium (5.5), sodium (3.5), REFERENCE Saari-Nordhaus, R.; Anderson, J.M. Jr. Alternative approach to enhancing cation selectivity in ion chromatography, J.Chromatogr.A, 2004, 1039, 123–127. 657 Trifluridine Trifluridine O H Molecular formula: C10 H11 F3 N2 O5 Molecular weight: 296.20 CAS Registry No: 70-00-8 Merck Index: 13, 9758 CF3 N HO O N O OH SAMPLE Matrix: blood, tissue Sample preparation: Mix 1 mL blood with 2 mL ice-cold MeCN, centrifuge, filter, inject a 5–20 µL aliquot. Homogenize brain tissue with 0.5 mL water, add 2 mL MeCN, centrifuge, filter, inject a 5–20 µL aliquot. HPLC VARIABLES Guard column: C18 Corasil (Whatman) Column: 100 × 3 Chrompack C18 Mobile phase: MeCN:50 mM sodium dihydrogen phosphate 15:85 Flow rate: 0.3–0.8 Injection volume: 5–20 Detector: UV 254, UV 280 KEY WORDS brain; rat; whole blood REFERENCE Rand, K.H.; Bodor, N.; el Koussi, A.A.; Raad, I.; Miyake, A.; Houck, H.; Gildersleeve, N. Potential treatment of herpes simplex virus encephalitis by brain-specific delivery of trifluorothymidine using a dihydropyridine in equilibrium pyridinium salt type redox delivery system, J.Med.Virol., 1986, 20, 1–8. 658 Triptorelin Triptorelin Molecular formula: C64 H82 N18 O13 Molecular weight: 1311.45 CAS Registry No: 57773-63-4, 140194-24-7 (acetate) Merck Index: 13, 9818 SAMPLE Matrix: blood Sample preparation: Mix 500 µL plasma with 2 mL EtOH for 30 min, centrifuge at 3000 g for 15 min. Evaporate the supernatant to ca. 500 µL under a stream of nitrogen at 40◦ for 1 h, lyophilize, reconstitute with mobile phase, inject a 600 µL aliquot. HPLC VARIABLES Column: Partisil PXS 10/25 SCX Mobile phase: EtOH:200 mM pH 4.6 ammonium acetate 10:90 Flow rate: 1.6 Injection volume: 600 Detector: Radioimmunoassay of fractions CHROMATOGRAM Retention time: 14 KEY WORDS plasma REFERENCE Barron, J.L.; Millar, R.P.; Searle, D.I. Metabolic clearance and plasma half-disappearance time of DTRP6 and exogenous luteinizing hormone-releasing hormone, J.Clin.Endocrinol.Metab., 1982, 54, 1169–1173. SAMPLE Matrix: blood Sample preparation: Condition a Sep-Pak C18 SPE cartridge with 3 mL MeOH and 5 mL water. Add 500 µL plasma to the SPE cartridge, wash with 5 mL 0.1% trifluoroacetic acid, elute with 5 mL MeOH:water:trifluoroacetic acid 80:19:1. Evaporate the eluate, freeze the residual aqueous solution, freeze, lyophilize, reconstitute with 300 µL 0.1% trifluoroacetic acid, inject a 100 µL aliquot. HPLC VARIABLES Column: µBondapak C18 Mobile phase: Gradient. A was 11 mM trifluoroacetic acid in MeCN:water 70:30. B was 11 mM trifluoroacetic acid in 3 mM acetic acid. A:B from 5:95 to 95:5 over 20 min. Flow rate: 1 Injection volume: 100 Detector: Radioimmunoassay of fractions; UV 210 CHROMATOGRAM Retention time: 18 KEY WORDS dog; pharmacokinetics; plasma; rat; SPE Triptorelin 659 REFERENCE Ezan, E.; Drieu, K.; Chapelat, M.; Rougeot, C.; Dray, F. Radioimmunoassay of [D-Trp6 ]-luteinizing hormone-releasing hormone: its application to animal pharmacokinetic studies after single injection and long-acting formulation administration, Regul.Pept., 1986, 14, 155–167. 660 Troleandomycin Troleandomycin O O H3C Molecular formula: C41 H67 NO15 H3C Molecular weight: 813.97 CAS Registry No: 2751-09-9 Merck Index: 13, 9839 H3C H3C CH3 OAc N CH3 O AcO H3C O O CH3 O O CH3 O OCH3 OAc CH3 SAMPLE Matrix: solutions Sample preparation: Inject a 10 µL aliquot of a 40 mg/mL solution in MeCN. HPLC VARIABLES Column: 250 × 4.6 5 µm Xterra RP18 Column temperature: 30 Mobile phase: MeCN:200 mM pH 6.0 ammonium acetate:water 45:5:50 Flow rate: 1 Injection volume: 10 Detector: UV 205 CHROMATOGRAM Retention time: 22 Limit of detection: 0.02% (S/N 3) Limit of quantitation: 0.05% REFERENCE Chepkwony, H.K.; Roets, E.; Hoogmartens, J. Liquid chromatography of troleandomycin, J.Chromatogr.A, 2001, 914, 53–58. 661 Troxipide Troxipide H N O Molecular formula: C15 H22 N2 O4 Molecular weight: 294.35 CAS Registry No: 99777-81-8 Merck Index: 13, 9860 OCH3 N H OCH3 OCH3 SAMPLE Matrix: tissue Sample preparation: Homogenize 5–30 mg gastric mucosal tissue with 1.2 mL 20 mM pH 7.4 phosphate buffer, centrifuge at 3000 rpm for 10 min. Mix 1 mL of the supernatant with 100 µL IS solution and 1.5 mL MeCN, let stand at 5–6◦ for 1 h, centrifuge at 3000 rpm at 4◦ for 10 min. Dry 2 mL of the supernatant, reconstitute with 1 mL EtOH, dry, reconstitute with 120 µL injection solvent (unspecified), inject a 60 µL aliquot. HPLC VARIABLES Guard column: 10 × 4 5 µm Capcell Pak C18 UG 120 Column: 50 × 4.6 3 µm Capcell Pak C18 UG 120 Mobile phase: MeCN:50 mM pH 5.0 acetate buffer containing 0.08% sodium 1-hexanesulfonate (ratio not given) Flow rate: 0.6 Injection volume: 60 Detector: UV 260 CHROMATOGRAM Internal standard: 3-amino-1-[3,4,5-trimethoxybenzoyl]piperidine HCl KEY WORDS gastric mucosa REFERENCE Kusugami, K.; Ina, K.; Hosokawa, T.; Kobayashi, F.; Kusajima, H.; Momo, K.; Nishio, Y. Troxipide, a novel antiulcer compound, has inhibitory effects on human neutrophil migration and activation induced by various stimulants, Dig.Liver Dis., 2000, 32, 305–311. Ubenimex NH2 O COOH CH3 N Molecular formula: C16 H24 N2 O4 OH Molecular weight: 308.37 CAS Registry No: 58970-76-6 Merck Index: 13, 9910 CH3 H SAMPLE Matrix: blood Sample preparation: Mix 20 µL serum with 20 µL water and 200 µL 4.2 mM acetic acid, heat in a boiling water bath for 5 min, centrifuge at 1000 g for 5 min. Mix 100 µL of the supernatant with 50 µL 1.5 M ammonium hydroxide and 25 µL 3 mM sodium periodate, let stand at room temperature for 20 min, add 25 µL 12 mM sodium sulfite to decompose excess periodate, add 200 µL DDB solution, heat at 37◦ for 50 min, add 50 µL 1 M NaOH, inject a 100 µL aliquot. (Prepare DDB solution by dissolving 26.5 mg 4,5dimethoxy-1,2-diaminobenzene monohydrochloride in 100 mL 300 mM HCl, use within 3 h. Dihydrochloride available from Molecular Probes or Dojindo Laboratories) HPLC VARIABLES Column: 150 × 4 5 µm LiChrosorb RP-18 Mobile phase: MeCN:100 mM pH 8.7 tris-HCl buffer 25:75 Flow rate: 0.8 Injection volume: 100 Detector: F ex 320 em 390 CHROMATOGRAM Retention time: 4.5 Limit of detection: 200 ng/mL OTHER SUBSTANCES Extracted: p-hydroxybestatin (10.5) KEY WORDS derivatization; serum REFERENCE Ishida, J.; Yamaguchi, M.; Kai, M.; Ohkura, Y.; Nakamura, M. Determination of bestatin in serum by high-performance liquid chromatography with fluorescence detection, J.Chromatogr., 1984, 305, 381–389. 662 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 663 Unoprostone isopropyl ester Unoprostone isopropyl ester Molecular formula: C25 H44 O5 Molecular weight: 424.61 CAS Registry No: 120373-24-2, 120373-36-6 (free acid) Merck Index: 13, 9917 H OH H O O HO H H O CH3 CH3 CH3 SAMPLE Matrix: aqueous humor, tissue Sample preparation: Inject a 50 µL aliquot of aqueous humor directly. Homogenize eye tissue with MeCN:0.1% acetate 20:80 at 4◦ , centrifuge at 15000 rpm at 4◦ for 30 min. Filter (Millipore Ultra-Free CL, 300 000 cut-off) while centrifuging at 15 000 rpm at 4◦ for 30 min, inject an aliquot of the ultrafiltrate HPLC VARIABLES Column: 150 × 4.6 C18-5A (Shodex) Mobile phase: Gradient. MeCN:water:acetic acid from 20:80:0.1 to 100:0:0.1 over 40 min Injection volume: 50 Detector: Radioactivity (3 H) CHROMATOGRAM Retention time: 30 OTHER SUBSTANCES Extracted: metabolites KEY WORDS eye; rabbit REFERENCE Kashiwagi, K.; Iizuka, Y.; Tsukahara, S. Metabolites of isopropyl unoprostone as potential ophthalmic solutions to reduce intraocular pressure in pigmented rabbits, Jpn.J.Pharmacol., 1999, 81, 56–62. Valacyclovir O H N N Molecular formula: C13 H20 N6 O4 Molecular weight: 324.33 CAS Registry No: 124832-26-4, 124832-27-5 (HCl) Merck Index: 13, 9966 H2N N N NH2 O O CH3 O CH3 SAMPLE Matrix: blood Sample preparation: Acidify plasma with trichloroacetic acid to a final trichloroacetic acid concentration of 3%, centrifuge at 9000 g at 4◦ for 10 min, inject an aliquot of the ultrafiltrate. HPLC VARIABLES Column: 250 × 4.6 Adsorbosphere C18 (Alltech) Mobile phase: MeCN:100 mM pH 3.5 ammonium formate buffer 10:90 Flow rate: 1 Detector: UV 254 CHROMATOGRAM Retention time: 8 Limit of quantitation: 80 ng/mL KEY WORDS plasma; ultrafiltrate REFERENCE Weller, S.; Blum, M.R.; Doucette, M.; Burnette, T.; Cederberg, D.M.; de Miranda, P.; Smiley, M.L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers, Clin.Pharmacol.Ther., 1993, 54, 595–605. SAMPLE Matrix: urine Sample preparation: Acidify urine with trichloroacetic acid to a final trichloroacetic acid concentration of 1%, filter (Centrifree) while centrifuging at 2000 g at 4◦ for 10–20 min, inject an aliquot of the ultrafiltrate. HPLC VARIABLES Column: 250 × 4.6 Adsorbosphere C18 (Alltech) Mobile phase: Gradient. A was 50 mM pH 3.5 ammonium formate buffer. B was MeCN:50 mM pH 7.2 ammonium phosphate buffer 50:50. A:B ratio not given. Flow rate: 1 Detector: UV 254, UV 280 CHROMATOGRAM Retention time: 27 Limit of quantitation: 160 ng/mL OTHER SUBSTANCES Extracted: acyclovir (20), CMMG (14) 664 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 Valacyclovir 665 KEY WORDS ultrafiltrate REFERENCE Weller, S.; Blum, M.R.; Doucette, M.; Burnette, T.; Cederberg, D.M.; de Miranda, P.; Smiley, M.L. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers, Clin.Pharmacol.Ther., 1993, 54, 595–605. 666 Valdecoxib Valdecoxib O O S NH2 Molecular formula: C16 H14 N2 O3 S Molecular weight: 314.36 CAS Registry No: 181695-72-7 N O CH3 SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg Bond Elut C18 SPE cartridge with 2 mL MeOH and 2 mL water. Centrifuge plasma at 2000 g at 4◦ for 5 min, vortex 400 µL of the supernatant with 400 µL 100 ng/mL IS in water, add to the SPE cartridge, wash with 2 mL water, elute with 250 µL MeCN. Evaporate the eluate to dryness under a stream of nitrogen, reconstitute the residue with 100 µL mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Column: 50 × 2.1 5 µm Zorbax XDB-C8 Mobile phase: MeCN:water 50:50 containing 10 mM ammonium acetate Flow rate: 0.1 Injection volume: 20 Detector: MS, PE Sciex API-III Plus quadrupole, electrospray, negative ion mode, electrospray interface – 3700 V, orifice – 62 V, nebulizer gas nitrogen at 50 psi, curtain gas nitrogen at 1.8 L/min, collision gas argon, collision offset energy 25 eV, m/z 313–118 CHROMATOGRAM Retention time: 3 Internal standard: 4-(5-methyl-3-(3-fluorophenyl)-isoxazol-4-yl)benzenesulfonamide (m/z 331–118) (3.5) Limit of quantitation: 0.5 ng/mL OTHER SUBSTANCES Extracted: metabolite (4-(5-hydroxymethyl-3-phenylisoxazol-4-yl)benzenesulfonamide) (m/z 329–196) (2) KEY WORDS plasma; SPE REFERENCE Zhang, J.Y.; Fast, D.M.; Breau, A.P. Development and validation of an automated SPE-LC-MS/MS assay for valdecoxib and its hydroxylated metabolite in human plasma, J.Pharm.Biomed.Anal., 2003, 33, 61–72. SAMPLE Matrix: blood, feces, urine Sample preparation: Blood. Extract plasma or red blood cells three times with MeCN. Combine the supernatants and evaporate to dryness under a stream of nitrogen, reconstitute the residue with mobile phase A, inject an aliquot. Urine. Centrifuge urine at 2000 g for 5 min, inject an aliquot. Feces. Homogenize feces three times with MeCN and twice with mobile phase A. HPLC VARIABLES Column: 150 × 3.9 4 µm Novapak C8 Valdecoxib 667 Mobile phase: Gradient. A was MeCN:MeOH:25 mM pH 4 ammonium acetate buffer 3:6:81. B was MeCN:MeOH:25 mM pH 4 ammonium acetate buffer 20:40:60. A:B from 100:0 to 0:100 over 25 min, maintain at 0:100 for 5 min, return to initial conditions over 2 min, re-equilibrate for 8 min. Flow rate: 1 Detector: UV 240; Radioactivity (14 C); MS, PE Sciex API-III Plus triple quadrupole, negative electrospray, capillary – 3700 V, orifice – 65 V, nebulizer gas at 50 psi, curtain gas nitrogen at 1.8 L/min, auxiliary gas nitrogen at 2 L/min, collision gas argon, collision energy 30 eV, turbo ionspray 400◦ , 0.2 mL/min of column effluent entered the detector CHROMATOGRAM Retention time: 26 OTHER SUBSTANCES Extracted: metabolites KEY WORDS mouse; pharmacokinetics; plasma; red blood cells REFERENCE Zhang, J.Y.; Yuan, J.J.; Wang, Y.-F.; Bible, R.H. Jr.; Breau, A.P. Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice, Drug Metab.Dispos., 2003, 31, 491–501. ANNOTATED BIBLIOGRAPHY Yuan, J.J.; Yang, D.-C.; Zhang, J.Y.; Bible, R.; Karim, A.; Findlay, J.W.A. Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human, Drug Metab.Dispos., 2002, 30, 1013–1021. [radioactivity detection (14 C); LC-MS; metabolites] Zhang, J.Y.; Fast, D.M.; Breau, A.P. Determination of valdecoxib and its metabolites in human urine by automated solid-phase extraction-liquid chromatography-tandem mass spectrometry, J.Chromatogr.B, 2003, 785, 123–134. [LOQ 1 ng/mL] 668 Valganciclovir Valganciclovir Molecular formula: C14 H22 N6 O5 Molecular weight: 354.36 CAS Registry No: 175865-60-8 Merck Index: 13, 9973 O H N N H2N N OH N O NH2 O CH3 O CH3 SAMPLE Matrix: blood Sample preparation: Vortex 250 µL plasma with 100 µL 1 M HCl and 100 µL cold 15% trichloroacetic acid, centrifuge, inject an aliquot of the supernatant. (A columnswitching system is used so that only the fraction of interest is diverted from the initial column on to the analytical column. Details are not provided.) HPLC VARIABLES Column: BDS Hypersil C18 Mobile phase: MeCN:0.0425% phosphoric acid 5:95 (diastereomers are separated) Detector: UV 254 CHROMATOGRAM Limit of quantitation: 40 ng/mL KEY WORDS pharmacokinetics; plasma REFERENCE Brown, F.; Banken, L.; Saywell, K.; Arum, I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers, Clin.Pharmacokinet., 1999, 37, 167–176. SAMPLE Matrix: formulations Sample preparation: Dilute oral solution with 25 mM pH 2.5 phosphate buffer containing 5 µg/mL IS, filter (0.2 µm), inject a 10 µL aliquot. HPLC VARIABLES Guard column: 15 × 4.6 5 µm MetaGuard Inertsil ODS-3 Column: 100 × 4.6 5 µm Inertsil ODS-3 Mobile phase: MeCN:25 mM pH 2.5 phosphate buffer 2.5:97.5 Flow rate: 1.6 Injection volume: 10 Detector: UV 254 CHROMATOGRAM Retention time: 5.9, 6.9 (diastereomers) Internal standard: hypoxanthine (1.8) OTHER SUBSTANCES Simultaneous: ganciclovir (2.5) KEY WORDS oral solution; stability-indicating Valganciclovir 669 REFERENCE Anaizi, N.H.; Dentinger, P.J.; Swenson, C.F. Stability of valganciclovir in an extemporaneously compounded oral liquid, Am.J.Health-Syst.Pharm., 2002, 59, 1267–1270. ANNOTATED BIBLIOGRAPHY Henkin, C.C.; Griener, J.C.; Ten Eick, A.P. Stability of valganciclovir in extemporaneously compounded liquid formulations, Am.J.Health-Syst.Pharm., 2003, 60, 687–690. [stability-indicating] 670 Valrubicin Valrubicin O OH O O OH Molecular formula: C34 H36 F3 NO13 Molecular weight: 723.64 CAS Registry No: 56124-62-0 Merck Index: 13, 9981 OCH3 O OH H3C CH3 O O O HN OH CF3 O SAMPLE Matrix: tissue Sample preparation: Homogenize (Duall ground glass grinder) 1 g of tissue with 9 mL 50 mM pH 8.5 Tris HCl buffer containing 3% sodium dodecyl sulfate, extract three times with 2 vol of ethyl acetate:n-propanol 90:10. Evaporate the combined extracts to dryness at 45◦ , reconstitute the residue with MeOH, inject an aliquot. HPLC VARIABLES Column: µBondapak phenyl Mobile phase: Gradient. MeCN:pH 4.00 ammonium formate buffer from 32:68 to 65:35 over 7 min. Flow rate: 5 Detector: F ex 482 em Schoeffel no. 2–73 filter CHROMATOGRAM Retention time: 7 OTHER SUBSTANCES Extracted: metabolites KEY WORDS liver; mouse; small intestine REFERENCE Israel, M.; Karkowsky, A.M.; Khetarpal, V.K. Distribution of radioactivity and anthracycline-fluorescence in tissues of mice one hour after [14 C]-labeled AD 32 administration. Evidence for tissue aglycone formation, Cancer Chemother.Pharmacol., 1981, 6, 25–30. Valsartan Valsartan H 3C O H3C Molecular formula: C24 H29 N5 O3 Molecular weight: 435.52 CAS Registry No: 137862-53-4 Merck Index: 13, 9982 N 671 CH3 COOH N N N N H SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 100 mg Bond Elut C8 SPE cartridge with 2 mL MeOH and 1 mL 100 mM pH 2 phosphate buffer. Mix 250 µL plasma with IS, add 250 µL 1 M phosphoric acid, shake, centrifuge at 10 000 g at 4◦ for 5 min, add the supernatant to the SPE cartridge, wash with 500 µL MeOH:100 mM pH 2 phosphate buffer 50:50, dry at full vacuum for 20 min, elute with 500 µL MeOH. Add 100 µL MeOH:ethylene glycol 90:10 to the eluate (to prevent adsorption of the drug), vortex, evaporate to dryness under a stream of nitrogen at 40◦ C, reconstitute the residue with 250 µL of the initial mobile phase, inject a 20 µL aliquot. HPLC VARIABLES Guard column: 20 × 3.9 4 µm Novapak C18 (Waters) Column: 300 × 3.9 10 µm µBondapak C18 Mobile phase: Gradient. MeCN:5 mM pH 4 acetate buffer from 30:70 to 60:40 over 15 min, to 95:5 over 6 min, return to initial conditions over 3 min, re-equilibrate at initial conditions for 1 min. Flow rate: from 1 to 1.2 over 15 min, maintain at 1.2 for 6 min, to 1 over 3 min, maintain at 1 for 1 min Injection volume: 20 Detector: F ex 250 em 375 CHROMATOGRAM Retention time: 14.4 Internal standard: bumetanide (13.5) Limit of quantitation: 50 ng/mL OTHER SUBSTANCES Extracted: metabolites, candesartan (22.6, LOQ 3 ng/mL), irbesartan (12.6, LOQ 50 ng/mL), losartan (11.5, LOQ 16 ng/mL) KEY WORDS plasma; SPE REFERENCE González, L.; López, J.A.; Alonso, R.M.; Jiménez, R.M. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection, J.Chromatogr.A, 2002, 949, 49–60. SAMPLE Matrix: formulations Sample preparation: Sonicate finely ground tablets in MeOH for 5 min, centrifuge, dilute with MeOH containing 290 ng/mL IS, inject a 20 µL aliquot. 672 Valsartan HPLC VARIABLES Column: 150 × 4.6 5 µm Supelcosil LC 18 Mobile phase: MeCN:20 mM pH 3.2 phosphate buffer 45:55 Flow rate: 0.9 Injection volume: 20 Detector: UV 225 CHROMATOGRAM Retention time: 6.99 Internal standard: trimethoprim (2.96) Limit of detection: 17 ng/mL Limit of quantitation: 58 ng/mL OTHER SUBSTANCES Extracted: hydrochlorothiazide (2.20) KEY WORDS comparison with derivative spectrophotometry; tablets REFERENCE Satana, E.; Altinay, S.; Göger, N.G.; Ozkan, S.A.; Sentürk, Z. Simultaneous determination of valsartan and hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC, J.Pharm.Biomed.Anal., 2001, 25, 1009–1013. ANNOTATED BIBLIOGRAPHY Carlucci, G.; Di Carlo, V.; Mazzeo, P. Simultaneous determination of valsartan and hydrochlorothiazide in tablets by high-performance liquid chromatography, Anal.Lett., 2000, 33, 2491–2500. Daneshtalab, N.; Lewanczuk, R.Z.; Jamali, F. High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method, J.Chromatogr.B, 2002, 766, 345–349. [fluorescence detection; LOQ 10 ng/mL; losartan is internal standard] Francotte, E.; Davatz, A.; Richert, P. Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester, J.Chromatogr.B, 1996, 686, 77–83. [LOQ 0.1%; LOD 0.04%] González, L.; Alonso, R.M.; Jiménez, R.M. A high-performance liquid chromatographic method for screening angiotensin II receptor antagonists in human urine, Chromatographia, 2000, 52, 735–740. [SPE; LOQ 400 ng/mL; losartan; irbesartan; valsartan; candesartan] Sioufi, A.; Marfil, F.; Jaouen, A.; Cardot, J.M.; Godbillon, J.; Ezzet, F.; Lloyd, P. The effect of age on the pharmacokinetics of valsartan, Biopharm.Drug Dispos., 1998, 19, 237–244. [LOQ 5 ng/mL; fluorescence detection] Tatar, S.; Saglik, S. Comparison of UV- and second derivative-spectrophotometric and LC methods for the determination of valsartan in pharmaceutical formulation, J.Pharm.Biomed.Anal., 2002, 30, 371–375. [capsules; losartan is internal standard; LOD 200 ng/mL; LOQ 1 µg/mL] Waldmeier, F.; Flesch, G.; Müller, P.; Winkler, T.; Kriemler, H.-P.; Bühlmayer, P.; de Gasparo, M. Pharmacokinetics, disposition and biotransformation of [14 C]-radiolabelled valsartan in healthy male volunteers after a single oral dose, Xenobiotica, 1997, 27, 59–71. Zaleplon CN N Molecular formula: C17 H15 N5 O Molecular weight: 305.33 CAS Registry No: 151319-34-5 Merck Index: 13, 10165 N N O N CH3 CH3 SAMPLE Matrix: blood Sample preparation: Evaporate 100 µL 1 µg/mL IS in MeOH in the bottom of a tube using a stream of nitrogen, add 1 mL whole blood, add 1 mL buffer, vortex for 1 min, add 5 mL dichloromethane:hexane:ethyl acetate 50:40:10, shake horizontally at 200 cycles/min for 30 min, centrifuge at 2000 rpm for 30 min. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 100 µL initial mobile phase, inject an aliquot. (Prepare the buffer by adjusting the pH of 1 L saturated ammonium chloride solution to 9.5 with 25% ammonium hydroxide.) HPLC VARIABLES Guard column: Inertsil ODS-3 Column: 150 × 2 3 µm Inertsil ODS-3 Mobile phase: Gradient. MeCN:1 mM pH 4.0 ammonium formate buffer 10:90 for 2 min, to 60:40 over 15 min, maintain at 60:40 for 3 min, return to initial conditions over 1 min, re-equilibrate for 10 min. Flow rate: 0.2 Detector: MS, PE Sciex API 150EX, single quadrupole, turbo ionspray, atmospheric pressure ionization, positive mode, heater gas nitrogen, ionspray 5000 V, nebulizer gas nitrogen at 1.2 L/min, curtain gas nitrogen at 1.0 L/min, turbo probe 475◦ , orifice 35 V, ring 175 V, m/z 306.21 CHROMATOGRAM Retention time: 14.35 Internal standard: methaqualone (m/z 251.11, orifice 20 V, ring 150 V) (16.12) Limit of detection: 0.1 ng/mL (S/N 5) Limit of quantitation: 1 ng/mL OTHER SUBSTANCES Extracted: zolpidem (m/z 308.21, orifice 40 V, ring 175 V) (9.78) KEY WORDS whole blood REFERENCE Giroud, C.; Augsburger, M.; Menetrey, A.; Mangin, P. Determination of zaleplon and zolpidem by liquid chromatography-turbo-ionspray mass spectrometry: application to forensic cases, J.Chromatogr.B, 2003, 789, 131–138. SAMPLE Matrix: blood Sample preparation: Add IS to 200 µL plasma, add 400 µL MeCN, vortex, centrifuge, inject an aliquot of the supernatant. HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 673 674 Zaleplon HPLC VARIABLES Column: 150 × 4.6 5 µm CSC-S-Octyl Mobile phase: MeCN:100 mM sodium dihydrogen phosphate:100 mM disodium hydrogen phosphate 32:32.5:32.5 Flow rate: 1 Detector: F ex 345 em 460 CHROMATOGRAM Internal standard: CL-218872 Limit of quantitation: 0.5 ng/mL OTHER SUBSTANCES Extracted: deethylzaleplon KEY WORDS pharmacokinetics; plasma REFERENCE Greenblatt, D.J.; Harmatz, J.S.; von Moltke, L.L.; Ehrenberg, B.L.; Harrel, L.; Corbett, K.; Counihan, M.; Graf, J.A.; Darwish, M.; Mertzanis, P.; Martin, P.T.; Cevallos, W.H.; Shader, R.I. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo, Clin.Pharmacol.Ther., 1998, 64, 553–561. SAMPLE Matrix: microsomal incubations Sample preparation: Add 2 vol of ice-cold MeCN to the microsomal incubation, stir vigorously, centrifuge at 1500 g for 15 min. Evaporate 500 µL of the supernatant to dryness under a stream of nitrogen, reconstitute the residue with 200–400 µL initial mobile phase, inject a 50 µL aliquot. HPLC VARIABLES Column: 150 × 4.6 Develosil ODS-UG-5 Mobile phase: Gradient. MeCN:50 mM pH 6.8 potassium phosphate buffer from 20:80 to 60:40 over 18 min. Flow rate: 1 Injection volume: 50 Detector: UV 245 CHROMATOGRAM Retention time: 17.6 Internal standard: CL 218,872 (20.8) Limit of quantitation: 50 nM OTHER SUBSTANCES Extracted: N-desethyl-5-oxozaleplon (3.4), N-desethylzaleplon (14.5), 5-oxozaleplon (8.5) KEY WORDS liver; monkey; rat REFERENCE Kawashima, K.; Hosoi, K.; Naruke, T.; Shiba, T.; Kitamura, M.; Watabe, T. Aldehyde oxidase-dependent marked species difference in hepatic metabolism of the sedative-hypnotic, zaleplon, between monkeys and rats, Drug Metab.Dispos., 1999, 27, 422–428. Zaleplon 675 ANNOTATED BIBLIOGRAPHY Feng, F.; Jiang, J.; Dai, H.; Wu, J. Development and validation of a high-performance liquid chromatography-electrospray ionization-mass spectrometry assay for the determination of zaleplon in human plasma, J.Chromatogr.Sci., 2003, 41, 17–21. [LOD 100 pg/mL; triazolam is internal standard] 676 Zaltoprofen Zaltoprofen S CH3 COOH Molecular formula: C17 H14 O3 S Molecular weight: 298.36 CAS Registry No: 74711-43-6, 89482-01-9 ((S)-form) Merck Index: 13, 10166 O SAMPLE Matrix: microsomal incubations Sample preparation: Mix microsomal incubation with MeCN containing IS, centrifuge at 9000 g for 10 min, inject an aliquot of the supernatant HPLC VARIABLES Guard column: 10 × 4 Capcell Pak C18 UG120 (Shiseido) Column: 250 × 4.6 L-Column ODS (Chemicals Evaluation and Research Institute, Tokyo) Column temperature: 35 Mobile phase: MeCN:water:acetic acid 60:40:1 Flow rate: 0.7 Detector: UV 330 CHROMATOGRAM Internal standard: mefenamic acid KEY WORDS human; liver REFERENCE Furuta, S.; Akagawa, N.; Kamada, E.; Hiyama, A.; Kawabata, Y.; Kowata, N.; Inaba, A.; Matthews, A.; Hall, M.; Kurimoto, T. Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential, Br.J.Clin.Pharmacol., 2002, 54, 295–303. SAMPLE Matrix: microsomal incubations Sample preparation: Mix microsomal incubation with 1 M pH 4.5 acetate buffer and dichloromethane, add IS, centrifuge at 2000 g for 10 min. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with mobile phase, inject an aliquot. HPLC VARIABLES Guard column: 10 × 4 Capcell Pak C18 UG120 (Shiseido) Column: 250 × 4.6 Capcell Pak C18 UG120 (Shiseido) Column temperature: 35 Mobile phase: MeCN:buffer 30:70 (The buffer was 65 mM sodium dihydrogen phosphate containing 5 mM tetrabutylammonium chloride, adjusted to pH 6.0 with triethylamine.) Flow rate: 1 Detector: UV 270 CHROMATOGRAM Retention time: 24 Internal standard: methyl paraben (8) Zaltoprofen 677 OTHER SUBSTANCES Extracted: metabolites KEY WORDS human; liver REFERENCE Furuta, S.; Akagawa, N.; Kamada, E.; Hiyama, A.; Kawabata, Y.; Kowata, N.; Inaba, A.; Matthews, A.; Hall, M.; Kurimoto, T. Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential, Br.J.Clin.Pharmacol., 2002, 54, 295–303. 678 Zanamivir Zanamivir Molecular formula: C12 H20 N4 O7 Molecular weight: 332.31 CAS Registry No: 139110-80-8 Merck Index: 13, 10167 OH HO H3C O HO HN OH NH O O H2N NH SAMPLE Matrix: blood Sample preparation: Condition a 1 mL 50 mg isolute SCX SPE cartridge with 500 µL MeOH and 500 µL 10% acetic acid water. Vortex 200 µL serum with 100 µL 5 µg/mL IS in water, 500 µL MeCN, and 100 µL 3% acetic acid in water, let stand at room temperature for 5 min, centrifuge at 1400 g for 10 min, add the supernatant to the SPE cartridge, elute with two 500 µL portions of 10% triethylamine in MeOH:water 50:50. Evaporate the eluate to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 200 µL mobile phase, vortex for 10 s, centrifuge at 5000 g for 5 min, inject a 20–200 µL aliquot. HPLC VARIABLES Column: 100 × 4.6 5 µm Hypersil SAS C1 Mobile phase: MeCN:water:acetic acid 50:50:1 Flow rate: 1 Injection volume: 20–200 Detector: MS, PE Sciex API 300 triple quadrupole, TurboIonSpray, positive ion mode, 20% of column effluent entered the detector, collision gas nitrogen, collision energy 28 eV, m/z 333–60 CHROMATOGRAM Retention time: 4 Internal standard: 13 C,15 N2 -zanamivir (m/z 336–63) Limit of quantitation: 10 ng/mL KEY WORDS serum; SPE REFERENCE Allen, G.D.; Brookes, S.T.; Barrow, A.; Dunn, J.A.; Grosse, C.M. Liquid chromatographic-tandem mass spectrometric method for the determination of the neuraminidase inhibitor zanamivir (GG167) in human serum, J.Chromatogr.B, 1999, 732, 383–393. SAMPLE Matrix: blood Sample preparation: Condition a Bond Elut SCX SPE cartridge with 2 mL MeOH and 2 mL 10% formic acid. Mix 1 mL serum with 1 mL 10% formic acid, add to the SPE cartridge, wash with 2 mL 1% trifluoroacetic acid in MeOH, wash with 2 mL water, elute with four 500 µL portions of 10% triethylamine in MeOH:water 50:50. Evaporate the eluate to dryness under a stream of nitrogen at 70◦ , reconstitute the residue with 75 µL 4 mM benzoin in ethylene glycol, add 150 µL reagent, vortex, heat at 100◦ for 3 min, cool, inject a 100 µL aliquot. (Prepare the reagent by diluting 750 µL β-mercaptoethanol, 2.52 g sodium sulfite, and 10 mL 5 M KOH to 100 mL with water.) HPLC VARIABLES Column: 100 × 4.6 Hypersil ODS Zanamivir 679 Mobile phase: Gradient. MeCN:buffer 20:80 for 12 min, to 80:20 (step gradient), maintain at 80:20 for 5 min, re-equilibrate at initial conditions for 10 min. (Prepare the buffer by adding 100 mL 1 M tris(hydroxymethyl)methylamine (Tris) and 29.4 mL 1 M HCl to water and making up to 2 L with water (50 mM pH 8.5).) Flow rate: 1 Injection volume: 100 Detector: F ex 325 em 442 CHROMATOGRAM Retention time: 14 Limit of quantitation: 10 ng/mL KEY WORDS derivatization; serum; SPE REFERENCE Stubbs, R.J.; Harker, A.J. Automated high-performance liquid chromatographic method for the determination of a neuraminidase inhibitor, J.Chromatogr.B, 1995, 670, 279–285. 680 Zinostatin Zinostatin CAS Registry No: 9014-02-2, 123760-07-6 Merck Index: 13, 10222 SAMPLE Matrix: solutions HPLC VARIABLES Column: TSK G-3000SW Mobile phase: 10 mM pH 7.9 ammonium bicarbonate containing 30 mM NaCl Flow rate: 1 Detector: UV 254, UV 280 REFERENCE Maeda, H.; Ueda, M.; Morinaga, T.; Matsumoto, T. Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties, J.Med.Chem., 1985, 28, 455–461. Zofenopril calcium Zofenopril calcium O H O H S Molecular formula: C44 H44 CaN2 O8 S4 Molecular weight: 897.17 CAS Registry No: 81938-43-4, 81872-10-8 (free acid) 681 Ca++ S N CH3 H COO− 2 SAMPLE Matrix: blood Sample preparation: Collect 10 mL whole blood in a heparinized tube containing 20 mg N-ethylmaleimide, centrifuge. Shake 1 mL plasma with 20 µL MeOH containing 10 µg/mL IS1 and 15 µg/mL IS2, 1 mL 2 M phosphoric acid containing 2% tetrabutylammonium hydrogen sulfate, and 7 mL toluene in a PTFE-lined tube on a rotating mixer at 32 rpm for 15 min, centrifuge at 1500 g for 5 min. Evaporate the organic layer to dryness under a stream of nitrogen at 60◦ , reconstitute the residue with 200 µL MeOH:water 50:50, inject an aliquot. HPLC VARIABLES Guard column: 10 × 3.2 5 µm C18 (Hichrom) Column: 75 × 4.6 3 µm Luna C18 Mobile phase: Gradient. MeCN:26 mM pH 4.5 ammonium acetate buffer 20:80 for 0.5 min, to 80:20 over 2.5 min, maintain at 80:20 for 3 min, re-equilibrate at initial conditions for 3 min. Flow rate: 0.4 Detector: MS, PE Sciex API 365 triple quadrupole, TurboIonSpray, probe 450◦ , negative ion mode, orifice – 35 V, ring – 200 V, nebulizer gas nitrogen at 10 units, curtain gas nitrogen at 12 units, auxiliary gas air, collision gas nitrogen at 2 units, m/z 428–137 CHROMATOGRAM Retention time: 6 Internal standard: IS1 (N-[3-mercapto-2-methylpropionyl]-4-(4-fluorophenylthio)-Lproline benzoate) (m/z 446–137) (6), IS2 (m/z 467–308) (Prepare a solution of IS2 by reacting 7 mg N-[3-mercapto-2-methylpropionyl]-4-(4-fluorophenylthio)-L-proline with 1.75 mL of a 25 mg/mL solution of N-ethylmaleimide in 60 mM pH 7 buffer in the dark at room temperature for 1 h, make up to 10 mL with acetone.) (5.3) Limit of detection: 50 pg/mL (S/N 3) Limit of quantitation: 1 ng/mL OTHER SUBSTANCES Extracted: zofenoprilat (N-[3-mercapto-2-methylpropionyl]-4-(phenylthio)-L-proline) (m/z 449–290 (as derivative)) (LOQ 2 ng/mL, LOD 100 pg/mL) (5.3) KEY WORDS derivatization; pharmacokinetics; plasma; whole blood REFERENCE Dal Bo, L.; Mazzucchelli, P.; Marzo, A. Assay of zofenopril and its active metabolite zofenoprilat by liquid chromatography coupled with tandem mass spectrometry, J.Chromatogr.B, 2000, 749, 287–294. SAMPLE Matrix: solutions HPLC VARIABLES Column: 250 × 4.6 5 µm Econosil 682 Zofenopril calcium Mobile phase: MeCN:water:triethylamine:phosphoric acid 65:35:0.02:0.13, pH 2.4 Flow rate: 1 Detector: UV 220 CHROMATOGRAM Internal standard: cephalothin OTHER SUBSTANCES Also analyzed: captopril, enalaprilat, fosinopril, quinapril, quinaprilat, ramipril REFERENCE Lin, C.J.; Akarawut, W.; Smith, D.E. Competitive inhibition of glycylsarcosine transport by enalapril in rabbit renal brush border membrane vesicles: interaction of ACE inhibitors with high-affinity H+ /peptide symporter, Pharm.Res., 1999, 16, 609–615. SAMPLE Matrix: solutions HPLC VARIABLES Column: 150 × 3.9 µBondapak phenyl Column temperature: 30–40 Mobile phase: MeOH:water:85% phosphoric acid 68:32:0.2 Detector: UV 215–220 OTHER SUBSTANCES Simultaneous: zofenoprilat REFERENCE Ranadive, S.A.; Chen, A.X.; Serajuddin, A.T. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors, Pharm.Res., 1992, 9, 1480–1486. ANNOTATED BIBLIOGRAPHY Marzo, A.; Dal Bo, L.; Mazzucchelli, P.; Monti, N.C.; Crivelli, F.; Ismaili, S.; Giusti, A.; Uhr, M.R. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers, Arzneimittelforschung, 2002, 52, 233–242. [LC-MS; LOQ 5 ng/mL] 683 Zolazepam hydrochloride Zolazepam hydrochloride Molecular formula: C15 H15 FN4 O.HCl Molecular weight: 322.77 CAS Registry No: 33754-49-3, 31352-82-6 (free base) H3C H3C O N N N HCl N H3C F SAMPLE Matrix: blood, tissue Sample preparation: Add IS to serum or tissue, make alkaline with pH 9.5 borate buffer, extract with ethyl acetate. Extract the organic layer with 1 mL 100 mM HCl. Basify the aqueous layer with 100 mg sodium borate, extract with ethyl acetate. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with MeCN:water 25:75 (serum) or mobile phase (tissue), inject a 70 µL aliquot. HPLC VARIABLES Column: 250 × 4 5 µm LiChrospher 60 RP-select B C8 Mobile phase: MeCN:50 mM pH 6.8 phosphate buffer 26:74 Flow rate: 1 Injection volume: 70 Detector: UV 233 CHROMATOGRAM Retention time: 12.5 Internal standard: pindolol (9.7) Limit of quantitation: 2 ng/mL OTHER SUBSTANCES Extracted: tiletamine (LOQ 10 ng/mL) (18.9) KEY WORDS bear; muscle; serum REFERENCE Semple, H.A.; Gorecki, D.K.J.; Farley, S.D.; Ramsay, M.A. Pharmacokinetics and tissue residues of Telazol in free-ranging polar bears, J.Wildlife Dis., 2000, 36, 653–662. SAMPLE Matrix: blood, urine Sample preparation: Mix 1 mL pH 7 buffer with 5 mL whole blood or urine, add 1 µg IS1, add 6 µg IS2, add 7 mL hexane:toluene:isoamyl alcohol 90:5:5, vortex, centrifuge, remove the organic layer. Add 1 mL pH 9.5 buffer to the aqueous layer, extract with 6 mL hexane:isoamyl alcohol 99:1. Combine the organic layers, evaporate to dryness under a stream of nitrogen, reconstitute the residue with 250 µL MeCN:water:trifluoroacetic acid 45:55:0.05, evaporate to half volume to remove MeCN, inject a 50 µL aliquot. HPLC VARIABLES Guard column: 5 µm Altima C18 Column: 20 × 2.1 5 µm Altima C18 Column temperature: 40 684 Zolazepam hydrochloride Mobile phase: Gradient. A was MeCN:water:trifluoroacetic acid 10:90:0.05. B was MeCN:water:trifluoroacetic acid 80:20:0.05. A:B 100:0 for 5 min, to 0:100 over 50 min, re-equilibrate at initial conditions for 15 min. Flow rate: 0.25 Injection volume: 50 Detector: MS, HP 5989B, electron impact; UV 205; UV 290 CHROMATOGRAM Internal standard: SKF-525 A (IS1), 5-ethyl-5-p-tolylbarbituric acid (IS2) OTHER SUBSTANCES Extracted: tiletamine KEY WORDS whole blood REFERENCE Cording, C.J.; Deluca, R.; Camporese, T.; Spratt, E. A fatality related to the veterinary anesthetic Telazol, J.Anal.Toxicol., 1999, 23, 552–555. SAMPLE Matrix: tissue Sample preparation: Homogenize 1.5 g tissue with 300 µL 1 µg/mL IS in water and 6 mL 500 mM pH 9.5 sodium borate buffer, add 10 mL ethyl acetate, vortex for 20 min, repeat the extraction. Combine the organic layers and extract twice with 2 mL portions of 100 mM HCl. Combine the aqueous layers and make basic with 200 mg sodium borate, extract with 12 mL ethyl acetate. Evaporate the organic layer to dryness under a stream of nitrogen, reconstitute the residue with 200 µL MeCN:water 20:80, inject a 70 µL aliquot. HPLC VARIABLES Column: 250 × 4 5 µm LiChrospher 60 RP-select B C8 Mobile phase: MeCN:50 mM pH 5.5 sodium phosphate buffer 16:84 Flow rate: 1 Injection volume: 70 Detector: UV 233 CHROMATOGRAM Retention time: 58 Internal standard: ripazapam (51.5) OTHER SUBSTANCES Extracted: tiletamine (45), metabolites KEY WORDS bear; fat; kidney; muscle REFERENCE Semple, H.A.; Gorecki, D.K.J.; Farley, S.D.; Ramsay, M.A. Pharmacokinetics and tissue residues of Telazol in free-ranging polar bears, J.Wildlife Dis., 2000, 36, 653–662. CUMULATIVE INDEX This index provides a comprehensive listing of the drugs for which analytical methods have been described in this volume and in earlier volumes in the series (available from John Wiley & Sons, Inc.). These volumes are designated as follows: I II III IV V CE HPLC Methods for Pharmaceutical Analysis HPLC Methods for Pharmaceutical Analysis, Volume 2 HPLC Methods for Pharmaceutical Analysis, Volume 3 HPLC Methods for Pharmaceutical Analysis, Volume 4 HPLC Methods for Recently Approved Pharmaceuticals (this volume) Capillary Electrophoresis Methods for Pharmaceutical Analysis (For obvious reasons non-interfering compounds are not listed in this index.) Abacavir, V 1 Acamprosate, II 1 Acarbose, CE 1, V 5 Acebutolol, CE 1, II 2 Aceclofenac, II 17 Acefylline, II 19 Acenocoumarol, CE 9, II 20 Acepromazine, CE 11, II 22 Aceprometazine, II 29 Acesulfame, II 31 Acetaminophen, CE 12, I 1, II 32 Acetazolamide, CE 27, II 37 Acetiamine, II 46 Acetohexamide, CE 28, II 47 Acetophenazine, II 49 Acetorphan, II 54 Acetyl sulfisoxazole, V 6 Acetylcholine, II 56 Acetylcysteine, CE 30, II 66 Acipimox, II 84 Acitretin, II 85 Aconitine, II 93 Acrivastine, II 95, V 7 Actinoquinol, II 96 Acyclovir, CE 33, I 27, II 97 Adapalene, V 10 Adefovir, II 101 Adefovir dipivoxil, V 11 Adenosine triphosphate, CE 39, II 111 Adenosine, CE 35, II 103 Adiphenine, I 33, II 118 Adrafinil, II 119 Adrenocorticotropic Hormone, V 13 Afloqualone, V 15 Ajmaline, II 120 Alacepril, V 16 Albendazole, II 122 Albuterol, CE 41, I 35, II 129 Alclometasone 17,21-Dipropionate, V 18 Aldesleukin, CE 51, II 131 Alendronate sodium, II 132 Alfentanil, II 136 Alfuzosin, II 138 Alitretinoin, V 21 Allantoin, CE 52, II 141 Allethrin, V 24 Allobarbital, CE 52 Allopurinol, CE 53, II 145 Alminoprofen, II 149 Almitrine, II 152 Almotriptan, V 27 Alosetron, CE 54, V 29 Alpidem, II 153 Alpiropride, II 156 Alprazolam, CE 55, I 48, II 158 Alprenolol, CE 57, II 160 Alprostadil, CE 62, II 166 Alteplase, I 56 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 685 686 Cumulative Index Altretamine, II 181 Amantadine, CE 62, II 183 Ambenonium chloride, II 187 Amcinonide, V 30 Amdinocillin, II 189 Amfenac, II 190 Amidox, II 191 Amifostine, II 193 Amikacin, CE 64, II 195 Amiloride, CE 67, II 198 Amineptine, II 205 Amino acids, CE 68, II 206 Aminobenzoic acid, CE 88, II 306 Aminocaproic acid, II 315 Aminoglutethimide, CE 91, II 318 Aminohippuric acid, CE 93, II 321 Aminolevulinic acid, V 33 Aminophylline, II 328 Aminopyrine, CE 94 Amiodarone, CE 95, II 331 Amiprilose, II 340 Amisulpride, II 341 Amitraz, II 348 Amitriptyline, CE 97, I 58, II 349 Amlexanox, II 355 Amlodipine, CE 101, I 87, II 356 Amobarbital, CE 103, II 359 Amodiaquin, II 368 Amorolfine, CE 107 Amosulalol, II 370 Amoxapine, II 372 Amoxicillin, CE 109, I 91, II 382 Amphetamine, CE 112, II 388 Amphotericin, II 424 Ampicillin, CE 124, I 107, II 434 Amprenavir, V 36 Amprolium, II 441 Amrinone, II 446 Amsacrine, II 449 Amylase, II 451 Amylocaine, II 452 Anagrelide, V 42 Anakinra, V 43 Angiotensin II, CE 127, II 454 Aniracetam, II 465 Anistreplase, II 467 Antazoline, II 468 Anthralin, II 470 Antipyrine, CE 130, II 472 Antitrypsin, II 487 Apigenin, II 489 Apomorphine, II 490 Apraclonidine, V 45 Apramycin, II 491 Aprepitant, V 46 Aprindine, II 493 Aprobarbital, CE 133, II 494 Aprotinin, CE 135, II 498 Aranidipine, V 48 Arbaprostil, II 500 Arbekacin, CE 136 Arbidol, II 502 Arecoline, II 503 Argatroban, II 504 Arotinolol, CE 137, V 49 Arteether, V 52 Artemisinin, II 505 Artesunate, CE 138 Articaine, V 54 Ascorbic acid, CE 139, II 509 Asparaginase, V 57 Aspartame, CE 147, II 526 Aspirin, CE 149, I 122, II 529 Aspoxicillin, CE 154, II 532 Astemizole, I 137, II 534 Atazanavir sulfate, V 58 Atenolol, CE 155, I 140, II 535 Atipamezole, V 60 Atomoxetine hydrochloride, V 62 Atorvastatin, V 64 Atosiban, CE 170, V 66 Atovaquone, II 543 Atracurium besylate, II 545 Atropine, CE 171, I 164, II 547 Auranofin, II 553 Avermectin, II 555 Avitriptan, II 557 Azacyclonol, II 558 Azaperone, CE 176, II 560 Azasetron, II 563 Azatadine, II 564 Azathioprine, CE 177, I 177, II 566 Azelaic acid, II 568 Azelastine, CE 177, II 572 Azithromycin, I 181, II 575 Azlocillin, II 578 Azosemide, II 580 Aztreonam, II 582 Bacampicillin, II 586 Bacitracin, CE 180, II 588 Baclofen, CE 180, II 590 Balofloxacin, V 67 Bambermycins, V 69 Bambuterol, CE 183, II 596 Bamethan, CE 185, II 598 Bamifylline, II 600 Barbital, CE 187, II 601 Barnidipine, II 604 Beclobrate, II 607 Beclomethasone, CE 190, II 609 Beclomethasone dipropionate, I 184 Befunolol, II 614, V 70 Benactyzine, II 615 Benazepril, I 188, II 617 Bendroflumethiazide, CE 191, II 619 Benfluorex, II 627 Benidipine, II 628 Benoxaprofen, II 630 Benperidol, II 632 Cumulative Index Benproperine, CE 194 Benserazide, CE 196 Benzalkonium chloride, CE 197, II 635, V 71 Benzbromarone, II 640 Benzethidine, II 641 Benzethonium chloride, II 643 Benzocaine, CE 199, II 645 Benzoctamine, II 655 Benzoic acid, CE 201, II 657 Benzonatate, II 676 Benzoyl peroxide, II 677 Benzphetamine, CE 208, II 679 Benzquinamide, CE 208, II 682 Benzthiazide, CE 209, II 684 Benztropine mesylate, II 688 Benzydamine, II 692 Benzyl alcohol, II 693 Benzyl benzoate, II 694 Bepridil, II 698 Berberine, II 702 Besipirdine, II 704 Beta-carotene, II 705 Betahistine, II 717 Betaine, II 718, V 72 Betamethasone, CE 210, I 191, II 720 Betaxolol, CE 212, II 723 Bethanechol chloride, V 74 Betotastine, II 729 Bevantolol, II 730 Bexarotene, V 75 Bezafibrate, II 732 BHT, CE 213 Biapenem, V 77 Bicalutamide, II 733 Bidisomide, II 734 Bifonazole, CE 214, II 735 Bimatoprost, V 79 Bioresmethrin, II 737, V 80 Biotin, CE 214, II 738 Biperiden, CE 217, II 744 Bisacodyl, II 746 Bisantrene, II 748 Bisoprolol, CE 219, II 752 Bitolterol, II 757 Bivalirudin, V 81 Bleomycin sulfate, II 759 Boldenone, II 763, V 82 Boldine, II 767 Bopindolol, II 768 Bosentan, V 83 β-Boswellic acid, V 86 Bretylium tosylate, CE 221, II 771 Brimonidine, V 88 Brodifacoum, II 772 Brodimoprim, CE 222, II 773 Bromadiolone, II 775 Bromazepam, CE 223, II 776 Bromfenac, V 90 Bromhexine, II 781 Bromocriptine, I 201, II 783 Bromodiphenhydramine, II 784 Bromperidol, II 786 Brompheniramine, CE 226, II 788 Brotizolam, CE 230, II 798 Brovincamine, V 92 Bucillamine, II 801, V 93 Bucladesine, II 802 Buclizine, CE 230, II 803 Bucumolol, II 807 Budesonide, II 809 Budipine, V 94 Buflomedil, II 816 Bufotenine, II 817 Bufuralol, II 819 Bulaquine, V 95 Bumadizon, II 820 Bumetanide, CE 231, II 822 Bunazosin, II 832 Bupivacaine, CE 233, II 833 Bupranolol, CE 244, II 851 Buprenorphine, II 854 Bupropion, CE 246, II 865 Buserelin, CE 247, II 868 Buspirone, CE 247, I 204, II 871 Busulfan, II 873 Butabarbital, CE 248, II 877 Butacaine, II 884, V 97 Butalbital, CE 250, I 211 Butamben, II 887, V 99 Butamirate, CE 253 Butethal, II 888 Butethamate, CE 254, II 890 Buthionine sulfoximine, CE 256, II 892 Butibufen, II 894 Butoconazole, V 100 Butorphanol, II 895 Butyl flufenamate, V 101 Butylscopolammonium bromide, CE 257 Cabergoline, II 897 Cadralazine, II 899 Caffeine, CE 257, II 901 Calcifediol, II 943 Calcipotriene, II 946 Calcitonin, CE 274, II 948 Calcitriol, II 952 Cambendazole, V 102 Camostat, II 955 Camphor, II 956 Camptothecin, II 958 Canadine, CE 274 Candesartan cilexetil, V 104 Candoxatril, II 960 Capecitabine, V 106 Capreomycin, CE 275 Capsaicin, II 962 Captan, CE 276, II 964 Captodiamine, II 966 Captopril, CE 276, I 215, II 967 Carazolol, CE 278, II 976 687 688 Cumulative Index Carbadox, II 977 Carbamazepine, CE 280, I 224, II 984 Carbaryl, CE 284, II 991 Carbenicillin, CE 285, II 1006 Carbetapentane, II 1010 Carbidopa, CE 286, II 1011 Carbimazole, II 1016 Carbinoxamine, CE 286, II 1017 Carbisocaine, II 1021 Carboplatin, CE 288, I 252, II 1022 Carbromal, II 1025 Carbutamide, II 1027 Carbuterol, CE 288 Carisoprodol, I 255 Carmustine, II 1028 Carnitine, CE 290, II 1031 Carpipramine, II 1042 Carprofen, CE 291, II 1044 Carteolol, CE 295, II 1046 Carumonam, II 1053 Carvedilol, CE 298, II 1055 Casanthranol, V 108 Caspofungin, V 109 Castor oil, V 112 Cefaclor, I 257, II 1061 Cefadroxil, I 265, II 1062 Cefamandole, CE 302, II 1065 Cefatrizine, II 1069 Cefazolin, II 1070 Cefbuperazone, II 1081, V 113 Cefdinir, II 1082 Cefditoren, V 114 Cefepime, II 1084 Cefetamet, II 1089 Cefixime, CE 303, I 274, II 1090 Cefmenoxime, CE 304, II 1091 Cefmetazole, II 1095 Cefminox, CE 304, II 1098 Cefoaxime, I 278 Cefodizime, CE 305, II 1099 Cefonicid, II 1102 Cefoperazone, CE 305, II 1104 Ceforanide, II 1115 Cefoselis, V 116 Cefotaxime, CE 306, II 1116 Cefotetan, II 1118 Cefotiam, II 1121 Cefoxitin, II 1125 Cefozopran, V 117 Cefpimizole, CE 308, II 1133 Cefpiramide, CE 309, II 1135 Cefpirome, CE 310, II 1139 Cefpodoxime proxetil, II 1142 Cefprozil, I 289, II 1146 Ceftazidime, CE 311, I 291, II 1147 Cefteram, II 1151 Ceftibuten, II 1153 Ceftiofur, CE 313, II 1160 Ceftizoxime, CE 313, II 1165 Ceftriaxone, CE 314, I 303, II 1170 Cefuroxime, CE 315, I 311, II 1173 Cefuzonam, V 118 Celecoxib, V 119 Celiprolol, CE 317, II 1176 Centchroman, II 1183 Cephalexin, CE 320, I 317, II 1185 Cephaloridine, II 1189 Cephalosporin C, II 1193 Cephalothin, CE 321, II 1194 Cephapirin sodium, CE 322, II 1200 Cephradine, CE 323, II 1208 Cerivastatin, V 123 Ceronapril, CE 324 Cetirizine, II 1214 Cetrorelix, V 125 Cetyl alcohol, V 128 Cevimeline hydrochloride, V 130 Chelidonine, II 1219 Chenodiol, CE 325, II 1221 Chlophedianol, CE 326 Chloral hydrate, II 1237 Chlorambucil, CE 327, II 1239 Chloramphenicol, CE 328, II 1244 Chlorcyclizine, CE 329, II 1257 Chlordiazepoxide, CE 331, II 1261 Chlorguanide, II 1276 Chlorhexidine, II 1278 Chlormadinone, II 1283 Chlormezanone, CE, II 1284 Chlorobutanol, V 132 Chloroprocaine, II 1288, V 133 Chloropyramine, II 1290 Chloroquine, CE 333, II 1291 Chlorothiazide, CE 338, II 1303 Chloroxine, II 1310 Chloroxylenol, II 1311 Chlorphenesin, II 1314 Chlorpheniramine, CE 340, II 1317 Chlorphenoxamine, CE 352, II 1334 Chlorpromazine, CE 353, II 1336 Chlorpropamide, CE 355, II 1356 Chlorprothixene, CE 357, II 1364 Chlorpyrifos, CE 358, II 1370 Chlortetracycline, CE 358, II 1375 Chlorthalidone, CE 362, II 1392 Chlorzoxazone, II 1402 Cholic acid, CE 365, II 1408 Choline, CE 366, II 1411 Chorionic gonadotropin, V 134 Chymopapain, II 1423 Chymotrypsin, CE 368, II 1424 Cicletanine, CE 368, II 1425 Ciclopirox, II 1429 Cicloprofen, CE 371 Cicloprolol, II 1431 Ciclotropium bromide, II 1432 Cidofovir, II 1434 Cifenline, II 1436 Cilastatin, I 330 Cilazapril, II 1441 Cumulative Index Cilnidipine, V 135 Cilostazol, II 1443 Cimetidine, CE 372, I 334, II 1445 Cimetropium bromide, V 136 Cinchonidine, II 1449 Cinchonine, II 1452 Cinnarizine, II 1454 Cinolazepam, II 1457 Cinoxacin, II 1458 Ciprofibrate, II 1460 Ciprofloxacin, CE 375, I 347, II 1463 Ciprostene, II 1474 Cirazoline, II 1475 Cisapride, CE 376, I 364, II 1476 Cisatracurium besylate, V 137 Cisplatin, CE 376, II 1478 Citalopram, II 1487 Citric acid, V 139 Cladribine, II 1492 Clarithromycin, CE 377, I 368, II 1495 Clavulanic acid, CE 378, I 371, II 1497 Clemastine, II 1498 Clenbuterol, CE 378, II 1501 Clentiazem, CE 383 Clidinium bromide, CE 384, II 1508 Clinafloxacin, II 1510 Clindamycin, CE 388, I 379, II 1512 Clioquinol, II 1514, V 142 Clobazam, CE 388, II 1516 Clobenzorex, II 1519 Clobetasol, CE 390 Clobetasol 17-propionate, V 143 Clobetasone, CE 391 Clobutinol, CE 391 Clocinizine, II 1521 Clodronic acid, II 1522 Clofazimine, II 1525 Clofibrate, II 1527 Clofibric acid, II 1529 Clomethiazole, II 1532 Clomiphene, CE 393, II 1533 Clomipramine, CE 394, II 1536 Clonazepam, CE 395, I 383, II 1556 Clonidine, II 1559 Clonixin, II 1568 Clopenthixol, CE 399 Clopidogrel, V 147 Clopidol, V 149 Clorazepate, CE 399, II 1570 Cloricromen, V 151 Clorprenaline, CE 400 Clorsulon, V 152 Closantel, II 1577 Clothiapine, II 1578 Clotiazepam, CE 401, II 1579 Clotrimazole, I 395 Cloxacillin, CE 402, II 1580 Cloxazolam, CE 404 Cloxyquin, II 1596 Clozapine, CE 406, I 400, II 1597 Cocaine, CE 407, II 1602 Codeine, CE 413, I 412, II 1628 Colchicine, II 1633 Colistin, II 1640, V 153 Copovithane, II 1642 Corticosterone, CE 424, II 1643 Corticotropin, CE 426, II 1644 Cortisone, CE 427, II 1646 Cortivazol, II 1665 Cotinine, II 1666 Coumachlor, CE 433 Coumaphos, CE 434, II 1668 Coumarin, II 1671 Cromolyn, I 436, II 1673 Crotamiton, II 1675 Cyamemazine, II 1677 Cyclamic acid, II 1679 Cyclandelate, II 1680 Cyclazocine, II 1682 Cyclizine, CE 435, II 1685 Cyclobarbital, CE 436 Cyclobenzaprine, I 439, II 1691 Cyclodrine, CE 437 Cycloguanil, II 1692 Cyclopentamine, II 1694 Cyclopentolate, CE 438, II 1696 Cyclophosphamide, II 1697 Cycloserine, II 1702 Cyclosporine, I 446, II 1704 Cyclothiazide, II 1708 Cyfluthrin, II 1712 Cyheptamide, II 1714 Cymarin, II 1716 Cypermethrin, II 1718, V 155 Cyproheptadine, II 1723 Cyromazine, II 1729 Cysteamine, II 1731 Cytarabine, CE 439, II 1736 Dacarbazine, II 1741 Dactinomycin, II 1746 Dalfopristin, V 156 Dalteparin, V 158 Danazol, II 1747 Danofloxacin, II 1752 Danthron, II 1754 Dantrolene, II 1756 Dapsone, CE 440, II 1759 Daptomycin, V 159 Daunorubicin, CE 441, II 1768 Debrisoquin, CE 442, II 1776 Decoquinate, II 1780 Deferiprone, V 161 Deferoxamine, II 1781 Defibrotide, II 1786 Deflazacort, II 1787, V 162 Dehydrocholic acid, II 1788 Delapril, II 1790 Delavirdine, II 1791 Demecarium bromide, II 1793 689 690 Cumulative Index Demeclocycline, CE 443, II 1794 Demexiptiline, II 1802 Demoxepam, II 1804 Denopamine, CE 445, II 1805 Deoxycholic acid, CE 447, II 1807 Deserpidine, CE 448, II 1821 Desipramine, CE 448, II 1823 Desloratadine, V 164 Deslorelin, II 1860 Desmopressin, II 1861 Desogestrel, I 457, V 166 Desonide, II 1862 Desoximetasone, V 167 Desoxycorticosterone, V 169 Detomidine, II 1863 Dexamethasone, CE 451, II 1865 Dexpanthenol, II 1887 Dexrazoxane, V 172 Dextran, II 1889, V 174 Dextromethorphan, CE 456, II 1890 Dextromoramide, II 1907 Dextrose, CE 457, II 1910 Dextrothyroxine, II 1942 Dezocine, II 1944 Diacerein, V 176 Diamorphine, CE 469, II 1945 Diatrizoate sodium, II 1951 Diaveridine, II 1953 Diazepam, CE 471, I 458, II 1954 Diazinon, II 1960 Diazoxide, II 1965 Dibekacin, II 1968 Dibucaine, CE 478, II 1970 Dichloroacetic acid, II 1973, V 177 Dichlorophen, V 178 Dichlorphenamide, CE 478, II 1974 Dichlorvos, CE 479, II 1976 Diclazuril, V 179 Diclofenac sodium, CE 480, I 486, II 1979 Dicloxacillin, CE 481, II 1993 Dicumarol, II 2006 Dicyclomine, I 500 Didanosine, CE 483, II 2007 Didox, II 2016 Dienestrol, II 2017 Diethylcarbamazine, II 2019 Diethylpropion, II 2021 Diethylstilbestrol, II 2026 Difemerine, II 2033 Difenoxin, II 2034 Diflorasone, II 2035 Difloxacin, II 2036 Diflunisal, CE 483, II 2038 Digitoxin, CE 484, II 2045 Digoxin, CE 485, I 503, II 2052 Dihydralazine, II 2055 Dihydroartemisinin, II 2057 Dihydrocodeine, CE 486, II 2058 Dihydroergotamine, II 2062 Dihydrostreptomycin, CE 488, II 2066 Dihydrotachysterol, V 181 Dihydroxyacetone, II 2071 Diitiazem, I 517 Dilevalol, CE 489, II 2073 Diltiazem, CE 490, II 2075 Dimenhydrinate, CE 495, II 2079 Dimethindene, CE 496, II 2080 Dimethyl sulfoxide, V 183 Dimethylaminobenzoic acid, II 2085 Dimetridazole, II 2087 Dinitolmide, V 185 Dinoprost, CE 500, II 2088 Dinoprostone, CE 501, II 2110 Diphenadione, II 2140 Diphenhydramine, CE 502, II 2141 Diphenidol, II 2159 Diphenoxylate, CE 503, II 2161 Dipipanone, II 2165 Dipivefrin, CE 504, V 186 Diprenorphine, II 2167 Dipyridamole, II 2170 Dipyrone, CE 506, II 2178 Dirithromycin, II 2184 Disopyramide, CE 507, II 2186 Disulfiram, II 2194 Dithiazanine iodide, V 187 Diuron, II 2198 Dobutamine, CE 513, II 2199 Docarpamine, V 188 Docetaxel, CE 516, II 2203 Docusate sodium, II 2205 Dofetilide, V 189 Dolasetron, V 191 Domperidone, II 2206 Donepezil, V 193 Dopamine, CE 517, II 2207 Dopexamine, II 2235 Doramectin, II 2236 Dorzolamide hydrochloride, II 2238 Dothiepin, II 2242 Doxacurium chloride, II 2248 Doxapram, CE 523, II 2249 Doxazosin, I 531, II 2254 Doxefazepam, V 195 Doxepin, CE 524, II 2255 Doxercalciferol, V 196 Doxifluridine, II 2276 Doxofylline, II 2277 Doxorubicin, CE 526, II 2279 Doxycycline, CE 527, I 534, II 2291 Doxylamine, CE 531, II 2295 Drofenine, II 2302 Droloxifene, II 2303 Dronabinol, II 2305 Droperidol, II 2312 Dropropizine, II 2320, V 198 Drospirenone, V 199 Droxicam, V 200 Droxidopa, V 201 Duloxetine, II 2321 Cumulative Index Dyclonine, II 2323 Dyphylline, CE 537, II 2324 Ebastine, III 1 Ebiratide, III 2 Ebrotidine, V 202 Econazole, CE 537, III 4 Edaravone, V 204 Edrophonium chloride, III 6 EDTA, CE 538, III 7, V 206 Efavirenz, V 208 Eflornithine, CE 540, III 10 Efonidipine, III 12 Efrotomycin, V 212 Egualen, V 213 Eletriptan, V 214 Eliprodil, III 13 Emedastine, III 14 Emetine, III 14 Emtricitabine, V 215 Enalapril, CE 541, I 543, III 15 Enalaprilat, CE 542, III 17 Encainide, III 19 Enilconazole, III 23 Enocitabine, III 24 Enoxacin, CE 542, III 24 Enoxaparin sodium, V 217 Enoximone, III 33 Enprostil, III 35 Enrofloxacin, III 36 Entacapone, V 218 Eperisone, CE 543, V 220 Ephedrine, CE 544, III 42 Epicillin, III 57 Epidermal growth factor, III 57 Epinastine, CE 560, III 60 Epinephrine, CE 562, III 61 Epinine, III 83 Epirizole, III 84 Epirubicin, CE 572, III 84 Epithiazide, CE 572 Eplerenone, V 222 Epoetin, CE 573, I 546, III 90 Epoprostenol, CE 574, III 90, V 224 Eprinomectin, III 91 Eprosartan, V 225 Eptastigmine, III 92 Eptazocine, V 227 Eptifibatide, V 228 Equilenin, CE 575 Equilin, III 93 Erdosteine, V 229 Ergocornine, III 94 Ergocristine, III 95 Ergocristinine, III 96 Ergocryptine, III 97 Ergoloid mesylates, III 98 Ergonovine, CE 576, III 99 Ergosine, III 104 Ergotamine, CE 576, III 105, V 230 691 Ertapenem, V 234 Erythrityl tetranitrate, III 108 Erythromycin, CE 578, I 549, III 109 Esculin, III 111 Esmolol, III 112 Estazolam, CE 580, III 114 Estradiol, CE 583, I 557, III 118 Estramustine, III 121 Estriol, III 123 Estrogens, conjugated, CE 586, I 569, III 124 Estrone, CE 587, III 128 Ethacrynic acid, CE 589, III 135 Ethambutol, III 141 Ethaverine, III 144 Ethchlorvynol, III 146 Ethenzamide, CE 590 Ethinyl estradiol, CE 591, I 579, III 147 Ethionamide, III 150 Ethoheptazine, CE 592 Ethopabate, III 151, V 236 Ethopropazine, CE 593, III 152 Ethosuximide, III 155, CE 594 Ethotoin, III 164 Ethyl icosapentate, V 237 Ethylmorphine, III 166 Ethynodiol diacetate, I 588 Ethynodiol, CE 596, III 166 Etidocaine, III 167 Etidronic acid, III 169 Etilefrin, CE 597 Etizolam, CE 599, III 170 Etodolac, CE 601, I 590, III 172 Etonitazene, III 173 Etonogestrel, V 238 Etoposide, I 597, III 174 Etoricoxib, V 240 Etorphine, III 177, V 242 Etoxeridine, III 179 Etretinate, III 181 Eugenol, III 184 Exemestane, V 243 Exifone, III 185 Ezetimibe, V 245 Factor VIII, III 186 Fadrozole, V 247 Falecalcitriol, V 248 Famciclovir, III 187 Famotidine, CE 603, I 605, III 189 Febantel, III 190 Felbamate, CE 603, III 191 Felbinac, III 196 Felodipine, III 199 Felypressin, III 203 Fenbendazole, III 204 Fenbufen, III 212 Fenbutrazate, III 216 Fencamfamine, III 217 Fenchone, III 219 Fendiline, CE 604 692 Cumulative Index Fenethazine, III 219 Fenfluramine, CE 606, III 220 Fenofibrate, III 228 Fenoldopam, III 229 Fenoprofen, CE 608, III 230 Fenoterol, CE 614, III 242 Fenoverine, III 243 Fenoxycarb, V 250 Fenozolone, III 244 Fenproporex, III 245 Fenprostalene, III 246 Fentanyl, CE 615, III 248 Fenthion, III 256 Fentiazac, III 258 Fenticonazole, III 259, V 251 Feprazone, III 260 Fexofenadine, V 253 Fibrinolysin, III 261 Finasteride, I 611, III 262 Flavoxate, III 263 Flecainide, CE 616, III 265 Fleroxacin, CE 618, III 271 Flezelastine, III 278 Floctafenine, III 278 Flomoxef, V 257 Florfenicol, V 258 Flosequinan, III 280 Floxacillin, III 282 Floxuridine, III 283 Flubendazole, III 289 Fluconazole, CE 618, I 615, III 291 Flucytosine, CE 619, III 293 Fludarabine, III 297 Fludeoxyglucose F18, III 299 Fludiazepam, CE 620 Fludrocortisone, CE 622, III 301, V 260 Flufenamic acid, CE 623, III 303 Fluindione, III 305 Flumazenil, III 306 Flumequine, CE 624, III 310 Flumethasone, CE 624, III 312 Flunarizine, III 315 Flunisolide, III 316 Flunitrazepam, CE 625, III 317 Flunixin, CE 628, III 321 Flunoxaprofen, III 325 Fluocinolone acetonide, CE 628, III 325 Fluocinonide, CE 630, III 329 Fluocortolone, CE 631, III 330 Fluorometholone, III 330 Fluorouracil, III 333 Fluoxetine, CE 632, I 621, III 347 Fluoxymesterone, III 351 Flupentixol, CE 633, III 357 Fluphenazine, CE 634, III 358 Flupirtine, III 366 Fluprostenol, V 262 Flurandrenolide, V 264 Flurazepam, CE 634, III 367 Flurbiprofen, CE 638, III 375 Flurithromycin, V 267 Flurogestone acetate, V 268 Flutamide, I 633, III 395 Flutazolam, III 396 Fluticasone propionate, CE 648, V 270 Flutoprazepam, III 397 Flutrimazole, III 398, V 273 Fluvastatin, I 634, III 398 Fluvoxamine, CE 649, III 399 Folic acid, CE 650, III 409 Fomepizole, V 274 Fomivirsen, V 276 Fonazine, III 414 Fondaparinux, V 277 Formestane, V 278 Formoterol, CE 650, III 415, V 279 Fosamprenavir calcium, V 281 Foscarnet sodium, III 417 Fosfosal, III 418 Fosinopril, CE 652, III 419, V 283 Fosphenytoin, III 420, V 284 Fotemustine, III 421 Frovatriptan, V 286 Fructose, III 422 Fumagillin, V 288 Furaltadone, III 423 Furazolidone, III 424 Furosemide, CE 652, I 637, III 434 Furprofen, III 440 Fusidic acid, III 440 Gabapentin, CE 655, III 442 Gadodiamide, III 446 Gadopentetic acid, III 447 Galantamine, V 290 Gallamine triethiodide, III 447 Gallopamil, CE 656, III 449 Ganciclovir, III 452 Ganirelix, V 292 Gatifloxacin, V 293 Gefitinib, V 295 Gemcitabine, V 296 Gemeprost, III 454 Gemfibrozil, I 654 Gemifloxacin, V 298 Gentamicin, CE 659, III 455 Gentian violet, III 462 Gentisic acid, III 466 Gestodene, V 300 Gestrinone, V 301 Glafenine, III 467 Glibornuride, III 468 Gliclazide, III 469 Glimepiride, III 470 Glipizide, CE 660, I 659, III 471 Glucagon, III 472 Gluconolactone, III 472 Glutethimide, CE 663, III 473 Glyburide, CE 664, I 665, III 480 Glycerin, CE 667, III 483, V 302 Cumulative Index Glycopyrrolate, III 487 Gonadorelin, CE 668, III 488 Gonadotropin, III 494 Goserelin, CE 669, I 672, III 495 Gossypol, III 495 Gramicidin, III 496 Granisetron, III 497 Grepafloxacin, III 503 Griseofulvin, III 503 Guaiacol, III 506 Guaifenesin, CE 669, I 673, III 508 Guanabenz, III 509, V 304 Guanadrel, V 305 Guanethidine, III 511 Guanfacine, III 512 Gusperimus, III 513 Halazepam, CE 672, III 515 Halcinonide, III 518 Halobetasol propionate, V 306 Halofantrine, CE 673, III 518 Halofuginone, V 308 Haloperidol, CE 674, III 525 Halothane, III 543 Haloxazolam, CE 677, III 543 Heparin, CE 678, III 544 Heptaminol, CE 680 Hesperidin, III 547 Hetacillin, III 551 Hetastarch, V 310 Hexachlorophene, III 553 Hexobarbital, CE 681, III 553 Hirudin, CE 682 Histamine, CE 683, III 554 Histrelin, III 571 Homatropine, CE 686, III 572 Hyaluronic acid, CE 691, III 575 Hydralazine, III 577 Hydrochiorothiazide, I 682, CE 693, III 583 Hydrocodone, I 699, III 586 Hydrocortisone, CE 695, I 705, III 587 Hydroflumethiazide, CE 707, III 592 Hydrogen peroxide, III 597 Hydromorphone, CE 708, III 598 Hydroquinone, CE 708, III 605, V 311 Hydroxychloroquine, CE 709, III 609 Hydroxyprogesterone, CE 710, III 615 Hydroxypropyl methylcellulose, III 623 Hydroxyquinoline, III 624 Hydroxyurea, III 625 Hydroxyzine, CE 713, III 626 Hygromycin B, V 312 Ibafloxacin, III 633 Ibogaine, III 634 Ibopamine, III 636 Ibufenac, III 638 Ibuprofen, CE 714, I 741, III 638 Ibutilide, III 646 Idarubicin, CE 724, III 647 Idazoxan, CE 724 Idebenone, III 648 Idoxuridine, III 649 Ifosfamide, III 652 Iloprost, III 654, V 313 Imatinib, V 314 Imidapril, III 655 Imidocarb, V 316 Imipenem, I 769, III 657 Imipramine, CE 725, III 658 Indalpine, III 689 Indapamide, CE 729, I 774, III 691 Indeloxazine hydrochloride, III 692 Indinavir, III 692 Indobufen, III 695 Indocyanine green, III 698 Indomethacin, CE 730, III 699 Indoprofen, CE 734 Indoramin, III 718 Inositol, III 719 Insulin, CE 738, I 778, III 719 Interferon, CE 741, I 787, III 721 Iobenguane, V 318 Iodinated glycerol, III 723 Iodixanol, V 320 Iodochlorhydroxyquin, III 723 Iodoquinol, III 726 Iofratol, III 727 Iohexol, CE 743, III 728 Iopamidol, CE 744, III 729 Iopanoic acid, CE 746, V 322 Iopromide, V 324 Iothalamate, III 730 Iothalamic acid, CE 746 Ioversol, V 326 Ipecac, III 735 Ipratropium bromide, CE 749, I 791, V 327 Ipriflavone, III 738, V 328 Iprindole, III 739 Iproniazid, III 740 Irbesartan, III 741 Irinotecan, III 742 Isepamicin, III 747 Isocarboxazid, CE 751, III 750 Isoetharine, III 752 Isofezolac, III 753 Isoflupredone, III 753, V 329 Isoflurane, III 754 Isoniazid, CE 752, III 755 Isopropamide iodide, V 330 Isoproterenol, CE 753, III 763 Isosorbide dinitrate, III 772 Isosorbide mononitrate, III 776 Isothipendyl, CE 763, III 778 Isoxicam, III 780 Isoxsuprine, CE 765, III 785 Isradipine, III 789 Itopride, V 332 Itraconazole, CE 767, III 792 Ivermectin, III 799 693 694 Cumulative Index Josamycin, CE 768, III 809 Kanamycin, CE 768, III 812 Ketamine, CE 769, III 815 Ketanserin, III 822 Ketoconazole, CE 776, I 792, III 824 Ketoprofen, CE 777, I 798, III 826 Ketorolac, I 819, III 833 Ketotifen, III 834 Kinetin, V 333 Labetalol, CE 787, III 835 Lacidipine, III 843 Lactulose, III 844 Lafutidine, V 334 Lamivudine, CE 792, III 848, V 335 Lamotrigine, CE 794, III 849 Lansoprazole, CE 794, III 855 Lasalocid A, III 858 Latanoprost, V 339 Lazabemide, III 862 Leflunomide, V 341 Lenampicillin, III 863 Lercanidipine, V 343 Letrozole, III 864, V 345 Leucovorin, CE 795, III 864 Leuprolide, I 829 Levallorphan, CE 795, III 869 Levamisole, CE 796, III 870 Levetiracetam, V 346 Levobunolol, CE 797, III 874 Levodopa, CE 798, III 875 Levonordefrin, III 887, V 348 Levorphanol, CE 802, III 888 Levosimendan, V 349 Levothyroxine sodium, CE 804, III 896 Levothyroxine, I 831 Lidamidine, V 351 Lidocaine, CE 805, III 901 Lidoflazine, III 920 Limaprost, III 921 Lincomycin, CE 809, III 922, V 352 Lindane, V 354 Linezolid, III 924, V 355 Linoleic acid, III 924 Linuron, III 955 Liothyronine, CE 810, III 956, V 357 Lisinopril, CE 811, I 836, III 961 Lisofylline, III 962 Lisuride, III 962 Litracen, CE 812 Lobeline, III 963 Lobenzarit, III 964 Lodamide, III 1722 Lodoxamide, III 965 Lofepramine, III 966 Lomefloxacin, CE 813, III 967 Lomerizine, V 358 Lometrexol, III 971 Lomustine, III 972 Lonidamine, III 973 Loperamide, III 975 Lopinavir, V 359 Loprazolam, III 977 Loracarbef, I 839 Loratadine, I 841, III 979 Lorazepam, CE 813, I 844, III 979 Lormetazepam, III 982 Lornoxicam, III 983 Losartan, III 984 Loteprednol etabonate, V 362 Lovastatin, I 858 Loxapine, III 990 Loxoprofen, III 999 Lufenuron, III 1004 Lypressin, CE 816, III 1005 Lysozyme, CE 816, III 1007 Mabuterol, III 1013 Maduramicin, III 1014 Mafenide, III 1014 Malachite green, III 1015 Malotilate, III 1017 Manidipine, III 1018 Mannitol, CE 821, III 1019 Maprotiline, CE 821, III 1025 Marbofloxacin, V 364 Masoprocol, V 367 Maxacalcitol, V 368 Mazindol, III 1039 Mebendazole, III 1042 Mecamylamine, III 1050 Mechlorethamine, III 1051 Meclizine, CE 823, III 1053 Meclocycline, CE 825, III 1057 Meclofenamic acid, CE 825, III 1058 Meclofenoxate, III 1061 Medazepam, CE 826, III 1063 Medetomidine, V 369 Medifoxamine, III 1066 Medroxyprogesterone, III 1069 Medroxyprogesterone acetate, I 862 Mefenamic acid, CE 828, III 1072 Mefenorex, III 1083 Mefloquine hydrochloride, CE 828, III 1083 Megazol, III 1089 Megestrol acetate, III 1090 Meglutol, III 1093, V 371 Melatonin, V 372 Melengestrol acetate, V 375 Melitracen, III 1094 Meloxicam, III 1094 Melphalan, CE 833, III 1095 Memantine, V 378 Menadione, III 1102 Menotropins, III 1106 Menthol, III 1107, V 380 Mepazine, III 1108 Mepenzolate bromide, CE 833, III 1109, V 381 Cumulative Index Meperidine, CE 835, III 1110 Mephenesin, III 1119 Mephentermine, III 1121 Mephenytoin, CE 837, III 1125 Mephobarbital, CE 837, III 1131 Mepindolol, CE 841 Mepivacaine, CE 843, III 1138 Mepixanox, V 383 Meprobamate, III 1145 Meptazinol, III 1146 Mequinol, V 384 Mequitazine, CE 848 Mercaptobenzothiazole, CE 850, III 1149 Mercaptopurine, III 1151 Meropenem, III 1159 Mesalamine, CE 851, III 1163 Mescaline, III 1168 Mesna, III 1169 Mesoridazine, CE 853, III 1172 Mestranol, CE 854, III 1181 Metaclazepam, CE 854 Metapramine, III 1184 Metaproterenol, CE 856, III 1188 Metaraminol, III 1192 Metformin, CE 861, III 1194 Methacholine chloride, CE 862, III 1200 Methacycline, CE 863, III 1201 Methadone, CE 863, III 1201 Methamphetamine, CE 868, III 1216 Methaphenilene, CE 876 Methapyrilene, III 1241 Methaqualone, CE 877, III 1243 Metharbital, CE 877 Methazolamide, III 1245 Methdilazine, III 1247 Methenamine, V 385 Methicillin sodium, III 1249 Methimazole, III 1255 Methocarbamol, III 1256 Methohexital, III 1262 Methoprene, III 1266, V 386 Methotrexate, CE 879, III 1266 Methotrimeprazine, CE 881, III 1278 Methoxamine, CE 882, III 1285 Methoxsalen, III 1290 Methoxychlor, V 387 Methoxyphenamine, CE 882, III 1292 Methoxypromazine, III 1293 Methscopolamine bromide, III 1294 Methsuximide, III 1295 Methyclothiazide, CE 883, III 1299 Methyl salicylate, III 1301 Methyldopa, CE 884, III 1304 Methyldopate, III 1309 Methylene blue, CE 884, III 1310 Methylephedrine, III 1313 Methylergonovine, III 1314 Methylphenidate, CE 885, I 867 Methylprednisolone, CE 886, I 874, III 1317 Methyltestosterone, CE 888, III 1319, V 392 Methylthiouracil, CE 889 Methyprylon, III 1327 Methysergide, III 1328 Metiamide, III 1330 Metipranolol, CE 890, III 1331 Metoclopramide, III 1332 Metocurine iodide, III 1341 Metolazone, CE 892, III 1342 Metopimazine, III 1346 Metoprolol, CE 893, I 887, III 1347 Metrizamide, V 393 Metronidazole, III 1354 Metyrapone, CE 904, III 1363 Metyrosine, V 394 Mexiletine, CE 904, III 1365 Mezlocillin, III 1376 Mianserin, CE 906, III 1380 Mibefradil, III 1384 Mibolerone, III 1384 Micafungin, V 396 Miconazole, CE 909, III 1386 Midazolam, I 911, III 1390 Midodrine, CE 909 Mifepristone, III 1395 Milnacipran, V 398 Miloxacin, III 1396 Milrinone, III 1397 Miltefosine, III 1399 Minaprine, III 1400 Minocycline, CE 910, III 1401 Minoxidil, III 1407 Miokamycin, III 1409 Mirtazapine, V 400, III 1410 Misoprostol, III 1411, V 405 Mitoguazone, III 1412 Mitolactol, III 1412 Mitomycin, III 1413 Mitotane, III 1419 Mitoxantrone, III 1421 Mivacurium chloride, III 1424 Mizolastine, V 406 Mizoribine, III 1426 Moclobemide, CE 912, III 1427 Modafinil, III 1432 Moexipril, V 411 Mofezolac, V 412 Molindone, CE 913, III 1433 Molsidomine, III 1433 Mometasone furoate, I 924, V 413 Monensin, III 1434, V 415 Montelukast, III 1441 Moperone, III 1443 Moprolol, III 1445 Morantel, III 1445, V 416 Morazone, III 1447 Moricizine, III 1448 Moroxydine, III 1449 Morphine, CE 913, III 1450 Morsuximide, III 1483 Mosapride, V 417 695 696 Cumulative Index Moxidectin, III 1484 Moxifloxacin, V 420 Moxonidine, III 1485, V 423 Mupirocin, I 925 Muzolimine, III 1485 Mycophenolic acid, III 1486 Nabumetone, I 927, III 1488 Nadifloxacin, V 424 Nadolol, CE 923, III 1488 Nadoxolol, III 1501 Nafarelin, CE 928, III 1502 Nafcillin, CE 929, III 1503 Nafronyl, CE 930, III 1511 Naftifine, III 1512 Naftopidil, V 425 Nalbuphine, CE 932, III 1513 Nalidixic acid, CE 933, III 1519 Nalmefene, III 1525 Nalorphine, CE 933, III 1526 Naloxone, III 1537 Naltrexone, III 1546 Nandrolone, CE 936, III 1552, V 427 Naphazoline, CE 937, III 1557 Naproxen, CE 938, I 929, III 1565 Narasin, III 1570, V 429 Naratriptan, III 1573 Nartograstim, V 430 Natamycin, III 1574 Nateglinide, V 431 Nebivolol, V 433 Nedocromil, CE 947, III 1576 Nefazodone, III 1577 Nefopam, CE 948, III 1579 Nelfinavir, III 1581, V 435 Nemonapride, III 1582 Neomycin, CE 951, I 951, III 1583 Neostigmine bromide, CE 952, III 1584 Nequinate, V 440 Neridronic acid, V 441 Netilmicin, CE 953, III 1587 Nevirapine, V 443 Niacin, CE 954, III 1591 Niacinamide, CE 959, III 1598 Nialamide, III 1605 Niaprazine, III 1606 Nicarbazin, III 1607, V 447 Nicardipine, CE 965, III 1610 Nicergoline, III 1616 Niclosamide, III 1616 Nicorandil, III 1618 Nicotine, CE 968, III 1620 Nifedipine, CE 971, I 958, III 1630 Nifenalol, CE 972, III 1633 Niflumic acid, III 1634 Nifuroxazide, III 1637 Nikethamide, CE 973, III 1637 Nilutamide, III 1638, V 448 Nilvadipine, III 1639 Nimesulide, III 1640 Nimetazepam, CE 947 Nimodipine, CE 975, III 1641 Nipradilol, V 449 Nisin, CE 976 Nisoldipine, CE 976, III 1646 Nitazoxanide, V 450 Nitenpyram, V 452 Nitrazepam, CE 977, III 1649 Nitrendipine, CE 981, III 1654 Nitrofurantoin, I 968, III 1660 Nitrofurazone, III 1661 Nitroglycerin, I 973 Nizatidine, I 979, III 1667 Nomegestrol, V 453 Nomifensine, III 1668 Nonoxynol-9, III 1671, V 454 Nordazepam, CE 982 Norepinephrine, CE 982, III 1672 Norethindrone, CE 992, I 984, III 1697 Norethynodrel, CE 994, III 1698 Norfenefrine, CE 994 Norfloxacin, CE 996, III 1698 Norgestimate, CE 997, III 1711 Norgestrel, CE 998, I 993, III 1713 Norpseudoephedrine, CE 999 Nortriptyline, CE 1000, I 1000, III 1715 Noscapine, CE 1003, III 1720 Novobiocin, III 1723 Nylidrin, CE 1004, III 1726 Nystatin, CE 1005, III 1728, V 455 Octhilinone, III 1730 Octocrylene, V 456 Octopamine, CE 1006, III 1731 Octreotide, III 1732 Octyl methoxycinnamate, III 1734 Odapipam, III 1735 Ofloxacin, CE 1007, I 1029, III 1735 Olanzapine, III 1741 Olaquindox, III 1743 Oleandomycin, CE 1012, III 1744 Oleic acid, V 457 Olmesartan, V 469 Olopatadine, V 470 Olsalazine, III 1744 Omeprazole, CE 1012, I 1044, III 1745 Ondansetron, CE 1013, I 1052, III 1747 Ontazolast, III 1749 Opipramol, CE 1014, III 1749 Orbifloxacin, V 472 Orlistat, V 475 Ormetoprim, CE 1015, III 1752 Ornidazole, CE 1016 Orphenadrine, CE 1018, III 1753 Oryzalin, III 1756 Oseltamivir, V 477 Oxacillin, CE 1021, III 1757 Oxaliplatin, V 479 Oxamniquine, CE 1023, III 1768 Oxandrolone, III 1769 Cumulative Index Oxaprozin, I 1062 Oxatomide, III 1770 Oxazepam, CE 1023, III 1771 Oxazolam, III 1793 Oxcarbazepine, III 1793 Oxeladin, III 1798 Oxfendazole, III 1799 Oxibendazole, III 1805 Oxiconazole, V 481 Oxiracetam, III 1806 Oxolinic acid, CE 1027, III 1808 Oxomemazine, CE 1028 Oxprenolol, CE 1029, III 1811 Oxybenzone, III 1817 Oxybutynin chloride, CE 1034, III 1819 Oxyclozanide, III 1819 Oxycodone, I 1065, III 1820 Oxymetazoline, CE 1035, III 1821 Oxymetholone, III 1825 Oxymorphone, III 1826 Oxyphenbutazone, III 1828 Oxyphencyclimine, CE 1036 Oxyquinoline, III 1829 Oxytetracycline, CE 1037, III 1830 Oxytocin, CE 1043, III 1850 Ozagrel, III 1855 Paclitaxel, CE 1045, I 1072, IV 1 Padimate O, IV 6 Palinavir, IV 6 Pamidronate, IV 7 Pamoic acid, CE 1047 Pancreatin, IV 12 Pancuronium bromide, IV 13 Panipenem, V 483 Panomifene, IV 14 Pantoprazole, CE 1047, IV 15 Pantothenic acid, CE 1048, IV 17 Papaverine, CE 1050, IV 20 Paramethadione, IV 29 Paramethasone, IV 30 Parathyroid hormone, IV 31 Parbendazole, IV 32 Parconazole, IV 33 Parecoxib, V 484 Pargyline, IV 34 Paricalcitol, V 485 Paromomycin, CE 1054, IV 36 Paroxetine, IV 39 Pazufloxacin, V 487 Pefloxacin, CE 1056, IV 44 Pemirolast, IV 51 Pemoline, CE 1056, IV 51 Penbutolol, CE 1057, IV 55 Penciclovir, CE 1057, IV 62, V 488 Penclomedine, IV 63 Penfluridol, IV 64 Penicillamine, IV 66 Penicillin G, CE 1058, IV 76 Penicillin V, CE 1061, I 1085, IV 95 697 Pentaerythritol tetranitrate, IV 98, V 490 Pentamidine, CE 1062, IV 100 Pentazocine, CE 1062, IV 104 Penthienate bromide, IV 115 Pentobarbital, CE 1064, IV 116 Pentosan polysulfate, V 491 Pentostatin, IV 124 Pentoxifylline, CE 1071, I 1096, IV 130 Perflubron, V 492 Pergolide, IV 131 Perhexiline, IV 132 Pericyazine, IV 133 Perindopril, IV 134 Permethrin, IV 135 Perospirone, V 493 Perphenazine, CE 1071, IV 139 Phenacemide, IV 146 Phenacetin, CE 1073, IV 147 Phenadoxone, IV 149 Phenampromide, IV 150 Phenazocine, IV 151 Phenazopyridine hydrochloride, CE 1075, IV 154, V 494 Phencyclidine, IV 156 Phendimetrazine, CE 1075, IV 159 Phenelzine, IV 161 Phenformin, CE 1076, IV 166 Phenglutarimide, IV 166 Phenindamine, IV 167 Phenindione, IV 169 Pheniramine, CE 1077, IV 170 Phenmetrazine, CE 1080, IV 178 Phenobarbital, CE 1081, IV 181 Phenol, CE 1091, IV 205 Phenolphthalein, IV 224 Phenomorphan, IV 228 Phenoperidine, IV 229 Phenothiazine, CE 1094, IV 230 Phenoxybenzamine, CE 1095, IV 235 Phenprocoumon, CE 1098 Phensuximide, CE 1098, IV 237 Phentermine, CE 1099, IV 239, V 497 Phentolamine, IV 245 Phenyl salicylate, IV 248 Phenylbutazone, IV 249 Phenylephrine, CE 1100, IV 258 Phenylpropanolamine, CE 1102, I 1103, IV 266 Phenyltoloxamine, IV 267 Phenytoin, CE 1108, I 1117, IV 270 Phloroglucinol, IV 274 Pholcodine, IV 275 Pholedrine, CE 1111 Phosmet, IV 276 Phosphatidylcholine, IV 277, V 501 Phosphatidylglycerol, V 504 Physostigmine, CE 1114, IV 284 Picotamide, IV 289 Picroside, IV 290 Picumeterol, CE 1114 Pidotimod, IV 290 698 Cumulative Index Piketoprofen, V 508 Pilocarpine, CE 1115, IV 291 Pilsicainide, V 509 Piminodine, IV 295 Pimobendan, IV 296 Pimozide, CE 1116, IV 298 Pinacidil, IV 303 Pinaverium bromide, IV 306 Pindolol, CE 1117, IV 307 Pioglitazone, V 511 Pipamazine, IV 323 Pipamperone, IV 324 Pipazethate, IV 326 Pipecuronium bromide, IV 327 Pipemidic acid, CE 1134, IV 328 Piperacetazine, IV 330 Piperacillin, CE 1134, IV 331 Piperazine, IV 340 Pipercuronium bromide, V 514 Piperidolate, IV 341 Piperine, IV 342 Piperocaine, IV 343 Piperonyl butoxide, IV 344 Piperoxan, CE 1136 Pipotiazine, IV 347 Pipradrol, IV 348 Piracetam, CE 1137, IV 349 Pirarubicin, IV 350 Pirbuterol, CE 1137 Pirenzepine, IV 352 Piretanide, CE 1140, IV 353 Piritramide, IV 354 Pirlimycin, V 515 Pirmenol, IV 355 Piromidic acid, CE 1141, IV 358 Piroxicam, CE 1141, I 1140, IV 359 Pivampicillin, IV 361 Pizotyline, IV 362 Podofilox, IV 364 Poloxalene, V 518 Polyethylene glycol, CE 1144 Polymyxin, I 1150, IV 365 Polythiazide, IV 367 Porfiromycin, IV 369 Practolol, IV 370 Pralidoxime chloride, IV 371 Pramipexole, V 519 Pramiracetam, IV 373 Pramlintide, IV 374 Pramoxine, IV 375 Pranlukast, V 521 Pranoprofen, CE 1144 Pravastatin sodium, I 1153, IV 378 Prazepam, CE 1145, IV 380 Praziquantel, CE 1146, IV 390 Prazosin, CE 1147, IV 393 Prednicarbate, IV 402, V 523 Prednisolone, CE 1147, IV 403 Prednisone, CE 1150, I 1156, IV 421 Premafloxacin, IV 424 Prenalterol, CE 1151 Prenylamine, IV 424 Prifinium bromide, IV 425 Prilocaine, CE 1152, IV 426 Primaquine, CE 1157, IV 432 Primidone, CE 1161, IV 437 Pristinamycin, IV 448 Proadifen, IV 449 Probenecid, CE 1164, IV 450 Probucol, IV 459 Procainamide, CE 1165, IV 460 Procaine, CE 1168, IV 469 Procarbazine, IV 478 Prochlorperazine, CE 1172, IV 481 Procyclidine, CE 1173, IV 488 Progabide, IV 490 Progesterone, CE 1175, IV 492 Proglumide, CE 1179 Proheptazine, IV 505 Prolintane, CE 1180, IV 506 Promazine, CE 1180, IV 507 Promethazine, CE 1182, I 1171, IV 515 Pronethalol, IV 517 Propafenone, CE 1187, IV 518 Propantheline bromide, IV 529 Proparacaine, IV 532 Propentofylline, CE 1190, IV 533 Properidine, IV 534 Propicillin, IV 535 Propiomazine, CE 1190, IV 536 Propionylpromazine, V 524 Propiverine, IV 541 Propofol, I 1185, IV 542 Propoxur, CE 1191, IV 545 Propoxycaine hydrochloride, V 527 Propoxyphene, CE 1191, I 1189, IV 551 Propranolol, CE 1193, IV 555 Propylene glycol, IV 602, V 528 Propylhexedrine, IV 605, V 529 Propylparaben, IV 606 Propylthiouracil, CE 1213, IV 607 Propyphenazone, CE 1214 Proscillaridin, IV 609 Prospidium chloride, CE 1214 Protamine sulfate, IV 609 Prothipendyl, IV 611 Protionamide, IV 612 Protirelin, CE 1215, IV 613, V 530 Protriptyline, CE 1216, IV 614 Prulifloxacin, V 532 Pseudoephedrine, CE 1219, IV 627 Psilocybin, IV 636 Pumactant, CE 1226, IV 637 Puromycin, IV 639 Pyrantel, IV 640 Pyrazinamide, IV 644 Pyrazoloacridine, IV 647 Pyrethrins, V 533 Pyridostigmine bromide, IV 648 Pyridoxal, CE 1227, IV 651 Cumulative Index Pyridoxamine dihydrochloride, CE 1228, IV 656 Pyridoxine, CE 1230, IV 658 Pyrilamine, CE 1235, IV 667 Pyrimethamine, CE 1236, IV 675 Pyrisuccideanol, IV 683 Pyrithione, IV 684 Pyrithyldione, IV 684 Pyrocatechol, IV 685 Pyrrobutamine, CE 1238 Quazepam, IV 686 Quercetin, IV 689 Quetiapine, V 536 Quinacrine, CE 1238, IV 690 Quinagolide, CE 1239 Quinaldic acid, IV 692 Quinapril, I 1202, IV 693 Quinestrol, IV 694 Quinethazone, IV 695 Quinfamide, V 539 Quinidine, CE 1240, IV 696 Quinine, CE 1243, IV 710 Quinupramine, IV 723 Quinupristin, V 540 Rabeprazole, V 542 Ractopamine, V 544 Raloxifene, V 547 Ramatroban, IV 725 Ramipril, I 1205, IV 726 Ramosetron, V 549 Ranitidine, CE 1246, I 1209, IV 727 Rapacuronium bromide, V 551 Rebamipide, IV 731 Reboxetine, IV 731 Remifentanil, V 553 Remikiren, IV 733 Remoxipride, CE 1251, IV 733 Repaglinide, V 555 Repirinast, IV 736 Reproterol, CE 1253, IV 737 Rescinnamine, IV 738 Reserpine, CE 1255, IV 740 Resorcinol, CE 1256, IV 748 Retinoic acid, CE 1256, I 1223, IV 753 Ribavirin, IV 757 Riboflavin, CE 1258, IV 760 Ricinoleic acid, IV 769, V 557 Rifabutin, IV 769 Rifampin, IV 773 Rifapentine, IV 782 Rifaximin, IV 784, V 558 Rilmazafone, IV 785, V 559 Rilmenidine, IV 786 Riluzole, IV 786 Rimantadine, CE 1262, IV 787 Risedronate sodium, V 560 Risperidone, IV 789 Ritodrine, CE 1263, IV 793 Ritonavir, IV 795 Rizatriptan, IV 798, V 561 Robenidine, IV 799 Rocuronium bromide, IV 800 Rofecoxib, V 562 Rokitamycin, IV 802 Romurtide, IV 803 Ronidazole, IV 803 Ropinirole, IV 804, V 565 Ropivacaine, CE 1264, IV 805 Rosiglitazone, V 566 Rosoxacin, CE 1265, IV 806 Rosuvastatin calcium, V 568 Rotenone, IV 807 Roxarsone, IV 809 Roxatidine acetate, IV 810 Roxithromycin, IV 811 Rufloxacin, IV 814 Rutin, CE 1266, IV 817 Saccharin, CE 1267, IV 818 Salicylamide, CE 1268, IV 825 Salicylic acid, CE 1270, IV 830 Salinomycin, IV 856 Salmeterol, I 1234 Salsalate, IV 859 Sampatrilat, IV 860 Saperconazole, IV 861 Saquinavir, IV 862 Sarafloxacin, IV 863, V 569 Scopolamine, CE 1279, I 1235, IV 865 Scopoletin, IV 867 Secnidazole, IV 868 Secobarbital, CE 1281, IV 869 Secretin, IV 880 Selamectin, V 571 Selegiline, CE 1286, IV 881 Selfotel, IV 883 Semduramicin, IV 884 Seratrodast, IV 885 Sermorelin, V 572 Sertaconazole, IV 886 Sertindole, IV 887 Sertraline, I 1244, IV 888 Sibutramine, V 574 Sildenafil, V 576 Simazine, IV 888 Simethicone, V 579 Simvastatin, I 1249, IV 889 Sincalide, IV 890 Sirolimus, IV 892 Sisomicin, IV 894 Sivelestat, V 580 Sobrerol, IV 895 Sodium nitroprusside, IV 895 Sodium oxybate, V 582 Somatomedin, IV 897 Somatrem, CE 1288, IV 899 Somatropin, CE 1289, I 1252, IV 900, V 583 Sorivudine, IV 902 699 700 Cumulative Index Sotalol, CE 1291, IV 904 Sparfloxacin, CE 1295, IV 917 Spectinomycin, IV 922 Spiperone, IV 926 Spiramycin, IV 927 Spirapril, CE 1296, IV 928 Spironolactone, CE 1296, IV 929 Squalane, V 584 Squalene, V 585 Stanozolol, IV 935, V 587 Stavudine, CE 1297, IV 937 Stearic acid, IV 941 Stiripentol, IV 942 Streptokinase, IV 943 Streptomycin, CE 1298, IV 944 Streptozocin, IV 948 Strychnine, IV 950 Succimer, IV 951, V 588 Succinylcholine chloride, IV 953, V 589 Sucralfate, I 1256 Sucrose, IV 954 Sufentanil, CE 1299, IV 954 Sulbactam, I 1257 Sulbenicillin, IV 956 Sulbentine, IV 957 Sulconazole, CE 1300, IV 958 Sulfabenzamide, CE 1301, IV 959 Sulfabromomethazine, V 591 Sulfacetamide, CE 1302, IV 962 Sulfachlorpyridazine, CE 1303, V 592 Sulfadiazine, CE 1305, IV 970 Sulfadimethoxine, CE 1309, IV 991 Sulfadoxine, CE 1312, IV 1010 Sulfaethidole, IV 1018 Sulfaethoxypyridazine, V 596 Sulfaguanidine, CE 1313, IV 1019 Sulfalene, CE 1314, IV 1020 Sulfamerazine, CE 1316, IV 1020, V 598 Sulfameter, CE 1318 Sulfamethazine, CE 1320, IV 1022 Sulfamethizole, CE 1324, IV 1047 Sulfamethoxazole, CE 1324, I 1263, IV 1054 Sulfamethoxypyridazine, IV 1059 Sulfamonomethoxine, CE 1330, IV 1059 Sulfanilamide, CE 1331, IV 1061 Sulfanilic acid, CE 1333, IV 1075 Sulfanitran, V 600 Sulfapyridine, CE 1334, IV 1076 Sulfaquinoxaline, CE 1335, IV 1079 Sulfasalazine, IV 1087 Sulfathiazole, CE 1339, IV 1090 Sulfinpyrazone, IV 1105 Sulfisomidine, CE 1342 Sulfisoxazole, CE 1344, IV 1109 Sulfur, IV 1114 Sulindac, CE 1347, IV 1115 Sulpiride, CE 1349, IV 1128 Sultamicillin, V 602 Sultopride, IV 1130 Sumatriptan, CE 1352, I 1284, IV 1132 Suprofen, CE 1353, IV 1134 Suramin, CE 1357 Suriclone, IV 1136 Synephrine, CE 1358, IV 1138 Tacalcitol, V 604 Tacrine, CE 1362, IV 1138 Tacrolimus, IV 1145 Talinolol, CE 1362 Talipexole, V 605 Taltirelin, V 607 Tamoxifen, CE 1364, IV 1150 Tamsulosin, IV 1160 Taurine, CE 1366, IV 1161 Tazarotene, IV 1176 Tazobactam, IV 1176 Tazofelone, IV 1180 Technetium Tc 99m bicisate, V 608 Tegafur, IV 1181 Tegaserod, V 609 Teicoplanin, IV 1182 Telithromycin, V 610 Telmesteine, V 611 Telmisartan, V 612 Temafloxacin, IV 1185 Temazepam, CE 1368, I 1286, IV 1189 Temocapril, V 614 Temocillin, IV 1191 Temozolomide, V 615 Teniposide, IV 1192 Tenofovir disoproxil fumarate, V 617 Tenoxicam, CE 1369, IV 1198 Teprenone, V 620 Terazosin, I 1302, IV 1203 Terbinafine, I 1306, IV 1204 Terbutaline, CE 1370, IV 1205 Terconazole, I 1310 Terfenadine, I 1312, IV 1214 Teriparatide, V 621 Teroxirone, IV 1217 Terpin, IV 1218 Tertatolol, IV 1218 Testolactone, IV 1220 Testosterone, CE 1383, IV 1222 Tetracaine, CE 1387, IV 1240 Tetrachlorvinphos, V 622 Tetracycline, CE 1390, I 1321, IV 1250 Tetrahydrozoline, CE 1395, IV 1256, V 623 Tetramethrin, IV 1259 Tetrazepam, IV 1262 Thalidomide, CE 1399, IV 1264, V 626 Thebaine, CE 1401, IV 1264 Thenyldiamine, IV 1265 Theobromine, IV 1266 Theodrenaline, CE 1402 Theophylline, CE 1404, I 1336, IV 1268 Thiabendazole, IV 1272 Thiacetarsamide, IV 1282 Thialbarbital, V 628 Thiambutene, IV 1282 Cumulative Index Thiamine, CE 1413, IV 1283 Thiamphenicol, CE 1418, IV 1296 Thiamylal, IV 1296 Thiethylperazine, IV 1301 Thimerosal, IV 1304 Thiobutabarbital, IV 1307 Thioctic acid, IV 1308 Thioguanine, IV 1309 Thiopental, CE 1419, IV 1313 Thiopropazate, IV 1329 Thioproperazine, IV 1330 Thioridazine, CE 1422, IV 1333 Thiosalicylic acid, IV 1346 Thiotepa, IV 1349 Thiothixene, CE 1424, IV 1351 Thonzylamine, IV 1360 Thymol, IV 1361 Thymopentin, IV 1363 Thyrotropin, V 629 Tiagabine, IV 1363, V 630 Tiamenidine, IV 1364 Tiamulin, IV 1364 Tianeptine, IV 1366 Tiapride, IV 1368 Tiaprofenic acid, CE 1425, IV 1370 Ticarcillin, CE 1427, IV 1373 Ticlopidine, CE 1428, IV 1377 Tiemonium iodide, IV 1380 Tiletamine hydrochloride, V 631 Tilisolol, IV 1381 Tilmicosin, IV 1383, V 633 Tiludronic acid, V 634 Timepidium bromide, CE 1429 Timiperone, IV 1384 Timolol, CE 1429, I 1371, IV 1384 Tinidazole, IV 1388 Tioclomarol, IV 1389 Tioconazole, CE 1434, IV 1391 Tiopronin, CE 1437, IV 1393 Tiracizine, IV 1397 Tirilazad, V 635 Tirofiban, V 637 Tiropramide, V 639 Tizanidine, V 641 Toborinone, IV 1398 Tobramycin, CE 1437, IV 1399 Tocainide, CE 1438, IV 1404 Tofisopam, IV 1411 Tolazamide, CE 1440, IV 1414 Tolazoline, IV 1416 Tolbutamide, CE 1443, IV 1419 Tolcapone, V 643 Tolfenamic acid, IV 1429 Tolmetin, CE 1446, IV 1430 Tolnaftate, IV 1435 Toloxatone, IV 1436 Tolperisone, CE 1447 Tolpropamine, IV 1439 Tolrestat, IV 1440 Tolterodine, IV 1442 Tolycaine, IV 1443 Topiramate, V 645 Topotecan, IV 1445, V 647 Toremifene, IV 1446 Torsemide, IV 1449 Tosufloxacin, V 649 Tramadol, CE 1448, I 1383, IV 1453 Tramazoline, IV 1455 Trandolapril, IV 1455 Tranexamic acid, IV 1456 Tranilast, IV 1458 Tranylcypromine, CE 1449, IV 1459 Travoprost, V 651 Trazodone, IV 1467 Trenbolone, IV 1476, V 652 Treprostinil, V 653 Tretoquinol, CE 1450 Triamcinolone, CE 1453, I 1385, IV 1483 Triamterene, CE 1456, I 1398, IV 1486 Triazolam, CE 1457, IV 1489 Trichlorfon, IV 1499, V 655 Trichlormethiazide, CE 1460, IV 1501 Triclocarban, IV 1505 Triclosan, IV 1506 Trientine, IV 1507 Triethanolamine, V 656 Trifluoperazine, CE 1461, IV 1507 Trifluperidol, IV 1518 Triflupromazine, CE 1463, IV 1521 Trifluridine, IV 1527, V 657 Trihexyphenidyl, CE 1463, IV 1528 Trilostane, IV 1532 Trimazosin, IV 1533 Trimebutine, CE 1468, IV 1534 Trimeperidine, IV 1534 Trimeprazine, CE 1469, IV 1535 Trimetazidine, IV 1545 Trimethadione, IV 1546 Trimethobenzamide, IV 1546 Trimethoprim, CE 1472, I 1409, IV 1548 Trimetrexate, IV 1551 Trimidox, IV 1554 Trimipramine, CE 1475, IV 1554 Trioxsalen, IV 1568 Tripelennamine, CE 1480, IV 1569 Triprolidine, CE 1481, IV 1574 Triptorelin, IV 1583, V 658 Tritoqualine, IV 1584 Troglitazone, CE 1482, IV 1584 Troleandomycin, CE 1483, V 660 Tromethamine, CE 1484, IV 1585 Tropacocaine, IV 1589 Tropic acid, IV 1590 Tropicamide, CE 1484, IV 1590 Tropisetron, IV 1591 Trospium chloride, IV 1593 Trovafloxacin, IV 1594 Troxipide, V 661 Trypsin, IV 1594 Tryptophan, IV 1596 701 702 Cumulative Index Tubocurarine chloride, IV 1596 Tylosin, IV 1600 Tyloxapol, IV 1606 Tymazoline, IV 1607 Ubenimex, V 662 Undecylenic acid, IV 1607 Unoprostone isopropyl ester, V 663 Urea, IV 1609 Urokinase, IV 1613 Ursodiol, CE 1489, IV 1614 Valacyclovir, IV 1626, V 664 Valdecoxib, V 666 Valganciclovir, V 668 Valproic acid, CE 1490, I 1429, IV 1627 Valrubicin, V 670 Valsartan, V 671 Valspodar, IV 1629 Vancomycin, CE 1491, I 1438, IV 1630 Vanillin, IV 1632 Vasopressin, IV 1633 Vecuronium bromide, IV 1636 Venlafaxine, CE 1491, I 1445, IV 1639 Verapamil, CE 1492, I 1448, IV 1640 Vesnarinone, IV 1647 Vidarabine, IV 1648 Vigabatrin, IV 1654 Viloxazine, IV 1657 Vinblastine, CE 1502, IV 1659 Vincamine, IV 1665 Vincristine, CE 1503, IV 1667 Vindesine, IV 1673 Vinorelbine, IV 1674 Vinylbital, IV 1678 Virginiamycin, IV 1679 Vitamin A, CE 1504, IV 1680 Vitamin B12 , CE 1506, IV 1705 Vitamin D2 , CE 1508, IV 1710 Vitamin D3 , CE 1509, IV 1714 Vitamin E, CE 1511, IV 1719 Vitamin K, IV 1741 Vitamin K1 , IV 1742 Voriconazole, IV 1747 Warfarin, CE 1512, I 1466, IV 1748 Xamoterol, IV 1752 Xanomeline, IV 1754 Xipamide, IV 1755 Xylazine, IV 1757 Xylometazoline, CE 1520, IV 1760 Xylose, CE 1521, IV 1764 Yohimbine, IV 1777 Zafirlukast, IV 1783 Zalcitabine, CE 1529, IV 1784 Zaleplon, V 673 Zaltoprofen, V 676 Zanamivir, V 678 Zearalenone, IV 1788 Zeranol, IV 1789 Zidovudine, CE 1529, I 1480, IV 1794 Zileuton, IV 1795 Zinostatin, IV 1797, V 680 Zipeprol, IV 1798 Ziprasidone, IV 1799 Zofenopril calcium, CE 1530, V 681 Zolazepam hydrochloride, V683 Zolpidem, CE 1531, I 1491, IV 1799 Zonisamide, IV 1801 Zopiclone, CE 1532, IV 1804 Zorubicin, IV 1812 Zoxazolamine, IV 1813 Zuclopenthixol, IV 1815 CROSS-INDEX TO OTHER SUBSTANCES In many cases other compounds may be chromatographed under the conditions described in the monographs in this book. Using the information in the monographs it may be possible to develop chromatographic procedures for these compounds. The compounds fall into the following categories: AL Also chromatographed Compounds which can be analyzed at the same time. It is not specified whether or not they interfere but they can be extracted. EX Extracted Compounds which can be extracted from the matrix in question and analyzed at the same time and do not interfere. IN Interfering Compounds which interfere with the analysis of the target compound. IS Internal Standard A compound added at some time during the sample preparation procedure to act as a standard. SI Simultaneous Compounds which can be analyzed at the same time and do not interfere. Note that the compound may or may not be extracted from the matrix in question. (For obvious reasons non-interfering compounds are not listed in this index.) Abacavir (EX) 335, 336 Abacavir 5’-carboxylate (EX) 3 Abacavir 5’-glucuronide (EX) 3 Acamprosate (EX) 387 Acebutolol (EX) 7, 230, 253, 387, 400, 406, 434, 495, 623; (IN) 499 Acefylline heptaminol (EX) 387 Acenocoumarol (EX) 387 Acepromazine (EX) 387, 525 Aceprometazine (EX) 387 Acetaminophen (EX) 7, 232, 254, 384, 387, 401, 407, 495, 498, 623; (IS) 315; (SI) 16, 173, 178, 202, 603, 614 Acetamiprid (EX) 452 Acetazolamide (EX) 387; (SI) 188, 220, 522 Acetiamin (EX) 387 Acetophenetidine (SI) 178 Acetorphan (EX) 387 Acetylcodeine (AL) 98 Acetylleucine (EX) 387 Acetylmethionine (EX) 387 6-Acetylmorphine (EX) 387 Acetylsulfabromomethazine (EX) 591, 594, 597 Acetylsulfachlorpyridazine (EX) 591, 594, 597 Acetylsulfadiazine (EX) 591, 594, 597 Acetylsulfadimethoxine (EX) 591, 594, 597 Acetylsulfaethoxypridazine (EX) 591, 594, 597 Acetylsulfamethazine (EX) 591, 594, 597 Acetylsulfisoxazole (EX) 599 N-Acetylprocainamide (EX) 495, 498 N-Acetyl-L-tyrosine ethyl ester (EX) 389 Acrivastine (EX) 230, 253, 400, 406, 623 Actinoquinol (EX) 387 Acyclovir (EX) 387, 488, 664; (SI) 188, 220, 522 Adefovir (EX) 12; (IS) 617 Adenosine (EX) 387; (IS) 372 Adipic acid (EX) 139, 371 Adrafinil (EX) 387 Aklomide (EX) 601 Alacepril (SI) 603, 614 HPLC Methods for Recently Approved Pharmaceuticals. by George Lunn Copyright  2005 John Wiley & Sons, Ltd. ISBN: 0-471-66941-5 703 704 Cross-Index to Other Substances Albendazole (EX) 102, 103, 387 Alclometasone 17,21-dipropionate (SI) 30, 32, 143, 145, 167, 170, 264, 271, 306 Aldicarb (EX) 387 Alendronate (SI) 441 Alfuzosin (EX) 387 Alimemazine (EX) 387 Alizapride (IN) 552 Allethrin (EX) 80, 535 Allopurinol (SI) 188, 220, 522 Alminoprofen (EX) 387 Almitrine (EX) 387 Alpiropride (IS) 50 Alprazolam (EX) 7, 230, 253, 387, 400, 406, 498, 623; (IN) 496; (SI) 194 Alprenolol (EX) 7, 230, 253, 400, 406, 434, 623 Alprostadil (EX) 460 Altazide (EX) 387 Altretamine (EX) 387 Amantadine (EX) 7, 230, 253, 400, 406, 623; (IS) 378 Ambemonium (EX) 387; (IS) 137 Amcinonide (SI) 18, 20, 143, 145, 167, 170, 264, 271, 306 Amfepramone (EX) 387 Amiloride (EX) 7, 230, 253, 387, 400, 406, 623 Amineptine (EX) 387, 495, 498 p-Aminobenzoic acid (EX) 97; (SI) 456 4-Amino-3-nitroanisole (IS) 334 Aminophenazone (EX) 7, 230, 253, 400, 406, 623 p-Aminosalicylic acid (EX) 390 Aminophylline (IN) 204; (SI) 178 Amiodarone (EX) 7, 230, 253, 387, 400, 406, 623; (IS) 343 Amisulpride (EX) 387, 537 Amitriptyline (EX) 7, 230, 253, 387, 400, 406, 495, 498, 537, 623; (SI) 47, 383, 512, 547 Amlodipine (EX) 387 Ammonium (SI) 656 Amobarbital (EX) 387, 495, 498; (SI) 178 Amoxapine (EX) 378, 387, 495, 498 Amoxicillin (EX) 387; (SI) 202 Amphetamine (AL) 98; (EX) 387, 495, 497, 498, 529 Amphotericin B (EX) 387 Ampicillin (EX) 387; (SI) 16, 603, 614 Amprenavir (EX) 209, 281, 282, 359, 360, 436, 444 Androstenedione (EX) 169 Anethole (EX) 387 Angiotensin I (SI) 13 Angiotensin II (SI) 13 Angiotensin III (SI) 13 Anhydrodaptomycin (SI) 159 Anhydroglucitol (EX) 302 Aniracetam (SI) 188, 220, 522 Anthraquinone (IS) 357 Antipyrine (EX) 204; (SI) 178 Antrenyl (SI) 331, 382 Apomorphine (EX) 387 Aprepitant (SI) 512, 547 Aprindine (EX) 387 Aprobarbital (EX) 495, 498; (SI) 178 Arachidonic acid (EX) 457, 458, 459, 460, 461, 462; (SI) 557 Arecoline (EX) 387 Artemisinin (IS) 52 Articaine (AL) 98 Articainic acid (EX) 55 Ascorbic acid (SI) 140 Aspartame (EX) 387 β-Asp daptomycin (SI) 159 Aspirin (SI) 16, 178, 202, 603, 614 Astemizole (AL) 38; (EX) 7, 231, 253, 387, 400, 406, 623 Atenolol (EX) 7, 231, 253, 387, 400, 406, 434, 495, 498, 623 Atipamazole (EX) 369, 370 Atracurium (IN) 552 Atrazine (EX) 387 Atrial natriuretic peptide (SI) 13 Atropine (EX) 327, 387, 495, 498 Azacyclonol (EX) 7, 231, 253, 400, 406, 623 Azaperol (EX) 525 Azaperone (EX) 525 Azithromycin (SI) 267 Bacampicillin (EX) 387 Baclofen (SI) 642 Bamethan (EX) 387 Bamifylline (EX) 387 Barbital (EX) 387, 495, 499; (SI) 178 Baythroid (cyfluthrin) (AL) 25; (EX) 26, 80, 535 Beclomethasone (EX) 168, 265 Beclomethasone 17,21-dipropionate (SI) 20, 32, 145, 167, 170, 264, 271, 306, 414 Befunolol (EX) 434 Benazepril (EX) 387; (SI) 104, 188, 220, 522 Bendroflumethiazide (EX) 387 Benfluorex (EX) 387 Benperidol (SI) 537 Bentazone (EX) 387 Benzanilide (IS) 6 Benzbromarone (EX) 387 Benzene (EX) 387 Benzhexol (EX) 7, 231, 253, 400, 406, 495, 499, 623 Benzoic acid (SI) 178 Benzophenone (EX) 387 Benzophenone-3 (SI) 456 Benzophenone-4 (SI) 456 Benzoylecgonine (EX) 7, 231, 253, 387, 400, 406, 495, 499, 623 Benztropine (EX) 495, 499 Benzydamine (EX) 387 Benzyl alcohol (IS) 136; (SI) 516 3-Benzylidene-d, l-camphor (SI) 456 Benzylidene camphorsulfonic acid (SI) 456 1-Benzylimidazole (IS) 100 Bepridil (EX) 387 Cross-Index to Other Substances Betahistine (EX) 388 Betamethasone (EX) 168, 265, 388; (IS) 523; (SI) 18, 20, 30, 32, 143, 145, 167, 170, 188, 220, 264, 271, 306, 522 Betamethasone-17-acetate (SI) 18, 30, 143 Betamethasone-21-acetate (SI) 18, 20, 30, 32, 143, 145, 167, 170, 264, 271, 306 Betamethasone 17-benzoate (SI) 18, 20, 30, 32, 143, 145, 167, 170, 271, 306 Betamethasone-17,21-diacetate (SI) 18, 30, 143 Betamethasone 17,21-dipropionate (IS) 18, 20, 30, 32, 143, 145, 167, 170, 264, 271, 306, 413 Betamethasone-17,21-divalerate (SI) 18, 30, 143 Betamethasone propionate (SI) 18, 30, 143 Betamethasone-17-propionate-21-butyrate (SI) 18, 30, 143 Betamethasone-17-propionate-21-stearate (SI) 18, 30, 143 Betamethasone 17-valerate (SI) 18, 20, 30, 32, 143, 145, 167, 170, 264, 271, 306 Betamethasone-17-valerate-21-acetate (SI) 18, 30, 143 Betaxolol (EX) 7, 231, 253, 388, 400, 406, 434, 623 Bezafibrate (EX) 388 BHT (EX) 388 Bidesethylchloroquine (EX) 388 Bifenthrin (EX) 26, 80, 535 Bifonazole (SI) 482 Bioallethrin (SI) 534 Biotin (Vitamin H) (EX) 391 Biperiden (EX) 388 Biperidine (EX) 7, 231, 253, 400, 406, 623 Biscoumacetate (EX) 388 Bisoprolol (EX) 7, 231, 253, 388, 400, 406, 434, 623 Boldine (EX) 388 Bombesin (SI) 13 Bradykinin (SI) 13 Bromadiolone (EX) 388 Bromazepam (EX) 388, 398, 495, 499 Bromocriptine (EX) 233, 388 4-Bromo-2,5-dimethoxyphenylethylamine (EX) 498 3-Bromoprimaquine diphosphate (IS) 96 5-Bromouracil (SI) 173 Brompheniramine (EX) 7, 231, 253, 388, 400, 406, 499, 623; (IN) 496 Buclizide (EX) 388 Budesonide (SI) 20, 32, 145, 167, 170, 264, 271, 306, 414 Buflomedil (EX) 388 Bumetanide (EX) 388; (IS) 105, 671 Bunitrolol (EX) 434 Bupivacaine (AL) 98; (EX) 7, 231, 254, 400, 406, 623 Bupranolol (IS) 433 Buprenorphine (EX) 7, 231, 254, 388, 400, 406, 495, 499, 623 705 Buspirone (EX) 7, 231, 254, 388, 400, 406, 495, 499, 623 Butabarbital (EX) 495, 499; (IN) 178 1,4-Butanediol (IS) 528 Butethal (SI) 178 Butobarbital (EX) 388 Butofilolol (EX) 434 2-n-Butylmercaptobenzimidazole (IS) 103 Butyl methoxydibenzoylmethane (SI) 456 Butyl paraben (EX) 388; (IS) 577 N-Butylscopolammonium bromide (EX) 388 Cafedrine (EX) 388 Caffeic acid (EX) 388 Caffeine (AL) 98; (EX) 7, 231, 254, 384, 388, 400, 406, 495, 499, 623; (SI) 16, 173, 178, 202, 603, 614, 656 Camostat mesylate (SI) 188, 220, 522 Campesterol (SI) 585 Camphor benzalkonium methosulfate (SI) 456 Candesartan (EX) 671 Canrenoate (EX) 388 Capric acid (EX) 461; (SI) 463 Caproic acid (EX) 461 Caprylic acid (EX) 461 Captodiamine (EX) 388 Captopril (AL) 682; (EX) 388; (IS) 229 Carazolol (EX) 434, 525 Carbamazepine (EX) 7, 231, 254, 388, 400, 406, 495, 499, 623; (IN) 349; (IS) 431; (SI) 188, 220, 522 Carbaryl (EX) 250, 388 Carbenicillin (SI) 16, 603, 614 Carbimazole (EX) 388 Carbinoxamine (EX) 8, 231, 254, 388, 401, 407, 624 Carbofuran (EX) 250; (SI) 354 Carboplatin (EX) 480 Carbovir (EX) 3 Carbutamide (EX) 388 Carisoprodol (EX) 8, 231, 254, 401, 407, 624 Carnitine (EX) 388 β-Carotene (EX) 22 Carpipramine (EX) 388 Carteolol (EX) 388, 434 Carvedilol (EX) 8, 231, 254, 401, 407, 426, 434, 624; (IS) 425 Cathinone (EX) 497, 529 Cefaclor (EX) 113, 118, 257 Cefadroxil (EX) 388 Cefamandole (EX) 113, 118, 257; (SI) 552 Cefatrizine (EX) 388 Cefazolin (EX) 113, 118, 257, 388 Cefbuperazone (EX) 118, 257 Cefixime (EX) 113, 118, 257, 388 Cefmenoxime (EX) 113, 118, 257 Cefmetazole (EX) 113, 118, 257 Cefoperazone (EX) 113, 118, 257 Cefotaxime (EX) 113, 118, 257; (IS) 114; (SI) 552 Cefotetan (EX) 113, 118, 257 706 Cross-Index to Other Substances Cefotiam (EX) 113, 118, 257; (SI) 16, 603, 614 Cefpiramide (EX) 113, 118, 257 Cefpirome sulfate (IS) 116 Cefpodoxime (EX) 388 Cefsulodin (EX) 113, 118, 257 Ceftazidime (EX) 113, 118, 257; (SI) 552 Ceftizoxime (EX) 113, 118, 257 Ceftriaxone (EX) 113, 118, 257, 388; (SI) 552 Cefuroxime (EX) 113, 118, 257, 388; (SI) 552 Cefuzonam (EX) 113, 257 Celecoxib (IS) 567 Celiprolol (EX) 8, 231, 254, 388, 401, 407, 434, 624 Cephalexin (EX) 113, 118, 257, 388 Cephaloglycine (EX) 113, 118, 257 Cephaloridine (EX) 113, 118, 257 Cephalothin (EX) 113, 118, 257; (IS) 682 Cephradine (SI) 552 Cetirizine (EX) 8, 231, 254, 388, 401, 407, 624 Chlorambucil (EX) 388 Chloramphenicol (EX) 388, 495, 499; (IS) 258; (SI) 178 Chlorcyclizine (EX) 8, 231, 254, 401, 407, 624 Chlordiazepoxide (EX) 8, 231, 254, 388, 401, 407, 495, 499, 624; (SI) 383 Chlorhexidine (EX) 388 Chloridazone (EX) 388 Chlormadinone (EX) 375, 388 Chlormethiazole (EX) 495; (IN) 499 Chlormezanone (EX) 8, 231, 254, 388, 401, 407, 624 Chlorobenzoic acid (EX) 388 Chloromadinone acetate (EX) 269, 376 Chlorophacinone (EX) 388 4-Chlorophenylbiguanide (EX) 388 m-Chlorophenylpiperazine (EX) 378, 537 Chloropicrin (EX) 388 Chloroquine (EX) 8, 231, 254, 388, 401, 407, 624; (SI) 95 Chlorotestosterone acetate (EX) 269, 376 8-Chlorotheophylline (IS) 173 Chlorothiazide (SI) 178 5-Chlorouracil (SI) 173 Chlorpheniramine (EX) 8, 231, 254, 388, 401, 407, 499, 624; (IN) 496; (SI) 331 Chlorpromazine (EX) 8, 231, 254, 388, 401, 407, 495, 499, 525, 624; (IS) 383; (SI) 16, 194, 603, 614 Chlorpropamide (EX) 8, 231, 254, 388, 401, 407, 624; (SI) 178 Chlorprothixene (EX) 8, 231, 254, 401, 407, 624; (SI) 537 Chlorpyrifos (SI) 354 Chlortetracycline (EX) 592 Chlortoluron (EX) 388 Chlorzoxazone (SI) 642 Cholesterol (SI) 585 Cibenzoline (EX) 388 Cicletanine (EX) 388 Cilazapril (EX) 388; (SI) 104, 188, 220, 522 Cimetidine (EX) 388, 495, 499; (SI) 188, 202, 220, 522 Cinchonine (EX) 388 Cinerin (SI) 534 Cinerin I (SI) 533 Cinerin II (SI) 533 Cinnarizine (EX) 8, 231, 254, 388, 401, 407, 624; (IS) 358 Cinoxacin (EX) 365 Ciprofibrate (EX) 388 Ciprofloxacin (EX) 365, 388, 473, 650; (IN) 364; (IS) 294; (SI) 293, 472 Cisapride (EX) 388; (IS) 194, 640 Citalopram (EX) 8, 231, 254, 401, 407, 495, 499, 537, 624; (SI) 399 Citric acid (EX) 371 Clarithromycin (SI) 267 Clemastine (EX) 8, 231, 254, 401, 407, 624 Clenbuterol (EX) 388; (IS) 304, 473 Clidinium bromide (EX) 330, 381, 388; (SI) 331, 382 Clindamycin (EX) 352, 353, 388; (SI) 251, 252, 516 Clobazam (EX) 8, 231, 254, 388, 401, 407, 495, 499, 624 Clobenzorex (EX) 388 Clobetasol 17-propionate (SI) 18, 20, 30, 32, 167, 170, 264, 271, 306 Clobetasone butyrate (SI) 18, 30, 143 Clobutinol (EX) 8, 231, 254, 401, 407, 624 Clocinizine (EX) 388 Clodronate (SI) 441 Clofazimine (SI) 627 Clofibrate (EX) 388; (SI) 188, 220, 522 Clomethiazole (EX) 8, 231, 254, 388, 401, 407, 624 Clomipramine (EX) 8, 231, 254, 388, 401, 407, 495, 499, 537, 624 Clonazepam (EX) 8, 231, 254, 388, 401, 407, 495, 499, 624; (SI) 188, 220, 522 Clonidine (EX) 8, 231, 254, 388, 401, 407, 495, 499, 624; (IS) 423; (SI) 45 Cloperastine (EX) 495, 499 Cloranolol (EX) 434 Clorazepate (EX) 388 Clotiazepam (EX) 388 Clotrimazole (EX) 273 Clovoxamine (EX) 378 Cloxacillin (EX) 388 Cloxazolam (EX) 495, 499 Clozapine (EX) 8, 231, 254, 401, 407, 499, 537, 624; (IN) 496 Cocaine (EX) 8, 231, 254, 388, 401, 407, 495, 499, 624 Codeine (AL) 98; (EX) 8, 231, 254, 388, 401, 407, 495, 499, 624; (IS) 290; (SI) 202 Codethyline (EX) 388 Colchicine (EX) 388; (SI) 178 Colchicoside (EX) 388 Colchicosine (EX) 388 Cross-Index to Other Substances Corticosterone (EX) 169, 171 Cortisone (EX) 169; (SI) 18, 20, 30, 32, 143, 145, 163, 167, 170, 178, 261, 264, 271, 306 Cortisone 21-acetate (SI) 19, 20, 30, 32, 143, 145, 167, 170, 264, 271, 306 Cortivazol (EX) 388 Cotinine (EX) 388 Coumachlor (EX) 388 Coumafen (EX) 388 Coumarin (SI) 178 Coumatetralyl (EX) 8, 231, 254, 388, 401, 407, 624 m-Cresol (SI) 654 Crimidine (EX) 388 Cromolyn (SI) 16, 603, 614 Cyamemazine (EX) 388 Cyclandelate (EX) 388 Cyclizine (EX) 8, 231, 254, 401, 407, 624 Cycloguanil (EX) 388 Cyclohexymethylguanidine (IS) 305 Cyclophosphamide (SI) 188, 220, 522 Cyclothiazide (SI) 178 Cyfluthrin (AL) 25; (EX) 26, 80, 535 Cyhalothrin (EX) 155 Cyheptamide (SI) 178 Cypermethrin (AL) 26; (SI) 24 Cyproheptadine (EX) 388 Cyromazine (EX) 388 Dacarbazine (EX) 388 Dalfopristin (EX) 540; (SI) 541 Danazol (SI) 178 Danofloxacin (EX) 365, 473, 650; (SI) 364; 472 Danthron (SI) 178 Dapsone (EX) 388; (IN) 304; (SI) 178, 627 Deacetylalacepril (EX) 17 Decanol (EX) 380 Deethylzaleplon 674 Deflazacort (EX) 261 Dehydrocorticosterone (SI) 19, 30, 143 Delapril (SI) 188, 220, 522 Delavirdine (EX) 208, 435, 443; (IN) 36 Delmadinone acetate (EX) 269, 376 Deltamethrin (EX) 155 Demoxepam (EX) 8, 231, 254, 401, 407, 624 3′ -Deoxy-2′ ,3′ -didehydrothymidine (IS) 215 11-Deoxycortisol (EX) 169, 260 Deoxycortone (EX) 168, 265 21-Deoxydexamethasone (EX) 168, 265 Deoxymethasone (SI) 19, 30, 144 Desethylatrazine (EX) 388 N-Desethyl-5-oxozaleplon (EX) 674 N-Desethylzaleplon (EX) 674 Desfluoroaprepitant (IS) 46, 47 Desipramine (EX) 378, 388, 495, 499, 537 Desmethylcitalopram (EX) 378; (SI) 399 Desmethylclomipramine (EX) 378 Desmethyldoxepin (EX) 378 Desmethylmaprotiline (EX) 378 Desmethylmianserin (EX) 378 707 Desmethylmirtazapine (SI) 399 Desmethylsertraline (EX) 378 Desmethyltrimipramine (EX) 378 Desmethylvenlafaxine (EX) 537; (SI) 399 Desonide (SI) 20, 32, 145, 167, 170, 265, 271, 306 Desoximetasone (EX) 265; (SI) 20, 32, 145, 167, 170, 264, 271, 306 Desoxy-2-phenobarbital (EX) 388 Desoxycorticosterone acetate (SI) 20, 32, 145, 167, 264, 271, 306 Desoxycorticosterone pivalate (SI) 20, 32, 145, 167, 264, 271, 306 Detomidine (IS) 60, 369 Dexamethasone (EX) 168, 260, 265, 388; (SI) 19, 20, 30, 32, 144, 145, 167, 170, 188, 220, 264, 271, 306, 522 Dexamethasone 21-acetate (EX) 169; (SI) 19, 20, 31, 32, 144, 145, 167, 170; 264, 271, 306; (IS) 414 Dexamethasone isonicotinate (SI) 19, 31, 144 Dexamethasone pivalate (SI) 19, 31, 144 Dexamethasone valerate (SI) 19, 31, 144 Dextromethorphan (EX) 8, 231, 254, 401, 407, 388, 624 Dextromoramide (EX) 388 Dextropropoxyphene (EX) 8, 231, 254, 388, 401, 407, 624; see also propoxyphene (EX) 495, 499 Dextrose (EX) 302, 303 DFdU (2′ ,2′ -difluorodeoxyuridine) (EX) 296 Diamorphine (AL) 98; (EX) 388 Diarachidoylphosphatidylcholine (EX) 502, 505 Diatrizoate (EX) 322, 325 Diaveridine (EX) 388 Diazepam (EX) 8, 231, 254, 388, 401, 407, 495, 499, 537, 624; (IS) 195, 539; (SI) 188, 194, 202, 220, 522 Diazinon (EX) 388 Dibekacin (EX) 388 Dibenzepin (IN) 537; (IS) 7, 230, 253, 400, 406, 623 Dibucaine (AL) 98 Dichlorisone (EX) 168, 265 Dichlorprop (EX) 388 Diclofenac (EX) 388; (SI) 47, 512, 547 Didanosine (EX) 1, 2, 335, 336; (SI) 2 Diethofencarb (EX) 250 Diethylstilbestrol (EX) 388; (SI) 178 Difemerine (EX) 388 Diflorasone 17,21-diacetate (SI) 20, 32, 145, 167, 170, 264, 271, 306 Difloxacin (EX) 569, 650; (SI) 364, 472 Diflucortolone valerate (SI) 19, 31, 144 2′ ,2′ -Difluorodeoxyuridine (dFdU) (EX) 296 Digitoxin (EX) 388 Digoxin (EX) 388; (SI) 188, 220, 522 Dihomo-gamma-linolenic acid (EX) 458 Dihydralazine (EX) 388 Dihydrobefunolol (EX) 70 Dihydrocodeine (EX) 388, 495, 499 708 Cross-Index to Other Substances Dihydrostreptomycin (EX) 312 3,4-Dihydroxybenzylamine (IS) 348 Dilazep (SI) 188, 220, 522 Dilinoleylphosphatidylcholine (EX) 502, 505 Diltiazem (EX) 8, 231, 254, 388, 401, 407, 495, 499, 624; (IS) 494; (SI) 188, 220, 522 Dimefline (SI) 383 Dimerazole (EX) 388 3-Dimethylaminomethyleneimino-2,4,6triiodobenzoic acid (IS) 393 N,N-Dimethylglycine (EX) 72 Dimethyl phthalate (EX) 388 2,2′ -Dimethylpropiophenone (IS) 533 Dimetridazole (EX) 388 Diminazene (EX) 316 2,4-Dinitrochlorobenzene (IS) 237 Dinoprost (EX) 460 Dinoprostone (EX) 460 Dinoseb (EX) 388 Dinsed (EX) 600 Dipalmitolyphosphatidylcholine 506 Diphacinone (EX) 388 Diphenhydramine (EX) 8, 231, 254, 401, 407, 495, 499, 624 Dipheniramine (EX) 388 Diphenylphosphate (IS) 284 Diphosphatidylglycerol (EX) 502, 505 Diprophylline (EX) 388 Dipropyline (EX) 388 Dipyridamole (EX) 8, 231, 254, 388, 401, 407, 624 Dipyrone (SI) 383 Disopyramine (EX) 8, 231, 254, 388, 401, 407, 495, 499, 624 Disulfiram (EX) 388 Di-syston (EX) 388 Dithiothreitol (EX) 588 Diuron (EX) 388 Dixyrazine (EX) 8, 231, 254, 401, 407, 624; (SI) 552 Docarpamine (SI) 220, 522 Docosahexaenoic acid (EX) 458, 459 Docosanoic acid (EX) 457 Dodecyl alcohol (SI) 129 Domperidone (EX) 388 Dopamine (IS) 394 Dosulepin (EX) 388 Dothiepin (EX) 495, 499 Doxapram (EX) 8, 231, 254, 401, 407, 624; (SI) 383 Doxazosin (EX) 189 Doxepin (EX) 8, 231, 254, 388, 401, 407, 495, 499, 537, 624 Doxorubicin (EX) 388 Doxylamine (EX) 388 Dronabinol (EX) 8, 232, 255, 402, 408, 624; (SI) 178 Droperidol (EX) 388 Dropropizine (EX) 388 Ebastine (EX) 8, 231, 254, 401, 407, 624 Econazole (EX) 388; (IS) 251 EDDP (EX) 388 Efavirenz (EX) 36, 38, 360, 435, 436, 443, 444 Eicosanoic acid (EX) 457 Eicosapentaenoic acid (EX) 458, 459 Eicosapentanoic acid (EX) 457 Eicosatrienoic acid (EX) 457 Eicosyl alcohol (SI) 129 Elaidic acid (EX) 459 Embutramide (EX) 8, 231, 254, 388, 401, 407, 624 Emetine (EX) 388 Emtricitabine diphosphate (EX) 216 Emtricitabine monophosphate (EX) 216 Emtricitabine triphosphate (EX) 216 Enalapril (EX) 388; (IS) 7, 230, 253, 400, 406, 623; (SI) 16, 603, 614 Enalaprilat (AL) 682 Endorphins (SI) 14 Enoxacin (EX) 365, 388; (SI) 47, 512, 547 Enrofloxacin (EX) 365, 473, 650; (SI) 364, 421, 472, 570 Eperisone (SI) 188, 522 Ephedrine (AL) 98; (EX) 388, 495, 497, 499, 529 Epigalantamine (EX) 291 Epinephrine (AL) 98; (EX) 348, 389, 498 Ergotamine (EX) 8, 254, 401, 407, 624 Erythritol (EX) 302 Erythromycin (EX) 495, 499; (SI) 267 Esculin (EX) 389 Eserine (EX) 389 Esmolol (EX) 434 Estazolam (EX) 389 Estradiol (EX) 169; (SI) 178 17α-Estradiol (IS) 558 β-Estradiol (EX) 389 Estriol (EX) 169, 389; (SI) 178 Estrone (EX) 169; (SI) 178 Ethanolamine (SI) 656 Ethazolastone (IS) 615, 616 Ethenzamide (EX) 8, 231, 254, 401, 407, 624 Ethinyl estradiol (EX) 300; (SI) 239 Ethiofencarb (EX) 250 Ethosuximide (EX) 389; (SI) 178, 188, 220, 522 4-Ethoxyphenol (IS) 384 3-(4′ -Ethylbenzylidene)-d,l-camphor (SI) 456 Ethylene glycol (EX) 302 Ethylmorphine (AL) 98; (EX) 8, 231, 254, 401, 407, 624 Ethyl paraben (EX) 389; (IS) 160 Ethylparathion (EX) 8, 231, 254, 401, 407, 624 Etidocaine (AL) 98; (IS) 54 Etidronate (SI) 441 Etodolac (EX) 389; (IS) 162 Etodroxizine (EX) 8, 231, 254, 401, 407, 624 Eugenol (SI) 178 Famciclovir (EX) 489 Famotidine (EX) 389 Cross-Index to Other Substances Febantel (EX) 103 Felodipine (EX) 8, 231, 254, 389, 401, 407, 624 Fenazepam (EX) 8, 231, 254, 401, 407, 624 Fenbendazole (EX) 102, 103 Fenbufen (EX) 389; (SI) 188, 220, 522 Fenfluramine (EX) 8, 231, 254, 378, 389, 401, 407, 497, 498, 499, 529, 624; (IN) 496 Fenkamfamine (EX) 8, 231, 254, 401, 407, 624 Fenobucarb (EX) 250 Fenofibrate (EX) 389; (SI) 47, 512, 548 Fenoprofen (EX) 389; (SI) 178 Fenoverine (EX) 389 Fenozolone (EX) 389 Fenpiverinium bromide (IS) 331 Fenpropathrin (AL) 26 Fenproporex (EX) 389 Fentanyl (EX) 8, 231, 254, 389, 401, 407, 495, 499, 624 Fenvalerate (AL) 26; (EX) 26, 80, 535 Fexofenadine (EX) 8, 231, 401, 407, 624 Finasteride (SI) 47, 512, 548 Flavone (EX) 389; (IS) 480 Flecaine (EX) 389 Flecainide (EX) 8, 231, 254, 401, 407, 495, 499, 624 Fleroxacin (EX) 650 Floctafenine (EX) 389 Flomoxef (EX) 113, 118 Flubendazole (EX) 103, 389 Fluclorolone acetonide (EX) 168, 265 Fluconazole (EX) 8, 231, 254, 389, 401, 407, 624; (SI) 188, 220, 522 Flucytosine (EX) 389 Fludrocortisone (EX) 168, 265; (IS) 260 Fludrocortisone 21-acetate (IS) 163, 261; (SI) 19, 20, 31, 32, 144, 145, 167, 170, 264, 271, 306 Flumazenil (EX) 8, 231, 254, 401, 407, 495, 499, 624 Flumequine (EX) 365, 473, 592 Flumethasone (EX) 168, 265 Flumethasone 21-pivalate (SI) 19, 20, 31, 32, 144, 145, 167, 170, 264, 271, 306 Flumethrin (EX) 155 Flunarizine (EX) 358, 389 Flunindione (EX) 389 Flunisolide (SI) 20, 32, 145, 167, 170, 264, 271, 306 Flunitrazepam (EX) 8, 231, 254, 389, 401, 407, 499, 624; (IN) 36, 496 Fluocinolone acetonide (EX) 168, 265; (SI) 19, 20, 31, 32, 144, 145, 167, 170, 264, 271, 306 Fluocinonide (EX) 168, 265; (SI) 19, 20, 31, 32, 144, 145, 167, 170, 264, 271, 306 Fluocortin butyl ester (SI) 19, 31, 144 Fluocortolone (EX) 168, 265 Fluocortolone caproate (SI) 19, 31, 144 Fluocortolone pivalate (SI) 19, 31, 144 6-Fluoroalosetron (IS) 29 5-Fluorocytosine (SI) 173 709 Fluorometholone (EX) 168, 265; (SI) 19, 20, 31, 32, 144, 145, 167, 170, 264, 271, 306 9-α-Fluoroprednisolone (SI) 19, 31, 144 9-α-Fluoroprednisolone acetate (SI) 19, 31, 144 5-Fluorouracil (EX) 389; (SI) 173, 178 Fluoxetine (EX) 8, 231, 254, 378, 389, 401, 407, 495, 499, 537, 624; (IS) 498; (SI) 399 Fluoxymesterone (EX) 427, 587; (SI) 178 Flupentixol (EX) 8, 231, 254, 389, 401, 407, 495, 499, 624 Fluphenazine (EX) 389, 495, 499; (SI) 383, 537 Fluprednisolone (EX) 168, 265; (SI) 20, 32, 145, 167, 170, 264, 271, 306 Flurandrenolide (EX) 168; (SI) 19, 20, 31, 32, 144, 145, 167, 170, 271, 306 Flurazepam (EX) 495, 499 Flurbiprofen (EX) 389 Flurogestone acetate (EX) 376 Flutamide (EX) 389; (SI) 188, 220, 522 Fluticasone 17-propionate (SI) 20, 32, 145, 167, 170, 264, 306, 414 Fluvoxamine (EX) 8, 231, 254, 378, 389, 401, 407, 495, 499, 624; (IN) 537; (SI) 399 Folic acid (EX) 389; (SI) 2 Fominoben (SI) 188, 220, 522 Fosinopril (AL) 682 Fosinoprilat (EX) 283 FTU (EX) 215 Fumaric acid (EX) 389 Furaltadone (EX) 389 Furazolidone (EX) 389, 601 Furosemide (EX) 389, 495, 499; (SI) 178 Fusidic acid (EX) 389 Ganciclovir (SI) 2, 668 Gentamicin (EX) 312, 389 Gitoxigenin (SI) 178 Glibenclamide (EX) 8, 231, 254, 389, 401, 407, 624 Gliclazide (EX) 389 Glipizide (EX) 8, 231, 254, 389, 401, 407, 624 Glutathione (EX) 389 Glutethimide (EX) 495, 499; (SI) 178 Glycopyrrolate (IS) 136; (SI) 331 Gonadorelin (LHRH) (SI) 13 Grepafloxacin (SI) 293 Griseofulvin (EX) 389 Guaiacol (EX) 389; (SI) 178 Guaifenesin (EX) 389, 495, 499; (IS) 641 Guanfacine (EX) 389 Halcinonide (SI) 19, 20, 31, 32, 144, 145, 167, 170, 264, 271, 306 Halobetasol propionate (SI) 20, 32, 145, 167, 170, 264, 271 Halofantrine (EX) 389 Haloperidol (EX) 8, 231, 254, 389, 401, 407, 495, 499, 525, 624; (SI) 537 Harpagoside (EX) 389 710 Cross-Index to Other Substances Hematoporphyrin (EX) 389 Heptadecanoic acid (IS) 462 Heptanoic acid (EX) 461 Hexachlorobenzene (SI) 354 Hexobarbital (IS) 335; (SI) 178 Hippuric acid (SI) 178 Histapyrrodine (EX) 8, 231, 254, 401, 407, 624 Histidine (EX) 389 Homosalate (SI) 456 Hydralazine (EX) 495, 499 Hydrochlorothiazide (EX) 104, 389, 672 Hydrocodone (EX) 8, 231, 254, 401, 407, 624 Hydrocortisone (EX) 168, 169, 260, 265, 389; (SI) 19, 20, 31, 32, 144, 145, 163, 167, 170, 178, 261, 264, 271, 306, 414 Hydrocortisone 21-acetate (SI) 19, 20, 31, 32, 144, 145, 167, 170, 188, 264, 271, 306, 522 Hydrocortisone-17-butyrate (SI) 19, 20, 31, 32, 144, 145, 167, 170, 264, 271, 306 Hydrocortisone 21-cypionate (SI) 20, 32, 145, 167, 170, 264, 271, 306 Hydrocortisone pivalate (SI) 19, 31, 144 Hydrocortisone 17-valerate (SI) 20, 32, 145, 167, 170, 264, 272, 306 Hydroflumethiazide (SI) 104 Hydroquinone (SI) 178 p-Hydroxybestatin (EX) 662 4-Hydroxybutyrate (EX) 389 Hydroxychloroquine (EX) 8, 231, 254, 401, 407, 624 21-Hydroxydeflazacort (EX) 163, 261 18-Hydroxydeoxycorticosterone (EX) 171 5-Hydroxyindole-3-acetic acid (IS) 77 10-Hydroxynortriptyline (EX) 378 Hydroxyprogesterone (EX) 169 9-Hydroxyrisperidone (EX) 537 3-Hydroxytyramine (EX) 389 Hydroxyzine (EX) 8, 231, 254, 389, 401, 407, 495, 499, 624 Hyoscyamine (EX) 389 Hypoxanthine (IS) 668 Ibuprofen (EX) 389, 495, 499; (SI) 178 Iloprost (EX) 405 Imidacloprid (EX) 452 Imidapril (SI) 188, 220, 522 Imidazole (EX) 273, 389 Imipramine (EX) 8, 231, 254, 389, 401, 407, 495, 499, 537, 624; (IN) 202; (IS) 403; (SI) 383 Inchonidine (EX) 389 Indenolol (EX) 434 Indinavir (AL) 38; (EX) 36, 37, 38, 208, 209, 359, 360, 435, 436, 443, 444; (SI) 47, 512, 548, 627 Indomethacin (EX) 8, 231, 254, 389, 401, 407, 495, 499, 624; (IS) 341; (SI) 178, 188, 221, 522 Indoramine (EX) 389 Iodoform (EX) 389 Iohexol (EX) 324, 325, 326 Iothalamic acid (EX) 322 Iotrolan (EX) 325 Ioxaglic acid (EX) 322 Irbesartan (EX) 105, 671 Irinotecan (SI) 188, 221, 522 Isoamyl p-methoxycinnamate (SI) 456 Isoflupredone (EX) 168, 265 Isoniazid (EX) 8, 231, 254, 401, 407, 624; (SI) 627 Iso-pirlimycin (IS) 516 Isoprocarb (EX) 250 Isopropamide iodide (EX) 381; (SI) 382 Isopropyl dibenzoylmethane (SI) 456 Isoquercitrin (EX) 389 Isosorbide (EX) 389 Isosorbide dinitrate (EX) 490 Isothipendyl (EX) 389 Isotretinoin (EX) 21, 22; (SI) 23 Isoxicam (SI) 200 Isoxsuprine (IS) 544 Isradipine (EX) 8, 231, 254, 389, 401, 407, 624 Jasmolin (SI) 534 Jasmolin I (SI) 533 Jasmolin II (SI) 533 Josamycine (EX) 389 Ketamine (EX) 8, 231, 254, 389, 401, 407, 495, 624; (IN) 499, 552 Ketobemidone (EX) 8, 231, 254, 401, 407, 624 Ketoconazole (AL) 38; (EX) 389, 495, 499 Ketogan (IN) 552 Ketoprofen (EX) 8, 231, 254, 389, 401, 407, 624 Ketorolac (EX) 8, 231, 254, 401, 407, 624 Labetalol (EX) 8, 231, 254, 401, 407, 434, 495, 499, 624; (IS) 49, 626 Lacidipine (EX) 389 Lactic acid (EX) 389 Lamivudine (EX) 1, 2; (SI) 2, 627 Lamotrigine (EX) 8, 231, 254, 401, 407, 624 Lanolin (SI) 112 Lanzoprazole (EX) 389 Lasalocid (EX) 415, 429 Latamoxef (EX) 113, 118, 257 Laudanosine (EX) 137; (SI) 138 Lauric acid (EX) 457, 458, 459, 460, 461; (SI) 463 Levamisole (EX) 389 Levobunolol (EX) 434; (IS) 70 Levocabastine (EX) 8, 231, 254, 401, 407, 624 Levodopa (EX) 389 Levomepromazine (EX) 8, 231, 254, 389, 401, 407, 624; (SI) 194, 383 Levonordefrin (SI) 527 Levopenbutolol (EX) 389 Levothyroxine (EX) 357 Levrazoxane (EX) 172 LHRH (gonadorelin) (SI) 13 Lidocaine (AL) 98; (EX) 8, 231, 254, 389, 401, 407, 495, 499, 624; (IN) 552; (IS) 133 Cross-Index to Other Substances Lincomycin (SI) 516 Linoleic acid (EX) 457, 458, 459, 460, 461, 462; (SI) 463, 557 Linolenic acid (EX) 457, 458, 459, 460, 461, 462; (SI) 463, 557 Gamma-linolenic acid (EX) 457 Linuron (EX) 389 Lipotropic hormone (SI) 14 Lisinopril (SI) 104 Lisuride (EX) 233, 389 Lithium (SI) 656 Lobeline (EX) 389 Loflazepate (EX) 389 Lomefloxacin (EX) 650; (IS) 420, 487 Lomustine (EX) 389 Loperamide (SI) 16, 603, 614 Lopinavir (EX) 37, 38, 209, 436, 444 Loprazolam (EX) 389 Loratadine (EX) 8, 164, 165, 231, 254, 389, 401, 407, 624 Lorazepam (EX) 8, 231, 254, 389, 401, 407, 495, 499, 624 Lormetazepam (EX) 8, 231, 254, 401, 407, 495, 499, 624 Losartan (EX) 105, 671; (IS) 124 Loxapine (EX) 389, 495, 499 LSD (EX) 8, 231, 254, 389, 401, 407, 624 Lufenuron (EX) 389 Luteinizing hormone (SI) 134 Lysophosphatidylcholine (EX) 502, 505 Magnesium (SI) 656 Malathion (EX) 8, 231, 254, 401, 407, 624 Malic acid (SI) 140 Maprotiline (EX) 8, 231, 254, 378, 389, 401, 407, 495, 499, 537, 624; (SI) 188, 221, 522 Marbofloxacin (SI) 472 Margaric acid (EX) 458, 460; (IS) 457, 459, 461, 557 MCPA (EX) 389 MDA (EX) 389, 497, 529; (IN) 499 MDEA (EX) 497, 529 MDMA (EX) 8, 231, 254, 389, 401, 407, 495, 499, 529, 624; (IN) 499 MDPA (EX) 389 Mebendazole (EX) 102, 103, 389 Mebezonium (EX) 389 Meclozine (EX) 8, 231, 254, 389, 401, 407, 624 Mecoprop (EX) 389 Medazepam (EX) 8, 231, 254, 389, 401, 407, 624 Medetomidine (EX) 60, 61, 389 Medroxyprogesterone (EX) 389 Medroxyprogesterone acetate (EX) 269, 376 Mefenamic acid (IS) 676; (SI) 178 Mefenorex (EX) 389 Mefloquine (EX) 389 Megasol (SI) 456 Megestrol (EX) 375, 389 Megestrol acetate (EX) 269, 376 Meglutol (EX) 139 711 Melanotropin (SI) 14 Melatonin (EX) 389 Melengestrol acetate (EX) 269 Meloxicam (EX) 8, 231, 254, 401, 407, 624 Melperone (EX) 8, 231, 254, 401, 407, 537, 624; (IS) 537 Melphalan (EX) 389 Menotropins (SI) 14 Mepenzolate bromide (EX) 330; (SI) 331 Meperidine (pethidine) (EX) 8, 231, 254, 389, 401, 407, 495, 499, 624; (SI) 552 Mepindolol (EX) 434 Mepivacaine (EX) 8, 54, 231, 254, 401, 407, 624 Meprednisone (SI) 20, 32, 145, 167, 170, 264, 272, 306 Meprobamate (EX) 8, 231, 254, 401, 407, 624 Meropenem (IS) 234 Mesalamine (EX) 389 Mesoridazine (EX) 8, 231, 254, 401, 407, 496, 499, 624 Mestranol (SI) 239 Metamitron (EX) 389 Metaproterenol (EX) 389 Metformin (EX) 389, 512 Methacycline (EX) 389 Methadone (AL) 38; (EX) 8, 231, 254, 389, 401, 407, 496, 499, 624 Methamphetamine (EX) 8, 231, 254, 389, 401, 407, 495, 497, 529, 624; (IN) 499 Methandienone (IS) 82 Methandrostenolone (EX) 427, 587 Methaqualone (EX) 495, 499; (IS) 673 Methiocarb (EX) 250 Methionine (EX) 389 Methocarbamal (SI) 178, 642 Metholcarb (EX) 250 Methoprene (SI) 533 Methoprene acid (EX) 386 Methotrexate (SI) 188, 221, 522 p-Methoxylevodropropizine (IS) 198 Methoxyselamectin (IS) 571 Methyclothiazide (EX) 389 Methylbenacyzine (SI) 331 Methyldopa (SI) 178, 389, 394 3-Methyldopamine (EX) 389 4-Methyldopamine (EX) 389 Methylene blue (SI) 187 Methylephedrine (EX) 495, 499 7-Methyleptazocine (IS) 227 Methylhydroxyprogesterone (EX) 389 3-Methylleflunomide (EX) 341 5-Methyl-2-nitrophenol (IS) 255 Methyl paraben (EX) 389; (IS) 512, 676; (SI) 178, 331 Methylparathion (EX) 8, 231, 254, 401, 407, 624 Methylphenidate (EX) 8, 231, 254, 401, 407, 496, 499, 624 Methylprednisolone (EX) 168, 260, 265, 389; (SI) 19, 20, 31, 32, 144, 145, 167, 170, 264, 270, 306 712 Cross-Index to Other Substances Methylprednisolone 21-acetate (SI) 20, 32, 145, 167, 170, 264, 272, 306 3-Methylpyrazole (IS) 274 Methyl salicylate (SI) 178 Methyltestosterone (EX) 427, 587; (IS) 652; (SI) 178 Metipranolol (EX) 434 Metoclopramide (EX) 8, 231, 254, 318, 384, 389, 401, 407, 495, 624; (IN) 499, 552 Metocurine (SI) 552 Metoprolol (EX) 8, 231, 254, 389, 401, 407, 434, 495, 499, 624; (SI) 552 Metronidazole (EX) 8, 231, 254, 389, 401, 407, 624 Mexiletine (EX) 8, 231, 254, 389, 401, 407, 624; (IS) 509 Mianserin (EX) 8, 231, 254, 389, 401, 407, 495, 499, 537, 624 Miconazole (EX) 389; (IS) 252 Midazolam (EX) 8, 60, 231, 254, 369, 389, 401, 407, 495, 499, 624 Mifepristone (IS) 301 Minaprin (EX) 389 Minocycline (EX) 389 Minoxidil (EX) 389 Mirtazapine (EX) 8, 231, 254, 407, 537, 624; (SI) 399 Misoprostol (EX) 313 Mitomycin C (EX) 89 Mivacurium (EX) 137; (SI) 589 Mizolastine (EX) 8, 231, 254, 401, 624 Moclobemide (EX) 8, 231, 254, 389, 401, 407, 495, 499, 537, 624 Molindone (EX) 8, 231, 254, 401, 407, 495, 499, 624 Molsidomine (EX) 389 Mometasone (EX) 413 Mometasone 17-furoate (SI) 19, 20, 31, 32, 144, 145, 167, 170, 264, 272, 306 Monensin (EX) 429 Monoacetylmorphine (AL) 98; (EX) 8, 231, 254, 401, 407, 624 Monodesbutylhalofantrine (EX) 389 Monodesethylchloroquine (EX) 389 Moprolol (EX) 434 Moroxydine (EX) 389 Morphine (AL) 98; (EX) 8, 231, 254, 389, 401, 407, 495, 499, 624 Moxifloxacin (SI) 293 Myristic acid (EX) 457, 458, 459, 460, 461, 462; (SI) 463, 557 Myristoleic acid (EX) 458, 459, 460, 461 Nadolol (EX) 389, 434, 495, 499 Nadoxolol (EX) 389 Naftidrofuryl (EX) 389 Naftopidil (IS) 426 Nalidixic acid (EX) 365, 389, 473 Nalorphine (EX) 389 Naloxone (EX) 389, 495, 499 Naltrexone (EX) 389 Nandrolone (EX) 587 2-Naphthoic acid (IS) 313, 405 Naphthol (SI) 354 Naproxen (EX) 495, 499; (IS) 147 Narasin (EX) 415 Nefazodone (EX) 537 Nefiracetam (SI) 188, 221, 522 Nefopam (EX) 389 Nelfinavir (AL) 38; (EX) 36, 37, 38, 208, 209, 281, 359, 360, 435, 443, 444 Nemonapride (EX) 389 Neomycin (EX) 312 Neopynamine (EX) 389 Neostigmine (EX) 389; (SI) 331 Netilmicin (EX) 389; (IS) 153 Nevirapine (EX) 1, 38, 208, 209, 335, 360, 435, 436; (SI) 2, 627 Niacin (EX) 389; (SI) 178 Niacinamide (EX) 389 Niaprazine (EX) 389 Nicarbazin (EX) 149 Nicardipine (EX) 390 Nicergoline (EX) 390 Niclosamide (EX) 390 Nicotine (EX) 8, 231, 254, 401, 407, 624 Nifedipine (EX) 8, 99, 231, 254, 390, 401, 407, 495, 499, 624; (IS) 48; (SI) 188, 221, 522 Nifenalol (EX) 434 Niflumic acid (EX) 390 Nifuroxazide (EX) 390; (IS) 450 Nikethamide (EX) 8, 231, 254, 390, 401, 407, 624; (SI) 383 Nimesulide (IS) 556 Nimodipine (IN) 552 Nitrazepam (EX) 8, 231, 254, 390, 401, 407, 495, 499, 624; (SI) 188, 194, 221, 522 Nitrendipine (EX) 390 o-Nitroacetanilide (IS) 77 Nitrofural (EX) 390 Nitrofurantoin (SI) 178 Nitrofurazone (EX) 601 Nitroglycerin (EX) 490 Nitromide (EX) 601 Nizatidine (EX) 8, 231, 254, 390, 401, 407, 624 Nomifensine (EX) 8, 231, 254, 401, 407, 624 Nonanoic acid (EX) 461 Nonanol (EX) 380 Noramidopyrine (EX) 390 Norclomipramine (EX) 390, 537 Norclozapine (EX) 378, 537 Nordiazepam (EX) 398, 495, 499 Nordoxepin (EX) 537 Norephedrine (EX) 390 Norepinephrine (EX) 348, 390, 498; (SI) 527 Norethisterone (EX) 390 Norfenfluramine (EX) 378, 497, 529; (S) 529 Norfloxacin (EX) 365, 650; (IN) 364; (IS) 472, 569 Norfluoxetine (EX) 378, 495, 499, 537; (SI) 399 Norgalantamine (EX) 290 Cross-Index to Other Substances Norgestrel (EX) 390; (IS) 243 Normaprotiline (IN) 537 Normethsuximide (SI) 178 Normirtazapine (SI) 537 Norpropoxyphene (EX) 390 17α-Nortestosterone (EX) 428 Nortriptyline (EX) 8, 231, 254, 378, 390, 401, 407, 495, 499, 537, 624 Norverapamil (EX) 8, 231, 254, 401, 407, 624 Noscapine (EX) 8, 231, 254, 390, 401, 407, 624 Octanol (EX) 380 Octocrylene (SI) 456 Octyl dimethyl PABA (SI) 456 Octyl methoxycinnamate (SI) 456 Octyl salicylate (SI) 456 Octyl triazone (SI) 456 Ofloxacin (EX) 365, 390, 495, 499, 650; (SI) 16, 293, 603, 614 Olanzapine (EX) 8, 231, 254, 401, 407, 624; (SI) 537 Oleandomycin (SI) 267 Oleic acid (SI) 557 Olpadronate (SI) 441 Omeprazole (EX) 390; (SI) 202 Ondansetron (EX) 8, 231, 254, 401, 407, 624 Opiclone (EX) 390 Opipramol (EX) 390; (IN) 537 Orbifloxacin (SI) 364 Orphenadrine (EX) 8, 231, 254, 401, 407, 624 Oxacillin (EX) 390 Oxalic acid (SI) 140 Oxamyl (EX) 250 Oxatomide (EX) 390 Oxazepam (EX) 8, 231, 254, 390, 401, 407, 499, 624; (IN) 496 Oxazolam (EX) 499; (IN) 496 Oxcarbazepine (EX) 8, 232, 254, 401, 407, 624 Oxfendazole (EX) 102, 103 Oxibendazole (EX) 102, 103 2-Oxoglutaric acid (EX) 139, 371 Oxolinic acid (EX) 365, 473 5-Oxozaleplon (EX) 674 Oxprenolol (EX) 8, 232, 254, 390, 401, 407, 434, 624 Oxycodone (EX) 8, 232, 254, 401, 407, 495, 499, 624 Oxymorphone (EX) 495, 499 Oxyphenbutazone (SI) 178 Oxytetracycline (EX) 592 Palmitic acid (EX) 457, 458, 459, 460, 461, 462; (SI) 463, 557 Palmitoleic acid (EX) 457, 458, 459, 460, 461, 462; (SI) 463, 557 Pamidronate (SI) 441 Pancuronium (EX) 137, 390 Pantothenic acid (Vitamin B5 ) (EX) 391 Papaverine (EX) 8, 232, 254, 390, 401, 407, 624 713 Paramethasone 21-acetate (SI) 20, 32, 145, 167, 170, 264, 272, 306 Paraxanthine (SI) 178 Parbendazole (EX) 102, 390 Parconazole (EX) 390 Paroxetine (EX) 8, 232, 254, 378, 390, 401, 407, 495, 499, 537, 624; (SI) 399 Pefloxacin (EX) 390 Pemoline (EX) 8, 232, 254, 401, 407, 624 Penbutolol (EX) 434; (IS) 473 Penfluridol (EX) 390 Pentaerythritol (EX) 390 Pentazocine (EX) 8, 232, 254, 390, 401, 407, 499, 624; (IN) 496; (IS) 242 Pentienate bromide (SI) 331 Pentifylline (EX) 8, 232, 254, 401, 407, 624 Pentobarbital (EX) 390, 495, 499; (SI) 178, 188, 221, 522 Pentoxifylline (EX) 390 Pentoxyverine (EX) 8, 232, 255, 390, 401, 407, 624 1-(4-Perfluorobutylphenyl)-1-hexanone (IN) 492 Pericyazine (EX) 495, 499 Perindopril (EX) 390 Permethrin (AL) 25; (EX) 26, 80, 386, 535; (SI) 24 Perphenazine (EX) 8, 232, 255, 390, 401, 407, 495, 499, 624 Pethidine (meperidine) (EX) 8, 231, 254, 389, 401, 407, 495, 499, 624; (SI) 552 Phenacetin (IS) 120, 204, 627 Phenazone (EX) 8, 232, 255, 401, 407, 624; (IS) 240 Phenazopyridine (EX) 495, 499 Phencyclidine (EX) 9, 232, 255, 401, 407, 495, 499, 624 Phenindione (EX) 390 Pheniramine (EX) 9, 232, 255, 401, 407, 495, 499, 624 Phenobarbital (EX) 390, 495, 499; (SI) 188, 221, 522 Phenol (EX) 390; (SI) 492 Phenolphthalein (EX) 499; (IN) 496 Phenoprolamine (IS) 574 Phenothrin (EX) 26, 80, 535 m-Phenoxybenzoic acid (EX) 386 m-Phenoxybenzyl alcohol (EX) 26, 80, 386, 535 Phenoxyethanol (EX) 390 Phentermine (EX) 495, 499, 529 Phenylbenzimidazole sulfonic acid (SI) 456 Phenylbutazone (EX) 9, 232, 255, 390, 402, 408, 624; (SI) 178 Phenylephrine (EX) 495, 499 2-Phenylethylamine (EX) 498, 529 Phenylethyleneglycol (SI) 173 Phenylpropanolamine (EX) 9, 232, 255, 402, 408, 495, 497, 499, 529, 624; (SI) 331 Phenyltoloxamine (EX) 495, 499 Phenytoin (EX) 9, 232, 255, 285, 390, 402, 408, 495, 499, 624; (SI) 188, 221, 522 714 Cross-Index to Other Substances Phloroglucinol (EX) 390 Pholcodine (EX) 390, 495, 499 Phorate (EX) 390 Phosdrin (EX) 390 Phosphatidic acid (EX) 502, 505 Phosphatidylcholine (EX) 504, 505; (SI) 505 Phosphatidylethanolamine (EX) 501, 502, 504, 505 Phosphatidylglycerol (EX) 502 Phosphatidylinositol (EX) 502, 504, 505 Phosphatidylserine (EX) 505, 504, 505 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA) (IS) 618 Phthalic acid (EX) 390 Pilocarpine (EX) 390 Pimaricin (EX) 390 Pimozide (EX) 390, 495, 499; (SI) 537 Pinaverium (EX) 390 Pinazepam (EX) 495, 499 Pindolol (EX) 9, 232, 255, 390, 402, 408, 434, 625; (IS) 631, 683; (SI) 188, 221, 522 Pioglitazone (IS) 566; (SI) 47, 548 Pipamperone (EX) 390 Pipecuronium (IS) 589 Pipemidic acid (EX) 650 Pipenzolate (SI) 331, 382 Piperacillin (EX) 390 Piperine (EX) 390 Piperonyl butoxide (EX) 390; (SI) 178, 533 Pipothiazine (EX) 390 Piracetam (EX) 390 Piretanide (EX) 390 Pirimicarb (EX) 250 Pirisudanol (EX) 390 Pirlimycin sulfone (EX) 516 Pirlimycin sulfoxide (EX) 516 Piromidic acid (EX) 473 Piroxicam (EX) 9, 232, 255, 390, 402, 408, 495, 499, 625; (IS) 577; (SI) 200 Pitofenone (EX) 9, 232, 255, 402, 408, 625 Pivampicillin (EX) 390 Pizotifen (EX) 9, 232, 255, 390, 402, 408, 625 PMEA (9-[2-(phosphonomethoxy)ethyl]adenine) (IS) 618 Porcine C-peptide (EX) 530 Porcine glucagon (EX) 530 Porcine monocomponent insulin (EX) 530 Porcine pancreatic polypeptide (EX) 530 Porcine proinsulin (EX) 530 Potassium (SI) 656 Practolol (EX) 9, 232, 255, 402, 408, 625 Pralidoxime (EX) 390 Pramipexole (EX) 605, 606 Pranlukast (SI) 188, 221 Pranoprofen (SI) 188, 221, 522 Prazosin (EX) 9, 232, 255, 390, 402, 408, 495, 499, 625 Prednicarbate (SI) 20, 32, 145, 167, 170, 264, 272, 306 Prednisolone (EX) 168, 260, 265, 390, 523; (SI) 20, 32, 145, 167, 170, 178, 188, 221, 264, 272, 306, 522 Prednisolone-21-acetate (SI) 19, 20, 31, 32, 144, 145, 170, 264, 272, 306 Prednisolone acetonide (SI) 19, 31, 144 Prednisolone 17-ethylcarbonate (EX) 523 Prednisolone 21-ethylcarbonate (EX) 523 Prednisolone pivalate (SI) 19, 31, 144 Prednisolone 21-tebuate (SI) 20, 32, 145, 167, 170, 264, 272, 306 Prednisone (EX) 168, 265, 390; (SI) 20, 32, 145, 167, 170, 178, 264, 272, 306, 414 Prednisone acetate (EX) 169 Prifinium (EX) 390 Prilocaine (AL) 98, (EX) 9, 232, 255, 402, 408, 625 Primaquine (EX) 96; (SI) 95 Primidone (EX) 9, 232, 255, 390, 402, 408, 495, 499, 625; (SI) 178, 188, 221, 522 Pristinamycin (EX) 390 Pristinamycin II A (EX) 156, 540 Probenecid (SI) 178 Procainamide (EX) 9, 232, 255, 402, 408, 495, 499, 625; (SI) 16, 603, 614 Procaine (EX) 97, 390; (SI) 16, 527, 603, 614 Prochlorperazine (EX) 9, 232, 255, 402, 408, 625; (IN) 552 Progesterone (EX) 169, 171, 390, 428; (IS) 239; (SI) 178 Proguanil (EX) 390 Prolactin (SI) 14 Promazine (EX) 9, 232, 255, 402, 408, 625; (SI) 383 Promethazine (EX) 9, 232, 255, 390, 402, 408, 495, 499, 625; (SI) 383, 537 Prometrine (EX) 390 Propafenone (EX) 9, 232, 255, 390, 402, 408, 625 Propantheline (SI) 331, 382 Propazine (EX) 390 Propericyazine (EX) 390 Propofol (SI) 138 Propoxur (EX) 250, 390 Propoxyphene (EX) 495, 499; see also Dextropropoxyphene (EX) 8, 231, 254, 401, 407, 388, 624 Propranolol (EX) 9, 232, 255, 378, 390, 402, 408, 434, 499, 625; (IN) 496; (SI) 16, 165, 603, 614 Propyl paraben (EX) 390; (IS) 16, 145; (SI) 112, 178 Propyphenazone (EX) 9, 232, 255, 402, 408, 499, 625; (IN) 496 Proscillaridine a (EX) 390 Protopine (EX) 390 Protriptyline (EX) 378, 495, 499 Pseudoephedrine (EX) 9, 232, 255, 402, 408, 495, 499, 625 Psilocybin (EX) 390 Pyramidon (IS) 205 Cross-Index to Other Substances Pyrantel tartrate (IS) 416 Pyrazinamide (EX) 390; (SI) 2 Pyrethrin I (EX) 26, 80 Pyrethrin II (EX) 26, 80 Pyridostigmine (EX) 390 Pyridoxine (Vitamin B6 ) (EX) 391 Pyrimethamine (EX) 390 Pyrithydione (SI) 178 Pyrocatechol (SI) 178 Pyroglutamic acid (EX) 390 Quercetin (EX) 390 Quetiapine (EX) 537 Quinapril (AL) 682; (EX) 390; (SI) 188, 221, 522 Quinaprilat (AL) 682 Quinidine (EX) 390, 495, 499 Quinine (EX) 9, 232, 255, 390, 402, 408, 625; (IS) 365 Quinupramine (EX) 390 Quinupristin (EX) 156; (SI) 157 Raloxifene (SI) 47, 512 Ramipril (AL) 682; (EX) 390 Ranitidine (EX) 9, 232, 255, 390, 402, 408, 495, 499, 625; (SI) 2, 202 Reboxetine (EX) 537 Reserpine (EX) 390; (SI) 178 Resmethrin (AL) 25; (EX) 26, 535 Resorcinol (EX) 390; (SI) 178 all-trans Retinal (EX) 22 Retinyl acetate (IS) 22 all-trans Retinyl stearate (EX) 22 all-trans Retinyl palmitate (EX) 22 Rhein (EX) 108 Riboflavin (Vitamin B2 ) (EX) 391 Rifabutin (AL) 38; (EX) 390 Rifampin (AL) 38; (EX) 390; (SI) 2, 627 Rifamycin (EX) 390 Rilmenidine (EX) 390 Rimantadine (EX) 378 Ripazapam (IS) 632, 684 Risperidone (EX) 9, 232, 255, 402, 408, 499, 537, 625; (IN) 496; (IS) 418 Ritodrine (IS) 545 Ritonavir (AL) 38; (EX) 36, 37, 38, 208, 209, 359, 360, 435, 436, 443, 444; (SI) 627 Rocurone (EX) 9, 232, 255, 402, 408, 625 Rocuronium (EX) 137; (SI) 589 Ronidazole (EX) 390 Ropivacaine (EX) 9, 232, 255, 402, 408, 625 Rosmarinic acid (EX) 390 Rosoxacin (EX) 390 Roxithromycin (EX) 390; (SI) 267 Rutine (EX) 390 Saccharin (EX) 390; (SI) 178 Salicylamide (EX) 9, 232, 255, 402, 408, 625; (SI) 178 715 Salicylic acid (EX) 384, 390, 495, 499; (SI) 178, 293 Salinomycin (EX) 415, 429 Saquinavir (AL) 38; (EX) 36, 37, 38, 208, 209, 359, 360, 435, 436, 443, 444, 627 Sarafloxacin (EX) 473; (SI) 364, 472 Scopolamine (EX) 390 Secnidazole (EX) 390 Secobarbital (EX) 390, 495, 499; (SI) 178 Selegiline (EX) 9, 232, 255, 390, 402, 408, 625 Sennidin A (EX) 108 Sennidin B (EX) 108 Sertindole (EX) 9, 232, 255, 402, 408, 625 Sertraline (EX) 9, 232, 255, 378, 402, 408, 495, 499, 537, 625; (SI) 399 Simazine (EX) 9, 232, 255, 390, 402, 408, 625 Sincocaine (EX) 9, 232, 255, 402, 408, 625 Sisapride (EX) 9, 232, 255, 402, 408, 625 Sisomicin (EX) 390 β-Sitosterol (SI) 585 Sodium (SI) 656 Somatoliberin (SI) 13 Somatostatin (EX) 530 Somatropin (SI) 14 Sotalol (EX) 9, 232, 255, 390, 402, 408, 434, 625 Spectinomycin (EX) 312 Sphingomyelin (EX) 501, 502, 505 Spirenone (EX) 199 Spironolactone (EX) 390, 495, 499; (IS) 427, 587; (SI) 188, 221, 522 Stanozolol (EX) 427; (SI) 178 Stavudine (EX) 1, 2, 335, 336; (SI) 2, 627 Stearic acid (EX) 457, 458, 459, 460, 461, 462; (SI) 463, 557 Stearyl alcohol (SI) 129 Streptomycin (EX) 312 Strychnine (EX) 9, 232, 255, 390, 402, 408, 625 Succinic acid (SI) 140 Sucrose (EX) 303; (SI) 5 Sulbutiamine (EX) 390 Sulfabenzamide (SI) 593 Sulfabromomethazine (EX) 594, 597 Sulfacetamide (EX) 592; (SI) 178, 593 Sulfachloropyrazine (EX) 390, 592 Sulfachlorpyridazine (EX) 591, 597; (SI) 596 Sulfadiazine (EX) 390, 591, 592, 594, 597, 598; (SI) 593, 596 Sulfadimethoxine (EX) 390, 591, 592, 594, 597; (SI) 178, 593, 596 Sulfadoxine (EX) 390, 592, 594; (SI) 596 Sulfaethidole (SI) 178 Sulfaethoxypridazine (EX) 591, 594 Sulfaguanidine (EX) 390, 592, 594, 599 Sulfamerazine (EX) 592, 594; (SI) 178, 593, 596 Sulfamethazine (EX) 591, 592, 593, 594, 597, 599; (IS) 598; (SI) 178, 593 Sulfamethizole (EX) 592, 594; (SI) 178, 593 Sulfamethoxazole (EX) 390, 495, 499, 592; (SI) 2, 178, 552, 593, 596 716 Cross-Index to Other Substances Sulfamethoxypyridazine (EX) 390, 592, 594; (SI) 596 Sulfanilamide (EX) 390, 592, 594, 599; (SI) 6, 178, 593, 596 Sulfapyridine (EX) 592, 594, 598, 599; (SI) 178, 593 Sulfaquinoxaline (IN) 185 Sulfathiazole (EX) 390, 592, 594, 599; (SI) 596 Sulfisoxazole (EX) 592, 599; (S) 6, 178, 593 Sulindac (EX) 9, 232, 255, 390, 402, 408, 625; (SI) 178 Sulpiride (EX) 9, 232, 255, 390, 402, 408, 495, 499, 537, 625; (SI) 188, 221, 522 Sultamicillin tosylate (SI) 16, 614 Sulthiame (EX) 9, 232, 255, 402, 408, 625; (SI) 188, 221, 522 Sultopride (EX) 390 Synephrine (EX) 390 Talinolol (EX) 434 Tamoxifen (EX) 390 Tartaric acid (SI) 140 Tegafur (SI) 16, 603, 614 Temazepam (EX) 9, 232, 255, 390, 402, 408, 495, 499, 625 Temocapril (SI) 16, 603 Tenoxicam (EX) 390 Terbutaline (EX) 9, 232, 255, 390, 402, 408, 625 Terephthalydiene dicamphor sulfonic acid (SI) 456 Terfenadine (AL) 38; (EX) 9, 232, 255, 390, 402, 408, 495, 499, 625 Terodiline (EX) 9, 232, 255, 402, 408, 625 Terpine (EX) 390 Testosterone (EX) 82, 169, 427, 428, 587; (IS) 268, 428 Testosterone acetate (SI) 178 Testosterone 17β-cypionate (SI) 178 Testosterone enanthate (SI) 178 Testosterone propionate (IS) 392; (SI) 178 Tetracaine (EX) 9, 232, 255, 390, 402, 408, 625; (IS) 97 Tetracosanoic acid (EX) 457 Tetracycline (EX) 390, 592 Tetradecyl alcohol (SI) 129 Tetrahydrozoline (EX) 9, 232, 255, 402, 408 Tetramethrin (AL) 25, 26; (EX) 26, 80, 535; (SI) 24 Tetramisole (EX) 390 Tetraplatin (EX) 480 Tetrazepam (EX) 390; (IS) 398 Theobromine (EX) 9, 232, 255, 390, 402, 408, 625; (SI) 178 Theodrenaline (EX) 390 Theophylline (EX) 9, 232, 255, 384, 390, 402, 408, 495, 499, 625; (SI) 16, 173, 202, 603, 614 Thiabendazole (EX) 102, 103 Thiamine (Vitamin B1 ) (EX) 391 Thiamphenicol (EX) 390; (SI) 259 Thiobarbituric acid (SI) 178 Thiobencarb (EX) 250 Thiopental (thiopentone) (EX) 390, 495, 499 Thioproperazine (EX) 390 Thioridazine (EX) 9, 232, 255, 390, 402, 408, 495, 499, 625; (SI) 383, 537 Thiosalicylic acid (SI) 178 Thiothixene (EX) 9, 232, 255, 402, 408, 495, 499, 625 Thyroid-stimulating hormone (SI) 134 Tianeptine (EX) 390 Tiapride (EX) 390 Tiaprofenic acid (EX) 391 Ticlopidine (EX) 391 Tiemonium iodide (EX) 391; (SI) 331 Tiletamine (EX) 683, 684 Timolol (EX) 9, 89, 232, 255, 391, 402, 408, 434, 625; (IS) 151 Tinidazole (EX) 391 Tioclomarol (EX) 391 Tiospirone (IS) 493 Tobramycin (EX) 312, 391 Tocainide (EX) 495, 499 Tocopherol (EX) 22; (SI) 585 Tofisopam (EX) 391 Tolbutamide (EX) 9, 232, 255, 402, 408, 495, 499, 625; (SI) 178, 188, 221, 522 Toliprolol (EX) 434 Tolmetin (SI) 178 Toloxatone (EX) 391 Tolperisone (IS) 220 Toluene (EX) 391 p-Toluenesulfonic acid (EX) 602 o-Toluidine (AL) 98 Toremifene (EX) 9, 232, 255, 402, 408, 625 Tramadol (EX) 9, 232, 255, 402, 408, 625 Trandolapril (EX) 391 Tranilast (SI) 188, 221, 522 Trazodone (EX) 9, 232, 255, 391, 402, 408, 495, 499, 625 Tretinoin (EX) 21, 22; (SI) 23 Triamcinolone (EX) 168, 265; (SI) 19, 20, 31, 32, 144, 145, 167, 170, 178, 188, 221, 264, 272, 306, 522 Triamcinolone acetonide (EX) 168, 265; (SI) 19, 20, 31, 32, 144, 145, 167, 170, 178, 264, 272, 306 Triamcinolone 16,21-diacetate (SI) 19, 20, 31, 32, 144, 145, 167, 170, 264, 272, 306 Triamcinolone hexacetonide (SI) 20, 32, 145, 167, 170, 264, 272, 306 Triamterene (EX) 9, 232, 255, 391, 402, 408, 625 Triazolam (EX) 9, 232, 255, 391, 402, 408, 495, 499, 625 Trichlorocarbanilide (EX) 391 Trichloromethiazide (EX) 391 Triclabendazole (EX) 103 Tridecanoic acid (EX) 461 Trifluoperazine (EX) 391 Trifluperidol (EX) 391; (SI) 537 Cross-Index to Other Substances Triflupromazine (EX) 495, 499 Trihexyphenidyl (EX) 391 2,4,6-Triiodobenzoic acid (IS) 322 Trimebutine (EX) 391 Trimeprazine (EX) 9, 232, 255, 402, 408, 496, 499, 625 Trimetazidine (EX) 391 Trimethoprim (AL) 38; (EX) 9, 232, 255, 391, 402, 408, 496, 499, 625; (IS) 672; (SI) 2, 552, 627 Trimipramine (EX) 9, 232, 255, 391, 402, 408, 496, 499, 537, 625 Triprolidine (EX) 391 Tritoqualine (EX) 391 Tropatepine (EX) 391 Trovafloxacin (IS) 293 Tryptophan (SI) 293 Tubocurarine (IN) 552 Tulobuterol (SI) 16, 603, 614 Undecanoic acid (EX) 461 Urocanic acid (SI) 456 Valdecoxib (SI) 484 Valethamate (SI) 331, 382 Valsartan (EX) 105 Vanillin (EX) 391 Vasoactive intestinal polypeptide (EX) 530 Vasopressin (SI) 13 Vecuronium (EX) 137, 514; (SI) 589 Venlafaxine (EX) 9, 232, 255, 402, 408, 537, 625; (SI) 399 Verapamil (EX) 9, 232, 255, 391, 402, 408, 496, 499, 625 Veratrine (EX) 391 Veratrole (EX) 391 Viloxazine (EX) 391 Vinblastine (EX) 391 Vincamine (EX) 391; (IS) 92 717 Vincristine (EX) 391 Vinylbital (EX) 391 Virginiamycin (EX) 391 Vitamin A (EX) 21, 22 Vitamin B1 (thiamine) (EX) 391 Vitamin B2 (riboflavin) (EX) 391 Vitamin B5 (pantothenic acid) (EX) 391 Vitamin B6 (pyridoxine) (EX) 391 Vitamin B12 (EX) 391 Vitamin C (EX) 391 Vitamin D2 (IS) 181 Vitamin E (EX) 22; (SI) 585 Vitamin H (biotin) (EX) 391 Warfarin (EX) 9, 232, 255, 391, 402, 408, 625; (IS) 342; (SI) 178, 188, 221, 522 Xanthydrol (EX) 391 Xipamide (EX) 391 Xylazine (EX) 525 Xylene (EX) 391 Yohimbine (EX) 9, 232, 255, 391, 402, 408, 625 Zalcitabine (EX) 1, 2, 335, 336 Zeranol (EX) 427, 587 Zidovudine (EX) 1, 2, 335, 336; (SI) 2, 627 Zipeprol (EX) 391 Ziprasidone (EX) 537 Zoalene (EX) 601 Zofenoprilat (EX) 681; (SI) 682 Zolazepam (EX) 631, 632 Zolpidem (EX) 9, 232, 255, 391, 402, 408, 625, 673; (SI) 537 Zonisamide (SI) 188, 221, 522 Zopiclone (EX) 9, 232, 255, 402, 408, 496, 499, 625 Zuclopenthixol (EX) 391, 496, 499

RELATED PAPERS

RELATED TOPICS

Log In

HPLC METHODS FOR RECENTLY APPROVED PHARMACEUTICALS

HPLC METHODS FOR RECENTLY APPROVED PHARMACEUTICALS

Related Papers

RELATED PAPERS

RELATED TOPICS